FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Becker, AE Roberts, AL Perloe, A Bainivualiku, A Richards, LK Gilman, SE Striegel-Moore, RH AF Becker, Anne E. Roberts, Andrea L. Perloe, Alexandra Bainivualiku, Asenaca Richards, Lauren K. Gilman, Stephen E. Striegel-Moore, Ruth H. TI Youth health-risk behavior assessment in Fiji: the reliability of Global School-based Student Health Survey content adapted for ethnic Fijian girls SO ETHNICITY & HEALTH LA English DT Article DE Global School-based Student Health Survey; reliability; ethnic Fijians; Fiji ID SURVEY QUESTIONNAIRE; ADOLESCENTS; TELEVISION; VALIDITY; KAPPA AB Objective. The Global School-based Student Health Survey (GSHS) is an assessment for adolescent health-risk behaviors and exposures, supported by the World Health Organization. Although already widely implemented - and intended for youth assessment across diverse ethnic and national contexts - no reliability data have yet been reported for GSHS-based assessment in any ethnicity or country-specific population. This study reports test-retest reliability for GSHS content adapted for a female adolescent ethnic Fijian study sample in Fiji. Design. We adapted and translated GSHS content to assess health-risk behaviors as part of a larger study investigating the impact of social transition on ethnic Fijian secondary schoolgirls in Fiji. In order to evaluate the performance of this measure for our ethnic Fijian study sample (n = 523), we examined its test-retest reliability with kappa coefficients, % agreement, and prevalence estimates in a sub-sample (n = 81). Reliability among strata defined by topic, age, and language was also examined. Results. Average agreement between test and retest was 77%, and average Cohen's kappa was 0.47. Mean kappas for questions from core modules about alcohol use, tobacco use, and sexual behavior were substantial, and higher than those for modules relating to other risk behaviors. Conclusions. Although test-retest reliability of responses within this country-specific version of GSHS content was substantial in several topical domains for this ethnic Fijian sample, only fair reliability for the module assessing dietary behaviors and other individual items suggests that population-specific psychometric evaluation is essential to interpreting language and country-specific GSHS data. C1 [Becker, Anne E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA. [Roberts, Andrea L.; Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Perloe, Alexandra] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Bainivualiku, Asenaca] Univ Victoria, Sch Child & Youth Care, Victoria, BC, Canada. [Richards, Lauren K.] Boston Univ, Dept Psychol, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Striegel-Moore, Ruth H.] Wesleyan Univ, Dept Psychol, Middletown, CT USA. RP Becker, AE (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA. EM anne_becker@hms.harvard.edu RI Gilman, Stephen/E-7632-2010; OI Gilman, Stephen/0000-0002-8331-6419; Roberts, Andrea/0000-0001-5023-4399 FU US National Institute of Mental Health [K23 MH068575]; Harvard University; Radcliffe Institute for Advanced Study (AEB) FX Supported by the US National Institute of Mental Health (K23 MH068575), a Harvard University Research Enabling Grant, and fellowship support from the Radcliffe Institute for Advanced Study (AEB). We gratefully acknowledge the assistance of Dr Lepani Waqatakirewa, CEO-Fiji Ministry of Health and his team; the Fiji Ministry of Education; Joana Rokomatu, the late Tui Sigatoka; Dr Jan Pryor, Chair of the FN-RERC; Professor Paul Geraghty; and Dr Tevita Qorimasi. We thank Professor Jane Murphy, Dr Deborah Blacker, Dr Gene Beresin, Dr Jennifer Derenne, Kesaia Navara, and Aliyah Shivji. We are grateful to members of the Senior Advisory Group for the HEALTHY Fiji Study (Health-risk and Eating attitudes and behaviors in Adolescents Living through Transition for Healthy Youth in Fiji Study), including Professor Bill Aalbersberg (Chair), Nisha Khan, Alumita Taganesia, Livinai Masei, Pushpa Wati Khan, and Fulori Sarai. Finally, we thank all the Fiji-based principals and teachers who facilitated this study. NR 30 TC 8 Z9 8 U1 0 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-7858 J9 ETHNIC HEALTH JI Ethn. Health PY 2010 VL 15 IS 2 BP 181 EP 197 DI 10.1080/13557851003615552 PG 17 WC Ethnic Studies; Public, Environmental & Occupational Health SC Ethnic Studies; Public, Environmental & Occupational Health GA 611IO UT WOS:000278809000004 PM 20234961 ER PT J AU Mondick, JT Johnson, BM Haberer, LJ Sale, ME Adamson, PC Cote, CJ Croop, JM Russo, MW Barrett, JS Hoke, JF AF Mondick, John T. Johnson, Brendan M. Haberer, Lynda J. Sale, Mark E. Adamson, Peter C. Cote, Charles J. Croop, James M. Russo, Mark W. Barrett, Jeffrey S. Hoke, J. Frank TI Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Article DE Ondansetron; Population pharmacokinetics; Pediatric ID PEDIATRIC-PATIENTS; DRUG DISPOSITION; DEVELOPMENTAL PHARMACOLOGY; CHILDREN; CYTOCHROME-P450; INFANTS; ONTOGENY; SURGERY; VARIABILITY; METABOLISM AB Purpose Until recently, ondansetron was approved for the prevention of nausea and vomiting only in patients older than 2 years. However, as the use of ondansetron in patients younger than 2 years had been documented, characterization of ondansetron pharmacokinetics in this younger pediatric age group was warranted. Methods The pharmacokinetics of intravenously administered ondansetron were evaluated in oncology and surgical patients aged 1-48 months. Pooled data from 124 patients, including 745 pharmacokinetic samples, were analyzed using nonlinear mixed-effects modeling. Results Ondansetron pharmacokinetics were described by a two-compartment model. Body-size effects on ondansetron disposition were accounted for via standard allometric relationships, normalized to 10.4 kg. A maturation process with a half-life of approximately 4 months was incorporated to describe a decrease in clearance (CL) in infants. Clearance [95% confidence interval (CI)] for a typical patient was 1.53 (1.34-1.78) L/h/kg(0.75) with an interindividual variability of 56.8%. Ondansetron CL was reduced by 31%, 53%, and 76% for the typical 6-month-, 3-month-, and 1-month-old patient, respectively. Simulations showed that an ondansetron dose of 0.1 mg/kg in children younger than 6 months produced exposure similar to a 0.15-mg/kg dose in older children. Conclusions The population pharmacokinetic analysis of ondansetron allows for characterization of individual patients based on body weight and age. It is recommended that patients younger than 4 months receiving ondansetron be closely monitored. C1 [Mondick, John T.] Metrum Inst, Tariffville, CT 06081 USA. [Adamson, Peter C.; Barrett, Jeffrey S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Johnson, Brendan M.; Haberer, Lynda J.; Hoke, J. Frank] GlaxoSmithKline Inc, Clin Pharmacokinet Modeling & Simulat, Res Triangle Pk, NC 27709 USA. [Sale, Mark E.] Next Level Solut, Raleigh, NC 27614 USA. [Cote, Charles J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Pediat Anesthesiol, Boston, MA 02214 USA. [Croop, James M.] Indiana Univ Sch Med, James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA. [Russo, Mark W.] GlaxoSmithKline Inc, Oncol Med Dev Ctr, Collegeville, PA 19426 USA. RP Mondick, JT (reprint author), Metrum Inst, 2 Tunxis Rd,Suite 112, Tariffville, CT 06081 USA. EM johnm@metrumrg.com RI Barrett, Jeffrey/B-4010-2010 FU University of North Carolina in collaboration with GlaxoSmithKline FX Brendan M. Johnson acknowledges support from a Clinical Pharmacokinetics/ Pharmacodynamics Fellowship provided by the University of North Carolina in collaboration with GlaxoSmithKline. The authors wish to acknowledge the following investigators of Study 1: Raafat Hannallah, Peter Davis, Joseph Tobin, and Victor Baum; and investigators who contributed pharmacokinetic data to Study 2: Jeanette Pullen, Lia Gore, Victor M. Aquino, Lisa Bomgaars, Jeffrey Blumer, Paul Gaynon, Stuart Goldman, Regina Jakacki, Mitchell Cairo, Henry Nicholson, Violet Shen, Burton Appel, James Alan Whitlock, Maxine L. Hetherington, Helen Irving, Amos Toren, Andreas Zoubek, Robert Klaassen, Purificacion Garcia-Miguel, and Arturo Munoz-Villa. The authors also wish to acknowledge Sharon C. Murray, Andrew P. Beelen, Linda M. Blackburn, Maura T. Watmuff, Vince Barnett, and Bonnie Whitehead of GlaxoSmithKline. NR 36 TC 11 Z9 11 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-6970 J9 EUR J CLIN PHARMACOL JI Eur. J. Clin. Pharmacol. PD JAN PY 2010 VL 66 IS 1 BP 77 EP 86 DI 10.1007/s00228-009-0730-8 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 549DH UT WOS:000274022100008 PM 19798490 ER PT J AU Eldridge, M Saltzman, E Lahav, A AF Eldridge, Marcus Saltzman, Elliot Lahav, Amir TI Seeing what you hear: Visual feedback improves pitch recognition SO EUROPEAN JOURNAL OF COGNITIVE PSYCHOLOGY LA English DT Article DE Crossmodal learning; Audiovisual; Music; Pitch recognition ID AUDITORY-MOTOR INTERACTIONS; MIRROR-NEURON SYSTEM; MULTISENSORY INTEGRATION; PROFESSIONAL PIANISTS; ACTION REPRESENTATION; ENCODING SPECIFICITY; BLIND HUMANS; PERCEPTION; MEMORY; MUSIC AB The present study examined the effect of visual feedback on the ability to recognise and consolidate pitch information. We trained two groups of nonmusicians to play a piano piece by ear, having one group receiving uninterrupted audiovisual feedback, while allowing the other only to hear, but not see their hand on the keyboard. Results indicate that subjects for whom visual information was deprived showed significantly poorer ability to recognise pitches from the musical piece they had learned. These results are interesting since pitch recognition ability would not intuitively seem to rely on visual feedback. In addition, we show that subjects with previous experience in computer touch-typing made fewer errors during training when trained with no visual feedback, but did not show improved pitch recognition ability posttraining. Our results demonstrate how sensory redundancy increases robustness of learning, and further encourage the use of audiovisual training procedures for facilitating the learning of new skills. C1 [Lahav, Amir] Boston Univ, Dept Rehabil Sci, Dept Newborn Med, Brigham & Womens Hosp,Dept Pediat,Mass Gen Hosp, Boston, MA 02115 USA. [Saltzman, Elliot] Haskins Labs Inc, New Haven, CT 06511 USA. [Lahav, Amir] Harvard Univ, Sch Med, Boston, MA USA. RP Lahav, A (reprint author), Boston Univ, Dept Rehabil Sci, Dept Newborn Med, Brigham & Womens Hosp,Dept Pediat,Mass Gen Hosp, Boston, MA 02115 USA. EM amir@hms.harvard.edu NR 55 TC 5 Z9 5 U1 1 U2 12 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0954-1446 J9 EUR J COGN PSYCHOL JI Eur. J. Cogn. Psychol. PY 2010 VL 22 IS 7 BP 1078 EP 1091 AR PII 922303041 DI 10.1080/09541440903316136 PG 14 WC Psychology, Experimental SC Psychology GA 659PO UT WOS:000282579600006 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Temporal changes in the age distribution of inflammatory bowel disease hospitalization: data from England and Scotland SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE age effects; birth cohort; environmental risk factors; epidemiology of inflammatory bowel disease; hospital statistics; time trends ID ULCERATIVE-COLITIS; CROHNS-DISEASE; TIME TRENDS; UNITED-STATES; MORTALITY; EPIDEMIOLOGY; PREVALENCE; COUNTY AB Objective The ages of patients with Crohn's disease and ulcerative colitis are characterized by a bimodal distribution. This study used separate hospital statistics from England and Scotland to follow the changes in the age distribution of inflammatory bowel disease. The objective of the analysis was to check whether the time trends of hospitalization would show different patterns among different age groups. Methods Hospital statistics from England (1989-2006) and Scotland (1981-2007) were obtained through special requests to the national statistical offices. Hospitalizations (with Crohn's disease or ulcerative colitis listed as primary or primary plus secondary discharge diagnosis) were expressed as age-specific and sex-specific rates per 10000 living population. The separate age-specific rates of Crohn's disease and ulcerative colitis of consecutive 6-year or 7-year time intervals were plotted against their respective age group. Results The hospital data reveal a bimodal age distribution, with a more prominent first peak occurring in younger patients with Crohn's disease and a more prominent second peak occurring in older patients with ulcerative colitis. During the past two decades, the hospitalization rates for both diseases increased in all age groups. However, the increase was relatively more pronounced in the elderly, especially with ulcerative colitis. The age-shift towards older patients was also more evident for Crohn's disease or ulcerative colitis listed as secondary than primary discharge diagnosis. Conclusion The age-related shift in the occurrence of inflammatory bowel disease could reflect the impact of a birth-cohort pattern that underlies the long-term time trends of ulcerative colitis and Crohn's disease. Eur J Gastroenterol Hepatol 22:95-101 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 21 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JAN PY 2010 VL 22 IS 1 BP 95 EP 101 DI 10.1097/MEG.0b013e32832e9d54 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 534XD UT WOS:000272929900014 PM 19738478 ER PT J AU Rauh-Hain, JA Costaaggini, I Olawaiye, AB Growdon, WB Horowitz, NS del Carmen, MG AF Rauh-Hain, J. A. Costaaggini, I. Olawaiye, A. B. Growdon, W. B. Horowitz, N. S. del Carmen, M. G. TI A comparison of outcome in patients with Stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy SO EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY LA English DT Article DE Uterine cancer; Uterine clear cell carcinoma; Endometrioid adenocarcinoma of the endometrium; Radiotherapy ID RADIATION-THERAPY; CARCINOMA; CANCER AB Objective: To determine the outcomes in patients with Stage I uterine clear cell carcinoma (UCCC) treated with and without adjuvant therapy, and to compare the outcomes in these patients to that of matched controls, patients with Stage I. grade 3, endometrioid adenocarcinoma of the endometrium (EC). Methods: Patients with FIGO Stage I UCCC who underwent comprehensive surgical staging between January 1996 and January 2007 were identified. Cases (UCCC) were matched by age, stage, adjuvant therapy, and year of diagnosis to controls consisting of patients with grade 3 EC. Recurrence and survival were analyzed using the Kaplan-Meier method. Results: 25 patients with Stage I UCCC were identified of whom 13 (52%) received no adjuvant therapy and 12 (48%) received adjuvant radiation therapy (XRT). The 5-year disease-free survival and overall survival rates for the observation and the XRT groups were 78% and 75%, (p = 0.7) and 85% and 82% (p = 0.1), respectively. When compared to controls, the 5-year disease-free survival rates and overall survival rates of patients with Stage I UCCC were not significantly different, 77% vs 75% (p = 0.8) and 84% vs 88% (p = 0.5), respectively. Conclusions: In patients with Stage I UCCC tumors there was no clear benefit to adjuvant radiation given the absence of improvement in recurrence risk or any survival benefit. These data question the benefit of radiation therapy in UCCC patients with disease confined to the uterus. C1 [Rauh-Hain, J. A.; Growdon, W. B.; del Carmen, M. G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA USA. [Costaaggini, I.; Horowitz, N. S.] Harvard Univ, Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol,Sch Med, Boston, MA 02115 USA. [Olawaiye, A. B.] Univ Pittsburgh, Div Gynecol Oncol, Pittsburgh, PA USA. RP del Carmen, MG (reprint author), 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA. EM mdelcarmen@partners.org NR 15 TC 4 Z9 4 U1 0 U2 0 PU I R O G CANADA, INC PI MONTREAL PA 4900 COTE ST-LUC, APT#212, MONTREAL, QUEBEC H3W 2H3, CANADA SN 0392-2936 J9 EUR J GYNAECOL ONCOL JI Eur. J. Gynaecol. Oncol. PY 2010 VL 31 IS 3 BP 284 EP 287 PG 4 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 601VH UT WOS:000278092900007 PM 21077469 ER PT J AU Tournoux, F Chan, RC Manzke, R Hanschumacher, MD Chen-Tournoux, AA Gerard, O Solis-Martin, J Heist, EK Allain, P Reddy, V Ruskin, JN Weyman, AE Picard, MH Singh, JP AF Tournoux, Francois Chan, Raymond C. Manzke, Robert Hanschumacher, Mark D. Chen-Tournoux, Annabel A. Gerard, Olivier Solis-Martin, Jorge Heist, E. Kevin Allain, Pascal Reddy, Vivek Ruskin, Jeremy N. Weyman, Arthur E. Picard, Michael H. Singh, Jagmeet P. TI Integrating functional and anatomical information to guide cardiac resynchronization therapy SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article ID VENTRICULAR LEAD POSITION; COMPUTED-TOMOGRAPHY; HEART-FAILURE; TISSUE; ECHOCARDIOGRAPHY; DYSSYNCHRONY; SITE C1 [Tournoux, Francois; Hanschumacher, Mark D.; Chen-Tournoux, Annabel A.; Solis-Martin, Jorge; Heist, E. Kevin; Reddy, Vivek; Ruskin, Jeremy N.; Weyman, Arthur E.; Picard, Michael H.; Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Manzke, Robert] Philips Res N Amer, Massachusetts Gen Hosp Clin Site, Boston, MA USA. [Chan, Raymond C.; Gerard, Olivier; Allain, Pascal] Philips Med Syst, Medisys Grp, Paris, France. [Tournoux, Francois] Univ Paris 07, Hop Lariboisiere, APHP, Serv Cardiol,Unite INSERM U942, F-75010 Paris, France. RP Tournoux, F (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. EM francois.tournoux@lrb.aphp.fr OI Picard, Michael/0000-0002-9264-3243 NR 14 TC 14 Z9 14 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JAN PY 2010 VL 12 IS 1 BP 52 EP 57 DI 10.1093/eurjhf/hfp167 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 534WJ UT WOS:000272927900010 PM 20023045 ER PT J AU Zhang, GH Chen, WL Lao, LJ Marvizon, JCG AF Zhang, Guohua Chen, Wenling Lao, Lijun Marvizon, Juan Carlos G. TI Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE mu-opioid receptor; C-fiber; dorsal horn; GABA(B) receptor; primary afferent ID CAPSAICIN-EVOKED RELEASE; IN-SITU HYBRIDIZATION; ROOT GANGLION NEURONS; DORSAL-HORN NEURONS; SUBARACHNOID SPACE; INFLAMMATORY PAIN; GABA(B) RECEPTORS; NEUROPATHIC PAIN; OPIOID AGONISTS; SENSORY NEURONS AB The contribution of CB1 receptors in the spinal cord to cannabinoid analgesia is still unclear. The objective of this study was to investigate the effect of CB1 receptors on substance P release from primary afferent terminals in the spinal cord. Substance P release was measured as neurokinin 1 (NK1) receptor internalization in lamina I neurons. It was induced in spinal cord slices by dorsal root stimulation and in live rats by a noxious stimulus. In spinal cord slices, the CB1 receptor antagonists AM251, AM281 and rimonabant partially but potently inhibited NK1 receptor internalization induced by electrical stimulation of the dorsal root. This was due to an inhibition of substance P release and not of NK1 receptor internalization itself, because AM251 and AM281 did not inhibit NK1 receptor internalization induced by exogenous substance P. The CB1 receptor agonist ACEA increased NK1 receptor internalization evoked by dorsal root stimulation. The effects of AM251 and ACEA cancelled each other. In vivo, AM251 injected intrathecally decreased NK1 receptor internalization in spinal segments L5 and L6 induced by noxious hind paw clamp. Intrathecal AM251 also produced analgesia to radiant heat stimulation of the paw. The inhibition by AM251 of NK1 receptor internalization was reversed by antagonists of mu-opioid and GABA(B) receptors. This indicates that CB1 receptors facilitate substance P release by inhibiting the release of GABA and opioids next to primary afferent terminals, producing disinhibition. This results in a pronociceptive effect of CB1 receptors in the spinal cord. C1 [Zhang, Guohua; Chen, Wenling; Marvizon, Juan Carlos G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Zhang, Guohua; Chen, Wenling; Lao, Lijun; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Dept Med,Div Digest Dis, Los Angeles, CA 90095 USA. RP Marvizon, JCG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU Rehabilitation Research & Development Service, Department of Veteran Affair [B4766I]; National Institutes of Health [R01 DA012609] FX Supported by grant B4766I from the Rehabilitation Research & Development Service, Department of Veteran Affairs to J.C.M., who is also a recipient of grant R01 DA012609 from the National Institutes of Health. NR 94 TC 16 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JAN PY 2010 VL 31 IS 2 BP 225 EP 237 DI 10.1111/j.1460-9568.2009.07075.x PG 13 WC Neurosciences SC Neurosciences & Neurology GA 545IX UT WOS:000273726800005 PM 20074214 ER PT J AU Lanius, RA Frewen, PA Vermetten, E Yehuda, R AF Lanius, Ruth A. Frewen, Paul A. Vermetten, Eric Yehuda, Rachel TI Fear conditioning and early life vulnerabilities: two distinct pathways of emotional dysregulation and brain dysfunction in PTSD SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Review DE Anterior cingulate cortex; medial prefrontal cortex; amygdale; DSM-V; emotion; attachment; HPA-axis; infant development AB The newly proposed criteria for posttraumatic stress disorder (PTSD) in the Diagnostic and Statistical Manual (DSM-V) include dysregulation of a variety of emotional states including fear, anger, guilt, and shame, in addition to dissociation and numbing. Consistent with these revisions, we postulate two models of emotion dysregulation in PTSD in which fear is not the prevailing emotion but is only one of several components implicated in a dysregulated emotional system that also mediates problems regulating anger, guilt, shame, dissociation, and numbing. We discuss whether there is a relationship between fear and other emotion regulation systems that may help further our understanding of PTSD and its underlying neurocircuitry. Two pathways describing the relationship between fear and other emotion regulation systems in PTSD are proposed. The first pathway describes emotion dysregulation as an outcome of fear conditioning through stress sensitization and kindling. The second pathway views emotion dysregulation as a distal vulnerability factor and hypothesizes a further exacerbation of fear and other emotion regulatory problems, including the development of PTSD after exposure to one or several traumatic event(s) later in life. Future research and treatment implications are discussed. C1 [Lanius, Ruth A.] Univ Western Ontario, Dept Psychiat, London, ON N6A 5A5, Canada. [Frewen, Paul A.] Univ Western Ontario, Dept Psychol, London, ON N6A 5A5, Canada. [Vermetten, Eric] Univ Med Ctr, Utrecht, Netherlands. [Yehuda, Rachel] Mt Sinai Sch Med, New York, NY 10029 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. RP Lanius, RA (reprint author), Univ Western Ontario, Dept Psychiat, 339 Windermere Rd, London, ON N6A 5A5, Canada. EM ruth.lanius@lhsc.on.ca RI Lanius, Ruth/J-6961-2015 OI Lanius, Ruth/0000-0002-3758-1393 NR 127 TC 33 Z9 33 U1 9 U2 16 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2010 VL 1 AR 5467 DI 10.3402/ejpt.v1i0.5467 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EV UT WOS:000208867800001 ER PT J AU Yehuda, R Bierer, LM Pratchett, L Malowney, M AF Yehuda, Rachel Bierer, Linda M. Pratchett, Laura Malowney, Monica TI Glucocorticoid augmentation of prolonged exposure therapy: rationale and case report SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Glucocorticoids; PTSD; cortisol; treatment; prolonged exposure; learning; memory AB Rationale: Prolonged exposure (PE) therapy has been found to reduce symptoms of posttraumatic stress disorder (PTSD); however, it is difficult for many patients to engage fully in the obligatory retelling of their traumatic experiences. This problem is compounded by the fact that habituation and cognitive restructuring - the main mechanisms through which PE is hypothesized to work - are not instantaneous processes, and often require several weeks before the distress associated with imaginal exposure abates. Case reports: Two cases are described that respectively illustrate the use of hydrocortisone and placebo, in combination with PE, for the treatment of combat-related PTSD. Based on known effects of glucocorticoids on learning and memory performance, we hypothesized that augmentation with hydrocortisone would improve the therapeutic effects of PE by hastening "new'' learning and facilitating decreases in the emotional impact of fear memories during the course of treatment. The veteran receiving hydrocortisone augmentation of PE displayed an accelerated and ultimately greater decline in PTSD symptoms than the veteran receiving placebo. Conclusions: While no general conclusion can be derived from comparison of two patients, the findings are consistent with the rationale for augmentation. These case reports support the potential for an appropriately designed and powered clinical trial to examine the efficacy of glucocorticoids in augmenting the effects of psychotherapy for PTSD. C1 [Yehuda, Rachel; Bierer, Linda M.; Pratchett, Laura] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel; Bierer, Linda M.; Malowney, Monica] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 116-1 526 OOMH,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@va.gov RI Malowney, Monica/F-8009-2014 OI Malowney, Monica/0000-0002-6521-9754 NR 41 TC 9 Z9 9 U1 2 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2010 VL 1 DI 10.3402/ejpt.v1i0.5643 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EV UT WOS:000208867800008 ER PT J AU Bandelow, B Demyttenaere, K Papakostas, G Trivedi, M Szamosi, J Earley, W Eriksson, H AF Bandelow, B. Demyttenaere, K. Papakostas, G. Trivedi, M. Szamosi, J. Earley, W. Eriksson, H. TI EVALUATION OF THE EFFECTS OF QUETIAPINE XR MONOTHERAPY ON SLEEP DISTURBANCE IN PATIENTS WITH MDD SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Bandelow, B.] Univ Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany. [Demyttenaere, K.] Univ Hosp Gathuisburg, Louvain, Belgium. [Papakostas, G.] Harvard Univ, Sch Med, Boston, MA USA. [Papakostas, G.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Trivedi, M.] UT SW Med Ctr Dallas, Dept Psychiat, Dallas, TX USA. [Szamosi, J.; Eriksson, H.] AstraZeneca R&D, Sodertalje, Sweden. [Earley, W.] AstraZeneca, Wilmington, DE USA. RI Bandelow, Borwin/E-7295-2011 OI Bandelow, Borwin/0000-0003-2511-3768 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2010 VL 25 SU 1 PG 1 WC Psychiatry SC Psychiatry GA V21RX UT WOS:000208225801417 ER PT J AU Gurrera, R Salisbury, D Mahowald, T AF Gurrera, R. Salisbury, D. Mahowald, T. TI PERSONALITY IN FIRST EPISODE PSYCHOSIS SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Gurrera, R.; Salisbury, D.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Gurrera, R.] VA Boston Healthcare Syst, Brockton, MA USA. [Salisbury, D.; Mahowald, T.] McLean Hosp, Belmont, MA 02178 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2010 VL 25 SU 1 PG 2 WC Psychiatry SC Psychiatry GA V21RX UT WOS:000208225801180 ER PT J AU Gurrera, R Salisbury, D Mahowald, T AF Gurrera, R. Salisbury, D. Mahowald, T. TI PERSONALITY IN FIRST EPISODE PSYCHOSIS SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Gurrera, R.; Salisbury, D.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Gurrera, R.] VA Boston Healthcare Syst, Brockton, MA USA. [Salisbury, D.; Mahowald, T.] McLean Hosp, Belmont, MA 02178 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2010 VL 25 SU 1 PG 2 WC Psychiatry SC Psychiatry GA V21RX UT WOS:000208225801181 ER PT J AU Gurrera, R Caroff, S Cohen, A AF Gurrera, R. Caroff, S. Cohen, A. TI NEUROLEPTIC MALIGNANT SYNDROME DIAGNOSIS: AN INTERNATIONAL CONSENSUS STUDY USING THE DELPHI TECHNIQUE SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Gurrera, R.] Harvard Univ, Sch Med, Philadelphia, PA USA. [Gurrera, R.] VA Boston Healthcare Syst, Brockton, MA USA. [Caroff, S.; Cohen, A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Caroff, S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Cohen, A.] Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. RI Cohen, Abigail/K-9180-2013 OI Cohen, Abigail/0000-0002-7425-7218 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2010 VL 25 SU 1 PG 1 WC Psychiatry SC Psychiatry GA V21RX UT WOS:000208225800937 ER PT J AU Montgomery, S Thase, M Papakostas, G Bauer, M Trivedi, M Svedsater, H Udd, M Gustafsson, U Eriksson, H AF Montgomery, S. Thase, M. Papakostas, G. Bauer, M. Trivedi, M. Svedsater, H. Udd, M. Gustafsson, U. Eriksson, H. TI EVALUATION OF THE EFFECTS OF QUETIAPINE XR MONOTHERAPY ACCORDING TO MDD SEVERITY: POOLED DATA FROM 4 PLACEBO-CONTROLLED TRIALS SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Montgomery, S.] Univ London, Imperial Coll Sch Med, London, England. [Thase, M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Papakostas, G.] Harvard Univ, Sch Med, Boston, MA USA. [Papakostas, G.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Bauer, M.] Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Dresden, Germany. [Trivedi, M.] UT SW Med Ctr Dallas, Dept Psychiat, Dallas, TX USA. [Svedsater, H.; Udd, M.; Gustafsson, U.; Eriksson, H.] AstraZeneca R&D, Sodertalje, Sweden. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2010 VL 25 SU 1 PG 1 WC Psychiatry SC Psychiatry GA V21RX UT WOS:000208225801437 ER PT J AU Blake, MA Setty, BN Cronin, CG Kalra, M Holalkere, NS Fischman, AJ Mueller, PR Sahani, DV AF Blake, Michael A. Setty, Bindu N. Cronin, Carmel G. Kalra, Mannudeep Holalkere, Nagaraj Setty Fischman, Alan J. Mueller, Peter R. Sahani, Dushyant V. TI Evaluation of the effects of oral water and low-density barium sulphate suspension on bowel appearance on FDG-PET/CT SO EUROPEAN RADIOLOGY LA English DT Article DE PET CT; Small bowel; FDG uptake; Oral contrast; PET CT protocols ID EMISSION TOMOGRAPHY-CT; CONTRAST AGENT; COMPUTED-TOMOGRAPHY; HELICAL CT; EXPERIENCE; ABDOMEN AB The purpose of this study is to assess which of five bowel preparation regimes offers superior bowel distension and to assess if these regimes adversely affect FDG activity on PET/CT imaging. The study conformed to HIPAA regulations. Ninety patients were divided into five groups of 18 who received no oral contrast agent (group A); 900 ml of water orally (group B); or 900, 1,350, or 1,800 ml of LDB (groups C, D, E, respectively). PET/CT examinations were assessed quantitatively (bowel diameter, SUV) and qualitatively (visual assessment grading scale) for bowel distension and FDG activity by two blinded readers. ANOVA was utilized to determine if a statistically significant difference (SSD) existed between the groups in terms of distension and FDG uptake. Qualitatively superior bowel distension was observed in group C (LDB) compared to B (water) and greater distension was noted with increased volumes of LDB in C, D, and E. Quantitatively there was an SSD in mean distension between groups C and B (P < 0.001 except duodenum). Qualitatively and quantitatively there was no significant difference in bowel FDG uptake among the groups (P > 0.05). LDB as an oral contrast agent provides superior bowel distension over water and does not induce increased FDG bowel activity. C1 [Cronin, Carmel G.; Fischman, Alan J.] Massachusetts Gen Hosp, Div Nucl Med, Dept Radiol, Boston, MA 02114 USA. [Blake, Michael A.; Setty, Bindu N.; Cronin, Carmel G.; Kalra, Mannudeep; Holalkere, Nagaraj Setty; Mueller, Peter R.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol, Boston, MA 02114 USA. RP Cronin, CG (reprint author), Massachusetts Gen Hosp, Div Nucl Med, Dept Radiol, Boston, MA 02114 USA. EM carmelcronin2000@hotmail.com OI Setty, Bindu/0000-0002-2749-6822; Holalkere, Nagaraj/0000-0001-6324-7682 NR 21 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0938-7994 J9 EUR RADIOL JI Eur. Radiol. PD JAN PY 2010 VL 20 IS 1 BP 157 EP 164 DI 10.1007/s00330-009-1527-y PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 542FR UT WOS:000273478900020 PM 19680659 ER PT B AU Choy, G Yager, PH Noviski, N Westra, SJ AF Choy, Garry Yager, Phoebe H. Noviski, Natan Westra, Sjirk J. BA Medina, LS Applegate, KE Blackmore, CC BF Medina, LS Applegate, KE Blackmore, CC TI Imaging of Chest Infections in Children SO EVIDENCE-BASED IMAGING IN PEDIATRICS: OPTIMIZING IMAGING IN PEDIATRIC PATIENT CARE LA English DT Article; Book Chapter ID COMMUNITY-ACQUIRED PNEUMONIA; COMPLICATED PARAPNEUMONIC EFFUSIONS; RESISTANT STAPHYLOCOCCUS-AUREUS; ASSISTED THORACOSCOPIC SURGERY; SEVERE PULMONARY COMPLICATIONS; CHILDHOOD PNEUMONIA; DIAGNOSTIC-ACCURACY; EMPYEMA; CT; RADIOGRAPHY C1 [Choy, Garry; Westra, Sjirk J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Yager, Phoebe H.; Noviski, Natan] Harvard Univ, Sch Med, Dept Pediat Crit Care Med, Boston, MA 02114 USA. RP Westra, SJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM swestra@partners.org NR 68 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0921-3 PY 2010 BP 401 EP 418 DI 10.1007/978-1-4419-0922-0_27 D2 10.1007/978-1-4419-0922-0 PG 18 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA BMM24 UT WOS:000272790700027 ER PT B AU Barnewolt, CE Connolly, LP Estrada, CR Applegate, KE AF Barnewolt, Carol E. Connolly, Leonard P. Estrada, Carlos R. Applegate, Kimberly E. BA Medina, LS Applegate, KE Blackmore, CC BF Medina, LS Applegate, KE Blackmore, CC TI Urinary Tract Infection in Infants and Children SO EVIDENCE-BASED IMAGING IN PEDIATRICS: OPTIMIZING IMAGING IN PEDIATRIC PATIENT CARE LA English DT Article; Book Chapter ID PRIMARY VESICOURETERAL REFLUX; DIMERCAPTOSUCCINIC ACID SCINTIGRAPHY; PRENATALLY DETECTED HYDRONEPHROSIS; RANDOMIZED CONTROLLED-TRIALS; RENAL PELVIC DILATATION; ACUTE PYELONEPHRITIS; VOIDING CYSTOURETHROGRAPHY; ANTIBIOTIC-PROPHYLAXIS; ANTENATAL HYDRONEPHROSIS; FEBRILE INFANTS C1 [Barnewolt, Carol E.] Childrens Hosp Boston, Dept Radiol, Boston, MA 02115 USA. [Connolly, Leonard P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Nucl Med Radiol, Boston, MA 02114 USA. [Estrada, Carlos R.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Urol, Boston, MA 02115 USA. [Applegate, Kimberly E.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA. RP Barnewolt, CE (reprint author), Childrens Hosp Boston, Dept Radiol, Boston, MA 02115 USA. EM carol.barnewolt@childrens.harvard.edu RI Estrada, Carlos/H-2199-2015 OI Estrada, Carlos/0000-0003-0586-9832 NR 155 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0921-3 PY 2010 BP 569 EP 592 DI 10.1007/978-1-4419-0922-0_38 D2 10.1007/978-1-4419-0922-0 PG 24 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA BMM24 UT WOS:000272790700038 ER PT B AU Bessa-Nogueira, RV Salmos-Brito, JAL Vasconcelos, BCD Niederman, R AF Bessa-Nogueira, Ricardo Viana Lima Salmos-Brito, Janaina Andrade do Egito Vasconcelos, Belmiro Cavalcanti Niederman, Richard BE Chiappelli, F TI Temporomandibular Joint Disorders, a Bibliometric Evidence-Based Approach to Analysis SO EVIDENCE-BASED PRACTICE: TOWARD OPTIMIZING CLINICAL OUTCOMES LA English DT Article; Book Chapter ID OPTIMAL SEARCH STRATEGIES; OF-THE-LITERATURE; SYSTEMATIC REVIEWS; INTERVENTIONS; DYSFUNCTION; ETIOLOGY; THERAPY; MEDLINE; TRIALS C1 [Bessa-Nogueira, Ricardo Viana; Lima Salmos-Brito, Janaina Andrade; do Egito Vasconcelos, Belmiro Cavalcanti] Univ Pernambuco, Sch Dent, BR-54753020 Camaragibe Pernambuco, Brazil. [Niederman, Richard] Forsyth Inst, Boston, MA 02115 USA. RP Bessa-Nogueira, RV (reprint author), Univ Pernambuco, Sch Dent, Ave Gen Newton Cavalcanti 1650, BR-54753020 Camaragibe Pernambuco, Brazil. EM ricardobessa@msn.com; janainasalmos@hotmail.com; belmiro@pesquisador.cnpq.br; rniederman@forsyth.org RI Bessa-Nogueira, Ricardo/G-2824-2011; OI Bessa-Nogueira, Ricardo/0000-0002-9776-6752; niederman, richard/0000-0001-6674-1774 NR 36 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-642-05024-4 PY 2010 BP 185 EP 193 DI 10.1007/978-3-642-05025-1_12 D2 10.1007/978-3-642-05025-1 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA BRG08 UT WOS:000282659400012 ER PT S AU Yared, K Baggish, AL AF Yared, Kibar Baggish, Aaron L. BE Connes, P Hue, O Perrey, S TI Heart Anatomy, Mechanisms of Contraction, and Cardiac Function During Exercise SO EXERCISE PHYSIOLOGY: FROM A CELLULAR TO AN INTEGRATIVE APPROACH SE Biomedical and Health Research LA English DT Article; Book Chapter ID STROKE VOLUME; UPRIGHT EXERCISE; ATHLETES HEART; ENDURANCE; RUNNERS; SUCTION; MUSCLE; YOUNG; ARCHITECTURE; ORIENTATION C1 [Yared, Kibar; Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Yared, K (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. EM abaggish@partners.org NR 49 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0929-6743 BN 978-1-60750-497-9; 978-1-60750-496-2 J9 BIOMED HEALTH RES JI Biom. Health Res. PY 2010 VL 75 BP 119 EP 133 DI 10.3233/978-1-60750-497-9-119 PG 15 WC Physiology SC Physiology GA BA7HI UT WOS:000337530000011 ER PT J AU Parhofer, KG Zeymer, U Stark, RG Binz, C Schwertfeger, M Bhatt, DL Steg, PG Roether, J AF Parhofer, K. G. Zeymer, U. Stark, R. G. Binz, C. Schwertfeger, M. Bhatt, D. L. Steg, Ph. G. Roether, J. CA REACH Registry Investigators TI In Germany Diabetic Patients with Coronary Artery Disease are Treated More Intensively than Diabetic Patients with Other Manifestations of Atherothrombosis - Results from the REACH Registry SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES LA English DT Article DE diabetes; atherosclerosis; treatment goals; LDL-cholesterol; blood pressure ID TRANSIENT ISCHEMIC ATTACK; 14 RANDOMIZED-TRIALS; MULTIFACTORIAL INTERVENTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; EVENT RATES; MELLITUS; STATINS; STROKE; METAANALYSIS AB Introduction: Atherothrombosis can present as coronary artery disease (CAD) cerebrovascular disease (CVD) and peripheral arterial disease (PAD). It is unknown whether diabetics with CAD differ from those with other manifestations of atherothrombosis such as CVD or PAD regarding clinical characteristics, biochemical parameters, or medications. Material and Methods: The REACH (REduction of Atherothrombosis for Continued Health) registry evaluated 67 888 patients with established atherothrombosis or risk factors. Of 5 646 recruited German patients, 2 381 (42%) are diabetic. Of these 1 438 (60%) have CAD (either only CAD or in combination with CVD and/or PAD CAD group) and 520 (22%) have other manifestations of atherothrombosis (either CVD or PAD or both - other manifestation group) and 18% have only risk factors. Differences between diabetics with CAD and diabetics with other manifestations of atherothrombosis were evaluated with multivariate models (79% male, 69 +/- 9 years, BMI 29 +/- 5 kg/m(2)) (SAS9.1). Results: After correcting for age, sex and BMI, CAD patients receive (OR; 95% CI) more aspirin (1.5; 1.2-1.9; p=0.0002), statins (3.1; 2.6-3.7), beta-blockers (4.0; 3.8-4.8), diuretics (1.4; 1.2-1.6), ACE-inhibitors/ARBs (1.4; 1.2-1.7) and nitrates (8.8; 6.7-11.7) and significantly less often metformin (0.75; 0.61-0.93; p = 0.01) with no differences concerning other antidiabetics. This resulted in significantly (p<0.05) lower blood-pressure (CAD 142/81 mmHg, other manifestations 145/82 mmHg) and LDL-cholesterol levels (CAD 108 +/- 37 mg/dl, other manifestations 123 +/- 37 mg/dl). Therefore more CAD patients reach LDL and blood-pressure-goals (CAD 47%/33%; other manifestations 30%/24%, respectively). Only few patients (CAD 7.1%, other manifestations 4.1%) reach all treatment goals. Furthermore, less CAD patients than patients with other manifestations of atherothrombosis are current smokers (11% vs. 22%). Discussion: These data indicate considerable treatment differences between diabetics with CAD and those with other manifestations of atherothrombosis such as CVD or PAD. CAD patients are treated more intensively and therefore reach lower lipid and blood-pressure values. C1 [Parhofer, K. G.] Univ Munich, Dept Internal Med 2, Munich, Germany. [Zeymer, U.] Klinikum Stadt Ludwigshafen, Dept Med B, D-6700 Ludwigshafen, Germany. [Stark, R. G.] Helmholtz Zentrum, Inst Hlth Econ & Hlth Care Management, Munich, Germany. [Binz, C.] Bristol Myers Squibb GmbH & Co, KGaA, Dept Med, Munich, Germany. [Schwertfeger, M.] Sanofi Aventis Deutschland GmbH, Med Affairs CVT, Berlin, Germany. [Bhatt, D. L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, D. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Steg, Ph. G.] Univ Paris 07, INSERM, U698, AP HP, Paris, France. [Roether, J.] Johannes Wesling Klinikum, Dept Neurol, Minden, Germany. RP Parhofer, KG (reprint author), Grosshadern Univ Munich, Dept Med 2, Marchioninistr 15, D-81377 Munich, Germany. EM Klaus.Parhofer@med.uni-muenchen.de RI Stark, Renee/B-6733-2013 OI Stark, Renee/0000-0002-6612-292X FU sanofi-aventis; Bristol-Myers Squibb; Waksman Foundation (Tokyo, Japan) FX We thank all the investigators of the REACH registry. The REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The sponsors provide logistical support. All the publication activity is controlled by the REACH Registry Global Publication Committee (Ph. Gabriel Steg, Deepak L. Bhatt, Mark Alberts, Ralph D'Agostino, Kim Eagle, Shinya Goto, Alan T. Hirsch, Chiau-Suong Liau, Jean-Louis Mas, E. Magnus Ohman, Joachim Rother, Sidney C. Smith, Peter W. F. Wilson). All manuscripts in the REACH Registry are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publication committee before submission. NR 21 TC 2 Z9 2 U1 0 U2 0 PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH PI STUTTGART PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0947-7349 J9 EXP CLIN ENDOCR DIAB JI Exp. Clin. Endocrinol. Diabet. PD JAN PY 2010 VL 118 IS 1 BP 51 EP 56 DI 10.1055/s-0029-1225648 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 551XC UT WOS:000274245700010 PM 19834877 ER PT S AU Poulaki, V AF Poulaki, Vassiliki BE Hammes, HP Porta, M TI Retinal Vascular Permeability in Health and Disease SO EXPERIMENTAL APPROACHES TO DIABETIC RETINOPATHY SE Frontiers in Diabetes LA English DT Article; Book Chapter ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; TIGHT JUNCTION PERMEABILITY; GLYCATION END-PRODUCTS; INTRAVITREAL TRIAMCINOLONE ACETONIDE; INTERCELLULAR-ADHESION MOLECULE-1; GLUCOSE-INDUCED APOPTOSIS; CONTRAST-ENHANCED MRI; NECROSIS-FACTOR-ALPHA; COMPLEMENT FACTOR-H AB Homeostasis in the retina microenvironment is maintained by the proper function of the blood-retinal barrier (BRB), which regulates the movement of chemicals and cells between the intravascular compartment and the retina. The BRB consists of two major topographically distinct components: the endothelium of the retinal vessels (inner BRB) and the retinal pigment epithelium (outer BRB). The barrier function of the retinal vascular endothelium depends on its lack of fenestrations, whereas the ability of the retinal pigment epithelium to regulate solute transport depends on the apical tight junctions. The tight junctions are membrane fusion areas between adjacent cells that serve as a diffusion barrier for paracellular transport and as a 'molecular fence, restricting the free movement of transmembrane proteins, and thus maintaining cell polarity and the asymmetric distribution of transmembrane proteins. Among the most important proteins that are associated with tight junctions are occludin, zonula occludens and claudins. Pathologic increase in blood retinal permeability can be caused by endothelial or pericyte cell death, tight junction disassembly, or cytokines such as vascular endothelial growth factor. Several assays have been developed to allow detection, quantification and monitoring of BRB breakdown in experimental and clinical settings. Assays used in animal models include the injection of chromophores, such as Evans blue, horseradish peroxidase, and fluorescein; the imaging techniques include electron microscopy and MRI. In humans, fluorescein angiography, vitreous fluorophotometry and optical coherence tomography are most commonly used. The disruption of the BRB contributes to the pathophysiology of several retinal diseases such as diabetic retinopathy, age-related macula degeneration, retinopathy of prematurity, central serous chorioretinopathy, vascular occlusive and inflammatory diseases. Several medical and surgical treatments have been developed to restore normal BRB function. Traditional procedures such as laser photocoagulation and corticosteroids have been recently supplemented with vascular endothelial growth factor pathway inhibitors, anti-TNF-alpha agents, mammalian target of rapamycin inhibitors and PKC beta inhibitors. Early results from clinical trials offer hope for effective vision-preserving therapies. Copyright (C) 2010 S. Karger AG, Basel C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA 02114 USA. RP Poulaki, V (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, 325 Cambridge St, Boston, MA 02114 USA. EM poulakiv@hotmail.com NR 183 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0251-5342 BN 978-3-8055-9275-8 J9 FRONT DIABETES JI Front.Diabetes PY 2010 VL 20 BP 20 EP 41 PG 22 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BMT27 UT WOS:000273524500002 ER PT J AU Almulki, L Noda, K Nakao, S Hisatomi, T Thomas, KL Hafezi-Moghadam, A AF Almulki, Lama Noda, Kousuke Nakao, Shintaro Hisatomi, Toshio Thomas, Kennard L. Hafezi-Moghadam, Ali TI Localization of vascular adhesion protein-1 (VAP-1) in the human eye SO EXPERIMENTAL EYE RESEARCH LA English DT Article DE inflammation; adhesion molecules; morphology; vasculature ID ENDOTOXIN-INDUCED UVEITIS; CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; ENZYMATIC-ACTIVITY; AMINE OXIDASE; MOLECULE; INFLAMMATION; INHIBITION; REVEALS; CLONING AB Recently we showed a critical role for Vascular Adhesion Protein-1 (VAP-1) in rodents during acute ocular inflammation, angiogenesis, and diabetic retinal leukostasis. However, the expression of VAP-1 in the human eye is unknown. VAP-1 localization was therefore investigated by immunohistochemistry. Five micrometer thick sections were generated from human ocular tissues embedded in paraffin. Sections were incubated overnight with primary mAbs against VAP-1 (5 mu g/ml), smooth muscle actin (1 mu g/ml), CD31 or isotype-matched IgG at 4 degrees C. Subsequently, a secondary mAb was used for 30 min at room temperature, followed by Dako Envision + HRP (AEC) System for signal detection. The stained sections were examined using light microscopy and the signal intensity was quantified by two evaluators and graded into 4 discrete categories. In all examined ocular tissues, VAP-1 staining was confined to the vasculature. VAP-1 labeling showed the highest intensity in both arteries and veins of neuronal tissues: retina and optic nerve, and the lowest intensity in the iris vasculature (p < 0.05). Scleral and choroidal vessels showed moderate staining for VAP-1. VAP-1 intensity was significantly higher in the arteries compared to veins (p < 0.05). Furthermore, VAP-I staining in arteries colocalized with both CD31 and smooth muscle actin (sm-actin) staining, suggesting expression of VAP-1 in endothelial cells, smooth muscle cells or potentially pericytes. In conclusion, immunohistochemistry reveals constitutive expression of VAP-1 in human ocular tissues. VAP-1 expression is nearly exclusive to the vasculature with arteries showing significantly higher expression than veins. Furthermore, VAP-1 expression in the ocular vasculature is heterogeneous, with the vessels of the optic nerve and the retina showing highest expressions. These results characterize VAP-1 expression in human ocular tissues. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Almulki, Lama; Noda, Kousuke; Nakao, Shintaro; Hisatomi, Toshio; Thomas, Kennard L.; Hafezi-Moghadam, Ali] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA. [Almulki, Lama; Noda, Kousuke; Nakao, Shintaro; Hisatomi, Toshio; Thomas, Kennard L.; Hafezi-Moghadam, Ali] Harvard Univ, Dept Ophthalmol, Sch Med, Boston, MA 02114 USA. RP Hafezi-Moghadam, A (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA. EM ahm@meei.harvard.edu OI Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam, Ali/0000-0002-5336-0697 FU RTECH-UENO; Bausch & Lomb Fellowships; NIH [HL086933, A1050775]; NEI [EY14104]; Massachusetts Lions Foundation FX The authors would like to thank Ms. Marion Athanas and Dr. Pooja Bhat, members of the David D. Cogan Ophthalmic Pathology Laboratory at the Massachusetts Eye and Ear Infirmary for providing the human specimens, Mr. Norman Michaud and Ms. Sreedevi Mallemadugula for their expert technical assistance.; This work was supported by research funds from RTECH-UENO, Bausch & Lomb Fellowships to (K.N. and S.N.), NIH grants HL086933 (Alan Cross) and A1050775 (AH-M), and NEI core grant EY14104. We are indebted to the Massachusetts Lions Foundation for generous funds provided for laboratory equipment used in this project. We would like to thank Research to Prevent Blindness and the American Health Assistance Foundation. We are grateful to the Marion W. and Edward F. Knight AMD Fund. NR 24 TC 16 Z9 16 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 J9 EXP EYE RES JI Exp. Eye Res. PD JAN PY 2010 VL 90 IS 1 BP 26 EP 32 DI 10.1016/j.exer.2009.09.005 PG 7 WC Ophthalmology SC Ophthalmology GA 542SW UT WOS:000273516500005 PM 19761765 ER PT J AU Ho, L Fivecoat, H Wang, J Pasinetti, GM AF Ho, Lap Fivecoat, Hayley Wang, Jun Pasinetti, Giulio Maria TI Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Alzheimer's disease (AD); Cognitive impairment; Dementia; Genetic risk factors; Biomarkers; Complementary DNA (cDNA) microarray analysis; Protein array analysis; Proteomics; MicroRNA (miRNA) ID SERVICES-TASK-FORCE; CEREBROSPINAL-FLUID; BREAST-CANCER; NEUROFIBRILLARY TANGLES; ALTERED EXPRESSION; SECRETASE ACTIVITY; NEURITIC PLAQUES; GENE-EXPRESSION; GAMMA-SECRETASE; RISK AB Alzheimer's disease (AD) is the most common form of dementia in the elderly. Current treatments for AD are not as effective as needed, nor is there any definitive antemortem diagnostic. Understanding the biological processes that occur during AD onset and/or progression will improve disease diagnosis and treatment. Recent applications of microarray technologies for analysis of messenger (m) RNA expression profiles have elucidated distinct changes in the brain as a function of AD dementia initiation and progression. However, mRNA analysis underestimates post-transcriptional modifications and therefore provides only a partial view of the molecular changes in the AD brain. Combining mRNA studies with protein expression analysis may provide a more global picture of the biological processes associated with AD dementia. Information gathered could lead to the development of select biological indices (biomarkers) for guiding AD diagnosis and therapy. We will provide a brief background on AD, followed by a review on the applications of microarray, proteomics, as well as microRNA expression profile analysis to develop novel diagnostic strategies that may be useful for the diagnosis AD and for monitoring disease progression. The availability of biomarkers that promote early disease diagnosis, particularly among asymptomatic patients, will lead to the application of personalized medicine in AD. Published by Elsevier Inc. C1 [Ho, Lap; Fivecoat, Hayley; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurodiagnost & N, Inst Brain, New York, NY 10029 USA. [Ho, Lap; Fivecoat, Hayley; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Complementary & Alternat Med Alzei, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Biomed Res & Training Program, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurodiagnost & N, Inst Brain, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIA [UO1-AG0293310]; Veteran's Affairs Medical Center (Bronx, NY) Geriatrics Research, Education and Clinical Center (GRECC) FX Supported by UO1-AG0293310 by the NIA, and the Veteran's Affairs Medical Center (Bronx, NY) Geriatrics Research, Education and Clinical Center (GRECC) to G.M.P. NR 68 TC 22 Z9 22 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JAN PY 2010 VL 45 IS 1 SI SI BP 15 EP 22 DI 10.1016/j.exger.2009.09.007 PG 8 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 547DQ UT WOS:000273866300004 PM 19796674 ER PT J AU Jonker, SS Giraud, MK Giraud, GD Chattergoon, NN Louey, S Davis, LE Faber, JJ Thornburg, KL AF Jonker, Sonnet S. Giraud, M. Kathryn Giraud, George D. Chattergoon, Natasha N. Louey, Samantha Davis, Lowell E. Faber, J. Job Thornburg, Kent L. TI Cardiomyocyte enlargement, proliferation and maturation during chronic fetal anaemia in sheep SO EXPERIMENTAL PHYSIOLOGY LA English DT Article ID CELL-CYCLE ACTIVITY; ADULT SHEEP; BLOOD-FLOW; HYPERTROPHY; ADAPTATIONS; GROWTH; HEART AB Chronic anaemia increases the workload of the growing fetal heart, leading to cardiac enlargement. To determine which cellular process increases cardiac mass, we measured cardiomyocyte sizes, binucleation as an index of terminal differentiation, and tissue volume fractions in hearts from control and anaemic fetal sheep. Fourteen chronically catheterized fetal sheep at 129 days gestation had blood withdrawn for 9 days to cause severe anaemia; 14 control fetuses were of similar age. At postmortem examination, hearts were either enzymatically dissociated or fixed for morphometric analysis. Daily isovolumetric haemorrhage reduced fetal haematocrit from a baseline value of 35% to 15% on the final day (P < 0.001). At the study conclusion, anaemic fetuses had lower arterial pressures than control fetuses (P < 0.05). Heart weights were increased by 39% in anaemic fetuses compared with control hearts (P < 0.0001), although the groups had similar body weights; the heart weight difference was not due to increased ventricular wall water content or disproportionate non-myocyte tissue expansion. Cardiomyocytes from anaemic fetuses tended to be larger than those of control fetuses. There were no statistically significant differences between groups in the cardiomyocyte cell cycle activity. The degree of terminal differentiation was greater in the right ventricle of anaemic compared with control fetuses by similar to 8% (P < 0.05). Anaemia substantially increased heart weight in fetal sheep. The volume proportions of connective and vascular tissue were unchanged. Cardiomyocyte mass expanded by a balanced combination of cellular enlargement, increased terminal differentiation and accelerated proliferation. C1 [Jonker, Sonnet S.; Giraud, M. Kathryn; Giraud, George D.; Chattergoon, Natasha N.; Louey, Samantha; Davis, Lowell E.; Faber, J. Job; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. [Jonker, Sonnet S.; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. RP Jonker, SS (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH14T, Portland, OR 97239 USA. EM jonkers@ohsu.edu OI Thornburg, Kent/0000-0002-5561-4785; Jonker, Sonnet/0000-0002-1097-2562 FU NICHD [P01HD34430]; M. Lowell Edwards Endowment; American Heart Association FX The authors would like to acknowledge the technical assistance of Robert Webber, Loni Socha and Kevin Hearn. This study was supported by the NICHD grant P01HD34430 and the M. Lowell Edwards Endowment. Sonnet Jonker was supported by an American Heart Association Fellowship. NR 20 TC 16 Z9 16 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0958-0670 J9 EXP PHYSIOL JI Exp. Physiol. PD JAN 1 PY 2010 VL 95 IS 1 BP 131 EP 139 DI 10.1113/expphysiol.2009.049379 PG 9 WC Physiology SC Physiology GA 533PI UT WOS:000272836300017 PM 19700519 ER PT J AU McClung, JM DeRuisseau, KC Whidden, MA Van Remmen, H Richardson, A Song, W Vrabas, IS Powers, SK AF McClung, Joseph M. DeRuisseau, Keith C. Whidden, Melissa A. Van Remmen, Holly Richardson, Arlan Song, Wook Vrabas, Ioannis S. Powers, Scott K. TI Overexpression of antioxidant enzymes in diaphragm muscle does not alter contraction-induced fatigue or recovery SO EXPERIMENTAL PHYSIOLOGY LA English DT Article ID RAT SOLEUS MUSCLE; SKELETAL-MUSCLE; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; FORCE PRODUCTION; REACTIVE OXYGEN; TRANSGENIC MICE; VITAMIN-E; DYSFUNCTION; ATROPHY AB Low levels of reactive oxygen species (ROS) production are necessary to optimize muscle force production in unfatigued muscle. In contrast, sustained high levels of ROS production have been linked to impaired muscle force production and contraction-induced skeletal muscle fatigue. Using genetically engineered mice, we tested the hypothesis that the independent transgenic overexpression of catalase (CAT), copper/zinc superoxide dismutase (CuZnSOD; SOD1) or manganese superoxide dismutase (MnSOD; SOD2) antioxidant enzymes would negatively affect force production in unfatigued diaphragm muscle but would delay the development of muscle fatigue and enhance force recovery after fatiguing contractions. Diaphragm muscle from wild-type littermates (WT) and from CAT, SOD1 and SOD2 overexpressing mice were subjected to an in vitro contractile protocol to investigate the force-frequency characteristics, the fatigue properties and the time course of recovery from fatigue. The CAT, SOD1 and SOD2 overexpressors produced less specific force (in N cm-2) at stimulation frequencies of 20-300 Hz and produced lower maximal tetanic force than WT littermates. The relative development of muscle fatigue and recovery from fatigue were not influenced by transgenic overexpression of any antioxidant enzyme. Morphologically, the mean cross-sectional area (in mu m2) of diaphragm myofibres expressing myosin heavy chain type IIA was decreased in both CAT and SOD2 transgenic animals, and the percentage of non-contractile tissue increased in diaphragms from all transgenic mice. In conclusion, our results do not support the hypothesis that overexpression of independent antioxidant enzymes protects diaphragm muscle from contraction-induced fatigue or improves recovery from fatigue. Moreover, our data are consistent with the concept that a basal level of ROS is important to optimize muscle force production, since transgenic overexpression of major cellular antioxidants is associated with contractile dysfunction. Finally, the transgenic overexpression of independent endogenous antioxidants alters diaphragm skeletal muscle morphology, and these changes may also contribute to the diminished specific force production observed in these animals. C1 [McClung, Joseph M.; Whidden, Melissa A.; Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA. [DeRuisseau, Keith C.] Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13244 USA. [Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Song, Wook] Seoul Natl Univ, Inst Sports Sci, Seoul 151742, South Korea. [Vrabas, Ioannis S.] Aristotle Univ Thessaloniki, Lab Exercise Physiol & Biochem, Dept Phys Educ & Sport Sci Serres, Thessaloniki, Greece. RP Powers, SK (reprint author), Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32608 USA. EM spowers@hhp.ufl.edu FU National Institutes of Health [RO1 HL072789] FX This work was supported by the National Institutes of Health (RO1 HL072789 to S.K.P.). NR 27 TC 14 Z9 15 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0958-0670 J9 EXP PHYSIOL JI Exp. Physiol. PD JAN 1 PY 2010 VL 95 IS 1 BP 222 EP 231 DI 10.1113/expphysiol.2009.049650 PG 10 WC Physiology SC Physiology GA 533PI UT WOS:000272836300026 PM 19783618 ER PT J AU Thompson, GR Lewis, JS AF Thompson, George R., III Lewis, James S., II TI Pharmacology and clinical use of voriconazole SO EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY LA English DT Review DE serum drug levels; therapeutic drug monitoring; voriconazole ID INFECTIOUS-DISEASES-SOCIETY; ACUTE MYELOID-LEUKEMIA; INVASIVE FUNGAL-INFECTIONS; AZOLE ANTIFUNGAL DRUGS; HEALTHY MALE-SUBJECTS; IN-VITRO ACTIVITIES; PRACTICE GUIDELINES; AMPHOTERICIN-B; ASPERGILLUS-FUMIGATUS; PHARMACOKINETIC INTERACTION AB Importance of the field. Voriconazole is an extended-spectrum triazole developed specifically to target Aspergillus spp. and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses. Areas covered in this review. This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent. An overview of therapeutic drug monitoring, drug-drug interactions and pivotal trials are also reviewed. What the reader will gain: The reader will gain further knowledge of the unique aspects of voriconazole compared to other currently available antifungal agents. Take home message: Voriconazole offers distinct advantages over several other antifungals. The side effect profile of voriconazole is unique compared to other triazole agents. Concern for drug-drug interactions due to a frequently shared common metabolic pathway has prompted heightened interest in the use of therapeutic drug monitoring for concerns of toxicity, drug-drug interactions and in attempts to ensure efficacy. These aspects as well as a review of important clinical information pertaining to voriconazole are discussed here. C1 [Thompson, George R., III; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Lewis, James S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX USA. [Thompson, George R., III] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thompsong2@uthscsa.edu NR 101 TC 15 Z9 15 U1 1 U2 10 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1742-5255 J9 EXPERT OPIN DRUG MET JI Expert Opin. Drug Metab. Toxicol. PD JAN PY 2010 VL 6 IS 1 BP 83 EP 94 DI 10.1517/17425250903463878 PG 12 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 546EB UT WOS:000273791600008 PM 19947892 ER PT J AU Smith, DJ AF Smith, Daniel J. TI Dental caries vaccines: prospects and concerns SO EXPERT REVIEW OF VACCINES LA English DT Editorial Material ID STREPTOCOCCUS-MUTANS; ANTIBODY C1 Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Smith, DJ (reprint author), Forsyth Inst, Dept Immunol, 140 Fenway, Boston, MA 02115 USA. EM dsmith@forsyth.org FU FIC NIH HHS [TW-06324]; NIAID NIH HHS [DE/AI-123434]; NIDCR NIH HHS [DE-04733, DE-06153] NR 11 TC 5 Z9 7 U1 2 U2 14 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD JAN PY 2010 VL 9 IS 1 BP 1 EP 3 DI 10.1586/ERV.09.143 PG 3 WC Immunology SC Immunology GA 544JA UT WOS:000273650800001 PM 20021297 ER PT J AU Nadel, AS AF Nadel, Allan S. TI Addition of Color Doppler to the Routine Obstetric Sonographic Survey Aids in the Detection of Pulmonic Stenosis SO FETAL DIAGNOSIS AND THERAPY LA English DT Article DE Second trimester; Antenatal screening; Color Doppler ultrasonography; Congenital heart defect; Fetal heart; Prenatal screening; Prenatal ultrasonography ID CONGENITAL HEART-DISEASE; FETAL ECHOCARDIOGRAM AB Objective: Most fetuses with congenital heart disease (CHD) occur in women that are not at increased risk, and since it is impractical to perform detailed fetal echocardiography on everyone, detection of CHD relies mainly on routine second trimester fetal anatomic surveys. We therefore attempted to improve the detection rate of CHD at the time of routine second trimester obstetrical sonography in low-risk patients. Methods: This was a retrospective review of an 18-month period in which color Doppler was added to the standard grey scale evaluation of the fetal heart at the time of our routine second trimester anatomic surveys that we performed on fetuses at low risk for CHD. Cases in which CHD was suspected were reviewed with special attention to those in which abnormalities on color Doppler were the primary finding. Results: CHD was suspected in 17 of 1,766 (1%) routine fetal anatomic surveys that we performed between 16 and 22 weeks. There were 13 cases with findings on grey scale, and 4 cases (24%) that relied on findings with color Doppler, as the grey scale evaluation was normal or near normal. Of these 4 cases, 3 had critical pulmonic stenosis requiring balloon valvuloplasty shortly after birth; the fourth case had a mildly dysplastic pulmonic valve that did not require intervention in the immediate newborn period. Conclusions: The addition of color Doppler evaluation of the fetal heart to routine obstetrical sonographic structural surveys in low-risk patients aids in the detection of pulmonic stenosis. Copyright (C) 2010 S. Karger AG, Basel C1 Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA. RP Nadel, AS (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Founders 4,55 Fruit St, Boston, MA 02115 USA. EM anadel@partners.org NR 13 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-3837 J9 FETAL DIAGN THER JI Fetal Diagn. Ther. PY 2010 VL 28 IS 3 BP 175 EP 179 DI 10.1159/000318192 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 671YA UT WOS:000283549000007 PM 20720393 ER PT J AU McGoldrick, T AF McGoldrick, Tom BE Harris, A Botticelli, S TI Where is the "post" in posttraumatic stress disorder? First impressions working with Iraq and Afghanistan soldiers SO FIRST DO NO HARM: PARADOXICAL ENCOUNTERS OF PSYCHOANALYSIS, WARMAKING, AND RESISTANCE SE Relational Perspectives Book Series LA English DT Article; Book Chapter C1 [McGoldrick, Tom] NYU, Postdoctoral Program Psychotherapy & Psychoanal, New York, NY 10003 USA. [McGoldrick, Tom] US Dept Vet Affairs, Readjustment Counseling Serv Ctr, Staten Isl, NY USA. RP McGoldrick, T (reprint author), NYU, Postdoctoral Program Psychotherapy & Psychoanal, New York, NY 10003 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-1-13584-296-3 J9 RELAT PERSPECT BOOK PY 2010 VL 45 BP 3 EP 14 PG 12 WC Psychology, Psychoanalysis SC Psychology GA BVZ64 UT WOS:000293214200003 ER PT B AU Stufflebeam, SM AF Stufflebeam, Steven M. BE Ulmer, S Jansen, O TI Clinical Magnetoencephalography and fMRI SO FMRI: BASICS AND CLINICAL APPLICATIONS LA English DT Article; Book Chapter ID EVOKED MAGNETIC-FIELDS; IMAGE-GUIDED NEUROSURGERY; SUPPLEMENTARY MOTOR AREA; LANGUAGE-SPECIFIC CORTEX; BRAIN-TUMORS; HEMISPHERIC DOMINANCE; SOMATOSENSORY CORTEX; CORTICAL ACTIVITY; MEG; LOCALIZATION C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. RP Stufflebeam, SM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, MIT,Athinoula A Martinos Ctr Biomed Imaging, 149 13th St 2301, Boston, MA 02129 USA. EM sms@nmr.mgh.harvard.edu NR 63 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-68131-1 PY 2010 BP 169 EP 178 DI 10.1007/978-3-540-68132-8_17 D2 10.1007/978-3-540-68132-8 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BML93 UT WOS:000272757000017 ER PT J AU McNeil, MR Katz, WF Fossett, TRD Garst, DM Szuminsky, NJ Carter, G Lim, KY AF McNeil, M. R. Katz, W. F. Fossett, T. R. D. Garst, D. M. Szuminsky, N. J. Carter, G. Lim, K. Y. TI Effects of Online Augmented Kinematic and Perceptual Feedback on Treatment of Speech Movements in Apraxia of Speech SO FOLIA PHONIATRICA ET LOGOPAEDICA LA English DT Article DE Apraxia of speech; Augmented feedback; Kinematic feedback; Perceptual feedback ID CONCURRENT; APHASIA AB Apraxia of speech (AOS) is a motor speech disorder characterized by disturbed spatial and temporal parameters of movement. Research on motor learning suggests that augmented feedback may provide a beneficial effect for training movement. This study examined the effects of the presence and frequency of online augmented visual kinematic feedback (AVKF) and clinician-provided perceptual feedback on speech accuracy in 2 adults with acquired AOS. Within a single-subject multiple-baseline design, AVKF was provided using electromagnetic midsagittal articulography (EMA) in 2 feedback conditions (50 or 100%). Articulator placement was specified for speech motor targets (SMTs). Treated and base-lined SMTs were in the initial or final position of single-syllable words, in varying consonant-vowel or vowel-con sonant contexts. SMTs were selected based on each participant's pre-assessed erred productions. Productions were digitally recorded and online perceptual judgments of accuracy (including segment and intersegment distortions) were made. Inter-and intra-judge reliability for perceptual accuracy was high. Results measured by visual inspection and effect size revealed positive acquisition and generalization effects for both participants. Generalization occurred across vowel contexts and to untreated probes. Results of the frequency manipulation were confounded by presentation order. Maintenance of learned and generalized effects were demonstrated for 1 participant. These data provide support for the role of augmented feedback in treating speech movements that result in perceptually accurate speech production. Future investigations will explore the independent contributions of each feedback type (i.e. kinematic and perceptual) in producing efficient and effective training of SMTs in persons with AOS. Copyright (C) 2010 S. Karger AG, Basel C1 [McNeil, M. R.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [McNeil, M. R.; Fossett, T. R. D.; Szuminsky, N. J.; Lim, K. Y.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Katz, W. F.; Garst, D. M.] Univ Texas Dallas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA. [Katz, W. F.; Garst, D. M.; Carter, G.] Dallas Vet Adm Med Ctr, Dallas, TX USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM mcneil@pitt.edu RI Mansourzadeh, Mohammad Javad/H-5779-2011 FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [B3670R] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service: Award #B3670R to Malcolm R. McNeil. NR 14 TC 8 Z9 9 U1 1 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7762 J9 FOLIA PHONIATR LOGO JI Folia Phoniatr. Logop. PY 2010 VL 62 IS 3 BP 127 EP 133 DI 10.1159/000287211 PG 7 WC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation SC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation GA 633QM UT WOS:000280519000007 PM 20424468 ER PT J AU Bhattacharya, A Jernigan, AL Sabia, M Li, Y Qi, WB Van Remmen, H AF Bhattacharya, Arunabh Jernigan, Amanda Leigh Sabia, Marian Li, Yan Qi, Wenbo Van Remmen, Holly TI Role of 12/15-lipoxygenase Pathway in Muscle Atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Bhattacharya, Arunabh; Jernigan, Amanda Leigh; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA. [Sabia, Marian; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S77 EP S77 DI 10.1016/j.freeradbiomed.2010.10.189 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000206 ER PT J AU Chaiswing, L Zhong, WX Oberley, T AF Chaiswing, Luksana Zhong, Weixiong Oberley, Terry TI Regulation of Prostate Cancer Cell Invasion via Modulation of Extracellular CyS/CySS Redox Couple SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry] Univ Wisconsin, Madison, WI 53706 USA. [Zhong, Weixiong; Oberley, Terry] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S57 EP S57 DI 10.1016/j.freeradbiomed.2010.10.129 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000147 ER PT J AU Hobai, IA Weiss, E Armoundas, A Buys, E Siwik, D Brouckaert, P Colucci, WS AF Hobai, Ion A. Weiss, Eric Armoundas, Antonis Buys, Emmanuel Siwik, Deborah Brouckaert, Peter Colucci, Wilson S. TI Beyond Nitric Oxide: cGMP-Independent Inhibition of Cardiac L-type Calcium Channels and SERCA Transport in Endotoxemic Mice SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Hobai, Ion A.; Armoundas, Antonis; Buys, Emmanuel] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hobai, Ion A.; Siwik, Deborah; Colucci, Wilson S.] Boston Univ, Med Ctr, Boston, MA 02215 USA. [Weiss, Eric] MIT, Boston, MA USA. [Brouckaert, Peter] Flanders Inst Biotechnol, Ghent, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S22 EP S23 DI 10.1016/j.freeradbiomed.2010.10.029 PG 2 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000050 ER PT J AU Mashmoushi, AK Hofbauer, AF Gilkeson, GS Oates, JC AF Mashmoushi, Ahmad K. Hofbauer, Ann F. Gilkeson, Gary S. Oates, Jim C. TI Podocytes: A Potential Source of Nitric Oxide Production in Murine Lupus Nephritis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Mashmoushi, Ahmad K.; Hofbauer, Ann F.; Gilkeson, Gary S.; Oates, Jim C.] Med Univ S Carolina, Charleston, SC USA. [Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S145 EP S145 DI 10.1016/j.freeradbiomed.2010.10.406 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000418 ER PT J AU Salmon, A Styskal, J Musi, N Levine, R Richardson, A AF Salmon, Adam Styskal, JennaLynn Musi, Nicolas Levine, Rodney Richardson, Arlan TI Obesity-induced Insulin Resistance is Regulated by Methionine Sulfoxide Reductase SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Salmon, Adam; Styskal, JennaLynn; Musi, Nicolas; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Musi, Nicolas; Richardson, Arlan] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Levine, Rodney] NHLBI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S41 EP S41 DI 10.1016/j.freeradbiomed.2010.10.085 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000105 ER PT S AU Blevins, JE Baskin, DG AF Blevins, James E. Baskin, Denis G. BE Langhans, W Geary, N TI Hypothalamic-Brainstem Circuits Controlling Eating SO FRONTIERS IN EATING AND WEIGHT REGULATION SE Forum of Nutrition LA English DT Article; Book Chapter ID C-FOS EXPRESSION; CORTICOTROPIN-RELEASING HORMONE; CONDITIONED TASTE-AVERSION; NERVOUS-SYSTEM CONTROL; PARAVENTRICULAR NUCLEUS; FOOD-INTAKE; PARABRACHIAL NUCLEUS; LEPTIN RECEPTOR; CATECHOLAMINERGIC NEURONS; LATERAL HYPOTHALAMUS AB It is now axiomatic that neurons in the hypothalamic arcuate nucleus have a primary role in responding to changes in circulating levels of leptin and transmitting signals to downstream circuits that influence eating and energy expenditure. Signals generated from the gastrointestinal tract during meals reach the brainstem, via the vagus nerve and other routes, and impinge on neural circuits that influence the timing and size of meals and amount of food consumed. One of the mechanisms by which leptin exerts its anorexic effects is by increasing the effectiveness of intestinal signals that cause satiation during a meal. It is clear that the effects of gut satiation signals such as CCK can be amplified by leptin acting in the CNS, and in the arcuate nucleus in particular. The present article describes the state of our knowledge about specific neural circuits between the hypothalamus and brainstem that play a role in the interaction of leptin and meal-control signals to control food intake. Copyright (C) 2010 S. Karger AG, Basel C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Blevins, James E.; Baskin, Denis G.] Univ Washington, Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Baskin, Denis G.] Dept Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA 98108 USA. RP Baskin, DG (reprint author), Dept Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Mail Stop S-151,1660 S Columbian Way, Seattle, WA 98108 USA. EM baskindg@uw.edu FU NIDDK NIH HHS [P30 DK-17047] NR 54 TC 43 Z9 43 U1 0 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-0347 BN 978-3-8055-9300-7 J9 FORUM NUTR JI Forum Nutr. PY 2010 VL 63 BP 133 EP 140 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BMQ74 UT WOS:000273355700011 PM 19955781 ER PT J AU Mathalon, DH Hoffman, RE Watson, TD Miller, RM Roach, BJ Ford, JM AF Mathalon, Daniel H. Hoffman, Ralph E. Watson, Todd D. Miller, Ryan M. Roach, Brian J. Ford, Judith M. TI Neurophysiological distinction between schizophrenia and schizoaffective disorder SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Article DE schizophrenia; schizoaffective disorder; event-related potential; P300; EEG ID CYCLOID PSYCHOSES; P300 AMPLITUDE; DUAL-TASK; CLASSIFICATION; PERFORMANCE; TOPOGRAPHY; REDUCTION; DIAGNOSIS; VALIDITY; FEATURES AB Schizoaffective disorder (SA) is distinguished from schizophrenia (SZ) based on the presence of prominent mood symptoms over the illness course. Despite this clinical distinction, SA and SZ patients are often combined in research studies, in part because data supporting a distinct pathophysiological boundary between the disorders are lacking. Indeed, few studies have addressed whether neurobiological abnormalities associated with SZ, such as the widely replicated reduction and delay of the P300 event-related potential (ERP), are also present in SA. Scalp EEG was acquired from patients with DSM-IV SA (n = 15) or SZ (n = 22), as well as healthy controls (HC; n = 22) to assess the P300 elicited by infrequent target (15%) and task-irrelevant distractor (15%) stimuli in separate auditory and visual "oddball" tasks. P300 amplitude was reduced and delayed in SZ, relative to HC, consistent with prior studies. These SZ abnormalities did not interact with stimulus type (target vs. task-irrelevant distractor) or modality (auditory vs. visual). Across sensory modality and stimulus type, SA patients exhibited normal P300 amplitudes (significantly larger than SZ patients and indistinguishable from HC). However, P300 latency and reaction time were both equivalently delayed in SZ and SA patients, relative to HC. P300 differences between SA and SZ patients could not be accounted for by variation in symptom severity, socio-economic status, education, or illness duration. Although both groups show similar deficits in processing speed, SA patients do not exhibit the P300 amplitude deficits evident in SZ, consistent with an underlying pathophysiological boundary between these disorders. C1 [Mathalon, Daniel H.; Miller, Ryan M.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Mathalon, Daniel H.; Miller, Ryan M.; Roach, Brian J.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Hoffman, Ralph E.; Ford, Judith M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Watson, Todd D.] Lewis & Clark Coll, Dept Psychol, Portland, OR 97219 USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Roach, Brian/0000-0002-3264-1465 FU VA Schizophrenia Biological Research Center; VA Merit Review and Research Career Development Award; National Institute of Mental Health [MH 40052, MH 58262, MH 67967]; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) FX This work was supported by the VA Schizophrenia Biological Research Center and VA Merit Review and Research Career Development Award, and grants from National Institute of Mental Health (MH 40052, MH 58262, MH 67967), and the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 45 TC 26 Z9 26 U1 2 U2 9 PU FRONTIERS RES FOUND PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD JAN PY 2010 VL 3 AR 70 DI 10.3389/neuro.09.070.2009 PG 10 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 556UW UT WOS:000274619800007 PM 20140266 ER PT J AU de Gelder, B AF de Gelder, Beatrice TI The grand challenge for Frontiers in Emotion Science SO FRONTIERS IN PSYCHOLOGY LA English DT Editorial Material C1 [de Gelder, Beatrice] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [de Gelder, Beatrice] Harvard Univ, Sch Med, Charlestown, MA USA. [de Gelder, Beatrice] Tilburg Univ, Cognit & Affect Neurosci Lab, NL-5000 LE Tilburg, Netherlands. RP de Gelder, B (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM degelder@uvt.nl NR 27 TC 1 Z9 1 U1 0 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PY 2010 VL 1 AR 187 DI 10.3389/fpsyg.2010.00187 PG 4 WC Psychology, Multidisciplinary SC Psychology GA V30XQ UT WOS:000208849100084 PM 21833247 ER PT J AU Hoang, MP Mahalingam, M Selim, MA AF Hoang, Mai P. Mahalingam, Meera Selim, M. Angelica TI Immunohistochemistry in the diagnosis of cutaneous neoplasms SO FUTURE ONCOLOGY LA English DT Review DE adnexal neoplasm; cutaneous neoplasm; dermatopathology; histiocytic neoplasm; immunohistochemistry; lymphoid neoplasm; melanocytic neoplasms; spindle cell neoplasms ID B-CELL LYMPHOMA; DISEASE FLUID PROTEIN-15; PARAFFIN-EMBEDDED TISSUE; MICROPHTHALMIA TRANSCRIPTION FACTOR; MALIGNANT MELANOCYTIC LESIONS; MICROCYSTIC ADNEXAL CARCINOMA; FACTOR-XIIIA IMMUNOREACTIVITY; PLASMACYTOID DENDRITIC CELLS; METASTATIC BREAST-CARCINOMA; CYTOKERATIN 20 EXPRESSION AB In recent years, there has been a significant increase in the number of diagnostic immunohistochemical stains available to pathologists and dermatopathologists. Immunohistochemistry has become an indispensable tool in dermatopathology, not only in diagnosis but also in the treatment and prognostication of cutaneous neoplasms. In this review we attempt to outline current, as well as new, immunohistochemical stains of relevance in the diagnosis and classification of cutaneous neoplasms. C1 [Hoang, Mai P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Mahalingam, Meera] Boston Univ, Sch Med, Boston, MA 02118 USA. [Selim, M. Angelica] Duke Univ, Med Ctr, Durham, NC USA. RP Hoang, MP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Warren 820, Boston, MA 02114 USA. EM mhoang@partners.org NR 173 TC 3 Z9 3 U1 0 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1479-6694 J9 FUTURE ONCOL JI Future Oncol. PD JAN PY 2010 VL 6 IS 1 BP 93 EP 109 DI 10.2217/fon.09.143 PG 17 WC Oncology SC Oncology GA 544EJ UT WOS:000273635000014 PM 20021211 ER PT J AU Ghany, MG Lok, ASF Everhart, JE Everson, GT Lee, WM Curto, TM Wright, EC Stoddard, AM Sterling, RK Di Bisceglie, AM Bonkovsky, HL Morishima, C Morgan, TR Dienstag, JL AF Ghany, Marc G. Lok, Anna S. F. Everhart, James E. Everson, Gregory T. Lee, William M. Curto, Teresa M. Wright, Elizabeth C. Stoddard, Anne M. Sterling, Richard K. Di Bisceglie, Adrian M. Bonkovsky, Herbert L. Morishima, Chihiro Morgan, Timothy R. Dienstag, Jules L. CA Halt C Trial Grp TI Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C SO GASTROENTEROLOGY LA English DT Article ID VIRUS-RELATED CIRRHOSIS; STAGE LIVER-DISEASE; INSULIN-RESISTANCE; NATURAL-HISTORY; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; FIBROSIS PROGRESSION; COMPENSATED CIRRHOSIS; RISK-FACTORS; STEATOSIS AB BACKGROUND & AIMS: Predictors of clinical outcomes and histologic progression among patients with chronic hepatitis C and advanced fibrosis are poorly defined. We developed statistical models to predict clinical and histologic outcomes in such patients. METHODS: Baseline demographic, clinical, and histologic data from Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial participants were Subjected to multivariate analyses to determine their ability to predict clinical outcomes (ascites, spontaneous bacterial peritonitis, Child-Turcotte-Pugh score >= 7 on 2 consecutive visits, variceal bleeding, hepatic encephalopathy, and liver-related death) and histologic outcome (>= 2-point increase in Ishak fibrosis stage) during the 33 years of the trial. RESULTS: of 1050 randomized patients, 135 had 1 or more clinical Outcomes a median of 23 (range, 1-45) months after randomization. Factors associated with a clinical outcome in multivariate analyses were higher aspartate aminotransferase/alanine aminotransferase ratio, lower albumin, lower platelet Count, higher total bilirubin, and more advanced Ishak fibrosis score (P < .0001). The Cumulative 3.5-year incidence of a clinical outcome was 2% in the lowest and 65% in the highest risk group. OF 547 patients without cirrhosis at baseline and at least 1 follow-up biopsy, 152 had a histologic outcome. Independent variables associated with a histologic Outcome were higher body mass index, lower platelet count, and greater hepatic steatosis (P < .0001). CONCLUSIONS: In patients with chronic hepatitis C and advanced fibrosis, risk of clinical complications and fibrosis progression during 3.5 years can be predicted using baseline laboratory tests and histologic data. Our models may be useful in counseling patients and determining the frequency of monitoring. C1 [Ghany, Marc G.] NIDDK, LDB, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Lok, Anna S. F.] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI USA. [Everhart, James E.] NIDDK, Div Digest Dis & Nutr, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Everson, Gregory T.] Univ Colorado, Sch Med, Div Gastroenterol & Hepatol, Sect Hepatol, Denver, CO USA. [Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Curto, Teresa M.; Stoddard, Anne M.] New England Res Inst, Watertown, MA 02172 USA. [Wright, Elizabeth C.] NIDDK, Off Director, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Sterling, Richard K.] Virginia Commonwealth Univ, Hepatol Sect, Med Ctr, Richmond, VA USA. [Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Mol & Struct Biol, Farmington, CT USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Farmington, CT USA. [Morishima, Chihiro] Univ Washington, Dept Lab Med, Div Virol, Seattle, WA 98195 USA. [Morgan, Timothy R.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA. [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Gastroenterol Serv, Long Beach, CA USA. [Dienstag, Jules L.] Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA. [Dienstag, Jules L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Ghany, MG (reprint author), NIDDK, LDB, NIH, US Dept HHS, Bldg 10,Room 9B-16,10 Ctr Dr,MSC 1800, Bethesda, MD 20892 USA. EM marcg@intra.niddk.nih.gov OI Yang, Shuman/0000-0002-9638-0890 FU University of Massachusetts Medical Center, Worcester, Massachusetts [N01-DK-9-2326]; University of Connecticut Health Center, Farmington, Connecticut [M01RR-06192]; St. Louis University School of Medicine, St. Louis, Missouri [N01-DK-9-2324]; Massachusetts General Hospital, Boston, Massachusetts [N01-DK-9-2319, M01RR-01066, UL1 RR025758-01] FX In addition to the authors of this manuscript, the following individuals were instrumental in the planning, conduct, and/or care of patients enrolled in this study at each of the participating institutions as follows:; University of Massachusetts Medical Center, Worcester, Massachusetts: (contract N01-DK-9-2326) Gyongyl Szabo, MD; Barbara F. Banner, MD; Maureen Cormier, RN; Donna Giansiracusa, RN.; University of Connecticut Health Center, Farmington, Connecticut: (grant M01RR-06192) Gloria Borders, RN; Michelle Kelley, RN, ANP. St. Louis University School of Medicine, St. Louis, Missouri:; St. Louis University School of Medicine, St. Louis, Missouri: (contract N01-DK-9-2324) Bruce Bacon, MD; Brent Neuschwander-Tetri, MD; Debra King, RN.; Massachusetts General Hospital, Boston, Massachusetts: (contract N01-DK-9-2319, grant M01RR-01066; grant I UL1 RR025758-01, Harvard Clinical and Translational Science Center) Raymond T. Chung, MD; Andrea E. Reid, MD; Atul K. Bhan, MD; Wallis A. Molchen, Cara C. Gooch.; University of Colorado School of Medicine, Denver, Colorado: (contract N01-DK-9-2327, grant M01RR-00051, grant 1 UL1 RR 025780-01) S. Russell Nash, MD; Jennifer DeSanto, RN; Carol McKinley, RN. University of California-Irvine, Irvine, California: (contract NO1-DK9-2320, grant M01RR-00827) John C. Hoefs, MD; John R. Craig, MD; M. Mazen Jamal, MD, MPH; Muhammad Sheikh, MD, Choon Park, RN. University of Texas Southwestern Medical Center, Dallas, Texas: (contract N01-DK-9-2321, grant MOIRR-00633, grant I UL1 RR024982-01, North and Central Texas Clinical and Translational Science Initiative) Thomas E. Rogers, MD; Janel Shelton, Nicole Crowder, LVN; Rivka Elbein, RN, BSN; Nancy Liston, MPH. University of Southern California, Los Angeles, California: (contract NOI-DK-9-2325, grant M01RR-00043) Karen L. Lindsay, MD, MMM; Sugantha Govindarajan, MD; Carol B. Jones, RN; Susan L. Milstein, RN. University of Michigan Medical Center, Ann Arbor, Michigan: (contract N01-DK-9-2323, grant MOIRR-00042, grant 1 ULI RR024986, Michigan Center for Clinical and Health Research) Robert J. Fontana, MD; Joel K. Greenson, MD; Pamela A. Richtmyer, LPN, CCRC; R. Tess Bonham, BS. Virginia Commonwealth University Health System, Richmond, Virginia: (contract N01-DK-9-2322, grant M01RR-00065) Mitchell L. Shiffman, MD; Melissa J. Contos, MD; A. Scott Mills, MD; Charlotte Hofmann, RN; Paula Smith, RN. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland: T. Jake Liang, MD; David Weiner, MD, PhD; Yoon Park, RN; Elenita Rivera, RN; Vanessa Haynes-Williams, RN. National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, Maryland: Leonard B. Seeff, MD; Patricia R. Robuck, PhD; Jay H. Hoofnagle, MD. University of Washington, Seattle, Washington: (contract N01-DK9-2318) David R. Gretch, MD, PhD; Minjun Chung Apodaca, BS, ASCP; Rohit Shankar, BC, ASCP; Natalia Antonov, MEd. New England Research Institutes, Watertown, Massachusetts: (contract NOI-DK-9-2328) Kristin K. Snow, MSc, ScD; Linda J. Massey; Deepa Naishadham, MA, MS. Armed Forces Institute of Pathology, Washington, DC: Zachary D. Goodman, MD. Data and Safety Monitoring board members: (chair) Gary L. Davis, MD; Guadalupe Garcia-Tsao, MD; Michael Kutner, PhD; Stanley M. Lemon, MD; Robert P. Perrillo, MD. H.L.B.'s current address is Carolinas Medical Center, Charlotte, North Carolina. This is publication number 40 from the HALT-C Trial Group. The HALT-C Trial was registered with clinicaltrials.gov (No. NCTO0006164). Conflicts of interest The authors disclose the following: financial relationships of the authors with Hoffmann-La Roche, Inc, are as follows: A. S. F. Lok is a consultant; G. T. Everson is a consultant, on the speaker's bureau, and receives research support; W. M. Lee receives research support; R. K. Sterling is consultant, on the speaker's bureau, and receives research support; A.M. Di Bisceglie is a consultant, on the speaker's bureau, and receives research support; H. L. Bonkovsky receives research support; and T. R. Morgan is a consultant, on the speaker's bureau, and receives research support. The remaining authors disclose no conflicts. In addition, many of the HALT-C Trial investigators have other associations with industry relating to the area of hepatitis C, and, to achieve the highest level of disclosure, we list these for you as well. A. S. F.; Lok: Schering-Plough Corporation, consultant and receives research support; Vertex Pharmaceuticals, consultant; denix Pharmaceuticals, receives research support; Eisai Pharmaceuticals, receives research support. G. T. Everson: receives research support from Schering-Plough, Pharmasset, Globelmmune, Source, Novartis/ Human Genome Sciences, and GlaxoSmithKline and is a consultant and receives research support from Vertex Pharmaceuticals. W. M. Lee: receives research support from Aegerion, Globelmmune, Orasure, Schering-Plough, Siemens Diagnostics, and Vertex Pharmaceuticals. A.M. Stoddard: equity interest in Johnson & Johnson, Procter & Gamble, Bristol-Myers Squibb, and Elan. R. K. Sterling: consultant and on the speaker's bureau for Schering-Plough; is on an advisory board for Vertex Pharmaceuticals; and is a consultant and receives research support from Wako Chemicals USA. A. M. Di Bisceglie: consultant, on the speaker's bureau, and receives research support from Idenix Pharmaceuticals; is a consultant for Schering-Plough, Novartis, Bristol-Myers Squibb, and Abbott; is a consultant and receives research support from Vertex Pharmaceuticals, Anadys, Globelmmune, Pharmasset, Scl-Clone, Gilead Sciences, and Novartis. H. L. Bonkovsky: serves on a data monitoring and safety committee for Glaxo Smith Kline; served as a paid consultant for Boehringer-Ingelheim and Infacare Pharmaceuticals receives research support from Merck; consultant and receives research support from Novartis Pharmaceuticals; consultant and on speaker's bureau for Ovation, Inc; receives research support from ScheringPlough Corporation; receives research support from Vertex Pharmaceuticals. T. R. Morgan: is on the speaker's bureau and receives research support from Schering-Plough and is a consultant and receives research support from Vertex Pharmaceuticals. J. L. Dienstag: receives research support from Vertex Pharmaceuticals; serves on a Data Monitoring Committee for Schering-Plough Research Institute and Human Genome Sciences; and is on ad hoc hepatitis advisory board for Boehringer-Ingelheim. Funding Supported by the National Institute of Diabetes and Digestive and Kidney Diseases (contract numbers are listed below) and the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health Disparities, and by General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed below). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Additional funding to conduct this study was supplied by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health. NR 38 TC 55 Z9 56 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD JAN PY 2010 VL 138 IS 1 BP 136 EP 146 DI 10.1053/j.gastro.2009.09.007 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 541PA UT WOS:000273427700024 PM 19766643 ER PT J AU Kang, D Suter, MJ Boudoux, C Yoo, H Yachimski, PS Puricelli, WP Nishioka, NS Mino-Kenudson, M Lauwers, GY Bouma, BE Tearney, GJ AF Kang, DongKyun Suter, Melissa J. Boudoux, Caroline Yoo, Hongki Yachimski, Patrick S. Puricelli, William P. Nishioka, Norman S. Mino-Kenudson, Mari Lauwers, Gregory Y. Bouma, Brett E. Tearney, Guillermo J. TI Comprehensive imaging of gastroesophageal biopsy samples by spectrally encoded confocal microscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID BARRETTS-ESOPHAGUS; IN-VIVO; ACETIC-ACID; LASER MICROSCOPY; HISTOLOGY; IMAGES; ENDOMICROSCOPY; COMPENSATION; ENDOSCOPY; NEOPLASIA AB Background: Spectrally encoded confocal microscopy (SECM) is a high-speed reflectance confocal microscopy technique that has the potential to be used for acquiring comprehensive images of the entire distal esophagus endoscopically with subcellular resolution. Objective: The goal of this study was to demonstrate large-area SECM in upper G1 tissues and to determine whether the images contain microstructural information that is useful for pathologic diagnosis. Design: A feasibility study. Setting: Gastrointestibal unit, massachusetts general hospital Patients: Fifty biopsy samples from 36 patients undergoing routine egd were imaged by secm, in theirentirety, immediately after their removal Results: The microstructure seen in rhw secm images was similar to that seen by histopathology. gastric cardiamucosa was clearly differentiated from squamous mucosa. Gastric fundic/body type mucosa showed more tightly packed glands than gastric cardia mucosa. Fundic gland polyps showed cystrically dilated glands lined with cubo8idal epithelium. The presence of intraepithelial eosinophils was detected with the cells demonstrating a characteristic bilobed nucleus. Specialized intestinal metaplasia was identified by columnar epithelium and the presence of goblet cells. Barrett's esophagus (BE) with dysplasia was differentiated from specialized intestinal metaplasis by the loss of nuclear polarity and disorganized glandular architecture. Limitations: Ex vivo, descriptive study Conclusion: Large-area secm images of gastroesophageal biopsy samples enabled the visualization of both subcellular and architectural features of various upper gi mucosal types and were similar to the corresponding histopathologic slides. These results suggest that the development of an endoscopic secm probe is merited. (Gastrointest Endosc 2010;71:35-43.) C1 [Mino-Kenudson, Mari; Lauwers, Gregory Y.; Tearney, Guillermo J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kang, DongKyun; Suter, Melissa J.; Yoo, Hongki; Bouma, Brett E.; Tearney, Guillermo J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Kang, DongKyun; Suter, Melissa J.; Yoo, Hongki; Bouma, Brett E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Puricelli, William P.; Nishioka, Norman S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Boudoux, Caroline] Ecole Polytech, Dept Engn Phys, Montreal, PQ H3C 3A7, Canada. [Yachimski, Patrick S.] Vanderbilt Univ, Med Ctr, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA. RP Tearney, GJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, 40 Blossom St,BAR 703, Boston, MA 02114 USA. RI Boudoux, Caroline/A-6399-2012; Yoo, Hongki/B-6421-2013; Kang, Dongkyun/C-1085-2013 OI Yoo, Hongki/0000-0001-9819-3135; Kang, Dongkyun/0000-0001-5063-5387 FU National Insitutes of Health/National Cancer Institute [R21CA122161] FX This research was supported by National Insitutes of Health/National Cancer Institute (grant number R21CA122161). All authors disclosed no financial relationships relevant to this publication. NR 33 TC 22 Z9 22 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2010 VL 71 IS 1 BP 35 EP 43 DI 10.1016/j.gie.2009.08.026 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 545YF UT WOS:000273772400006 PM 19922916 ER PT J AU Turner, BG Cizginer, S Agarwal, D Yang, JY Pitman, MB Brugge, WR AF Turner, Brian G. Cizginer, Sevdenur Agarwal, Deepak Yang, Jingyun Pitman, Martha Bishop Brugge, William R. TI Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID FINE-NEEDLE-ASPIRATION; ENDOCRINE TUMORS; GUIDED FNA; BIOPSY; CANCER; MASSES; RESECTION; EXPERIENCE; CARCINOMA; SURVIVAL AB Background: EUS-guided FNA has the potential to provide diagnostic cytologic material from pancreatic lesions that are suspicious for Malignancy. Objective: To determine the operating characteristics of EUS-FNA in the diagnosis Of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms (PENs). Design: Retrospective analysis of a prospectively maintained database. Setting: Academic tertiary-care center. Patients: This study involved 559 patients undergoing evaluation of pancreatic masses Or diffuse pancreatic parenchymal abnormalities. Main Outcome Measurements: Performance characteristics of EUS-FNA of pancreatic adenocarcinoma and PEN. Results: From January 1997 to December 2005, 737 patients Undergoing initial EUS-FNA evaluation for a pancreatic mass were identified-In the final analysis, 559 patients with 560 FNA-sampled lesions were induced. Overall, 442 lesions were pancreatic adenocarcinoma, and 40 were PEN. The sensitivity of EUS-FNA in the diagnosis of pancreatic adenocarcinomas and PENs was 77% (95% CI, 72.8%-80.8%) and 68% (95% CI, 50.8%-80.9%), respectively T, using strict cytologic criteria. Reclassification of atypical and suspicious cytologies as diagnostic of malignancy resulted in a sensitivity of 93%, (95% Cl, 90.9%-99.7%) in adenocarcinoma and 80% (95% Cl, 63.9%-90.4%) in PEN. Tumor size, tumor location, and number of needle passes did not significantly influence diagnosis, but immediate cytologic evaluation was influential. Limitations: Retrospective analysis at a single center. Conclusions: In a large, well-controlled study, EUS-FNA was formed to be all accurate test (80%) for the detection of pancreatic adenocarcinoma by using aspiration cytology The accuracy of the examination is significantly improved (94%) when atypical and suspicious samples are considered positive. Finally, only 2 to 3 FNA passes rnay, be needed to achieve a good diagnostic yield. (Gastrointest Endose 2010-71:91-8.) C1 [Turner, Brian G.; Cizginer, Sevdenur; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Agarwal, Deepak] Univ Hosp Cleveland, Dept Gastroenterol, Cleveland, OH 44106 USA. [Yang, Jingyun] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Pitman, Martha Bishop] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Brugge, WR (reprint author), 55 Fruit St,Blake 4, Boston, MA 02114 USA. NR 41 TC 95 Z9 99 U1 1 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2010 VL 71 IS 1 BP 91 EP 98 DI 10.1016/j.gie.2009.06.017 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 545YF UT WOS:000273772400014 PM 19846087 ER PT J AU Turner, BG Gee, DW Cizginer, S Konuk, Y Karaca, C Willingham, F Mino-Kenudson, M Morse, C Rattner, DW Brugge, WR AF Turner, Brian G. Gee, Denise W. Cizginer, Sevdenur Konuk, Yusuf Karaca, Cetin Willingham, Field Mino-Kenudson, Mari Morse, Cliristopher Rattner, David W. Brugge, William R. TI Feasibility of endoscopic transesophageal thoracic sympathectomy SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID MEDIASTINOSCOPY; HYPERHIDROSIS; THORACOSCOPY AB Background: Thoracoscopic sympathectomy is the preferred surgical treatment for patients with disabling palmar hyperhidrosis. Current methods require a transthoracic approach to permit ablation of the thoracic sympathetic chain. Objective: To develop a minimally invasive, transesophageal endoscopic technique for a sympathectomy in a swine model. Design: Nonsurvival animal study. Setting: Animal trial at a tertiary care academic center. Subjects: This study involved 8 healthy Yorkshire swine. Interventions: After insertion of a double-channel gastroscope, a Duette Band mucosectomy device was used to create a small esophageal mucosal defect. A short, 5-cm submucosal tunnel was created by using the top of the endoscope and biopsy forceps. Within the submucosal space, a needle-knife was used to incise the muscular esophageal wall and permit entry into the mediastinum and chest. The sympathetic chain was identified at the desired thoracic level and was ablated or transected. The animals were killed at the completion of the procedure. Main Outcome Measurements: Feasibility of endoscopic transesophageal thoracic sympathectomy. Results: The sympathetic chain was successfully ablated in 7 of 8 swine, as confirmed by gross surgical pathology and histology. In 1 swine, muscle fibers were inadvertently transected. On average, the procedure took 61.4 +/- 24.5 minutes to gain access to the chest, whereas the sympathectomy was performed in less than 3 minutes in all cases. One animal was killed immediately after sympathectomy, before the completion of the observation period, because of hemodynamic instability. Limitations: Nonsurvival series, animal study. Conclusions: Endoscopic transesophageal thoracic sympathectomy is technically feasible, simple, and can be performed in a porcine model. C1 [Turner, Brian G.; Cizginer, Sevdenur; Karaca, Cetin; Willingham, Field; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Gee, Denise W.; Konuk, Yusuf; Morse, Cliristopher; Rattner, David W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Gastroenterol Unit, 55 Fruit St, Boston, MA 02114 USA. FU Center for Integration of Medicine and Innovative Technology FX This project was funded by the Center for Integration of Medicine and Innovative Technology. Dr Brugge disclosed a consultant relationship with Boston Scientific. All other authors disclosed no other financial relationships relevant to this publication. NR 9 TC 13 Z9 18 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD JAN PY 2010 VL 71 IS 1 BP 171 EP 175 DI 10.1016/j.gie.2009.07.016 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 545YF UT WOS:000273772400027 PM 19879572 ER PT J AU Sun, X Pawlyk, B Xu, X Liu, X Bulgakov, OV Adamian, M Sandberg, MA Khani, SC Tan, MH Smith, AJ Ali, RR Li, T AF Sun, X. Pawlyk, B. Xu, X. Liu, X. Bulgakov, O. V. Adamian, M. Sandberg, M. A. Khani, S. C. Tan, M-H Smith, A. J. Ali, R. R. Li, T. TI Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations SO GENE THERAPY LA English DT Article DE Leber's congenital amaurosis; retinal degeneration; PDE6; AIPL1 ID LEBER CONGENITAL AMAUROSIS; RETINITIS-PIGMENTOSA; CGMP PHOSPHODIESTERASE; MURINE MODEL; MOUSE MODEL; PHOTORECEPTORS; PROTEIN; VISION; DEGENERATION; BLINDNESS AB Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is required for the biosynthesis of photoreceptor phosphodiesterase (PDE). Gene defects in AIPL1 cause a heterogeneous set of conditions ranging from Leber's congenital amaurosis (LCA), the severest form of early-onset retinal degeneration, to milder forms such as retinitis pigmentosa (RP) and cone-rod dystrophy. In mice, null and hypomorphic alleles cause retinal degeneration similar to human LCA and RP, respectively. Thus these mouse models represent two ends of the disease spectrum associated with AIPL1 gene defects in humans. We evaluated whether adeno-associated virus (AAV)-mediated gene replacement therapy in these models could restore PDE biosynthesis in rods and cones and thereby improve photoreceptor survival. We validated the efficacy of human AIPL1 (isoform 1) replacement gene controlled by a promoter derived from the human rhodopsin kinase (RK) gene, which is active in both rods and cones. We found substantial and long-term rescue of the disease phenotype as a result of transgene expression. This is the first gene therapy study in which both rods and cones were targeted successfully with a single photoreceptor-specific promoter. We propose that the vector and construct design used in this study could serve as a prototype for a human clinical trial. Gene Therapy (2010) 17, 117-131; doi: 10.1038/gt.2009.104; published online 27 August 2009 C1 [Sun, X.; Pawlyk, B.; Xu, X.; Liu, X.; Bulgakov, O. V.; Adamian, M.; Sandberg, M. A.; Li, T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab,Study Retinal Regenerat, Boston, MA 02114 USA. [Khani, S. C.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Tan, M-H; Smith, A. J.; Ali, R. R.] UCL, NIHR Biomed Res Ctr, Inst Ophthalmol, Dept Genet, London, England. RP Li, T (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab,Study Retinal Regenerat, 243 Charles St, Boston, MA 02114 USA. EM tli@meei.harvard.edu RI Smith, Alexander/A-5142-2009 FU National Eye Institute [EY10581]; NEI [P30EY14104]; Foundation Fighting Blindness; Foundation for Retina Research; Macular Vision Research Foundation; Massachusetts Lions Eye Research Fund; European Union; UK Department of Health; National Institute of Health Research BMRC for Ophthalmology FX We thank Dr Michael Dyer (St Jude Children's Research Hospital, Memphis, TN, USA) for providing the Aipl1-/- mice, Dr Visvanathan Ramamurthy (West Virginia University, Morgantown, WV, SA) for human AIPL1 antiserum, Norman Michaud (Massachusetts Eye & Ear Histology Core) for a portion of the histology processing and Dr Jeng-Shin Lee (the Research Vector Core, Harvard Medical School) for AAV vector packaging. This work was supported by National Eye Institute Grant EY10581, NEI core grant for Vision Research (P30EY14104), the Foundation Fighting Blindness, the Foundation for Retina Research, the Macular Vision Research Foundation, the Massachusetts Lions Eye Research Fund and by grants from the European Union (AAVEYE), the UK Department of Health and National Institute of Health Research BMRC for Ophthalmology. NR 48 TC 64 Z9 65 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0969-7128 J9 GENE THER JI Gene Ther. PD JAN PY 2010 VL 17 IS 1 BP 117 EP 131 DI 10.1038/gt.2009.104 PG 15 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA 541IJ UT WOS:000273408200012 PM 19710705 ER PT J AU Bryan, C Songer, T Brooks, MM Rush, AJ Thase, ME Gaynes, B Balasubramani, GK Trivedi, MH Fava, M Wisniewski, SR AF Bryan, Charlene Songer, Thomas Brooks, Maria Mori Rush, A. John Thase, Michael E. Gaynes, Bradley Balasubramani, G. K. Trivedi, Madhukar H. Fava, Maurizio Wisniewski, Stephen R. TI The impact of diabetes on depression treatment outcomes SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Depression; Diabetes; Remission ID STAR-ASTERISK-D; PLACEBO-CONTROLLED TRIAL; DIAGNOSTIC SCREENING QUESTIONNAIRE; SEQUENCED TREATMENT ALTERNATIVES; CHRONIC MEDICAL ILLNESS; MEASUREMENT-BASED CARE; REPORT QIDS-SR; MAJOR DEPRESSION; RATING-SCALE; DOUBLE-BLIND AB Background: Individuals with diabetes mellitus (DM) are two to four times more likely to be diagnosed with major depressive disorder (MDD). However, few controlled studies have examined the impact of DM on the treatment of MDD. Understanding the effect of DM on depressed patients could provide valuable clinical information toward adjusting current treatment modalities to produce a more effective treatment for depressed patients with DM. Methods: This study was conducted using an evaluable sample of 2876 outpatient participants enrolled in the Sequenced Treatment Alternatives to Relieve Depression study. Sociodemographic and clinical characteristics and treatment characteristics with the selective serotonin reuptake inhibitor (SSRI) citalopram, as well as remission rates for MDD and time to remission, were compared between participants with DM and participants without DM. Results: The odds of remission were lower in participants with DM than in those without DM prior to adjustment [odds ratio (OR)=0.68; 95% confidence interval (95% CI)=(0.49, 0.94); P=.0184]. These differences were no longer present after adjustment [OR=0.92; 95% CI= (0.64, 1.32); P=.6399]. Participants with DM reported fewer side effects than participants without DM despite similar dosing. Conclusions: Depressed patients with DM and depressed patients without DM appear to have similar rates of MDD remission, indicating that a diagnosis of DM per se has no impact on MDD remission. The findings of fewer side effects and psychiatric serious adverse events in participants with DM imply that depressed patients with DM may be excellent candidates for more aggressive SSRI dosing. This lower prevalence of side effects reported by depressed participants with DM warrants further exploration. (C) 2010 Elsevier Inc. All rights reserved. C1 [Brooks, Maria Mori; Balasubramani, G. K.; Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA 15260 USA. [Bryan, Charlene] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA. [Songer, Thomas] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Rush, A. John; Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Gaynes, Bradley] Univ N Carolina, Chapel Hill, NC USA. [Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Wisniewski, SR (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA 15260 USA. EM wisniew@edc.pitt.edu OI Wisniewski, Stephen/0000-0002-3877-9860; Songer, Thomas/0000-0002-5253-2514; Gaynes, Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382; Brooks, Maria/0000-0002-2030-7873; Goundappa K, Balasubramani/0000-0001-7221-1825 FU NIMH FX Funding for this work was provided by the NIMH. NR 44 TC 13 Z9 13 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2010 VL 32 IS 1 BP 33 EP 41 DI 10.1016/j.genhosppsych.2009.07.009 PG 9 WC Psychiatry SC Psychiatry GA 584OE UT WOS:000276761200005 PM 20114126 ER PT J AU Payami, H Kay, DM Zabetian, CP Schellenberg, GD Factor, SA McCulloch, CC AF Payami, Haydeh Kay, Denise M. Zabetian, Cyrus P. Schellenberg, Gerard D. Factor, Stewart A. McCulloch, Colin C. TI Visualizing Disease Associations: Graphic Analysis of Frequency Distributions as a Function of Age Using Moving Average Plots (MAP) with Application to Alzheimer's and Parkinson's Disease SO GENETIC EPIDEMIOLOGY LA English DT Article DE GWAS; MAPT; SNCA; APOE; coffee ID GENETIC ASSOCIATION; ALPHA-SYNUCLEIN; ONSET; RISK; METAANALYSIS; SMOKING; COFFEE AB Age-related variation in marker frequency can be a confounder in association studies, leading to both false-positive and false-negative findings and subsequently to inconsistent reproducibility. We have developed a simple method, based on a novel extension of moving average plots (MAP), which allows investigators to inspect the frequency data for hidden age-related variations. MAP uses the standard case-control association data and generates a birds-eye view of the frequency distributions across the age spectrum; a picture in which one can see if, how, and when the marker frequencies in cases differ from that in controls. The marker can be specified as an allele, genotype, haplotype, or environmental factor; and age can be age-at-onset, age when subject was last known to be unaffected, or duration of exposure. Signature patterns that emerge can help distinguish true disease associations from spurious associations due to age effects, age-varying associations from associations that are uniform across all ages, and associations with risk from associations with age-at-onset. Utility of MAP is illustrated by application to genetic and epidemiological association data for Alzheimer's and Parkinson's disease. MAP is intended as a descriptive method, to complement standard statistical techniques. Although originally developed for age patterns, MAP is equally useful for visualizing any quantitative trait. Genet. Epidemiol. 34:92-99, 2010. (c) 2009 Wiley-Liss, Inc. C1 [Payami, Haydeh; Kay, Denise M.] Wadsworth Ctr, New York State Dept Hlth, Genom Inst, Albany, NY 12201 USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Schellenberg, Gerard D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [McCulloch, Colin C.] Gen Elect Global Res Ctr, Appl Stat Lab, Niskayuna, NY USA. RP Payami, H (reprint author), Wadsworth Ctr, New York State Dept Hlth, Genom Inst, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU National Institute for Neurological Disorders and Stroke [R01NS36960, K08-NS044138]; Michael J. Fox Foundation Edmond J. Safra Global Genetics Consortia; VA MeritAwardNational Institute of Aging [P30AG 08017, U24AG021886, P50AG05136] FX Authors thank Drs. Tatiana Foroud, Donald Higgins, Jeffrey Kaye, Patricia Kramer, Eric Molho, John Nutt, and colleagues at NeuroGenetics Research Consortium, Layton Aging & Alzheimer's Disease Center, University of Washington Alzheimer's Disease Research Center, and the National Cell Repository for Alzheimer's Disease for contributing data for analysis. This study was funded by a grant from National Institute for Neurological Disorders and Stroke (R01NS36960 Payami). Data collection was funded by Michael J. Fox Foundation Edmond J. Safra Global Genetics Consortia grant (Payami); National Institute for Neurological Disorders and Stroke (R01NS36960 Payami, K08-NS044138 Zabetian); VA MeritAward (Zabetian); and National Institute of Aging (P30AG 08017 Kaye, U24AG021886 Foroud, P50AG05136 Schellenberg). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. NR 20 TC 3 Z9 3 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD JAN PY 2010 VL 34 IS 1 BP 92 EP 99 DI 10.1002/gepi.20439 PG 8 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 542RP UT WOS:000273513000012 PM 19582778 ER PT J AU Hekmat-Scafe, DS Mercado, A Fajilan, AA Lee, AW Hsu, R Mount, DB Tanouye, MA AF Hekmat-Scafe, Daria S. Mercado, Adriana Fajilan, Adriel A. Lee, Ann W. Hsu, Richard Mount, David B. Tanouye, Mark A. TI Seizure Sensitivity Is Ameliorated by Targeted Expression of K+-Cl- Cotransporter Function in the Mushroom Body of the Drosophila Brain SO GENETICS LA English DT Article ID CATION-CHLORIDE COTRANSPORTER; A RECEPTOR LOCUS; OLFACTORY MEMORY; MOLECULAR-BIOLOGY; ADULT BRAIN; GABA; GENE; NEURONS; MELANOGASTER; SYSTEM AB The kcc(DHS1) allele of kazachoc (kcc) was identified as a seizure-enhancer mutation exacerbating the bang-sensitive (BS) paralytic behavioral phenotypes of several seizure-sensitive Drosophila mutants. On their own, young kcc(DHS1) flies also display seizure-like behavior and demonstrate a reduced threshold for seizures induced by electroconvulsive shock. The product of kcc shows substantial homology to KCC2, the mammalian neuronal K+-Cl- cotransporter. The kcc(DHS1) allele is a hypomorph, and its seizure-like phenotype reflects reduced expression of the kcc gene. We report here that kcc functions as a K+-Cl- cotransporter when expressed heterologously in Xenopus laevis oocytes: under hypotonic conditions that induce oocyte swelling, oocytes that express Drosophila kcc display robust ion transport activity observed as a Cl--dependent uptake of the K+ congener Rb-86(+). Ectopic, spatially restricted expression of a UAS-kcc(+) transgene was used to determine where cotransporter function is required in order to rescue the kcc(DHS1) BS paralytic phenotype. Interestingly, phenotypic rescue is largely accounted for by targeted, circumscribed expression in the mushroom bodies (MBs) and the ellipsoid body (EB) of the central complex. Intriguingly, we observed that MB induction of kcc(+) functioned as a general seizure suppressor in Drosophila. Drosophila MBs have generated considerable interest especially for their role as the neural substrate for olfactory learning and memory; they have not been previously implicated in seizure susceptibility. We show that kcc(DHS1) seizure sensitivity in MB neurons acts via a weakening of chemical synaptic inhibition by GABAergic transmission and suggest that this is due to disruption of intracellular Cl- gradients in MB neurons. C1 [Hekmat-Scafe, Daria S.; Fajilan, Adriel A.; Tanouye, Mark A.] Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA. [Hekmat-Scafe, Daria S.; Tanouye, Mark A.] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Div Organisms & Environm, Berkeley, CA 94720 USA. [Lee, Ann W.] Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA. [Hsu, Richard] Univ Calif Berkeley, Div Genet & Dev, Berkeley, CA 94720 USA. [Mercado, Adriana; Mount, David B.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Mount, David B.] Harvard Univ, Sch Med, Div Renal, VA Boston Healthcare Syst, Boston, MA 02115 USA. RP Hekmat-Scafe, DS (reprint author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, 229 Stanley Hall, Berkeley, CA 94720 USA. EM dariahs@alum.mit.edu FU McKnight Foundation; National Institute of Neurological Disorders and Stroke [NS-31231, R01 DK57708]; Howard Hughes Medical Institute for undergraduate biological science majors at the University of California, Berkeley FX We are most grateful to Scott Waddell (University of Massachusetts Medical School), Julie Simpson (Janelia Farms), Gero Miesenboeck (Yale University), Christopher Tabone and J. Steven de Belle (University of Nevada, Las Vegas), Xu Liu and Ron Davis (Baylor University Medical College), Roland Strauss (University of Wuerzburg), Nara Muraro and Richard Baines (University of Manchester), Gautam Agarwal and Ehud Isacoff (University of California, Berkeley), the Bloomington Drosophila Stock Center, and the Vienna Drosophila RNAi Center for Drosophila stocks. Gautam Agarwal and Grant Kauwe provided helpful advice and assistance with the GFP imaging of Drosophila brains. This work was supported by grants from the McKnight Foundation and the National Institute of Neurological Disorders and Stroke (NS-31231) to M. T., by R01 DK57708 to D. M., and by a summer research grant to R. H. from the Biology Fellows Program, which is funded by the Howard Hughes Medical Institute for undergraduate biological science majors at the University of California, Berkeley. NR 64 TC 11 Z9 12 U1 1 U2 4 PU GENETICS SOC AM PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 J9 GENETICS JI Genetics PD JAN PY 2010 VL 184 IS 1 BP 171 EP 183 DI 10.1534/genetics.109.109074 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 649PH UT WOS:000281784000016 PM 19884312 ER PT J AU Weinreb, NJ Cappellini, MD Cox, TM Giannini, EH Grabowski, GA Hwu, WL Mankin, H Martins, AM Sawyer, C vom Dahl, S Yeh, MS Zimran, A AF Weinreb, Neal J. Cappellini, Maria D. Cox, Timothy M. Giannini, Edward H. Grabowski, Gregory A. Hwu, Wuh-Liang Mankin, Henry Martins, Ana Maria Sawyer, Carolyn vom Dahl, Stephan Yeh, Michael S. Zimran, Ari TI A validated disease severity scoring system for adults with type 1 Gaucher disease SO GENETICS IN MEDICINE LA English DT Article DE Gaucher disease; severity scoring; inherited metabolic disorders; DS3; acid beta-glucosidase ID LYSOSOMAL STORAGE DISEASES; CLINICAL-TRIALS; BONE INVOLVEMENT; RECOMMENDATIONS; CONSENSUS; IMIGLUCERASE; PREVALENCE; THERAPY AB Purpose: A validated disease severity scoring system (DS3) for Gaucher disease type 1 (GD1) is needed to standardize patient monitoring and to define patient cohorts in clinical studies. Methods: DS3 domains were established by an expert physician group using the nominal group technique of consensus formation. Items were selected by 36 GD1 physicians. The expert group determined appropriate measurement techniques for each item. Measurements were weighted considering contributions to GD1 morbidity and mortality. Consensus Clinical Global Impression Severity scores for sample cases were compared with average DS3 scores. A minimal clinically important difference in GD1 DS3 score was calculated. Results: The GD1 DS3 includes bone (42% of score), hematologic (32%), and visceral domains (26%); individual items use routine assessments, including medical history, blood chemistry, organ volume measurements, and bone evaluations (magnetic resonance imaging and dual x-ray absorptiometry). The maximum score is 19. Interrater reliability was 0.97 (Cohen's kappa). DS3 scores were highly correlated with Clinical Global Impression Severity scores (r(2) = 0.89). The minimal clinically important difference was -3.2 improvement and +3.9 deterioration. Conclusion: This DS3 accurately quantifies GD1 status and intrapatient change over time. Testing of reliability and validity will continue to allow eventual implementation of the DS3 in clinical studies and routine practice. Genet Med 2010:12(1):44-51. C1 [Weinreb, Neal J.] Univ Res Fdn Lysosomal Storage Disorders, Coral Springs, FL 33065 USA. [Cappellini, Maria D.] Univ Milan, Dept Internal Med, Milan, Italy. [Cox, Timothy M.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 1TN, England. [Giannini, Edward H.] Cincinnati Childrens Hosp, Ctr Med, Div Rheumatol, Cincinnati, OH USA. [Grabowski, Gregory A.] Cincinnati Childrens Hosp, Ctr Med, Div Human Genet, Cincinnati, OH USA. [Hwu, Wuh-Liang] Natl Taiwan Univ Hosp, Dept Pediat & Med Genet, Taipei, Taiwan. [Mankin, Henry] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Martins, Ana Maria] Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil. [Sawyer, Carolyn; Yeh, Michael S.] Genzyme Corp, Cambridge, MA USA. [vom Dahl, Stephan] St Franziskus Hosp, Innere Med Klin, Cologne, Germany. [Zimran, Ari] Shaare Zedek Med Ctr, Jerusalem, Israel. RP Weinreb, NJ (reprint author), Univ Res Fdn Lysosomal Storage Disorders, 8170 Royal Palm Blvd, Coral Springs, FL 33065 USA. EM boneal@winning.com OI HWU, WUH-LIANG/0000-0001-6690-4879; CAPPELLINI, MARIA DOMENICA/0000-0001-8676-6864 FU NIDDK NIH HHS [R01 DK036729] NR 26 TC 20 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD JAN PY 2010 VL 12 IS 1 BP 44 EP 51 DI 10.1097/GIM.0b013e3181c39194 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 549ZQ UT WOS:000274095300007 PM 20027115 ER PT J AU Boca, SM Kinzler, KW Velculescu, VE Vogelstein, B Parmigiani, G AF Boca, Simina M. Kinzler, Kenneth W. Velculescu, Victor E. Vogelstein, Bert Parmigiani, Giovanni TI Patient-oriented gene set analysis for cancer mutation data SO GENOME BIOLOGY LA English DT Article ID MYELOID-LEUKEMIA GENOME; COLORECTAL CANCERS; HUMAN BREAST; EXPRESSION; CONSENSUS; PATHWAYS AB Recent research has revealed complex heterogeneous genomic landscapes in human cancers. However, mutations tend to occur within a core group of pathways and biological processes that can be grouped into gene sets. To better understand the significance of these pathways, we have developed an approach that initially scores each gene set at the patient rather than the gene level. In mutation analysis, these patient-oriented methods are more transparent, interpretable, and statistically powerful than traditional gene-oriented methods. C1 [Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Boca, Simina M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA. [Kinzler, Kenneth W.; Velculescu, Victor E.; Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA. [Kinzler, Kenneth W.; Velculescu, Victor E.; Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA. [Parmigiani, Giovanni] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Parmigiani, G (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, 44 Binney St, Boston, MA 02115 USA. EM gp@jimmy.harvard.edu FU Virginia and D.K. Ludwig Fund for Cancer Research; NIH [CA43460, CA62924, CA121113, T32GM074906, T32MH019901]; NSF [DMS 1041698]; Johns Hopkins Sommer Scholar Program FX This work was supported by the Virginia and D.K. Ludwig Fund for Cancer Research, NIH grants CA43460, CA62924, CA121113, T32GM074906, and T32MH019901, NSF grant DMS 1041698, and the Johns Hopkins Sommer Scholar Program. The authors also acknowledge code generously provided by M. A. Newton. NR 25 TC 33 Z9 33 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2010 VL 11 IS 11 AR R112 DI 10.1186/gb-2010-11-11-r112 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 728EU UT WOS:000287857900009 PM 21092299 ER PT J AU Cenik, C Derti, A Mellor, JC Berriz, GF Roth, FP AF Cenik, Can Derti, Adnan Mellor, Joseph C. Berriz, Gabriel F. Roth, Frederick P. TI Genome-wide functional analysis of human 5 ' untranslated region introns SO GENOME BIOLOGY LA English DT Article ID HUMAN HOUSEKEEPING GENES; HIGHLY EXPRESSED GENES; PRE-MESSENGER-RNA; REGULATORY ELEMENTS; RAPID TRANSCRIPTION; ANTISENSE GENES; 5'-UTR INTRON; SPLICE SITES; DESIGN-MODEL; CODON USAGE AB Background: Approximately 35% of human genes contain introns within the 5'untranslated region (UTR). Introns in 5'UTRs differ from those in coding regions and 3'UTRs with respect to nucleotide composition, length distribution and density. Despite their presumed impact on gene regulation, the evolution and possible functions of 5'UTR introns remain largely unexplored. Results: We performed a genome-scale computational analysis of 5'UTR introns in humans. We discovered that the most highly expressed genes tended to have short 5'UTR introns rather than having long 5'UTR introns or lacking 5'UTR introns entirely. Although we found no correlation in 5'UTR intron presence or length with variance in expression across tissues, which might have indicated a broad role in expression-regulation, we observed an uneven distribution of 5'UTR introns amongst genes in specific functional categories. In particular, genes with regulatory roles were surprisingly enriched in having 5'UTR introns. Finally, we analyzed the evolution of 5'UTR introns in non-receptor protein tyrosine kinases (NRTK), and identified a conserved DNA motif enriched within the 5'UTR introns of human NRTKs. Conclusions: Our results suggest that human 5'UTR introns enhance the expression of some genes in a length-dependent manner. While many 5'UTR introns are likely to be evolving neutrally, their relationship with gene expression and overrepresentation among regulatory genes, taken together, suggest that complex evolutionary forces are acting on this distinct class of introns. C1 [Cenik, Can; Derti, Adnan; Mellor, Joseph C.; Berriz, Gabriel F.; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Roth, FP (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave,SGMB 322, Boston, MA 02115 USA. EM fritz_roth@hms.harvard.edu RI Roth, Frederick/H-6308-2011; OI Cenik, Can/0000-0001-6370-0889; Roth, Frederick/0000-0002-6628-649X FU National Institutes of Health (NIH) [MH087394, HG003224, HG007115, HL081341, NS035611, HG004233]; Keck Foundation; Canadian Institute for Advanced Research; National Human Genome Res Institute [HG004825] FX We thank the West Quad Computing Group at Harvard Medical School for research computing support, Murat Taan, and Murat Cokol for helpful discussions. FPR was supported in part by the National Institutes of Health (NIH; grants MH087394, HG003224, HG007115, HL081341, NS035611, and HG004233) and the Keck Foundation, and by a Fellowship from the Canadian Institute for Advanced Research. JCM was supported by an NIH National Research Service Award Fellowship from the National Human Genome Res Institute (HG004825). NR 74 TC 31 Z9 34 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PY 2010 VL 11 IS 3 AR R29 DI 10.1186/gb-2010-11-3-r29 PG 17 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 591NY UT WOS:000277309100009 PM 20222956 ER PT J AU Nathan, DG Orkin, SH AF Nathan, David G. Orkin, Stuart H. TI Musings on genome medicine: Hepatitis C SO GENOME MEDICINE LA English DT Editorial Material AB Hepatitis C is a viral disease transmitted principally by blood, which affects millions of people worldwide. A significant proportion of those affected develop severe liver disease as a result. Only a fraction of patients are responsive to interferon treatment, highlighting the need for further research into genetic factors involved in response to therapy in order to optimize treatment. The only current approach for end-stage disease is liver transplant, which ironically does not cure the condition, and thus poses a clinical dilemma in the face of liver-donor shortage. C1 [Nathan, David G.; Orkin, Stuart H.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Nathan, DG (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM david_nathan@dfci.harvard.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2010 VL 2 AR 4 DI 10.1186/gm125 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA V27QG UT WOS:000208627100004 PM 20193049 ER PT J AU Ruderfer, DM Korn, J Purcell, SM AF Ruderfer, Douglas M. Korn, Joshua Purcell, Shaun M. TI Family-based genetic risk prediction of multifactorial disease SO GENOME MEDICINE LA English DT Article AB Genome-wide association studies have detected dozens of variants underlying complex diseases, although it is uncertain how often these discoveries will translate into clinically useful predictors. Here, to improve genetic risk prediction, we consider including phenotypic and genotypic information from related individuals. We develop and evaluate a family-based liability-threshold prediction model and apply it to a simulation of known Crohn's disease risk variants. We show that genotypes of a relative of known phenotype can be informative for an individual's disease risk, over and above the same locus genotyped in the individual. This approach can lead to better-calibrated estimates of disease risk, although the overall benefit for prediction is typically only very modest. C1 [Ruderfer, Douglas M.; Purcell, Shaun M.] Mass Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Ruderfer, Douglas M.; Purcell, Shaun M.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA. [Ruderfer, Douglas M.; Korn, Joshua; Purcell, Shaun M.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. [Purcell, Shaun M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. RP Purcell, SM (reprint author), Mass Gen Hosp, Ctr Human Genet Res, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. EM shaun@pngu.mgh.harvard.edu RI Ruderfer, Douglas/M-5795-2016 OI Ruderfer, Douglas/0000-0002-2365-386X FU NARSAD Young Investigator Award FX This work was supported by a NARSAD Young Investigator Award (SMP). We thank Colm O'Dushlaine, James Wilkins, Ben Neale and Mark Daly for helpful discussion. NR 14 TC 6 Z9 6 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2010 VL 2 AR 2 DI 10.1186/gm123 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA V27QG UT WOS:000208627100002 PM 20193047 ER PT J AU Mahoney, DF Ladd, E AF Mahoney, Diane Feeney Ladd, Elissa TI More than a Prescriber: Gerontological Nurse Practitioners' Perspectives on Prescribing and Pharmaceutical Marketing SO GERIATRIC NURSING LA English DT Article ID QUALITATIVE RESEARCH; PHYSICIANS; BEHAVIOR; INDUSTRY; GIFT AB The purpose of this study was to gain understanding about nurse practitioners' (NPs') prescriptive decision making for geriatric patients with attention to pharmaceutical marketing influences. Prior research has focused on physician prescribers and identified suboptimal practices. Because the majority of medications are prescribed to older adults, NPs in geriatric practice were targeted as an information-rich group to interview about prescribing issues. Given the exploratory nature of this research, qualitative focus group methods were employed using content analysis. Fifteen NPs were recruited at an annual national geriatric NP conference. They worked in all regions of the United States, had an average of 9 years prescribing experience, and participated in 1 of the 2 focus groups. The key theme that emerged was that they were more than a prescriber. Findings revealed overwhelming consistency among the NP participants that their nursing background instilled a holistic approach that encompassed both nondrug and therapeutic drug options and skepticism about drug marketing, as well as offered a positive difference by tailoring to their patients' biophysical, psychological, and economic needs with an involvement in the interplay of geriatric care issues not typically addressed by physicians. The participants' reported approaches were in alignment with geriatric prescribing recommendations. (Geriatr Nurs 2010;31:17-27) C1 [Mahoney, Diane Feeney; Ladd, Elissa] Massachusetts Gen Hosp, Inst Hlth Profess, Sch Nursing, Boston, MA 02114 USA. RP Mahoney, DF (reprint author), Massachusetts Gen Hosp, Inst Hlth Profess, Sch Nursing, Boston, MA 02114 USA. OI Mahoney, Diane/0000-0002-6415-475X NR 27 TC 2 Z9 2 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4572 EI 1528-3984 J9 GERIATR NURS JI Geriatr. Nurs. PD JAN-FEB PY 2010 VL 31 IS 1 BP 17 EP 27 DI 10.1016/j.gerinurse.2009.09.003 PG 11 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 598UQ UT WOS:000277864700003 PM 20159350 ER PT B AU Pasquale, LR AF Pasquale, Louis R. BE Schacknow, PN Samples, JR TI An Evidence-Based Approach to Glaucoma Care SO GLAUCOMA BOOK: A PRACTICAL, EVIDENCE-BASED APPROACH TO PATIENT CARE LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; OCULAR HYPERTENSION TREATMENT; INTRAOCULAR-PRESSURE; RISK-FACTORS; SUPRACHOROIDAL HEMORRHAGE; CATARACT-EXTRACTION; FIXED COMBINATION; MEDICATION DELAYS; CORNEAL ABRASIONS; DOSE-RESPONSE C1 Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Glaucoma Serv, Boston, MA 02114 USA. RP Pasquale, LR (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Glaucoma Serv, Boston, MA 02114 USA. NR 51 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-76699-7 PY 2010 BP 23 EP 34 DI 10.1007/978-0-387-76700-0_2 D2 10.1007/978-0-387-76700-0 PG 12 WC Ophthalmology SC Ophthalmology GA BOP21 UT WOS:000277200600002 ER PT B AU Filippopoulos, T Colby, KA Grosskreutz, CL AF Filippopoulos, Theodoros Colby, Kathryn A. Grosskreutz, Cynthia L. BE Schacknow, PN Samples, JR TI Descemet's Stripping Endothelial Keratoplasty (DSEK) and Glaucoma SO GLAUCOMA BOOK: A PRACTICAL, EVIDENCE-BASED APPROACH TO PATIENT CARE LA English DT Article; Book Chapter ID POSTERIOR LAMELLAR KERATOPLASTY; GOLDMANN APPLANATION TONOMETRY; DYNAMIC CONTOUR TONOMETRY; PENETRATING KERATOPLASTY; CORNEAL TRANSPLANT; EYES; INCISION; COMPLICATIONS; THICKNESS C1 [Filippopoulos, Theodoros; Colby, Kathryn A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Cornea Serv, Boston, MA 02115 USA. [Filippopoulos, Theodoros] Athens Vis Eye Inst, Athens, Greece. [Grosskreutz, Cynthia L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Glaucoma Serv, Boston, MA USA. RP Filippopoulos, T (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Cornea Serv, Boston, MA 02115 USA. NR 34 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-76699-7 PY 2010 BP 885 EP 888 DI 10.1007/978-0-387-76700-0_76 D2 10.1007/978-0-387-76700-0 PG 4 WC Ophthalmology SC Ophthalmology GA BOP21 UT WOS:000277200600076 ER PT B AU Hamilton, AR Mudgal, CS Jupiter, JB AF Hamilton, Abigail R. Mudgal, Chaitanya S. Jupiter, Jesse B. BE Beckingsworth, RH TI Degradable Polymers in Hand Surgery SO HAND SURGERY: PREOPERATIVE EXPECTATIONS TECHNIQUES AND RESULTS SE Surgery-Procedures Complications and Results LA English DT Article; Book Chapter ID DISTAL RADIUS FRACTURES; BIOABSORBABLE OSTEOFIXATION DEVICES; INTERNAL-FIXATION; RHEUMATOID-ARTHRITIS; METACARPAL FRACTURES; OPEN REDUCTION; IMPLANTS; PLATE; ARTHRODESIS; LIGAMENT AB Implants used in the hand and wrist have to satisfy certain criteria. They should be small, biomechanically strong enough to withstand loading in the hand and wrist and should have a low profile. In addition to these features, it is extremely useful, if they are inert enough to avoid causing local soft tissue or bony reaction and therefore do not require additional procedures for removal. Bioabsorbable implants fulfill all these criteria, and although their use in the hand and wrist is still in its infancy, early data suggest that the rates of success and complications associated with their use, are comparable to that associated with their metal counterparts. As costs associated with their production and use reduce, and more data regarding their efficacy become available, it appears that universal acceptance will follow. C1 [Mudgal, Chaitanya S.] Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA. [Hamilton, Abigail R.; Mudgal, Chaitanya S.] Massachusetts Gen Hosp, Harvard Combined Orthopaed Surg Residency Program, Boston, MA 02114 USA. [Mudgal, Chaitanya S.; Jupiter, Jesse B.] Harvard Univ, Sch Med, Yawkey Ctr, Boston, MA 02114 USA. RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM cmudgal@partners.org NR 47 TC 2 Z9 2 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-280-4 J9 SURG-PROCED COMPLICA PY 2010 BP 139 EP 152 PG 14 WC Surgery SC Surgery GA BOA77 UT WOS:000276043600009 ER PT B AU Mona, LR Goldwaser, G Syme, ML Cameron, RP Clemency, C Miller, AR Lemos, L Ballan, MS AF Mona, Linda R. Goldwaser, Gali Syme, Maggie L. Cameron, Rebecca P. Clemency, Colleen Miller, Aletha R. Lemos, Larry Ballan, Michelle S. BE Lichtenberg, PA TI Assessment and Conceptualization of Sexuality Among Older Adults SO HANDBOOK OF ASSESSMENT IN CLINICAL GERONTOLOGY, 2ND EDITION LA English DT Article; Book Chapter ID ERECTILE DYSFUNCTION; CONSENT CAPACITY; AROUSAL DISORDER; UNITED-STATES; DOUBLE-BLIND; CROSS-OVER; AGING MALE; WOMEN; SILDENAFIL; HEALTH C1 [Mona, Linda R.] Long Beach Healthcare Syst, VA, Behav Hlth 06 116B, Long Beach, CA 90822 USA. [Goldwaser, Gali] VA San Diego Healthcare Syst, PTSD & Stress Related Disorders, Res Serv 151, San Diego, CA USA. [Syme, Maggie L.] VA Boston Healthcare Syst, Psychol Serv, Boston, MA USA. [Cameron, Rebecca P.] Calif State Univ Sacramento, Sacramento, CA 95819 USA. [Clemency, Colleen] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Miller, Aletha R.] Deer Oaks Mental Hlth Associates Behav Hlth Org, Ft Worth, TX USA. [Lemos, Larry] VA Long Beach Healthcare Syst, Community Living Ctr, Long Beach, CA USA. [Ballan, Michelle S.] Columbia Univ, Sch Social Work, New York, NY USA. RP Mona, LR (reprint author), Long Beach Healthcare Syst, VA, Behav Hlth 06 116B, Long Beach, CA 90822 USA. OI Syme, Maggie/0000-0003-3260-5568 NR 87 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-095972-6; 978-0-12-374961-1 PY 2010 BP 331 EP 356 DI 10.1016/B978-0-12-374961-1.10013-2 PG 26 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA BA2PQ UT WOS:000333761000014 ER PT B AU Blais, M Baer, L AF Blais, Mark Baer, Lee BE Baer, L Blais, MA TI Understanding Rating Scales and Assessment Instruments SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Rating scales; Questionnaires; Psychometrics; Assessment; Psychiatry AB The successful integration of screening tests and brief rating scales into clinical practice requires an adequate understanding of a few basic psychometric and statistical concepts. This chapter provides an overview of such concepts as reliability, validity, diagnostic accuracy and sensitivity to change. In addition we attempt to demonstrate how these concepts relate to clinical care. We believe that a solid understanding of these concepts will increase the utility and benefit patients and clinicians obtain through the integration of brief measurement tools into their practice. C1 [Blais, Mark; Baer, Lee] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blais, Mark; Baer, Lee] Harvard Univ, Sch Med, Boston, MA USA. RP Blais, M (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM mblais@partners.org NR 0 TC 24 Z9 24 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 1 EP 6 DI 10.1007/978-1-59745-387-5_1 D2 10.1007/978-1-59745-387-5 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000001 ER PT B AU Cusin, C Yang, HY Yeung, A Fava, M AF Cusin, Cristina Yang, Huaiyu Yeung, Albert Fava, Maurizio BE Baer, L Blais, MA TI Rating Scales for Depression SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Depression; Rating scales; Questionnaires; Assessment; Mood; Psychiatry ID MONTGOMERY-ASBERG DEPRESSION; STRUCTURED INTERVIEW GUIDE; PLACEBO-CONTROLLED TRIAL; REPORT QIDS-SR; MAJOR DEPRESSION; ANTIDEPRESSANT TREATMENT; PSYCHOMETRIC PROPERTIES; CHILDRENS DEPRESSION; SOMATIC SYMPTOMS; SELF-REPORT AB Over the past few decades, a number of clinician-rated and patient-rated instruments have been developed as primary efficacy measures in depression clinical trials. All those scales have relative strengths and weaknesses and some of them have been more successful than others, and have become the gold standards for depression clinical research. With all these measures available and with the evidence of their variable performance in clinical trials, it is becoming increasingly important to select primary efficacy measures that are reliable, valid, and that fit well within the aims of depression clinical trials. This article will review the main considerations that investigators need to make when choosing a primary efficacy measure for major depressive disorder (MDD). There is a clear need for a thorough discussion of the methodological issues concerning the use of these scales, as suggested also by Demyttenaere and De Fruyt in a recent review [1], because clinical trials researchers in depression continue to struggle with the ability to detect signals of the efficacy of antidepressant agents. C1 [Cusin, Cristina; Yang, Huaiyu; Yeung, Albert; Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Cusin, Cristina; Yang, Huaiyu; Yeung, Albert; Fava, Maurizio] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Cusin, C (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Wang Ambulatory Care Ctr 812,15 Parkman St, Boston, MA 02114 USA. EM ccusin@partners.org NR 93 TC 44 Z9 44 U1 1 U2 6 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 7 EP 35 DI 10.1007/978-1-59745-387-5_2 D2 10.1007/978-1-59745-387-5 PG 29 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000002 ER PT B AU Marques, L Chosak, A Simon, NM Phan, DM Wilhelm, S Pollack, M AF Marques, Luana Chosak, Anne Simon, Naomi M. Phan, Dieu-My Wilhelm, Sabine Pollack, Mark BE Baer, L Blais, MA TI Rating Scales for Anxiety Disorders SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Anxiety; GAD; OCD; Panic disorder; Social anxiety; Rating scales; Questionnaires; Assessment; Psychiatry ID POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE SCALE; SOCIAL-INTERACTION ANXIETY; VENLAFAXINE EXTENDED-RELEASE; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; AGORAPHOBIC COGNITIONS QUESTIONNAIRE; BODY SENSATIONS QUESTIONNAIRE; SELF-REPORT VERSION; PANIC DISORDER; PSYCHOMETRIC PROPERTIES AB Anxiety is defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association (Diagnostic and Statistical Manual of Mental Disorders, 2000)) as an "apprehensive anticipation of future danger or misfortune accompanied by a feeling of dysphoria or somatic symptoms of tension" (American Psychiatric Association (Diagnostic and Statistical Manual of Mental Disorders, 2000 p. 820)). The anxiety disorders in the DSM-IV include panic disorder with and without agoraphobia, generalized anxiety disorder, social phobia, specific phobia, posttraumatic stress disorder, and obsessive compulsive disorder. Measures for evaluating anxiety disorders can be useful in clinical practice and research as a tool for measuring change due to treatment, comparing disorder severity and symptom presentation across groups, motivating patients by systematically discussing the extent of their symptoms and impairment, and informing the clinician of symptom presentation and areas of impairment in each individual patient. This chapter is designed to aid clinicians and researchers in choosing empirically driven measures to guide their clinical and research endeavors for each of the aforementioned anxiety disorders. Whenever appropriate, measures are reprinted to facilitate this process. C1 [Wilhelm, Sabine] Massachusetts Gen Hosp, Body Dysmorph Disorder Clin, Dept Psychiat, Boston, MA 02114 USA. [Marques, Luana; Chosak, Anne; Simon, Naomi M.; Phan, Dieu-My; Wilhelm, Sabine; Pollack, Mark] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Wilhelm, S (reprint author), Massachusetts Gen Hosp, Body Dysmorph Disorder Clin, Dept Psychiat, Boston, MA 02114 USA. EM wilhelm@psych.mgh.harvard.edu NR 100 TC 5 Z9 5 U1 3 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 37 EP 72 DI 10.1007/978-1-59745-387-5_3 D2 10.1007/978-1-59745-387-5 PG 36 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000003 ER PT B AU Perlis, RH AF Perlis, Roy H. BE Baer, L Blais, MA TI Rating Scales for Bipolar Disorder SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Bipolar disorder; Mania; Depression; Mood; Rating scales; Questionnaires; Assessment; Psychiatry ID DEPRESSION; MANIA; INVENTORY; OUTCOMES AB Patients with bipolar disorder may experience both manic and depressive symptoms which fluctuate over time, so appropriate monitoring includes assessment of both sets of symptoms. As these symptoms may persist even in the absence of a DSM-IV-defined mood episode, tools for monitoring must be sensitive to milder or subthreshold symptoms. In addition, as patients commonly experience concomitant axis I disorders, particularly anxiety disorders, symptom monitoring should address these symptoms as well. C1 [Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Bipolar Disorder Program, Boston, MA 02114 USA. [Perlis, Roy H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Bipolar Disorder Program, Boston, MA 02114 USA. EM rperlis@partners.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 73 EP 86 DI 10.1007/978-1-59745-387-5_4 D2 10.1007/978-1-59745-387-5 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000004 ER PT B AU Yeterian, J Pachas, G Evins, E Kelly, J AF Yeterian, Julie Pachas, Gladys Evins, Eden Kelly, John BE Baer, L Blais, MA TI Rating Scales for Alcohol and Nicotine Addictions SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Addiction; Alcoholism; Nicotine; Smoking; Rating scales; Questionnaires; Assessment ID LEEDS-DEPENDENCE-QUESTIONNAIRE; SUSTAINED-RELEASE BUPROPION; SMOKING-CESSATION; PSYCHOMETRIC PROPERTIES; TOBACCO WITHDRAWAL; CONTROLLED-TRIAL; UNITED-STATES; SHORT INDEX; RELAPSE; VALIDATION AB Alcohol and tobacco are among the leading causes of preventable deaths and are frequently used in combination. Because of the exceptional morbidity and mortality associated with the use of these substances, it is important to maximize opportunities for the detection of maladaptive use and subsequent intervention whenever a healthcare point of contact is made. This chapter provides a brief description of the health impact of these substances, as well as concise descriptions of helpful alcohol- and tobacco-related screening and assessment tools. The tools that are highlighted were chosen because of their excellent psychometric properties, but also for their high clinical utility and free availability for ease of use in a busy practice setting. C1 [Yeterian, Julie; Pachas, Gladys; Evins, Eden; Kelly, John] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Evins, Eden; Kelly, John] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Kelly, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM jkelly11@partners.org NR 64 TC 3 Z9 3 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 87 EP 123 DI 10.1007/978-1-59745-387-5_5 D2 10.1007/978-1-59745-387-5 PG 37 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000005 ER PT B AU Siefert, CJ AF Siefert, Caleb J. BE Baer, L Blais, MA TI Screening for Personality Disorders in Psychiatric Settings: Four Recently Developed Screening Measures SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Personality disorder; Screening; Rating scales; Questionnaires; Assessment; Psychiatry ID INTERPERSONAL PROBLEMS; 5-FACTOR MODEL; PSYCHOMETRIC PROPERTIES; STANDARDIZED ASSESSMENT; PRELIMINARY VALIDATION; AXIS-I; INVENTORY; METAANALYSIS; VALIDITY; SCALES AB Prevalence rates for Personality Disorders are higher in psychiatric settings. Nonetheless, the presence of a personality disorder may go undetected for some time during the early phases of treatment. This is problematic as a failure to detect a Personality Disorder as part of the initial evaluation can result in less beneficial treatment plans, negative outcomes, and a more difficult treatment course. Nonetheless, the benefits of early detection must be weighed against practical considerations, including time and resources. Currently gold-standard assessment measures for Personality Disorders are lengthy and time consuming which may limit their practical utility. The present chapter reviews data on the importance of assessing for personality disorders, reviews the benefits of stage I (screening for Personality Disorders) and stage II (thorough evaluation for a Personality Disorder), and then reviews four recently developed measures that can be used as part of the personality disorder screening process. Information on more detailed measures for stage II assessment is also briefly presented and clinical implications are discussed. C1 [Siefert, Caleb J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Siefert, Caleb J.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Siefert, CJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. EM csiefert@partners.org NR 45 TC 5 Z9 5 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 125 EP 144 DI 10.1007/978-1-59745-387-5_6 D2 10.1007/978-1-59745-387-5 PG 20 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000006 ER PT B AU Derenne, JL Baker, CW Delinsky, SS Becker, AE AF Derenne, Jennifer L. Baker, Christina W. Delinsky, Sherrie S. Becker, Anne E. BE Baer, L Blais, MA TI Clinical Ratings Scales and Assessment in Eating Disorders SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Eating disorder; Anorexia nervosa; Bulimia nervosa; Screening; Rating scales; Questionnaires; Assessment; Psychiatry ID BODY SHAPE QUESTIONNAIRE; SELF-REPORT QUESTIONNAIRE; DSM-III-R; TEST-RETEST RELIABILITY; QUALITY-OF-LIFE; ANOREXIA-NERVOSA; PSYCHOMETRIC PROPERTIES; WEIGHT PATTERNS; SIZE ESTIMATION; ATTITUDES TEST AB Eating disorders have one of the highest mortality rates among psychiatric condition. However, these conditions are difficult to detect by both primary-care physicians and mental health professionals. As a result, eating-disordered patients often go unrecognized and untreated. The utilization of standardized rating scales and structured interviews can increase the recognition of these conditions and also improve treatment planning and outcome monitoring. This chapter provides a detailed review of the available self-report instruments and semi-structured interviews for the eating disorders. C1 [Baker, Christina W.; Becker, Anne E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Baker, Christina W.; Becker, Anne E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Derenne, Jennifer L.] Med Coll Wisconsin, Div Child & Adolescent Psychiat, Milwaukee, WI 53226 USA. [Delinsky, Sherrie S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Delinsky, Sherrie S.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Becker, AE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, WACC 8th Floor,15 Parkman St, Boston, MA 02115 USA. EM abecker@partners.org NR 132 TC 3 Z9 3 U1 3 U2 8 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 145 EP 174 DI 10.1007/978-1-59745-387-5_7 D2 10.1007/978-1-59745-387-5 PG 30 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000007 ER PT B AU White, GW Jellinek, MS Murphy, JM AF White, Gwyne W. Jellinek, Michael S. Murphy, J. Michael BE Baer, L Blais, MA TI The Use of Rating Scales to Measure Outcomes in Child Psychiatry and Mental Health SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Child psychiatry; Adolescent psychiatry; Rating scales; Questionnaires; Assessment; Psychiatry ID PEDIATRIC SYMPTOM CHECKLIST; GLOBAL ASSESSMENT SCALE; SCHOOL-AGE-CHILDREN; PSYCHOSOCIAL PROBLEMS; BEHAVIORAL-PROBLEMS; ANCHORED VERSION; CHRONICALLY ILL; PRIMARY-CARE; LOW-INCOME; OPEN-LABEL AB Objective. To help clinicians and administrators select among rating scales in common use in child and adolescent psychiatry. Background. In Massachusetts, many insurers now require the use of standardized scales to rate child and adult mental health patients. With literally hundreds scales available, clinicians and administrators who have to choose a rating scale may find the vast assortment of instruments bewildering. This chapter brings a theoretical framework to bear on a review of some of the most commonly used scales and provides a case study example of a recent set of decisions in Massachusetts. Results. We conducted a PubMed search using the term 'Rating scales' combined with 'Child psychiatry' and came up with over 700 papers. Restricting our search to the years from 2002-present reduced the list to 149 articles and 103 named scales in current use. Further restricting our search to those measures mentioned in three or more publications resulted in a list of I I commonly and recently used measures, only three of which were broadband scales. Since a number of scales commonly used in clinical practice were not on the above list, we added the ten recommended child and adolescent instruments named on the website of a large mental health carve-out insurance company as well as two of the most widely used scales that were not on either of these two lists. We then reviewed the resultant list of 15 scales in terms of a sixteen dimensions that are important to consider in making selection decisions. Conclusions. Results from the current review identified hundreds of instruments that potentially meet the requirements of insurers but just over a dozen broadband scales which appear to be in common recent use in child psychiatry. All of these rating scales have been used to establish profiles at intake and although all have been used as pre-post measures, none have been expressly validated as measures of clinically significant change. Thus, although there appears to be growing pressure to use standardized rating scales at intake in psychiatry, there is no evidence to support the validity of any available scale as a 'gold standard' yardstick to demonstrate diagnostic or treatment efficacy, let alone for using any scale to restrict access to care or length of treatment. Too little is known about the real world reliability and true clinical predictive validity of such measures to allow them to replace the judgment of experienced clinicians in these matters at this time. C1 [White, Gwyne W.; Jellinek, Michael S.; Murphy, J. Michael] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [White, Gwyne W.; Jellinek, Michael S.; Murphy, J. Michael] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Jellinek, Michael S.] Newton Wellesley Hosp, Newton, MA USA. RP Murphy, JM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Yawkey 6A, Boston, MA 02114 USA. EM mmurphy6@partners.org NR 55 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 175 EP 194 DI 10.1007/978-1-59745-387-5_8 D2 10.1007/978-1-59745-387-5 PG 20 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000008 ER PT B AU Knouse, LE Safren, SA AF Knouse, Laura E. Safren, Steven A. BE Baer, L Blais, MA TI Adult Attention-Deficit Hyperactivity Disorder SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Attention-Deficit/Hyperactivity Disorder; ADHD; Adults; Assessment; Rating scales AB Attention-Deficit Hyperactivity Disorder (ADHD) in adults is a valid and impairing disorder for which psychopharmacological and psychosocial treatments are recommended. Self-report ratings scales for adult ADHD can serve several functions in clinical work with this population including screening, providing information in a comprehensive assessment, and tracking treatment-related change. The use of two symptom-based ratings scales for screening and tracking treatment progress - the Current Symptoms Scale (CSS) [5] and the Adult ADHD Self-Report Scale (ASRS) [6] - is outlined for the practicing clinician. Key issues in the assessment of adult ADHD are briefly discussed, highlighting the role of rating scales within a comprehensive assessment. C1 [Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Knouse, Laura E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Knouse, Laura E.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Safren, SA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM ssafren@partners.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 195 EP 208 DI 10.1007/978-1-59745-387-5_9 D2 10.1007/978-1-59745-387-5 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000009 ER PT B AU Gottlieb, JD Fan, XD Goff, DC AF Gottlieb, Jennifer D. Fan, Xiaoduo Goff, Donald C. BE Baer, L Blais, MA TI Rating Scales in Schizophrenia SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Schizophrenia; Psychosis; Rating scales; Assessment; Psychotic symptoms; Negative symptoms; Quality of life; Antipsychotic medication; Side effects; Cognitive functioning ID QUALITY-OF-LIFE; NEGATIVE SYNDROME SCALE; VERSION; RELIABILITY; DISORDERS; PSYCHOSIS; INTERVIEW; ATTITUDES; VALIDITY; PSYRATS AB In the field of schizophrenia treatment and research, psychiatric symptom rating scales have served to evaluate and elucidate the value of antipsychotic medications and psychosocial interventions in treating this disorder. Useful scales have also been developed to assist in measuring side effects of medications, to assess areas of cognitive functioning, to evaluate quality of life, and to monitor medication treatment compliance. In this chapter, the following commonly used "gold standard" scales to assess important domains of schizophrenia are described: the Positive and Negative Syndrome Scale (PANSS), the Psychotic Symptom Rating Scales (PSYRATS), the Quality,of Life Scale (QLS), the Schizophrenia Cognition Rating Scale (SCoRS), the Drug Attitude Inventory (DAI), and the Abnormal Involuntary Movement Scale (AIMS). Additional important domains to assess are also discussed, and scales to evaluate these areas are recommended. The authors posit that utilizing a combination of these useful assessment tools will allow for a thorough evaluation of patients with schizophrenia, which in turn can significantly improve clinical care and outcome. C1 [Goff, Donald C.] Massachusetts Gen Hosp, Schizophrenia Program, Freedom Trail Clin, Boston, MA 02114 USA. [Fan, Xiaoduo] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Fan, Xiaoduo] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gottlieb, Jennifer D.] Massachusetts Gen Hosp, Dartmouth Med Sch, Concord, NH 03301 USA. [Gottlieb, Jennifer D.] Dept Psychiat, Concord, NH 03301 USA. RP Goff, DC (reprint author), Massachusetts Gen Hosp, Schizophrenia Program, Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA. EM goff@psych.mgh.harvard.edu NR 27 TC 0 Z9 1 U1 2 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 209 EP 238 DI 10.1007/978-1-59745-387-5_10 D2 10.1007/978-1-59745-387-5 PG 30 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000010 ER PT B AU Sinclair, SJ LoCicero, A AF Sinclair, Samuel J. LoCicero, Alice BE Baer, L Blais, MA TI Assessing the Ongoing Psychological Impact of Terrorism SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Terrorism catastrophizing scale; TCS; Pre-traumatic stress syndrome; Anticipatory fear; Terrorism; Trauma ID POSTTRAUMATIC-STRESS-DISORDER; PSYCHOMETRIC PROPERTIES; SEPTEMBER 11; DEPRESSION; ANXIETY; RESPONSES; DURATION; EPISODES; SAMPLE; MOOD AB The terror attacks of 9/11/2001 dealt a serious blow to the sense of security, well-being, and economic stability of Americans, and altered the mental health landscape for those within the United States and other parts of the world. Paralleling this, new threats to emotional and psychological well-being have materialized in the form of anticipatory, prospective fears of future terrorist attacks. In light of this evolving environment, the present chapter seeks to augment the current science by presenting an assessment paradigm relevant to terrorist events specifically. This approach to psychological assessment expands on current models which focus on the impact of discrete events by also evaluating the impact of prospective fears of future attacks. Reflecting this paradigm shift, we introduce the Terrorism Catastrophizing Scale (TCS) as a means of evaluating the ongoing impact of terrorism on psychological functioning. C1 [Sinclair, Samuel J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sinclair, Samuel J.] Harvard Univ, Sch Med, Dept Psychiat, Psychol Evaluat & Res Lab PEaRL, Boston, MA 02114 USA. [LoCicero, Alice] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA. [LoCicero, Alice] Boston Univ, Ctr Multicultural Mental Hlth, Boston, MA 02215 USA. RP Sinclair, SJ (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM jsincl@post.harvard.edu NR 33 TC 0 Z9 0 U1 2 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 271 EP 285 DI 10.1007/978-1-59745-387-5_13 D2 10.1007/978-1-59745-387-5 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000013 ER PT B AU Wiechers, IR Weiss, A AF Wiechers, Ilse R. Weiss, Anthony BE Baer, L Blais, MA TI The Role of Outcomes Assessment in Clinical Quality Improvement SO HANDBOOK OF CLINICAL RATING SCALES AND ASSESSMENT IN PSYCHIATRY AND MENTAL HEALTH SE Current Clinical Psychiatry LA English DT Article; Book Chapter DE Outcomes; Assessment; Quality improvement; Quality control AB Although there has been a great deal of discussion about healthcare quality in recent years, the best way to identify high-quality healthcare remains a matter of some debate. Within the field of mental health, this debate is often focused on the optimal use of clinical rating scales and outcomes assessment tools. Much of the current thinking regarding the use of these scales is presented in this book. This chapter will provide the context for the use of these instruments as a core component of quality improvement efforts. C1 [Wiechers, Ilse R.; Weiss, Anthony] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Wiechers, Ilse R.; Weiss, Anthony] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Weiss, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,Room 734, Boston, MA 02114 USA. EM aweiss@partners.org NR 9 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-966-6 J9 CURR CLIN PSYCHIAT PY 2010 BP 303 EP 307 DI 10.1007/978-1-59745-387-5_15 D2 10.1007/978-1-59745-387-5 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA BLW47 UT WOS:000271223000015 ER PT S AU Twomey, JG AF Twomey, John G. BE Tercyak, KP TI Informed Consent and the Protection of Human Subjects in Genomic Research with Children and Families SO HANDBOOK OF GENOMICS AND THE FAMILY: PSYCHOSOCIAL CONTEXT FOR CHILDREN AND ADOLESCENTS SE Issues in Clinical Child Psychology LA English DT Article; Book Chapter ID HEREDITARY COLORECTAL-CANCER; RANDOMIZED CONTROLLED-TRIALS; ADULT-ONSET CONDITIONS; ETHICAL-ISSUES; CLINICAL-RESEARCH; PARENTAL CONSENT; DECISION-MAKING; HEALTHY-CHILDREN; TESTING CHILDREN; SURGERY RESEARCH C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Twomey, JG (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 110 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 1574-0471 BN 978-1-4419-5799-3 J9 ISSUES CLIN CHILD PS PY 2010 BP 457 EP 483 DI 10.1007/978-1-4419-5800-6_19 D2 10.1007/978-1-4419-5800-6 PG 27 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA BQD65 UT WOS:000280742700019 ER PT S AU Patenaude, AF AF Patenaude, Andrea Farkas BE Tercyak, KP TI Training, Practice, and Collaboration: New Opportunities for Pediatric Psychology and Genomic Medicine SO HANDBOOK OF GENOMICS AND THE FAMILY: PSYCHOSOCIAL CONTEXT FOR CHILDREN AND ADOLESCENTS SE Issues in Clinical Child Psychology LA English DT Article; Book Chapter ID LI-FRAUMENI-SYNDROME; OVARIAN-CANCER; FAMILY-HISTORY; INCREASED RISK; BREAST-CANCER; GENETICS; WOMEN; CHILDHOOD; DIAGNOSIS; HEALTH C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Patenaude, AF (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 49 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 1574-0471 BN 978-1-4419-5799-3 J9 ISSUES CLIN CHILD PS PY 2010 BP 559 EP 575 DI 10.1007/978-1-4419-5800-6_22 D2 10.1007/978-1-4419-5800-6 PG 17 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA BQD65 UT WOS:000280742700022 ER PT B AU Vasterling, JJ Grande, L Graefe, AC Alvarez, JA AF Vasterling, Jennifer J. Grande, Laura Graefe, Anna C. Alvarez, Julie A. BE Armstrong, CL Morrow, L TI Neuropsychological Assessment of Posttraumatic Stress Disorder (PTSD) SO HANDBOOK OF MEDICAL NEUROPSYCHOLOGY: APPLICATIONS OF COGNITIVE NEUROSCIENCE LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; VIETNAM COMBAT VETERANS; CHILDHOOD SEXUAL-ABUSE; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; SHORT-TERM-MEMORY; COGNITIVE-BEHAVIORAL THERAPY; PREDICTS TREATMENT RESPONSE; SMALLER HIPPOCAMPAL VOLUME; ANTERIOR CINGULATE VOLUME C1 [Vasterling, Jennifer J.; Grande, Laura] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA. [Vasterling, Jennifer J.] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA 02130 USA. [Vasterling, Jennifer J.; Grande, Laura] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Alvarez, Julie A.] Tulane Univ, Dept Psychol, New Orleans, LA 70118 USA. [Graefe, Anna C.] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA. RP Vasterling, JJ (reprint author), VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA. EM jvaster@bu.edu; laura.grande@va.gov; anna.graefe@gmail.com; jalvar@tulane.edu NR 265 TC 1 Z9 1 U1 3 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-1363-0 PY 2010 BP 447 EP 465 DI 10.1007/978-1-4419-1364-7_24 D2 10.1007/978-1-4419-1364-7 PG 19 WC Medicine, General & Internal; Neurosciences; Psychology SC General & Internal Medicine; Neurosciences & Neurology; Psychology GA BQT44 UT WOS:000281792900024 ER PT J AU Huang, YY Chen, ACH Hamblin, MR AF Huang, Ying-Ying Chen, Aaron C. -H. Hamblin, Michael R. BE Tuchin, VV TI Advances in Low-Intensity Laser and Phototherapy SO HANDBOOK OF PHOTONICS FOR BIOMEDICAL SCIENCE SE Series in Medical Physics and Biomedical Engineering LA English DT Article; Book Chapter DE photobiomodulation; low-level laser therapy; ROS; mitochondria; cytochrome c oxidase; NF-kB; gene transcription; AP1; cells; blood; healing; pain relief ID LOW-LEVEL LASER; HELIUM-NEON LASER; NF-KAPPA-B; DIABETIC PERIPHERAL NEUROPATHY; EMITTING DIODE IRRADIATION; RAT-LIVER MITOCHONDRIA; CARPAL-TUNNEL-SYNDROME; CYTOCHROME-C-OXIDASE; PHYSICAL-THERAPY INTERVENTIONS; PLACEBO-CONTROLLED TRIAL AB The use of low levels of visible or near infrared light for reducing pain, inflammation and edema, promoting healing of wounds, deeper tissues and nerves, and preventing tissue damage and death has been known for almost forty years since the invention of lasers. Originally thought to be a peculiar property of laser light (soft or cold lasers), the subject has now broadened to include photobiomodulation and photobiostimulation using noncoherent light. Despite many reports of positive findings from experiments conducted in vitro, in animal models and in randomized controlled clinical trials, low level light therapy (LLLT) remains controversial. This controversy is likely due to two main reasons; first, the biochemical mechanisms underlying the positive effects are incompletely understood, and second, the complexity of rationally choosing among a large number of illumination parameters such as wavelength, fluence, power density, pulse structure, and treatment timing has led to the publication of a number of negative studies as well as many positive ones. In particular, a biphasic dose response has been frequently observed where low levels of light have a much better effect than higher levels. This chapter will cover some of the proposed cellular chromophores responsible for the effect of visible light on mammalian cells, including cytochrome c oxidase (with absorption peaks in the near infrared region of the spectrum) and photoactive porphyrins and flavins. Mitochondria are thought to be a likely site for the initial effects of light and the involvement of nitric oxide had been postulated. Activation of the respiratory chain leads to increased ATP production, modulation of reactive oxygen species, and activation of transcription factors. These effects in turn lead to increased cell proliferation and migration (particularly by fibroblasts), modulation in levels of cytokines, growth factors and inflammatory mediators, prevention of cell death by anti-apoptotic signaling, and increased tissue oxygenation. The results of these biochemical and cellular changes in animals and patients include such benefits as increased healing in chronic wounds, improvements in sports injuries and carpal tunnel syndrome, pain reduction in arthritis and neuropathies, and amelioration of damage after heart attacks, stroke, nerve injury, and retinal toxicity. C1 [Huang, Ying-Ying; Chen, Aaron C. -H.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Guangxi, Peoples R China. [Chen, Aaron C. -H.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Huang, YY (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 161 TC 7 Z9 7 U1 1 U2 3 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-0628-9 J9 SER MED PHYS BIOMED PY 2010 BP 687 EP 716 D2 10.1201/9781439806296-f PG 30 WC Biophysics; Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Biophysics; Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BTC62 UT WOS:000286455800027 ER PT J AU Huang, YY Hamblin, MR De Taboada, L AF Huang, Ying-Ying Hamblin, Michael R. De Taboada, Luis BE Tuchin, VV TI Low-Level Laser Therapy in Stroke and Central Nervous System SO HANDBOOK OF PHOTONICS FOR BIOMEDICAL SCIENCE SE Series in Medical Physics and Biomedical Engineering LA English DT Article; Book Chapter DE low-level laser therapy; neurological disorders; stroke; ROS; mitochondria; photobiomodulation ID LOW-ENERGY LASER; TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; LOW-POWER LASER; TERM NEUROLOGICAL DEFICITS; NEAR-INFRARED LIGHT; ALZHEIMERS-DISEASE; PERIPHERAL-NERVE; SPINAL-CORD; PROMOTES REGENERATION AB Low-level laser/light therapy (LLLT) for neurological disorders in the central nervous system (CNS) is currently an experimental concept. The broad goals for clinical utilization are the prevention and/or repair of damage, relief of symptoms, slowing of disease progression, and correction of genetic abnormalities. Experimental studies have tested and continue to test these goals by investigating LLLT in animal models of diseases and injuries that affect the brain and spinal cord. Successful clinical trials have been carried out of transcranial laser therapy for stroke. Discoveries concerning the molecular basis of various neurological diseases, combined with advances that have been made in understanding the molecular and cellular mechanisms in LLLT, both in vitro and in vivo, have allowed rational light-based therapeutic approaches for a wide variety of CNS disorders to be investigated. Limitations in knowledge are still apparent, such as the optimal wavelength, light source, doses, pulsed or CW, polarization state, treatment timing, and repetition frequency. Collaborative efforts between clinicians and basic researchers will likely increase the usage and understanding of effective laser-based therapies in the CNS. C1 [Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet Plast Laser Ctr, Nanning, Guangxi, Peoples R China. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [De Taboada, Luis] PhotoThera Inc, Carlsbad, CA USA. RP Huang, YY (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 80 TC 4 Z9 4 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-0628-9 J9 SER MED PHYS BIOMED PY 2010 BP 717 EP 737 D2 10.1201/9781439806296-f PG 21 WC Biophysics; Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Biophysics; Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BTC62 UT WOS:000286455800028 ER PT B AU Nisenbaum, S Weiss, MC Shapiro, D AF Nisenbaum, Steven Weiss, Madelaine Claire Shapiro, Daniel BE Miller, TW TI Ethical and Legal Issues in Transitioning the Lifespan SO HANDBOOK OF STRESSFUL TRANSITIONS ACROSS THE LIFESPAN LA English DT Article; Book Chapter ID ULTIMATUM GAME; CHIMPANZEES C1 [Nisenbaum, Steven] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [Nisenbaum, Steven] Harvard Univ, Sch Law, Int Negotiat Initiat, Cambridge, MA 02138 USA. [Weiss, Madelaine Claire] Amer Immigrat Lawyers Assoc, Washington, DC USA. [Shapiro, Daniel] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Cambridge, MA 02138 USA. RP Nisenbaum, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. NR 57 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0747-9 PY 2010 BP 271 EP 296 DI 10.1007/978-1-4419-0748-6_14 D2 10.1007/978-1-4419-0748-6 PG 26 WC Psychology, Developmental SC Psychology GA BMR87 UT WOS:000273428600014 ER PT J AU Dixon, R AF Dixon, Ronald TI The Technology That Can Revolutionize Health Care Hint: it's not high cost or high tech SO HARVARD BUSINESS REVIEW LA English DT Editorial Material C1 [Dixon, Ronald] Massachusetts Gen Hosp, Virtual Practice Project, Boston, MA 02114 USA. [Dixon, Ronald] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Dixon, R (reprint author), Massachusetts Gen Hosp, Virtual Practice Project, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU HARVARD BUSINESS SCHOOL PUBLISHING CORPORATION PI WATERTOWN PA 300 NORTH BEACON STREET, WATERTOWN, MA 02472 USA SN 0017-8012 J9 HARVARD BUS REV JI Harv. Bus. Rev. PD JAN-FEB PY 2010 VL 88 IS 1-2 SI SI BP 45 EP 46 PG 2 WC Business; Management SC Business & Economics GA 536JE UT WOS:000273039900026 PM 20088371 ER PT J AU Pierre, JM AF Pierre, Joseph M. TI Hallucinations in Nonpsychotic Disorders: Toward a Differential Diagnosis of "Hearing Voices" SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE auditory hallucinations; conversion disorder; culture; diagnosis; DSM-V; pseudohallucination; psychosis; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; AUDITORY VERBAL HALLUCINATIONS; CHILDHOOD SEXUAL-ABUSE; MUSICAL HALLUCINATIONS; PSYCHOTIC SYMPTOMS; GENERAL-POPULATION; CONVERSIVE HALLUCINATIONS; ACQUIRED DEAFNESS; PSEUDO-HALLUCINATIONS; TRUE HALLUCINATIONS AB While auditory hallucinations (AH) are prototypic psychotic symptoms whose clinical presence is often equated with a psychotic disorder, they are commonly found among those without mental illness as well as those with nonpsychotic disorders not typically associated with hallucinations in DSM-IV. This incongruity presents a significant challenge for clinical work and efforts to revise the next iteration of the DSM. Auditory hallucinations found among "normal" people suggest that either AH are not as pathologic as they are typically taken to be, or that less-than-hallucinatory experiences are routinely mischaracterized as AH. Such hallucinations in the context of conversion disorder, trauma, sensory deprivation, and certain cultural settings strengthen an association between AH and psychopathology but suggest limited diagnostic specificity and relevance. It may be useful to think of AH like coughs-common experiences that are often, but not always, symptoms of pathology associated with a larger illness. Although these issues have been known for many years, they are rarely discussed In American psychiatry and need to be addressed in future research and clinical work. (HARV REV PSYCHIATRY 2010;18:22-35.) C1 [Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Pierre, Joseph M.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. RP Pierre, JM (reprint author), VA Greater Los Angeles Healthcare Syst Psychiat, 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 154 TC 32 Z9 32 U1 12 U2 26 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2010 VL 18 IS 1 BP 22 EP 35 DI 10.3109/10673220903523706 PG 14 WC Psychiatry SC Psychiatry GA 562NF UT WOS:000275057900002 PM 20047459 ER PT J AU Ansari, A Osser, DN AF Ansari, Arash Osser, David N. TI The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Bipolar Depression SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE algorithms; antidepressive agents; bipolar depression; bipolar disorder; electroconvulsive therapy; lamotrigine; lithium; psychopharmacology; quetiapine ID LITHIUM MAINTENANCE TREATMENT; ANTIDEPRESSANT-INDUCED MANIA; PLACEBO-CONTROLLED TRIAL; OLANZAPINE-FLUOXETINE COMBINATION; UNIPOLAR MAJOR DEPRESSION; CONTROLLED 18-MONTH TRIAL; DOUBLE-BLIND TRIAL; PROOF-OF-CONCEPT; ADD-ON TREATMENT; I-DISORDER AB This updated version of the bipolar depression algorithm of the Psychopharmacology Algorithm Project at the Harvard South Shore Program aims to provide an organized, sequential, and evidence supported approach for the treatment of that disorder. After initial evaluation and diagnosis, the psychiatrist should first assess whether there is an urgent indication for ECT. If ECT is not indicated, and the patient has psychotic symptoms, then an antipsychotic should be part of the medication regimen. Next, if the patient is not currently treated with mood stabilizers, there is a slight preference for lithium. If lithium is not effective or tolerated, treatment with quetiapine or lamotrigine should be initiated. If the patient is currently taking other mood stabilizers, their dosage should be optimized, and the clinician should consider adding or switching to lithium, quetiapine, or lamotrigine. Next, if the patient is not at especially high risk of mood destabilization, an antidepressant can be added in the bipolar depressed patient who has failed trials of lithium, quetiapine, and lamotrigine. Rapid-cycling depressed patients may require combinations of two or three mood stabilizers. ECT, along with other psychopharmacological options, could be reconsidered for the treatment of refractory bipolar depressed patients. (HARV REV PSYCHIATRY 2010;18:36-55.) C1 [Ansari, Arash] Faulkner Hosp, Dept Psychiat, Boston, MA 02130 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Osser, David N.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA. RP Ansari, A (reprint author), Faulkner Hosp, Dept Psychiat, 1153 Ctr St, Boston, MA 02130 USA. EM aansari@partners.org NR 189 TC 10 Z9 10 U1 4 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2010 VL 18 IS 1 BP 36 EP 55 DI 10.3109/10673220903523524 PG 20 WC Psychiatry SC Psychiatry GA 562NF UT WOS:000275057900003 PM 20047460 ER PT J AU Quinn, DK Flaherty, AW Herman, JB Kleinschmidt, TL AF Quinn, Davin K. Flaherty, Alice W. Herman, John B. Kleinschmidt, Trude L. TI Over the Rainbow: A Case of Traumatic Brain Injury SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE flat affect; music; psychodynamic psychotherapy; self-esteem; stroke; traumatic brain injury; VIP C1 [Quinn, Davin K.] Univ New Mexico, Ctr Psychiat, Albuquerque, NM 87106 USA. [Flaherty, Alice W.; Herman, John B.; Kleinschmidt, Trude L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Flaherty, Alice W.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Herman, John B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kleinschmidt, Trude L.] McLean Hosp, Belmont, MA 02178 USA. RP Quinn, DK (reprint author), Univ New Mexico, Ctr Psychiat, 2600 Marble Ave NE, Albuquerque, NM 87106 USA. EM davinquinn@yahoo.com NR 20 TC 1 Z9 1 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2010 VL 18 IS 1 BP 56 EP 66 DI 10.3109/10673220903523953 PG 11 WC Psychiatry SC Psychiatry GA 562NF UT WOS:000275057900004 PM 20047461 ER PT J AU Hall, MH Smoller, JW AF Hall, Mei-Hua Smoller, Jordan W. TI A New Role for Endophenotypes in the GWAS Era: Functional Characterization of Risk Variants SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE endophenotypes; genomewide association studies (GWAS); psychiatric genetics ID GENOME-WIDE ASSOCIATION; OBSESSIVE-COMPULSIVE DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; BIPOLAR DISORDER; NEUROPHYSIOLOGICAL ENDOPHENOTYPES; PSYCHIATRIC-DISORDERS; 1ST-DEGREE RELATIVES; AUDITORY-STIMULATION; EXECUTIVE FUNCTION; TWINS DISCORDANT C1 [Hall, Mei-Hua] Harvard Univ, McLean Hosp, Sch Med, Psychol Res Lab, Belmont, MA 02478 USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat Genet Program Mood & Anxiety Disorders, Boston, MA 02114 USA. [Smoller, Jordan W.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Hall, MH (reprint author), Harvard Univ, McLean Hosp, Sch Med, Psychol Res Lab, 115 Mill St, Belmont, MA 02478 USA. EM mhall@mclean.harvard.edu FU NIMH NIH HHS [2T32MH016259-29A1, R01 MH085542, R01 MH079799, K01 MH086714, T32 MH016259, MH079799, MH085542] NR 87 TC 32 Z9 33 U1 1 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2010 VL 18 IS 1 BP 67 EP 74 DI 10.3109/10673220903523532 PG 8 WC Psychiatry SC Psychiatry GA 562NF UT WOS:000275057900005 PM 20047462 ER PT J AU Konetzka, RT Werner, RM AF Konetzka, R. Tamara Werner, Rachel M. TI Applying Market-Based Reforms To Long-Term Care SO HEALTH AFFAIRS LA English DT Article ID PAY-FOR-PERFORMANCE; QUALITY-OF-CARE; NEW-YORK-STATE; NURSING-HOME RESIDENTS; ARTERY-BYPASS-SURGERY; HEALTH-CARE; CARDIAC-SURGERY; PUBLICATION; INFORMATION; OUTCOMES AB Recent trends in U. S. long-term care policy reflect three broad goals Americans have for the quality of long-term care: improving quality of life, reducing fragmentation of delivery and financing, and increasing use of home and community-based care. At the same time, market-based reforms-namely, public reporting and pay-for-performance-have taken on their own momentum, aimed at improving the clinical quality of care among nursing home and home health care providers. The focus of reporting systems should be broadened to include quality of life in addition to clinical quality and to make measures less dependent on the setting in which care is delivered. C1 [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Konetzka, RT (reprint author), Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. EM konetzka@uchicago.edu NR 44 TC 11 Z9 11 U1 1 U2 10 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2010 VL 29 IS 1 BP 74 EP 80 DI 10.1377/hlthaff.2009.0559 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 539JZ UT WOS:000273251500011 PM 20048363 ER PT J AU Werner, RM Konetzka, RT AF Werner, Rachel M. Konetzka, R. Tamara TI Advancing Nursing Home Quality Through Quality Improvement Itself SO HEALTH AFFAIRS LA English DT Article ID RESIDENT ASSESSMENT INSTRUMENT; PAY-FOR-PERFORMANCE; HEALTH-CARE; OF-LIFE; IMPACT AB The traditional approaches to improving the quality of care at U. S. nursing homes-regulation, inspection, and accountability through public reporting-have produced modest results. Greater progress could be made by focusing incentives on broader processes related to improving quality. This could foster a culture of upstream identification and solving of problems that would supplement existing downstream requirements to meet specific safety and care standards. C1 [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM rwerner@mail.med.upenn.edu FU AHRQ HHS [R01HS016478-01] NR 37 TC 15 Z9 15 U1 1 U2 6 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2010 VL 29 IS 1 BP 81 EP 86 DI 10.1377/hlthaff.2009.0555 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 539JZ UT WOS:000273251500012 PM 20048364 ER PT J AU Thrall, JH AF Thrall, James H. TI MRI Use In Medicare SO HEALTH AFFAIRS LA English DT Letter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Thrall, JH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2010 VL 29 IS 1 BP 219 EP 220 PG 2 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 539JZ UT WOS:000273251500038 PM 20063452 ER PT J AU Taylor-Clark, KA Viswanath, K Blendon, RJ AF Taylor-Clark, Kalahn Alexandra Viswanath, Kasisomayajula Blendon, Robert J. TI Communication Inequalities During Public Health Disasters: Katrina's Wake SO HEALTH COMMUNICATION LA English DT Article ID HURRICANE-KATRINA; CRISIS COMMUNICATION; NATURAL DISASTERS; UNITED-STATES; RACE; VULNERABILITY; COMMUNITY; ETHNICITY; BARRIERS; HAZARD AB We evaluate effects of low socioeconomic position (SEP) and social networks among Black Hurricane Katrina victims on access to and processing of evacuation orders, and abilities to evacuate before the storm hit. We also explore whether SEP, moderating conditions, and communication outcomes affected risk perceptions of the storm's severity and compliance with evacuation orders. We conducted stepwise logistic regression analyses using survey data collected in September 2005 among Black respondents in shelters throughout Houston, TX. Having few social networks, being unemployed, and being of younger age were significantly associated with having heard evacuation orders and whether victims' perceived having heard clear orders. This study provides implications for targeted public health emergency campaigns and future research to understand the effects of sociodemographic influences on communication inequalities and public health preparedness. C1 [Taylor-Clark, Kalahn Alexandra] Brookings Inst, Econ Studies, Washington, DC 20036 USA. [Viswanath, Kasisomayajula; Blendon, Robert J.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Viswanath, Kasisomayajula] Dana Farber Canc Inst, Boston, MA USA. [Blendon, Robert J.] John F Kennedy Sch Govt, Cambridge, MA USA. RP Taylor-Clark, KA (reprint author), Brookings Inst, Econ Studies, Suite 600,1775 Massachusetts Ave, Washington, DC 20036 USA. EM ktclark@brookings.edu NR 58 TC 13 Z9 13 U1 2 U2 13 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1041-0236 J9 HEALTH COMMUN JI Health Commun. PY 2010 VL 25 IS 3 BP 221 EP 229 AR PII 922111613 DI 10.1080/10410231003698895 PG 9 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA 595BM UT WOS:000277585700003 PM 20461607 ER PT J AU Frakt, AB Pizer, SD AF Frakt, Austin B. Pizer, Steven D. TI BENEFICIARY PRICE SENSITIVITY IN THE MEDICARE PRESCRIPTION DRUG PLAN MARKET SO HEALTH ECONOMICS LA English DT Article DE Medicare; prescription drug plans; Part D; elasticity; premium ID INDUSTRY; MODELS; CHOICE; RISK AB The Medicare stand-alone prescription drug plan (PDP) came into existence in 2006 as part of the Medicare prescription drug benefit. It is the most popular plan type among Medicare drug plans and large numbers of plans are available to all beneficiaries. I it this article we present the first analysis of beneficiary price sensitivity in the PDP market. Our estimate of elasticity of enrollment with respect to premium, -1.45, is larger in magnitude than has been found in the Medicare HMO market. This high degree of beneficiary price sensitivity for PDPs is consistent with relatively low product differentiation, low fixed costs of entry in the PDP market, and the fact that, in contrast to changing HMOs. beneficiaries can select a PDP without disrupting doctor-patient relationships. Published in 2009 by John Wiley & Sons, Ltd. C1 [Frakt, Austin B.; Pizer, Steven D.] VA Boston Healthcare Syst, Hlth Care Financing & Econ, Boston, MA 02130 USA. [Frakt, Austin B.; Pizer, Steven D.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. RP Frakt, AB (reprint author), VA Boston Healthcare Syst, Hlth Care Financing & Econ, 150 S Huntington Ave 152H, Boston, MA 02130 USA. EM frakt@bu.edu NR 26 TC 6 Z9 6 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD JAN PY 2010 VL 19 IS 1 BP 88 EP 100 DI 10.1002/hec.1451 PG 13 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 538MR UT WOS:000273189100007 PM 19191252 ER PT J AU Searl, MM Borgi, L Chemali, Z AF Searl, Meghan M. Borgi, Lea Chemali, Zeina TI It is time to talk about people: a human-centered healthcare system SO HEALTH RESEARCH POLICY AND SYSTEMS LA English DT Article AB Examining vulnerabilities within our current healthcare system we propose borrowing two tools from the fields of engineering and design: a) Reason's system approach [1] and b) User-centered design [2,3]. Both approaches are human-centered in that they consider common patterns of human behavior when analyzing systems to identify problems and generate solutions. This paper examines these two human-centered approaches in the context of healthcare. We argue that maintaining a human-centered orientation in clinical care, research, training, and governance is critical to the evolution of an effective and sustainable healthcare system. C1 [Searl, Meghan M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Searl, Meghan M.; Chemali, Zeina] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Borgi, Lea] St Elizabeth Hosp, Boston, MA 02135 USA. [Chemali, Zeina] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Searl, MM (reprint author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA. EM msearl@partners.org NR 82 TC 9 Z9 9 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-4505 J9 HEALTH RES POLICY SY JI Health Res. Policy Syst. PY 2010 VL 8 AR 35 DI 10.1186/1478-4505-8-35 PG 7 WC Health Policy & Services SC Health Care Sciences & Services GA V21PM UT WOS:000208219500035 PM 21110859 ER PT J AU Malaty, HM AF Malaty, H. M. BE Sutton, P Mitchell, HM TI Epidemiology of Helicobacter pylori Infection SO HELICOBACTER PYLORI IN THE 21ST CENTURY SE Advances in Molecular and Cellular Microbiology LA English DT Article; Book Chapter ID PEPTIC-ULCER MORTALITY; RISK-FACTORS; GASTRIC-CANCER; BIRTH-COHORT; DUODENAL-ULCER; SOCIOECONOMIC-STATUS; PERUVIAN CHILDREN; EARLY-CHILDHOOD; UNITED-STATES; ETHNIC-GROUPS C1 Vet Affairs Med Ctr 111D, Houston, TX 77030 USA. RP Malaty, HM (reprint author), Vet Affairs Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Hmalaty@bcm.tmc.edu NR 75 TC 3 Z9 3 U1 3 U2 3 PU CABI PUBLISHING-C A B INT PI WALLINGFORD PA CABI PUBLISHING, WALLINGFORD 0X10 8DE, OXON, ENGLAND BN 978-1-84593-594-8 J9 ADV M C M PY 2010 IS 17 BP 1 EP 12 DI 10.1079/9781845935948.0001 D2 10.1079/9781845935948.0000 PG 12 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Infectious Diseases; Microbiology SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Infectious Diseases; Microbiology GA BVZ78 UT WOS:000293218300002 ER PT B AU Tan, KY Kim, FS Wagers, AJ Mayack, SR AF Tan, Kah Yong Kim, Francis S. Wagers, Amy J. Mayack, Shane R. BE Kondo, M TI Hematopoietic Stem Cells and Somatic Stem Cells SO HEMATOPOIETIC STEM CELL BIOLOGY SE Stem Cell Biology and Regenerative Medicine LA English DT Article; Book Chapter ID COLONY-STIMULATING FACTOR; PRECURSOR-PRODUCT RELATIONSHIP; MUSCLE PROGENITOR CELLS; REGENERATING RAT-LIVER; MURINE YOLK-SAC; BONE-MARROW; IN-VIVO; OVAL CELLS; SELF-RENEWAL; SATELLITE CELLS AB Stem cells are unspecialized cells that can differentiate to generate more specialized cell types responsible for tissue-specific function. During development, the differentiation of pluripotent embryonic stem cells leads to the production of specialized somatic cells that are ultimately responsible for the structure and function of all adult tissues and organs. "Naturally" pluripotent cells exist only at the earliest stages of embryonic development. However, less differentiated stein and progenitor cells are also present in adult tissues. In contrast to pluripotent embryonic stem cells, adult stem cells generally only form a limited number of cell types corresponding to their tissues of origin. These multipotent or unipotent adult stem cells exist in many, though probably not all, adult tissues including bone marrow (BM), brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, and retina. "Multipotent" stem cells can generate several types of cells within a given tissue (e.g., hematopoietic/blood forming stem cells), whereas "unipotent" stem cells give rise to only one differentiated cell type (e.g., skeletal muscle stem cells). Though adult stem cells exist at a very low frequency in adult tissues, they serve a critical function in maintaining tissue homeostasis and generating replacement cells to repair tissues after injury. Here, we review the current literature on adult stein cells and specifically highlight the regulation of multipotent hematopoietic stems cells in contrast with that of unipotent skeletal muscle stem cells, as well as discuss their respective roles in tissue homeostasis and repair. C1 [Tan, Kah Yong; Kim, Francis S.; Wagers, Amy J.; Mayack, Shane R.] Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA. [Tan, Kah Yong; Kim, Francis S.; Wagers, Amy J.; Mayack, Shane R.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Tan, Kah Yong; Kim, Francis S.; Wagers, Amy J.; Mayack, Shane R.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Tan, Kah Yong] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. RP Tan, KY (reprint author), Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA. NR 200 TC 1 Z9 1 U1 0 U2 4 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-346-6 J9 STEM CELLS BIOL REG JI Stem Cell Biol. Regen. Med. PY 2010 BP 57 EP 92 DI 10.1007/978-1-60327-347-3_3 D2 10.1007/978-1-60327-347-3 PG 36 WC Developmental Biology SC Developmental Biology GA BND84 UT WOS:000274241800003 ER PT J AU Seethala, S Hess, R Bossola, M Unruh, ML Weisbord, SD AF Seethala, Srikanth Hess, Rachel Bossola, Maurizio Unruh, Mark L. Weisbord, Steven D. TI Sexual function in women receiving maintenance dialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Women; sexual dysfunction; dialysis ID BUPROPION-SUSTAINED-RELEASE; QUALITY-OF-LIFE; ERECTILE DYSFUNCTION; HEMODIALYSIS-PATIENTS; SILDENAFIL TREATMENT; KIDNEY-DISEASE; FUNCTION INDEX; RENAL-DISEASE; MINI-COG; VALIDATION AB While substantial attention has been paid to the issue of sexual dysfunction in men on chronic dialysis, less is known about this problem in women with end-stage renal disease. We sought to assess sexual dysfunction in women on chronic dialysis and determine whether patients discuss this problem with their providers and receive treatment. We prospectively enrolled women receiving chronic hemodialysis or peritoneal dialysis in Pittsburgh, PA. We asked patients to complete the 19-item Female Sexual Function Index (FSFI) to assess sexual function and a 5-item survey that assessed whether patients had discussed sexual dysfunction with their providers and/or received treatment for this problem in the past. We enrolled 66 patients; 59 (89%) on hemodialysis and 7 (11%) on peritoneal dialysis. All patients completed the FSFI, of whom 53 (80%) had FSFI scores < 26.55, consistent with the presence of sexual dysfunction. Of 37 patients who were married or residing with a significant other, 27 (73%) had sexual dysfunction. Among 24 participants who reported having been sexually active over the previous 4 weeks, 11 (46%) had sexual dysfunction. Only 21% of patients with sexual dysfunction had discussed this problem with their gynecologist, renal or primary provider, and 3 (6%) reported having received treatment. Sexual dysfunction is common in women on dialysis, even among patients who are married or residing with a significant other and those who are sexually active. However, few women discuss this issue with their providers or receive treatment. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Unruh, Mark L.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Bossola, Maurizio] Catholic Univ, Dept Surg, Dialysis Unit, Rome, Italy. [Hess, Rachel] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Seethala, Srikanth] Univ Pittsburgh, Med Ctr, Mercy Hosp, Dept Med, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Seethala, Srikanth/0000-0002-2672-6884 NR 25 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD JAN PY 2010 VL 14 IS 1 BP 55 EP 60 DI 10.1111/j.1542-4758.2009.00404.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 554RR UT WOS:000274452600008 PM 19758295 ER PT J AU Chatterjee, N Mishra, A Soni, R Kulkarni, H Mamtani, M Shrivasatava, M AF Chatterjee, Nirupama Mishra, Amit Soni, Ravindra Kulkarni, Hemant Mamtani, Manju Shrivasatava, Manisha TI BAYESIAN ESTIMATES OF THE PREVALENCE OF beta-THALASSEMIA TRAIT IN VOLUNTARY BLOOD DONORS OF CENTRAL INDIA: A SURVEY SO HEMOGLOBIN LA English DT Article DE beta-Thalassemia (beta-thal) trait; Voluntary blood donors; Bayesian methods; Madhya Pradesh; India ID TRANSFUSION-DEPENDENT THALASSEMIA; PRENATAL-DIAGNOSIS; DISEASE PREVALENCE; CHELATION-THERAPY; EXPERIENCE; HETEROGENEITY; POPULATIONS; MAHARASHTRA; ORIGIN; CLINES AB Early detection of beta-thalassemia (beta-thal) trait is important. Voluntary blood donors represent an important group who are accessible and cooperative for this purpose. However, the usefulness of this population in beta-thal trait detection programs has not been studied in India. We conducted a hematological survey of 5,045 blood donors who visited the Bhopal Memorial Hospital & Research Centre, Bhopal in central India. Using robust Bayesian methods, we estimated the prevalence of beta-thal trait. The overall prevalence of beta-thal trait in the study population was 9.59% [95% confidence interval (95% CI) 8.78-10.4%]. The prevalence of beta-thal trait varied across the states of origin and within the state of Madhya Pradesh. We observed a cline effect for beta-thal trait prevalence in relation to the latitude (p = 0.024). We conclude that blood donors offer an attractive adjunct to beta-thal trait detection in national programs. Our study also offers insights into the beta-thal trait gene flow and migration in India. C1 [Chatterjee, Nirupama; Mishra, Amit; Soni, Ravindra; Shrivasatava, Manisha] Bhopal Mem Hosp & Res Ctr, Dept Transfus Med, Thalassaemia Unit, Bhopal, India. [Kulkarni, Hemant; Mamtani, Manju] Lata Med Res Fdn, Nagpur, Maharashtra, India. [Kulkarni, Hemant; Mamtani, Manju] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kulkarni, Hemant; Mamtani, Manju] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. RP Mamtani, M (reprint author), 12023 Waterway Rdg, San Antonio, TX 78249 USA. EM manjuhemant@gmail.com NR 44 TC 2 Z9 2 U1 0 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0363-0269 J9 HEMOGLOBIN JI Hemoglobin PY 2010 VL 34 IS 6 BP 548 EP 560 DI 10.3109/03630269.2010.526488 PG 13 WC Biochemistry & Molecular Biology; Hematology SC Biochemistry & Molecular Biology; Hematology GA 680GS UT WOS:000284221000005 PM 21077762 ER PT B AU White, DL Firozi, A El-Serag, HB AF White, Donna L. Firozi, Amir El-Serag, Hashem B. BE Carr, BI TI Epidemiology of Hepatocellular Carcinoma SO HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND TREATMENT, SECOND EDITION SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Hepatitis C; hepatitis B; cirrhosis; incidence; prevalence; risk; genetic association; coffee; insulin resistance; liver cancer; epidemiology; determinants; risk factors ID CHRONIC HEPATITIS-C; VIRUS-RELATED CIRRHOSIS; CHRONIC LIVER-DISEASE; S-TRANSFERASE M1; GENETIC POLYMORPHISMS; UNITED-STATES; RISK-FACTORS; CANCER-RISK; COFFEE CONSUMPTION; INTERFERON THERAPY AB Hepatocellular carcinoma (HCC) affects more than half a million individuals per year worldwide. It is a largely preventable disease. Most cases are related to hepatitis B virus infection in sub-Saharan Africa and Eastern Asia (except Japan). Hepatitis C virus has emerged as an important cause of HCC particularly in North America and some parts of Europe, where a recent sharp increase in HCC has been reported. There is growing evidence of an association between obesity and diabetes and increased risk of HCC; however, the causal link is still unclear. The striking geographic and racial variations in the occurrence of HCC are partly explained by the distribution of HBV and HCV infections. Additional established risk factors for HCC include older age, male sex, heavy alcohol intake, aflatoxin exposure, iron overload related to hemochromatosis, and possibly tobacco smoking. The role of diet except for alcohol drinking and aflatoxin contamination in the etiology of HCC in human Populations is largely unknown. Host genetic factors are being examined but definitive data are lacking. Most of these risk factors operate by promoting the development of cirrhosis which is present in most HCC cases. The annual risk of HCC in cirrhosis ranges between I and 7%. This review discusses in detail the epidemiology of HCC from a global perspective. C1 [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Houston Ctr Qual Care & Utilizat Studies, Clin Epidemiol & Outcomes Program, Houston, TX USA. RP White, DL (reprint author), Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. NR 86 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-373-2 J9 CURR CLIN ONCOL PY 2010 BP 1 EP 25 DI 10.1007/978-1-60327-376-3_1 D2 10.1007/978-1-60327-376-3 PG 25 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BLX28 UT WOS:000271269800001 ER PT J AU Neumann-Haefelin, C Timm, J Schmidt, J Kersting, N Fitzmaurice, K Oniangue-Ndza, C Kemper, MN Humphreys, I McKiernan, S Kelleher, D Lohmann, V Bowness, P Huzly, D Rosen, HR Kim, AY Lauer, GM Allen, TM Barnes, E Roggendorf, M Blum, HE Thimme, R AF Neumann-Haefelin, Christoph Timm, Joerg Schmidt, Julia Kersting, Nadine Fitzmaurice, Karen Oniangue-Ndza, Cesar Kemper, Michael N. Humphreys, Isla McKiernan, Susan Kelleher, Dermot Lohmann, Volker Bowness, Paul Huzly, Daniela Rosen, Hugo R. Kim, Arthur Y. Lauer, Georg M. Allen, Todd M. Barnes, Eleanor Roggendorf, Michael Blum, Hubert E. Thimme, Robert TI Protective Effect of Human Leukocyte Antigen B27 in Hepatitis C Virus Infection Requires the Presence of a Genotype-Specific Immunodominant CD8+ T-Cell Epitope SO HEPATOLOGY LA English DT Article ID MHC-CLASS-I; LYMPHOCYTE RESPONSE; VIRAL CLEARANCE; ESCAPE; EVOLUTION; PEPTIDES; TYPE-1; HCV; POLYMORPHISMS; DETERMINANTS AB Human leukocyte antigen B27 (HLA-B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HI.A-B27-restricted CD8+ T-cell epitopes in both infections. In order to define the relative contribution of a specific HLA-B27-restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype I epitope, for which the protective role has been described, with the corresponding region in genotype 3 that differs in its sequence by three amino acid residues. The genotype 3a peptide was not recognized by CD8+ T cells specific for the genotype 1 peptide. Furthermore, patients with acute or chronic infection with HCV genotype 3a did not mount T-cell responses to this epitope region, and their autologous viral sequences showed no evidence of T-cell pressure. Finally, we found a significantly higher frequency of HLA-B27 positivity in patients with chronic HCV genotype 3a infection compared to genotype I infection, indicating that there is no protection by HLA-B27 in HCV genotype 3 infection. Conclusion: Our data indicate that the protective effect of HLA-B27 is limited to HCV genotype I infection and does not expand to other genotypes such as genotype 3a. This can most likely be explained by intergenotype sequence diversity leading to the loss of the immunodominant HLA-B27 epitope in viral strains other than genotype 1. Our results underline the central role of a single HLA-B27-restricted epitope-specific CD8+ T-cell response in mediating protection in HCV genotype I infection. (HEPATOLOGY 2010;51:54-62.) C1 [Neumann-Haefelin, Christoph; Schmidt, Julia; Kersting, Nadine; Blum, Hubert E.; Thimme, Robert] Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany. [Neumann-Haefelin, Christoph; Schmidt, Julia] Univ Freiburg, CCI, D-79106 Freiburg, Germany. [Neumann-Haefelin, Christoph; Oniangue-Ndza, Cesar; Kemper, Michael N.; Kim, Arthur Y.; Lauer, Georg M.; Allen, Todd M.] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA. [Timm, Joerg; Roggendorf, Michael] Univ Essen Gesamthsch, Dept Virol, Essen, Germany. [Fitzmaurice, Karen; McKiernan, Susan; Kelleher, Dermot] St James Hosp, Trinity Ctr Hlth Sci, Dublin 8, Ireland. [Humphreys, Isla; Barnes, Eleanor] Univ Oxford, Nuffield Dept Clin Med, Oxford OX1 2JD, England. [Lohmann, Volker] Univ Heidelberg, Dept Mol Virol, D-6900 Heidelberg, Germany. [Bowness, Paul] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England. [Huzly, Daniela] Univ Freiburg, Dept Virol, D-79106 Freiburg, Germany. [Rosen, Hugo R.] Univ Colorado Hlth Sci, Dept Med, Denver, CO USA. [Schmidt, Julia] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany. RP Thimme, R (reprint author), Univ Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany. EM robert.thimme@uniklinik-freiburg.de RI Neumann-Haefelin, Christoph/E-5550-2011; Allen, Todd/F-5473-2011; OI Lohmann, Volker/0000-0001-8719-7608; bowness, paul/0000-0003-4597-0484 FU Bundesministerium fur Bildung und Forschung (BMBF) [01KI0793, 01EO0803]; Deutsche Forschungsgemeinschaft [TH 719/3-1]; [FOR 1202]; [TI323/3-1] FX Supported by the Bundesministerium fur Bildung und Forschung (BMBF 01KI0793 and 01EO0803) and the Deutsche Forschungsgemeinschaft (Heisenberg Professorship TH 719/3-1, FOR 1202 "Mechanisms of persistence of hepatotropic viruses", and TI323/3-1). NR 28 TC 36 Z9 38 U1 0 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2010 VL 51 IS 1 BP 54 EP 62 DI 10.1002/hep.23275 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 541RV UT WOS:000273438400010 PM 20034048 ER PT J AU Corey, KE Chung, RT AF Corey, Kathleen E. Chung, Raymond T. TI Hepatitis C Virus Infection, Lipids, and Coronary Heart Disease: a Pandora's Box Reply SO HEPATOLOGY LA English DT Letter ID CHOLESTEROL C1 [Corey, Kathleen E.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA. RP Corey, KE (reprint author), Massachusetts Gen Hosp, Dept Gastroenterol, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JAN PY 2010 VL 51 IS 1 BP 343 EP 344 DI 10.1002/hep.23413 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 541RV UT WOS:000273438400041 ER PT J AU Moriguchi, H Chung, RT Sato, C AF Moriguchi, Hisashi Chung, Raymond T. Sato, Chifumi TI New Translational Research on Novel Drugs for Hepatitis C Virus 1b Infection by Using a Replicon System and Human Induced Pluripotent Stem Cells SO HEPATOLOGY LA English DT Letter ID REPLICATION; STATINS C1 [Moriguchi, Hisashi] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan. [Moriguchi, Hisashi; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Moriguchi, Hisashi; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA. [Moriguchi, Hisashi; Sato, Chifumi] Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Dept Analyt Hlth Sci, Tokyo, Japan. RP Moriguchi, H (reprint author), Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan. NR 4 TC 3 Z9 3 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2010 VL 51 IS 1 BP 344 EP 345 DI 10.1002/hep.23378 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 541RV UT WOS:000273438400042 PM 19957377 ER PT J AU Moriguchi, H Chung, RT Sato, C AF Moriguchi, Hisashi Chung, Raymond T. Sato, Chifumi TI An Identification of the Novel Combination Therapy for Hepatitis C Virus 1b Infection by Using a Replicon System and Human Induced Pluripotent Stem Cells SO HEPATOLOGY LA English DT Letter ID REPLICATION; INTERFERON C1 [Moriguchi, Hisashi] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan. [Moriguchi, Hisashi; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Moriguchi, Hisashi; Chung, Raymond T.] Harvard Univ, Sch Med, Boston, MA USA. [Moriguchi, Hisashi; Sato, Chifumi] Tokyo Med & Dent Univ, Grad Sch Hlth Sci, Dept Analyt Hlth Sci, Tokyo, Japan. RP Moriguchi, H (reprint author), Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan. NR 5 TC 4 Z9 4 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2010 VL 51 IS 1 BP 351 EP 352 DI 10.1002/hep.23423 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 541RV UT WOS:000273438400050 PM 20034040 ER PT J AU Steinvorth, S Wang, CM Ulbert, I Schomer, D Halgren, E AF Steinvorth, Sarah Wang, Chunmao Ulbert, Istvan Schomer, Donald Halgren, Eric TI Human Entorhinal Gamma and Theta Oscillations Selective for Remote Autobiographical Memory SO HIPPOCAMPUS LA English DT Article DE remote memory; medial temporal lobes; episodic memory; consolidation; intracranial EEG ID WORKING-MEMORY; DECLARATIVE MEMORY; FUNCTIONAL NEUROANATOMY; PHASE SYNCHRONIZATION; SEMANTIC MEMORY; BAND ACTIVITY; HIPPOCAMPAL; RETRIEVAL; TASK; EEG AB Current source densities in different layers of the human entorhinal cortex (ER) were recorded using a linear array of 24 micro-electrodes during three memory conditions: a remote autobiographical condition eliciting recollections of events that occurred 10 or more years ago in the participant's past, a semantic icon condition invoking the mental image of a well-known object, and a semantic knowledge condition asking about general information. Our data demonstrate theta, gamma, and delta oscillations in left ER particularly for remote autobiographical memory. Gamma is predominant in hippocampally projecting layers during presentation of the memory cue, whereas the a is prolonged and dominant in cortically projecting layers during memory retrieval. Gamma interactions between ER and hippocampal formation (HF) may elicit an HF contribution to recall under influences relayed from the association cortex (AC). This contribution may then be relayed back to AC during retrieval of the memory orchestrated by theta interactions with ER. Accordingly, theta oscillations were recorded simultaneously in frontal and temporal cortices. (C) 2009 Wiley-Liss, Inc. C1 [Steinvorth, Sarah] Harvard Univ, Sch Med, Martinos Ctr Biomed Imaging, MIT,Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Wang, Chunmao] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA. [Ulbert, Istvan] Hungarian Acad Sci, Inst Psychol, Budapest, Hungary. [Ulbert, Istvan] Peter Pazmany Catholic Univ, Dept Informat Technol, Budapest, Hungary. [Schomer, Donald] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Neurol, Boston, MA 02215 USA. [Halgren, Eric] Univ Calif San Diego, Ctr Multimodal Imaging, San Diego, CA 92103 USA. RP Steinvorth, S (reprint author), Harvard Univ, Sch Med, Martinos Ctr Biomed Imaging, MIT,Massachusetts Gen Hosp, Bld 149 13th St, Charlestown, MA 02129 USA. EM ssteinv@nmr.mgh.harvard.edu RI Ulbert, Istvan/F-2213-2010 FU NIH [NS18741, NS44623] FX Grant sponsor: NIH; Grant numbers: NS18741, NS44623 NR 62 TC 19 Z9 22 U1 0 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2010 VL 20 IS 1 BP 166 EP 173 DI 10.1002/hipo.20597 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 545JF UT WOS:000273727600018 PM 19338019 ER PT J AU Wang, L Negreira, A La Violette, P Bakkour, A Sperling, RA Dickerson, BC AF Wang, Liang Negreira, Alyson La Violette, Peter Bakkour, Akram Sperling, Reisa A. Dickerson, Bradford C. TI Intrinsic Interhemispheric Hippocampal Functional Connectivity Predicts Individual Differences in Memory Performance Ability SO HIPPOCAMPUS LA English DT Article DE functional magnetic resonance imaging; hippocampus; episodic memory ID EPISODIC MEMORY; SPONTANEOUS FLUCTUATIONS; ALZHEIMERS-DISEASE; COORDINATE SYSTEM; CORTICAL SURFACE; BRAIN ACTIVITY; RESTING BRAIN; HUMAN DORSAL; FREE-RECALL; NETWORK AB When given challenging episodic memory tasks, young adults demonstrate notable individual differences in performance. Recent evidence suggests that individual differences in human behavior may be related to the strength of functional connectivity of large-scale functional networks as measured by spontaneous fluctuations in regional brain activity during quiet wakefulness (the "resting state"), in the absence of task performance. In this study, we sought to determine whether individual differences in memory performance could be predicted by the interhemispheric functional connectivity of the two hippocampi, hypothesized to reflect the intrinsic connectivity within the large-scale medial temporal lobe memory system. Results demonstrated that interhemispheric hippocampal functional connectivity during quiet wakefulness was predictive of the capacity to freely recall recently learned information (r = 0.47, P < 0.05). In contrast, functional connectivity of bilateral motor cortices had no relationship to free recall, supporting the specificity of the hippocampal data. Thus, individual differences in the capacity to perform episodic memory tasks, which may be persistent behavioral traits or transient states, may be at least partly subserved by individual differences in the functional connectivity of large-scale functional-anatomic memory networks. (C) 2010 Wiley-Liss, Inc. C1 [Wang, Liang; Negreira, Alyson; La Violette, Peter; Bakkour, Akram; Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02114 USA. [Wang, Liang; Negreira, Alyson; La Violette, Peter; Bakkour, Akram; Sperling, Reisa A.; Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA. [Wang, Liang; Negreira, Alyson; La Violette, Peter; Bakkour, Akram] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Sperling, Reisa A.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Sperling, Reisa A.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA. [Sperling, Reisa A.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Sperling, Reisa A.; Dickerson, Bradford C.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Boston, MA 02115 USA. RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Charlestown, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu RI Wang, Liang/E-8652-2011; OI Bakkour, Akram/0000-0002-6070-4945 FU NIA [R01-AG29411, R21-AG29840, P50-AG05134]; NINDS [R01-NS042861]; NCRR [P41-RR14075, U24-RR021382]; Alzheimer's Association; Mental Illness and Neuroscience Discovery (MIND) Institute FX Grant sponsor: NIA; Grant numbers: R01-AG29411, R21-AG29840, P50-AG05134; Grant sponsor: NINDS; Grant number: R01-NS042861; Grant sponsor: NCRR; Grant numbers: P41-RR14075, U24-RR021382; Grant sponsor: The Alzheimer's Association and the Mental Illness and Neuroscience Discovery (MIND) Institute. NR 34 TC 41 Z9 42 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2010 VL 20 IS 3 BP 345 EP 351 DI 10.1002/hipo.20771 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 571TJ UT WOS:000275778400001 PM 20087893 ER PT B AU Friedlich, AL Tanzi, RE Perry, G Takeda, A Zhu, XW Smith, MA AF Friedlich, Avi L. Tanzi, Rudolph E. Perry, George Takeda, Atsushi Zhu, Xiongwei Smith, Mark A. BE Costa, A Villalba, E TI REGULATION OF alpha-SYNUCLEIN GENE EXPRESSION: IMPLICATIONS FOR PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS SO HORIZONS IN NEUROSCIENCE RESEARCH, VOL 2 SE Horizons in Neuroscience Research LA English DT Article; Book Chapter DE alpha-synuclein; GATA hematopoetic transcription factors; iron regulatory protein; iron responsive element; Lewy body disease; Parkinson's disease; RNA splicing; SNCA ID IRON-METABOLISM; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; LEWY BODIES; AGGREGATION; RNA; DROSOPHILA; ALZHEIMER; TOXICITY; PROTEINS AB The alpha-synuclein protein is implicated in the etiopathogenesis of spectrum neurodegenerative disorders referred to as synucleinopathies, which include Parkinson's disease and Lewy body variant of Alzheimer's disease. Production of the alpha-synuclein protein is a key step in the development of these synucleinopathies in which neurodegeneration is thought to result from abnormal alpha-synuclein folding and aggregation. Here, we review alpha-synuclein gene expression as a coordinated network of transcriptional, post-transcriptional, and pre-translational events. It is our belief that alpha-synuclein is a pathognominic signature and that determining factors that regulate production of alpha-synuclein may lead to the development of mechanism-based therapeutics and improved pharmacotherapy for the synucleinopathies. C1 [Perry, George; Zhu, Xiongwei; Smith, Mark A.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Friedlich, Avi L.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Tanzi, Rudolph E.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA USA. [Tanzi, Rudolph E.] Harvard Univ, Sch Med, Charlestown, MA USA. [Perry, George] Univ Texas San Antonio, Coll Sci, UTSA Neurosci Inst, San Antonio, TX USA. [Perry, George] Univ Texas San Antonio, Coll Sci, Dept Biol, San Antonio, TX USA. [Takeda, Atsushi] Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 980, Japan. RP Smith, MA (reprint author), Case Western Reserve Univ, Dept Pathol, 2103 Cornell Rd, Cleveland, OH 44106 USA. EM mark.smith@case.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-876-9 J9 HORIZ NEUROSCI RES PY 2010 BP 171 EP 178 PG 8 WC Neurosciences SC Neurosciences & Neurology GA BSB69 UT WOS:000284081300008 ER PT J AU Goldfine, AB Fonseca, VA Jones, MR Wang, AC Ford, DM Truitt, KE AF Goldfine, A. B. Fonseca, V. A. Jones, M. R. Wang, A. C. Ford, D. M. Truitt, K. E. TI Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes SO HORMONE AND METABOLIC RESEARCH LA English DT Article DE antidiabetes agent; bile acid sequestrant; glucose; glycemic control; lipids ID GLYCEMIC CONTROL; LDL CHOLESTEROL; BILE-ACIDS; MELLITUS; GLUCOSE; THERAPY; RECEPTOR; DISEASE AB The bile acid sequestrant, colesevelam hydrochloride, is approved for glycemic control in adults with type 2 diabetes. In three double-masked, placebo-controlled studies, colesevelam hydrochloride 3.75 g/day demonstrated its glycemic-lowering properties when added to existing metformin-, insulin-, or sulfonylurea-based therapy in adults with inadequately controlled type 2 diabetes. This was a 52-week open-label extension study conducted at 63 sites in the United States and one site in Mexico to further evaluate the safety and tolerability of colesevelam hydrochloride in subjects with type 2 diabetes. All subjects who completed the three double-masked, placebo-controlled studies were eligible to enroll in this open-label extension. In total, 509 subjects enrolled and received open-label colesevelam hydrochloride 3.75 g/day for 52 weeks. Safety and tolerability of colesevelam hydrochloride was evaluated by the incidence and severity of adverse events. In total, 360 subjects (70.7%) completed the extension. Of the safety population, 361 subjects (70.9%) experienced an adverse event, most (88.1%) being mild or moderate in severity. Fifty-six adverse events (11.0%) were drug-related; the most frequent drug-related adverse events were constipation and dyspepsia. Thirty-five subjects (6.9%) discontinued due to an adverse event. Fifty-four subjects (10.6%) experienced a serious adverse event; only one was considered drug-related ( diverticulitis). Seventeen subjects (3.3%) experienced hypoglycemia; most episodes were mild or moderate in severity. Glycemic improvements with colesevelam hydrochloride were seen without change in weight over 52 weeks (0.2 kg mean reduction from baseline). Colesevelam hydrochloride was safe and well-tolerated as long-term therapy for patients with type 2 diabetes. C1 [Goldfine, A. B.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Fonseca, V. A.] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Jones, M. R.; Wang, A. C.] Daiichi Sankyo Inc, Parsippany, NJ USA. [Ford, D. M.; Truitt, K. E.] Daiichi Sankyo Pharma Dev, Edison, NJ USA. RP Goldfine, AB (reprint author), Harvard Univ, Sch Med, 1 Joslin Pl, Boston, MA 02115 USA. EM allison.goldfine@joslin.harvard.edu FU Daiichi Sankyo, Inc. FX This study was funded by Daiichi Sankyo, Inc. The authors thank Soamnauth Misir, Pharm. D., for his critical review of the manuscript. Editorial assistance for the preparation of this manuscript was provided by Karen Stau. er, Ph.D., and funded by Daiichi Sankyo, Inc. NR 14 TC 17 Z9 17 U1 1 U2 3 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 J9 HORM METAB RES JI Horm. Metab. Res. PD JAN PY 2010 VL 42 IS 1 BP 23 EP 30 DI 10.1055/s-0029-1241195 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 548AW UT WOS:000273932200004 PM 19862667 ER PT J AU Chan, YM Fenoglio-Simeone, KA Paraschos, S Muhammad, L Troester, MM Ng, YT Johnsonbaugh, RE Coons, SW Prenger, EC Kerrigan, JF Seminara, SB AF Chan, Yee-Ming Fenoglio-Simeone, Kristina A. Paraschos, Sophia Muhammad, Laura Troester, Matthew M. Ng, Yu-tze Johnsonbaugh, Roger E. Coons, Stephen W. Prenger, Erin C. Kerrigan, John F., Jr. Seminara, Stephanie B. TI Central Precocious Puberty due to Hypothalamic Hamartomas Correlates with Anatomic Features but Not with Expression of GnRH, TGF alpha, or KISS1 SO HORMONE RESEARCH IN PAEDIATRICS LA English DT Article DE Kisspeptin; KISS1R; GPR54; Reproduction; LHRH; Hypothalamic hamartoma ID HORMONE-RELEASING HORMONE; GROWTH-FACTOR-ALPHA; ELECTROPHYSIOLOGICAL PROPERTIES; GELASTIC SEIZURES; EPILEPSY; SURGERY; NEURONS AB Background/Aims: Hypothalamic hamartomas are the most common identifiable cause of central precocious puberty (CPP). Hamartoma characteristics proposed to be associated with CPP include specific anatomic features and expression of molecules such as gonadotropin-releasing hormone (GnRH), transforming growth factor alpha (TGF alpha), and GRM1A, which encodes the type 1 metabotropic glutamate receptor alpha isoform. We sought to determine whether hamartomas that cause CPP could be distinguished by anatomic features, expression of these molecules, or expression of KISS1, whose products signal through the receptor GPR54 to stimulate GnRH release. Methods: Clinical records and radiologic images were reviewed for 18 patients who underwent hamartoma resection for intractable seizures; 7 had precocious puberty. Resected tissue was examined for expression of GnRH, GnRH receptor (GnRHR), TGF alpha, KISS1, GPR54, and GRM1A Results: Hypothalamic hamartomas associated with CPP were more likely to contact the infundibulum or tuber cinereum and were larger than hamartomas not associated with CPP. GnRH, TGF alpha, and GnRHR were expressed by all hamartomas studied. Expression of KISS1, GPR54, and GRM1A did not differ significantly between hamartomas associated and not associated with CPP. Conclusion: Anatomic features rather than expression patterns of candidate molecules distinguish hypothalamic hamartomas that are associated with CPP from those that are not. Copyright (C) 2010 S. Karger AG, Basel C1 [Chan, Yee-Ming; Paraschos, Sophia; Seminara, Stephanie B.] Massachusetts Gen Hosp, Harvard Reprod Sci Ctr, Boston, MA 02114 USA. [Chan, Yee-Ming; Paraschos, Sophia; Seminara, Stephanie B.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Chan, Yee-Ming] Childrens Hosp, Dept Med, Div Endocrinol, Boston, MA 02115 USA. [Fenoglio-Simeone, Kristina A.; Muhammad, Laura; Troester, Matthew M.; Ng, Yu-tze; Kerrigan, John F., Jr.] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA. [Fenoglio-Simeone, Kristina A.; Muhammad, Laura; Troester, Matthew M.; Ng, Yu-tze; Kerrigan, John F., Jr.] St Josephs Hosp, Barrow Neurol Inst, Div Pediat Neurol, Phoenix, AZ 85013 USA. [Fenoglio-Simeone, Kristina A.; Muhammad, Laura; Troester, Matthew M.; Ng, Yu-tze; Kerrigan, John F., Jr.] St Josephs Hosp, Childrens Hlth Ctr, Phoenix, AZ 85013 USA. [Fenoglio-Simeone, Kristina A.; Muhammad, Laura; Troester, Matthew M.; Ng, Yu-tze; Kerrigan, John F., Jr.] Med Ctr, Phoenix, AZ USA. [Johnsonbaugh, Roger E.] Arizona Pediat Endocrinol, Phoenix, AZ USA. [Coons, Stephen W.] Barrow Neurol Inst, Div Neuropathol, Phoenix, AZ 85013 USA. [Prenger, Erin C.] Barrow Neurol Inst, Div Neuroimaging, Phoenix, AZ 85013 USA. RP Chan, YM (reprint author), 55 Fruit St,BHX 5, Boston, MA 02114 USA. EM ymchan@partners.org FU US Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54 HD 028138, T32 HD 07369, F32 HD 056759]; Barrow Neurological Foundation; Novo Nordisk Lawson Wilkins Pediatric Endocrine Society FX We thank Douglas Hayden for statistical advice and members of the Massachusetts General Hospital Reproductive Endocrine Unit for valuable discussions. This work was supported by the US Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant U54 HD 028138) and the Barrow Neurological Foundation. Y.-M.C. received support from the US NICHD (grants T32 HD 07369 and F32 HD 056759) and a Novo Nordisk Lawson Wilkins Pediatric Endocrine Society Research Fellowship Award. NR 28 TC 11 Z9 12 U1 1 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1663-2818 J9 HORM RES PAEDIAT JI Horm. Res. Paediatr. PY 2010 VL 73 IS 5 BP 312 EP 319 DI 10.1159/000308162 PG 8 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 594WL UT WOS:000277570100002 PM 20389100 ER PT J AU Ahlfors, SP Han, J Lin, FH Witzel, T Belliveau, JW Hamalainen, MS Halgren, E AF Ahlfors, Seppo P. Han, Jooman Lin, Fa-Hsuan Witzel, Thomas Belliveau, John W. Haemaelaeinen, Matti S. Halgren, Eric TI Cancellation of EEG and MEG Signals Generated by Extended and Distributed Sources SO HUMAN BRAIN MAPPING LA English DT Article DE magnetoencephalography; electroencephalography; forward model; inverse problem; cerebral cortex; cortical patch analysis ID ANTIDROMIC CORTICAL RESPONSE; EVENT-RELATED POTENTIALS; SURFACE-BASED ANALYSIS; TO-NOISE-RATIOS; MAGNETIC-FIELDS; BRAIN ACTIVITY; RE-ANALYSIS; MAGNETOENCEPHALOGRAPHY; ELECTROENCEPHALOGRAPHY; LOCALIZATION AB Extracranial patterns of scalp potentials and magnetic fields, as measured with electro- and magnetoencephalography (EEG, MEG), are spatially widespread even when the underlying source in the brain is focal. Therefore, loss in signal magnitude due to cancellation is expected when multiple brain regions are simultaneously active. We characterized these cancellation effects in EEG and MEG using a forward model with sources constrained on an anatomically accurate reconstruction of the cortical surface. Prominent cancellation was found for both EEG and MEG in the case of multiple randomly distributed source dipoles, even when the number of simultaneous dipoles was small. Substantial cancellation occurred also for locally extended patches of simulated activity, when the patches extended to opposite walls of sulci and gyri. For large patches, a difference between EEG and MEG cancellation was seen, presumably due to selective cancellation of tangentially vs. radially oriented sources. Cancellation effects can be of importance when electrophysiological data are related to hemo-dynamic measures. Furthermore, the selective cancellation may be used to explain some observed differences between EEG and MEG in terms of focal vs. widespread cortical activity. Hum Brain Mapp 31:140-149, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Ahlfors, Seppo P.; Han, Jooman; Lin, Fa-Hsuan; Witzel, Thomas; Belliveau, John W.; Haemaelaeinen, Matti S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Ahlfors, Seppo P.; Witzel, Thomas; Belliveau, John W.; Haemaelaeinen, Matti S.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Lin, Fa-Hsuan] Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan. [Halgren, Eric] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Ahlfors, SP (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr, 149 13th St,Rm 2301, Charlestown, MA 02129 USA. EM seppo@nmr.mgh.harvard.edu RI Hamalainen, Matti/C-8507-2013; Lin, Fa-Hsuan/G-6988-2012; Witzel, Thomas/P-1402-2014; Ahlfors, Seppo/P-3644-2016 OI Lin, Fa-Hsuan/0000-0002-9539-1731; FU Whitaker foundation [RG-01-0294]; NIH [NS57500, NS44623, NS18741, NS37462, HD40712, DA14178, EB07298]; National Center for Research Resources [P41RR14075]; MIND Research Network (MRN); National Science Council, Taiwan [NSC 97-2320-B-002-058-MY3, NSC 97-2221-E-002-005]; National Health Research Institute, Taiwan [NHRI-EX98-9715EC] FX Contract grant sponsor: Whitaker foundation; Contract grant number: RG-01-0294; Contract grant sponsor: NIH; Contract grant numbers: NS57500, NS44623, and NS18741; Contract grant sponsor: National Center for Research Resources; Contract grant number: P41RR14075; Contract grant sponsor: MIND Research Network (MRN); Contract grant sponsor: NIH; Contract grant numbers: NS37462, HD40712, DA14178, EB07298; Contract grant sponsor: National Science Council, Taiwan; Contract grant numbers: NSC 97-2320-B-002-058-MY3, NSC 97-2221-E-002-005; Contract grant sponsor: National Health Research Institute, Taiwan; Contract grant number: NHRI-EX98-9715EC. NR 60 TC 48 Z9 49 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2010 VL 31 IS 1 BP 140 EP 149 DI 10.1002/hbm.20851 PG 10 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 543BM UT WOS:000273544700012 PM 19639553 ER PT J AU Thameem, F Puppala, S Lehman, DM Stern, MP Blangero, J Abboud, HE Duggirala, R Habib, SL AF Thameem, Farook Puppala, Sobha Lehman, Donna M. Stern, Michael P. Blangero, John Abboud, Hanna E. Duggirala, Ravindranath Habib, Samy L. TI The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans SO HUMAN HEREDITY LA English DT Article DE Mexican Americans; OGG1; Type 2 diabetes; Ser326Cys polymorphism; Association; Tagging SNPs; rs1052133 ID OXIDATIVE DNA-DAMAGE; MEASURED GENOTYPE; MELLITUS; EXPRESSION; ISLETS; ENZYME; HOGG1; GENE; RATS AB Objective: Human 8-oxoguanine glycosylase 1 (OGG1) excises oxidatively damaged promutagenic base 8-oxoguanine, a lesion previously observed in a rat model of type 2 diabetes (T2DM). The objective of the present study is to determine whether genetic variation in OGG1 is associated with type 2 diabetes (T2DM) in a Mexican American cohort. Methods: Ten SNPs including two tagging SNPs (rs1052133, rs2072668) across the OGG1 gene region were selected from the Hapmap database and genotyped in the entire cohort (n = 670; 29% diabetes; 39 families) by TaqMan assay. Association analyses between the SNPs and T2DM were performed using the measured genotype approach as implemented in the program SOLAR. Results: Of the ten SNPs genotyped, only five were polymorphic. The minor allele frequencies of these 5 SNPs ranged from 1-38%. Of the SNPs examined for association, the Ser(326)Cys (rs1052133) exhibited significant association with T2DM (p = 0.016) after accounting for age and sex effects. Another intronic variant (rs2072668), which was in strong linkage disequilibrium (r(2) = 0.96) with Ser(326)Cys also exhibited significant association with T2DM (p = 0.031). Conclusions: These results suggest for the first time that the variants in OGG1 could influence diabetes risk in these Mexican American families and support a role for alterations of OGG1 in the pathogenesis of T2DM. Copyright (C) 2010 S. Karger AG, Basel C1 [Thameem, Farook] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. [Lehman, Donna M.; Stern, Michael P.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Thameem, Farook; Abboud, Hanna E.; Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, George OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Puppala, Sobha; Blangero, John; Duggirala, Ravindranath] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Abboud, Hanna E.; Habib, Samy L.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thameem@uthscsa.edu FU NIDDK NIH HHS [DK53889, DK47482, R01 DK042273-10, R01 DK047482, R01 DK047482-15, DK42273, R01 DK053889, R01 DK053889-10] NR 19 TC 15 Z9 19 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2010 VL 70 IS 2 BP 97 EP 101 DI 10.1159/000291964 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 633QJ UT WOS:000280518700003 PM 20606456 ER PT J AU Moskvina, V Smith, M Ivanov, D Blackwood, D StClair, D Hultman, C Toncheva, D Gill, M Corvin, A O'Dushlaine, C Morris, DW Wray, NR Sullivan, P Pato, C Pato, MT Sklar, P Purcell, S Holmans, P O'Donovan, MC Owen, MJ Kirov, G AF Moskvina, Valentina Smith, Michael Ivanov, Dobril Blackwood, Douglas StClair, David Hultman, Christina Toncheva, Draga Gill, Michael Corvin, Aiden O'Dushlaine, Colm Morris, Derek W. Wray, Naomi R. Sullivan, Patrick Pato, Carlos Pato, Michele T. Sklar, Pamela Purcell, Shaun Holmans, Peter O'Donovan, Michael C. Owen, Michael J. Kirov, George CA Int Schizophrenia Consortium TI Genetic Differences between Five European Populations SO HUMAN HEREDITY LA English DT Article DE Population; Gene; Stratification; Pigmentation; Immunity ID GENOME-WIDE ASSOCIATION; SKIN PIGMENTATION; STRATIFICATION; SELECTION; FOXP2; HAIR AB Aims: We sought to examine the magnitude of the differences in SNP allele frequencies between five European populations (Scotland, Ireland, Sweden, Bulgaria and Portugal) and to identify the loci with the greatest differences. Methods: We performed a population-based genome-wide association analysis with Affymetrix 6.0 and 5.0 arrays. We used a 4 degrees of freedom chi(2) test to determine the magnitude of stratification for each SNP. We then examined the genes within the most stratified regions, using a highly conservative cutoff of p < 10(-45). Results: We found 40,593 SNPs which are genome-wide significantly (p <= 10(-8)) stratified between these populations. The largest differences clustered in gene ontology categories for immunity and pigmentation. Some of the top loci span genes that have already been reported as highly stratified: genes for hair color and pigmentation (HERC2, EXOC2, IRF4), the LCT gene, genes involved in NAD metabolism, and in immunity (HLA and the Toll-like receptor genes TLR10, TLR1, TLR6). However, several genes have not previously been reported as stratified within European populations, indicating that they might also have provided selective advantages: several zinc finger genes, two genes involved in glutathione synthesis or function, and most intriguingly, FOXP2, implicated in speech development. Conclusion: Our analysis demonstrates that many SNPs show genome-wide significant differences within European populations and the magnitude of the differences correlate with the geographical distance. At least some of these differences are due to the selective advantage of polymorphisms within these loci. Copyright (C) 2010 S. Karger AG, Basel C1 [Moskvina, Valentina; Smith, Michael; Ivanov, Dobril; Holmans, Peter; O'Donovan, Michael C.; Owen, Michael J.; Kirov, George] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Dept Psychol Med & Neurol, Sch Med, Cardiff CF14 4XN, S Glam, Wales. [Blackwood, Douglas] Univ Edinburgh, Div Psychiat, Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland. [StClair, David] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland. [Hultman, Christina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Toncheva, Draga] Univ Hosp Maichin Dom, Dept Med Genet, Sofia, Bulgaria. [Gill, Michael; Corvin, Aiden; O'Dushlaine, Colm; Morris, Derek W.] Trinity Coll Dublin, Neuropsychiat Genet Res Grp, Dept Psychiat, Dublin, Ireland. [Gill, Michael; Corvin, Aiden; O'Dushlaine, Colm; Morris, Derek W.] Trinity Coll Dublin, Inst Mol Med, Dublin, Ireland. [Wray, Naomi R.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Sullivan, Patrick] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Pato, Carlos; Pato, Michele T.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Franz Alexander Chair Psychiat, Los Angeles, CA 90033 USA. [Sklar, Pamela; Purcell, Shaun] Broad Inst Harvard & MIT, Cambridge, MA USA. [Sklar, Pamela; Purcell, Shaun] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Moskvina, V (reprint author), Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Dept Psychol Med & Neurol, Sch Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales. EM MoskvinaV1@cardiff.ac.uk; Kirov@cardiff.ac.uk RI Wray, Naomi/C-8639-2015; Holmans, Peter/F-4518-2015; OI Wray, Naomi/0000-0001-7421-3357; Holmans, Peter/0000-0003-0870-9412; Corvin, Aiden/0000-0001-6717-4089; O'Donovan, Michael/0000-0001-7073-2379; Morris, Derek/0000-0002-3413-570X; Gill, Michael/0000-0003-0206-5337; Ivanov, Dobril/0000-0001-6271-6301; Escott-Price, Valentina/0000-0003-1784-5483 FU NIMH NIH HHS [R01 MH080403, R01 MH077139] NR 25 TC 14 Z9 14 U1 1 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2010 VL 70 IS 2 BP 141 EP 149 DI 10.1159/000313854 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 633QJ UT WOS:000280518700007 PM 20616560 ER PT B AU Crilly, J Lewis, J AF Crilly, John Lewis, JoAnn BE Baralt, J Callaos, N Lesso, W Tremante, A Welsch, F TI Internet-Based Psychiatric Interventions: Applications for Rural Veterans at Risk for Suicide SO ICSIT 2010: INTERNATIONAL CONFERENCE ON SOCIETY AND INFORMATION TECHNOLOGIES (POST-CONFERENCE EDITION) LA English DT Proceedings Paper CT International Conference on Society and Information Technologies CY APR 06-09, 2010 CL Orlando, FL SP Int Inst Informat & Syst DE Internet; psychiatric interventions; rural; Veteran and suicide ID RANDOMIZED CONTROLLED-TRIAL; DEPRESSION; COMPUTER; DISORDER; PARTICIPATION; COMMUNICATION; INFORMATION; SUPPORT; ANXIETY; URBAN AB The Internet is increasingly used to host interventions to treat depression, anxiety, post traumatic stress disorder, and substance abuse. It is also used to deliver suicide prevention interventions and has particular potential for reaching groups facing distance barriers to healthcare or who are socially isolated, factors which can increase risk for suicide. Veterans with mental health problems living in rural areas pose particular access challenges for Veterans Health Affairs (VHA), the federal agency charged with providing their healthcare. Rural Veterans can easily become isolated from mental healthcare providers. Telemedicine provides some access but requires knowledge of its operation by the user as well as the proper equipment and venue. VHA recently launched an Internet crisis chat service to help address this issue. In this paper we review the field of Internet-based psychiatric interventions and discuss the potential of online applications to deliver suicide prevention for rural Veterans. C1 [Crilly, John; Lewis, JoAnn] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY 14424 USA. RP Crilly, J (reprint author), US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY 14424 USA. NR 37 TC 0 Z9 0 U1 1 U2 1 PU INT INST INFORMATICS & SYSTEMICS PI ORLANDO PA 14269 LORD BARCLAY DR, ORLANDO, FL 32837 USA BN 978-1-934272-90-9 PY 2010 BP 39 EP 44 PG 6 WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic SC Computer Science; Engineering GA BG7KX UT WOS:000391415500008 ER PT J AU Hahn, JO McCombie, DB Reisner, AT Hojman, HM Asada, HH AF Hahn, Jin-Oh McCombie, Devin B. Reisner, Andrew T. Hojman, Horacio M. Asada, H. Harry TI Identification of Multichannel Cardiovascular Dynamics Using Dual Laguerre Basis Functions for Noninvasive Cardiovascular Monitoring SO IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY LA English DT Article DE Cardiovascular (CV) system; Laguerre basis function; noninvasive CV monitoring; two-channel blind system identification (ID) ID CARDIAC-OUTPUT; PRESSURE WAVE; SYSTEM-IDENTIFICATION; DERIVATION; SIGNALS; FORM AB This paper presents a novel method to identify the cardiovascular (CV) system using two distinct peripheral blood pressure (BP) signals. The method can characterize the distinct arterial path dynamics that shape each of the BP signals and recover the common central-flow signal fed to them. A Laguerre series data-compression technique is used to obtain a compact representation of the CV system, whose coefficients are identified using the multichannel blind system identification. A Laguerre model deconvolution algorithm is developed to stably recover the central-flow signal. Persistent excitation, model identifiability, and asymptotic variance are analyzed to quantify the method's validity and reliability, without using any direct measurement of central-flow input signal. Experimental results based on 7000 data segments obtained from nine swine subjects show that, for all the swine subjects under diverse physiologic conditions, the CV dynamics can be identified very reliably and the waveform of the central flow can be recovered stably from peripheral BP signals. C1 [Hahn, Jin-Oh; McCombie, Devin B.; Asada, H. Harry] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Reisner, Andrew T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Hojman, Horacio M.] Yale Univ, Dept Surg, New Haven, CT 06520 USA. RP Hahn, JO (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA. EM jinoh.hahn@alum.mit.edu; mccombie@mit.edu; areisner@partners.org; hhojman@yale.edu; asada@mit.edu FU Sharp Corporation FX This work was supported in part by Sharp Corporation. Recommended by Associate Editor J. Lee. NR 21 TC 4 Z9 4 U1 0 U2 3 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 1063-6536 J9 IEEE T CONTR SYST T JI IEEE Trans. Control Syst. Technol. PD JAN PY 2010 VL 18 IS 1 BP 170 EP 176 DI 10.1109/TCST.2008.2009996 PG 7 WC Automation & Control Systems; Engineering, Electrical & Electronic SC Automation & Control Systems; Engineering GA 537CU UT WOS:000273091300016 ER PT S AU Ruvkun, G Samuelson, AV Carr, CE Curran, SP Shore, DE AF Ruvkun, Gary Samuelson, Andrew V. Carr, Christopher E. Curran, Sean P. Shore, David E. BE Clemmons, D Robinson, ICAF Christen, Y TI Signaling Pathways that Regulate C. elegans Life Span SO IGFS: LOCAL REPAIR AND SURVIVAL FACTORS THROUGHOUT LIFE SPAN SE Research and Perspectives in Endocrine Interactions LA English DT Proceedings Paper CT 8th Symposium on Medicine and Endocrinology Research CY DEC 01, 2008 CL Paris, FRANCE ID NEMATODE CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS RESISTANCE; SYSTEMATIC RNAI SCREEN; HEAT-SHOCK FACTOR; AGE-1 PI3 KINASE; INSULIN-RECEPTOR; TRANSCRIPTION FACTOR; CALORIC RESTRICTION; DIETARY RESTRICTION; METABOLIC-RATE AB Insulin-like growth factor signaling and other endocrine axes contribute to stress and longevity regulation in C. elegans and other animals. By genetic and functional genomic analysis, we have identified players in this pathway. Many of these genes are conserved and likely to mediate endocrine regulation of longevity across the animal kingdom. C1 [Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Simches Res Bldg,185 Cambridge St,CPZN 7250, Boston, MA 02114 USA. RP Ruvkun, G (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Simches Res Bldg,185 Cambridge St,CPZN 7250, Boston, MA 02114 USA. EM ruvkun@molbio.mgh.harvard.edu OI Carr, Christopher/0000-0002-7946-5622 NR 108 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1861-2253 BN 978-3-642-04301-7 J9 RES PERSPECT END INT JI Res. Perspect. End. Int. PY 2010 BP 69 EP + DI 10.1007/978-3-642-04302-4_6 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BOE61 UT WOS:000276392100006 ER PT J AU Palley, LS O'Rourke, PP Niemi, SM AF Palley, Lori S. O'Rourke, P. Pearl Niemi, Steven M. TI Mainstreaming Animal-Assisted Therapy SO ILAR JOURNAL LA English DT Article DE animal-assisted activities (AAA); animal-assisted therapy (AAT); dog; human-animal interaction; One Health; pet therapy; randomized controlled trial ID SOCIAL-INTERACTION; CARE FACILITIES; ROMANTIC LOVE; DOG; PET; RESPONSES; HEALTH; STRESS; INTERVENTIONS; METAANALYSIS AB The term animal-assisted therapy (AAT) commonly refers to the presentation of an animal to one or more persons for the purpose of providing a beneficial impact on human health or well-being. AAT is an ideal example of "One Health" because of numerous studies and widespread testimonials indicating that many humans feel better in the presence of pets and other domesticated animals, and, conversely, that some of those creatures appear to respond positively to human company for their emotional and perhaps physical betterment. Many AAT studies have claimed a wide range of human health benefits, but much of the research is characterized by small-scale interventions among disparate fields, resulting in criticisms about weak study design or inconsistent methodology. Such criticisms contrast with the strongly held belief among many that interaction with friendly animals has a strong and innate value for the persons involved. Consequently the appeal of AAT in human medicine today may be generally characterized as a "push" by enthusiastic advocates rather than a "pull" by prescribing physicians. To fully integrate AAT into conventional medical practice as an accepted therapeutic modality, more convincing intervention studies are necessary to confirm its clinical merits, along with an understanding of the underlying mechanism of the human response to the company of friendly animals. C1 [Palley, Lori S.] Massachusetts Gen Hosp, Human Anim Relationships Program, Ctr Comparat Med, Charlestown, MA 02129 USA. [O'Rourke, P. Pearl] Partners HealthCare Syst, Human Res Affairs, Boston, MA USA. [O'Rourke, P. Pearl] Harvard Univ, Sch Med, Boston, MA USA. RP Palley, LS (reprint author), Massachusetts Gen Hosp, Human Anim Relationships Program, Ctr Comparat Med, 149 13th St,Room 5249, Charlestown, MA 02129 USA. EM lpalley@partners.org NR 77 TC 21 Z9 21 U1 6 U2 52 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1084-2020 EI 1930-6180 J9 ILAR J JI ILAR J. PY 2010 VL 51 IS 3 BP 199 EP 207 PG 9 WC Veterinary Sciences SC Veterinary Sciences GA 736LI UT WOS:000288495800002 PM 21131720 ER PT B AU Borsook, D Bullmore, ET Becerra, L Hargreaves, R AF Borsook, David Bullmore, Edward T. Becerra, Lino Hargreaves, Richard BE Borsook, D Beccera, L Bullmore, E Hargreaves, R TI The Challenges and Opportunities SO IMAGING IN CNS DRUG DISCOVERY AND DEVELOPMENT: IMPLICATIONS FOR DISEASE AND THERAPY LA English DT Article; Book Chapter ID DRUG DISCOVERY; FMRI; DISORDERS C1 [Becerra, Lino] McLean Hosp, Brain Imaging Ctr, Imaging & Anal Grp, Belmont, MA 02178 USA. [Bullmore, Edward T.] Addenbrookes Hosp, Dept Psychiat, Cambridge, England. [Hargreaves, Richard] Merck Basic Neurosci, West Point, PA USA. [Hargreaves, Richard] Mercks Neurosci Res Ctr, Harlow, Essex, England. [Bullmore, Edward T.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Bullmore, Edward T.] St George Hosp, London, England. [Bullmore, Edward T.] Univ Cambridge, Cambridge CB2 1TN, England. [Bullmore, Edward T.] Behav & Clin Neurosci Inst, Cambridge, England. [Bullmore, Edward T.] GlaxoSmithKline, Res Triangle Pk, NC USA. [Bullmore, Edward T.] GSKs Clin Unit, Cambridge, England. [Becerra, Lino] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Becerra, Lino] McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. [Becerra, Lino] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Becerra, Lino] McLean Hosp, Imaging Consortium Drug Dev ICD, Belmont, MA 02178 USA. [Becerra, Lino] McLean Hosp, PAIN Grp, Belmont, MA 02178 USA. [Borsook, David] Massachusetts Gen Hosp, Pain Ctr, Boston, MA 02114 USA. [Borsook, David] MsLean Hosp, Brain Imaging Ctr, Belmont, MA USA. RP Borsook, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, PAIN Grp, Cambridge, MA 02138 USA. EM dborsook@partners.org OI Bullmore, Edward/0000-0002-8955-8283 NR 17 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0133-0 PY 2010 BP 3 EP 9 DI 10.1007/978-1-4419-0134-7_1 PG 7 WC Biotechnology & Applied Microbiology; Neurosciences; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Neurosciences & Neurology; Pharmacology & Pharmacy GA BMI15 UT WOS:000272425300001 ER PT B AU Jennings, DL Sorensen, AG AF Jennings, Dominique L. Sorensen, A. Gregory BE Borsook, D Beccera, L Bullmore, E Hargreaves, R TI Diffusion Tensor Imaging and Drug Development SO IMAGING IN CNS DRUG DISCOVERY AND DEVELOPMENT: IMPLICATIONS FOR DISEASE AND THERAPY LA English DT Article; Book Chapter ID WHITE-MATTER ABNORMALITIES; MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; PRESYMPTOMATIC HUNTINGTONS-DISEASE; OBSESSIVE-COMPULSIVE DISORDER; CORTICOSPINAL TRACT STROKE; EARLY-ONSET SCHIZOPHRENIA; TRAUMATIC BRAIN-INJURY; WATER DIFFUSION; MULTIPLE-SCLEROSIS C1 [Sorensen, A. Gregory] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Sorensen, A. Gregory] MIT, Boston, MA USA. [Sorensen, A. Gregory] Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA USA. RP Sorensen, AG (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. EM sorensen@nmr.mgh.harvard.edu NR 104 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0133-0 PY 2010 BP 47 EP 65 DI 10.1007/978-1-4419-0134-7_4 PG 19 WC Biotechnology & Applied Microbiology; Neurosciences; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Neurosciences & Neurology; Pharmacology & Pharmacy GA BMI15 UT WOS:000272425300004 ER PT B AU Upadhyay, J Borsook, D Becerra, L AF Upadhyay, Jaymin Borsook, David Becerra, Lino BE Borsook, D Beccera, L Bullmore, E Hargreaves, R TI Functional Magnetic Resonance Imaging in Drug Development SO IMAGING IN CNS DRUG DISCOVERY AND DEVELOPMENT: IMPLICATIONS FOR DISEASE AND THERAPY LA English DT Article; Book Chapter ID INDEPENDENT COMPONENT ANALYSIS; CEREBRAL BLOOD-FLOW; HUMAN SOMATOSENSORY CORTICES; NOXIOUS THERMAL STIMULI; TEST-RETEST RELIABILITY; RESTING-STATE NETWORKS; CENTRAL-NERVOUS-SYSTEM; REGIONAL PAIN SYNDROME; WORKING-MEMORY TASK; HUMAN VISUAL-CORTEX C1 [Becerra, Lino] Harvard Univ, Sch Med, Belmont, MA 02478 USA. [Becerra, Lino] McLean Hosp, Brain Imaging Ctr, Imaging & Anal Grp, Belmont, MA 02478 USA. [Upadhyay, Jaymin] Harvard Univ, McLean Hosp, Sch Med, Imaging Consortium Drug Dev, Belmont, MA 02478 USA. [Borsook, David] MsLean Hosp, Brain Imaging Ctr, Belmont, MA USA. [Becerra, Lino] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Becerra, Lino] McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA. [Borsook, David] Massachusetts Gen Hosp, Pain Ctr, Boston, MA 02114 USA. RP Becerra, L (reprint author), Harvard Univ, Sch Med, 115 Mill St, Belmont, MA 02478 USA. EM lbecerra@mclean.harvard.edu NR 142 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0133-0 PY 2010 BP 67 EP 89 DI 10.1007/978-1-4419-0134-7_5 PG 23 WC Biotechnology & Applied Microbiology; Neurosciences; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Neurosciences & Neurology; Pharmacology & Pharmacy GA BMI15 UT WOS:000272425300005 ER PT B AU Rodriguez, E Chen, JW AF Rodriguez, Elisenda Chen, John W. BE Borsook, D Beccera, L Bullmore, E Hargreaves, R TI Molecular Imaging: Basic Approaches SO IMAGING IN CNS DRUG DISCOVERY AND DEVELOPMENT: IMPLICATIONS FOR DISEASE AND THERAPY LA English DT Article; Book Chapter ID SUPERPARAMAGNETIC IRON-OXIDE; MR CONTRAST AGENTS; IN-VIVO TRACKING; S-TRAIL; TUMOR-REGRESSION; CELL-MIGRATION; BRAIN-TUMORS; MYELOPEROXIDASE; THERAPY; EXPRESSION C1 [Rodriguez, Elisenda; Chen, John W.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Chen, John W.] Massachusetts Gen Hosp, Ctr Mol Imagaing Res, Boston, MA 02114 USA. RP Chen, JW (reprint author), Massachusetts Gen Hosp, Ctr Mol Imagaing Res, Boston, MA 02114 USA. EM chenjo@helix.mgh.harvard.edu NR 56 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0133-0 PY 2010 BP 105 EP 119 DI 10.1007/978-1-4419-0134-7_7 PG 15 WC Biotechnology & Applied Microbiology; Neurosciences; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Neurosciences & Neurology; Pharmacology & Pharmacy GA BMI15 UT WOS:000272425300007 ER PT B AU Dickerson, BC AF Dickerson, Bradford C. BE Borsook, D Beccera, L Bullmore, E Hargreaves, R TI Imaging CNS Disease States: Alzheimer's Disease SO IMAGING IN CNS DRUG DISCOVERY AND DEVELOPMENT: IMPLICATIONS FOR DISEASE AND THERAPY LA English DT Article; Book Chapter ID MILD COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE SPECTROSCOPY; MEDIAL TEMPORAL-LOBE; POSITRON-EMISSION-TOMOGRAPHY; VOXEL-BASED MORPHOMETRY; N-ACETYL ASPARTATE; HIPPOCAMPAL ATROPHY; FOLLOW-UP; FDG-PET; CHOLINERGIC ENHANCEMENT C1 Massachusetts Gen Hosp, Gerontol Res Unit, Dept Neurol, Boston, MA 02129 USA. RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Gerontol Res Unit, Dept Neurol, 149 13th St,Suite 2691, Boston, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu NR 97 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0133-0 PY 2010 BP 303 EP 318 DI 10.1007/978-1-4419-0134-7_19 PG 16 WC Biotechnology & Applied Microbiology; Neurosciences; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Neurosciences & Neurology; Pharmacology & Pharmacy GA BMI15 UT WOS:000272425300019 ER PT B AU Folio, LS Wollstein, G Ishikawa, H Kagemann, L Schuman, JS AF Folio, Lindsey S. Wollstein, Gadi Ishikawa, Hiroshi Kagemann, Larry Schuman, Joel S. BE Huang, D Duker, JS Fujimoto, JG Lumbroso, B Schuman, JS Weinreb, RN TI Diagnosis of Glaucomatous Optic Neuropathy SO IMAGING THE EYE FROM FRONT TO BACK WITH RTVUE FOURIER-DOMAIN OPTICAL COHERENCE TOMOGRAPHY LA English DT Article; Book Chapter C1 [Folio, Lindsey S.] Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Ishikawa, Hiroshi] Univ Pittsburgh, Sch Med, UPMC Eye Ctr, Pittsburgh, PA USA. [Wollstein, Gadi; Ishikawa, Hiroshi; Schuman, Joel S.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Kagemann, Larry] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Kagemann, Larry] Univ Pittsburgh, Sch Med, Dept Bioengn, Pittsburgh, PA USA. [Schuman, Joel S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Cambridge, MA 02138 USA. [Schuman, Joel S.] Tufts Univ, Sch Med, New England Eye Ctr, Medford, MA 02155 USA. RP Folio, LS (reprint author), Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Pittsburgh, PA 15260 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-963-7 PY 2010 BP 219 EP 243 PG 25 WC Ophthalmology; Radiology, Nuclear Medicine & Medical Imaging SC Ophthalmology; Radiology, Nuclear Medicine & Medical Imaging GA BOL12 UT WOS:000276925700026 ER PT S AU Baskin, DG Bastian, LS AF Baskin, Denis G. Bastian, L. Scot BE Oliver, C Jamur, MC TI Immuno-Laser Capture Microdissection of Rat Brain Neurons for Real Time Quantitative PCR SO IMMUNOCYTOCHEMICAL METHODS AND PROTOCOLS, THIRD EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Laser capture microdissection; Immunocytochemistry; Immunohistochemistry; Fixation; PCR; Brain; Neuron; Gene expression ID MESSENGER-RNA ANALYSIS; ETHANOL FIXATION; GENE-EXPRESSION; CELL PICKING; PRESERVATION; SECTIONS AB Laser capture microdissection (LCM) is a technical approach for obtaining microscopic samples as small as individual cells from tissues for Molecular analysis. While the principles and details of the operation of LCM instruments, the technical requirements for obtaining identified cells for LCM "picking", all share the common feature of using a laser in combination with a microscope to microdissect and remove cells from tissue slices (or cultured cells) mounted oil a glass slide. The use of LCM is becoming widespread in pathology laboratories and is increasingly being used for gene expression Studies in cell biology. The approach is particularly powerful when used in conjunction with immunostaining techniques to obtain enriched RNA samples from cells that have been collected by picking and gathering phenotypically similar cells from anatomically complex organs such as the brain. In the present chapter, we describe all approach for combining immunocytochemistry with LCM to obtain RNA for real time quantitative PCR. C1 [Baskin, Denis G.; Bastian, L. Scot] VA Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. RP Baskin, DG (reprint author), VA Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. FU NIDDK NIH HHS [DK17046] NR 24 TC 2 Z9 3 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-58829-463-0 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 588 BP 219 EP 230 DI 10.1007/978-1-59745-324-0_23 D2 10.1007/978-1-59745-324-0 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BND72 UT WOS:000274239800023 PM 20012834 ER PT S AU Cho, YH Yoo, SD AF Cho, Young-Hee Yoo, Sang-Dong BE Schwartzbach, SD Osafune, T TI Expression of Epitope-Tagged Proteins in Arabidopsis Leaf Mesophyll Protoplasts SO IMMUNOELECTRON MICROSCOPY: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Leaf mesophyll protoplasts; transient expression; epitope tag; high-throughput; Arabidopsis ID VACUOLAR TRAFFICKING; GENE-EXPRESSION; PLANTS; COMPLEX; SYSTEM; SIGNAL; MAIZE AB Advances in genomic and proteomic platforms enable high-throughput studies for regulatory factors and interactors involved in signaling network at a molecular level. However, it has never been trivial to verify the omics data in vivo or functionally integrate the data in a cell signaling context. For plants, genetic approaches using knockout mutants and transgenic lines have been mainly used to characterize functions of gene products in vivo. In general, such approaches demand a longer time and a higher cost and have difficulties in understanding gene functions comprehensively in a high-throughput manner. Transient gene expression is a method of choice to examine the cellular functions of genetic components in vivo. The leaf mesophyll protoplasts (LMP) provide a perfect system to transiently express a gene encoding an epitope-tagged protein of interest and quickly and reliably trace subcellular locales of the protein in a near high-throughput manner. Here, a simple and straightforward method for isolating leaf meshophyll protoplasts from Arabidopsis has been described in detail to help beginners initiate their first cell-based functional genomic analysis. C1 [Cho, Young-Hee] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Cho, Young-Hee; Yoo, Sang-Dong] Sungkyunkwan Univ, Coll Nat Sci, Dept Biol Sci, Lab Plant Signaling Syst Biol, Suwon, South Korea. RP Cho, YH (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. NR 13 TC 3 Z9 3 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-782-2 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 657 BP 33 EP 42 DI 10.1007/978-1-60761-783-9_3 D2 10.1007/978-1-60761-783-9 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BQA76 UT WOS:000280523600003 PM 20602205 ER PT J AU Rittling, SR Zetterberg, C Yagiz, K Skinner, S Suzuki, N Fujimura, A Sasaki, H AF Rittling, Susan R. Zetterberg, Craig Yagiz, Kader Skinner, Stephen Suzuki, Noriyuki Fujimura, Akira Sasaki, Hajime TI Protective role of osteopontin in endodontic infection SO IMMUNOLOGY LA English DT Article DE bone loss; cytokine; migration; neutrophil; osteopontin; peri-apical ID ALCOHOLIC LIVER-DISEASE; RESORPTION IN-VIVO; BONE-RESORPTION; PORPHYROMONAS-GINGIVALIS; DEFICIENT MICE; DENDRITIC CELLS; ENDOTHELIAL-CELLS; HOST-RESISTANCE; PGG-GLUCAN; EXPRESSION AB P>Endodontic infections are polymicrobial infections resulting in bone destruction and tooth loss. The host response to these infections is complex, including both innate and adaptive mechanisms. Osteopontin (OPN), a secreted, integrin-binding protein, functions in the regulation of immune responses and enhancement of leucocyte migration. We have assessed the role of OPN in the host response to endodontic infection using a well-characterized mouse model. Periapical bone loss associated with endodontic infection was significantly more severe in OPN-deficient mice compared with wild-type 3 weeks after infection, and was associated with increased areas of inflammation. Expression of cytokines associated with bone loss, interleukin-1 alpha (IL-1 alpha) and RANKL, was increased 3 days after infection. There was little effect of OPN deficiency on the adaptive immune response to these infections, as there was no effect of genotype on the ratio of bacteria-specific immunoglobulin G1 and G2a in the serum of infected mice. Furthermore, there was no difference in the expression of cytokines associated with T helper type 1/type2 balance: IL-12, IL-10 and interferon-gamma. In infected tissues, neutrophil infiltration into the lesion area was slightly increased in OPN-deficient animals 3 days after infection: this was confirmed by a significant increase in expression of neutrophil elastase in OPN-deficient samples at this time-point. We conclude that OPN has a protective effect on polymicrobial infection, at least partially because of alterations in phagocyte recruitment and/or persistence at the sites of infection, and that this molecule has a potential therapeutic role in polymicrobial infections. C1 [Rittling, Susan R.; Zetterberg, Craig; Yagiz, Kader; Skinner, Stephen; Sasaki, Hajime] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. [Suzuki, Noriyuki] Tokyo Med & Dent Univ, Grad Sch, Tokyo, Japan. [Fujimura, Akira] Iwate Med Univ, Sch Dent, Dept Oral Anat 1, Morioka, Iwate, Japan. RP Rittling, SR (reprint author), Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA. EM srittling@forsyth.org FU NIDDK/NIH [DK067685]; Japanese Ministry of Education, Culture, Sports, Science, and Technology FX The authors thank Martha O'Hara for help with immunohistochemistry, and Justine Dobeck for expert tissue sectioning. This work was supported by grant DK067685 from the NIDDK/NIH (SRR) and by the High-Tech Research Center Program at Private Universities from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. NR 59 TC 10 Z9 11 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0019-2805 J9 IMMUNOLOGY JI Immunology PD JAN PY 2010 VL 129 IS 1 BP 105 EP 114 DI 10.1111/j.1365-2567.2009.03159.x PG 10 WC Immunology SC Immunology GA 529RJ UT WOS:000272534600011 PM 19824920 ER PT B AU Bordeianou, L Trudel, JL AF Bordeianou, Liliana Trudel, Judith L. BE Whitlow, CB Beck, DE Margolin, DA Hicks, TC Timmcke, AE TI Chemotherapy for colon and rectal cancer SO IMPROVED OUTCOMES IN COLON AND RECTAL SURGERY LA English DT Article; Book Chapter ID METASTATIC COLORECTAL-CANCER; ACTIVE SPECIFIC IMMUNOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; SURGICAL ADJUVANT BREAST; PROSPECTIVELY RANDOMIZED-TRIAL; STAGE-II; PREOPERATIVE RADIOTHERAPY; PHASE-III; FOLINIC ACID; DUKES B C1 [Bordeianou, Liliana] Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA. [Trudel, Judith L.] Univ Minnesota, St Paul, MN 55108 USA. RP Bordeianou, L (reprint author), Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA. NR 37 TC 0 Z9 0 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL ST, LONDON, EC2A 4LQ, ENGLAND BN 978-1-4200-7153-5; 978-1-4200-7152-8 PY 2010 BP 300 EP 305 PG 6 WC Surgery SC Surgery GA BC7CK UT WOS:000354739300031 ER PT J AU Heindl, JE Saran, I Yi, CR Lesser, CF Goldberg, MB AF Heindl, Jason E. Saran, Indrani Yi, Chae-ryun Lesser, Cammie F. Goldberg, Marcia B. TI Requirement for Formin-Induced Actin Polymerization during Spread of Shigella flexneri SO INFECTION AND IMMUNITY LA English DT Article ID ARP2/3 COMPLEX; N-WASP; LISTERIA-MONOCYTOGENES; RICKETTSIA-CONORII; VACCINIA VIRUS; BURKHOLDERIA-PSEUDOMALLEI; INTERCELLULAR SPREAD; EPITHELIAL-CELLS; STRESS FIBERS; F-ACTIN AB Actin polymerization in the cytosol and at the plasma membrane is locally regulated by actin nucleators. Several microbial pathogens exploit cellular actin polymerization to spread through tissue. The movement of the enteric pathogen Shigella flexneri, both within the cell body and from cell to cell, depends on actin polymerization. During intercellular spread, actin polymerization at the bacterial surface generates protrusions of the plasma membrane, which are engulfed by adjacent cells. In the cell body, polymerization of actin by Shigella spp. is dependent on N-WASP activation of the Arp2/Arp3 complex. Here we demonstrate that, in contrast, efficient protrusion formation and intercellular spread depend on actin polymerization that involves activation of the Diaphanous formin Dia. While the Shigella virulence protein IpgB2 can bind and activate Dia1 (N. M. Alto et al., Cell 124: 133-145, 2006), its absence does not result in a detectable defect in Dia-dependent protrusion formation or spread. The dependence on the activation of Dia during S. flexneri infection contrasts with the inhibition of this pathway observed during vaccinia virus infection. C1 [Goldberg, Marcia B.] Massachusetts Gen Hosp, Div Infect Dis, Cambridge, MA 02139 USA. Harvard Univ, Sch Med, Cambridge, MA 02139 USA. RP Goldberg, MB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 65 Landsdowne St, Cambridge, MA 02139 USA. EM mgoldberg1@partners.org OI Heindl, Jason/0000-0003-3919-8045 FU National Institutes of Allergy and Infectious Diseases [AI052354, AI073967, AI081724]; Mustard Seed Foundation; Executive Committee on Research of the Massachusetts General Hospital FX This research was supported by National Institutes of Allergy and Infectious Diseases grants AI052354 ( to S. B. Snapper and M. B. G.), AI073967 ( to M. B. G.), and AI081724 ( to M. B. G.), by a Harvey Fellowship from the Mustard Seed Foundation ( to J.E.H.), and by funds from the Executive Committee on Research of the Massachusetts General Hospital ( to M. B. G.). NR 50 TC 29 Z9 29 U1 3 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2010 VL 78 IS 1 BP 193 EP 203 DI 10.1128/IAI.00252-09 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 535QC UT WOS:000272984300019 PM 19841078 ER PT J AU Kendall, EA Tarique, AA Hossain, A Alam, MM Arifuzzaman, M Akhtar, N Chowdhury, F Khan, AI LaRocque, RC Harris, JB Ryan, ET Qadri, F Calderwood, SB AF Kendall, Emily A. Tarique, Abdullah A. Hossain, Azim Alam, Mohammad Murshid Arifuzzaman, Mohammad Akhtar, Nayeema Chowdhury, Fahima Khan, Ashraful I. LaRocque, Regina C. Harris, Jason B. Ryan, Edward T. Qadri, Firdausi Calderwood, Stephen B. TI Development of Immunoglobulin M Memory to Both a T-Cell-Independent and a T-Cell-Dependent Antigen following Infection with Vibrio cholerae O1 in Bangladesh SO INFECTION AND IMMUNITY LA English DT Article ID B-CELLS; IMMUNE-RESPONSES; SECRETING CELLS; ANTIBODIES; IGM; VACCINE; DIFFERENTIATION; AUTOREACTIVITY; IMMUNOGENICITY; IGM(+)CD27(+) AB Vibrio cholerae O1 can cause severe watery diarrhea that can be life-threatening without treatment. Infection results in long-lasting protection against subsequent disease. Development of memory B cells of the immunoglobulin G (IgG) and IgA isotypes to V. cholerae O1 antigens, including serotype-specific lipopolysaccharide (LPS) and the B subunit of cholera toxin (CTB), after cholera infection has been demonstrated. Memory B cells of the IgM isotype may play a role in long-term protection, particularly against T-cell-independent antigens, but IgM memory has not been studied in V. cholerae O1 infection. Therefore, we assayed acute-and convalescent-phase blood samples from cholera patients for the presence of memory B cells that produce cholera antigen-specific IgM antibody upon polyclonal stimulation in in vitro culture. We also examined the development of serological and antibody-secreting cell responses following infection. Subjects developed significant IgM memory responses by day 30 after infection, both to the T-cell-independent antigen LPS and to the T-cell-dependent antigen CTB. No significant corresponding elevations in plasma IgM antibodies or circulating IgM antibody-secreting cells to CTB were detected. In 17 subjects followed to day 90 after infection, significant persistence of elevated IgM memory responses was not observed. The IgM memory response to CTB was negatively correlated with the IgG plasma antibody response to CTB, and there was a trend toward negative correlation between the IgM memory and IgA plasma antibody responses to LPS. We did not observe an association between the IgM memory response to LPS and the vibriocidal titer. C1 [LaRocque, Regina C.; Harris, Jason B.; Ryan, Edward T.; Calderwood, Stephen B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Kendall, Emily A.; Tarique, Abdullah A.; Hossain, Azim; Alam, Mohammad Murshid; Arifuzzaman, Mohammad; Akhtar, Nayeema; Chowdhury, Fahima; Khan, Ashraful I.; Qadri, Firdausi] ICDDR B, Dhaka, Bangladesh. [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [LaRocque, Regina C.; Ryan, Edward T.; Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. RP Calderwood, SB (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM scalderwood@partners.org RI Tarique, Abdullah/M-2860-2013; OI Tarique, Abdullah/0000-0003-3782-345X; Kendall, Emily/0000-0002-0083-422X FU ICDDR, B Centre for Health and Population Research [U01 AI058935, R03 AI 063079, U01 AI077883]; International Research Scientist Development Award [K01 TW07144, K01 TW07409]; Fogarty International Center Global Infectious Disease Research Training Program Award in Vaccine Development [D43 TW05572]; Fogarty International Center at the National Institutes of Health [R24 TW007988] FX This research was supported by the ICDDR, B Centre for Health and Population Research and by the following grants: U01 AI058935 (S. B. C.); R03 AI 063079 (F. Q.); U01 AI077883 (E. T. R.); International Research Scientist Development Award K01 TW07144 (R. C. L.); International Research Scientist Development Award K01 TW07409 (J.B.H.); and a Fogarty International Center Global Infectious Disease Research Training Program Award in Vaccine Development D43 TW05572 (M. A. and A. A. T.). E. A. K. is a recipient of a Fogarty International Clinical Research Scholars award from the Fogarty International Center at the National Institutes of Health (R24 TW007988). NR 47 TC 9 Z9 10 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2010 VL 78 IS 1 BP 253 EP 259 DI 10.1128/IAI.00868-09 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 535QC UT WOS:000272984300025 PM 19858296 ER PT J AU Huett, A Xavier, RJ AF Huett, Alan Xavier, Ramnik J. TI Autophagy at the Gut Interface: Mucosal Responses to Stress and the Consequences for Inflammatory Bowel Diseases SO INFLAMMATORY BOWEL DISEASES LA English DT Review DE autophagy; Crohn's disease; bacterial infection; systems biology; mucosal immunology ID ENDOPLASMIC-RETICULUM STRESS; TOLL-LIKE RECEPTORS; INTESTINAL EPITHELIAL-CELLS; GENOME-WIDE ASSOCIATION; CLASS-II PRESENTATION; PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOTIC CELLS; DENDRITIC CELLS; CROHNS-DISEASE; SALMONELLA-TYPHIMURIUM AB Autophagy is a conserved homeostatic process by which cells degrade and recycle cytoplasmic contents and organelles. Recently, autophagy has come to prominence as a factor in many disease states, including inflammatory bowel diseases. In this review we explore the recent discoveries in autophagy and how these relate to the special conditions experienced by the gut mucosa. We will pay particular attention to autophagy as an innate immune process and its role in the development and education of the adaptive immune system. C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Richard B Simches Res Ctr,Sch Med, Boston, MA 02114 USA. [Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Inflammatory Bowel Dis,Gastrointestinal Unit, Boston, MA USA. [Huett, Alan; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Huett, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Richard B Simches Res Ctr,Sch Med, 185 Cambridge St,7th Floor, Boston, MA 02114 USA. EM ahuett@ccib.mgh.harvard.edu; Xavier@molbio.mgh.harvard.edu FU National Institutes of Health (NIH) [A1062773, DK83756, DK043351] FX Supported by the National Institutes of Health (NIH) grants A1062773. DK83756, and DK043351. NR 156 TC 13 Z9 13 U1 1 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2010 VL 16 IS 1 BP 152 EP 174 DI 10.1002/ibd.20991 PG 23 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 543LN UT WOS:000273579200024 PM 19575363 ER PT S AU Dec, GW AF Dec, G. William BE Schultheiss, HP Noutsias, M TI Epidemiology and prognosis of myocarditis and dilated cardiomyopathy: Predictive value of clinical parameters and biopsy findings SO INFLAMMATORY CARDIOMYOPATHY (DCMI): PATHOGENESIS AND THERAPY SE Progress in Inflammation Research Series LA English DT Article; Book Chapter ID LEFT-VENTRICULAR DYSFUNCTION; IMMUNOSUPPRESSIVE THERAPY; LYMPHOCYTIC MYOCARDITIS; ENDOMYOCARDIAL BIOPSY; VIRAL MYOCARDITIS; MANAGEMENT; DIAGNOSIS; DEATH AB The true incidence of myocarditis is difficult to assess due to the extreme diversity of its clinical manifestations. Myocarditis has been implicated in sudden death of young adults in 8-12% of cases and has been identified by endomyocardial biopsy as a cause of unexplained dilated cardiomyopathy in 10-12% of cases. Among cases of biopsy-proven myocarditis, the pathological distribution is typically lymphocytic 55%, borderline 22%, granulomatous 15%, and eosinophilic approximately 5%. Newer immunohistochemical techniques are better able to characterize specific inflammatory cellular infiltrates and have increased the sensitivity of biopsy for diagnosing myocarditis. The spectrum of viral genome detected by biopsy has shifted from Coxsackie virus B to adenovirus in the late 1990s and, more recently, to parvovirus B19 and other viruses. Clinical manifestations range from asymptomatic electrocardiographic abnormalities during viral pandemics to frank cardiogenic shock. Although endomyocardial biopsy remains the "gold standard" for establishing the diagnosis, cardiac magnetic resonance imaging with gadolinium enhancement has rapidly emerged as the screening procedure of choice. The natural history of myocarditis varies based on its initial clinical presentation. Myocarditis masquerading as acute myocardial infarction almost always results in full recovery of cardiovascular function and rapid improvement in segmental or global wall motion abnormalities. Acute dilated cardiomyopathy is the most frequent, clinically relevant presentation. Patients with mildly impaired left ventricular function typically improve within weeks or months, while patients with more marked ventricular dilatation or more longstanding symptoms may have substantial residual cardiac dysfunction. Fulminant myocarditis appears to have an excellent, long-term prognosis with event-free survival rate exceeding 90% at 10 years if aggressive hemodynamic support is provided during the acute phase of the illness. Mortality for biopsy-verified lymphocytic myocarditis averages 20% at 1 year and over 50% at 4 years. The survival rates are similar to observational data for patients with idiopathic dilated cardiomyopathy. Survival with giant cell myocarditis is substantially lower with fewer than 20% of patients surviving 5 years. Important predictors of adverse prognosis with biopsy-proven myocarditis include giant cell histopathology, persistent viral genome on repeat endomyocardial biopsy, elevated myocardial or circulatory Fas and Fas ligand levels, extent of left ventricular enlargement and sphericity, pulmonary hypertension and bundle branch block. Treatment remains supportive as no specific treatment for biopsy-proven myocarditis has yet been shown to be effective in randomized controlled trails. C1 Massachusetts Gen Hosp, Div Cardiol, Heart Failure & Transplantat Unit, Boston, MA 02114 USA. RP Dec, GW (reprint author), Massachusetts Gen Hosp, Div Cardiol, Heart Failure & Transplantat Unit, Boston, MA 02114 USA. EM gdec@partners.org NR 26 TC 0 Z9 0 U1 0 U2 2 PU BIRKHAUSER VERLAG AG PI BASEL PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND SN 1422-7746 BN 978-3-7643-8351-0 J9 PROG INFLAMM RES SER JI Prog. Inflamm. Res. PY 2010 BP 25 EP 34 DI 10.1007/978-3-7643-8352-7_2 D2 10.1007/978-3-7643-8352-7 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BQG89 UT WOS:000280959700002 ER PT S AU Hayakawa, K Qiu, JH Lo, EH AF Hayakawa, Kazuhide Qiu, Jianhua Lo, Eng H. BE DelZoppo, GJ Gorelick, PB Eisert, W TI Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke SO INNATE INFLAMMATION AND STROKE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Innate Inflammation as the Common Pathway of Risk Factors Leading to Transient Ischemic Attacks and Stroke: Pathophysiology and Potential Interventions CY MAY 09-11, 2010 CL New York Acad Sci, New York, NY HO New York Acad Sci DE stroke; inflammation; stroke recovery; HMGB1 ID GROUP BOX-1 PROTEIN; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; T-LYMPHOCYTES; NEURITE OUTGROWTH; PIVOTAL ADVANCE; DENDRITIC CELLS; NEURONAL DEATH; MESSENGER-RNA AB Stroke induces a complex web of pathophysiology that may evolve over hours to days and weeks after onset. It is now recognized that inflammation is an important phenomenon that can dramatically influence outcomes after stroke. In this minireview, we explore the hypothesis that inflammatory signals after stroke are biphasic in nature. The high-mobility group box 1 (HMGB1) protein is discussed as an example of this idea. HMGB1 is normally present in the nucleus. Under ischemic conditions, it is released extracellularly from many types of cells. During the acute phase poststroke, HMGB1 promotes necrosis and influx of damaging inflammatory cells. However, during the delayed phase poststroke, HMGB1 can mediate beneficial plasticity and recovery in many cells of the neurovascular unit. These emerging findings support the hypothesis that inflammation after stroke can be both detrimental and beneficial, depending on the cellular situations involved. C1 [Hayakawa, Kazuhide; Qiu, Jianhua; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Neuroprotect Res Lab, Sch Med,Dept Radiol, Charlestown, MA 02129 USA. [Hayakawa, Kazuhide; Qiu, Jianhua; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Neuroprotect Res Lab, Sch Med,Dept Neurol, Charlestown, MA 02129 USA. [Qiu, Jianhua] Harvard Univ, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Sch Med,Dept Radiol, Charlestown, MA 02129 USA. RP Hayakawa, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Neuroprotect Res Lab, Sch Med,Dept Radiol, MGH E 149-2401, Charlestown, MA 02129 USA. EM khayakawa1@partners.org FU NIH; American Heart Association; Deane Institute; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Japan Society for the Promotion of Science FX Supported in part by NIH grants, the American Heart Association, the Deane Institute, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and a Postdoctoral Fellowship for Research Abroad from the Japan Society for the Promotion of Science. NR 81 TC 54 Z9 60 U1 0 U2 15 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-813-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1207 BP 50 EP 57 DI 10.1111/j.1749-6632.2010.05728.x PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA BSK36 UT WOS:000284744000010 PM 20955426 ER PT J AU Kreeger, PK Wang, YF Haigis, KM Lauffenburger, DA AF Kreeger, Pamela K. Wang, Yufang Haigis, Kevin M. Lauffenburger, Douglas A. TI Integration of multiple signaling pathway activities resolves K-RAS/N-RAS mutation paradox in colon epithelial cell response to inflammatory cytokine stimulation SO INTEGRATIVE BIOLOGY LA English DT Article ID INDUCIBLE AUTOCRINE CASCADE; N-RAS; INDUCED APOPTOSIS; CANCER; PROLIFERATION; ONCOGENES AB Colon tumors frequently harbor mutation in K-RAS and/or N-RAS, members of a GTPase family operating as a central hub for multiple key signaling pathways. While these proteins are strongly homologous, they exhibit diverse downstream effects on cell behavior. Utilizing an isogenic panel of human colon carcinoma cells bearing oncogenic mutations in K-RAS and/or N-RAS, we observed that K-RAS and double mutants similarly yield elevated apoptosis in response to treatment with TNF alpha compared to N-RAS mutants. Regardless, and in surprising contrast, key phospho-protein signals were more similar between N-RAS and dual mutants. This apparent contradiction could not be explained by any of the key signals individually, but a multi-pathway model constructed from the single-mutant cell line data was able to predict the behavior of the dual-mutant cell line. This success arises from a quantitative integration of multiple pro-apoptotic (pI kappa B alpha, pERK2) and pro-survival (pJNK, pHSP27) signals in manner not easily discerned from intuitive inspection. C1 [Kreeger, Pamela K.; Lauffenburger, Douglas A.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Wang, Yufang; Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA. [Wang, Yufang; Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Wang, Yufang; Haigis, Kevin M.] Harvard Univ, Dept Pathol, Sch Med, Boston, MA 02115 USA. [Lauffenburger, Douglas A.] MIT, Ctr Canc Res, Cambridge, MA 02139 USA. RP Kreeger, PK (reprint author), Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA. EM lauffen@mit.edu OI Kreeger, Pamela/0000-0001-8193-1007 FU National Institutes of Health [U54-CA112967, P50-GM68762]; American Cancer Society [PF-08-026-01-CCG] FX We wish to acknowledge Roli Mandhana for her assistance in collecting lysate samples and members of the Lauffenburger lab for helpful discussions. We gratefully acknowledge Glenn Paradis of the Koch Institute Flow Cytometry Core Facility for technical assistance. This work was funded by National Institutes of Health Grants U54-CA112967 and P50-GM68762, and by the American Cancer Society (PF-08-026-01-CCG to P. K. K). NR 20 TC 12 Z9 13 U1 1 U2 7 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2010 VL 2 IS 4 BP 202 EP 208 DI 10.1039/b925935j PG 7 WC Cell Biology SC Cell Biology GA 580CO UT WOS:000276424700005 PM 20473400 ER PT J AU Ambravaneswaran, V Wong, IY Aranyosi, AJ Toner, M Irimia, D AF Ambravaneswaran, Vijayakrishnan Wong, Ian Y. Aranyosi, Alexander J. Toner, Mehmet Irimia, Daniel TI Directional decisions during neutrophil chemotaxis inside bifurcating channels SO INTEGRATIVE BIOLOGY LA English DT Article ID EUKARYOTIC CHEMOTAXIS; CELL-MIGRATION; POLYMORPHONUCLEAR LEUKOCYTES; EXTRACELLULAR-MATRIX; DYNAMIC INSTABILITY; IN-VIVO; GRADIENTS; MICROTUBULES; POLARITY; FORCE AB The directional migration of human neutrophils in classical chemotaxis assays is often described as a "biased random walk" implying significant randomness in speed and directionality. However, these experiments are inconsistent with in vivo observations, where neutrophils can navigate effectively through complex tissue microenvironments towards their targets. Here, we demonstrate a novel biomimetic assay for neutrophil chemotaxis using enclosed microfluidic channels. Remarkably, under these enclosed conditions, neutrophils recapitulate the highly robust and efficient navigation observed in vivo. In straight channels, neutrophils undergo sustained, unidirectional motion towards a chemoattractant source. In more complex maze-like geometries, neutrophils are able to select the most direct route over 90% of the time. Finally, at symmetric bifurcations, neutrophils split their leading edge into two sections and a "tug of war" ensues. The competition between the two new leading edges is ultimately resolved by stochastic, symmetry-breaking behavior. This behavior is suggestive of directional decision-making localized at the leading edge and a signaling role played by the cellular cytoskeleton. C1 [Ambravaneswaran, Vijayakrishnan] Massachusetts Gen Hosp, BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Ambravaneswaran, V (reprint author), Massachusetts Gen Hosp, BioMEMS Resource Ctr, Ctr Engn Med & Surg Serv, Shriners Hosp Children, Boston, MA 02129 USA. EM dirimia@hms.harvard.edu RI Wong, Ian/G-1611-2012; OI Wong, Ian/0000-0002-9439-2548; Aranyosi, Alexander/0000-0002-8133-5026; Irimia, Daniel/0000-0001-7347-2082 FU National Institutes of Health (NIH) [AI076760, EB002503, GM092804] FX We thank Dr Jungwoo Lee for help with the scanning electron microscope imaging, Dr Jagesh Shah for helpful suggestions and critical reading of this manuscript, and Dr Liedewij Laan for useful discussions. This work was supported by the National Institutes of Health (NIH) grants AI076760, EB002503, and GM092804. NR 39 TC 42 Z9 42 U1 0 U2 17 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2010 VL 2 IS 11-12 BP 639 EP 647 DI 10.1039/c0ib00011f PG 9 WC Cell Biology SC Cell Biology GA 674KN UT WOS:000283741400008 PM 20676444 ER PT B AU Rittling, SR AF Rittling, Susan R. BE Sasano, T Suzuki, O TI Osteopontin and CSF-1 in bone resorption SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE osteopontin; bone metastasis; CSF-1; integrin; signaling ID COLONY-STIMULATING-FACTOR; DEFICIENT MICE; TISSUE FORMATION; CELL-SURFACE; RAT BONE; EXPRESSION; CD44; INTEGRIN; OSTEOCLASTS; SURVIVAL AB Osteopontin (OPN) is a secreted phosphoprotein that is found in high levels in bone tissues. Expression of OPN is required for optimal bone resorption under pathological conditions, with a notable exception being in the case of bone metastases, where OPN deficiency does not affect tumor-associated bone loss. It is suggested that tumor cells are the primary source of CSF-1 in tumors metastatic to the bone, and that CSF-1 and integrin signaling pathways crosstalk in osteoclasts in the vicinity of tumors expressing CSF-1. Thus, high-level expression of CSF-1 in tumor cells may override the osteoclast defect seen in OPN-deficient mice. C1 Forsyth Inst, Boston, MA 02115 USA. RP Rittling, SR (reprint author), Forsyth Inst, 140 Fenway, Boston, MA 02115 USA. EM srittling@forsyth.org NR 39 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 363 EP 368 DI 10.1007/978-4-431-99644-6_108 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500108 ER PT B AU Margolis, HC Wiedemann-Bidlack, FB Aichmayer, B Fratzl, P Kwak, SY Beniash, E Yamakoshi, Y Simmer, JP AF Margolis, Henry C. Wiedemann-Bidlack, Felicitas B. Aichmayer, Barbara Fratzl, Peter Kwak, Seo-Young Beniash, Elia Yamakoshi, Yasuo Simmer, James P. BE Sasano, T Suzuki, O TI Role of amelogenin self-assembly in protein-mediated dental enamel formation SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE amelogenesis; amelogenin; dental enamel; mineralization; calcium phosphates ID DYNAMIC LIGHT-SCATTERING; IN-VITRO; RECOMBINANT AMELOGENIN; SECRETORY-STAGE; MATRIX; ORGANIZATION; NANOSPHERES; TEMPERATURE; MICE; PH AB Extracellular matrix molecules play a critical role in regulating biological mineralization. This brief review describes recent advances made in our laboratory on elucidating the role of amelogenin, the predominant enamel matrix protein, in regulating the formation of the highly organized enamel tissue. Based on results obtained using dynamic light scattering, transmission electron microscopy, and small-angle X-ray scattering, we have found that the self-assembly of amelogenins is primarily regulated by pH and that the full-length amelogenin can form higher-order chain-like structures. These latter structures are comprised of uniformly sized aggregates of amelogenin called nanospheres. Based on in vitro mineralization studies, full-length amelogenin was also found to uniquely regulate the formation of parallel arrays of hydroxyapatite crystals. The unique ability of full-length amelogenin to form chain-like structures and induce organized mineral formation was dependent upon the presence of its hydrophilic C terminus. C1 [Margolis, Henry C.; Wiedemann-Bidlack, Felicitas B.; Kwak, Seo-Young] Forsyth Inst, Dept Biomineralizat, 140 Fenway, Boston, MA 02115 USA. [Aichmayer, Barbara; Fratzl, Peter] Max Planck Inst Colloids & Interfaces, Dept Biomet, D-14424 Potsdam, Germany. [Beniash, Elia] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA 48109 USA. [Yamakoshi, Yasuo; Simmer, James P.] Univ Michigan, Dept Res Lab, Ann Arbor, MI 15261 USA. RP Margolis, HC (reprint author), Forsyth Inst, Dept Biomineralizat, 140 Fenway, Boston, MA 02115 USA. EM hmargolis@forsyth.org RI Fratzl, Peter/H-9095-2012 OI Fratzl, Peter/0000-0003-4437-7830 FU National Institute of Dental and Craniofacial Research [DE-016376 (HCM)]; [T32 DE-007327] FX This work was supported by grant DE-016376 (HCM) from the National Institute of Dental and Craniofacial Research. FBW-B was partially supported by grant T32 DE-007327. NR 23 TC 1 Z9 1 U1 2 U2 6 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 369 EP + DI 10.1007/978-4-431-99644-6_109 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500109 ER PT B AU Bartlett, JD AF Bartlett, John D. BE Sasano, T Suzuki, O TI The human genetics of amelogenesis imperfecta SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE enamel; amelogenesis imperfecta; mutation ID CONE-ROD DYSTROPHY; TRICHODENTOOSSEOUS SYNDROME; ENAMEL DEFECTS; FAM83H MUTATIONS; TURKISH FAMILIES; CANDIDATE GENES; MICE DISPLAY; PHENOTYPE AB Amelogenesis imperfecta (AI) results from the mutation of gene(s) that affect enamel development. The resulting enamel may have alterations of enamel quantity, composition, and/or structure and typically appears abnormally thin, soft, rough, and/or stained. AI is defined as enamel defects occurring in the absence of any other generalized or systemic disease. Mutations in five different genes (AMEL, ENAM, MMP20, KLK4, and FAM83H) have been demonstrated to cause AI. However, mutations of these genes alone are not responsible for all known cases of AI. Therefore, AI causative genes remain to be discovered. This chapter summarizes the mutations that cause AI (genotype) and the effect of each mutation on the appearance of the dental enamel (phenotype). The goal of this chapter is to provide clinicians with a concise guide that will suggest possible genotypes by careful examination of an individual's AI phenotype and pattern of malformed enamel inheritance. C1 Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. RP Bartlett, JD (reprint author), Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA. EM jbartlett@forsyth.org NR 32 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 375 EP 381 DI 10.1007/978-4-431-99644-6_110 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500110 ER PT B AU Arndt, A Davey, ME AF Arndt, Annette Davey, Mary Ellen BE Sasano, T Suzuki, O TI Porphyromonas gingivalis: surface poilysaccharides as virulence determinants SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE Porphyromonas gingivalis; exopolysaccharides; lipopolysaccharides; K-antigen capsule ID 6 CAPSULAR SEROTYPES; PERIODONTITIS PATIENTS; POLYSACCHARIDE; LIPOPOLYSACCHARIDE; BIOSYNTHESIS; CELLS; W50; IDENTIFICATION; CARBOHYDRATE; COMPLEMENT AB The proliferation of anaerobic bacteria in the subgingival crevice of the oral cavity is central to the progression of periodontal disease, with Porphyromonas gingivalis being implicated as one of the key pathogens. Research has clearly shown that surface polysaccharides are key virulence determinants for this organism. Here, we review what is known about the different surface polysaccharides synthesized by P gingivalis as well as their role in the pathogenicity of this oral anaerobe. C1 [Arndt, Annette; Davey, Mary Ellen] Forsyth Inst, Dept Mol Genet, Boston, MA 02115 USA. RP Davey, ME (reprint author), Forsyth Inst, Dept Mol Genet, Boston, MA 02115 USA. EM mdavey@forsyth.org NR 36 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 382 EP 387 DI 10.1007/978-4-431-99644-6_111 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500111 ER PT B AU Izard, J AF Izard, Jacques CA Forsyth Metagenomic Support Consor BE Sasano, T Suzuki, O TI Building the genomic base-layer of the oral "omic" world SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE oral microbiome; oral biofilm; bacterial phylogeny; metagenome; bacterial diversity ID TREPONEMA-DENTICOLA; SUBGINGIVAL PLAQUE; CORNCOB FORMATION; BACTERIAL; CAVITY; ASSAY AB With the shift of molecular technologies directed toward the understanding of greater biological complexity of the oral cavity, a knowledge gap was created by the lack of genomic data from the diverse oral microorganisms. To facilitate and enable the interpretation of metagenomic, transcriptomic, and proteomic data generated or soon to be generated from oral biofilms, we are providing reference genomic information from phylogenetically diverse oral bacterial isolates. This work, initiated by the National Institute of Dental and Craniofacial Research as an isolated effort, is now part of the Human Microbiome Project. The goal of this effort is the public release of genomic data in support of functional and phylogenetic analyses of the complex oral microbiome. The genomic information acquired will be a key component in understanding the interaction of the oral biofilms with the human host and in developing novel healthcare strategies to prevent and treat oral diseases. C1 [Izard, Jacques] Forsyth Inst, Dept Mol Genet, Boston, MA 02135 USA. RP Izard, J (reprint author), Forsyth Inst, Dept Mol Genet, Boston, MA 02135 USA. EM JIzard@forsyth.org NR 19 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 388 EP 393 DI 10.1007/978-4-431-99644-6_112 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500112 ER PT B AU Smith, DJ Taubman, MA AF Smith, Daniel J. Taubman, Martin A. BE Sasano, T Suzuki, O TI Cariogenic microflora and the immune response SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE Streptococcus mutans; dental caries; mucosal immunity; SIgA ID MUTANS STREPTOCOCCAL INFECTION; BINDING-PROTEIN-B; DENTAL-CARIES; PASSIVE-IMMUNIZATION; ANTIBODY; DIVERSITY; ANTIGEN; PROTECTION; INDUCTION; BACTERIA AB Streptococcus mutans has been associated with dental caries, especially in children. These cariogenic microorganisms are one of many species of oral streptococci, some of which begin to colonize the oral cavity and induce mucosal immune responses shortly after birth. Mucosal SIgA responses to early colonizing oral streptococcal epitopes, which are shared with S. mutans virulence antigens, may influence the rate of mutans streptococcal colonization. Especially important may be responses to adhesin, glucosyltransferase and glucan-binding protein epitopes. Active and passive immune strategies have been pursued in animals and in human clinical trials to explore the ability of orally available antibody to interfere with the colonization and accumulation of cariogenic streptococci. C1 [Smith, Daniel J.; Taubman, Martin A.] Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Smith, DJ (reprint author), Forsyth Inst, Dept Immunol, 140 Fenway, Boston, MA 02115 USA. EM dsmith@forsyth.org NR 28 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 394 EP 399 DI 10.1007/978-4-431-99644-6_113 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500113 ER PT B AU Han, XZ Lin, XP Kawai, T LaRosa, KB Taubman, MA AF Han, Xiaozhe Lin, Xiaoping Kawai, Toshihisa LaRosa, Karen B. Taubman, Martin A. BE Sasano, T Suzuki, O TI Porphyromonas gingivalis infection elicits immune-mediated RANKL-dependent periodontal bone loss in rats SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE receptor activator of nuclear factor-kappaB ligand; Porphyromonas gingivalis; periodontal bone loss; periodontitis; immune cells ID RESORPTION; DISEASE AB This study sought to determine the role of receptor activator of nuclear factor-kappaB ligand (RANKL) in the Porphyromonas gingivalis infection-associated periodontal bone loss. Rowett rats were infected orally on Day 0-3 with 10(8) live Pg (ATCC 33277). Separate groups received anti-RANKL antibody, osteoprotegerin (OPG)-Fc, or control L6-Fc injection into gingival papilla in addition to P. gingivalis infection. After 4 weeks, robust immune responses to P gingivalis were detected in infected rats. The majority of RANKL-expressing cells in rat gingival tissues are T and B cells. Soluble RANKL in gingival homogenates and periodontal bone loss were significantly elevated in P gingivalis infected rats compared to uninfected rats (p < 0.05). Injection of anti-RANKL antibody or OPG-Fc into rat gingival papillae after P gingivalis infection significantly reduced periodontal bone loss (p < 0.05). This study suggests that P gingivalis infection-associated bone loss is mediated by immune cells in a RANKL-dependent manner. C1 [Han, Xiaozhe; Lin, Xiaoping; Kawai, Toshihisa; LaRosa, Karen B.; Taubman, Martin A.] Forsyth Inst, Dept Immunol, Boston, MA 02115 USA. RP Han, XZ (reprint author), Forsyth Inst, Dept Immunol, 140 Fenway, Boston, MA 02115 USA. EM xhan@forsyth.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 400 EP 402 DI 10.1007/978-4-431-99644-6_114 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500114 ER PT B AU Kanzaki, H Han, XZ Lin, XP Kawai, T Taubman, MA AF Kanzaki, Hiroyuki Han, Xiaozhe Lin, Xiaoping Kawai, Toshihisa Taubman, Martin A. BE Sasano, T Suzuki, O TI Is RANKL shedding involved in immune cell-mediated osteoclastogenesis? SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE osteoclastogenesis; TACE; sRANKL; periodontitis; immune cell ID KAPPA-B LIGAND; GINGIVAL CREVICULAR FLUID; DIFFERENTIATION FACTOR; PERIODONTAL-DISEASE; RECEPTOR ACTIVATOR; BONE-RESORPTION; MESSENGER-RNA; OSTEOPROTEGERIN; EXPRESSION; ENZYME AB Host immune responses play a key role in promoting bone resorption in periodontitis. RANKL-positive T- and B-lymphocytes have been described in periodontal lesions, along with induction of osteoclastogenesis. RANKL initially exists as a membrane-bound form, and cell-to-cell contact is required for inducing osteoclastogenesis. However, membrane-bound RANKL can be cleaved by enzymes, such as TNF-alpha-converting enzyme (TACE), and its product soluble RANKL (sRANKL) also has osteoclastogenic activity. We hypothesized that TACE might function as a main RANKL-shedding enzyme from activated immune cells, and that sRANKL cleaved by TACE might be important in osteoclastogenesis. To clarify our hypothesis, in vitro experiments using human peripheral blood mononuclear cells were performed. Consistent with a previous report (Lum et al. J Biol Chem 274:13613-13618, 1999), our data suggested that TACE might be the only functionally active sheddase for RANKL expressed by immune cells. sRANKL cleaved from activated immune cells by TACE could play a pivotal role in osteoclastogenesis. C1 [Kanzaki, Hiroyuki; Han, Xiaozhe; Lin, Xiaoping; Kawai, Toshihisa; Taubman, Martin A.] Forsyth Inst, Dept Immunol, Boston, MA USA. RP Kanzaki, H (reprint author), Forsyth Inst, Dept Immunol, 140 Fenway, Boston, MA USA. EM hkanzaki@forsyth.org NR 17 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 403 EP 405 DI 10.1007/978-4-431-99644-6_115 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500115 ER PT B AU Ouhara, K Kajiya, M Stashenko, P Taubman, MA Kawai, T AF Ouhara, Kazuhisa Kajiya, Mikihito Stashenko, Philip Taubman, Martin A. Kawai, Toshihisa BE Sasano, T Suzuki, O TI Possible IgG transportation mechanism mediated by neonatal Fc receptor expressed in gingival epithelial cells SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE immunoglobulin; IgG; neonatal Fc receptor; gingival epithelial cells; pH-dependent transportation AB The neonatal Fc receptor (FcRn) for immunoglobulin G (IgG) expressed in intestinal epithelium has been shown to be responsible for IgG transport and to be involved in IgG catabolism (Simister, Vaccine 21:3365-3369, 2003; Ghetie and Ward, Immunol Res 25:97-113, 2002). In this study, we first examined the expression of FcRn in normal gingival epithelial cells (GECs) and then tested the possibility that IgG transportation is mediated by such FcRn expressed in GEC. To make these determinations, experiments were carried out to: (1) evaluate the expression pattern of FcRn using immunohistochemical staining of FcRn in human gingival tissue, (2) measure the expression of FcRn-mRNA in the cultured GEC, and (3) examine the transport of IgG via FcRn expressed in the GEC cultured in cell culture insert. Immunohistochemistry detected the expression of FcRn in human GEC. Primary culture of both GEC and human GEC line (OBA9) demonstrated the expression of FcRn-mRNA. Since RNAi-based inhibition of FcRn expression resulted in the diminished transportation of IgG, it was determined that FcRn expressed in GEC was responsible for the transport of IgG. Strikingly, the transport of IgG mediated by epithelial FcRn was pH-dependent. These results suggested that FcRn expressed in GEC may contribute to the recycling of IgG in the oral cavity. C1 [Ouhara, Kazuhisa; Kajiya, Mikihito; Stashenko, Philip; Taubman, Martin A.; Kawai, Toshihisa] Forsyth Inst, Boston, MA USA. RP Kawai, T (reprint author), Forsyth Inst, Boston, MA USA. EM tkawai@forsyth.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 406 EP 408 DI 10.1007/978-4-431-99644-6_116 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500116 ER PT B AU Silva, MJ Mackler, HE Ouhara, K Cardoso, CR Taubman, MA Kawai, T AF Silva, Marcelo Jose Mackler, Harrison E. Ouhara, Kazuhisa Cardoso, Cristina Ribeiro Taubman, Martin A. Kawai, Toshihisa BE Sasano, T Suzuki, O TI Effects of extracellular adenosine on sRANKL production from activated T cells SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE T cells; T cell receptor (TCR); CD28; receptor activator of NT-kappa B ligand (RANKL); adenosine ID RECEPTORS AB This study investigated the effects of extracellular adenosine and four adenosine receptor agonists on the proliferation of activated T cells isolated from mice, as well as the production of soluble receptor activator of NF-kappa B ligand (sRANKL) derived from the activated T cells. All five compounds were applied to the T cells stimulated in vitro by TCR/CD28 engagement. The culture supernatants from the in-vitro-activated T cells were collected for the measurement of sRANKL production using ELISA, and proliferation of activated T cells was analyzed using the H-3 thymidine incorporation assay. The results obtained from this study indicated that extracellular adenosine and adenosine receptor agonists can suppress both proliferation of activated T cells and sRANKL production by the activated T cells, suggesting that adenosine receptor agonists may potentially lead to the development of new therapies for the prevention and treatment of inflammatory diseases affecting bone remodeling. C1 [Silva, Marcelo Jose; Mackler, Harrison E.; Ouhara, Kazuhisa; Taubman, Martin A.; Kawai, Toshihisa] Forsyth Inst, Boston, MA 02142 USA. [Cardoso, Cristina Ribeiro] Univ Fed Triangulo Mineiro, Uberaba, MG, Brazil. RP Kawai, T (reprint author), Forsyth Inst, Boston, MA 02142 USA. EM tkawai@forsyth.org RI Silva, Marcelo/J-4298-2012 OI Silva, Marcelo/0000-0002-5807-4286 FU NIH [DE-18499] FX This study was supported by NIH grant DE-18499. NR 4 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 409 EP + DI 10.1007/978-4-431-99644-6_117 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500117 ER PT B AU Tye, CE Bartlett, JD AF Tye, Coralee E. Bartlett, John D. BE Sasano, T Suzuki, O TI Activation of the critical enamel protease kallikrein-4 SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE enamel; kallikrein-4; matrix metalloproteinase-20; dipeptidyl peptidase I ID EXPRESSION; KLK4 AB Kallikrein-4 (KLK4) is a serine protease expressed during enamel maturation, which is critical for proper enamel formation. KLK4 is secreted as an inactive zymogen and identification of its activator remains elusive. Herein we discuss what is currently known about the activation of pro-KLK4. C1 [Tye, Coralee E.; Bartlett, John D.] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. RP Bartlett, JD (reprint author), Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA. EM jbartlett@forsyth.org NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 413 EP 415 DI 10.1007/978-4-431-99644-6_118 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500118 ER PT B AU King, WF Chen, T Nogueira, R Mattos-Graner, R Smith, DJ AF King, William F. Chen, Tsute Nogueira, Ruchele Mattos-Graner, Renata Smith, Daniel J. BE Sasano, T Suzuki, O TI Epitopes shared among pioneer oral flora and Streptococcus mutans GbpB SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE ontogeny; pioneer flora; commensal; Streptococcus mutans AB The establishment of microorganisms in emerging oral biofilms of humans is likely to be modulated by a constellation of infant, maternal, and microbial factors. We have shown that pioneer microbiota on epithelial surfaces (e.g., Streptococcus mitis, Streptococcus salivarius) and initially erupting dental surfaces (e.g., Streptococcus sanguinis, Streptococcus gordonii, and Streptococcus oralis) induce mucosal SIgA antibody in saliva. The resulting immune responses may modulate subsequent colonization of bacteria that later join the oral biofilm (e.g., cariogenic Streptococcus mutans), a speculation supported by the observation that (a) several S. mutans virulence components share MHC Class II binding peptides with pioneer protein homologues, (b) cross-reactive antibody among homologues can be demonstrated and (c) initial S. mutans colonization can apparently be delayed when some of these responses are present a priori. C1 [King, William F.; Chen, Tsute; Smith, Daniel J.] Forsyth Inst, Boston, MA 02115 USA. [Nogueira, Ruchele; Mattos-Graner, Renata] Univ Estadual Campinas, Sao Paulo, Brazil. RP Smith, DJ (reprint author), Forsyth Inst, Boston, MA 02115 USA. EM dsmith@forsyth.org RI Mattos-Graner, Renata/C-9410-2012; OI Mattos-Graner, Renata/0000-0001-8309-8135; Nogueira, Ruchele Dias/0000-0002-7706-1376 FU U.S. Public Health Service [DE-06133, DE-04733, DE/AI-12434, TW-06324]; FAPESP [02/07156-1, 04/07425-8]; CAPES [029/03] FX Grant support for the authors research has come from the U.S. Public Health Service (DE-06133, DE-04733, DE/AI-12434, and TW-06324), FAPESP (proc. 02/07156-1, proc. 04/07425-8) and CAPES (ProDoc, proc. 029/03). NR 4 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 416 EP + DI 10.1007/978-4-431-99644-6_119 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500119 ER PT B AU Kwak, SY Wiedemann-Bidlack, FB Litman, A Beniash, E Yamakoshi, Y Simmer, JP Margolis, HC AF Kwak, Seo-Young Wiedemann-Bidlack, Felicitas B. Litman, Amy Beniash, Elia Yamakoshi, Yasuo Simmer, James P. Margolis, Henry C. BE Sasano, T Suzuki, O TI Inhibitory effect of porcine amelogenins on spontaneous mineralization SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE enamel; amelogenin; biomineralization; hydroxyapatite ID IN-VITRO AB The potential role of amelogenin phosphorylation in enamel formation has been elucidated through in vitro mineralization studies. Studies focused on the native 20-kDa porcine amelogenin proteolytic cleavage product P148 that is prominent in developing enamel. Under conditions of spontaneous calcium phosphate precipitation, in the presence of nonphosphorylated recombinant full-length porcine amelogenin, rP172, immediately formed nanoparticles of amorphous calcium phosphate (ACP) were found to transform into parallel arrays of needle-like apatitic crystals. In contrast to these findings, P148, with a single phosphate group on serine-16, was found to inhibit calcium phosphate precipitation and stabilize ACP formation for more than 1 day. The present study has provided evidence suggesting that the proteolytic cleavage product P148 may have an important functional role in regulating mineralization during enamel formation. C1 [Kwak, Seo-Young; Wiedemann-Bidlack, Felicitas B.; Litman, Amy; Beniash, Elia; Margolis, Henry C.] Forsyth Inst, Dept Biomineralizat, 140 Fenway, Boston, MA 02115 USA. [Yamakoshi, Yasuo; Simmer, James P.] Univ Michigan, Dent Res Lab, Ann Arbor, MI 15261 USA. [Beniash, Elia] Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA 48109 USA. RP Margolis, HC (reprint author), Forsyth Inst, Dept Biomineralizat, 140 Fenway, Boston, MA 02115 USA. EM hmargolis@forsyth.org FU National Institute of Dental and Craniofacial Research [DE-016376 (HCM)]; [T32 DE-007327] FX This work was supported by grant DE-016376 (HCM) from the National Institute of Dental and Craniofacial Research. FBW-B was also partially supported by grant T32 DE-007327. NR 2 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 418 EP + DI 10.1007/978-4-431-99644-6_120 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500120 ER PT B AU Sharma, R Bartlett, JD AF Sharma, Ramaswamy Bartlett, John D. BE Sasano, T Suzuki, O TI A stress-based mechanism to explain dental fluorosis SO INTERFACE ORAL HEALTH SCIENCE 2009 LA English DT Proceedings Paper CT 1st Tohoku-Forsyth Symposium CY MAR 10-11, 2009 CL Boston, MA DE fluoride; fluorosis; ER stress; unfolded protein response ID ENDOPLASMIC-RETICULUM STRESS; FLUORIDE AB Excess fluoride (F-) causes dental fluorosis (DF). However, the mechanisms underlying DF are not clear. We have previously shown that F- affects homeostasis of the endoplasmic reticulum (ER), leading to ER stress and the activation of the unfolded protein response (UPR). The UPR is a signaling pathway designed to restore ER homeostasis. Herein, we describe the UPR and summarize the UPR components activated by F-. C1 [Sharma, Ramaswamy; Bartlett, John D.] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. RP Bartlett, JD (reprint author), Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA. EM jbartlett@forsyth.org NR 7 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG TOKYO PI TOKYO PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN BN 978-4-431-99643-9 PY 2010 BP 421 EP 423 DI 10.1007/978-4-431-99644-6_121 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BTU47 UT WOS:000288113500121 ER PT J AU Papakostas, GI Clain, A Ameral, VE Baer, L Brintz, C Smith, WT Londborg, PD Glaudin, V Painter, JR Fava, M AF Papakostas, George I. Clain, Alisabet Ameral, Victoria E. Baer, Lee Brintz, Carrie Smith, Ward T. Londborg, Peter D. Glaudin, Vincent Painter, John R. Fava, Maurizio TI Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE anxiety; anxious; clonazepam; cotherapy; depression; fluoxetine ID STAR-ASTERISK-D; BENZODIAZEPINE RECEPTOR; ANXIETY DISORDERS; MAJOR DEPRESSION; CLINICAL-TRIALS; GABA; AUGMENTATION; OUTPATIENTS; CIRCUITS; SUBTYPES AB Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results. We sought to examine the relative benefits of antidepressant-anxiolytic cotherapy versus antidepressant monotherapy for patients with anxious depression versus without anxious depression. We conducted a post-hoc analysis of an existing dataset (N=80), from a 3-week, randomized, double-blind trial which demonstrated cotherapy with fluoxetine and clonazepam to result in superior efficacy than fluoxetine monotherapy in MDD. The present analysis involved examining whether anxious depression status served as a predictor and moderator of symptom improvement. Anxious depression status was not found to predict symptom improvement, or serve as a moderator of clinical improvement to cotherapy versus monotherapy. However, the advantage in remission rates in favor of cotherapy versus monotherapy was, numerically, much larger for patients with anxious depression (32.2%) than it was for patients without anxious MDD (9.7%). The respective number needed to treat statistic for these two differences in response rates were, approximately, one in three for patients with anxious depression versus one in 10 for patients without anxious depression. The efficacy of fluoxetine-clonazepam cotherapy compared with fluoxetine monotherapy was numerically but not statistically enhanced for patients with anxious depression than those without anxious depression. Int Clin Psychopharmacol 25:17-21 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Papakostas, George I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Depress Clin & Res Program, Boston, MA 02114 USA. [Smith, Ward T.; Londborg, Peter D.; Glaudin, Vincent; Painter, John R.] Summit Res Network, Portland, OR USA. RP Papakostas, GI (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Depress Clin & Res Program, 15 Parkman St,WACC B12, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU Hoffman LaRoche, Inc. FX Original trial supported by a grant from Hoffman LaRoche, Inc. NR 30 TC 5 Z9 5 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2010 VL 25 IS 1 BP 17 EP 21 DI 10.1097/YIC.0b013e32833205a4 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 537FL UT WOS:000273098400003 PM 19898245 ER PT J AU Lichterfeld, M Ferraro, MJ Davis, BT AF Lichterfeld, Mathias Ferraro, Mary Jane Davis, Benjamin T. TI High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Letter C1 [Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Microbiol, Boston, MA 02114 USA. RP Lichterfeld, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Cox 5,55 Fruit St, Boston, MA 02114 USA. EM mlichterfeld@partners.org NR 4 TC 11 Z9 11 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD JAN PY 2010 VL 35 IS 1 BP 96 EP 96 DI 10.1016/j.ijantimicag.2009.08.019 PG 1 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 545FL UT WOS:000273717800021 PM 19896341 ER PT J AU Li, CL Li, YP Fu, XY Deng, CX AF Li, Cuiling Li, Yi-Ping Fu, Xin-Yuan Deng, Chu-Xia TI Anterior Visceral Endoderm SMAD4 Signaling Specifies Anterior Embryonic Patterning and Head Induction in Mice SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES LA English DT Article DE TGF-beta; SMAD4; AVE; epiblast; mesoderm patterning ID CONDITIONAL KNOCKOUT MICE; SQUAMOUS-CELL CARCINOMA; EARLY MOUSE EMBRYO; STEM-CELLS; TARGETED DISRUPTION; MESODERM INDUCTION; JUVENILE POLYPOSIS; GENE-EXPRESSION; GASTRULATION; SKIN AB SMAD4 serves as a common mediator for signaling of TGF-beta superfamily. Previous studies illustrated that SMAD4-null mice die at embryonic day 6.5 (E6.5) due to failure of mesoderm induction and extraembryonic defects; however, functions of SMAD4 in each germ layer remain elusive. To investigate this, we disrupted SMAD4 in the visceral endoderm and epiblast, respectively, using a Cre-loxP mediated approach. We showed that mutant embryos lack of SMAD4 in the visceral endoderm (Smad4(Co/Co);TTR-Cre) died at E7.5-E9.5 without head-fold and anterior embryonic structures. We demonstrated that TGF-beta regulates expression of several genes, such as Hex1, Cer1, and Lim1, in the anterior visceral endoderm (AVE), and the failure of anterior embryonic development in Smad4Co/Co; TTR-Cre embryos is accompanied by diminished expression of these genes. Consistent with this finding, SMAD4-deficient embryoid bodies showed impaired responsiveness to TGF-beta-induced gene expression and morphological changes. On the other hand, embryos carrying Cre-loxP mediated disruption of SMAD4 in the epiblasts exhibited relatively normal mesoderm and head-fold induction although they all displayed profound patterning defects in the later stages of gastrulation. Cumulatively, our data indicate that SMAD4 signaling in the epiblasts is dispensable for mesoderm induction although it remains critical for head patterning, which is significantly different from SMAD4 signaling in the AVE, where it specifies anterior embryonic patterning and head induction. C1 [Li, Cuiling; Deng, Chu-Xia] NIDDK, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA. [Li, Yi-Ping] Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA. [Fu, Xin-Yuan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore. RP Deng, CX (reprint author), NIDDK, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA. EM chuxiad@bdg10.niddk.nih.gov RI deng, chuxia/N-6713-2016 FU National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA FX We thank Dr. T Mak for providing Smad4-/- ES cells, and members of Dr. Deng lab for their critical discussion of this work. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA. NR 53 TC 2 Z9 2 U1 0 U2 0 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1449-2288 J9 INT J BIOL SCI JI Int. J. Biol. Sci. PY 2010 VL 6 IS 6 BP 569 EP 583 PG 15 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 677LD UT WOS:000283993000005 PM 20941375 ER PT J AU Al-Maatouq, M Al-Arouj, M Assaad, SH Assaad, SN Azar, ST Hassoun, AAK Jarrah, N Zatari, S Alberti, KGMM AF Al-Maatouq, M. Al-Arouj, M. Assaad, S. H. Assaad, S. N. Azar, S. T. Hassoun, A. A. K. Jarrah, N. Zatari, S. Alberti, K. G. M. M. TI Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE LA English DT Article ID BLOOD-GLUCOSE CONTROL; RANDOMIZED CONTROLLED-TRIAL; PIOGLITAZONE CLINICAL-TRIAL; SAUDI-ARABIA; MYOCARDIAL-INFARCTION; MACROVASCULAR EVENTS; EUROPEAN-ASSOCIATION; CONSENSUS STATEMENT; OVERWEIGHT PATIENTS; COST-EFFECTIVENESS AB Aims: Increases in the prevalence of type 2 diabetes will likely be greater in the Middle East and other developing countries than in most other regions during the coming two decades, placing a heavy burden on regional healthcare resources. Methodology: Medline search, examination of data from major epidemiological studies in the Middle Eastern countries. Results: The aetiology and pathophysiology of diabetes appears comparable in Middle Eastern and other populations. Lifestyle intervention is key to the management of diabetes in all type 2 diabetes patients, who should be encouraged strongly to diet and exercise. The options for pharmacologic therapy in the management of diabetes have increased recently, particularly the number of potential antidiabetic combinations. Metformin appears to be used less frequently to initiate antidiabetic therapy in the Middle East than in other countries. Available clinical evidence, supported by current guidelines, strongly favours the initiation of antidiabetic therapy with metformin in Middle Eastern type 2 diabetes patients, where no contraindications exist. This is due to its equivalent or greater efficacy relative to other oral antidiabetic treatments, its proven tolerability and safety profiles, its weight neutrality, the lack of clinically significant hypoglycaemia, the demonstration of cardiovascular protection for metformin relative to diet in the UK Prospective Diabetes Study and in observational studies, and its low cost. Additional treatments should be added to metformin and lifestyle intervention as diabetes progresses, until patients are receiving an intensive insulin regimen with or without additional oral agents. Conclusions: The current evidence base strongly favours the initiation of antidiabetic therapy with metformin, where no contraindications exist. However, metformin may be under-prescribed in the Middle East. C1 [Al-Maatouq, M.] King Saud Univ, King Khalid Univ Hosp, Riyadh 11461, Saudi Arabia. [Al-Arouj, M.] Dasman Ctr Res & Treatment Diabet, Dasman, Kuwait. [Assaad, S. H.; Assaad, S. N.] Univ Alexandria, Alexandria, Egypt. [Azar, S. T.] Amer Univ Beirut, Beirut, Lebanon. [Hassoun, A. A. K.] Joslin Diabet Ctr, Dubai, U Arab Emirates. [Jarrah, N.] Mutah Univ, Mutah, Karak, Jordan. [Zatari, S.] Al Hada Armed Forces Hosp, At Taif, Saudi Arabia. [Alberti, K. G. M. M.] Univ London Imperial Coll Sci Technol & Med, London, England. RP Al-Maatouq, M (reprint author), King Saud Univ, Coll Med, Dept Med 38, POB 2925, Riyadh 11461, Saudi Arabia. EM mmaatouq@ksu.edu.sa FU Merck Serono FX The recommendations given above arose from a meeting of an expert panel of physicians from Middle-Eastern countries supported by an for their contributions. Dr SH Assaad is a Principal Investigator for a research project supported by Merck Serono. NR 74 TC 6 Z9 7 U1 2 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1368-5031 J9 INT J CLIN PRACT JI Int. J. Clin. Pract. PD JAN PY 2010 VL 64 IS 2 BP 149 EP 159 DI 10.1111/j.1742-1241.2009.02235.x PG 11 WC Medicine, General & Internal; Pharmacology & Pharmacy SC General & Internal Medicine; Pharmacology & Pharmacy GA 531HT UT WOS:000272656000007 PM 20089006 ER PT J AU Paik, EJ Zon, LI AF Paik, Elizabeth J. Zon, Leonard I. TI Hematopoietic development in the zebrafish SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY LA English DT Article DE hematopoietic stem cell; HSC; hemangioblast; primitive hematopoiesis; definitive hematopoiesis ID T-CELL LEUKEMIA; TRANSCRIPTION FACTOR GATA-2; LYMPHOCYTE DEVELOPMENT; DEFINITIVE HEMATOPOIESIS; ENDOTHELIAL DEVELOPMENT; VASCULAR DEVELOPMENT; UBIQUITIN LIGASE; BLOOD FORMATION; MICE LACKING; DANIO-RERIO AB The model organism Danio rerio, also known as the zebrafish, is an excellent system for studying the developmental process of hematopoiesis. It is an ideal model for in vivo imaging, and it is useful for large-scale genetic screens. These have led to the discovery of previously unknown players in hematopoiesis, as well as helped our understanding of hematopoietic development. In this review, we will summarize hematopoiesis in the zebrafish and discuss how genetic approaches using the zebrafish system have helped to build our current knowledge in the field of hematopoiesis. C1 [Zon, Leonard I.] Childrens Hosp Boston, Stem Cell Program, Boston, MA 02115 USA. Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Zon, LI (reprint author), Childrens Hosp Boston, Stem Cell Program, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu NR 98 TC 68 Z9 69 U1 2 U2 6 PU U B C PRESS PI BILBAO PA UNIV BASQUE COUNTRY, EDITORIAL SERVICES, PO BOX 1397, E-48080 BILBAO, SPAIN SN 0214-6282 J9 INT J DEV BIOL JI Int. J. Dev. Biol. PY 2010 VL 54 IS 6-7 SI SI BP 1127 EP 1137 DI 10.1387/ijdb.093042ep PG 11 WC Developmental Biology SC Developmental Biology GA 658HM UT WOS:000282481100020 PM 20711990 ER PT J AU Chae, DH Krieger, N Bennett, GG Lindsey, JC Stoddard, AM Barbeau, EM AF Chae, David H. Krieger, Nancy Bennett, Gary G. Lindsey, Jane C. Stoddard, Anne M. Barbeau, Elizabeth M. TI IMPLICATIONS OF DISCRIMINATION BASED ON SEXUALITY, GENDER, AND RACE/ETHNICITY FOR PSYCHOLOGICAL DISTRESS AMONG WORKING-CLASS SEXUAL MINORITIES: THE UNITED FOR HEALTH STUDY, 2003-2004 SO INTERNATIONAL JOURNAL OF HEALTH SERVICES LA English DT Article ID AFRICAN-AMERICAN MEN; ISLANDER GAY MEN; BISEXUAL ADULTS; HIV-RISK; PERCEIVED DISCRIMINATION; MULTIPLE IMPUTATION; SOCIAL HAZARDS; US CITIES; DISORDERS; WOMEN AB This study investigated the distribution of demographic characteristics, the prevalence of discrimination based on sexuality, gender, and race, and relationships with psychological distress among 178 working-class sexual minorities (i. e, who identified as lesbian, gay, or bisexual (LGB) or had ever engaged in same-sex sexual behaviors) recruited to the United for Health Study (2003-2004). The results indicated considerable heterogeneity in responses to items assessing sexual orientation and sexual behavior, with a majority of sexual minority participants not identifying as LGB (74 2%) The authors found significant demographic differences in LGB identification by gender, race/ethnicity, nativity, and socioeconomic factors In addition, LGB participants had higher levels of psychological distress than non-LGB-identified sexual minorities. Linear regression analyses revealed that reports of racial/ethnic discrimination and sexuality discrimination were associated with higher levels of psychological distress among sexual minority participants The results underscore the need to collect multiple measures of sexuality in conducting research on racially diverse working-class communities, to consider demographic factors in collecting sexuality data, and to disaggregate information on sexuality by LGB identification Findings also highlight the importance of addressing discrimination in ameliorating problematic mental health outcomes among working-class sexual minorities C1 [Chae, David H.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Chae, David H.; Krieger, Nancy] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Bennett, Gary G.] Duke Univ, Durham, NC USA. [Barbeau, Elizabeth M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Stoddard, Anne M.] Univ Massachusetts, Sch Publ Hlth, Biostat Fac, Amherst, MA 01003 USA. [Stoddard, Anne M.] Univ Massachusetts, Ctr Res & Educ Womens Hlth, Amherst, MA 01003 USA. [Chae, David H.] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. RP Chae, DH (reprint author), Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,Room 512, Atlanta, GA 30322 USA. RI Chae, David/F-6956-2015 FU NIOSH [R01 OH07366-01, R01 OH7366-01S]; Williams Institute; Institute for Gay and Lesbian Strategic Studies FX The United for Health Study was supported by NIOSH grants R01 OH07366-01 and R01 OH7366-01S. David H. Chac was a Robert Wood Johnson Health and Society Scholar, and during the time of this research he was with the Harvard School of Public Health, Department of Society, Human Development and Health, and the University of Washington, School of Social Work. He was supported by a grant from the Williams Institute and the Institute for Gay and Lesbian Strategic Studies, and was a W. K. Kellogg Fellow in Health Policy. NR 56 TC 13 Z9 13 U1 3 U2 17 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0020-7314 J9 INT J HEALTH SERV JI Int. J. Health Serv. PY 2010 VL 40 IS 4 BP 589 EP 608 DI 10.2190/HS.40.4.b PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 669GL UT WOS:000283335800002 PM 21058533 ER PT J AU Hurwitz, M AF Hurwitz, Mark TI The crossroads of prostate cancer and thermal medicine SO INTERNATIONAL JOURNAL OF HYPERTHERMIA LA English DT Editorial Material C1 Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. RP Hurwitz, M (reprint author), Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0265-6736 J9 INT J HYPERTHER JI Int. J. Hyperthermia PY 2010 VL 26 IS 8 SI SI BP 735 EP 736 DI 10.3109/02656736.2010.525227 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 674JW UT WOS:000283738500001 PM 21043570 ER PT J AU Nair, G Shen, Q Duong, TQ AF Nair, Govind Shen, Qiang Duong, Timothy Q. TI Relaxation Time Constants and Apparent Diffusion Coefficients of Rat Retina at 7 Tesla SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE spin-spin relaxation time; spin-lattice relaxation time; BOLD; brain; apparent diffusion coefficient; eye ID BLOOD-FLOW; IN-VIVO; T-2 RELAXATION; RESOLUTION; BRAIN; MRI; COLUMNS; TISSUE; LAYERS; WATER AB MRI has recently been applied to study the retina in vivo. Measurements of relaxation time constants (T(1), T(2), and T(2)*) and the apparent diffusion coefficient (ADC) of the retina would be useful to systemically optimize structural, physiological, and functional MRI contrasts. MRI studies were performed on 12 anesthetized and paralyzed rats. High-resolution T(1), T(2), T(2)* and ADC of the rat eyes were measured at 50 x 50 x 800 mu m at 7 Tesla. Profiles of T(1), T(2), T(2)* and ADC across the retinal thickness were analyzed. Region of interests of three layers across the retinal thickness were tabulated. This study demonstrated that high resolution T(1), T(2), T(2)* and ADC of the rat retina could be imaged. Profile analysis of T(1), T(2), T(2)* and ADC across the retinal thickness were helpful to minimize partial volume effects. T(1), T(2), T(2)* and ADC of the rat retina were overall similar to those of the brain. Quantitative T1, T2, T2* and ADC may change in retinal diseases and their measurements could help to stage retinal disease progression and monitor therapeutic intervention. (C) 2010 Wiley-Periodicals, Inc. Int J Imaging Syst Technol, 20, 126-130, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/ima.20237 C1 [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, Res Imaging Inst, San Antonio, TX 78229 USA. [Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Amherst, MA 01003 USA. [Nair, Govind] Worcester Polytech Inst, Worcester, MA USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, Res Imaging Inst, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Shen, Qiang/B-8784-2008; Duong, Timothy/B-8525-2008 OI Shen, Qiang/0000-0002-4287-3403; NR 21 TC 19 Z9 19 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-9457 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PY 2010 VL 20 IS 2 SI SI BP 126 EP 130 DI 10.1002/ima.20237 PG 5 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 604KP UT WOS:000278278200005 ER PT J AU Netravali, IA Holt, RJ Webb, C AF Netravali, Ilka A. Holt, Robert J. Webb, Charles TI Perceptual Denoising of Color Images SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE denoising; perception; color images; filtering; image analysis ID RESTORATION AB Denoising of color images is a trade-off between sharpness of an image and perceived noise. We formulate a novel optimization problem that can maximize sharpness of an image while limiting the perceived noise under a model of visibility of additive random noise. We derive a closed-form expression for an optimal two-dimensional finite impulse response filter, show its uniqueness and existence, and present simulation results for black and white as well as color images. Simulation results show remarkable reduction in perceptibility of noise, while preserving sharpness. The computational burden required for the optimal filter is reduced by a new ad hoc filter which is simple but has near optimal performance. (C) 2010 Wiley Periodicals, Inc. Int J Imaging Syst Technol, 20, 215-222, 2010; View this article online at wileyonlinelibrary.com. DOI 10.1002/ima.20240 C1 [Holt, Robert J.] CUNY, Dept Math & Comp Sci, Bayside, NY USA. [Netravali, Ilka A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA. [Netravali, Ilka A.] Harvard Univ, Sch Med, Harvard MIT Div Hlth Sci & Technol, Boston, MA USA. [Webb, Charles] ANUE Syst, Austin, TX USA. RP Holt, RJ (reprint author), CUNY, Dept Math & Comp Sci, Bayside, NY USA. EM rjholt@alcatel-lucent.com RI Holt, Robert/B-5460-2009 FU Bell Laboratories (Lucent Technologies)Alcatel-Lucent FX Grant sponsor: Bell Laboratories (Lucent Technologies)Alcatel-Lucent. NR 22 TC 0 Z9 0 U1 2 U2 5 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-9457 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PY 2010 VL 20 IS 3 BP 215 EP 222 DI 10.1002/ima.20240 PG 8 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 639HV UT WOS:000280966800003 ER PT J AU Gavathiotis, E Ruiz, DR Davis, ML Bird, GH Walensky, LD AF Gavathiotis, Evripidis Ruiz, Denis R. Davis, Marguerite L. Bird, Gregory H. Walensky, Loren D. TI Dissecting and targeting the activation pathway of BAX to reactivate apoptosis in cancer SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Gavathiotis, Evripidis; Ruiz, Denis R.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Ruiz, Denis R.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Ruiz, Denis R.; Davis, Marguerite L.; Bird, Gregory H.; Walensky, Loren D.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Gavathiotis, Evripidis; Bird, Gregory H.; Walensky, Loren D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. EM evripidis_gavathiotis@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2010 VL 26 SU 1 MA 262 BP S45 EP S45 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 667OM UT WOS:000283203400163 ER PT J AU Porichis, F Quigley, M Percyra, F Zupkosky, J Tighe, DP Kwon, DS McMullen, A Kavanagh, DG Freeman, GJ Ebert, B Walker, BD Haining, WN Kaufmann, DE AF Porichis, Filippos Quigley, Michael Percyra, Florencia Zupkosky, Jennifer Tighe, Daniel P. Kwon, Douglas S. McMullen, Ashley Kavanagh, Daniel G. Freeman, Gordon J. Ebert, Benjamin Walker, Bruce D. Haining, W. Nicholas Kaufmann, Daniel E. TI Immunosuppressive pathways governing HIV-Specific T cell dysfunction: the PD-1 and BATF story SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Porichis, Filippos; Percyra, Florencia; Zupkosky, Jennifer; Tighe, Daniel P.; Kwon, Douglas S.; McMullen, Ashley; Kavanagh, Daniel G.; Walker, Bruce D.; Kaufmann, Daniel E.] MIT & Harvard, Ragom Inst MGH, Boston, MA USA. [Quigley, Michael; Ebert, Benjamin; Haining, W. Nicholas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2010 VL 26 SU 1 MA 274 BP S48 EP S48 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 667OM UT WOS:000283203400175 ER PT J AU Spandidos, A Wang, XW Wang, HJ Seed, B AF Spandidos, Athanasia Wang, Xiaowei Wang, Huajun Seed, Brian TI The PrimerBank resource of human and mouse primer pairs for PCR and QPCR SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Spandidos, Athanasia; Wang, Xiaowei; Wang, Huajun; Seed, Brian] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Spandidos, Athanasia; Wang, Xiaowei; Wang, Huajun; Seed, Brian] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2010 VL 26 SU 1 MA 170 BP S22 EP S22 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 667OM UT WOS:000283203400071 ER PT J AU Papakostas, G AF Papakostas, G. TI Predictors, moderators, and mediators of symptom improvement in major depressive disorder: Overview, definition, and significance SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 27th CINP Congress Meeting 2010 CY JUN 06-10, 2010 CL Hong Kong, PEOPLES R CHINA C1 [Papakostas, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 0 TC 0 Z9 0 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PY 2010 VL 13 SU 1 BP 5 EP 5 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 643FN UT WOS:000281281100010 ER PT J AU Nierenberg, A AF Nierenberg, A. TI Evaluating the evidence for evidence-based treatment of bipolar depression SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 27th CINP Congress Meeting 2010 CY JUN 06-10, 2010 CL Hong Kong, PEOPLES R CHINA C1 [Nierenberg, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PY 2010 VL 13 SU 1 BP 28 EP 28 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 643FN UT WOS:000281281100095 ER PT J AU Papakostas, G Bandelow, B Demyttenaere, K Trivedi, M Earley, W Szamosi, J Eriksson, H AF Papakostas, G. Bandelow, B. Demyttenaere, K. Trivedi, M. Earley, W. Szamosi, J. Eriksson, H. TI Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy on sleep disturbance in patients with major depressive disorder SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 27th CINP Congress Meeting 2010 CY JUN 06-10, 2010 CL Hong Kong, PEOPLES R CHINA C1 [Papakostas, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bandelow, B.] Univ Gottingen, D-3400 Gottingen, Germany. [Demyttenaere, K.] Uni Hosp Gasthuisberg, Louvain, Belgium. [Trivedi, M.] UT SW Med Ctr, Dallas, TX USA. [Earley, W.] AstraZeneca, Wilmington, DE USA. [Szamosi, J.; Eriksson, H.] AstraZeneca R&D, Sodertalje, Sweden. RI Bandelow, Borwin/E-7295-2011 OI Bandelow, Borwin/0000-0003-2511-3768 NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PY 2010 VL 13 SU 1 BP 159 EP 159 PG 1 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 643FN UT WOS:000281281100580 ER PT J AU Kaufmann, L Sauter, TB Lee, DJ AF Kaufmann, Lisa Sauter, Todd B. Lee, Daniel J. TI Dysplasia of the cerebellum in Waardenburg syndrome: Outcomes following cochlear implantation SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY LA English DT Article DE Waardenburg syndrome; Cochlear implant; Cerebellar dysplasia ID CHILDREN; TYPE-4; DELETIONS; DISEASE; GENE AB This study provides the first description of isolated cerebellar dysplasia associated with Waardenburg syndrome (WS) and includes a review of cochlear implant outcomes in 42 WS patients. A 1-year-old male infant presented with speech delay, iris heterochromia, profound hearing loss, and an asymmetric, underdeveloped right occipital skull on CT imaging. Brain MRI demonstrated a hypoplastic right cerebellum, no hydrocephalus, normal auditory nerves and brainstem. He underwent successful bilateral sequential cochlear implantation. Cochlear implants remain a reasonable habilitative option for WS patients with congenital deafness, including those with cerebellar abnormalities. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Lee, Daniel J.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. [Kaufmann, Lisa] Charite, D-13353 Berlin, Germany. [Sauter, Todd B.] Univ Massachusetts, Sch Med, Dept Audiol, Worcester, MA USA. [Sauter, Todd B.] Univ Massachusetts, Sch Med, Dept Otolaryngol, Worcester, MA USA. RP Lee, DJ (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM daniel_lee@meei.harvard.edu NR 18 TC 5 Z9 5 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-5876 EI 1872-8464 J9 INT J PEDIATR OTORHI JI Int. J. Pediatr. Otorhinolaryngol. PD JAN PY 2010 VL 74 IS 1 BP 93 EP 96 DI 10.1016/j.ijporl.2009.10.007 PG 4 WC Otorhinolaryngology; Pediatrics SC Otorhinolaryngology; Pediatrics GA 547PP UT WOS:000273901800020 PM 19926145 ER PT J AU Wulkersdorfer, B Kao, KK Agopian, VG Ahn, A Dunn, JC Wu, BM Stelzner, M AF Wulkersdorfer, B. Kao, K. K. Agopian, V. G. Ahn, A. Dunn, J. C. Wu, B. M. Stelzner, M. TI Bimodal Porous Scaffolds by Sequential Electrospinning of Poly(glycolic acid) with Sucrose Particles SO INTERNATIONAL JOURNAL OF POLYMER SCIENCE LA English DT Article AB Electrospinning is a method to produce fine, biopolymer mesh with a three-dimensional architecture that mimics native extracellular matrix. Due to the small fiber diameter created in this process, conventional electrospun scaffolds have pore sizes smaller than the diameter of most cells. These scaffolds have limited application in tissue engineering due to poor cell penetration. We developed a hybrid electrospinning/particulate leaching technique to create scaffolds with increased porosity and improved cellular ingrowth. Poly(glycolic acid) (PGA) and a sucrose-ethanol suspension were electrospun in equal, alternating sequences at intervals of one, two, and ten minutes each. The scaffolds revealed fiber mesh with micropores of 10 mu m and uniformly distributed sucrose particles. Particulate leaching of sucrose from the one- or two-minute scaffolds revealed honeycomb structures with interconnected macropores between 50 and 250 mu m. Sucrose leaching from the ten-minute scaffolds resulted in laminated structures with isolated macropores between 200 and 350 mu m. Macropore size was directly proportional to the duration of the sucrose spinning interval. After 24 hours of cell culture, conventionally spun scaffolds demonstrated no cellular penetration. Conversely, the PGA/sucrose scaffolds demonstrated deep cellular penetration. This hybrid technique represents a novel method of generating electrospun scaffolds with interconnected pores suitable for cellular ingrowth. C1 [Wulkersdorfer, B.; Kao, K. K.; Agopian, V. G.; Ahn, A.; Stelzner, M.] VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA 90073 USA. [Kao, K. K.; Agopian, V. G.; Dunn, J. C.; Wu, B. M.; Stelzner, M.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90095 USA. [Dunn, J. C.; Wu, B. M.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. RP Stelzner, M (reprint author), VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA 90073 USA. EM matthias.stelzner@med.va.gov NR 36 TC 4 Z9 4 U1 0 U2 18 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-9422 J9 INT J POLYM SCI JI Int. J. Polym. Sci. PY 2010 AR 436178 DI 10.1155/2010/436178 PG 9 WC Polymer Science SC Polymer Science GA V24QR UT WOS:000208425400015 ER PT J AU Boyajian, R Nekhlyudov, L AF Boyajian, Richard Nekhlyudov, Larissa TI THE QUEST TO SOLVE THE CANCER SURVIVORSHIP PUZZLE: STARTING AT THE EDGES SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Editorial Material DE cancer; cancer survivorship; late effects C1 [Boyajian, Richard] Dana Farber Canc Inst, Lance Armstrong Fdn Adult Survivorship Program, Boston, MA 02115 USA. [Nekhlyudov, Larissa] Harvard Univ, Dept Populat Med, Sch Med, Boston, MA USA. [Nekhlyudov, Larissa] Harvard Vanguard Med Associates, Dept Med, Boston, MA USA. RP Boyajian, R (reprint author), Dana Farber Canc Inst, Lance Armstrong Fdn Adult Survivorship Program, 44 Binney St,LW 513A, Boston, MA 02115 USA. EM Richard_Boyajian@dfci.harvard.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2010 VL 40 IS 2 BP 183 EP 186 DI 10.2190/PM.40.2.d PG 4 WC Psychiatry SC Psychiatry GA 640LN UT WOS:000281052800004 PM 20848874 ER PT J AU Huffman, JC Doughty, CT Januzzi, JL Pirl, WF Smith, FA Fricchione, GL AF Huffman, Jeff C. Doughty, Christopher T. Januzzi, James L. Pirl, William F. Smith, Felicia A. Fricchione, Gregory L. TI SCREENING FOR MAJOR DEPRESSION IN POST-MYOCARDIAL INFARCTION PATIENTS: OPERATING CHARACTERISTICS OF THE BECK DEPRESSION INVENTORY-II SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE depression; major depressive disorder; myocardial infarction; ROC curve ID ACUTE MYOCARDIAL-INFARCTION; CORONARY-HEART-DISEASE; ARTERY-DISEASE; HEALTH; VALIDATION; MORTALITY; ANXIETY; EVENTS; METAANALYSIS; ASSOCIATION AB Objective: To assess the operating characteristics of the Beck-Depression Inventory-II (BDI-II) and the BDI-II cognitive subscale (BDI-II-cog) in screening for major depression (MDD) in post-myocardial infarction (MI) patients. Methods: Between October 2003 and July 2005, 131 post-MI patients admitted to an urban academic medical center completed the BDI-II and a semi-structured interview for depression within 72 hours of symptom onset. Sensitivity, specificity, positive and negative predictive values, overall correct classification, and likelihood ratios for various cutoff values on both scales were evaluated by comparing scores to interview diagnosis of MDD. Receiver-operator curves (ROC) were also calculated and area under the curve (AUC) measured. Results: The optimal cutoff value for the BDI-II was >= 16, with a sensitivity of 88.2% and a specificity of 92.1%. Cutoff values of >= 3 or >= 4 were both acceptable for the BDI-II-cog (sensitivity = 88.2% and 82.4%, respectively; specificity = 81.6% and 88.6 %, respectively). AUC was 0.96 for the BDI-II and 0.89 for the cognitive subscale. Conclusions: Effective depression screening is important in post-MI patients because of depression's independent association with morbidity and mortality following MI. Our results suggest that the BDI-II and its cognitive subscale are effective tools for screening for MDD in post-MI patients. (Int'l. J. Psychiatry in Medicine 2010;40:187-197) C1 [Huffman, Jeff C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Huffman, Jeff C.; Doughty, Christopher T.; Januzzi, James L.; Pirl, William F.; Smith, Felicia A.; Fricchione, Gregory L.] Harvard Univ, Sch Med, Boston, MA USA. RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St,Blake 11, Boston, MA 02114 USA. EM jhuffman@partners.org NR 34 TC 11 Z9 11 U1 1 U2 3 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2010 VL 40 IS 2 BP 187 EP 197 DI 10.2190/PM.40.2.e PG 11 WC Psychiatry SC Psychiatry GA 640LN UT WOS:000281052800005 PM 20848875 ER PT J AU Wulsin, L Somoza, E Heck, J Bauer, L AF Wulsin, Lawson Somoza, Eugene Heck, Jeffery Bauer, Leah TI PREVALENCE OF DEPRESSION AMONG MOTHERS OF YOUNG CHILDREN IN HONDURAS SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE depression mothers; maternal health; maternal depression; Central America; Latin America; Honduras ID POSTPARTUM DEPRESSION; MATERNAL DEPRESSION; MAJOR DEPRESSION; DISORDERS; SYMPTOMS; RISK; HEALTH AB Objective Maternal depression is a substantial problem that has negative consequences on the health of both mother and child Little research has been done on the prevalence of maternal depression in the developing world This study aims to estimate the prevalence of current depression among mothers in Honduras and identify demographic predictors of depression in this sample Methods A modified Spanish version of the PHQ-9 and a demographic questionaire were administered by trained Interviewers to 415 rural and urban women aged 15 66 who had children between 1 and 10 years old Results Prevalence of current major depressive syndrome was 17 6% Mild depressive symptoms were detected in 52% of the sample The estimated prevalence of current major depressive syndrome in the urban sample (19%) was not significantly greater than in the rural sample (16% p = 0 49) None of the demographic variables measured, including age, number of children, or marital status predicted major depression in this sample Conclusions Maternal depression occurred at a high rate in this sample of Honduran women The estimated prevalence rates in this study are similar to rates of maternal depression in studies of mothers in other Latin American countries, as well as in samples of mothers on Medicaid in the United States Further study is needed to confirm and extend these findings, and to identify predictors of maternal depression in this population (Int l J Psychiatry in Medicine 2010 40 259 271) C1 [Heck, Jeffery] Univ N Carolina, Asheville, NC 28804 USA. [Bauer, Leah] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Wulsin, Lawson; Somoza, Eugene] Univ Cincinnati, Cincinnati, OH 45221 USA. RP Wulsin, L (reprint author), POB 670559, Cincinnati, OH 45267 USA. FU Pfizer Inc FX This study was supported in part by an unrestricted educational grant from Pfizer Inc NR 21 TC 0 Z9 0 U1 3 U2 8 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2010 VL 40 IS 3 BP 259 EP 271 DI 10.2190/PM.40.3.c PG 13 WC Psychiatry SC Psychiatry GA 681RT UT WOS:000284335200003 PM 21166337 ER PT J AU Alexander, BM Wang, X Niemierko, A Roof, KS Fidias, PM Mathisen, DJ Weaver, DT Choi, NC AF Alexander, B. M. Wang, X. Niemierko, A. Roof, K. S. Fidias, P. M. Mathisen, D. J. Weaver, D. T. Choi, N. C. TI DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiation in Esophageal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Alexander, B. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Wang, X.; Weaver, D. T.] On Q Ity Inc, Waltham, MA USA. [Niemierko, A.; Fidias, P. M.; Mathisen, D. J.; Choi, N. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Roof, K. S.] Carolinas Med Ctr, Charlotte, NC 28203 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S91 EP S91 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700196 ER PT J AU Aristophanous, M Berbeco, R Killoran, J Yap, J Sher, D Allen, A Larson, E Chen, A AF Aristophanous, M. Berbeco, R. Killoran, J. Yap, J. Sher, D. Allen, A. Larson, E. Chen, A. TI Investigation of the Clinical Utility of 4D FDG-PET/CT Scans In Radiation Treatment Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Aristophanous, M.; Berbeco, R.; Killoran, J.; Sher, D.; Allen, A.; Larson, E.; Chen, A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Aristophanous, M.; Berbeco, R.; Killoran, J.; Yap, J.; Sher, D.; Allen, A.; Larson, E.; Chen, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S539 EP S539 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701249 ER PT J AU Arvold, ND Catalano, PJ Sweeney, CJ Hoffman, KE Nguyen, PL Balboni, TA Fossa, SD Travis, LB Beard, CJ AF Arvold, N. D. Catalano, P. J. Sweeney, C. J. Hoffman, K. E. Nguyen, P. L. Balboni, T. A. Fossa, S. D. Travis, L. B. Beard, C. J. TI Patterns of Care for Stage I Seminoma: A Survey of American Radiation Oncologists SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Arvold, N. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Catalano, P. J.; Sweeney, C. J.; Nguyen, P. L.; Balboni, T. A.; Beard, C. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Fossa, S. D.] Norwegian Radium Hosp, Oslo, Norway. [Travis, L. B.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S193 EP S193 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700413 ER PT J AU Beard, CJ Chen, M Arvold, ND Nguyen, PL Ng, AK Hoffman, KE AF Beard, C. J. Chen, M. Arvold, N. D. Nguyen, P. L. Ng, A. K. Hoffman, K. E. TI Long-term Survival and Competing Causes of Death in Men with Stage I Seminoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Beard, C. J.; Nguyen, P. L.; Ng, A. K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Arvold, N. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S60 EP S60 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700128 ER PT J AU Bekelman, JE Mitra, N Efstathiou, J Liao, K Sunderland, R Yeboa, DN Armstong, K AF Bekelman, J. E. Mitra, N. Efstathiou, J. Liao, K. Sunderland, R. Yeboa, D. N. Armstong, K. TI Comparative Effectiveness of Intensity Modulated (IMRT) versus 3D Conformal (CRT) Radiotherapy for Non-metastatic Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Bekelman, J. E.; Sunderland, R.] Univ Penn, Abramson Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Mitra, N.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Efstathiou, J.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Liao, K.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Yeboa, D. N.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S77 EP S77 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700165 ER PT J AU Berbeco, RI Ngwa, W Makrigiorgos, M AF Berbeco, R. I. Ngwa, W. Makrigiorgos, M. TI Localized Dose Enhancement to Tumor Blood Vessel Endothelial Cells Via Targeted Gold Nanoparticles: New Potential for External Beam Radiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S649 EP S650 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701493 ER PT J AU Boutrus, RR Wang, J Wirth, L McIntyre, J Clark, JR Chan, AW AF Boutrus, R. R. Wang, J. Wirth, L. McIntyre, J. Clark, J. R. Chan, A. W. TI Risk-stratified Treatment for Patients with Locally Advanced Oropharyngeal Carcinoma (OPC) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Boutrus, R. R.; Wang, J.; Wirth, L.; McIntyre, J.; Clark, J. R.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S477 EP S477 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701113 ER PT J AU Chan, A Hasan, M Chen, G Wolfgang, J AF Chan, A. Hasan, M. Chen, G. Wolfgang, J. TI Implementation of Virtual Endoscopy in Head and Neck Cancer Treatment Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Chan, A.; Hasan, M.; Chen, G.; Wolfgang, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S430 EP S430 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701009 ER PT J AU Chen, AB Neville, BA Schrag, D AF Chen, A. B. Neville, B. A. Schrag, D. TI Patterns of Care in the Management of Stage III Non-small Cell Lung Cancer in the Medicare Population SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Chen, A. B.; Neville, B. A.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S11 EP S12 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700026 ER PT J AU Chen, MH Ng, AK Chu, TF Zhou, J Gauvreau, K Mauch, PM AF Chen, M. H. Ng, A. K. Chu, T. F. Zhou, J. Gauvreau, K. Mauch, P. M. TI A Prospective Cardiac Screening Study in Asymptomatic Long-term Survivors of Hodgkin's Lymphoma Treated with Mediastinal Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Chen, M. H.; Ng, A. K.; Chu, T. F.; Zhou, J.; Gauvreau, K.] Childrens Hosp, Boston, MA 02115 USA. [Chen, M. H.; Ng, A. K.; Mauch, P. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S545 EP S546 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701263 ER PT J AU Chen, RC Chen, MH Zhang, Y McMahon, E Loffredo, M Nguyen, PL Beard, CJ D'Amico, AV AF Chen, R. C. Chen, M. H. Zhang, Y. McMahon, E. Loffredo, M. Nguyen, P. L. Beard, C. J. D'Amico, A. V. TI Patient-reported Quality of Life (QOL) in Unfavorable-Risk Prostate Cancer: Sexual Function Recovery after External Beam Radiation (RT) and 6 months of Androgen Deprivation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Chen, R. C.] UNC Sch Med, Chapel Hill, NC USA. [Chen, M. H.; Zhang, Y.] Univ Connecticut, Storrs, CT USA. [McMahon, E.; Loffredo, M.; Nguyen, P. L.; Beard, C. J.; D'Amico, A. V.] Dana Farber Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S603 EP S603 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701389 ER PT J AU Chen, Y Adams, J Abramson, JS Hochberg, EP Tarbell, NJ DeLaney, T AF Chen, Y. Adams, J. Abramson, J. S. Hochberg, E. P. Tarbell, N. J. DeLaney, T. TI Preliminary Experience with Proton Radiotherapy in Mediastinal Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Chen, Y.; Adams, J.; Abramson, J. S.; Hochberg, E. P.; Tarbell, N. J.; DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S547 EP S547 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701266 ER PT J AU Choe, KS Cowan, JE Carroll, PR D'Amico, AV Liauw, SL AF Choe, K. S. Cowan, J. E. Carroll, P. R. D'Amico, A. V. Liauw, S. L. TI Aspirin Use and the Risk of Prostate Cancer Death in Men Treated with Prostatectomy or Radiotherapy: Results from the CaPSURE Database SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Choe, K. S.] Univ Texas SW, Sch Med, Dallas, TX USA. [Cowan, J. E.; Carroll, P. R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Liauw, S. L.] Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S126 EP S127 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700270 ER PT J AU Choi, NC Chun, T Niemierko, A Ancukiewicz, M Fidias, P Kradin, R Mathisen, D Lynch, T Fischman, A AF Choi, N. C. Chun, T. Niemierko, A. Ancukiewicz, M. Fidias, P. Kradin, R. Mathisen, D. Lynch, T. Fischman, A. TI FDG Uptake Quantified with FDG PET 10-12 Days after Radiotherapy or Chemoradiotherapy in Lung Cancer is Molecular-Biomarker Capable for Predicting Therapy Outcome and Identifying Patients in Need for Timely Salvage Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Choi, N. C.; Chun, T.; Niemierko, A.; Ancukiewicz, M.; Fidias, P.; Kradin, R.; Mathisen, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lynch, T.] Yale Canc Ctr, New Haven, CT USA. [Fischman, A.] Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S34 EP S34 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700073 ER PT J AU Christodouleas, JP Susil, RC McNutt, TR Song, DY DeWeese, TL Bekelman, J Vapiwala, N Shinkle, B Lu, H Both, S AF Christodouleas, J. P. Susil, R. C. McNutt, T. R. Song, D. Y. DeWeese, T. L. Bekelman, J. Vapiwala, N. Shinkle, B. Lu, H. Both, S. TI The Impact of a Rectal-Prostate Spacer on Proton Radiation of the Prostate: A Planning Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Christodouleas, J. P.; Bekelman, J.; Vapiwala, N.; Shinkle, B.; Both, S.] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Susil, R. C.; McNutt, T. R.; Song, D. Y.; DeWeese, T. L.] Johns Hopkins Univ Hosp, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21287 USA. [Lu, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S134 EP S134 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700286 ER PT J AU Coen, J Paly, J Niemierko, A Rodrigues, A Weyman, E Shipley, WU Zietman, AL Talcott, JA AF Coen, J. Paly, J. Niemierko, A. Rodrigues, A. Weyman, E. Shipley, W. U. Zietman, A. L. Talcott, J. A. TI Long-term QOL Outcome after Proton Radiation for Localized Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Coen, J.; Paly, J.; Niemierko, A.; Rodrigues, A.; Weyman, E.; Shipley, W. U.; Zietman, A. L.; Talcott, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S348 EP S349 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700757 ER PT J AU Cotter, SE Chen, M Moul, JW Lee, WR Koontz, BF Anscher, MS D'Amico, AV AF Cotter, S. E. Chen, M. Moul, J. W. Lee, W. R. Koontz, B. F. Anscher, M. S. D'Amico, A. V. TI Salvage Radiation in Men with PSA Failure following Radical Prostatectomy and the Risk of Death SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Cotter, S. E.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M.] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. [Moul, J. W.] Duke Univ, Div Urol Surg, Dept Surg, Durham, NC USA. [Moul, J. W.] Duke Univ, Dept Surg, Duke Prostate Center, Durham, NC USA. [Lee, W. R.; Koontz, B. F.] Duke Univ, Dept Radiat Oncol, Durham, NC USA. [Anscher, M. S.] Virginia Commonwealth Univ, Richmond, VA USA. [D'Amico, A. V.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S149 EP S149 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700317 ER PT J AU Cury, F Hunt, D Roach, M Lawton, C Gore, E Hsu, I Krisch, RE Seider, MJ Sandler, H Shipley, W AF Cury, F. Hunt, D. Roach, M., III Lawton, C. Gore, E. Hsu, I. Krisch, R. E. Seider, M. J. Sandler, H. Shipley, W. TI PSA Response after Short-term Hormonal Therapy Plus External Beam Radiotherapy and Outcome in Patients Treated on RTOG 9413 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Cury, F.] McGill Univ, Montreal, PQ, Canada. [Hunt, D.] RTOG Stat Ctr, Philadelphia, PA USA. [Roach, M., III; Hsu, I.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lawton, C.] Med Coll Wisconsin, Madison, WI USA. [Krisch, R. E.] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Seider, M. J.] Akron City Hosp, Akron, OH USA. [Sandler, H.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. [Shipley, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S124 EP S124 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700264 ER PT J AU DeLaney, TF Bosch, WR Roberge, D Finkelstein, SE Petersen, IA Haddock, MG Chen, YE Saito, NG Kirsch, DG Wang, D AF DeLaney, T. F. Bosch, W. R. Roberge, D. Finkelstein, S. E. Petersen, I. A. Haddock, M. G. Chen, Y. E. Saito, N. G. Kirsch, D. G. Wang, D. TI RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) on Computed Tomography Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in RTOG Studies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [DeLaney, T. F.; Chen, Y. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bosch, W. R.] Washington Univ, St Louis, MO USA. [Roberge, D.] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada. [Finkelstein, S. E.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Petersen, I. A.; Haddock, M. G.] Mayo Clin, Rochester, MN USA. [Saito, N. G.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Kirsch, D. G.] Duke Univ, Med Ctr, Durham, NC USA. [Wang, D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S87 EP S87 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700187 ER PT J AU Efstathiou, JA Adams, JA Paly, JJ Bekelman, JE Coen, JJ Shipley, WU Zietman, AL Lu, H AF Efstathiou, J. A. Adams, J. A. Paly, J. J. Bekelman, J. E. Coen, J. J. Shipley, W. U. Zietman, A. L. Lu, H. TI Adjuvant Radiation Therapy for Early Stage Seminoma: A Proton-photon Treatment Planning Comparison SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Efstathiou, J. A.; Adams, J. A.; Paly, J. J.; Coen, J. J.; Shipley, W. U.; Zietman, A. L.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bekelman, J. E.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S338 EP S339 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700736 ER PT J AU Finkelstein, SE Trotti, A Letson, GD Caracciolo, J DeLaney, TF Kraybill, W Eisenberg, B Alektiar, KM Michalski, J Wang, D AF Finkelstein, S. E. Trotti, A. Letson, G. D. Caracciolo, J. DeLaney, T. F. Kraybill, W. Eisenberg, B. Alektiar, K. M. Michalski, J. Wang, D. TI Radiation Therapy Oncology Group (RTOG) Consensus Panel Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Extremities SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Finkelstein, S. E.; Trotti, A.; Letson, G. D.; Caracciolo, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kraybill, W.] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA. [Eisenberg, B.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA. [Alektiar, K. M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Michalski, J.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. [Wang, D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S612 EP S612 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701410 ER PT J AU Goldsmith, T Wang, J Holman, A Chan, AW AF Goldsmith, T. Wang, J. Holman, A. Chan, A. W. TI Risk of Cervical Esophageal Stricture with Intensity Modulated vs. Conventional Radiation Therapy for Head and Neck Cancer: A Systemic Review SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Goldsmith, T.; Wang, J.; Holman, A.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S453 EP S454 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701060 ER PT J AU Gunderson, LL Moughan, J Ajani, JA Pedersen, JE Benson, AB Thomas, CR Mayer, RJ Haddock, MG Rich, TA Willett, CG AF Gunderson, L. L. Moughan, J. Ajani, J. A. Pedersen, J. E. Benson, A. B. Thomas, C. R. Mayer, R. J. Haddock, M. G. Rich, T. A. Willett, C. G. TI Anal Carcinoma: Impact of TN Category of Disease on Survival, Disease Relapse, and Colostomy Failure in US GI Intergroup RTOG 98-11 Phase III Trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Gunderson, L. L.] Mayo Clin, Ctr Canc, Scottsdale, AZ USA. [Moughan, J.] RTOG Stat Ctr, Philadelphia, PA USA. [Ajani, J. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Pedersen, J. E.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. [Benson, A. B.] Northwestern Univ, Chicago, IL 60611 USA. [Thomas, C. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Mayer, R. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Haddock, M. G.] Mayo Clin, Ctr Canc, Rochester, MN USA. [Rich, T. A.] Univ Virginia, Med Ctr, Charlottesville, VA USA. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S55 EP S56 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700118 ER PT J AU Halasz, LM Catalano, PJ Mauch, PM Ng, AK AF Halasz, L. M. Catalano, P. J. Mauch, P. M. Ng, A. K. TI Favorable Outcomes of Combined Modality Treatment for Non-Hodgkin Lymphoma Despite Positive Mid- or Post-chemotherapy PET SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Halasz, L. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Catalano, P. J.; Mauch, P. M.; Ng, A. K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mauch, P. M.; Ng, A. K.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S549 EP S549 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701271 ER PT J AU Hasan, M Sharp, GC Chen, G Pfister, H Wolfgang, J AF Hasan, M. Sharp, G. C. Chen, G. Pfister, H. Wolfgang, J. TI Interactive 4D Visualization of Radiological Path Length Variation for Proton Treatment Port Selection SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Hasan, M.; Sharp, G. C.; Chen, G.; Wolfgang, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pfister, H.] Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S803 EP S803 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701830 ER PT J AU Hong, TS Ryan, DP Blaszkowsky, LS Mamon, HJ Wadlow, RC Kwak, EL Ferrone, CR Adams, J Yeap, B Winrich, B AF Hong, T. S. Ryan, D. P. Blaszkowsky, L. S. Mamon, H. J. Wadlow, R. C. Kwak, E. L. Ferrone, C. R. Adams, J. Yeap, B. Winrich, B. TI Phase I/II study of Proton-based Short Course Chemoradiation and Early Surgery for Adenocarcinoma of the Pancreas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Hong, T. S.; Ryan, D. P.; Blaszkowsky, L. S.; Wadlow, R. C.; Kwak, E. L.; Ferrone, C. R.; Adams, J.; Yeap, B.; Winrich, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mamon, H. J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S99 EP S100 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700214 ER PT J AU Hurwitz, M Halabi, S Archer, L McGinnis, LS Kuettel, MR DiBiase, SJ Small, EJ AF Hurwitz, M. Halabi, S. Archer, L. McGinnis, L. S. Kuettel, M. R. DiBiase, S. J. Small, E. J. TI Combination External Beam Radiation and Brachytherapy Boost with Androgen Suppression for Treatment of Intermediate-risk Prostate Cancer: Long-term Results of CALGB 99809 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Hurwitz, M.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Halabi, S.; Archer, L.] Duke Univ Med Ctr, Durham, NC USA. [McGinnis, L. S.] Presbyterian Hosp, Charlotte, NC USA. [Kuettel, M. R.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [DiBiase, S. J.] Robert Wood Johnson Med Sch, Cherry Hill, NJ USA. [Small, E. J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S146 EP S146 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700311 ER PT J AU Kelly, PJ Lin, YB Yu, AYC Ropper, AE Nguyen, PL Marcus, KJ Hacker, FL Weiss, SE AF Kelly, P. J. Lin, Y. B. Yu, A. Y. C. Ropper, A. E. Nguyen, P. L. Marcus, K. J. Hacker, F. L. Weiss, S. E. TI Linear Accelerator-based Stereotactic Radiosurgery for Single Brainstem Metastases: The Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Kelly, P. J.; Nguyen, P. L.; Marcus, K. J.; Hacker, F. L.; Weiss, S. E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Lin, Y. B.; Yu, A. Y. C.] Harvard Univ, Sch Med, Boston, MA USA. [Ropper, A. E.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S282 EP S282 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700608 ER PT J AU Khimani, N Ng, AK Chen, Y Catalano, P Silver, B Mauch, PM AF Khimani, N. Ng, A. K. Chen, Y. Catalano, P. Silver, B. Mauch, P. M. TI Salvage Radiotherapy in Patients with Recurrent or Refractory CNS Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Khimani, N.] Harvard Univ, Sch Med, Boston, MA USA. [Ng, A. K.; Chen, Y.; Catalano, P.; Silver, B.; Mauch, P. M.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S547 EP S548 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701267 ER PT J AU Kim, PJ Kobayashi, W Chen, YL Homicek, FC Ebb, DH Choy, E Schwab, JH Harmon, DC Rosenberg, AE DeLaney, TF AF Kim, P. J. Kobayashi, W. Chen, Y. L. Homicek, F. C. Ebb, D. H. Choy, E. Schwab, J. H. Harmon, D. C. Rosenberg, A. E. DeLaney, T. F. TI Radiotherapy in the Management of Mesenchymal Chondrosarcomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Kim, P. J.; Kobayashi, W.; Chen, Y. L.; Homicek, F. C.; Ebb, D. H.; Choy, E.; Schwab, J. H.; Harmon, D. C.; Rosenberg, A. E.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S613 EP S613 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701411 ER PT J AU Kleinberg, LR Catalano, PJ Gibson, MK Staley, CA Montgomery, EA Song, W Mulcahy, MF Leichman, LP Benson, AB AF Kleinberg, L. R. Catalano, P. J. Gibson, M. K. Staley, C. A. Montgomery, E. A. Song, W. Mulcahy, M. F. Leichman, L. P. Benson, A. B. TI ECOG 2205: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy (CRT) (IMRT permitted) with Oxaliplatin (O) and Infusional 5-Fluorouracil (5FU) Plus Cetuximab (C225) in Patients with Operable Adenocarcinoma of the Esophagus: High Risk of Post-op Adult Respiratory Distress Syndrome (ARDS) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Kleinberg, L. R.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Catalano, P. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gibson, M. K.; Montgomery, E. A.] Univ Pittsburgh, Pittsburgh, PA USA. [Staley, C. A.] Emory Univ, Atlanta, GA 30322 USA. [Song, W.] Pottstown Mem Med Ctr, Pottstown, PA USA. [Mulcahy, M. F.; Benson, A. B.] Northwestern Univ, Chicago, IL 60611 USA. [Leichman, L. P.] Desert Reg Med Ctr, Ctr Comprehens Canc, Palm Springs, CA USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S72 EP S72 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700155 ER PT J AU Kukluk, J Czerminska, M Cormack, R Killoran, J AF Kukluk, J. Czerminska, M. Cormack, R. Killoran, J. TI Comprehensive Verification of External Beam Radiotherapy Treatment Delivery Parameters SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Kukluk, J.; Czerminska, M.; Cormack, R.; Killoran, J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Radiat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S489 EP S489 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701138 ER PT J AU Li, Y Chen, Y Ng, A Mauch, P Kozono, D AF Li, Y. Chen, Y. Ng, A. Mauch, P. Kozono, D. TI Peri-transplant Radiation Therapy for Non-Hodgkin Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Li, Y.] Harvard Univ, Sch Med, Boston, MA USA. [Chen, Y.; Ng, A.; Mauch, P.] Dana Farber Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S548 EP S548 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701269 ER PT J AU Lim, K Fyles, A Portelance, L Creutzberg, C Jurgenliemk-Schulz, IM Viswanathan, A Erickson, B Bosch, W El Naqa, I Varia, M AF Lim, K. Fyles, A. Portelance, L. Creutzberg, C. Juergenliemk-Schulz, I. M. Viswanathan, A. Erickson, B. Bosch, W. El Naqa, I. Varia, M. TI Variability in Clinical Target Volume Delineation for Intensity Modulated Radiotherapy in Three Challenging Cervix Cancer Scenarios SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Lim, K.; Fyles, A.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Portelance, L.] McGill Univ, Dept Radiat Oncol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. [Creutzberg, C.] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands. [Juergenliemk-Schulz, I. M.] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands. [Viswanathan, A.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Viswanathan, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Erickson, B.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. [Bosch, W.; El Naqa, I.] Washington Univ, Sch Med, St Louis, MO USA. [Varia, M.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S121 EP S122 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700259 ER PT J AU Mak, RH Doran, E Muzikansky, A Neal, JW Baldini, EH Choi, NC Willers, H Jackman, DM Sequist, LV AF Mak, R. H. Doran, E. Muzikansky, A. Neal, J. W. Baldini, E. H. Choi, N. C. Willers, H. Jackman, D. M. Sequist, L. V. TI KRAS Mutation is Associated with Decreased Overall Survival after Thoracic Radiation Therapy in Patients with Locally Advanced Non-small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Mak, R. H.] Harvard Radiat Oncol Program, Boston, MA USA. [Doran, E.; Baldini, E. H.; Jackman, D. M.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Muzikansky, A.] Massachusetts Gen Hosp, Ctr Canc, Ctr Biostat, Boston, MA USA. [Neal, J. W.; Sequist, L. V.] Massachusetts Gen Hosp, Ctr Canc, Ctr Thorac Canc, Boston, MA USA. [Neal, J. W.; Choi, N. C.; Willers, H.; Jackman, D. M.; Sequist, L. V.] Harvard Univ, Sch Med, Boston, MA USA. [Baldini, E. H.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Baldini, E. H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Choi, N. C.; Willers, H.] Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S36 EP S36 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700077 ER PT J AU Margalit, DN Sreedhara, M Chen, Y Catalano, P Nguyen, PL Harris, JR Brock, JE AF Margalit, D. N. Sreedhara, M. Chen, Y. Catalano, P. Nguyen, P. L. Harris, J. R. Brock, J. E. TI Microinvasive Breast Cancer: Incidence of Axillary Metastases at Diagnosis and Recurrence Rates after Breast-conserving Therapy (BCT) or Mastectomy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Margalit, D. N.] Harvard Radiat Oncol Program, Boston, MA USA. [Sreedhara, M.; Nguyen, P. L.; Harris, J. R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S222 EP S222 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700475 ER PT J AU Miyamoto, DT Tanaka, CK Viswanathan, AN AF Miyamoto, D. T. Tanaka, C. K. Viswanathan, A. N. TI Concurrent Chemoradiation Improves Survival in Patients with Vaginal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Miyamoto, D. T.] Harvard Radiat Oncol Program, Boston, MA USA. [Tanaka, C. K.; Viswanathan, A. N.] Brigham & Womens Hosp, DFCI, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S120 EP S121 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700257 ER PT J AU Mohan, R Zhang, X Matney, J Bluett, J Dong, L Balter, P Engelsman, M Choi, N Komaki, R Liao, Z AF Mohan, R. Zhang, X. Matney, J. Bluett, J. Dong, L. Balter, P. Engelsman, M. Choi, N. Komaki, R. Liao, Z. TI IMRT vs. Passively Scattered Proton Therapy (PSPT) for Locally Advanced Non-small Cell Lung CA (LA NSCLC) Randomized Trial - Is there Equipoise? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Mohan, R.; Zhang, X.; Matney, J.; Bluett, J.; Dong, L.; Balter, P.; Komaki, R.; Liao, Z.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Engelsman, M.; Choi, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Zhang, Xiaodong/H-2262-2013 NR 0 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S201 EP S202 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700432 ER PT J AU Mori, S Kanematsu, N Asakura, H Sharp, GC Kumagai, M Dobashi, S Nakajima, M Yamamoto, N Kandatsu, S Baba, M AF Mori, S. Kanematsu, N. Asakura, H. Sharp, G. C. Kumagai, M. Dobashi, S. Nakajima, M. Yamamoto, N. Kandatsu, S. Baba, M. TI Four-dimensional Lung Treatment Planning in a Layer-stacking Carbon Ion Beam Treatment: Comparison Layer-stacking and Conventional Irradiations SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Mori, S.; Kanematsu, N.; Asakura, H.; Kumagai, M.; Dobashi, S.; Nakajima, M.; Yamamoto, N.; Kandatsu, S.; Baba, M.] NIRS, Chiba, Japan. [Sharp, G. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sharp, G. C.] Harvard Univ, Sch Med, Boston, MA USA. RI Kanematsu, Nobuyuki/B-9130-2008 OI Kanematsu, Nobuyuki/0000-0002-2534-9933 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S802 EP S803 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701828 ER PT J AU Nguyen, PL Chen, MH Dosoretz, DE Moran, BJ Salenius, SA Braccioforte, MH Beard, CJ Hoffman, KE D'Amico, AV Ennis, RD AF Nguyen, P. L. Chen, M. H. Dosoretz, D. E. Moran, B. J. Salenius, S. A. Braccioforte, M. H. Beard, C. J. Hoffman, K. E. D'Amico, A. V. Ennis, R. D. TI The Adverse Impact of Androgen Deprivation Therapy on All-cause Mortality in Men with High-risk Prostate Cancer and a History of Congestive Heart Failure (CHF) or Myocardial Infarction (MI) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Nguyen, P. L.; Braccioforte, M. H.; Beard, C. J.; D'Amico, A. V.] Dana Farber Brigham & Womens Hosp, Boston, MA USA. [Chen, M. H.] Univ Connecticut, Storrs, CT USA. [Dosoretz, D. E.; Salenius, S. A.] 21st Century Oncol, Ft Myers, FL USA. [Moran, B. J.] Chicago Prostate Ctr, Westmont, IL USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ennis, R. D.] Albert Einstein Coll Med, Continuum Canc Ctr NY, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S350 EP S350 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700760 ER PT J AU Pacold, ME Sharp, GC Doppke, K Prichard, H Lu, H Arvold, ND Niemierko, A Choi, NC AF Pacold, M. E. Sharp, G. C. Doppke, K. Prichard, H. Lu, H. Arvold, N. D. Niemierko, A. Choi, N. C. TI Effect of Mid-course Replanning CT on Tumor and Normal Structure Dosimetry and Projected Toxicities during Chemoradiotherapy for Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Pacold, M. E.; Arvold, N. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Sharp, G. C.; Doppke, K.; Prichard, H.; Lu, H.; Niemierko, A.; Choi, N. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S117 EP S117 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700249 ER PT J AU Pashtan, IM Ancukiewicz, M Wo, JY Hirsch, AE Smith, BL Powell, SN Recht, A Taghian, AG AF Pashtan, I. M. Ancukiewicz, M. Wo, J. Y. Hirsch, A. E. Smith, B. L. Powell, S. N. Recht, A. Taghian, A. G. TI Triple-Negative Breast Cancer is Associated with Higher Risk of Local Recurrence after 3D-Conformal External Beam Accelerated Partial Breast Irradiation (3D-APBI) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Pashtan, I. M.; Wo, J. Y.] Harvard Radiat Oncol Program, Boston, MA USA. [Ancukiewicz, M.; Smith, B. L.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsch, A. E.] Boston Med Ctr, Boston, MA USA. [Powell, S. N.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Recht, A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S53 EP S53 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700113 ER PT J AU Rosenberg, JE Chen, M Nguyen, PL Braccioforte, MH Moran, BJ D'Amico, AV AF Rosenberg, J. E. Chen, M. Nguyen, P. L. Braccioforte, M. H. Moran, B. J. D'Amico, A. V. TI Hormonal Therapy or External Beam Radiation with Brachytherapy and the Risk of Death from Prostate Cancer in Men with Intermediate Risk Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Rosenberg, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Nguyen, P. L.; D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Braccioforte, M. H.; Moran, B. J.] Prostate Canc Fdn Chicago, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S367 EP S368 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700799 ER PT J AU Rottmann, J Aristophanous, M Chen, A Sher, D Killoran, J Hacker, F Berbeco, R AF Rottmann, J. Aristophanous, M. Chen, A. Sher, D. Killoran, J. Hacker, F. Berbeco, R. TI Lung SBRT Verification with Continuous MV EPID Imaging SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Rottmann, J.; Aristophanous, M.; Chen, A.; Sher, D.; Killoran, J.; Hacker, F.; Berbeco, R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. [Rottmann, J.] German Canc Res Ctr, D-6900 Heidelberg, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S44 EP S45 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700095 ER PT J AU Schoenfeld, JD Sher, DJ Posner, MR Haddad, RI Balboni, T Tishler, RB AF Schoenfeld, J. D. Sher, D. J. Posner, M. R. Haddad, R. I. Balboni, T. Tishler, R. B. TI Salivary Gland Tumors Treated with Adjuvant Intensity Modulated Radiation with or without Concurrent Chemotherapy: A Recent Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Schoenfeld, J. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Sher, D. J.; Posner, M. R.; Haddad, R. I.; Balboni, T.; Tishler, R. B.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S457 EP S458 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701069 ER PT J AU Sher, DJ Posner, MR Tishler, RB Sarlis, NJ Devlin, PM AF Sher, D. J. Posner, M. R. Tishler, R. B. Sarlis, N. J. Devlin, P. M. TI Relationship between Radiation Treatment Parameters and Overall Survival following Induction Chemotherapy in a Sequential Regimen for Locally Advanced Head and Neck Carcinoma (LAHNC): A Subset Analysis of TAX324 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Sher, D. J.; Posner, M. R.; Tishler, R. B.; Devlin, P. M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sarlis, N. J.] Sanofi Aventis, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S82 EP S83 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700178 ER PT J AU Shih, HA Arvold, ND Niemierko, A Broussard, GP Fullerton, B Loeffler, JS AF Shih, H. A. Arvold, N. D. Niemierko, A. Broussard, G. P. Fullerton, B. Loeffler, J. S. TI Second Tumor Risk and Projected Late Effects after Proton vs. Intensity Modulated Photon Radiotherapy for Benign Meningioma: A Dosimetric Comparison SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Shih, H. A.; Niemierko, A.; Broussard, G. P.; Fullerton, B.; Loeffler, J. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Arvold, N. D.] Harvard Radiat Oncol Program, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S272 EP S272 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700586 ER PT J AU Shipley, WU Hunt, D Lukka, H Major, P Heney, NM Grignon, D Patel, M Bahary, J Lawton, C Sandler, H AF Shipley, W. U. Hunt, D. Lukka, H. Major, P. Heney, N. M. Grignon, D. Patel, M. Bahary, J. Lawton, C. Sandler, H. TI Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Shipley, W. U.; Heney, N. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hunt, D.] RTOG Stat Ctr, Philadelphia, PA USA. [Lukka, H.; Major, P.; Patel, M.] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada. [Grignon, D.] Indiana Univ, Indianapolis, IN 46204 USA. [Bahary, J.] Univ Montreal CHUM, Montreal, PQ, Canada. [Lawton, C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Sandler, H.] Cedars Sinai Canc Ctr, Los Angeles, CA USA. NR 0 TC 29 Z9 29 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S27 EP S27 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700059 ER PT J AU Son, CH Loeffler, JS Oh, KS Shih, HA AF Son, C. H. Loeffler, J. S. Oh, K. S. Shih, H. A. TI Outcomes after Whole Brain Reirradiation in Patients with Brain Metastases SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Son, C. H.; Loeffler, J. S.; Oh, K. S.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S170 EP S171 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700364 ER PT J AU Sperduto, PW Xu, Z Sneed, P Luo, X Roberge, D Bhatt, AK Jensen, AW Shih, HA Kirkpatrick, J Gaspar, LE AF Sperduto, P. W. Xu, Z. Sneed, P. Luo, X. Roberge, D. Bhatt, A. K. Jensen, A. W. Shih, H. A. Kirkpatrick, J. Gaspar, L. E. TI The Graded Prognostic Assessment for Women with Brain Metastases front Breast Cancer (GPA-Breast): A Diagnosis-specific Prognostic Index SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Sperduto, P. W.] Univ Minnesota, Gamma Knife Ctr, Minneapolis, MN USA. [Xu, Z.] Cleveland Clin, Cleveland, OH 44106 USA. [Sneed, P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Luo, X.] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Roberge, D.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. Univ Wisconsin, Madison, WI USA. [Jensen, A. W.] Mayo Clin, Rochester, MN USA. [Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kirkpatrick, J.] Duke Univ, Med Ctr, Durham, NC USA. [Gaspar, L. E.] Univ Colorado, Denver, CO 80202 USA. RI Xu, Zhiyuan/B-3762-2012 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S6 EP S7 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700014 ER PT J AU Tang, S Both, S Bentefour, H Tochner, Z Efstathiou, J Lu, H AF Tang, S. Both, S. Bentefour, H. Tochner, Z. Efstathiou, J. Lu, H. TI Anterior and Anterior Oblique Fields Improve Proton Prostate Treatment SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Tang, S.; Efstathiou, J.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Both, S.; Tochner, Z.] Univ Penn, Philadelphia, PA 19104 USA. [Bentefour, H.] Ion Beam Applicat, Louvain, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S368 EP S368 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700800 ER PT J AU Trofimov, A Kang, J Unkelbach, J Adams, JA Zhang, X Bortfeld, T Liebsch, NJ DeLaney, TF AF Trofimov, A. Kang, J. Unkelbach, J. Adams, J. A. Zhang, X. Bortfeld, T. Liebsch, N. J. DeLaney, T. F. TI Evaluation of Dosimetric Gain and Uncertainties in Proton Therapy Delivery with Scanned Pencil Beam in Treatment of Base-of-skull and Spinal Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Trofimov, A.; Kang, J.; Unkelbach, J.; Adams, J. A.; Bortfeld, T.; Liebsch, N. J.; DeLaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, X.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S133 EP S134 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700285 ER PT J AU Verburg, JM Joshi, MC Madden, TM Kooy, HM Seco, JC AF Verburg, J. M. Joshi, M. C. Madden, T. M. Kooy, H. M. Seco, J. C. TI Impact of CT Metal Artifacts on Proton Radiotherapy Treatment Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Verburg, J. M.; Madden, T. M.; Kooy, H. M.; Seco, J. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Verburg, J. M.; Madden, T. M.; Kooy, H. M.; Seco, J. C.] Harvard Univ, Sch Med, Boston, MA USA. [Verburg, J. M.] Eindhoven Univ Technol, NL-5600 MB Eindhoven, Netherlands. [Joshi, M. C.] GE Healthcare, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S809 EP S810 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701844 ER PT J AU Wakatsuki, M Magpayo, N Held, KD AF Wakatsuki, M. Magpayo, N. Held, K. D. TI The Lack of a Bystander Response Induced by Photon Irradiation in Chondrosarcoma Cells SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Wakatsuki, M.; Magpayo, N.; Held, K. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Wakatsuki, M.] Gunma Univ, Grad Sch Med, Maebashi, Gumma 371, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S628 EP S628 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701447 ER PT J AU Wang, D Bosch, W Kirsch, D Lozi, R Naqa, I Roberge, D Finkelstein, S Petersen, I Saito, N DeLaney, T AF Wang, D. Bosch, W. Kirsch, D. Lozi, R. Naqa, I. Roberge, D. Finkelstein, S. Petersen, I. Saito, N. DeLaney, T. TI Variations in the Gross Target Volume and Clinical Target Volume Evaluated by RTOG Sarcoma Radiation Oncologists for Preoperative Radiotherapy of Primary Extremity Sarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Wang, D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Bosch, W.; Lozi, R.; Naqa, I.] Washington Univ, St Louis, MO USA. [Kirsch, D.] Duke Univ, Durham, NC USA. [Roberge, D.] McGill Univ, Montreal, PQ, Canada. [Finkelstein, S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa Bay, FL USA. [Petersen, I.] Mayo Clin, Rochester, MN USA. [Saito, N.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S620 EP S620 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701427 ER PT J AU Wang, JJ Truong, M Adams, J Cianchetti, M Liebsch, N Busse, P McIntyre, J Chan, A AF Wang, J. J. Truong, M. Adams, J. Cianchetti, M. Liebsch, N. Busse, P. McIntyre, J. Chan, A. TI A Comparison of Definitive with Postoperative Proton Beam Therapy for Locally Advanced Sinonasal Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Wang, J. J.; Truong, M.; Adams, J.; Cianchetti, M.; Liebsch, N.; Busse, P.; McIntyre, J.; Chan, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S176 EP S176 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700376 ER PT J AU Westover, KD Westover, M Weiner, E Richardson, A Iglehart, J Punglia, R AF Westover, K. D. Westover, M. Weiner, E. Richardson, A. Iglehart, J. Punglia, R. TI Should a Sentinel Node Biopsy be Performed in Patients with High Risk Breast Cancer? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Westover, K. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Westover, M.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Weiner, E.; Richardson, A.; Iglehart, J.; Punglia, R.] Harvard Univ, Sch Med, Boston, MA USA. [Weiner, E.; Richardson, A.; Iglehart, J.; Punglia, R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S256 EP S257 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700552 ER PT J AU White, JR Khalid, N Tao, ML Pierce, LJ DeRobertis, A Crozier, C Owen, JB Wilson, JF AF White, J. R. Khalid, N. Tao, M. L. Pierce, L. J. DeRobertis, A. Crozier, C. Owen, J. B. Wilson, J. F. TI QRRO 2007 Practice Survey Documents Dramatic Technical Changes in How Radiotherapy for Operable Breast Cancer is Delivered SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [White, J. R.; Wilson, J. F.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Khalid, N.; Crozier, C.; Owen, J. B.] Amer Coll Radiol, Philadelphia, PA 90034 USA. [Pierce, L. J.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Tao, M. L.] Epic Care, Orinda, CA USA. [DeRobertis, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S4 EP S4 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700009 ER PT J AU Wo, JY Mannarino, E Killoran, J Chen, AB AF Wo, J. Y. Mannarino, E. Killoran, J. Chen, A. B. TI The Impact of IV Contrast on Dose Calculations in the Treatment of Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Wo, J. Y.] Harvard Radiat Oncol Program, Boston, MA USA. [Mannarino, E.; Killoran, J.; Chen, A. B.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S750 EP S750 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701709 ER PT J AU Zelefsky, MJ Khalid, N Lee, W Zietman, A Crozier, C Owen, J Wilson, J AF Zelefsky, M. J. Khalid, N. Lee, W. Zietman, A. Crozier, C. Owen, J. Wilson, J. TI Results from the Quality Research in Radiation Oncology (QRRO) Survey Evaluating Adherence to Quality Measures for Prostate Cancer Radiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Zelefsky, M. J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Khalid, N.; Crozier, C.; Owen, J.] Amer Coll Radiol, Philadelphia, PA 90034 USA. [Lee, W.] Duke Univ, Sch Med, Durham, NC USA. [Zietman, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wilson, J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S78 EP S78 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700167 ER PT J AU Zhang, X Zhang, RX Dong, L Li, Y Trofimov, A Delaney, TF Mahajan, A Mohan, R AF Zhang, X. Zhang, R. X. Dong, L. Li, Y. Trofimov, A. Delaney, T. F. Mahajan, A. Mohan, R. TI Improving Clinical Potential, Efficiency and Robustness of Planning and Delivery of IMPT for Skull-based Chordomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Zhang, X.; Zhang, R. X.; Dong, L.; Li, Y.; Mahajan, A.; Mohan, R.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. [Trofimov, A.; Delaney, T. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Zhang, Xiaodong/H-2262-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S804 EP S804 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775701832 ER PT J AU Zietman, AL Hunt, D Kaufman, DS Uzzo, R Wu, C Buyyounouski, MK Sandler, H Shipley, WU AF Zietman, A. L. Hunt, D. Kaufman, D. S. Uzzo, R. Wu, C. Buyyounouski, M. K. Sandler, H. Shipley, W. U. TI Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 52nd Annual Meeting of the American-Society-For-Radiation-Oncology CY OCT 31-NOV 04, 2010 CL San Diego, CA SP Amer Soc Radiation Oncol C1 [Zietman, A. L.; Kaufman, D. S.; Wu, C.; Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hunt, D.] Amer Coll Radiol, Radiat Therapy Oncol Grp, Philadelphia, PA 90034 USA. [Uzzo, R.; Buyyounouski, M. K.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Sandler, H.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 78 IS 3 SU S BP S31 EP S32 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 740EZ UT WOS:000288775700068 ER PT J AU Viswanathan, AN Erickson, BA AF Viswanathan, Akila N. Erickson, Beth A. TI THREE-DIMENSIONAL IMAGING IN GYNECOLOGIC BRACHYTHERAPY: A SURVEY OF THE AMERICAN BRACHYTHERAPY SOCIETY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 29th Annual Meeting of the American-Brachytherapy-Society/World Congress of Brachytherapy CY MAY 04-06, 2008 CL Boston, MA SP Amer Brachytherapy Soc DE 3D image based brachytherapy; Cervical cancer; Survey ID DOSE-VOLUME PARAMETERS; CERVICAL-CANCER BRACHYTHERAPY; INTRACAVITARY BRACHYTHERAPY; COMPUTED-TOMOGRAPHY; WORKING GROUP; UTERINE CERVIX; CARCINOMA; BLADDER; RECTUM; OPTIMIZATION AB Purpose: To determine current practice patterns with regard to three-dimensional (3D) imaging for gynecologic brachytherapy among American Brachytherapy Society (ABS) members. Methods and Materials: Registered physician members of the ABS received a 19-item survey by e-mail in August 2007. This report excludes physicians not performing brachytherapy for cervical cancer. Results: Of the 256 surveys sent, we report results for 133 respondents who perform one or more implantations per year for locally advanced cervical cancer. Ultrasound aids 56% of physicians with applicator insertion. After insertion, 70% of physicians routinely obtain a computed tomography (CT) scan. The majority (55%) use CT rather than X-ray films (43%) or magnetic resonance imaging (MRI; 2%) for dose specification to the cervix. However, 76% prescribe to Point A alone instead of using a 3D-derived tumor volume (14%), both Point A and tumor volume (7%), or mg/h (3%). Those using 3D imaging routinely contour the bladder and rectum (94%), sigmoid (45%), small bowel (38%), and/or urethra (8%) and calculate normal tissue dose-volume histogram (DVH) analysis parameters including the D2cc (49%), D1cc (36%), D0.1cc (19%), and/or D5cc (19%). Respondents most commonly modify the treatment plan based on International Commission on Radiation Units bladder and/or rectal point dose values (53%) compared with DVH values (45%) or both (2%). Conclusions: More ABS physician members use CT postimplantation imaging than plain films for visualizing the gynecologic brachytherapy apparatus. However, the majority prescribe to Point A rather than using 3D image based dosimetry. Use of 3D image-based treatment planning for gynecologic brachytherapy has the potential for significant growth in the United States. (C) 2010 Elsevier Inc. C1 [Viswanathan, Akila N.] Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA. [Erickson, Beth A.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. RP Viswanathan, AN (reprint author), Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Brigham & Womens Hosp,Sch Med, 75 Francis St L2, Boston, MA 02115 USA. EM aviswanathan@lroc.harvard.edu OI Viswanathan, Akila/0000-0002-2003-0392 NR 35 TC 99 Z9 103 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2010 VL 76 IS 1 BP 104 EP 109 DI 10.1016/j.ijrobp.2009.01.043 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 541TA UT WOS:000273442300017 PM 19619956 ER PT J AU Samkoe, KS Chen, A Rizvi, I O'Hara, JA Hoopes, PJ Pereira, SP Hasan, T Pogue, BW AF Samkoe, Kimberley S. Chen, Alina Rizvi, Imran O'Hara, Julia A. Hoopes, P. Jack Pereira, Stephen P. Hasan, Tayyaba Pogue, Brian W. TI IMAGING TUMOR VARIATION IN RESPONSE TO PHOTODYNAMIC THERAPY IN PANCREATIC CANCER XENOGRAFT MODELS SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Photodynamic therapy; Pancreatic cancer; Magnetic resonance imaging; Tumor aggressiveness; Orthotopic tumor ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; ADENOCARCINOMA; GEMCITABINE AB Purpose: A treatment monitoring study investigated the differential effects of orthotopic pancreatic cancer models in response to interstitial photodynamic therapy (PDT), and the validity of using magnetic resonance imaging as a surrogate measure of response was assessed. Methods and Materials: Different orthotopic pancreatic cancer xenograft models (AsPC-1 and Panc-1) were used to represent the range of pathophysiology observed in human beings. Identical dose escalation studies (10, 20, and 40J/cm) using interstitial verteporfin PDT were performed, and magnetic resonance imaging with T2-weighted and T1-weighted contrast were used to monitor the total tumor volume and the vascular perfusion volume, respectively. Results: There was a significant amount of necrosis in the slower-growing Panc-1 tumor using high light dose, although complete necrosis was not observed. Lower doses were required for the same level of tumor kill in the faster-growing AsPC-1 cell line. Conclusions: The tumor growth rate and vascular pattern of the tumor affect the optimal PDT treatment regimen, with faster-growing tumors being relatively easier to treat. This highlights the fact that therapy in human beings shows a heterogeneous range of outcomes, and suggests a need for careful individualized treatment outcomes assessment in clinical work. (C) 2010 Elsevier Inc. C1 [Samkoe, Kimberley S.; Chen, Alina; Rizvi, Imran; O'Hara, Julia A.; Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03766 USA. [Rizvi, Imran; Hasan, Tayyaba; Pogue, Brian W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Surg, Hanover, NH 03756 USA. [Pereira, Stephen P.] UCL, Sch Med, Inst Hepatol, London W1N 8AA, England. RP Samkoe, KS (reprint author), Dartmouth Coll, Thayer Sch Engn, 8000 Cummings Hall, Hanover, NH 03766 USA. EM samkoe@dartmouth.edu; pogue@dartmouth.edu OI Rizvi, Imran/0000-0001-9673-4700 FU National Institutes of Health [PO1CA84203] FX Support was provided by National Institutes of Health grant PO1CA84203. The verteporfin was a gift from QLT Inc (Vancouver, BC, Canada). NR 27 TC 32 Z9 32 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2010 VL 76 IS 1 BP 251 EP 259 DI 10.1016/j.ijrobp.2009.08.041 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 541TA UT WOS:000273442300037 PM 20005458 ER PT J AU Mori, S Yanagi, T Hara, R Sharp, GC Asakura, H Kumagai, M Kishimoto, R Yamada, S Kato, H Kandatsu, S Kamada, T AF Mori, Shinichiro Yanagi, Takeshi Hara, Ryusuke Sharp, Gregory C. Asakura, Hiroshi Kumagai, Motoki Kishimoto, Riwa Yamada, Shigeru Kato, Hirotoshi Kandatsu, Susumu Kamada, Tadashi TI COMPARISON OF RESPIRATORY-GATED AND RESPIRATORY-UNGATED PLANNING IN SCATTERED CARBON ION BEAM TREATMENT OF THE PANCREAS USING FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Carbon beam; Computed tomography; Four-dimensional; Pancreas; Treatment planning ID INTERNAL LUNG MOTION; DOSE CALCULATIONS; TUMOR MOTION; CONFORMAL RADIOTHERAPY; IRRADIATION SYSTEM; RADIATION-THERAPY; MARGIN REDUCTION; PARTICLE-BEAM; TARGET; CANCER AB Purpose: We compared respiratory-gated and respiratory-ungated treatment strategies using four-dimensional (4D) scattered carbon ion beam distribution in pancreatic 4D computed tomography (CT) datasets. Methods and Materials: Seven inpatients with pancreatic tumors underwent 4DCT scanning under free-breathing conditions using a rapidly rotating cone-beam CT, which was integrated with a 256-slice detector, in cine mode. Two types of bolus for gated and ungated treatment were designed to cover the planning target volume (PTV) using 4DCT datasets in a 30% duty cycle around exhalation and a single respiratory cycle, respectively. Carbon ion beam distribution for each strategy was calculated as a function of respiratory phase by applying the compensating bolus to 4DCT at the respective phases. Smearing was not applied to the bolus, but consideration was given to drill diameter. The accumulated dose distributions were calculated by applying deformable registration and calculating the dose-volume histogram. Results: Doses to normal tissues in gated treatment were minimized mainly on the inferior aspect, which thereby minimized excessive doses to normal tissues. Over 95% of the dose, however, was delivered to the clinical target volume at all phases for both treatment strategies. Maximum doses to the duodenum and pancreas averaged across all patients were 43.1/43.1 GyE (ungated/gated) and 43.2/43.2 GyE (ungated/gated), respectively. Conclusions: Although gated treatment minimized excessive dosing to normal tissue, the difference between treatment strategies was small. Respiratory gating may not always be required in pancreatic treatment as long as dose distribution is assessed. Any application of our results to clinical use should be undertaken only after discussion with oncologists,, particularly with regard to radiotherapy combined with chemotherapy. (C) 2010 Elsevier Inc. C1 [Mori, Shinichiro; Yanagi, Takeshi; Hara, Ryusuke; Kumagai, Motoki; Kishimoto, Riwa; Yamada, Shigeru; Kato, Hirotoshi; Kandatsu, Susumu; Kamada, Tadashi] Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Inage Ku, Chiba 2638555, Japan. [Sharp, Gregory C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Sharp, Gregory C.] Harvard Univ, Sch Med, Boston, MA USA. [Asakura, Hiroshi] Accelerator Engn Corp, Chiba, Japan. RP Mori, S (reprint author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Inage Ku, Chiba 2638555, Japan. EM shinshin@nirs.go.jp OI Mori, Shinichiro/0000-0002-0412-4399 NR 42 TC 15 Z9 15 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2010 VL 76 IS 1 BP 303 EP 312 DI 10.1016/j.ijrobp.2009.05.026 PG 10 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 541TA UT WOS:000273442300043 PM 19733015 ER PT J AU Gierga, DP Taghian, AG Chen, GTY AF Gierga, David P. Taghian, Alphonse G. Chen, George T. Y. TI CLINICAL EXPERIENCE WITH IMAGE-GUIDED RADIOTHERAPY IN AN ACCELERATED PARTIAL BREAST INTENSITY-MODULATED RADIOTHERAPY PROTOCOL: IN REGARD TO LEONARD CE ET AL. (INT J RADIAT ONCOL BIOL PHYS EPUB MAY 19, 2009) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Letter ID LUMPECTOMY CAVITY; SURGICAL CLIPS; IRRADIATION; ALIGNMENT; GUIDANCE; SETUP C1 [Gierga, David P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Gierga, DP (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2010 VL 76 IS 1 BP 315 EP 315 DI 10.1016/j.ijrobp.2009.08.062 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 541TA UT WOS:000273442300046 PM 20005463 ER PT J AU Gagliardi, G Constine, LS Moiseenko, V Correa, C Pierce, LJ Allen, AM Marks, LB AF Gagliardi, Giovanna Constine, Louis S. Moiseenko, Vitali Correa, Candace Pierce, Lori J. Allen, Aaron M. Marks, Lawrence B. TI RADIATION DOSE-VOLUME EFFECTS IN THE HEART SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Radiation heart disease; Dose-volume predictors; NTCP; Breast cancer; Lymphoma; Esophagus cancer ID BREAST-CANCER PATIENTS; TERM CARDIAC MORTALITY; RELATIVE SERIALITY MODEL; CORONARY-ARTERY DISEASE; HODGKINS-DISEASE; POSTOPERATIVE RADIOTHERAPY; MEDIASTINAL IRRADIATION; CARDIOVASCULAR-DISEASE; ADJUVANT RADIOTHERAPY; MANTLE IRRADIATION AB The literature is reviewed to identify the main clinical and dose-volume predictors for acute and late radiation-induced heart disease. A clear quantitative dose and/or volume dependence for most cardiac toxicity h as not yet been shown, primarily because of the scarcity of the data. Several clinical factors, such as age, comorbidities and doxorubicin use, appear to increase the risk of injury. The existing dose-volume data is presented, as well as suggestions for future investigations to better define radiation-induced cardiac injury. (C) 2010 Elsevier Inc. C1 [Gagliardi, Giovanna] Karolinska Univ Hosp, Dept Med Phys, S-17176 Stockholm, Sweden. [Gagliardi, Giovanna] Karolinska Inst, Stockholm, Sweden. [Constine, Louis S.] Univ Rochester, Ctr Canc, Dept Radiat Oncol, Rochester, NY 14642 USA. [Moiseenko, Vitali] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada. [Correa, Candace; Pierce, Lori J.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Allen, Aaron M.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Allen, Aaron M.] Rabin Med Ctr Petach Tikvah, Petah Tiqwa, Israel. [Marks, Lawrence B.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA. RP Gagliardi, G (reprint author), Karolinska Univ Hosp, Dept Med Phys, S-17176 Stockholm, Sweden. EM giovanna.gagliardi@karolinska.se OI Moiseenko, Vitali/0000-0002-8394-743X FU NIH [CA69579]; Lance Armstrong Foundation FX Supported in part by grants from the NIH (CA69579) and the Lance Armstrong Foundation (LBM). NR 66 TC 159 Z9 168 U1 0 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 76 IS 3 SU S BP S77 EP S85 DI 10.1016/j.ijrobp.2009.04.093 PG 9 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 562RV UT WOS:000275072400012 PM 20171522 ER PT J AU Viswanathan, AN Yorke, ED Marks, LB Eifel, PJ Shipley, WU AF Viswanathan, Akila N. Yorke, Ellen D. Marks, Lawrence B. Eifel, Patricia J. Shipley, William U. TI RADIATION DOSE-VOLUME EFFECTS OF THE URINARY BLADDER SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Bladder dose; toxicity ID 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; TRANSITIONAL CELL-CARCINOMA; LOCALIZED PROSTATE-CANCER; CERVICAL-CANCER; RANDOMIZED-TRIAL; LATE COMPLICATIONS; RADICAL HYSTERECTOMY; CONCOMITANT BOOST; UTERINE CERVIX; ICRU REFERENCE AB An in-depth overview of the normal-tissue radiation tolerance of the urinary bladder is presented. The most informative studies consider whole-organ irradiation. The data on partial-organ/nonuniform irradiation are suspect because the bladder motion is not accounted for, and many studies lack long enough follow-up data. Future studies are needed. (C) 2010 Elsevier Inc. C1 [Viswanathan, Akila N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Radiat Oncol, Boston, MA 02115 USA. [Yorke, Ellen D.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA. [Marks, Lawrence B.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA. [Eifel, Patricia J.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Shipley, William U.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Viswanathan, AN (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Dept Radiat Oncol, 75 Francis St,L2, Boston, MA 02115 USA. EM aviswanathan@lroc.harvard.edu OI Viswanathan, Akila/0000-0002-2003-0392 FU NCI NIH HHS [R01 CA129182, R01 CA129182-01A2] NR 57 TC 95 Z9 97 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2010 VL 76 IS 3 SU S BP S116 EP S122 DI 10.1016/j.ijrobp.2009.02.090 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 562RV UT WOS:000275072400017 PM 20171505 ER PT J AU Schnell-Inderst, P Schwarzer, R Gohler, A Grandi, N Grabein, K Stollenwerk, B Manne, J Klauss, V Siebert, U Wasem, J AF Schnell-Inderst, Petra Schwarzer, Ruth Goehler, Alexander Grandi, Norma Grabein, Kristin Stollenwerk, Bjoern Manne, Jennifer Klauss, Volker Siebert, Uwe Wasem, Juergen TI Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE LA English DT Article DE Coronary artery disease; Risk prediction; High-sensitivity C-reactive protein; Systematic review; Cost-effectiveness; Health technology assessment ID CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK PREDICTION; PRIMARY PREVENTION; STATIN THERAPY; CHOLESTEROL LEVELS; ROC CURVE; INFLAMMATION; RECLASSIFICATION; WOMEN; MEN AB Objectives: The aim of this study was to compare the predictive value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein (hs-CRP)-screening in addition to traditional risk factor screening in apparently healthy persons as a means of preventing coronary artery disease. Methods and Results: The systematic review was performed according to internationally recognized methods. Seven studies on risk prediction, one clinical decision-analytic modeling study, and three decision-analytic cost-effectiveness studies were included. The adjusted relative risk of high hs-CRP-level ranged from 0.7 to 2.47 (p < .05 in four of seven studies). Adding hs-CRP to the prediction models increased the areas under the curve by 0.00 to 0.027. Based on the clinical decision analysis, both individuals with elevated hs-CRP-levels and those with hyperlipidemia have a similar gain in life expectancy following statin therapy. One high-quality economic modeling study suggests favorable incremental cost-effectiveness ratios for persons with elevated hs-CRP and higher risk. However, many model parameters were based on limited evidence. Conclusions: Adding hs-CRP to traditional risk factors improves risk prediction, but the clinical relevance and cost-effectiveness of this improvement remain unclear. C1 [Schnell-Inderst, Petra; Grabein, Kristin; Wasem, Juergen] Univ Duisburg Essen, Inst Hlth Care Management, D-45127 Essen, Germany. [Goehler, Alexander; Siebert, Uwe] Inst Technol Assessment, Cardiovasc Res Program, Boston, MA 02114 USA. [Goehler, Alexander; Siebert, Uwe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Stollenwerk, Bjoern] Helmholtz Zentrum Munchen GmbH, Inst Hlth Econ & Hlth Care Management, D-85764 Neuherberg, Germany. [Manne, Jennifer] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Klauss, Volker] Univ Munich, Univ Hosp Munich, Med Clin, Dept Cardiol, Munich, Germany. [Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA. EM petra.schnell-inderst@umit.at; ruth.schwarzer@umit.at; public-health@umit.at; public-health@umit.at; Kristin.grabein@uni-due.de; bjoern.stollenwerk@helmholtz-muenchen.de; jmanne@hsph.harvard.edu; klauss@med.uni-muenchen.de; public-health@umit.at; juergen.wasem@uni-due.de RI Stollenwerk, Bjorn/G-5408-2013; OI Wasem, Juergen/0000-0001-9653-168X NR 44 TC 10 Z9 11 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0266-4623 J9 INT J TECHNOL ASSESS JI Int. J. Technol. Assess. Health Care PD JAN PY 2010 VL 26 IS 1 BP 30 EP 39 DI 10.1017/S0266462309990870 PG 10 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics GA 546TW UT WOS:000273836800005 PM 20059778 ER PT B AU Simon, MV AF Simon, Mirela V. BE Simon, MV TI NEUROPHYSIOLOGIC TESTS IN THE OPERATING ROOM SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID SOMATOSENSORY-EVOKED-POTENTIALS; BRAIN-STEM RESPONSES; CERVICAL SPINAL-CORD; ELECTRICAL-STIMULATION; NERVE; SURGERY; LESIONS; MOTOR; SEPS; IDENTIFICATION C1 Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 56 TC 2 Z9 2 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 1 EP 46 PG 46 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500002 ER PT B AU Chiappa, KH Simon, MV AF Chiappa, Keith H. Simon, Mirela V. BE Simon, MV TI EEG MONITORING DURING CAROTID ENDARTERECTOMY SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; SOMATOSENSORY-EVOKED-POTENTIALS; FALSE-NEGATIVE DIFFUSION; ACUTE ISCHEMIC-STROKE; STUMP PRESSURE; ARTERY OCCLUSION; HYPERPERFUSION SYNDROME; UROKINASE INFUSION; ELECTROENCEPHALOGRAPHY C1 [Chiappa, Keith H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,EEG EP Lab, Boston, MA 02115 USA. [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. RP Chiappa, KH (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,EEG EP Lab, Boston, MA 02115 USA. NR 89 TC 2 Z9 2 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 47 EP 94 PG 48 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500003 ER PT B AU Simon, MV Gerrard, JL Eskandar, EN AF Simon, Mirela V. Gerrard, Jason L. Eskandar, Emad N. BE Simon, MV TI ELECTROCORTICOGRAPHY SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID TEMPORAL-LOBE EPILEPSY; INDUCED EPILEPTIFORM ACTIVITY; FOCAL CORTICAL DYSPLASIA; INTRAOPERATIVE ELECTROCORTICOGRAPHY; SURGICAL-TREATMENT; ELECTRICAL-STIMULATION; PREDICTIVE-VALUE; INTRACTABLE EPILEPSY; PULSE STIMULATION; SURGERY C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Gerrard, Jason L.; Eskandar, Emad N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 92 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 95 EP 129 PG 35 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500004 ER PT B AU Simon, MV Shields, DC Eskandar, EN AF Simon, Mirela V. Shields, Donald C. Eskandar, Emad N. BE Simon, MV TI FUNCTIONAL CORTICAL MAPPING SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID MOTOR EVOKED-POTENTIALS; REFRACTORY STATUS EPILEPTICUS; TEMPORAL-LOBE EPILEPTICS; BURST-SUPPRESSION; ELECTRICAL-STIMULATION; BRAIN-TUMORS; PROGNOSTIC-FACTORS; INTRAOPERATIVE STIMULATION; ISOFLURANE ANESTHESIA; VOLATILE ANESTHETICS C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Shields, Donald C.; Eskandar, Emad N.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 97 TC 4 Z9 4 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 131 EP 176 PG 46 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500005 ER PT B AU Simon, MV Borges, L AF Simon, Mirela V. Borges, Lawrence BE Simon, MV TI Intramedullary Spinal Cord Tumor Resection SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID MOTOR-EVOKED-POTENTIALS; SURGERY; STIMULATION; ANESTHESIA C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Borges, Lawrence] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg,Neurol Spine Ctr, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 28 TC 2 Z9 2 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 177 EP 208 PG 32 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500006 ER PT B AU Simon, MV Borges, L AF Simon, Mirela V. Borges, Lawrence BE Simon, MV TI Decompressive Surgery of the Spine SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID SOMATOSENSORY-EVOKED-POTENTIALS; RANDOMIZED CONTROLLED-TRIAL; CORD-INJURY; TIRILAZAD MESYLATE; NERVE COMPRESSION; RISK-FACTORS; METHYLPREDNISOLONE; INTERVENTION; MANAGEMENT C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Borges, Lawrence] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg,Neurol Spine Ctr, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 209 EP 221 PG 13 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500007 ER PT B AU Simon, MV Hart, ES Grottkau, BE AF Simon, Mirela V. Hart, Erin S. Grottkau, Brian E. BE Simon, MV TI Spine Deformity Surgery SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID MOTOR-EVOKED-POTENTIALS; SCOLIOSIS SURGERY; IDIOPATHIC SCOLIOSIS; KYPHOSIS CORRECTION; COMBINED ANTERIOR; MANAGEMENT; FUSION C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Hart, Erin S.; Grottkau, Brian E.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 19 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 223 EP 235 PG 13 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500008 ER PT B AU Peck, MA Simon, MV Conrad, MF AF Peck, Michael A. Simon, Mirela V. Conrad, Mark F. BE Simon, MV TI Thoracoabdominal Aneurysm Repair SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID SPINAL-CORD ISCHEMIA; CEREBROSPINAL-FLUID DRAINAGE; THORACIC AORTIC-ANEURYSM; MOTOR-EVOKED-POTENTIALS; LEFT-HEART BYPASS; OPEN-SURGICAL REPAIR; DELAYED NEUROLOGIC DEFICIT; ADAMKIEWICZ ARTERY; HIGH-RISK; ENDOVASCULAR TREATMENT C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Conrad, Mark F.] Harvard Univ, Sch Med, Dept Vasc & Endovasc Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 92 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 237 EP 266 PG 30 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500009 ER PT B AU Coumans, JVCE Simon, MV Cooper, JS Winograd, JM AF Coumans, Jean-Valerie C. E. Simon, Mirela V. Cooper, Jason S. Winograd, Jonathan M. BE Simon, MV TI PERIPHERAL NERVE SURGERY SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID TETHERED CORD SYNDROME; CEREBELLOPONTINE ANGLE SURGERY; PEDICLE SCREW PLACEMENT; MOTOR-EVOKED POTENTIALS; SPINAL ACCESSORY NERVE; BRACHIAL-PLEXUS; ROOT INJURY; C5 PALSY; ELECTROMYOGRAPHY; ACCURACY C1 [Coumans, Jean-Valerie C. E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Cooper, Jason S.; Winograd, Jonathan M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Plast & Reconstruct Surg, Boston, MA 02115 USA. RP Coumans, JVCE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA. NR 54 TC 1 Z9 1 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 267 EP 298 PG 32 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500010 ER PT B AU Asaad, WF Simon, MV Eskandar, EN AF Asaad, Wael F. Simon, Mirela V. Eskandar, Emad N. BE Simon, MV TI INTRAOPERATIVE NEUROPHYSIOLOGIC MONITORING OF THE CRANIAL NERVES AND BRAINSTEM SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID RECURRENT LARYNGEAL NERVE; AUDITORY EVOKED-POTENTIALS; SKULL BASE SURGERY; ACOUSTIC NEUROMA SURGERY; VESTIBULAR-SCHWANNOMA SURGERY; CEREBELLOPONTINE ANGLE TUMOR; SINGLE BIPOLAR ELECTRODE; FACIAL-NERVE; MICROVASCULAR DECOMPRESSION; HEMIFACIAL SPASM C1 [Simon, Mirela V.] Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. [Eskandar, Emad N.] Harvard Univ, Sch Med, Dept Neurosurg, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 110 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 299 EP 324 PG 26 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500011 ER PT B AU Simon, MV AF Simon, Mirela V. BE Simon, MV TI THE EFFECTS OF ANESTHETICS ON INTRAOPERATIVE NEUROPHYSIOLOGY STUDIES SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Article; Book Chapter ID SOMATOSENSORY-EVOKED-POTENTIALS; HIGH-DOSE FENTANYL; INDUCED EPILEPTIFORM ACTIVITY; COMPLEX PARTIAL EPILEPSY; TEMPORAL-LOBE EPILEPSY; NITROUS-OXIDE; NEUROMUSCULAR BLOCKADE; ISOFLURANE ANESTHESIA; ENFLURANE ANESTHESIA; CEREBRAL-CIRCULATION C1 Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 81 TC 2 Z9 2 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 BP 325 EP 334 PG 10 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500012 ER PT B AU Simon, MV AF Simon, Mirela V. BE Simon, MV TI INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY A Comprehensive Guide to Monitoring and Mapping PREFACE SO INTRAOPERATIVE CLINICAL NEUROPHYSIOLOGY: A COMPREHENSIVE GUIDE TO MONITORING AND MAPPING LA English DT Editorial Material; Book Chapter C1 Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. RP Simon, MV (reprint author), Harvard Univ, Sch Med, Intraoperat Monitoring Unit, Massachusetts Gen Hosp,Dept Neurol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-46-4 PY 2010 PG 1 WC Neurosciences SC Neurosciences & Neurology GA BMN54 UT WOS:000272972500001 ER PT J AU Heaton, JT Kowaleski, J Edwards, C Smitson, C Hadlock, TA AF Heaton, James T. Kowaleski, Jeffrey Edwards, Colin Smitson, Christopher Hadlock, Tessa A. TI Evidence for Facial Nerve-Independent Mechanisms of Blinking in the Rat SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID FUNCTIONAL RECOVERY; CRUSH INJURY; MOVEMENTS; RESPONSES; PROMOTES; REFLEX; SYSTEM; MUSCLE; MODEL AB PURPOSE. The rat facial nerve (CN VII) controls the orbicularis oculi (OO) muscle, which contracts to close the palpebral fissure during blinking. It was recently observed that rats are able to achieve nearly complete eye closure shortly after CN VII lesion, and hypothesized that the retractor bulbi (RB) muscle assumes an important compensatory role after CN VII lesion. This study was undertaken to determine the maintenance of rat corneal health and eye closure capability after lesion of the OO, RB, or both. METHODS. Twenty-two rats underwent RB transection; 12 of them had undergone complete unilateral CN VII transection (OO denervation) 15 weeks earlier. Corneal appearance and ability to blink in response to a corneal air puff was monitored weekly for 9 weeks. An additional 13 rats received CN VII transection and were video recorded (1000 frames/s) during elicited blinks at days 1, 3, 5/6, and 11 after surgery. RESULTS. Rats achieved nearly full or full eye closure after OO paralysis or RB myotomy, respectively. Ninety-two percent of rats maintained good corneal health after OO denervation over 9 weeks, consistent with compensatory eyelid movement served by the RB muscles. In contrast, only 40% of rats with loss of RB function alone and only 17% of rats with concurrent OO and RB paralysis were able to maintain corneal health by week 3. CONCLUSIONS. Like other small mammals, the rat RB musculature can support nearly complete eye closure when CN VII is lesioned, and must be carefully considered when using blink as a functional recovery parameter of facial nerve lesion. (Invest Ophthalmol Vis Sci. 2010; 51: 179-182) DOI:10.1167/iovs.083371 C1 [Heaton, James T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Kowaleski, Jeffrey; Edwards, Colin; Smitson, Christopher; Hadlock, Tessa A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA USA. RP Hadlock, TA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. EM hadlock@meei.harvard.edu FU National Institute of Dental and Craniofacial Research (NIDCR) [K-08DE015665-01A2] FX Supported by National Institute of Dental and Craniofacial Research (NIDCR) Grant K-08DE015665-01A2. NR 17 TC 3 Z9 3 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2010 VL 51 IS 1 BP 179 EP 182 DI 10.1167/iovs.08-3371 PG 4 WC Ophthalmology SC Ophthalmology GA 539OI UT WOS:000273264200027 PM 19710413 ER PT S AU Davalos, RV Garcia, PA Edd, JF AF Davalos, Rafael V. Garcia, Paulo A. Edd, Jon F. BE Rubinsky, B TI Thermal Aspects of Irreversible Electroporation SO IRREVERSIBLE ELECTROPORATION SE Series in Biomedical Engineering LA English DT Article; Book Chapter ID PULSED ELECTRIC-FIELDS; IN-VIVO ELECTROPORATION; HAMSTER OVARY CELLS; HIGH-VOLTAGE PULSES; TISSUE ELECTROPORATION; THEORETICAL-ANALYSIS; DIELECTRIC-PROPERTIES; IMPEDANCE TOMOGRAPHY; INJURY MECHANISMS; ABLATION C1 [Davalos, Rafael V.; Garcia, Paulo A.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA. [Edd, Jon F.] Shriners Hosp Children, Boston, MA 02114 USA. [Edd, Jon F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA. [Edd, Jon F.] Vanderbilt Univ, Dept Mech Engn, Nashville, TN 37212 USA. RP Davalos, RV (reprint author), Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA. EM davalos@vt.edu NR 64 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1864-5763 BN 978-3-642-05419-8 J9 SER BIOMED ENG PY 2010 BP 123 EP 154 DI 10.1007/978-3-642-05420-4_5 D2 10.1007/978-3-642-05420-4 PG 32 WC Cell Biology; Engineering, Biomedical; Mathematical & Computational Biology SC Cell Biology; Engineering; Mathematical & Computational Biology GA BMR15 UT WOS:000273384100005 ER PT S AU Liu, ZY Habener, JF AF Liu, Zhengyu Habener, Joel F. BE Islam, MS TI Wnt Signaling in Pancreatic Islets SO ISLETS OF LANGERHANS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter ID GENOME-WIDE ASSOCIATION; TYPE-2 DIABETES RISK; BETA-CELL PROLIFERATION; ENDOPLASMIC-RETICULUM STRESS; PROGLUCAGON GENE-EXPRESSION; INDUCED INSULIN-SECRETION; ANIMAL-MODELS; TCF7L2 GENE; SUSCEPTIBILITY LOCI; EXOCRINE PANCREAS AB The Wnt signaling pathway is critically important not only for stem cell amplification, differentiation, and migration, but also is important for organogenesis and the development of the body plan. Beta-catenin/TCF7L2-dependent Wnt signaling (the canonical pathway) is involved in pancreas development, islet function, and insulin production and secretion. The glucoincretin hormone glucagon-like peptide-1 and the chemokine stromal cell-derived factor-1 modulate canonical Wnt signaling in beta-cells which is obligatory for their mitogenic and cytoprotective actions. Genome-wide association studies have uncovered 19 gene loci that confer susceptibility for the development of type 2 diabetes. At least 14 of these diabetes risk alleles encode proteins that are implicated in islet growth and functioning. Seven of them are either components of, or known target genes for, Wnt signaling. The transcription factor TCF7L2 is particularly strongly associated with risk for diabetes and appears to be fundamentally important in both canonical Wnt signaling and beta-cell functioning. Experimental loss of TCF7L2 function in islets and polymorphisms in TCF7L2 alleles in humans impair glucose-stimulated insulin secretion, suggesting that perturbations in the Wnt signaling pathway may contribute substantially to the susceptibility for, and pathogenesis of, type 2 diabetes. This review focuses on considerations of the hormonal regulation of Wnt signaling in islets and implications for mutations in components of the Wnt signaling pathway as a source for risk-associated alleles for type 2 diabetes. C1 [Liu, Zhengyu; Habener, Joel F.] Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA. RP Habener, JF (reprint author), Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA. EM zlieu4@partners.org; jhabener@partners.org NR 147 TC 39 Z9 40 U1 1 U2 6 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-90-481-3270-6 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2010 VL 654 BP 391 EP 419 DI 10.1007/978-90-481-3271-3_17 D2 10.1007/978-90-481-3271-3 PG 29 WC Cell Biology; Medicine, General & Internal; Medicine, Research & Experimental SC Cell Biology; General & Internal Medicine; Research & Experimental Medicine GA BOY83 UT WOS:000278074700017 PM 20217507 ER PT S AU Kawamori, D Welters, HJ Kulkarni, RN AF Kawamori, Dan Welters, Hannah J. Kulkarni, Rohit N. BE Islam, MS TI Molecular Pathways Underlying the Pathogenesis of Pancreatic alpha-Cell Dysfunction SO ISLETS OF LANGERHANS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Diabetes; Hypoglycemia; Pancreatic islets; alpha-cells; Glucagon; Secretion; Insulin; GABA; Zinc; Somatostatin; GLP-1; Counter regulation; Neurotransmitters and nervous systems; Development; Hypertrophy ID GLUCAGON GENE-TRANSCRIPTION; PERFUSED RAT PANCREAS; GASTRIC-INHIBITORY POLYPEPTIDE; IMPAIRED GLUCOSE-TOLERANCE; COUNTERREGULATORY HORMONE-RELEASE; DEPENDENT INSULINOTROPIC PEPTIDE; MOUSE ENDOCRINE PANCREAS; TYPE-2 DIABETES-MELLITUS; ACTIVATED-RECEPTOR-GAMMA; SWITCH-OFF HYPOTHESIS AB Glucagon plays a critical role in glucose homeostasis by counteracting insulin action, especially during hypoglycemia. Glucagon secretion from pancreatic alpha-cells is regulated by various mechanisms including glycemia, neural input, and secretion from neighboring beta-cells. However, glucagon secretion is dysregulated in diabetic states, causing exacerbation of glycennic disorders. Recently, new therapeutic approaches targeting excess glucagon secretion are being explored for use in diabetes treatment. Therefore, understanding the molecular mechanism of how glucagon secretion is regulated is critical for treating the a-cell dysfunction observed in diabetes. C1 [Kawamori, Dan; Welters, Hannah J.; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Dept Cellular & Mol Physiol, Joslin Diabet Ctr, Boston, MA 02215 USA. [Kawamori, Dan; Welters, Hannah J.; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. RP Kulkarni, RN (reprint author), Harvard Univ, Sch Med, Dept Cellular & Mol Physiol, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM dan.kawamori@joslin.harvard.edu; hannah.welters@joslin.harvard.edu; Rohit.Kulkarni@joslin.harvard.edu NR 174 TC 12 Z9 13 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-90-481-3270-6 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2010 VL 654 BP 421 EP 445 DI 10.1007/978-90-481-3271-3_18 D2 10.1007/978-90-481-3271-3 PG 25 WC Cell Biology; Medicine, General & Internal; Medicine, Research & Experimental SC Cell Biology; General & Internal Medicine; Research & Experimental Medicine GA BOY83 UT WOS:000278074700018 PM 20217508 ER PT J AU Finn, AV Jain, RK AF Finn, Aloke V. Jain, Rakesh K. TI Coronary Plaque Neovascularization and Hemorrhage A Potential Target for Plaque Stabilization? SO JACC-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE angiogenesis; plaque; coronary disease ID ATHEROSCLEROTIC PLAQUES; INTRAPLAQUE HEMORRHAGE; ANTIANGIOGENIC THERAPY; VESSEL MATURATION; MICROVESSELS; NORMALIZATION; ANGIOGENESIS; VASCULATURE; PROGRESSION; EXPRESSION C1 [Finn, Aloke V.] Emory Univ, Emory Crawford Long Hosp, Sch Med, Dept Internal Med, Atlanta, GA 30308 USA. [Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA USA. RP Finn, AV (reprint author), Emory Univ, Emory Crawford Long Hosp, Sch Med, Dept Internal Med, 550 Peachtree St NE, Atlanta, GA 30308 USA. EM avfinn@emory.edu FU NCI NIH HHS [R01 CA126642, R01 CA115767-05, R01 CA115767, R01 CA085140-10, R01 CA085140, P01 CA080124, R01-CA85140, R01-CA126642, P01-CA80124, R01 CA126642-02, R01-CA115767, P01 CA080124-06A2] NR 24 TC 11 Z9 12 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JAN PY 2010 VL 3 IS 1 BP 41 EP 44 DI 10.1016/j.jcmg.2009.11.001 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 647NN UT WOS:000281625300006 PM 20129529 ER PT J AU Tuboi, SH Pacheco, AG Harrison, LH Stone, RA May, M Brinkhof, MWG Dabis, F Egger, M Nash, D Bangsberg, D Braitstein, P Yiannoutsos, CT Wood, R Sprinz, E Schechter, M AF Tuboi, Suely Hiromi Pacheco, Antonio Guilherme Harrison, Lee H. Stone, Roslyn A. May, Margaret Brinkhof, Martin W. G. Dabis, Francois Egger, Matthias Nash, Denis Bangsberg, David Braitstein, Paula Yiannoutsos, Constantin T. Wood, Robin Sprinz, Eduardo Schechter, Mauro CA IeDEA TI Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE antiretroviral therapy; cohort; CD4 lymphocyte count; highly active; low-income population; mortality; treatment outcome; viral load ID IMMUNODEFICIENCY-VIRUS-INFECTION; COUNTRIES ART-LINC; T-CELL-ACTIVATION; VIROLOGICAL RESPONSES; INCOME COUNTRIES; HIV-1 INFECTION; COMBINATION THERAPY; DISEASE PROGRESSION; FOLLOW-UP; RECOVERY AB Objectives: We assessed mortality associated with immunologic and virologic patterns of response at 6 months of highly active antiretroviral therapy (HAART) in HIV-infected individuals from resource-limited countries in Africa and South America. Methods: Patients who initiated HAART between 1996 and 2007, aged 16 years or older, and had at least 1 measurement (HTV-1 RNA plasma viral load or CD4 cell count) at 6 months of therapy (3-9 month window) were included. Therapy response was categorized as complete, discordant (virologic only or immunologic only), and absent. Associations between 6-month response to therapy and all-cause mortality were assessed by Cox proportional hazards regression. Robust standard errors were calculated to account for intrasite correlation. Results: A total of 7160 patients, corresponding to 15,107 person-years, were analyzed. In multivariable analysis adjusted for age at HAART initiation, baseline clinical stage and CD4 cell count, year of HAART initiation, clinic, occurrence of an AIDS-defining condition within the first 6 months of treatment, and discordant and absent responses were associated with increased risk of death. Conclusions: Similar to reports from high-income countries, discordant immunologic and virologic responses were associated with intermediate risk of death compared with complete and no response in this large cohort of HIV-1 patients from resource-limited countries. Our results support a recommendation for wider availability of plasma viral load testing to monitor antiretroviral therapy in these settings. C1 [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil. [Tuboi, Suely Hiromi] Univ Fed Fluminense, Dept Epidemiol & Biostat, Niteroi, RJ, Brazil. [Pacheco, Antonio Guilherme] Fiocruz MS, PROCC, BR-21045900 Rio De Janeiro, Brazil. [Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA. [Harrison, Lee H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [May, Margaret] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England. [Brinkhof, Martin W. G.; Egger, Matthias] Univ Bern, Dept Social & Prevent Med, Bern, Switzerland. [Dabis, Francois] Univ Victor Segalen, ISPED, INSERM, U897, Bordeaux, France. [Nash, Denis] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, Mailman Sch Publ Hlth, New York, NY USA. [Bangsberg, David] Massachusetts Gen Hosp, Ctr Global Hlth, Harvard Initiat Global Hlth, Boston, MA 02114 USA. [Yiannoutsos, Constantin T.] Indiana Univ, Sch Med, Div Biostat, Indianapolis, IN USA. [Braitstein, Paula] Regenstrief Inst Informat, Indianapolis, IN USA. [Braitstein, Paula] Moi Univ, Sch Med, Eldoret, Kenya. [Wood, Robin] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa. [Wood, Robin] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa. [Sprinz, Eduardo] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, BR-90046900 Porto Alegre, RS, Brazil. RP Schechter, M (reprint author), Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rua Prof Rodolpho Paulo Rocco 255, BR-21941590 Rio De Janeiro, Brazil. EM maurosch@hucff.ufrj.br RI Wood, Robin/G-8509-2011; Pacheco, Antonio Guilherme/E-6378-2013; May, Margaret/E-8099-2013; OI Pacheco, Antonio Guilherme/0000-0003-3095-1774; May, Margaret/0000-0002-9733-1003; Brinkhof, Martin/0000-0002-9319-665X FU US National Institutes of Health (Office of AIDS Research and National Institute of Allergy and Infectious Diseases); French Agence Nationale de Recherches sur le Sida et les hepatitis virales (ANRS); Fogarty International Center, NIH [3 D43 TW01038] FX The ART-LINC collaboration of the International epidemiological Databases to Evaluate AIDS (leDEA) is funded by the US National Institutes of Health (Office of AIDS Research and National Institute of Allergy and Infectious Diseases) and the French Agence Nationale de Recherches sur le Sida et les hepatitis virales (ANRS). This study was partially supported by the Fogarty International Center, NIH (grant 3 D43 TW01038). NR 35 TC 23 Z9 24 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2010 VL 53 IS 1 BP 70 EP 77 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 538KG UT WOS:000273182400011 PM 20035163 ER PT J AU Kang, JS Schumacher, HR Pullman-Mooar, S AF Kang, Jane S. Schumacher, H. Ralph Pullman-Mooar, Sally TI Tendon Sheath Gout Diagnosed by Ultrasound SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article C1 Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kang, JS (reprint author), Columbia Univ, Div Rheumatol, 630 W 168th St,P&S 10-508, New York, NY 10032 USA. EM jsk2182@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JAN PY 2010 VL 16 IS 1 BP 52 EP 52 DI 10.1097/RHU.0b013e3181c8877b PG 1 WC Rheumatology SC Rheumatology GA 546BN UT WOS:000273782300019 PM 20051763 ER PT J AU Carter, AS Godoy, L Wagmiller, RL Veliz, P Marakovitz, S Briggs-Gowan, MJ AF Carter, Alice S. Godoy, Leandra Wagmiller, Robert L. Veliz, Philip Marakovitz, Susan Briggs-Gowan, Margaret J. TI Internalizing Trajectories in Young Boys and Girls: The Whole is Not a Simple Sum of its Parts SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE Internalizing; Trajectories; Early childhood; Sex differences; Infant-Toddler Social and Emotional Assessment (ITSEA) ID SEPARATION ANXIETY DISORDER; BEHAVIORAL-INHIBITION; DEVELOPMENTAL PSYCHOPATHOLOGY; PRESCHOOL PSYCHOPATHOLOGY; ENVIRONMENTAL-INFLUENCES; EMOTIONAL ASSESSMENT; CHILDHOOD; TEMPERAMENT; CHILDREN; SYMPTOMS AB There is support for a differentiated model of early internalizing emotions and behaviors, yet researchers have not examined the course of multiple components of an internalizing domain across early childhood. In this paper we present growth models for the Internalizing domain of the Infant-Toddler Social and Emotional Assessment and its component scales (General Anxiety, Separation Distress, Depression/Withdrawal, and Inhibition to Novelty) in a sample of 510 one- to three-year-old children. For all children, Internalizing domain scores decreased over the study, although girls had significantly higher initial levels and boys had steeper declines. General Anxiety increased over the study period and, when modeled individually, girls evidenced higher initial levels and greater increases. For all children, Separation Distress and Inhibition to Novelty decreased significantly over time, while Depression/Withdrawal remained low without change. Findings from our parallel process model, in which all components were modeled simultaneously, revealed that initial levels of internalizing scales were closely associated while rates of change were less closely related. Sex differences in variability around initial levels and rates of change emerged on some scales. Findings suggest that, for one- to three-year-olds, examining scales of the internalizing domain separately rather than as a unitary construct reveals more meaningful developmental and gender variation. C1 [Carter, Alice S.; Godoy, Leandra] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA. [Wagmiller, Robert L.; Veliz, Philip] SUNY Coll Buffalo, Dept Sociol, Buffalo, NY 14222 USA. [Marakovitz, Susan] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Briggs-Gowan, Margaret J.] Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06032 USA. RP Carter, AS (reprint author), Univ Massachusetts, Dept Psychol, 100 Morrissey Blvd, Boston, MA 02125 USA. EM Alice.Carter@umb.edu FU NIMH NIH HHS [R01 MH055278] NR 48 TC 11 Z9 11 U1 6 U2 17 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD JAN PY 2010 VL 38 IS 1 BP 19 EP 31 DI 10.1007/s10802-009-9342-0 PG 13 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA 546YY UT WOS:000273852900002 PM 19662525 ER PT J AU Batki, SL Canfield, KM Smyth, E Ploutz-Snyder, R Levine, RA AF Batki, Steven L. Canfield, Kelly M. Smyth, Emily Ploutz-Snyder, Robert Levine, Robert A. TI Hepatitis C Treatment Eligibility and Comorbid Medical Illness in Methadone Maintenance (MMT) and Non-MMT Patients: A Case-Control Study SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Hepatitis C; treatment; methadone; opioid; substance abuse; comorbidity; psychiatry ID INJECTION-DRUG USERS; QUALITY-OF-LIFE; VIRUS-INFECTION; RATING-SCALE; HUMAN-IMMUNODEFICIENCY; ANTIVIRAL TREATMENT; UNITED-STATES; RISK-FACTORS; RIBAVIRIN; HIV AB Comorbid medical illness is common in patients with chronic hepatitis C (HCV) infection and in methadone treatment (MMT) patients, yet little is known about the impact of medical illness on HCV treatment eligibility. Medical illness and HCV treatment eligibility were compared in a case-control study of 80 MMT patients entering an HCV treatment trial and 80 matched non-MMT patients entering HCV treatment in a gastroenterology clinic. 91% of MMT and 85% of non-MMT patients had chronic medical conditions. Despite similar medical severity ratings, a significantly higher proportion (77%) of non-MMT patients were eligible for HCV treatment than were MMT patients (56%) (p .01). Specific comorbid medical and psychiatric illness led to ineligibility in only 18% of MMT and 16% of non-MMT patients. However, failure to complete the medical evaluation process was significantly (p .001) more likely to cause ineligibility among MMT patients (19%) than non-MMT patients (0%). C1 [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Canfield, Kelly M.; Smyth, Emily; Levine, Robert A.] SUNY Upstate Med Univ, Syracuse, NY USA. [Ploutz-Snyder, Robert] Univ Space Res Assoc, NASA JSC, Houston, TX USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Canfield, Kelly M.; Smyth, Emily; Levine, Robert A.] SUNY Upstate Med Univ, Syracuse, NY USA. [Ploutz-Snyder, Robert] NASA JSC, Univ Space Res Assoc, Houston, TX USA. RP Batki, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu FU NIDA NIH HHS [R01 DA016764-06, R01 DA 016764, R01 DA016764] NR 52 TC 2 Z9 2 U1 0 U2 3 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 2010 VL 29 IS 3 BP 359 EP 369 AR PII 924377213 DI 10.1080/10550887.2010.489449 PG 11 WC Substance Abuse SC Substance Abuse GA 626JY UT WOS:000279963500011 PM 20635285 ER PT J AU Primack, BA Fertman, CI Rice, KR Adachi-Mejia, AM Fine, MJ AF Primack, Brian A. Fertman, Carl I. Rice, Kristen R. Adachi-Mejia, Anna M. Fine, Michael J. TI Waterpipe and Cigarette Smoking Among College Athletes in the United States SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Athletes; Waterpipe; Hookah; Tobacco; Team sports; Club sports; Intramural sports; Varsity sports; Organized sports; College ID TOBACCO SMOKING; CARBON-MONOXIDE; DRUG-USE; STUDENTS; PREVALENCE; NICOTINE; PIPE; DRINKING; FREQUENCY; PRODUCTS AB Purpose: Tobacco use using a waterpipe is an emerging trend among college students. Although cigarette smoking is low among college athletes, waterpipe tobacco smoking may appeal to this population. The purpose of this study was to compare cigarette and waterpipe tobacco smoking in terms of their associations with organized sport participation. Methods: In the spring of 2008, we conducted an online survey of 8,745 college students at eight institutions as part of the revised National College Health Assessment. We used multivariable regression models to assess the associations between tobacco use (cigarette and waterpipe) and organized sports participation. Results: Participants reported participation in varsity (5.2%), club (11.9%), and intramural (24.9%) athletics. Varsity athletes and individuals who were not varsity athletes had similar rates of waterpipe tobacco smoking (27.6% vs. 29.5%, p = .41). However, other types of athletes were more likely than their counterparts to have smoked waterpipe tobacco (35.1% vs. 28.7%, p < .001 for club sports and 34.8% vs. 27.7%, p < .001 for intramural sports). In fully-adjusted multivariable models, sports participants of any type had lower odds of having smoked cigarettes, whereas participants who played intramural sports (odds ratio = 1.15, 95% confidence interval = 1.03, 1.29) or club sports (odds ratio = 1.15, 95% confidence interval = 1.001, 1.33) had significantly higher odds of having smoked waterpipe tobacco. Conclusions: College athletes are susceptible to waterpipe tobacco use. In fact, compared with their nonathletic counterparts, club sports participants and intramural sports participants generally had higher odds of waterpipe tobacco smoking. Allure for waterpipe tobacco smoking may exist even for individuals who are traditionally considered at low risk for tobacco use. (C) 2010 Society for Adolescent Medicine. All rights reserved. C1 [Primack, Brian A.; Rice, Kristen R.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. [Fertman, Carl I.] Univ Pittsburgh, Sch Educ, Dept Hlth & Phys Act, Pittsburgh, PA 15213 USA. [Adachi-Mejia, Anna M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat,Hood Ctr Children & Families, Hanover, NH 03756 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] VA Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Adachi-Mejia, Anna/0000-0001-5980-3850 FU National Cancer Institute [K07-CA114315]; Maurice Falk Foundation FX Dr. Primack is supported in part by a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation, a career development award from the National Cancer Institute (K07-CA114315), and a grant from the Maurice Falk Foundation. Dr. Primack had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors thank Drs. Mary Hoban and E. Victor Leino for their assistance with data management. NR 30 TC 51 Z9 52 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD JAN PY 2010 VL 46 IS 1 BP 45 EP 51 DI 10.1016/j.jadohealth.2009.05.004 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 548RE UT WOS:000273983100008 PM 20123257 ER PT J AU Lu, Q Ding, K Frosch, MP Jones, S Wolfe, M Xia, WM Lanford, GW AF Lu, Qun Ding, Kai Frosch, Matthew P. Jones, Shiloh Wolfe, Michael Xia, Weiming Lanford, George W. TI Alzheimer's Disease-Linked Presenilin Mutation (PS1M146L) Induces Filamin Expression and gamma-Secretase Independent Redistribution SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Actin; dentate gyrus; filamin; hilar neurons; presenilin mutation; gamma-secretase ID INTRACELLULAR DOMAIN; CEREBRAL-CORTEX; DELTA-CATENIN; NEURONS; PROTEIN; HIPPOCAMPUS; CLEAVAGE; CELLS; MORPHOGENESIS; SOMATOSTATIN AB Presenilin mutations are linked to the early onset familial Alzheimer's disease (FAD) and lead to a range of neuronal changes, indicating that presenilins interact with multiple cellular pathways to regulate neuronal functions. In this report, we demonstrate the effects of FAD-linked presenilin 1 mutation (PS1M146L) on the expression and distribution of filamin, an actin cross-linking protein that interacts with PS1 both physically and genetically. By using immunohistochemical methods, we evaluated hippocampal dentate gyrus for alterations of proteins involved in synaptic plasticity. Among many proteins expressed in the hippocampus, calretinin, glutamic acid decarboxylase (GAD67), parvalbumin, and filamin displayed distinct changes in their expression and/or distribution patterns. Striking anti-filamin immunoreactivity was associated with the polymorphic cells of hilar region only in transgenic mice expressing PS1M146L. In over 20% of the PS1M146L mice, the hippocampus of the left hemisphere displayed more pronounced upregulation of filamin than that of the right hemisphere. Anti-filamin labeled the hilar neurons only after the PS1M146L mice reached after four months of age. Double labeling immunohistochemical analyses showed that anti-filamin labeled neurons partially overlapped with cholecystokinin (CCK), somatostatin, GAD67, parvalbumin, and calretinin immunoreactive neurons. In cultured HEK293 cells, PS1 overexpression resulted in filamin redistribution from near cell peripheries to cytoplasm. Treatment of CHO cells stably expressing PS1 with WPE-III-31C or DAPT, selective gamma-secretase inhibitors, did not suppress the effects of PS1 overexpression on filamin. These studies support a gamma-secretase-independent role of PS1 in modulation of filamin-mediated actin cytoskeleton. C1 [Lu, Qun; Jones, Shiloh; Lanford, George W.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA. [Lu, Qun] E Carolina Univ, Brody Sch Med, Harriet & John Wooten Lab Alzheimers Dis & Neurod, Greenville, NC 27834 USA. [Ding, Kai; Wolfe, Michael; Xia, Weiming] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA. [Frosch, Matthew P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, CS Kubik Lab Neuropathol, Boston, MA USA. RP Lu, Q (reprint author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA. EM luq@ecu.edu RI xia, weiming/E-5465-2016; OI xia, weiming/0000-0002-7463-3295; Jones, Shiloh/0000-0002-6430-8042 FU NIH/NIA [026630]; NIH/NCI [CA111891] FX We thank Melissa Clark and Christi Boykin for technical assistance. This study was supported in part by NIH/NIA (026630) and NIH/NCI (CA111891) grants (Q.L.). NR 40 TC 5 Z9 5 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 1 BP 235 EP 245 DI 10.3233/JAD-2010-100585 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 668TS UT WOS:000283294100020 PM 20847418 ER PT J AU Lambert, JC Sleegers, K Gonzalez-Perez, A Ingelsson, M Beecham, GW Hiltunen, M Combarros, O Bullido, MJ Brouwers, N Bettens, K Berr, C Pasquier, F Richard, F DeKosky, ST Hannequin, D Haines, JL Tognoni, G Fievet, N Dartigues, JF Tzourio, C Engelborghs, S Arosio, B Coto, E De Deyn, P Zompo, M Mateo, I Boada, M Antunez, C Lopez-Arrieta, J Epelbaum, J Schjcide, BMM Frank-Garcia, A Gicdraitis, V Helisalmi, S Porcellini, E Pilotto, A Forti, P Ferri, R Delepine, M Zelenika, D Lathrop, M Scarpini, E Siciliano, G Solfrizzi, V Sorbi, S Spalletta, G Ravaglia, G Valdivieso, F Vepsalainen, S Alvarez, V Bosco, P Mancuso, M Panza, F Nacmias, B Bossu, P Hanon, O Piccardi, P Annoni, G Mann, D Marambaud, P Seripa, D Galimberti, D Tanzi, RE Bertram, L Lendon, C Lannfelt, L Licastro, F Campion, D Pericak-Vance, MA Soininen, H Van Broeckhoven, C Alperovitch, A Ruiz, A Kamboh, MI Amouyel, P AF Lambert, Jean-Charles Sleegers, Kristel Gonzalez-Perez, Antonio Ingelsson, Martin Beecham, Gary W. Hiltunen, Mikko Combarros, Onofre Bullido, Maria J. Brouwers, Nathalie Bettens, Karolien Berr, Claudine Pasquier, Florence Richard, Florence DeKosky, Steven T. Hannequin, Didier Haines, Jonathan L. Tognoni, Gloria Fievet, Nathalie Dartigues, Jean-Francois Tzourio, Christophe Engelborghs, Sebastiaan Arosio, Beatrice Coto, Elicer De Deyn, Peter Del Zompo, Maria Mateo, Ignacio Boada, Merce Antunez, Carmen Lopez-Arrieta, Jesus Epelbaum, Jacques Schjcide, Brit-Marcn Michaud Frank-Garcia, Ana Gicdraitis, Vilmentas Helisalmi, Seppo Porcellini, Elisa Pilotto, Alberto Forti, Paola Ferri, Raffaele Delepine, Marc Zelenika, Diana Lathrop, Mark Scarpini, Elio Siciliano, Gabriele Solfrizzi, Vincenzo Sorbi, Sandro Spalletta, Gianfranco Ravaglia, Giovanni Valdivieso, Fernando Vepsalainen, Saila Alvarez, Victoria Bosco, Paolo Mancuso, Michelangelo Panza, Francesco Nacmias, Benedetta Bossu, Paola Hanon, Olivier Piccardi, Paola Annoni, Giorgio Mann, David Marambaud, Philippe Seripa, Davide Galimberti, Daniela Tanzi, Rudolph E. Bertram, Lars Lendon, Corinne Lannfelt, Lars Licastro, Federico Campion, Dominique Pericak-Vance, Margaret A. Soininen, Hilkka Van Broeckhoven, Christine Alperovitch, Annick Ruiz, Agustin Kamboh, M. Ilyas Amouyel, Philippe TI The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Age at onset; Alzheimer's disease; apolipoprotein E; CALHM1; polymorphism ID GENOME-WIDE ASSOCIATION; S-TRANSFERASE OMEGA-1; NO ASSOCIATION; AT-ONSET; SYSTEMATIC METAANALYSES; POPULATION-STRUCTURE; IDENTIFIES VARIANTS; PARKINSON-DISEASE; RISK; HETEROGENEITY AB The only established genetic determinant of non-Mendelian forms of Alzheimer's disease (AD) is the epsilon 4 allele of the apolipoprotein E gene (APOE). Recently, it has been reported that the P86L polymorphism of the calcium homeostasis modulator 1 gene (CALHM1) is associated with the risk of developing AD. In order to independently assess this association, we performed a meta-analysis of 7,873 AD cases and 13,274 controls of Caucasian origin (from a total of 24 centers in Belgium, Finland, France, Italy, Spain, Sweden, the UK, and the USA). Our results indicate that the CALHM1 P86L polymorphism is likely not a genetic determinant of AD but may modulate age of onset by interacting with the effect of the epsilon 4 allele of the APOE gene. C1 [Lambert, Jean-Charles; Richard, Florence; Fievet, Nathalie; Amouyel, Philippe] Inst Pasteur, Unite INSERM 744, F-59019 Lille, France. [Lambert, Jean-Charles; Pasquier, Florence; Richard, Florence; Amouyel, Philippe] Univ Lille Nord France, Lille, France. [Sleegers, Kristel; Brouwers, Nathalie; Bettens, Karolien] Dept Mol Genet VIB, Neurodegenerat Brain Dis Grp, Antwerp, Belgium. [Brouwers, Nathalie; Bettens, Karolien; De Deyn, Peter; Van Broeckhoven, Christine] Univ Antwerp, B-2020 Antwerp, Belgium. [Brouwers, Nathalie; Bettens, Karolien; De Deyn, Peter; Van Broeckhoven, Christine] Inst Born Bunge, Antwerp, Belgium. [Gonzalez-Perez, Antonio; Ruiz, Agustin] Dept Struct Genom, Seville, Spain. [Ingelsson, Martin; Gicdraitis, Vilmentas; Vepsalainen, Saila; Lannfelt, Lars] Uppsala Univ, Stockholm, Sweden. [Beecham, Gary W.; Pericak-Vance, Margaret A.] Univ Miami, Sch Med, John P Hussman Inst Human Gen, Miami, FL USA. [Hiltunen, Mikko; Soininen, Hilkka] Univ Hosp, Kuopio, Finland. [Hiltunen, Mikko; Soininen, Hilkka] Univ Kuopio, Dept Neurol, Kuopio, Finland. [Combarros, Onofre; Mateo, Ignacio; Helisalmi, Seppo] Univ Cantabria, Marques Valdecilla Univ Hosp, Neurol Serv, Santander, Spain. [Combarros, Onofre; Mateo, Ignacio; Helisalmi, Seppo] Univ Cantabria, CIBERNED, Santander, Spain. [Bullido, Maria J.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa UAM CSIC, Madrid, Spain. [Bullido, Maria J.; Valdivieso, Fernando] Univ Autonoma Madrid, CIBERNED, Madrid, Spain. [Berr, Claudine] Hop Colombiere, INSERM U888, Montpellier, France. [Pasquier, Florence; Richard, Florence; Amouyel, Philippe] CHRU Lille, Lille, France. [DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Hannequin, Didier; Sorbi, Sandro; Nacmias, Benedetta; Campion, Dominique] Fac Med Pharmacie Rouen, INSERM U614, Rouen, France. [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Human Genet Res, Nashville, TN USA. [Tognoni, Gloria; Siciliano, Gabriele; Mancuso, Michelangelo] Univ Pisa, Dept Neurosci, Neurol Clin, Pisa, Italy. [Dartigues, Jean-Francois] Victor Segalen Univ, INSERM U897, Bordeaux, France. [Tzourio, Christophe; Alperovitch, Annick] INSERM U708, Paris, France. [Tzourio, Christophe; Alperovitch, Annick] UPMC Univ Paris 06, Paris, France. [Engelborghs, Sebastiaan; De Deyn, Peter] ZNA Middelheim, Memory Clin, Antwerp, Belgium. [Engelborghs, Sebastiaan; De Deyn, Peter] ZNA Middelheim, Dept Neurol, Antwerp, Belgium. [Arosio, Beatrice] Fdn Policlin IRCCS, Dept Internal Med, Milan, Italy. [Coto, Elicer] Hosp Univ Cent Asturias, Mol Genet Unit, Oviedo, Spain. [Del Zompo, Maria; Piccardi, Paola] Univ Cagliari, Dept Neurosci, Clin Pharmacol Sect, Cagliari, Italy. [Boada, Merce] Memory Clin Fdn ACE, Inst Neurociencies Aplicades, Barcelona, Spain. [Boada, Merce] Hosp G Univ Vall Hebron, Dept Neurol, Barcelona, Spain. [Antunez, Carmen] Alzheimur Fdn, Murcia, Spain. [Antunez, Carmen] Univ Hosp Virgen Arrixaca, Dementia Unit, Murcia, Spain. [Lopez-Arrieta, Jesus] Univ Hosp Paz Cantoblanco, Memory Unit, Madrid, Spain. [Epelbaum, Jacques; Hanon, Olivier] Univ Paris 05, UMR 894, INSERM Fac Med, Paris, France. [Schjcide, Brit-Marcn Michaud; Bertram, Lars] Max Planck Inst Mol Genet, Neuropsychiat Genet Grp, Dept Vertebrate Gen, Berlin, Germany. [Frank-Garcia, Ana] Hosp Univ Paz UAM, Serv Neurol, Madrid, Spain. [Frank-Garcia, Ana] CIBERNED, Madrid, Spain. [Porcellini, Elisa; Licastro, Federico] Univ Bologna, Sch Med, Dept Expt Pathol, Bologna, Italy. [Pilotto, Alberto; Seripa, Davide] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Geriatr Unit & Gerontol Geriatr Res Lab, San Giovanni Rotondo, Italy. [Forti, Paola] Univ Hosp S Orsola Malpighi, Dept Internal Med Cardiol & Hepatol, Bologna, Italy. [Ferri, Raffaele; Bosco, Paolo] IRCCS Oasi Maria SS, Troina, Italy. [Delepine, Marc; Zelenika, Diana; Lathrop, Mark] Inst Genom, Commissariat Energie Atom, Ctr Natl Genotypage, Evry, France. [Lathrop, Mark] Fdn Jean Dausset CEPH, Paris, France. [Scarpini, Elio; Galimberti, Daniela] Univ Milan, Dept Neurol Sci, Dino Ferrari Ctr, IRCCS Osped Maggiore Policlin, Milan, Italy. [Solfrizzi, Vincenzo; Panza, Francesco] Univ Bari, Dept Geriatr, Ctr Aging Brain, Memory Unit, Bari, Italy. [Sorbi, Sandro; Nacmias, Benedetta] Dept Neurol & Psychiat Sci, Florence, Italy. [Spalletta, Gianfranco; Bossu, Paola] IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, Rome, Italy. [Annoni, Giorgio] Univ Milano Bicocca, Dept Clin Med & Prevent, Monza, Italy. [Mann, David] Univ Manchester, Greater Manchester Neurosci Ctr, Manchester, Lancs, England. [Marambaud, Philippe] N Shore LIJ, Feinstein Inst Med Res, Litwin Zucker Res Ctr Study Alzheimers Dis, Manhasset, NY USA. [Marambaud, Philippe] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA. [Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA USA. [Lendon, Corinne] PO Royal Brisbane Hosp, Queensland Inst Med Res, Mol Psychiat Lab, Queenland, Australia. [Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Kamboh, M. Ilyas] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA USA. RP Lambert, JC (reprint author), Inst Pasteur, Unite INSERM 744, BP 245,1 Rue,Professeur Calmette, F-59019 Lille, France. EM jean-charles.lambert@pasteur-lille.fr RI Lambert, jean-charles/A-9553-2014; Porcellini, Elisa/K-5346-2016; Siciliano, Gabriele/K-7259-2016; Tzourio, christophe/B-4015-2009; Gonzalez-Perez, Antonio/A-5247-2010; Haines, Jonathan/C-3374-2012; Bullido, Maria/C-8509-2014; Bertram, Lars/K-3889-2015; Ferri, Raffaele/B-5439-2013; Epelbaum, Jacques/B-2263-2013; berr, Claudine/D-5238-2014; Bosso, Paola/E-4832-2014; lambert, jean-charles/F-8787-2013; Frank Garcia, Ana/I-5159-2015; Brouwers, Nathalie/L-2089-2014 OI Marambaud, Philippe/0000-0002-8983-1497; Panza, Francesco/0000-0002-7220-0656; NACMIAS, Benedetta/0000-0001-9338-9040; Lambert, jean-charles/0000-0003-0829-7817; Porcellini, Elisa/0000-0003-3991-5294; Siciliano, Gabriele/0000-0002-6142-2384; galimberti, daniela/0000-0002-9284-5953; sorbi, sandro/0000-0002-0380-6670; Arosio, Beatrice/0000-0002-0615-3580; Kamboh, M. Ilyas/0000-0002-3453-1438; scarpini, elio/0000-0002-6395-2119; Tzourio, christophe/0000-0002-6517-2984; Gonzalez-Perez, Antonio/0000-0001-9771-5982; Bullido, Maria/0000-0002-6477-1117; Bertram, Lars/0000-0002-0108-124X; Ferri, Raffaele/0000-0001-6937-3065; berr, Claudine/0000-0001-5254-7655; Bosso, Paola/0000-0002-1432-0078; Frank Garcia, Ana/0000-0003-3858-9116; Brouwers, Nathalie/0000-0002-9808-9394 FU National Foundation for Alzheimer's disease and related disorders; Institut Pasteur de Lille; Centre National de Genoty page; Fondation pour la Recherche Medicale; French Ministry of Research/INSERM; Eisai; VIB Genetic Service Facility; Biobank of the Institute Born-Bunge; University of Antwerp; Fund for Scientific Research-Flanders (FWO-V); Foundation for Alzheimer Research (SAOFRMA); Belgian Federal Science Policy Office; Belgium [P6/43]; Health Research Council of the Academy of Finland, Kuopio University Hospital [5772708]; Nordic Centre of Excellence in Neurodegeneration; Italian Ministry of research and University; Carimonte Foundation; Sanpaolo [1070IT/CV2007.0548]; Fondazione Cassa di resparmio di Pistoia e pescia [2009.0220]; Fondazione Monzino; Italian Ministry of Health; Italian Ministry of Health (Progetti di Ricerca Finalizzati); Ministerio de Educacion y Ciencia; Ministerio de Sanidad y Consumo (Instituto de Salud CarlosIII); Fundacion Alzheimur (Murcia); Ministerio de Educacion y Ciencia (Gobierno de Espana) [PCT-010000-2007-18]; USA National Institute on Aging (NIA) [AG030653, AG005133, AG20135, AG19757]; National Institute of Neurological Disorders and Stroke [NS31153]; Alzheimer's Association; Institut de France; Aquitaine and Bourgogne Regional Councils, Fondation de France FX This work was made possible by the generous participation of the control subjects, the patients, and their families. We thank Dr. Anne Boland (CNG) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille and the Centre National de Genoty page. The Three-City Study was performed as part of a collaboration between the Institut National de la Sante et de la Recherche Medicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale d'assurance des Maladie des Travailleurs Salaries, Direction Generale de la Sante, MGEN, Institut de la Longevite, Agence Francaise de Securite Sanitaire des Produits de Sante, the Aquitaine and Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM"Cohortes et collections de donnees biologiques" programme. Lille Genopole received an unconditional grant from Eisai.; Belgium sample collection: the Antwerp site (CVB) was in part supported by the VIB Genetic Service Facility (http://www.vibgeneticservicefacility.be) and the Biobank of the Institute Born-Bunge; the Special Research Fund of the University of Antwerp; the Fund for Scientific Research-Flanders (FWO-V); the Foundation for Alzheimer Research (SAOFRMA), the Interuniversity Attraction Poles (IAP) program P6/43 of the Belgian Federal Science Policy Office; Belgium; K.S. is a postdoctoral fellow and K.B. a PhD fellow of the FWO-V.; Finish sample collection: Financial support for this project was provided by the Health Research Council of the Academy of Finland, EVO grant 5772708 of Kuopio University Hospital, and the Nordic Centre of Excellence in Neurodegeneration.; Italian sample collections: the Bologna site (FL) obtained funds from the Italian Ministry of research and University as well as Carimonte Foundation. The Florence site was supported by grants from Sanpaolo 1070IT/CV2007.0548 and the Fondazione Cassa di resparmio di Pistoia e pescia (prot. 2009.0220). The Milan site was supported by grants from the "Fondazione Monzino" and the Italian Ministry of Health. We thank the expert contribution of Mr. Carmelo Romano. This work was performed in the frame of AMBISEN Center, High Technology Center for the study of the Environmental Damage of Endocrine and Nervous System, University of Pisa. We thank Dr. A. LoGerfo for the preparation of the DNA collection. The Cagliari site was partly supported by a grant from the Italian Ministry of Health (Progetti di Ricerca Finalizzati).; Spanish sample collection: the Madrid site (MB) was supported by grants of the Ministerio de Educacion y Ciencia and the Ministerio de Sanidad y Consumo (Instituto de Salud CarlosIII), and an institutional grant of the Fundacion Ramon Areces to the CBMSO. We thank I. Sastre and Dr. A Martinez-Garcia for the preparation and control of the DNA collection, and Drs. P. Gil and P. Coria for their cooperation in the cases/controls recruitment. We are grateful to the Asociacion de Familiares de Alzheimer de Madrid (AFAL) for continuous encouragement and help. The Neocodex centre thanks the staff of the Memory Clinic of Fundacio ACE. Institut Catala de Neurociencies Aplicades (Barcelona, Spain), Ana Mauleon, Maitee Rosende-Roca, Pablo Martinez-Lage, Montserrat Alegret, Susana Ruiz and Lluis Tarraga. We are indebted to the Unidad de Demencias, Hospital Universitario Virgen de la Arrixaca (Murcia, Spain), JuanMarin, and to the Memory Unit of the Hospital Universitario La Paz-Cantoblanco (Madrid, Spain). This study has been partially funded by Fundacion Alzheimur (Murcia) and the Ministerio de Educacion y Ciencia (Gobierno de Espana)(PCT-010000-2007-18).; US sample collections. The study was partly supported by USA National Institute on Aging (NIA) grant AG030653, AG005133, AG20135, AG19757), by National Institute of Neurological Disorders and Stroke (NS31153), the Alzheimer's Association, and the Louis D. Scientific Award of the Institut de France. A subset of the participants was ascertained while Margaret A. Pericak-Vance was a faculty member at Duke University. NR 41 TC 34 Z9 36 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 1 BP 247 EP 255 DI 10.3233/JAD-2010-100933 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 668TS UT WOS:000283294100021 PM 20847397 ER PT J AU Baker, LD Frank, LL Foster-Schubert, K Green, PS Wilkinson, CW McTiernan, A Cholerton, BA Plymate, SR Fishel, MA Watson, GS Duncan, GE Mehta, PD Craft, S AF Baker, Laura D. Frank, Laura L. Foster-Schubert, Karen Green, Pattie S. Wilkinson, Charles W. McTiernan, Anne Cholerton, Brenna A. Plymate, Stephen R. Fishel, Mark A. Watson, G. Stennis Duncan, Glen E. Mehta, Pankaj D. Craft, Suzanne TI Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aerobic exercise; Alzheimer's disease; cognition; dementia; diabetes; executive function; glucose intolerance; prediabetes ID INSULIN-RESISTANCE SYNDROME; EXECUTIVE DYSFUNCTION; ELDERLY INDIVIDUALS; NEUROTROPHIC FACTOR; DIABETES-MELLITUS; PHYSICAL-ACTIVITY; TRANSGENIC MODEL; WORKING-MEMORY; FRONTAL-LOBE; AGING HUMANS AB Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. Although the benefits of aerobic exercise for physical health are well-documented, exercise effects on cognition have not been examined for older adults with poor glucose regulation associated with prediabetes and early T2DM. Using a randomized controlled design, twenty-eight adults (57-83 y old) meeting 2-h tolerance test criteria for glucose intolerance completed 6 months of aerobic exercise or stretching, which served as the control. The primary cognitive outcomes included measures of executive function (Trails B, Task Switching, Stroop, Self-ordered Pointing Test, and Verbal Fluency). Other outcomes included memory performance (Story Recall, List Learning), measures of cardiorespiratory fitness obtained via maximal-graded exercise treadmill test, glucose disposal during hyperinsulinemic-euglycemic clamp, body fat, and fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulin-like growth factor-1, amyloid-beta (A beta(40) and A beta(42)). Six months of aerobic exercise improved executive function (MANCOVA, p = 0.04), cardiorespiratory fitness (MANOVA, p = 0.03), and insulin sensitivity (p = 0.05). Across all subjects, 6-month changes in cardiorespiratory fitness and insulin sensitivity were positively correlated (p = 0.01). For A beta(42), plasma levels tended to decrease for the aerobic group relative to controls (p = 0.07). The results of our study using rigorous controlled methodology suggest a cognition-enhancing effect of aerobic exercise for older glucose intolerant adults. Although replication in a larger sample is needed, our findings potentially have important therapeutic implications for a growing number of adults at increased risk of cognitive decline. C1 [Baker, Laura D.; Frank, Laura L.; Wilkinson, Charles W.; Cholerton, Brenna A.; Watson, G. Stennis; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Foster-Schubert, Karen; Green, Pattie S.; McTiernan, Anne; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Foster-Schubert, Karen; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA. [Green, Pattie S.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Fishel, Mark A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Duncan, Glen E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Nutr Sci Program, Seattle, WA 98195 USA. [Mehta, Pankaj D.] New York State Inst Basic Res Dev Disabil, Dept Immunol, New York, NY USA. [Baker, Laura D.; Frank, Laura L.; Wilkinson, Charles W.; Cholerton, Brenna A.; Plymate, Stephen R.; Fishel, Mark A.; Watson, G. Stennis; Craft, Suzanne] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. RP Baker, LD (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, GRECC A-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM ldbaker@uw.edu RI Duncan, Glen/A-3771-2008 OI Duncan, Glen/0000-0001-6909-1869 FU Office of Research and Development Medical Research Service; Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs; American Diabetes Association [7-04-CR-02] FX This work was supported by the Office of Research and Development Medical Research Service and the Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs, and the American Diabetes Association (Clinical Research Award: 7-04-CR-02). Neither funding source provided scientific input to the study. The principal investigator, Dr. Baker, had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis which was conducted without input from the funding agencies. The authors have no conflict of interest to disclose. Throughout the study, the YMCA of Greater Seattle, the YMCA of Tacoma-Pierce County, and the South Sound YMCA worked closely with us to provide exercise facilities for participants. We are grateful to the members of our laboratory who contributed many hours to this project including Karen Enstrom, RN, Darla Chapman, RN, Donna Davis, RN, Laura Fisher, Lauren Smith, Jaime Tidwell, Tracia Clark, Amy Morgan, Brenna Renn, and Meg Wojtowicz, and to Elizabeth Colasurdo for her assistance with the cortisol assays. NR 72 TC 57 Z9 58 U1 6 U2 41 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 569 EP 579 DI 10.3233/JAD-2010-100768 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200017 PM 20847403 ER PT J AU Subramanian, S Ayala, P Wadsworth, TL Harris, CJ Vandenbark, AA Quinn, JF Offner, H AF Subramanian, Sandhya Ayala, Patricia Wadsworth, Teri L. Harris, Christopher J. Vandenbark, Arthur A. Quinn, Joseph F. Offner, Halina TI CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE 3xTg-AD Mice; Alzheimer's Disease; CCR6; inflammation ID REGULATORY T-CELLS; A-BETA; CLONAL EXPANSIONS; ELEVATED LEVELS; CD4(+) T; MICE; MEMORY; BRAIN; MICROGLIA; STROKE AB The inflammatory status of the brain in patients as well as animal models of Alzheimer's disease (AD) has been extensively studied. Accumulation of activated microglia producing tumor necrosis factor-alpha and monocyte chemotactic protein-1 contribute to the pathology of the disease. However, little is known about the changes in the spleen and associated peripheral immunity that might contribute to AD pathology. The goal of this study was to characterize phenotypic and functional changes in spleen, blood and brain cell populations that contribute to development of an AD-like disease in a triple transgenic (3xTg-AD) mouse model. The 3xTg-AD mice had increased percentages of brain Gr-1+ granulocytes, dendritic cells and macrophages, spleen and blood derived CD8+Ly6C+ memory T cells and CCR6+ B cells, as well as increased levels of secreted interleukin-6. Brain tissue from older 12 month old symptomatic 3xTg-AD female mice exhibited highly elevated mRNA expression of CCR6 compared to wild-type mice. Importantly, this pronounced increase in expression of CCR6 was also detected in brain and spleen tissue from pre-symptomatic 5-6 month old 3xTg-AD females and males. Our data demonstrate increased expression of CCR6 in the brain and peripheral immune organs of both pre-symptomatic and symptomatic 3xTg-AD mice, strongly suggesting an ongoing inflammatory process that precedes onset of clinical AD-like disease. C1 [Subramanian, Sandhya; Wadsworth, Teri L.; Harris, Christopher J.; Vandenbark, Arthur A.; Quinn, Joseph F.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Ayala, Patricia; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Subramanian, Sandhya; Ayala, Patricia; Vandenbark, Arthur A.; Quinn, Joseph F.; Offner, Halina] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU Department of Veterans' Affairs; National Institutes of Health [NS45445, NS47661]; Biomedical Laboratory R&D Service, Department of Veterans Affairs FX This work was supported in part by a Department of Veterans' Affairs Merit Review Grant (Joseph Quinn); National Institutes of Health Grants NS45445 (Halina Offner) and NS47661 (Arthur A. Vandenbark); and The Biomedical Laboratory R&D Service, Department of Veterans Affairs. The authors wish to thank Ms. Eva K. Niehaus for assistance in manuscript preparation. NR 49 TC 18 Z9 18 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 619 EP 629 DI 10.3233/JAD-2010-100852 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200021 PM 20847401 ER PT J AU Wang, J Santa-Maria, I Ho, L Ksiezak-Reding, H Ono, K Teplow, DB Pasinetti, GM AF Wang, Jun Santa-Maria, Ismael Ho, Lap Ksiezak-Reding, Hanna Ono, Kenjiro Teplow, David B. Pasinetti, Giulio Maria TI Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aggregation; Alzheimer's disease; hyperphosphorylation; neurofibrillary tangles; tauopathies ID PAIRED HELICAL FILAMENTS; PROGRESSIVE SUPRANUCLEAR PALSY; BETA-STRUCTURE; IN-VITRO; PROTEIN; KINASE; PHOSPHORYLATION; SEED; BRAIN; ERK2 AB Aggregation of microtubule-associated protein tau into insoluble intracellular neurofibrillary tangles is a characteristic hallmark of Alzheimer's disease (AD) and other neurodegenerative diseases, including progressive supranuclear palsy, argyrophilic grain disease, corticobasal degeneration, frontotemporal dementias with Parkinsonism linked to chromosome 17, and Pick's disease. Tau is abnormally hyperphosphorylated in AD and aberrant tau phosphorylation contributes to the neuropathology of AD and other tauopathies. Anti-aggregation and anti-phosphorylation are main approaches for tau-based therapy. In this study, we report that a select grape-seed polyphenol extract (GSPE) could potently interfere with the assembly of tau peptides into neurotoxic aggregates. Moreover, oral administration of GSPE significantly attenuated the development of AD type tau neuropathology in the brain of TMHT mouse model of AD through mechanisms associated with attenuation of extracellular signal-receptor kinase 1/2 signaling in the brain. C1 [Wang, Jun; Santa-Maria, Ismael; Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Santa-Maria, Ismael; Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Santa-Maria, Ismael] Queen Sofia Fdn, CIEN Fdn, Alzheimer Dis Res Unit, Madrid, Spain. [Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] James J Peters Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Takara Machi, Kanazawa, Japan. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration; Office of Research and Development and Biomedical Laboratory Research and Development at the James J. Peters Veteran Affairs Medical Center; National Institute of Health [PO1AT004511, AG027818]; CurePSP; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development and Biomedical Laboratory Research and Development at the James J. Peters Veteran Affairs Medical Center to GMP; the National Institute of Health grant PO1AT004511 to GMP; and in part by funding from CurePSP awarded to GMP. This work was further supported by the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA to DBT and National Institute of Health grant AG027818 to DBT. NR 37 TC 42 Z9 43 U1 1 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 653 EP 661 DI 10.3233/JAD-2010-101074 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200024 PM 20858961 ER PT J AU Zhang, C Browne, A DiVito, JR Stevenson, JA Romano, D Dong, YL Xie, ZC Tanzi, RE AF Zhang, Can Browne, Andrew DiVito, Jason R. Stevenson, Jesse A. Romano, Donna Dong, Yuanlin Xie, Zhongcong Tanzi, Rudolph E. TI Amyloid-beta Production Via Cleavage of Amyloid-beta Protein Precursor is Modulated by Cell Density SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; amyloid-beta protein precursor; cell density ID ALZHEIMERS-DISEASE; SECRETASE CLEAVAGE; A-BETA; GAMMA-SECRETASE; PRESENILINS; HYPOTHESIS; CATENIN; DOMAIN; FORMS AB Mounting evidence suggests that Alzheimer's disease ( AD) is caused by the accumulation of the small peptide, amyloid-beta (A beta), a proteolytic cleavage product of amyloid-beta protein precursor (A beta PP). A beta is generated through a serial cleavage of A beta PP by beta- and gamma-secretase. A beta(40) and A beta(42) are the two main components of amyloid plaques in AD brains, with A beta(42) being more prone to aggregation. A beta PP can also be processed by alpha-secretase, which cleaves A beta PP within the A beta sequence, thereby preventing the generation of A beta. Little is currently known regarding the effects of cell density on A beta PP processing and A beta generation. Here we assessed the effects of cell density on A beta PP processing in neuronal and non-neuronal cell lines, as well as mouse primary cortical neurons. We found that decreased cell density significantly increases levels of A beta(40), A beta(42), total A beta, and the ratio of A beta(42): A beta(40). These results also indicate that cell density is a significant modulator of A beta PP processing. Overall, these findings carry profound implications for both previous and forthcoming studies aiming to assess the effects of various conditions and genetic/chemical factors, e.g., novel drugs on A beta PP processing and A beta generation in cell-based systems. Moreover, it is interesting to speculate whether cell density changes in vivo may also affect A beta PP processing and A beta levels in the AD brain. C1 [Zhang, Can; Browne, Andrew; DiVito, Jason R.; Stevenson, Jesse A.; Romano, Donna; Dong, Yuanlin; Xie, Zhongcong; Tanzi, Rudolph E.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Zhang, Can; Browne, Andrew; DiVito, Jason R.; Stevenson, Jesse A.; Romano, Donna; Dong, Yuanlin; Xie, Zhongcong; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Dept Neurol, MIND, Genet & Aging Res Unit, Charlestown, MA 02129 USA. [Dong, Yuanlin; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Dong, Yuanlin; Xie, Zhongcong] Harvard Univ, Sch Med, Boston, MA USA. RP Tanzi, RE (reprint author), Harvard Univ, Sch Med, 114 16th St, Charlestown, MA 02129 USA. EM tanzi@helix.mgh.harvard.edu FU Cure Alzheimer Fund; Massachusetts General Hospital; Ruth L. Kirschstein National Research Service Award (NRSA) [5T32AG000222-18]; Harvard NeuroDiscovery Center; Massachusetts Alzheimer's Disease Research Center FX The research and salary support were from Cure Alzheimer Fund (http://www.curealzfund.org/), the Funds for Medical Discovery (FMD) from the Massachusetts General Hospital (http://www.massgeneral.org/give/mghfund/), a Ruth L. Kirschstein National Research Service Award (NRSA) (5T32AG000222-18) (http://grants.nih.gov/training/nrsa.htm), and the Neurodegenerative Disease Pilot Study Program from Harvard NeuroDiscovery Center and Massachusetts Alzheimer's Disease Research Center (http://madrc.mgh.harvard.edu/). The sponsors played no role in the study design, collection, analysis and interpretation of data and preparation and submission of the manuscript. NR 30 TC 5 Z9 5 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 683 EP 694 DI 10.3233/JAD-2010-100816 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200027 PM 20847415 ER PT J AU Vanderweyde, T Bednar, MM Forman, SA Wolozin, B AF Vanderweyde, Tara Bednar, Martin M. Forman, Stuart A. Wolozin, Benjamin TI Iatrogenic Risk Factors for Alzheimer's Disease: Surgery and Anesthesia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; amyloid-beta protein; anesthetics; coronary artery bypass operation dementia; surgery ID POSTOPERATIVE COGNITIVE DYSFUNCTION; BYPASS GRAFT-SURGERY; CORONARY-ARTERY-DISEASE; CENTRAL NICOTINIC RECEPTORS; ELECTIVE CARDIAC OPERATION; AMYLOID PRECURSOR PROTEIN; MAJOR NONCARDIAC SURGERY; OUTCOMES 5 YEARS; APOLIPOPROTEIN-E; NEUROCOGNITIVE DYSFUNCTION AB Increasing evidence indicates that patients develop post-operative cognitive decline (POCD) following surgery. POCD is characterized by transient short-term decline in cognitive ability evident in the early post-operative period. This initial decline might be associated with increased risk of a delayed cognitive decline associated with dementia 3 to 5 years post-surgery. In some studies, the conversion rates to dementia are up to 70% in patients who are 65 years or older. The factors responsible for the increased risk of dementia are unclear; however, clinical studies investigating the prevalence of POCD and dementia following surgery do not show an association with the type of anesthesia or duration of surgery. Epidemiological studies from our group support this observation. The adjusted Hazard Ratios for developing dementia (or AD specifically) after prostate or hernia surgery were 0.65 (95% CI, 0.51 to 0.83, prostate) and 0.65 (95% CI, 0.49 to 0.85, hernia) for cohorts of subjects exposed to general anesthesia compared to those exposed only to local anesthesia. Animal studies suggest that prolonged exposure to some volatile-inhalational anesthetics increase production of amyloid-fi and vulnerability to neurodegeneration, but these results are weakened by the absence of clinical support. Inflammation and a maladaptive stress response might also contribute to the pathophysiology of this disorder. Future research needs to identify predisposing factors, and then strategies to protect against POCD and subsequent dementia. The field also needs to adopt a more rigorous approach to codifying the frequency and extent of early and delayed post-operative cognitive decline. C1 [Wolozin, Benjamin] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Vanderweyde, Tara] Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA. [Bednar, Martin M.] Pfizer Inc, Neurosci Res Unit, Groton, CT 06340 USA. [Forman, Stuart A.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Wolozin, B (reprint author), Boston Univ, Sch Med, Dept Neurol, 72 E Concord St,R-614, Boston, MA 02118 USA. EM bwolozin@bu.edu FU Retirement Research Foundation; Casten Foundation FX This work was supported by grants to BW from the Retirement Research Foundation and the Casten Foundation. NR 87 TC 6 Z9 6 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 SU 3 BP S91 EP S104 DI 10.3233/JAD-2010-100843 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 684US UT WOS:000284577400011 ER PT J AU Arrieta-Cruz, I Wang, J Pavlides, C Pasinetti, GM AF Arrieta-Cruz, Isabel Wang, Jun Pavlides, Constantine Pasinetti, Giulio Maria TI Carvedilol Reestablishes Long-Term Potentiation in a Mouse Model of alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; carvedilol; epileptic discharges; hippocampus; LTP; neuronal transmission; synaptic plasticity; TgCRND8 mice ID ADRENERGIC-RECEPTOR ACTIVATION; MICE; STIMULATION; EPILEPSY; LTP AB In this study, we examined acute effects of carvedilol, a nonselective alpha/beta-adrenergic receptor blocker, on neuronal transmission and long-term potentiation (LTP) in six month-old TgCRND8 mice and their wild-type age-matched controls. Field excitatory postsynaptic potentials were recorded in the CA1 region of the hippocampus from carvedilol-or vehicle dimethyl sulfoxide-treated slices, and differences in basal synaptic transmission and LTP were assessed. Carvedilol treatment produced a significant increase in basal synaptic transmission and LTP in TgCRND8 mice, as compared to their vehicle-treated slices, in which basal neuronal transmission and LTP decreased. Interestingly, carvedilol significantly suppressed spontaneous seizure activity in TgCRND8 mice as measured by the number of slices showing epileptic discharges as well as the number of spikes within these and the amplitude of the second spike, measured at baseline and end of recording. In contrast, vehicle-treated slices in TgCRND8 mice did not show a significant decrease in epileptic discharges. These results suggest that carvedilol reestablishes basal synaptic transmission, enhances neuronal plasticity and suppresses neuronal hyperexcitability in TgCRND8 mice. C1 [Arrieta-Cruz, Isabel; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pavlides, Constantine] Rockefeller Univ, New York, NY 10021 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Altschul Foundation; National Institute of Aging [U01 AG02219]; Geriatrics, Research, Education and Clinical Center at the James J. Peters Veteran Affairs Medical Center FX These studies were generously supported by funding from the Altschul Foundation, the National Institute of Aging (U01 AG02219), and the Geriatrics, Research, Education and Clinical Center at the James J. Peters Veteran Affairs Medical Center awarded to GMP. We would like to thank Dr. Bing Gong for his comments and Miss Hayley Fivecoat for her assistance in the preparation of this manuscript. NR 15 TC 15 Z9 16 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 21 IS 2 BP 649 EP 654 DI 10.3233/JAD-2010-100225 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 650XM UT WOS:000281887600029 PM 20571219 ER PT J AU Quinn, JF Harris, CJ Cobb, KE Domes, C Ralle, M Brewer, G Wadsworth, TL AF Quinn, Joseph F. Harris, Christopher J. Cobb, Katherine E. Domes, Christopher Ralle, Martina Brewer, George Wadsworth, Teri L. TI A Copper-Lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; copper; tetrathiomolybdate; Tg2576 ID TARGETING A-BETA; AMMONIUM TETRATHIOMOLYBDATE; WILSON-DISEASE; DOUBLE-BLIND; ZINC; MICE; THERAPY; EFFICACY; PEPTIDE; TRIAL AB There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-beta are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-beta pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-beta levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process. C1 [Quinn, Joseph F.] P3 R&D, Portland Vet Affairs Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Harris, Christopher J.; Cobb, Katherine E.; Wadsworth, Teri L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Domes, Christopher] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Ralle, Martina] Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97201 USA. [Brewer, George] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, Dept Neurol CR 131, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM quinnj@ohsu.edu FU Department of Veteran [R21 AG027445] FX This work was supported by a Department of Veteran's Affairs Merit Review Grant and R21 AG027445 to Joseph F. Quinn. NR 27 TC 11 Z9 11 U1 4 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 21 IS 3 BP 903 EP 914 DI 10.3233/JAD-2010-100408 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 651DA UT WOS:000281903600020 PM 20693639 ER PT J AU Bartzokis, G Lu, PH Tishler, TA Peters, DG Kosenko, A Barrall, KA Finn, JP Villablanca, P Laub, G Altshuler, LL Geschwind, DH Mintz, J Neely, E Connor, JR AF Bartzokis, George Lu, Po H. Tishler, Todd A. Peters, Douglas G. Kosenko, Anastasia Barrall, Katherine A. Finn, J. Paul Villablanca, Pablo Laub, Gerhard Altshuler, Lori L. Geschwind, Daniel H. Mintz, Jim Neely, Elizabeth Connor, James R. TI Prevalent Iron Metabolism Gene Variants Associated with Increased Brain Ferritin Iron in Healthy Older Men SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alpha synuclein; amyloid; basal ganglia; chelation; dementia; diet; free radicals; gene; gray matter; iron; Lewy body; metal; myelin; oligodendrocytes; prevention; risk; tau; treatment ID AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; HEMOCHROMATOSIS GENE; HEREDITARY HEMOCHROMATOSIS; COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; BASAL GANGLIA; HFE MUTATIONS; MR EVALUATION AB Prevalent gene variants involved in iron metabolism [hemochromatosis (HFE) H63D and transferrin C2 (TfC2)] have been associated with higher risk and earlier age at onset of Alzheimer's disease (AD), especially in men. Brain iron increases with age, is higher in men, and is abnormally elevated in several neurodegenerative diseases, including AD and Parkinson's disease, where it has been reported to contribute to younger age at onset in men. The effects of the common genetic variants (HFE H63D and/or TfC2) on brain iron were studied across eight brain regions (caudate, putamen, globus pallidus, thalamus, hippocampus, white matter of frontal lobe, genu, and splenium of corpus callosum) in 66 healthy adults (35 men, 31 women) aged 55 to 76. The iron content of ferritin molecules ( ferritin iron) in the brain was measured with MRI utilizing the Field Dependent Relaxation Rate Increase (FDRI) method. 47% of the sample carried neither genetic variant (IRON-) and 53% carried one and/or the other (IRON+). IRON+ men had significantly higher FDRI compared to IRON- men (p = 0.013). This genotype effect was not observed in women who, as expected, had lower FDRI than men. This is the first published evidence that these highly prevalent genetic variants in iron metabolism genes can influence brain iron levels in men. Clinical phenomena such as differential gender-associated risks of developing neurodegenerative diseases and age at onset may be associated with interactions between iron genes and brain iron accumulation. Clarifying mechanisms of brain iron accumulation may help identify novel interventions for age-related neurodegenerative diseases. C1 [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Barrall, Katherine A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Barrall, Katherine A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, Dept Neurol, Div Brain Mapping, Lab Neuroimaging, Los Angeles, CA 90024 USA. [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Altshuler, Lori L.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Lu, Po H.; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Finn, J. Paul; Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Laub, Gerhard] Siemens Med Solut, Los Angeles, CA USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Neely, Elizabeth; Connor, James R.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA. RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIH [MH 0266029, AG027342, MH51928]; Department of Veterans Affairs; RCS Alzheimer's Foundation; George M Leader Family FX This work was supported in part by NIH grants (MH 0266029; AG027342; MH51928), the Department of Veterans Affairs, the RCS Alzheimer's Foundation, and the George M Leader Family. NR 67 TC 32 Z9 32 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 1 BP 333 EP 341 DI 10.3233/JAD-2010-1368 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 582TS UT WOS:000276622600031 PM 20164577 ER PT J AU Faux, NG Ritchie, CW Gunn, A Rembach, A Tsatsanis, A Bedo, J Harrison, J Lannfelt, L Blennow, K Zetterberg, H Ingelsson, M Masters, CL Tanzi, RE Cummings, JL Herd, CM Bush, AI AF Faux, Noel G. Ritchie, Craig W. Gunn, Adam Rembach, Alan Tsatsanis, Andrew Bedo, Justin Harrison, John Lannfelt, Lars Blennow, Kaj Zetterberg, Henrik Ingelsson, Martin Masters, Colin L. Tanzi, Rudolph E. Cummings, Jeffrey L. Herd, Caroline M. Bush, Ashley I. TI PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; clinical trials Randomized controlled; cognition; PBT2 ID PLACEBO-CONTROLLED TRIAL; TARGETING A-BETA; CLINICAL-TRIALS; DOUBLE-BLIND; CERULOPLASMIN; HYPOTHESIS; SERUM AB PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD). A recent Phase IIa double-blind, randomized, placebo-controlled trial found that the 250 mg dose of PBT2 was well-tolerated, significantly lowered cerebrospinal fluid (CSF) levels of amyloid-beta(42), and significantly improved executive function on a Neuro-psychological Test Battery (NTB) within 12 weeks of treatment in patients with AD. In the post-hoc analysis reported here, the cognitive, blood marker, and CSF neurochemistry outcomes from the trial were subjected to further analysis. Ranking the responses to treatment after 12 weeks with placebo, PBT2 50 mg, and PBT2 250 mg revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group. Receiver-operator characteristic analyses revealed that the probability of an improver at any level coming from the PBT2 250 mg group was significantly greater, compared to placebo, for Composite z-scores (Area Under the Curve [AUC] = 0.76, p = 0.0007), Executive Factor z-scores (AUC = 0.93, p = 1.3 x 10(-9)), and near-significant for the ADAS-cog (AUC = 0.72, p = 0.056). There were no correlations between changes in CSF amyloid-beta or tau species and cognitive changes. These findings further encourage larger-scale testing of PBT2 for AD. C1 [Faux, Noel G.; Gunn, Adam; Rembach, Alan; Tsatsanis, Andrew; Masters, Colin L.; Bush, Ashley I.] Univ Melbourne, Mental Hlth Res Inst, Parkville, Vic 3052, Australia. [Ritchie, Craig W.] Univ London Imperial Coll Sci Technol & Med, Dept Psychol Med, London, England. [Rembach, Alan] CSIRO Parkville, Parkville, Vic, Australia. [Lannfelt, Lars; Ingelsson, Martin] Univ Uppsala Hosp, Dept Publ Hlth Geriatr, Uppsala, Sweden. [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden. [Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Boston, MA 02114 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, Mary S Easton Ctr Alzheimers Dis Res, Los Angeles, CA USA. [Herd, Caroline M.] Prana Biotechnol Ltd, Parkville, Vic, Australia. [Bush, Ashley I.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia. RP Bush, AI (reprint author), Univ Melbourne, Mental Hlth Res Inst, 155 Oak St, Parkville, Vic 3052, Australia. EM a.bush@mhri.edu.au RI Faux, Noel/C-4423-2011; Gunn, Adam/D-5437-2012; Bush, Ashley/A-1186-2007 OI Faux, Noel/0000-0003-4594-8818; Gunn, Adam/0000-0002-8181-4975; Bush, Ashley/0000-0001-8259-9069 FU Prana Biotechnology Ltd FX This study was sponsored by Prana Biotechnology Ltd. NR 19 TC 181 Z9 186 U1 1 U2 32 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 2 BP 509 EP 516 DI 10.3233/JAD-2010-1390 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 620XY UT WOS:000279537700016 PM 20164561 ER PT J AU Carlsson, CM AF Carlsson, Cynthia M. TI Type 2 Diabetes Mellitus, Dyslipidemia, and Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; biological markers; cognition; diabetes mellitus; dyslipidemia; prevention ID AMYLOID PRECURSOR PROTEIN; VASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; MILD COGNITIVE IMPAIRMENT; TOTAL CHOLESTEROL LEVEL; POPULATION-BASED COHORT; GLYCATION END-PRODUCTS; METABOLIC SYNDROME; LATE-LIFE; ENDOTHELIAL DYSFUNCTION AB The prevalence of Alzheimer's disease (AD) is increasing rapidly, heightening the importance of finding effective preventive therapies for this devastating disease. Midlife vascular risk factors, including type 2 diabetes mellitus (T2DM), have been associated with increased risk of AD decades later and may serve as targets for AD prevention. Studies to date suggest that T2DM and hyperinsulinemia increase risk for AD, possibly through their effects on amyloid-beta metabolism and cerebrovascular dysfunction - two early findings in preclinical AD pathology. This paper reviews the evidence supporting a relationship between T2DM, hyperinsulinemia, and diabetic dyslipidemia on the development of AD, discusses DM treatment trials and their preliminary results on cognitive function, and proposes some strategies for optimizing future AD prevention trial design. C1 [Carlsson, Cynthia M.] Univ Wisconsin, Sect Geriatr & Gerontol, Sch Med & Publ Hlth, Madison VA GRECC D4211,Dept Med, Madison, WI 53705 USA. [Carlsson, Cynthia M.] William S Middleton Mem Vet Adm Med Ctr, Wisconsin Alzheimers Dis Res Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Carlsson, CM (reprint author), Univ Wisconsin, Sect Geriatr & Gerontol, Sch Med & Publ Hlth, Madison VA GRECC D4211,Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. EM cmc@medicine.wisc.edu FU National Institute on Aging [K23 AG026752] FX Dr. Carlsson was supported in part through National Institute on Aging grant K23 AG026752. This is Madison VA GRECC manuscript number # 2010-03. NR 108 TC 41 Z9 43 U1 0 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 3 BP 711 EP 722 DI 10.3233/JAD-2010-100012 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 620YH UT WOS:000279538600004 PM 20413858 ER PT J AU Middleton, LE Yaffe, K AF Middleton, Laura E. Yaffe, Kristine TI Targets for the Prevention of Dementia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Cognitive activity; dementia; diet; physical activity; prevention; social engagement; vascular risk ID MILD COGNITIVE IMPAIRMENT; INCIDENT ALZHEIMER-DISEASE; PLACEBO-CONTROLLED TRIAL; MIDLIFE BLOOD-PRESSURE; N-3 FATTY-ACIDS; PHYSICAL-ACTIVITY; METABOLIC SYNDROME; DIABETES-MELLITUS; OLDER-ADULTS; MEDITERRANEAN DIET AB The prevalence of dementia is expected to increase dramatically over the upcoming decades due to the aging population. Since treatment is still short of a cure, preventative strategies are of the utmost importance. Stimulating activity (cognitive, physical, and social), vascular risk factors, and diet may be important in preventative strategies. Dementia risk may be modified by participation in stimulating activities. One study suggested that the cognitive, physical, and social components of activity were of equal importance to cognitive outcomes. However, while exercise interventions appear to benefit global cognition, the benefits from cognitive training appear to be domain specific. People with vascular risk factors (hypertension, diabetes, dyslipidemia, and obesity) appear to be at higher risk for dementia than those without in observational and clinical trials. Controlled trials suggest that vascular risk management via some pharmaceutical interventions may benefit cognition, though results are inconsistent. Finally, people who adhere to a Mediterranean diet or who have high intake of antioxidants and omega-3 fatty acids have reduced likelihood of dementia in observational studies. However, supplementation in controlled trials has not generally proved successful at improving cognitive outcomes. A single supplement may be insufficient to prevent dementia; it may be that the overall diet is more important. Future large randomized controlled studies should examine whether interventions can reduce the risk of dementia and whether combining cognitive, physical, and social activity, vascular risk reduction, and dietary interventions might have additive or multiplicative effects. C1 [Middleton, Laura E.] Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Middleton, LE (reprint author), 2075 BayviewAve, Toronto, ON M4N 3M5, Canada. EM Middleton_1@hotmail.com RI Middleton, Laura/C-6024-2009 OI Middleton, Laura/0000-0001-8624-3123 FU Canadian Institute of Health Research (CIHR); NIA [AG031155] FX Dr. Middleton is supported by a Canadian Institute of Health Research (CIHR) fellowship. Dr. Yaffe is supported in part by NIA grant AG031155. NR 122 TC 39 Z9 39 U1 3 U2 36 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 3 BP 915 EP 924 DI 10.3233/JAD-2010-091657 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 620YH UT WOS:000279538600023 PM 20413867 ER PT J AU Hernandez, S McClendon, MJ Zhou, XHA Sachs, M Lerner, AJ AF Hernandez, Santiago McClendon, McKee J. Zhou, Xiao-Hua Andrew Sachs, Michael Lerner, Alan J. TI Pharmacological Treatment of Alzheimer's Disease: Effect of Race and Demographic Variables SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Acetylcholinesterase inhibitor; Alzheimer's disease; disparity; ethnicity; memantine; race ID PRESCRIPTION DRUG-USE; 600,000 OLDER-PEOPLE; RACIAL DISPARITIES; ETHNIC DISPARITIES; DEMENTIA DRUGS; POPULATION; SCHIZOPHRENIA; MEDICATIONS; SERVICES; WHITES AB Existing research shows differences in medication use for Alzheimer's disease (AD) based on demographics such as race, ethnicity, and geographical location. To determine individual and community characteristics associated with differences in acetylcholinesterase inhibitor (AChEI) and memantine use in AD, 3,049 AD subjects were drawn from 30 centers and evaluated using the Uniform data set (UDS). Cases were evaluated at the individual level within the context of 31 communities (one center encompassed two separate geographical regions). Multivariate analysis was used to determine the significance of individual variables on medication use. Compared to non-Hispanic Whites, Blacks were less likely to use AChEI and memantine with odds ratios (OR) of 0.59 (95% CI 0.46-0.76) and 0.43 (95% CI 0.32-0.57), respectively. Compared to non-Hispanic Whites, non-Black Hispanics were less likely to use memantine (OR = 0.69 (95% CI 0.49-0.98)). No association was found between the proportion of Blacks or non-Black Hispanics versus non-Hispanic Whites at an Alzheimer Disease Center and individual use of AChEI or memantine. Other significant variables include gender, age, marital status, dementia severity, source of referral, AChEI use, and education. Education and age somewhat mitigated disparity. Significant racial and ethnic differences in AChEI and memantine use exist at the individual level regardless of the racial and ethnic composition of the individual's community. Research and initiatives at the societal level may be an important consideration toward addressing these differences. C1 [Hernandez, Santiago] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [McClendon, McKee J.; Lerner, Alan J.] Case Western Reserve Univ, Univ Memory & Cognit Ctr, Cleveland, OH 44106 USA. [Zhou, Xiao-Hua Andrew] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Sch Publ Hlth & Community Med,Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua Andrew; Sachs, Michael] Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, US Dept Vet Affairs, Seattle, WA USA. [Lerner, Alan J.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA. [Lerner, Alan J.] Univ Hosp, Case Med Ctr, Cleveland, OH USA. RP Lerner, AJ (reprint author), Memory & Cognit Ctr, 3619 Pk E Dr 211, Beachwood, OH 44122 USA. EM alan.lerner@case.edu FU NIA [P50 AG08012] FX The authors wish to acknowledge Nathaniel Mercaldo, MS and the staff of the National Alzheimer's Coordinating Center (U01 AG016976) for assistance in providing access to the database and preparation of datasets. This work was supported in part by NIA grant P50 AG08012. NR 27 TC 9 Z9 9 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 2 BP 665 EP 672 DI 10.3233/JAD-2010-1269 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 582RL UT WOS:000276616000024 PM 20110610 ER PT J AU DeMichele-Sweet, MA Sweet, RA AF DeMichele-Sweet, Mary Ann Sweet, Robert A. TI Genetics of Psychosis in Alzheimer's Disease: A Review SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE APOE; association analysis; COMT; dopamine; heritability; linkage analysis; NRG1; serotonin ID SEROTONIN TRANSPORTER GENE; APOLIPOPROTEIN-E GENOTYPE; O-METHYLTRANSFERASE GENE; CARDIO-FACIAL SYNDROME; CEREBRAL AMYLOID ANGIOPATHY; INCREASED FAMILIAL RISK; D3 RECEPTOR GENE; LATE-ONSET; PSYCHOLOGICAL SYMPTOMS; NEUROPSYCHIATRIC SYMPTOMS AB In and of itself, late-onset Alzheimer's disease (AD) can be a devastating illness. However, a sub-group of AD patients develop psychosis as the disease progresses. These patients have an added burden of greater cognitive impairment, higher rates of institutionalization, and higher mortality than AD patients without psychosis. While the etiopathogenesis of psychosis in AD (AD+P) is not known, mounting evidence accrued over the past ten years indicates that AD+P represents a distinct phenotype with a genetic basis. Elucidating the genetic mechanism of AD+P is crucial if better pharmaceutical treatments are to be developed for these patients. The goal of this review is to summarize what is currently known regarding the genetic basis of psychosis in AD. Specific attention is given to familial aggregation and heritability, linkage to chromosomal loci, and associations of candidate genes such as APOE and the monoamine neurotransmitter system. C1 [DeMichele-Sweet, Mary Ann; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU USPHS [AG027224, AG05133] FX This work was supported by USPHS grant AG027224 and AG05133. NR 120 TC 29 Z9 29 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 3 BP 761 EP 780 DI 10.3233/JAD-2010-1274 PG 20 WC Neurosciences SC Neurosciences & Neurology GA 582RU UT WOS:000276617100001 PM 20157235 ER PT J AU Canu, E McLaren, DG Fitzgerald, ME Bendlin, BB Zoccatelli, G Alessandrini, F Pizzini, FB Ricciardi, GK Beltramello, A Johnson, SC Frisoni, GB AF Canu, Elisa McLaren, Donald G. Fitzgerald, Michele E. Bendlin, Barbara B. Zoccatelli, Giada Alessandrini, Franco Pizzini, Francesca B. Ricciardi, Giuseppe K. Beltramello, Alberto Johnson, Sterling C. Frisoni, Giovanni B. TI Microstructural Diffusion Changes are Independent of Macrostructural Volume Loss in Moderate to Severe Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; diffusion weighted imaging; fractional anisotropy; mean diffusivity; microstructure ID MILD COGNITIVE IMPAIRMENT; WHITE-MATTER CHANGES; MOTOR CORTEX INVOLVEMENT; AGE-RELATED-CHANGES; IN-VIVO; CORPUS-CALLOSUM; HUMAN BRAIN; NEURODEGENERATIVE DISORDERS; AMYLOID DEPOSITS; TRACT INTEGRITY AB Although it is established that Alzheimer's disease (AD) leads to cerebral macrostructural atrophy, microstructural diffusion changes have also been observed, but it is not yet known whether these changes offer unique information about the disease pathology. Thus, a multi-modal imaging study was conducted to determine the independent contribution of each modality in moderate to severe AD. Seventeen patients with moderate-severe AD and 13 healthy volunteers underwent diffusion-weighted and T1-weighted MR scanning. Images were processed to obtain measures of macrostructural atrophy (gray and white matter volumes) and microstructural damage (fractional anisotropy and mean diffusivity). Microstructural diffusion changes independent of macrostructural loss were investigated using an ANCOVA where macrostructural maps were used as voxel-wise covariates. The reverse ANCOVA model was also assessed, where macrostructural loss was the dependent variable and microstructural diffusion tensor imaging maps were the imaging covariates. Diffusion differences between patients and controls were observed after controlling for volumetric differences in medial temporal, retrosplenial regions, anterior commissure, corona radiata, internal capsule, thalamus, corticopontine tracts, cerebral peduncle, striatum, and precentral gyrus. Independent volumetric differences were observed in the entorhinal cortex, inferior temporal lobe, posterior cingulate cortex, splenium and cerebellum. While it is well known that AD is associated with pronounced volumetric change, this study suggests that measures of microstructure provide unique information not obtainable with volumetric mapping in regions known to be pivotal in AD and in those thought to be spared. As such this work provides great understanding of the topography of pathological changes in AD that can be captured with imaging. C1 [Canu, Elisa; Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, LENITEM, Brescia, Italy. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53706 USA. [Zoccatelli, Giada; Alessandrini, Franco; Pizzini, Francesca B.; Ricciardi, Giuseppe K.; Beltramello, Alberto] Osped Maggiore, Serv Neuroradiol, Verona, Italy. [Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, Psychogeriatr Ward, Brescia, Italy. [Frisoni, Giovanni B.] AFaR, Rome, Italy. RP Frisoni, GB (reprint author), IRCCS San Giovanni di Dio FBF, LENITEM, Via Pilastroni 4, I-25125 Brescia, Italy. EM gfrisoni@fatebenefratelli.it RI McLaren, Donald/G-9906-2011; Frisoni, Giovanni B/K-1360-2016; Pizzini, Francesca Bendetta/O-5291-2016; Canu, Elisa/K-1423-2016; OI Frisoni, Giovanni B/0000-0002-6419-1753; Pizzini, Francesca Bendetta/0000-0002-6285-0989; Ricciardi, Giuseppe Kenneth/0000-0001-8536-5794; Canu, Elisa/0000-0001-5804-3378; Bendlin, Barbara/0000-0002-0580-9875 FU Italian Ministry of Health [125/2004]; Lundbeck Italia SpA; National Institutes of Health [AG021155, AG000213] FX This work has been supported by research grant 125/2004 of the Italian Ministry of Health, Ricerca Finalizzata "Malattie neurodegenerative legate all'invecchiamento: dalla patogenesi alle prospettive terapeutiche per un progetto traslazionale" and by Lundbeck Italia SpA. This study was also supported by National Institutes of Health grants AG021155 and AG000213, and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital. NR 69 TC 46 Z9 48 U1 0 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 3 BP 963 EP 976 DI 10.3233/JAD-2010-1295 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 582RU UT WOS:000276617100018 PM 20157252 ER PT J AU VanFossen, BT Watson, GS Baker, LD Rhoads, KW Cholerton, BA Reger, MA Plymate, SR Schellenberg, G Craft, S AF VanFossen, Brian T. Watson, G. Stennis Baker, Laura D. Rhoads, Kristoffer W. Cholerton, Brenna A. Reger, Mark A. Plymate, Stephen R. Schellenberg, Gerald Craft, Suzanne TI Statin Users Without an APOE-epsilon 4 Allele have Increased Insulin Resistance SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; dementia; diabetes; insulin; statin ID APOLIPOPROTEIN-E GENOTYPE; INCIDENT ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; RISK; DEMENTIA; POPULATION; PATHOLOGY; GENDER; HEALTH; MODEL AB The present study examined the relationships among statin use, APOE genotype, and insulin resistance as measured by the homeostasis model assessment of insulin resistance (HOMA-IR) in healthy older adults. APOE epsilon 4- (i.e., not having an epsilon 4 allele) statin users had higher HOMA-IR values compared with epsilon 4+/statin users (p = 0.0169), and with non-users who were epsilon 4( p = 0.0003) or epsilon 4+ (p = 0.0006). These results suggest that statin use may modulate insulin levels for individuals without an APOE epsilon 4 allele. C1 [VanFossen, Brian T.; Watson, G. Stennis; Baker, Laura D.; Rhoads, Kristoffer W.; Cholerton, Brenna A.; Reger, Mark A.; Plymate, Stephen R.; Schellenberg, Gerald; Craft, Suzanne] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [VanFossen, Brian T.; Watson, G. Stennis; Baker, Laura D.; Rhoads, Kristoffer W.; Cholerton, Brenna A.; Reger, Mark A.; Schellenberg, Gerald; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA USA. RP Watson, GS (reprint author), VA Puget Sound Hlth Care Syst, GRECC, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM gswatson@u.washington.edu FU Department of Veterans Affairs, NIH/NIA [T32 AG000258, R37AG010880, K01AG23640] FX This paper was supported by the Department of Veterans Affairs, NIH/NIA grants T32 AG000258 (BVF), R37AG010880 (SC), and K01AG23640 (GSW). NR 27 TC 4 Z9 4 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 4 BP 1149 EP 1153 DI 10.3233/JAD-2009-1319 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 582SS UT WOS:000276619700005 PM 20308781 ER PT J AU Nguyen, HM Graber, CJ AF Nguyen, Hien M. Graber, Christopher J. TI Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Review DE MRSA; combination treatment; bactericidal agents; community-acquired infections ID BLOOD-STREAM INFECTIONS; VITRO PHARMACODYNAMIC MODEL; PANTON-VALENTINE LEUKOCIDIN; SKIN-STRUCTURE INFECTIONS; SIMULATED ENDOCARDIAL VEGETATIONS; VANCOMYCIN PLUS RIFAMPIN; FOREIGN-BODY INFECTION; SMALL-COLONY VARIANT; IN-VITRO; QUINUPRISTIN-DALFOPRISTIN AB Invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA), particularly those involving persistent bacteraemia, necrotizing pneumonia, osteomyelitis and other deep-seated sites of infections, are associated with high mortality and are often difficult to treat. The response to treatment of severe MRSA infection with currently available antibiotics active against MRSA is often unsatisfactory, leading some physicians to resort to combination antibiotic therapy. Now, with the emergence of community-associated MRSA (CA-MRSA) clones that display enhanced virulence potentially related to up-regulated toxin production, the use of adjuvant protein synthesis-inhibiting antibiotics to reduce toxin production also has been advocated by some experts. In this review, we discuss the limitations of antibiotics currently available for the treatment of serious invasive MRSA infections and review the existing literature that examines the potential role of combination therapy in these infections. C1 [Nguyen, Hien M.; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. EM cgraber@ucla.edu FU Merck; Ortho-McNeil-Janssen FX H. M. N. has no conflict of interest to report. C. J. G. has received research support from Merck and an educational grant from Ortho-McNeil-Janssen. NR 161 TC 40 Z9 42 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD JAN PY 2010 VL 65 IS 1 BP 24 EP 36 DI 10.1093/jac/dkp377 PG 13 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 534XT UT WOS:000272931500005 PM 19861337 ER PT J AU Berbeco, RI Nishioka, S Shirato, H AF Berbeco, Ross I. Nishioka, Seiko Shirato, Hiroki TI Evaluation of the need for simultaneous orthogonal gated setup imaging SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE respiratory gating; organ motion; IGRT ID TUMOR-TRACKING; LUNG-TUMORS; RADIOTHERAPY; MOTION; SYSTEM; MARKERS AB Image-guided patient setup for respiratory-gated radiotherapy often relies on a pair of respiratory-gated orthogonal radiographs, acquired one after the other. This study quantifies the error due to changes in the internal/external correlation which may affect asynchronous (non-simultaneous) imaging. The dataset from eight patients includes internal and external coordinates acquired at 30Hz during multi-fraction SBRT treatments using the Mitsubishi RTRT system coupled with an external surrogate gating device. We performed a computational simulation of the position of an implanted fiducial marker in an asynchronous orthogonal image set. A comparison is made to the reference position, the actual 3D fiducial location at the initial time point, as would be obtainable by simultaneous orthogonal setup imaging at that time point. The time interval between the two simulated radiographic acquisitions was set to a minimum of 30, 60 or 90 seconds, based on our clinical experience. The setup position is derived from a combination of both the initial (AP) and the final (LR) simulated 2D images in the following way: LR(setup) = LR(initial), SI(setup) = SI(initial) + (SI(final) = SI(initial))/2, AP(setup) = AP(final). The 3D error is then the magnitude of the vector from the initial (reference) position to the setup position. The calculation was done for every exhale phase in the data for which there was another one at least 30, 60 or 90 seconds later, at an amplitude within 0.5 mm from the first. A correlation between the time interval and the 3D error was also sought. The mean 3D error is found to be roughly equivalent for time intervals (t(interval)) of 30, 60 and 90 seconds between the orthogonal simulated images (0.8 mm, 0.8 mm, 0.6 mm, respectively). The 3D error is less than 1, 2 and 3 mm for 77%, 89% and 98% of the data points, respectively. The actual time between simulated images turned out to be very close to t(interval), with 90% of the second simulated image acquisitions being completed within 38, 68 and 95 seconds of the first simulated image for t(interval) of 30, 60 and 90 seconds, respectively. No correlation was found between the length of the time interval and the 3D error. When acquiring respiratory-gated radiographs for patient setup, only small errors should be expected if those images are not taken simultaneously. C1 [Berbeco, Ross I.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Berbeco, Ross I.] Harvard Univ, Sch Med, Boston, MA USA. [Nishioka, Seiko] NTT E Sapporo Hosp, Dept Radiat Oncol, Sapporo, Hokkaido, Japan. [Shirato, Hiroki] Hokkaido Univ, Dept Radiat Med, Grad Sch Med, Sapporo, Hokkaido, Japan. RP Berbeco, RI (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. EM rberbeco@partners.org RI Shirato, Hiroki/A-7068-2010 FU Varian Medical Systems, Inc. FX This project was funded, in part, by a grant from Varian Medical Systems, Inc. NR 18 TC 0 Z9 0 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2010 VL 11 IS 2 BP 158 EP 167 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 636KW UT WOS:000280734600012 ER PT J AU Court, L Urribarri, J Makrigiorgos, M AF Court, Laurence Urribarri, Jaime Makrigiorgos, Mike TI Carbon fiber couches and skin sparing SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Letter ID BEAM ATTENUATION C1 [Court, Laurence; Urribarri, Jaime; Makrigiorgos, Mike] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Faber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. RP Court, L (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Faber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. EM lcourt@lroc.harvard.edu NR 3 TC 2 Z9 2 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2010 VL 11 IS 2 BP 220 EP 221 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 636KW UT WOS:000280734600017 ER PT J AU Wolfsberger, LD Wagar, M Nitsch, P Bhagwat, MS Zygmanski, P AF Wolfsberger, Luciant D. Wagar, Matthew Nitsch, Paige Bhagwat, Mandar S. Zygmanski, Piotr TI Angular dose dependency of MatriXX TM and its calibration SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE MatriXX; angular dependence; calibration AB One of the applications of MatriXX (IBA Dosimetry) is experimental verification of dose for IMRT, VMAT, and tomotherapy. For cumulative plan verification, dose is delivered for all the treatment gantry angles to a stationary detector. Experimental calibration of MatriXX detector recommended by the manufacturer involves only AP calibration fields and does not address angular dependency of MatriXX. Angular dependency may introduce dose bias in cumulative plan verification if not corrected. For this reason, we characterized angular dependency of MatriXX and developed a method for its calibration. We found relatively large discrepancies in responses to posterior vs. anterior fields for four MatriXX (Evolution series) detectors (up to 11%), and relatively large variability of responses as a function of gantry angle in the gantry angle ranges of 91 degrees-110 degrees and 269 degrees-260 degrees. With our calibration method, the bias due to angular dependency is effectively removed in experimental verification of IMRT and VMAT plans. C1 [Wolfsberger, Luciant D.; Wagar, Matthew; Nitsch, Paige; Bhagwat, Mandar S.; Zygmanski, Piotr] Harvard Univ, Brigham & Womens Hosp, Div Med Phys & Biophys, Dana Farber Canc Inst,Dept Radiat Oncol,Sch Med, Boston, MA 02115 USA. RP Wolfsberger, LD (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Med Phys & Biophys, Dana Farber Canc Inst,Dept Radiat Oncol,Sch Med, 75 Francis St, Boston, MA 02115 USA. EM lwolfsberger@lroc.harvard.edu NR 5 TC 20 Z9 21 U1 0 U2 2 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2010 VL 11 IS 1 BP 241 EP 251 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 556DC UT WOS:000274567500022 ER PT J AU Akila, G Chandra, TS AF Akila, G. Chandra, T. S. TI Stimulation of biomethanation by Clostridium sp PXYL1 in coculture with a Methanosarcina strain PMET1 at psychrophilic temperatures SO JOURNAL OF APPLIED MICROBIOLOGY LA English DT Article DE acetoclastic; biogas; Clostridium; coculture; low-temperature; methanogen; stimulation; volatile fatty acids ID SP-NOV; SYNTROPHIC ASSOCIATION; BIOGAS PRODUCTION; FATTY-ACIDS; BACTERIUM; METHANOGENS; IMPROVEMENT AB Aim: Bioaugumentation of low temperature biogas production was attempted by addition of cold-adapted Clostridium and a methanogen. Methods and Results: A psychrotrophic xylanolytic acetogenic strain Clostridium sp. PXYL1 growing optimally at 20 degrees C and pH 5 center dot 3 and a Methanosarcina strain, PMET1, growing optimally on acetate and producing methane at 15 degrees C were isolated from a cattle manure digester. Anaerobic conversion of xylose at 15 degrees C with the coculture of the two strains was performed, and batch culture methane production characteristics indicated that methanogenesis occurred via acetate through 'acetoclastic' pathway. Stimulation studies were also undertaken to evaluate the effect of exogenous addition of the coculture on biogas yields at 15 degrees C. Addition of 3 ml of PXYL1 at the rate of 12 x 102 CFU ml-1 increased the biogas 1 center dot 7-fold (33 l per kg cowdung) when compared to control (19 center dot 3 l per kg cowdung) as well as increased the volatile fatty acid (VFA) levels to 3210 mg l-1 when compared to 1140 mg l-1 in controls. Exogenous of addition of 10 ml PMET1 inoculum at the rate of 6 center dot 8 +/- 102 CFU ml-1 in addition to PXYL1 served to further improve the biogas yields to 46 l kg-1 as well as significantly brought down the VFA levels to 1350 mg l-1. Conclusions: Our results suggest that the rate-limiting methanogenic step at low temperatures could be overcome and that biogas yields improved by manipulating the population of the acetoclastic methanogens. Significance and Impact of the Study: Stimulation of biomethanation at low temperature by coculture. C1 [Akila, G.; Chandra, T. S.] Indian Inst Technol Madras, Dept Chem, Biochem Lab, Madras, Tamil Nadu, India. RP Akila, G (reprint author), Forsyth Inst, Dept Mol Genet, 140 Fenway, Boston, MA 02115 USA. EM g_akila@hotmail.com NR 29 TC 3 Z9 4 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1364-5072 EI 1365-2672 J9 J APPL MICROBIOL JI J. Appl. Microbiol. PD JAN PY 2010 VL 108 IS 1 BP 204 EP 213 DI 10.1111/j.1365-2672.2009.04412.x PG 10 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 531IA UT WOS:000272656800022 PM 19566719 ER PT J AU Jibodh, SR Kandil, AO Malchau, H Estok, DM AF Jibodh, Stefan R. Kandil, Abdurrahman O. Malchau, Henrik Estok, Daniel M., II TI Do Commonly Reported Outcome Measures Reflect Patient Satisfaction After Revision Hip Arthroplasty? SO JOURNAL OF ARTHROPLASTY LA English DT Article DE revision hip arthroplasty; patient satisfaction; Harris hip score; anxiety; depression ID QUALITY-OF-LIFE; KNEE ARTHROPLASTY; REPLACEMENT; DEPRESSION; SURGERY; HEALTH; AGE AB The purpose of this study was to determine which commonly reported outcome measures best correlated with patient satisfaction after revision hip arthroplasty and to identify factors unrelated to hip status that may also play a role. From our institutional database, we identified 78 patients (SO hips) who underwent revision total hip arthroplasty and collected follow-up data. Patients with moderate or severe pain and those with limited walking ability reported significantly lower satisfaction scores. Harris hip score and patient-rated general health status were independently associated with patient satisfaction. Patient-rated anxiety and depression correlated inversely with satisfaction. Commonly reported outcome measures do reflect patient satisfaction after revision hip arthroplasty. However, satisfaction also appears to be influenced by psychologic factors. C1 [Jibodh, Stefan R.; Kandil, Abdurrahman O.; Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Estok, Daniel M., II] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. RP Jibodh, SR (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, 55 Fruit St,GRJI 126, Boston, MA 02114 USA. NR 30 TC 5 Z9 6 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 J9 J ARTHROPLASTY JI J. Arthroplast. PD JAN PY 2010 VL 25 IS 1 BP 41 EP 45 DI 10.1016/j.arth.2008.10.016 PG 5 WC Orthopedics SC Orthopedics GA 594ZQ UT WOS:000277580800009 PM 19056218 ER PT J AU Durell, T Adler, L Wilens, T Paczkowski, M Schuh, K AF Durell, Todd Adler, Lenard Wilens, Timothy Paczkowski, Martin Schuh, Kory TI Atomoxetine Treatment for ADHD Younger Adults Compared With Older Adults SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE atomoxetine; attention-deficit/hyperactivity disorder; ADHD; adult ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OUTCOMES AB Objective: Atomoxetine is a nonstimulant medication for treating child, adolescent, and adult ADHD. This meta-analysis compared the effects in younger and older adults. Method: A post hoc analysis was conducted using data from two double-blind, placebo-controlled clinical trials. Data from patients aged 18-25 years were compared with data from patients older than 25 years. Results: In younger adults (mean age = 21.7), atomoxetine produces greater improvement than placebo on the Conners' Adult ADHD Rating Scale's total ADHD symptom score (p = .041, effect size = .797) and the clinical global impressions severity (p = .006, effect size = 1.121). In older adults (mean age = 43.4 years), atomoxetine also produces significant benefit on the CAARS-Inv: SV (p < .001, effect size = .326) and CGI-ADHD-S (p < .001, effect size = .346). The study findings reveal response rates to be 56.4% and 47.8% for the younger and older adults, respectively (p = .188). Tolerability is similar although older adults reported more sexual side effects. Conclusion: Younger and older adults show similar improvements at endpoint. The effect size is higher in younger adults, but this is due primarily to greater variability of response in older patients. (J. of Att. Dis. 2010; 13(4) 401-406) C1 [Durell, Todd; Paczkowski, Martin; Schuh, Kory] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Adler, Lenard] NYU, Sch Med, New York, NY 10003 USA. [Wilens, Timothy] Massachusetts Gen Hosp, Pediat Clin, Subst Abuse Serv, Boston, MA 02114 USA. [Wilens, Timothy] Massachusetts Gen Hosp, Adult Psychopharmacol Clin, Subst Abuse Serv, Boston, MA 02114 USA. RP Durell, T (reprint author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. OI Adler, Len/0000-0002-9812-8234 NR 14 TC 13 Z9 13 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD JAN PY 2010 VL 13 IS 4 BP 401 EP 406 DI 10.1177/1087054709342203 PG 6 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA 583PO UT WOS:000276691000010 PM 19706876 ER PT J AU Makris, N Seidman, LJ Valera, EM Biederman, J Monuteaux, MC Kennedy, DN Caviness, VS Bush, G Crum, K Brown, AB Faraone, SV AF Makris, Nikos Seidman, Larry J. Valera, Eve M. Biederman, Joseph Monuteaux, Michael C. Kennedy, David N. Caviness, Verne S., Jr. Bush, George Crum, Katherine Brown, Ariel B. Faraone, Stephen V. TI Anterior Cingulate Volumetric Alterations in Treatment-Naive Adults With ADHD A Pilot Study SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE ADHD; treatment-naive ADHD; ACC; volumetry; morphometry; MRI ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; MOTOR CONTROL; CHILDREN; MRI; CORTEX; ABNORMALITIES; BRAIN; ADOLESCENTS; NETWORKS AB Objective: We sought to examine preliminary results of brain alterations in anterior cingulate cortex (ACC) in treatment-naive adults with ADHD. The ACC is a central brain node for the integration of cognitive control and allocation of attention, affect and drive. Thus its anatomical alteration may give rise to impulsivity, hyperactivity and inattention, which are cardinal behavioral manifestations of ADHD. Method: Segmentation and parcellation of the ACC was performed on controls (n = 22), treated (n = 13) and treatment-naive adults with ADHD (n = 13). Results: There was a 21% volume reduction in the left ACC of the treatment-naive group relative to the control group. Also, there was a 23% volume reduction in the right ACC of the treated group relative to the control group. Conclusion: These results raise the possibility that in ADHD there are volumetric deficits persistent into adulthood, that are independent of medical treatment. (J. of Att. Dis. 2010; 13(4) 407-413) C1 [Makris, Nikos] Massachusetts Gen Hosp, Ctr Morphometr Anal, Charlestown, MA 02129 USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [Makris, Nikos; Brown, Ariel B.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA. [Biederman, Joseph; Monuteaux, Michael C.] Massachusetts Gen Hosp, ADHD, Charlestown, MA 02129 USA. [Biederman, Joseph; Monuteaux, Michael C.] Massachusetts Gen Hosp, Clin & Res Programs Pediat Psychopharmacol, Charlestown, MA 02129 USA. [Brown, Ariel B.] Massachusetts Gen Hosp, Pediat Psychopharmacol Clin, Charlestown, MA 02129 USA. [Brown, Ariel B.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Makris, N (reprint author), Massachusetts Gen Hosp, Ctr Morphometr Anal, Bldg 149,13th St, Charlestown, MA 02129 USA. EM nikos@cma.mgh.harvard.edu RI Kennedy, David/H-3627-2012; OI Faraone, Stephen/0000-0002-9217-3982 FU NIMH [MH 62152]; National Association for Research in Schizophrenia and Depression (NARSAD); National Institutes of Health National Center for Complementary and Alternative Medicine NCAM; National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award; Janssen Pharmaceuticals; Johnson and Johnson Center for the Study of Psychopathology; Fairway Trust; National Research Service Award [NIMH F32 MH065040-01A1]; Harvard Medical School Department of Psychiatry; Clinical Research Training Program Fellowship in Biological and Social Psychiatry [MH-16259]; National Center for Research Resources [P41RR14075]; March of Dimes Foundation; Mental Illness and Neuroscience Discovery (MIND) Institute FX This research was primarily supported by a grant from the NIMH MH 62152 (LJS). Preparation of this article was also supported in part by grants from: The National Association for Research in Schizophrenia and Depression (NARSAD) and the National Institutes of Health National Center for Complementary and Alternative Medicine NCAM (NM); the National Alliance for Research on Schizophrenia and Depression Distinguished Investigator Award (JB), Janssen Pharmaceuticals and the Johnson and Johnson Center for the Study of Psychopathology (JB); the Fairway Trust (DK); National Research Service Award (NIMH F32 MH065040-01A1), Peter Livingston Fellowship through the Harvard Medical School Department of Psychiatry, and the Clinical Research Training Program Fellowship in Biological and Social Psychiatry MH-16259 (EMV); The National Center for Research Resources (P41RR14075); the March of Dimes Foundation (LJS), and the Mental Illness and Neuroscience Discovery (MIND) Institute (LJS). NR 28 TC 24 Z9 24 U1 1 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD JAN PY 2010 VL 13 IS 4 BP 407 EP 413 DI 10.1177/1087054709351671 PG 7 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA 583PO UT WOS:000276691000011 PM 20008822 ER PT J AU Eisen, SV Seal, P Glickman, ME Cortes, DE Gerena-Melia, M Aguilar-Gaxiola, S Miguel, VEFS Soto-Espinosa, J Magana, C Canino, G AF Eisen, Susan V. Seal, Pradipta Glickman, Mark E. Cortes, Dharma E. Gerena-Melia, Mariana Aguilar-Gaxiola, Sergio Miguel, Vivian E. Febo San Soto-Espinosa, Jesus Magana, Cristina Canino, Glorisa TI Psychometric Properties of the Spanish BASIS-24A (c) Mental Health Survey SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID COMORBIDITY SURVEY REPLICATION; QUALITY-OF-LIFE; CULTURAL-ADAPTATION; INTERVIEW SCHEDULE; MEXICAN-AMERICANS; RELIABILITY; CARE; TRANSLATION; SERVICES; VALIDITY AB To assess mental health status among Latinos, culturally and linguistically appropriate instruments are needed. The purpose of this study was to assess psychometric properties and sensitivity of the Spanish revised Behavior and Symptom Identification Scale (BASIS-24A (c)), a self-report mental health assessment instrument first developed and validated in English. The Spanish translation was field tested among Spanish-speaking recipients of inpatient (N = 283) or outpatient (N = 311) mental health services in Massachusetts, Puerto Rico, and California. BASIS-24A (c) was completed within 72 h of admission and up to 48 h before discharge (for inpatients) or at intake and 30-60 days later for outpatients. Confirmatory factor analysis indicated adequate fit for the model obtained from the English instrument. Internal consistency reliability exceeded 0.70 for five of the six factors. Concurrent and discriminant validity were partially supported. Improvement following treatment was statistically significant, with small to moderate effect sizes. C1 [Eisen, Susan V.; Glickman, Mark E.] Boston Univ, Edith Nourse Rogers Mem Vet Hosp, Dept Hlth Policy & Management, Sch Publ Hlth,CHQOER, Bedford, MA 01730 USA. [Seal, Pradipta] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Cortes, Dharma E.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02139 USA. [Gerena-Melia, Mariana] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res COLMR 152M, Boston, MA 02130 USA. [Aguilar-Gaxiola, Sergio] Calif State Univ Sacramento, UC Davis Sch Med, CRHD, Sacramento, CA 95817 USA. [Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA. [Magana, Cristina] Calif State Univ Fresno, Coll Sci & Math, Fresno, CA 93740 USA. RP Eisen, SV (reprint author), Boston Univ, Edith Nourse Rogers Mem Vet Hosp, Dept Hlth Policy & Management, Sch Publ Hlth,CHQOER, 200 Springs Rd 152, Bedford, MA 01730 USA. EM seisen@bu.edu; pseal@math.bu.edu; mg@bu.edu; dharma_cortes@hms.harvard.edu; mariana.gerena-melia@va.gov; sergio.aguilar-gaxiola@ucdmc.ucdavis.edu; vfebo@upr.edu; jessesotoespinos@hotmail.com; cmagana@csufresno.edu; gcanino@rcm.upr.edu FU NIMH NIH HHS [R01 MH58240] NR 53 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JAN PY 2010 VL 37 IS 1 BP 124 EP 143 DI 10.1007/s11414-009-9170-6 PG 20 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 544VB UT WOS:000273686300009 PM 19330453 ER PT J AU Shi, FX Cheng, YF Wang, XL Edge, ASB AF Shi, Fuxin Cheng, Yen-fu Wang, Xiaohui L. Edge, Albert S. B. TI beta-Catenin Up-regulates Atoh1 Expression in Neural Progenitor Cells by Interaction with an Atoh1 3 ' Enhancer SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID DEVELOPING NERVOUS-SYSTEM; EAR HAIR-CELLS; INNER-EAR; WNT/BETA-CATENIN; STEM-CELLS; NEURONAL DIFFERENTIATION; INTESTINAL CRYPTS; COLON-CANCER; MATH1; MORPHOGENESIS AB Atoh1, a basic helix-loop-helix transcription factor, plays a critical role in the differentiation of several epithelial and neural cell types. We found that beta-catenin, the key mediator of the canonical Wnt pathway, increased expression of Atoh1 in mouse neuroblastoma cells and neural progenitor cells, and baseline Atoh1 expression was decreased by siRNA directed at beta-catenin. The up-regulation of Atoh1 was caused by an interaction of beta-catenin with the Atoh1 enhancer that could be demonstrated by chromatin immunoprecipitation. We found that two putative Tcf-Lef sites in the 3' enhancer of the Atoh1 gene displayed an affinity for beta-catenin and were critical for the activation of Atoh1 transcription because mutation of either site decreased expression of a reporter gene downstream of the enhancer. Tcf-Lef co-activators were found in the complex that bound to these sites in the DNA together with beta-catenin. Inhibition of Notch signaling, which has previously been shown to induce bHLH transcription factor expression, increased beta-catenin expression in progenitor cells of the nervous system. Because this could be a mechanism for up-regulation of Atoh1 after inhibition of Notch, we tested whether siRNA to beta-catenin prevented the increase in Atoh1 and found that beta-catenin expression was required for increased expression of Atoh1 after Notch inhibition. C1 [Shi, Fuxin; Cheng, Yen-fu; Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Shi, Fuxin; Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Cheng, Yen-fu; Edge, Albert S. B.] Harvard & MIT, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA. [Wang, Xiaohui L.] Boston Univ, Sch Med, Dept Internal Med, Boston, MA 02118 USA. RP Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM albert_edge@meei.harvard.edu FU National Institutes of Health [R01 DC007174, P30 DC05209]; NIDCD; Hamilton H. Kellogg and Mildred H. Kellogg Charitable Trust FX This work was supported, in whole or in part, by National Institutes of Health Grants R01 DC007174 and P30 DC05209 from the NIDCD and by the Hamilton H. Kellogg and Mildred H. Kellogg Charitable Trust. NR 36 TC 48 Z9 48 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 1 PY 2010 VL 285 IS 1 BP 392 EP 400 DI 10.1074/jbc.M109.059055 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 536UT UT WOS:000273070100041 PM 19864427 ER PT J AU Hughes, S Jenkins, V Dar, MJ Engelman, A Cherepanov, P AF Hughes, Siobhan Jenkins, Victoria Dar, Mohd Jamal Engelman, Alan Cherepanov, Peter TI Transcriptional Co-activator LEDGF Interacts with Cdc7-Activator of S-phase Kinase (ASK) and Stimulates Its Enzymatic Activity SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID HUMAN CDC7-RELATED KINASE; IN-VITRO PHOSPHORYLATION; CELL-CYCLE REGULATION; DNA HELICASE ACTIVITY; HIV-1 INTEGRASE; PROTEIN-KINASE; REGULATORY SUBUNIT; CHROMATIN-BINDING; CDC7 KINASE; SACCHAROMYCES-CEREVISIAE AB Lens epithelium-derived growth factor (LEDGF) is an important co-factor of human immunodeficiency virus DNA integration; however, its cellular functions are poorly characterized. We now report identification of the Cdc7-activator of S-phase kinase (ASK) heterodimer as a novel interactor of LEDGF. Both kinase subunits co-immunoprecipitated with endogenous LEDGF from human cell extracts. Truncation analyses identified the integrase-binding domain of LEDGF as essential and minimally sufficient for the interaction with Cdc7-ASK. Reciprocally, the interaction required autophosphorylation of the kinase and the presence of 50 C-terminal residues of ASK. The kinase phosphorylated LEDGF in vitro, with Ser-206 being the major target, and LEDGF phosphorylated at this residue could be detected during S phase of the cell cycle. LEDGF potently stimulated the enzymatic activity of Cdc7-ASK, increasing phosphorylation of MCM2 in vitro by more than 10-fold. This enzymatic stimulation as well as phosphorylation of LEDGF depended on the protein-protein interaction. Intriguingly, removing the C-terminal region of ASK, involved in the interaction with LEDGF, resulted in a hyperactive kinase. Our results indicate that the interaction with LEDGF relieves autoinhibition of Cdc7-ASK kinase, imposed by the C terminus of ASK. C1 [Hughes, Siobhan; Jenkins, Victoria; Cherepanov, Peter] Univ London Imperial Coll Sci Technol & Med, Div Med, London W2 1PG, England. [Dar, Mohd Jamal; Engelman, Alan] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Cherepanov, P (reprint author), Univ London Imperial Coll Sci Technol & Med, Div Med, St Marys Campus,Norfolk Pl, London W2 1PG, England. EM p.cherepanov@imperial.ac.uk RI Cherepanov, Peter/F-6859-2010 OI Cherepanov, Peter/0000-0002-0634-538X FU National Institutes of Health [AI039394]; United Kingdom Medical Research Council [G0600009] FX This work was supported, in whole or in part, by National Institutes of Health Grant AI039394 (to A. E.). This work was also supported by United Kingdom Medical Research Council Grant G0600009 (to P. C.). NR 78 TC 36 Z9 36 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 1 PY 2010 VL 285 IS 1 BP 541 EP 554 DI 10.1074/jbc.M109.036491 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 536UT UT WOS:000273070100056 PM 19864417 ER PT J AU Ge, L Sotiropoulos, F AF Ge, Liang Sotiropoulos, Fotis TI Direction and Magnitude of Blood Flow Shear Stresses on the Leaflets of Aortic Valves: Is There a Link With Valve Calcification? SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article ID ARTERIAL WALL SHEAR; ATHEROSCLEROSIS; ATHEROMA; PATTERNS; STENOSIS AB Aortic stenosis caused by valve calcification is a major cause of death around the world. Hemodynamic factors have been suggested to be major players in the development of valve calcification, yet a detailed knowledge of the blood flow dynamics as experienced by endothelial cells on valve surfaces is still lacking. In this study we carry out high-resolution numerical simulations of the blood flow through a polymeric trileaflet valve in order to elucidate the differential flow dynamics on the aortic and ventricular sides of the valve leaflets. Limiting streamlines and surface shear stress contours are used to probe and quantify the blood flows on its side. Complicated flow patterns were only observed on the aortic side of the valve near the region where focalized distribution of valve calcification is typically observed. [DOI: 10.1115/1.4000162] C1 [Ge, Liang] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Ge, Liang] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sotiropoulos, Fotis] Univ Minnesota, Dept Civil Engn, St Anthony Falls Lab, Minneapolis, MN 55414 USA. RP Ge, L (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RI Sotiropoulos, Fotis/C-2163-2012 FU NIH [R01-HL-07262]; Minnesota Supercomputing Institute FX We thank Ajit Yoganathan and the members of Cardiovascular Fluid Mechanics Laboratory (Georgia Tech) and Rami Haj-Ali (Georgia Tech) for kindly providing us with the valve geometry and kinematics used in this study. This study has been supported by NIH under Grant No. R01-HL-07262 and Minnesota Supercomputing Institute. NR 20 TC 20 Z9 20 U1 1 U2 6 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD JAN PY 2010 VL 132 IS 1 AR 014505 DI 10.1115/1.4000162 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 550CW UT WOS:000274106900015 PM 20524753 ER PT J AU Kim, SS Park, MS Cho, SW Kang, SW Ahn, KM Lee, JH Kim, BS AF Kim, Sang-Soo Park, Min Sun Cho, Seung-Woo Kang, Sun Woong Ahn, Kang-Min Lee, Jong-Ho Kim, Byung-Soo TI Enhanced bone formation by marrow-derived endothelial and osteogenic cell transplantation SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A LA English DT Article DE angiogenesis; bone marrow cells; bone regeneration; cell transplantation; endothelial cells; tissue engineering ID MESENCHYMAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; IN-VITRO; COMPOSITE SCAFFOLDS; STROMAL CELLS; HEART-VALVES; REGENERATION; VIVO; DIFFERENTIATION; OSTEOBLASTS AB Bone marrow-derived osteogenic cells can regenerate bone tissues in vivo. The aim of the present study is to determine whether the cotransplantation of bone marrow-derived endothelial-like cells (BMECs) enhances bone regeneration by bone marrow-derived osteogenic cell (BMOC) transplantation in osseous defects. Canine bone marrow cells were differentiated separately into BMECs and BMOCs. Using apatite-coated poly(lactide-co-glycolide)/hydroxyapatite composite scaffolds as cell delivery vehicles, BMOCs were transplanted with or without BMECs into critical-sized calvarial defects in immunodeficient mice. Histological analyses, microcomputed tomography, and soft X-ray were performed to assess mineralized bone formation at 8 weeks. Cotransplantation of BMECs and BMOCs resulted in greater bone formation than transplantation of BMOCs alone. There was a significant (p < 0.05) increase in bone formation area following cotransplantation (30.8% +/- 2.5%), compared with transplantation of BMOCs alone (15.3% +/- 1.9%). These results demonstrate that the cotransplantation of BMECs enhances bone regeneration mediated by BMOC transplantation in osseous defects. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res 92A: 246-253, 2010 C1 [Kim, Sang-Soo; Cho, Seung-Woo; Kim, Byung-Soo] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea. [Kim, Sang-Soo] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Kim, Sang-Soo] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Park, Min Sun; Kang, Sun Woong] Hanyang Univ, Dept Chem Engn, Seoul 133791, South Korea. [Ahn, Kang-Min] Univ Ulsan, Sch Med, Asan Med Ctr, Dept Oral & Maxillofacial Surg, Seoul 138736, South Korea. [Lee, Jong-Ho] Seoul Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Seoul 110744, South Korea. RP Kim, BS (reprint author), Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea. EM bskim@hanyang.ac.kr RI Kim, Byung-Soo/O-2352-2013; OI Ahn, Kang-Min/0000-0003-1215-5643 FU Ministry of Science and Technology, Republic of Korea [SC 3220] FX Contract grant sponsor: Ministry of Science and Technology, Republic of Korea; contract grant number: SC 3220 NR 32 TC 9 Z9 9 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1549-3296 J9 J BIOMED MATER RES A JI J. Biomed. Mater. Res. Part A PD JAN PY 2010 VL 92A IS 1 BP 246 EP 253 DI 10.1002/jbm.a.32360 PG 8 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 531BF UT WOS:000272637000027 PM 19180524 ER PT J AU Aguirre, AD Chen, Y Bryan, B Mashimo, H Huang, Q Connolly, JL Fujimoto, JG AF Aguirre, Aaron D. Chen, Yu Bryan, Bradley Mashimo, Hiroshi Huang, Qin Connolly, James L. Fujimoto, James G. TI Cellular resolution ex vivo imaging of gastrointestinal tissues with optical coherence microscopy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE imaging; microscopy; endoscopy ID SCANNING CONFOCAL MICROSCOPY; IN-VIVO; BARRETTS-ESOPHAGUS; SPECKLE REDUCTION; ULTRAHIGH-RESOLUTION; REFLECTANCE MICROSCOPY; HIGH-SPEED; GI TRACT; TOMOGRAPHY; HISTOLOGY AB Optical coherence microscopy (OCM) combines confocal microscopy and optical coherence tomography (OCT) to improve imaging depth and contrast, enabling cellular imaging in human tissues. We aim to investigate OCM for ex vivo imaging of upper and lower gastrointestinal tract tissues, to establish correlations between OCM imaging and histology, and to provide a baseline for future endoscopic studies. Co-registered OCM and OCT imaging were performed on fresh surgical specimens and endoscopic biopsy specimens, and images were correlated with histology. Imaging was performed at 1.06-mu m wavelength with <2-mu m transverse and <4-mu m axial resolution for OCM, and at 14-mu m transverse and <3-mu m axial resolution for OCT. Multiple sites on 75 tissue samples from 39 patients were imaged. OCM enabled cellular imaging of specimens from the upper and lower gastrointestinal tracts over a smaller field of view compared to OCT. Squamous cells and their nuclei, goblet cells in Barrett's esophagus, gastric pits and colonic crypts, and fine structures in adenocarcinomas were visualized. OCT provided complementary information through assessment of tissue architectural features over a larger field of view. OCM may provide a complementary imaging modality to standard OCT approaches for endoscopic microscopy. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3322704] C1 [Aguirre, Aaron D.; Chen, Yu; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Aguirre, Aaron D.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Aguirre, Aaron D.; Chen, Yu; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. [Bryan, Bradley; Connolly, James L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA. [Mashimo, Hiroshi; Huang, Qin] Harvard Univ, Sch Med, Boston, MA 02132 USA. [Mashimo, Hiroshi; Huang, Qin] VA Boston Healthcare Syst, Boston, MA 02132 USA. RP Fujimoto, JG (reprint author), MIT, Dept Elect Engn & Comp Sci, 50 Vassar St,Rm 36-361, Cambridge, MA 02139 USA. EM jgfuji@mit.edu FU National Institutes of Health [R01-CA75289-13, R01-EY11289-24, 5F31EB005978-03, R01-NS057476-02, R01HL095717-01]; Air Force Office of Scientific Research [FA9550-07-1-0101, FA9550-07- 1-0014]; National Science Foundation [BES-0522845]; Cancer Research and Prevention Foundation; VA Medical Center FX This work was supported by the National Institutes of Health R01-CA75289-13, R01-EY11289-24, 5F31EB005978-03, R01-NS057476-02, and R01HL095717-01; the Air Force Office of Scientific Research FA9550-07-1-0101 and FA9550-07- 1-0014; the National Science Foundation BES-0522845; the Cancer Research and Prevention Foundation; and the VA Medical Center. We thank Daniel Kopf, Saleem Desai, Marisa Figuereido, Marcos Pedrosa, Ashish Sharma, and Shu-Wei Huang for helpful scientific discussions and assistance. J.F. receives royalties for intellectual property licensed by MIT to LightLab Imaging and Carl Zeiss. NR 41 TC 23 Z9 23 U1 0 U2 8 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2010 VL 15 IS 1 AR 016025 DI 10.1117/1.3322704 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 586VY UT WOS:000276944200054 PM 20210470 ER PT J AU Boas, DA Dunn, AK AF Boas, David A. Dunn, Andrew K. TI Laser speckle contrast imaging in biomedical optics SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE laser speckle contrast; blood flow; biomedical imaging ID CEREBRAL-BLOOD-FLOW; RAT BARREL CORTEX; CORTICAL SPREADING DEPRESSION; FUNCTIONAL ACTIVATION; PERIINFARCT DEPOLARIZATIONS; SOMATOSENSORY CORTEX; LIGHT-SCATTERING; NERVE HEAD; 2-DIMENSIONAL MEASUREMENT; DOPPLER MEASUREMENTS AB First introduced in the 1980s, laser speckle contrast imaging is a powerful tool for full-field imaging of blood flow. Recently laser speckle contrast imaging has gained increased attention, in part due to its rapid adoption for blood flow studies in the brain. We review the underlying physics of speckle contrast imaging and discuss recent developments to improve the quantitative accuracy of blood flow measures. We also review applications of laser speckle contrast imaging in neuroscience, dermatology and ophthalmology. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3285504] C1 [Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anthinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Dunn, Andrew K.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. RP Boas, DA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anthinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA. EM dboas@nmr.mgh.harvard.edu RI Dunn, Andrew/I-9527-2014 FU National Institutes of Health (NIH) [P50-NS010828, P01-NS055104, R01-NS057476]; American Heart Association [0735136N]; National Science Foundation [CBET/0737731] FX The authors acknowledge Sean Kirkpatrick, Donald Duncan, and Shuai Yuan for insightful discussions that improved the quality of this manuscript, thank Bernard Choi for providing Fig. 4, and acknowledge support from the National Institutes of Health (NIH) Grants P50-NS010828, P01-NS055104, R01-NS057476, the American Heart Association (Grant No. 0735136N), and the National Science Foundation (Grant No. CBET/0737731). NR 74 TC 278 Z9 281 U1 9 U2 76 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2010 VL 15 IS 1 AR 011109 DI 10.1117/1.3285504 PG 12 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 586VY UT WOS:000276944200019 PM 20210435 ER PT J AU Calfon, MA Vinegoni, C Ntziachristos, V Jaffer, FA AF Calfon, Marcella A. Vinegoni, Claudio Ntziachristos, Vasilis Jaffer, Farouc A. TI Intravascular near-infrared fluorescence molecular imaging of atherosclerosis: toward coronary arterial visualization of biologically high-risk plaques SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE atherosclerosis; imaging; fluorescence; inflammation; catheter; intravascular; molecular imaging; optical imaging ID IN-VIVO; CARDIOVASCULAR-DISEASE; VULNERABLE PLAQUE; TOMOGRAPHY; INFLAMMATION; BREAST; SPECTROSCOPY; CATHETER; PROBES; MRI AB New imaging methods are urgently needed to identify high-risk atherosclerotic lesions prior to the onset of myocardial infarction, stroke, and ischemic limbs. Molecular imaging offers a new approach to visualize key biological features that characterize high-risk plaques associated with cardiovascular events. While substantial progress has been realized in clinical molecular imaging of plaques in larger arterial vessels (carotid, aorta, iliac), there remains a compelling, unmet need to develop molecular imaging strategies targeted to high-risk plaques in human coronary arteries. We present recent developments in intravascular near-IR fluorescence catheter-based strategies for in vivo detection of plaque inflammation in coronary-sized arteries. In particular, the biological, light transmission, imaging agent, and engineering principles that underlie a new intravascular near-IR fluorescence sensing method are discussed. Intravascular near-IR fluorescence catheters appear highly translatable to the cardiac catheterization laboratory, and thus may offer a new in vivo method to detect high-risk coronary plaques and to assess novel atherosclerosis biologics. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3280282] C1 [Calfon, Marcella A.; Jaffer, Farouc A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Calfon, Marcella A.; Jaffer, Farouc A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Vinegoni, Claudio] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Vinegoni, Claudio; Jaffer, Farouc A.] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02114 USA. [Ntziachristos, Vasilis] Helmholtz Ctr Munich, D-85764 Neuherberg, Germany. [Ntziachristos, Vasilis] Tech Univ Munich, Munich, Germany. RP Jaffer, FA (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St,Simches Bldg Rm 3206, Boston, MA 02114 USA. EM fjaffer@mgh.harvard.edu OI Jaffer, Farouc/0000-0001-7980-384X FU Howard Hughes Medical Institute; American Heart Association; Donald W. Reynolds Foundation; MGH William Schreyer Fellowship FX Support for this work was provided by the Howard Hughes Medical Institute Career Development Award (FAJ), the American Heart Association Scientist Development Grant (FAJ), the Donald W. Reynolds Foundation (FAJ), and the MGH William Schreyer Fellowship (MAC). NR 27 TC 23 Z9 24 U1 2 U2 16 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2010 VL 15 IS 1 AR 011107 DI 10.1117/1.3280282 PG 6 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 586VY UT WOS:000276944200017 PM 20210433 ER PT J AU Tanaka, A Tearney, GJ Bouma, BE AF Tanaka, Atsushi Tearney, Guillermo J. Bouma, Brett E. TI Challenges on the frontier of intracoronary imaging: atherosclerotic plaque macrophage measurement by optical coherence tomography SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE optical imaging; optical coherence tomography; macrophage; coronary imaging; vulnerable plaque; acute coronary syndrome ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY-SYNDROME; C-REACTIVE PROTEIN; SIROLIMUS-ELUTING STENTS; INTRAVASCULAR ULTRASOUND; VULNERABLE PLAQUE; LESION MORPHOLOGY; CARDIOVASCULAR-DISEASE; NEOINTIMAL COVERAGE; STRUCTURAL-ANALYSIS AB Cellularity of the fibrous caps of coronary atheromas, manifested by the infiltration of macrophages (average size, 20 to 30 mu m), is thought to weaken the structural integrity of the cap and predispose plaques to rupture. Therefore, an imaging technology capable of identifying macrophages within fibroatheroma caps in patients could provide valuable information for assessing plaque rupture risk. Recently, intravascular optical coherence tomography (OCT), a high-resolution coronary imaging modality, with an axial resolution of similar to 10 mu m, has been introduced into the clinical setting. OCT images of the microstructure of the coronary artery wall enable accurate plaque-type characterization, supported by histopathological comparison data. Because of its high resolution, OCT may also be used to identify macrophages in vivo. In this paper we review recent developments in OCT for measuring macrophages in atherosclerotic plaques. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3290810] C1 [Tearney, Guillermo J.; Bouma, Brett E.] Harvard Univ, Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol, Wellman Ctr Photomed,Dept Dermatol,Sch Med, Boston, MA 02138 USA. RP Tearney, GJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol, Wellman Ctr Photomed,Dept Dermatol,Sch Med, BAR 703,40 Blossom St, Boston, MA 02138 USA. EM gtearney@partners.org NR 69 TC 15 Z9 15 U1 0 U2 7 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2010 VL 15 IS 1 AR 011104 DI 10.1117/1.3290810 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 586VY UT WOS:000276944200014 PM 20210430 ER PT J AU van Soest, G Goderie, T Regar, E Koljenovic, S van Leenders, GLJH Gonzalo, N van Noorden, S Okamura, T Bouma, BE Tearney, GJ Oosterhuis, JW Serruys, PW van der Steen, AFW AF van Soest, Gijs Goderie, Thade Regar, Evelyn Koljenovic, Senada van Leenders, Geert L. J. H. Gonzalo, Nieves van Noorden, Sander Okamura, Takayuki Bouma, Brett E. Tearney, Guillermo J. Oosterhuis, J. Wolter Serruys, Patrick W. van der Steen, Anton F. W. TI Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE biomedical optics; attenuation; endoscopy; tissues; medicine; medical imaging ID CORONARY PLAQUE CHARACTERISTICS; INTRAVASCULAR ULTRASOUND; VULNERABLE PLAQUE; SPECKLE REDUCTION; SCATTERING MEDIA; IMAGES; CLASSIFICATION; ELASTOGRAPHY; MICROSCOPY; ANGIOSCOPY AB Optical coherence tomography (OCT) is rapidly becoming the method of choice for assessing arterial wall pathology in vivo. Atherosclerotic plaques can be diagnosed with high accuracy, including measurement of the thickness of fibrous caps, enabling an assessment of the risk of rupture. While the OCT image presents morphological information in highly resolved detail, it relies on interpretation of the images by trained readers for the identification of vessel wall components and tissue type. We present a framework to enable systematic and automatic classification of atherosclerotic plaque constituents, based on the optical attenuation coefficient mu(t) of the tissue. OCT images of 65 coronary artery segments in vitro, obtained from 14 vessels harvested at autopsy, are analyzed and correlated with histology. Vessel wall components can be distinguished based on their optical properties: necrotic core and macrophage infiltration exhibit strong attenuation, mu(t) >= 10 mm(-1), while calcific and fibrous tissue have a lower mu(t) approximate to 2 - 5 mm(-1). The algorithm is successfully applied to OCT patient data, demonstrating that the analysis can be used in a clinical setting and assist diagnostics of vessel wall pathology. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3280271] C1 [van Soest, Gijs; Goderie, Thade; Regar, Evelyn; Gonzalo, Nieves; van Noorden, Sander; Okamura, Takayuki; Serruys, Patrick W.; van der Steen, Anton F. W.] Erasmus MC, Ctr Thorax, NL-3000 CA Rotterdam, Netherlands. [Koljenovic, Senada; van Leenders, Geert L. J. H.; Oosterhuis, J. Wolter] Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands. [Bouma, Brett E.; Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Bouma, Brett E.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA. [Bouma, Brett E.; Tearney, Guillermo J.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Tearney, Guillermo J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA. [van der Steen, Anton F. W.] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands. RP van Soest, G (reprint author), Erasmus MC, Ctr Thorax, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM g.vansoest@erasmusmc.nl RI van Soest, Gijs/B-4881-2008 NR 53 TC 79 Z9 81 U1 0 U2 0 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2010 VL 15 IS 1 AR 011105 DI 10.1117/1.3280271 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 586VY UT WOS:000276944200015 PM 20210431 ER PT J AU Banu, J Bhattacharya, A Rahman, M Kang, JX Fernandes, G AF Banu, Jameela Bhattacharya, Arunabh Rahman, Mizanur Kang, J. X. Fernandes, Gabriel TI Endogenously produced n-3 fatty acids protect against ovariectomy induced bone loss in fat-1 transgenic mice SO JOURNAL OF BONE AND MINERAL METABOLISM LA English DT Article DE fat-1 mice; pQCT; mu CT; Postmenopausal bone loss; Biochemical markers ID BREAST-CANCER RISK; AGED MALE RATS; FOOD RESTRICTION; SOY ISOFLAVONES; MINERAL DENSITY; GROWTH-HORMONE; FEMALE MICE; OMEGA-3-FATTY-ACIDS; OSTEOPOROSIS; EXERCISE AB Aging is associated with bone loss, leading to increased risk of fractures. Recently, there is growing interest in identifying nutritional supplements that can prevent bone loss with minimum side effects. There is increasing evidence for the beneficial effects of n-3 fatty acids in the prevention of bone loss. A transgenic mouse model (fat-1) that produces n-3 fatty acids endogenously and its wild type counterpart were used in this study to determine the effects of endogenously produced n-3 fatty acids on serum bone turnover markers, long bones, and lumbar vertebrae. Serum alkaline phosphatase and P1NP levels decreased significantly in wild type mice after ovariectomy. No significant changes were seen in osteocalcin. Cancellous and cortical bone mass were higher in the femur of fat-1 mice. In wild type mice, there was significant loss of bone after ovariectomy in the distal femur, femoral neck, proximal tibia, and fourth lumbar vertebra. However, in fat-1 mice, there was no, or significantly less, bone lost after ovariectomy in all the sites studied. We conclude that endogenously produced n-3 fatty acids can attenuate ovariectomy induced bone loss in the different bone sites studied, mainly as a consequence of decreased bone resorption at the endosteal surface. C1 [Banu, Jameela] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Immunol & Rheumatol, Edinburg, TX 78541 USA. [Banu, Jameela] Univ Texas Hlth Sci Ctr San Antonio, Div Med Res, E RAHC, Edinburg, TX 78541 USA. [Rahman, Mizanur; Fernandes, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Immunol & Rheumatol, Dept Med, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Kang, J. X.] Massachusetts Gen Hosp, Dept Med & Dermatol, Boston, MA 02114 USA. [Kang, J. X.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Banu, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Immunol & Rheumatol, 1214 W Schunior, Edinburg, TX 78541 USA. EM banu@uthscsa.edu FU [RO1 AG023648] FX This study was supported by RO1 AG023648. This work was presented as plenary poster in the 29th Annual Meeting of The American Society for Bone and Mineral Research, 2007. NR 48 TC 6 Z9 7 U1 0 U2 1 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0914-8779 J9 J BONE MINER METAB JI J. Bone Miner. Metab. PY 2010 VL 28 IS 6 BP 617 EP 626 DI 10.1007/s00774-010-0175-2 PG 10 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 701XV UT WOS:000285859400003 PM 20393761 ER PT J AU Kemp, EH Gavalas, NG Akhtar, S Krohn, KJE Pallais, JC Brown, EM Watson, PF Weetman, AP AF Kemp, E. Helen Gavalas, Nikos G. Akhtar, Sarnia Krohn, Kai J. E. Pallais, J. Carl Brown, Edward M. Watson, Philip F. Weetman, Anthony P. TI Mapping of Human Autoantibody Binding Sites on the Calcium-Sensing Receptor SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE AUTOANTIBODY; AUTOIMMUNE POLYENDOCRINE SYNDROME TYPE 1; PARATHYROID; CALCIUM-SENSING RECEPTOR; HYPOPARATHYROIDISM ID ACQUIRED HYPOCALCIURIC HYPERCALCEMIA; CANDIDIASIS-ECTODERMAL DYSTROPHY; GLUTAMIC-ACID DECARBOXYLASE; PEPTIDE PHAGE DISPLAY; HUMAN CA2+ RECEPTOR; EXTRACELLULAR DOMAIN; ADDISONS-DISEASE; AUTOIMMUNE HYPOPARATHYROIDISM; CA2+-SENSING RECEPTOR; PARATHYROID CELLS AB Previously, we have demonstrated the presence of anti-calcium-sensing receptor (CaSR) antibodies in patients with autoimmune polyglandular syndrome type 1 (APS1), a disease that is characterized in part by hypoparathyroidism involving hypocalcemia, hyperphosphatemia, and low serum levels of parathyroid hormone. The aim of this study was to define the binding domains on the CaSR of anti-CaSR antibodies found in APS1 patients and in one patient suspected of having autoimmune hypocalciuric hypercalcemia (AHH). A phage-display library of CaSR peptides was constructed and used in biopanning experiments with patient sera. Selectively enriched IgG-binding peptides were identified by DNA sequencing, and subsequently, immunoreactivity to these peptides was confirmed in ELISA. Anti-CaSR antibody binding sites were mapped to amino acid residues 41-69, 114-126, and 171-195 at the N-terminal of the extracellular domain of the receptor. The major autoepitope was localized in the 41-69 amino acid sequence of the CaSR with antibody reactivity demonstrated in 12 of 12 (100%) APS1 patients with anti-CaSR antibodies and in I AHH patient with anti-CaSR antibodies. Minor epitopes were located in the 114-126 and 171-195 amino acid domains, with antibody reactivity shown in 5 of 12 (42%) and 4 of 12 (33%) APS1 patients, respectively. The results indicate that epitopes for anti-CaSR antibodies in the AHH patient and in the APS1 patients who were studied are localized in the N-terminal of the extracellular domain of the receptor. The present work has demonstrated the successful use of phage-display technology in the discovery of CaSR-specific epitopes targeted by human anti-CaSR antibodies. (C) 2010 American Society for Bone and Mineral Research. C1 [Kemp, E. Helen; Gavalas, Nikos G.; Akhtar, Sarnia; Watson, Philip F.; Weetman, Anthony P.] Univ Sheffield, Sch Med, Dept Human Metab, Sheffield S10 2JF, S Yorkshire, England. [Krohn, Kai J. E.] Univ Tampere, Tampere Univ Hosp, Dept Pathol, FIN-33101 Tampere, Finland. [Krohn, Kai J. E.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland. [Pallais, J. Carl] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Brown, Edward M.] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Brown, Edward M.] Harvard Univ, Sch Med, Boston, MA USA. RP Kemp, EH (reprint author), Univ Sheffield, Royal Hallamshire Hosp, Dept Human Metab, Sch Med, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England. EM e.h.kemp@sheffield.ac.uk RI Kemp, Elizabeth Helen/D-1665-2011 OI Kemp, Elizabeth Helen/0000-0002-0313-8916 FU European Union; NIH [DK67111] FX This study was supported by a European Union Framework Programme 6 Grant (EURAPS) to Professor A. P. Weetman. Dr. E. M. Brown was supported by NIH Grant DK67111. We wish to thank Professor J. Perheentupa (The Hospital for Children and Adolescents, Helsinki University Hospital, FIN-00029 Helsinki, Finland) for kindly supplying the APSI patient clinical details. NR 34 TC 14 Z9 14 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2010 VL 25 IS 1 BP 132 EP 140 DI 10.1359/jbmr.090703 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 555NC UT WOS:000274517600018 PM 19580466 ER PT J AU Mosier, MJ Pham, TN Klein, MB Gibran, NS Arnoldo, BD Gamelli, RL Tompkins, RG Herndon, DN AF Mosier, Michael J. Pham, Tam N. Klein, Matthew B. Gibran, Nicole S. Arnoldo, Brett D. Gamelli, Richard L. Tompkins, Ronald G. Herndon, David N. TI Early Acute Kidney Injury Predicts Progressive Renal Dysfunction and Higher Mortality in Severely Burned Adults SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID CRITICALLY-ILL PATIENTS; BASE DEFICIT; RIFLE CRITERIA; SHOCK RESUSCITATION; FAILURE; ASSOCIATION; MULTICENTER AB The incidence and prognosis of acute kidney injury (AKI) developing during acute resuscitation have not been well characterized in burn patients. The recently developed Risk, Injury, Failure, Loss, and End-stage (RIFLE) classification provides a stringent stratification of AKI severity and can allow for the study of AKI after burn injury. We hypothesized that AKI frequently develops early during resuscitation and is associated with poor outcomes in severely burned patients. We conducted a retrospective review of patients enrolled in the prospective observational multicenter study "Inflammation and the Host Response to Injury." A RIFLE score was calculated for all patients at 24 hours and throughout hospitalization. Univariate and multivariate analyses were performed to distinguish the impact of early AKI on progressive renal dysfunction, need for renal replacement therapy, and hospital mortality. A total of 221 adult burn patients were included, with a mean TBSA burn of 42%. Crystalloid resuscitation averaged 5.2 ml/kg/%TBSA, with urine output of 1.0 +/- 0.6 ml/kg/hr at 24 hours. Sixty-two patients met criteria for AKI at 24 hours: 23 patients (10%) classified as risk, 32 patients (15%) as injury, and 7 (3%) as failure. After adjusting for age, TBSA, inhalation injury, and nonrenal Acute Physiology and Chronic Health Evaluation II >= 20, early AKI was associated with an adjusted odds ratio 2.9 for death (95% CI 1.1-7.5, P = .03). In this cohort of severely burned patients, 28% of patients developed AKI during acute resuscitation. AKI was not always transient, with 29% developing progressive renal deterioration by RIFLE criteria. Early AM was associated with early multiple organ dysfunction and higher mortality risk. Better understanding of how early AKI develops and which patients are at risk for progressive renal dysfunction may lead to improved outcomes. (J Burn Care Res 2010;31:83-92) C1 [Mosier, Michael J.; Pham, Tam N.; Klein, Matthew B.; Gibran, Nicole S.] Univ Washington, Harborview Med Ctr, Burn Ctr, Seattle, WA 98104 USA. [Arnoldo, Brett D.] UT SW Parkland Mem Hosp, Dallas, TX USA. [Gamelli, Richard L.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Tompkins, Ronald G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Herndon, David N.] UT Med Branch, Galveston, TX USA. RP Mosier, MJ (reprint author), Univ Washington, Harborview Med Ctr, Burn Ctr, Box 359796,325 9th Ave, Seattle, WA 98104 USA. FU National Institute of General Medical Sciences; National Institute of General Medical Sciences [2-U54-GM062119]; National Center for Research Resources [KL2 (1KL2RR025015-01)]; David and Nancy Auth-Washington Research Foundation Endowment FX Supported by the National Institute of General Medical Sciences.; We thank the contribution of the Inflammation and the Host Response to Injury Large-Scale Collaborative Project Award 2-U54-GM062119 from the National Institute of General Medical Sciences, KL2 (1KL2RR025015-01) from the National Center for Research Resources), and the David and Nancy Auth-Washington Research Foundation Endowment. NR 30 TC 35 Z9 36 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD JAN-FEB PY 2010 VL 31 IS 1 BP 83 EP 92 DI 10.1097/BCR.0b013e3181cb8c87 PG 10 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 544FF UT WOS:000273637900011 PM 20061841 ER PT J AU Ucuzian, AA Gassman, AA East, AT Greisler, HP AF Ucuzian, Areck A. Gassman, Andrew A. East, Andrea T. Greisler, Howard P. TI Molecular Mediators of Angiogenesis SO JOURNAL OF BURN CARE & RESEARCH LA English DT Review ID ENDOTHELIAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; CAPILLARY-TUBE FORMATION; BLOOD-VESSEL FORMATION; PROTEIN-KINASE-C; 3-DIMENSIONAL EXTRACELLULAR MATRICES; UP-REGULATES ANGIOPOIETIN-2; ACTIVATOR INHIBITOR TYPE-1; FOCAL ADHESION KINASE; THICKNESS SKIN-GRAFTS AB Angiogenesis, or the formation of new blood vessels from the preexisting vasculature, is a key component in numerous physiologic and pathologic responses and has broad impact in many medical and surgical specialties. In this review, we discuss the key cellular steps that lead to the neovascularization of tissues and highlight the main molecular mechanisms and mediators in this process. We include discussions on proteolytic enzymes, cell-matrix interactions, and pertinent cell signaling pathways and end with a survey of the mechanisms that lead to the stabilization and maturation of neovasculatures. (J Burn Care Res 2010;31:158-175) C1 [Ucuzian, Areck A.; Gassman, Andrew A.; Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA. [Ucuzian, Areck A.; Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. [East, Andrea T.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Surg Serv, Hines, IL 60141 USA. RP Greisler, HP (reprint author), Loyola Univ, Med Ctr, Dept Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. FU National Institutes of Health [NIH R01-HL41272]; Department of Veterans' Affairs; American Heart Association [AHA 0815674G]; Falk Medical Research Trust FX Supported by grants from the National Institutes of Health (NIH R01-HL41272), the Department of Veterans' Affairs, the American Heart Association (AHA 0815674G), and the Falk Medical Research Trust. NR 263 TC 25 Z9 28 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD JAN-FEB PY 2010 VL 31 IS 1 BP 158 EP 175 DI 10.1097/BCR.0b013e3181c7ed82 PG 18 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 544FF UT WOS:000273637900022 PM 20061852 ER PT J AU Evangelista, LS Rasmusson, KD Laramee, AS Barr, J Ammon, SE Dunbar, S Ziesche, S Patterson, JH Yancy, CW AF Evangelista, Lorraine S. Rasmusson, Kismet D. Laramee, Ann S. Barr, Joan Ammon, Susan E. Dunbar, Sandra Ziesche, Susan Patterson, J. Herbert Yancy, Clyde W. TI Health Literacy and the Patient With Heart Failure-Implications for Patient Care and Research: A Consensus Statement of the Heart Failure Society of America SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; health literacy; communication; self-care ID HOSPITAL ADMISSION; MEDICARE ENROLLEES; CHRONIC DISEASE; SELF-CARE; KNOWLEDGE; RISK; MANAGEMENT; BARRIER; ADULTS; HYPERTENSION AB Background: Low health literacy compromises patient safety, quality health care, and desired health outcomes. Specifically, low health literacy is associated with decreased knowledge of one's medical condition, poor medication recall, nonadherence to treatment plans, poor self-care behaviors, compromised physical and mental health, greater risk of hospitalization, and increased mortality. Methods: The health literacy literature was reviewed for: definitions, scope, risk factors, assessment, impact on health outcomes (cardiovascular disease and heart failure), and interventions. Implications for future research and for clinical practice to address health literacy in heart failure patients were summarized. Results: General health literacy principles should be applied to patients with heart failure, similar to others with chronic conditions. Clinicians treating, patients with heart failure should address health literacy using five steps: recognize the consequences of low health literacy, screen patients at risk, document literacy levels and learning preferences, and integrate effective strategies to enhance patients' understanding into practice. Conclusion: Although the literature specifically addressing low health literacy in patients with heart failure is limited, it is consistent with the larger body of health literacy evidence. Timely recognition of low health literacy combined with tailored interventions should be integrated into clinical practice. (J Cardiac Fail 2010:16:9-16) C1 [Evangelista, Lorraine S.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Rasmusson, Kismet D.] Intermt Med Ctr, Salt Lake City, UT USA. [Laramee, Ann S.] Fletcher Allen Hlth Care, Burlington, VT USA. [Barr, Joan] Methodist Hosp, Indianapolis, IN USA. [Ammon, Susan E.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Dunbar, Sandra] Emory Univ, Sch Nursing, Atlanta, GA USA. [Ziesche, Susan] Univ Minnesota, Epidemiol Res Ctr, Minneapolis, MN USA. [Patterson, J. Herbert] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA. [Yancy, Clyde W.] Baylor Univ, Med Ctr, Dallas, TX USA. RP Evangelista, LS (reprint author), Univ Calif Los Angeles, Sch Nursing, 700 Tiverton,Factor Bldg, Los Angeles, CA 90095 USA. EM levangel@ucla.edu FU NHLBI NIH HHS [R01 HL093466, R01 HL093466-01, R01 HL093466-02] NR 60 TC 57 Z9 60 U1 6 U2 17 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2010 VL 16 IS 1 BP 9 EP 16 DI 10.1016/j.cardfail.2009.10.026 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 594ZU UT WOS:000277581300002 PM 20123313 ER PT J AU Deo, R Katz, R Kestenbaum, B Fried, L Sarnak, MJ Psaty, BM Siscovick, DS Shlipak, MG AF Deo, Rajat Katz, Ronit Kestenbaum, Bryan Fried, Linda Sarnak, Mark J. Psaty, Bruce M. Siscovick, David S. Shlipak, Michael G. TI Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Kidney function; cystatin C; arrhythmias; elderly; epidemiology ID LEFT-VENTRICULAR DYSFUNCTION; CYSTATIN-C; RISK-FACTORS; CARDIOVASCULAR-DISEASE; HEART-FAILURE; SINUS RHYTHM; HEALTH; ALDOSTERONE; MORTALITY; ENALAPRIL AB Background: Impaired kidney function is associated with increased risk for cardiovascular events. We evaluated whether kidney function is associated with atrial fibrillation (AF) risk in elderly persons. Methods and Results: Subjects were participants in the Cardiovascular Health Study (CHS), a population-based cohort of ambulatory elderly. Measures of kidney function were cystatin C and creatinine-based estimated glomerular filtration rate (eGFR). Among the 4663 participants, 342 (7%) had AF at baseline and 579 (13%) developed incident AF during follow-up (mean 7.4 years). In unadjusted analyses, cystatin C quartiles were strongly associated with prevalent AF with a nearly 3-fold odds in the highest quartile compared with the lowest (HR = 1.19, 95% CI [0.80-1.76] in quartile 2; FIR = 2.00, 95% Cl [1.38-2.88] in quartile 3; and FIR = 2.87, 95% Cl [2.03-4.07] in quartile 4). This increased risk for prevalent AF remained significant after multivariate adjustment. The risk for incident AF increased across cystatin C quartiles in the unadjusted analysis (HR = 1.37, 95% Cl [1.07-1.75] in quartile 2; HR = 1.43, 95% CI [1.11-1.84] in quartile 3; and HR = 1.88, 95% Cl [1.47-2.41] in quartile 4); however, after multivariate adjustment, these findings were no longer significant. An estimated GFR <60 mL . min . 1.73 m(2) was associated with prevalent and incident AF in unadjusted, but not multivariate analyses. Conclusions: Impaired kidney function, as measured by cystatin C, is an independent marker of prevalent AF; however, neither cystatin C nor eGFR are predictors of incident AF. (J Cardiac Fail 2010:16:55-60) C1 [Deo, Rajat] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Fried, Linda] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Dept Internal Med, Div Nephrol, Boston, MA USA. [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA USA. RP Deo, R (reprint author), Univ Penn, Div Cardiol, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA. EM Rajat.Deo@uphs.upenn.edu FU National Heart, Lung, and Blood Institute [N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079, N01-HC-85086, N01 HC-15103, N01 HC-55222, U01 HL080295] FX Supported by contracts N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079 through N01-HC-85086, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. NR 37 TC 21 Z9 26 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2010 VL 16 IS 1 BP 55 EP 60 DI 10.1016/j.cardfail.2009.07.002 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 594ZU UT WOS:000277581300008 PM 20123319 ER PT J AU Steele, BG Belza, B Cain, K Coppersmith, J Howard, J Lakshminarayan, S Haselkorn, J AF Steele, Bonnie G. Belza, Basia Cain, Kevin Coppersmith, Jeff Howard, JoEllen Lakshminarayan, Sambasiva Haselkorn, Jodi TI The Impact of Chronic Obstructive Pulmonary Disease Exacerbation on Pulmonary Rehabilitation Participation and Functional Outcomes SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Article DE COPD exacerbation; exercise training; pulmonary rehabilitation ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CHRONIC LUNG-DISEASE; PHYSICAL-ACTIVITY; RESPIRATORY REHABILITATION; ENERGY-EXPENDITURE; COPD EXACERBATIONS; OLDER-ADULTS; EXERCISE; DYSPNEA AB PURPOSE: The purpose of this study was to determine the impact of chronic obstructive Pulmonary disease exacerbation (COPDE) on pulmonary rehabilitation (PR) participation and completion and oil outcomes of daily activity, self-reported daily exercise, and functional capacity. METHODS: Participants in an 8-week outpatient PR program were studied pre- and post-PR. Variables included COPDE Occurrence (computerized patient record system), self-reported exercise (daily activity diary), daily activity (accelerometer), exercise capacity (6-minute walk distance), dyspnea today and over the past 30 days (Lareau's Functional Status and Dyspnea Questionnaire), health status (The Medical Outcomes Study 36-Item Short-Form Health Survey adapted for Veterans), and quality of life (Seattle Obstructive Lung Disease Questionnaire). RESULTS: Outpatients with COPD (N = 146, 140 men) started PR; 112 completed the program and were studied. Of the 30 participants who had at least 1 COPDE during the program, 10 quit the program. Subjects who exacerbated had a lower body mass index than did patients without COPDE (28.4 compared with 30.8, respectively, P < .05), more severe COPD (percent-predicted forced expiratory volume in the first second of expiration, FEV1% predicted, 32%, compared with 40%, respectively, P < .05), and required supplemental oxygen (70% compared with 36%, respectively, P < .05). Exacerbators who completed PR were more likely to be nonsmokers, on oxygen, and have a higher FEV1% predicted than were exacerbators who quit. It was found that postprogram exercise capacity improved overall, with exacerbators performing better than nonexacerbators on the 6-minute walk test (P = .044). There were no significant differences in other outcomes. CONCLUSIONS: Findings suggest that COPD exacerbators who completed PR had similar outcomes as did nonexacerbators and should be encouraged to return to PR after COPDE. C1 [Steele, Bonnie G.; Lakshminarayan, Sambasiva] Dept Vet Affairs Puget Sound Hlth Care Syst, Primary Care & Specialty Med Serv, Seattle, WA USA. [Haselkorn, Jodi] Univ Washington, Sch Med, Dept Vet Affairs Puget Sound Hlth Care Syst & Reh, Rehabil Care Serv, Seattle, WA USA. [Coppersmith, Jeff; Howard, JoEllen] VA Puget Sound Hlth Care Syst, VA Hlth Serv Res & Dev, Seattle, WA USA. RP Steele, BG (reprint author), Dept Vet Affairs Puget Sound Hlth Care Syst S 111, Primary Care & Specialty Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bonnie.steele@va.gov FU Offiice of Research and Development Health Service R & D Service, Department of Veterans Affairs, Nursing Research Initiative [NRI 98-194]; School of Nursing, University of Washington FX This material is based upon work supported by the Offiice of Research and Development Health Service R & D Service, Department of Veterans Affairs, Nursing Research Initiative (NRI 98-194), and a Research and Intramural Funding Grant from the School of Nursing, University of Washington. NR 55 TC 11 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-7501 EI 1932-751X J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD JAN-FEB PY 2010 VL 30 IS 1 BP 53 EP 60 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 547IK UT WOS:000273880400009 PM 20068424 ER PT J AU Grunfeld, C Scherzer, R Varosy, PD Gopal, A Nasir, K Budoff, M AF Grunfeld, Carl Scherzer, Rebecca Varosy, Paul D. Gopal, Ambarish Nasir, Khurram Budoff, Matthew TI Relation of coronary artery plaque location to extent of coronary artery disease studied by computed tomographic angiography SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY LA English DT Article DE Computed tomography angiography; CTA; Coronary artery calcium; CAC; Noninvasive angiography; Prevalence AB BACKGROUND: Distal coronary artery disease (CAD) is less amenable to surgery or stenting compared with proximal disease. However, little is known about the epidemiology of distal versus proximal CAD. METHODS: We determined the prevalence and factors associated with proximal, mid, and distally located plaque in the left anterior descending, left circumflex, and right coronary arteries in 418 subjects without prior CAD history who underwent coronary computed tomographic angiography for symptoms or stress test results. Clinical characteristics and coronary artery calcium (CAC) scores were also determined. RESULTS: Most subjects (88%) had plaque, but only 18% of plaques were associated with stenosis >50%. In subjects with single-vessel plaque, only 7% had distal plaque, whereas 75% had proximal plaque. With 3-vessel plaque, 70% had distal and 100% had proximal plaques. Of subjects with a single location of plaque along a vessel, most had proximal plaque (69%); isolated distal-vessel plaque was rare (2%). Distal plaque was dominantly found in association with both proximal and mid plaque (88%). After multivariable adjustment for demographics, traditional, and nontraditional risk factors, both increasing number of vessels with plaque and clinically significant CAC scores were independently associated with higher odds of distal plaque, whereas associations of traditional risk factors were weaker. Distal plaque was independently associated with stenosis > 50%. CONCLUSION: These data support the concept that early lesions are most often proximal and that CAC scoring may be a poor screening tool for detecting proximal disease. Furthermore, distal lesions are more associated with advanced disease than with traditional cardiovascular risk factors. (c) 2010 Society of Cardiovascular Computed Tomography. All rights reserved. C1 [Grunfeld, Carl; Scherzer, Rebecca] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Grunfeld, Carl; Scherzer, Rebecca] Vet Affairs Med Ctr, Metab Sect 111F, San Francisco, CA 94121 USA. [Varosy, Paul D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Sch Med, Denver, CO USA. [Gopal, Ambarish; Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA. [Nasir, Khurram] Boston Med Ctr, Dept Med, Boston, MA USA. RP Grunfeld, C (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM carl.grunfeld@ucsf.edu FU Veterans Affairs Health Services Research and Development Service Research Career Development Award [RCD 04-115-2]; Albert L. and Janet A. Schulz Supporting Foundation FX Supported in part by a Veterans Affairs Health Services Research and Development Service Research Career Development Award (RCD 04-115-2 to P.D.V.), the Albert L. and Janet A. Schulz Supporting Foundation, and with resources and the use of facilities of the VA Medical Center, San Francisco. CA. NR 34 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-5925 J9 J CARDIOVASC COMPUT JI J. Cardiovasc. Comput. Tomogr. PD JAN-FEB PY 2010 VL 4 IS 1 BP 19 EP 26 DI 10.1016/j.jcct.2010.01.009 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA V26BE UT WOS:000208520300003 PM 20159623 ER PT J AU Mahabadi, AA Truong, QA Schlett, CL Samy, B O'Donnell, CJ Fox, CS Bamberg, F Hoffmann, U AF Mahabadi, Amir A. Truong, Quynh A. Schlett, Christopher L. Samy, Bharat O'Donnell, Christopher J. Fox, Caroline S. Bamberg, Fabian Hoffmann, Udo TI Axial, area and anteroposterior diameter as estimates of Left atrial size using computed tomography of the chest: Comparison with 3-dimensional volume SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY LA English DT Article DE Axial area; Electron beam computed tomography (EBCT); Left atrium; Multidetector computed tomography (MDCT); Reproducibility AB BACKGROUND: Left atrial (LA) size has incremental value in risk stratification. OBJECTIVES: We aimed to assess feasibility and reproducibility of 2 quick measures of LA size by chest CT (axial LA area and LA anteroposterior [AP] diameter) by using contrast-enhanced and CT scans. METHODS: We measured LA size in 100 contrast-enhanced 64-slice multidetector CT (MDCT) scans (randomly selected from the ROMICAT collective) by (1) axial LA area at the level of the left ventricular outflow tract and the mitral valve leaflets, (2) AP diameter in 3-chamber view, and (3) 3-dimensional (3D) LA volume by Simpson's methods. We assessed interobserver and intraobserver intraclass correlation coefficient (ICC) for axial LA area and AP diameter as well as their correlation to 3D LA volume. For axial area, feasibility and reproducibility were also determined in 100 non contrast MDCT scans, randomly selected from the Framingham Heart Offspring collective. RESULTS: in contrast-enhanced CT, both LA axial area and AP diameter had excellent reproducibility (interobserver: axial area: ICC, 0.96, mean relative difference, 2.4% +/- 7.4%; AP diameter: ICC, 0.91, 3.6% +/- 7.2%; intraobserver: axial area: ICC, 0.99, 0.4% +/- 5.2%; AP diameter: ICC, 0.94, 1.7% +/- 5.5%). Correlations with 3D volume were better for axial area (r = 0.88) than for AP diameter = 0.67). In non contrast images, axial area could be assessed with excellent reproducibility (interobserver: ICC, 0.96, 0.5% +/- 8.3%; intraobserver: ICC, 0.99, 0.01% +/- 4.4%). CONCLUSION: Both AP diameter and axial LA area permit quick and reproducible estimates of LA volume in contrast-enhanced and non contrast electrocardiographic-gated chest CT. However, LA area should be used preferably over AP diameter because of its better agreement to 3D LA volume. (c) 2010 Society of Cardiovascular Computed Tomography. All rights reserved. C1 [Mahabadi, Amir A.; Truong, Quynh A.; Schlett, Christopher L.; Bamberg, Fabian; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program,Dept Radiol, Boston, MA 02114 USA. [Truong, Quynh A.; O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA. [Samy, Bharat] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Cardiol, Boston, MA 02114 USA. [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol, Boston, MA 02114 USA. [O'Donnell, Christopher J.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA. RP Mahabadi, AA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program,Dept Radiol, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM amir.mahabadi@stud.uni-due.de FU National Heart, Lung, and Blood Institute's Framingham Heart Study [N01-HC-25195]; National Institutes of Health (NIH) [R01 HL080053]; German National Academic Foundation; NIH [T32HL076136, L30HL093896]; Federal Ministry of Education and Research; Foundation of German Business, Berlin FX This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (N01-HC-25195) and by the National Institutes of Health (NIH) (R01 HL080053). A.A.M. is supported by a grant from the German National Academic Foundation. Q.A.T. has received support from NIH (T32HL076136 and L30HL093896). C.L.S. is supported by grants from the Federal Ministry of Education and Research, and Foundation of German Business, Berlin. NR 23 TC 18 Z9 18 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-5925 J9 J CARDIOVASC COMPUT JI J. Cardiovasc. Comput. Tomogr. PD JAN-FEB PY 2010 VL 4 IS 1 BP 49 EP 54 DI 10.1016/j.jcct.2009.10.013 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA V26BE UT WOS:000208520300009 PM 20159629 ER PT J AU Wu, XP Yan, QX Huang, YD Huang, HX Su, ZJ Xiao, J Zeng, YY Wang, Y Nie, CJ Yang, YG Li, XK AF Wu, Xiaoping Yan, Qiuxia Huang, Yadong Huang, Huixian Su, Zhijian Xiao, Jian Zeng, Yaoying Wang, Yi Nie, Changjun Yang, Yongguang Li, Xiaokun TI Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE LA English DT Article DE angiogenesis; basic fibroblast growth factor; phage display; tumor ID FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTORS; COMPLEMENTARY PEPTIDES; TUMOR-GROWTH; ANGIOGENESIS; SPECIFICITY; INHIBITION; LIBRARY AB Basic fibroblast growth factor (bFGF), which plays an important role in tumour angiogenesis and progression, provides a potential target for cancer therapy. Here we screened a phage display heptapeptide library with bFGF and identified 11 specific bFGF-binding phage clones. Two of these clones had identical sequence and the corresponding peptide (referred to as P7) showed high homology to the immunoglobulin-like (Ig-like) domain III (D3) of high-affinity bFGF receptors, FGFR1 (IIIc) and FGFR2 (IIIc). The P7 peptide and its corresponding motif in D3 of FGFRs both carried negative charges and shared similar hydrophobic profiles. Functional analysis demonstrated that synthetic P7 peptides mediate strong inhibition of bFGF-induced cell proliferation and neovascularization. Our results demonstrate that the P7 peptide is a potent bFGF antagonist with strong antiangiogenetic activity, and might have therapeutic potential in cancer therapy. C1 [Wu, Xiaoping; Yan, Qiuxia; Xiao, Jian; Wang, Yi; Nie, Changjun; Li, Xiaokun] Wenzhou Med Coll, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn Zhejiang Pro, Wenzhou 325035, Peoples R China. [Wu, Xiaoping; Zeng, Yaoying] Jinan Univ, Inst Tissue Transplantat & Immunol, Guangzhou, Guangdong, Peoples R China. [Huang, Yadong; Huang, Huixian; Su, Zhijian; Nie, Changjun; Li, Xiaokun] Jinan Univ, Natl Engn Res Ctr Gene Med, Guangzhou, Guangdong, Peoples R China. [Wang, Yi; Yang, Yongguang] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Li, XK (reprint author), Wenzhou Med Coll, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn Zhejiang Pro, Wenzhou 325035, Peoples R China. EM xiaokunli@163.net FU Science Foundation of Zhejiang Province of China [Z205755]; Program of New Century Excellent Talents in University; Cultivation of High-level Innovative Health; Wenzhou Medical College [5010] FX The work was supported by a grant from the Science Foundation of Zhejiang Province of China (No. Z205755), the Program of New Century Excellent Talents in University (Li, XK), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents (Li, XK) and the 5010 Project of Wenzhou Medical College. NR 22 TC 28 Z9 31 U1 0 U2 10 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1582-1838 J9 J CELL MOL MED JI J. Cell. Mol. Med. PD JAN-FEB PY 2010 VL 14 IS 1-2 BP 351 EP 356 DI 10.1111/j.1582-4934.2008.00506.x PG 6 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 569YV UT WOS:000275639700030 PM 20414975 ER PT J AU Uong, A Zon, LI AF Uong, Audrey Zon, Leonard I. TI Melanocytes in Development and Cancer SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Review ID CRANIAL NEURAL CREST; ENDOTHELIN-B RECEPTOR; TRANSCRIPTION FACTOR; C-KIT; WAARDENBURG-SYNDROME; MALIGNANT-MELANOMA; IN-VIVO; CUTANEOUS MELANOMA; LINEAGE SURVIVAL; CELL-DEVELOPMENT AB Melanocytes are pigment-producing cells in the skin of humans and other vertebrates. A number of genes involved in melanocyte development and vertebrate pigmentation have been characterized, largely through studies of a diversity of pigment mutations in a variety of species. Embryonic development of the melanocyte initiates with cell fate specification in the neural crest, which is then followed by cell migration and niche localization. Many genes involved in melanocyte development have also been implicated in the development of melanoma, an aggressive and fatal form of skin cancer that originates in the melanocyte. Although early stage melanomas that have not spread to the lymph nodes can be excised with little risk of recurrence, patients diagnosed with metastatic melanoma have a high mortality rate due to the resistance of most tumors to radiotherapy and chemotherapy. Transformed melanocytes that develop into melanomas proliferate abnormally and often begin to grow radially in the skin. Vertical growth can then follow this radial growth, leading to an invasion through the basement membrane into the underlying dermis and subsequent metastasis. It is still unclear, however, how a normal melanocyte becomes a melanoma cell, and how melanoma utilizes the properties of the normal melanocyte and its progenitors in its progression. The goal of this mini-review is to highlight the role of melanocyte developmental pathways in melanoma, and to discuss recent studies and tools being used to illuminate this connection. J. Cell. Physiol. 222: 38-41, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Uong, Audrey; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Uong, Audrey; Zon, Leonard I.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Zon, LI (reprint author), Karp Res Labs, 7th Floor,1 Blackfan Circle, Boston, MA 02115 USA. EM zon@enders.tch.harvard.edu FU NIH [DK53298-08] FX Contract grant number: DK53298-08. NR 60 TC 40 Z9 41 U1 1 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 2010 VL 222 IS 1 BP 38 EP 41 DI 10.1002/jcp.21935 PG 4 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 529OY UT WOS:000272528300006 PM 19795394 ER PT J AU Weinstein, JS Varallyay, CG Dosa, E Gahramanov, S Hamilton, B Rooney, WD Muldoon, LL Neuwelt, EA AF Weinstein, Jason S. Varallyay, Csanad G. Dosa, Edit Gahramanov, Seymur Hamilton, Bronwyn Rooney, William D. Muldoon, Leslie L. Neuwelt, Edward A. TI Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE blood-brain barrier; CNS tumors; magnetic resonance imaging; ultrasmall superparamagnetic iron oxide nanoparticles ID CEREBRAL BLOOD-VOLUME; HUMAN BRAIN-TUMORS; IN-VIVO TRACKING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CAROTID ATHEROSCLEROTIC PLAQUE; WATER SUPPRESSION IRON; SPINAL-CORD-INJURY; MR CONTRAST AGENTS; MULTIPLE-SCLEROSIS; ENHANCED MRI AB Superparamagnetic iron oxide nanoparticles have diverse diagnostic and potential therapeutic applications in the central nervous system (CNS). They are useful as magnetic resonance imaging (MRI) contrast agents to evaluate: areas of blood-brain barrier (BBB) dysfunction related to tumors and other neuroinflammatory pathologies, the cerebrovasculature using perfusion-weighted MRI sequences, and in vivo cellular tracking in CNS disease or injury. Novel, targeted, nanoparticle synthesis strategies will allow for a rapidly expanding range of applications in patients with brain tumors, cerebral ischemia or stroke, carotid atherosclerosis, multiple sclerosis, traumatic brain injury, and epilepsy. These strategies may ultimately improve disease detection, therapeutic monitoring, and treatment efficacy especially in the context of antiangiogenic chemotherapy and antiinflammatory medications. The purpose of this review is to outline the current status of superparamagnetic iron oxide nanoparticles in the context of biomedical nanotechnology as they apply to diagnostic MRI and potential therapeutic applications in neurooncology and other CNS inflammatory conditions. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 15-35; doi: 10.1038/jcbfm.2009.192; published online 16 September 2009 C1 [Weinstein, Jason S.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA. [Varallyay, Csanad G.; Dosa, Edit; Gahramanov, Seymur; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Varallyay, Csanad G.] Univ Klinikum Wurzburg, Dept Neuroradiol, Wurzburg, Germany. [Hamilton, Bronwyn] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA. [Rooney, William D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU National Institute of Neurological Disorders and Stroke, a Department of Defense Center of Excellence [NS33618, NS34608, NS053468, NS44687]; AMAG Pharmaceuticals Inc; Department of Veterans Affairs; Neurosurgery Research and Education Foundation grant sponsored by Codman; Johnson & Johnson Company; NIH [RO1-EB007258]; WM Keck Foundation FX We thank Ms. Audrey Selzer for her assistance with 12T MRI acquisitions, Mr. William Woodward for collecting data for Figure 5b, and Ms. Emily Hochhalter for her administrative assistance. This research was funded in part by the National Institutes of Health grants NS33618, NS34608, NS053468, and NS44687 from the National Institute of Neurological Disorders and Stroke, a Department of Defense Center of Excellence Award, AMAG Pharmaceuticals Inc, and by the Department of Veterans Affairs, all to EAN. This research was also funded in part by a Neurosurgery Research and Education Foundation grant sponsored by Codman, a Johnson & Johnson Company to JSW, NIH RO1-EB007258 to WDR, The Oregon Opportunity and a grant from the WM Keck Foundation. NR 126 TC 206 Z9 209 U1 13 U2 108 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2010 VL 30 IS 1 BP 15 EP 35 DI 10.1038/jcbfm.2009.192 PG 21 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 539IL UT WOS:000273247500003 PM 19756021 ER PT J AU Tishelman, AC Meyer, SK Haney, P McLeod, SK AF Tishelman, Amy C. Meyer, Susanne K. Haney, Penny McLeod, Sara K. TI The Clinical-Forensic Dichotomy in Sexual Abuse Evaluations: Moving Toward an Integrative Model SO JOURNAL OF CHILD SEXUAL ABUSE LA English DT Article DE clinical evaluation of child sexual abuse; forensic evaluation of child sexual abuse; assessment; evaluation of child sexual abuse; assessment of child sexual abuse; integrative model; clinical-forensic dichotomy AB We propose the use of an approach to evaluation that can be undertaken in a clinical setting when concerns regarding child sexual abuse are unclear or ambiguous and other systems are not involved, thus providing an option for the nondisclosing child often discussed in the "delayed disclosure" literature. This approach can also be appropriate for a child with a questionable prior disclosure not being served by other intervention systems. We have labeled this an "integrative" model, incorporating forensically sound practices into evaluations conducted in a clinical setting. The goals of this manuscript are to (a) provide a rationale for conducting child sexual abuse extended evaluations in a clinical setting, (b) delineate the purposes of such evaluations, (c) differentiate this "integrative" model from the forensic-clinical dichotomy framework discussed by Kuehnle (1996), and (d) briefly describe the format, which can be refined by future practice and research. C1 [Tishelman, Amy C.] Childrens Hosp Boston, Child Protect Program, Boston, MA 02115 USA. [Tishelman, Amy C.] Harvard Univ, Sch Med, Boston, MA USA. [Meyer, Susanne K.] Massachusetts Gen Hosp, Law & Psychiat Serv, Children & Law Program, Boston, MA 02114 USA. [Haney, Penny] Boston Coll, Dept Counseling Dev & Educ Psychol, Chestnut Hill, MA USA. RP Tishelman, AC (reprint author), Childrens Hosp Boston, Child Protect Program, IC Smith Bldg,300 Longwood Ave, Boston, MA 02115 USA. EM amy.tishelman@childrens.harvard.edu NR 41 TC 3 Z9 3 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1053-8712 J9 J CHILD SEX ABUS JI J. Child Sex. Abus. PY 2010 VL 19 IS 5 BP 590 EP 608 DI 10.1080/10538712.2010.512553 PN 1 PG 19 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA V14BQ UT WOS:000207710300006 PM 20924912 ER PT J AU Applebaum, AJ Otto, MW Richardson, MA Safren, SA AF Applebaum, Allison J. Otto, Michael W. Richardson, Mark A. Safren, Steven A. TI Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE HIV; Neuropsychological impairment; Depression; Opiate dependence; Methadone maintenance therapy ID METHADONE-MAINTENANCE TREATMENT; ACTIVE ANTIRETROVIRAL THERAPY; INTRAVENOUS-DRUG-USERS; MONTGOMERY-ASBERG DEPRESSION; NEUROPSYCHIATRIC INTERVIEW MINI; AIDS DEMENTIA COMPLEX; VERBAL-LEARNING TEST; COGNITIVE IMPAIRMENT; SUBSTANCE USE; NEUROCOGNITIVE IMPAIRMENT AB Neuropsychological (NP) impairment is multiply determined among HIV-infected and HIV-uninfected individuals who are also dually diagnosed with depression and who use illicit substances. The purpose of the present study was to assess the impact of HIV status, depression, and problematic substance use on NP performance. A total of 160 opiate-dependent outpatients undergoing methadone maintenance (80 HIV-infected, 80 HIV-uninfected) completed diagnostic and NP evaluations. Raw scores from individual NP tests were converted to Z scores relative to standard norms and were averaged to form a composite score. HIV-infected participants had significantly lower overall NP performanceas well as lower performance on tests of attention, motor speed, and verbal memorythan HIV-uninfected participants. In multiple regression analyses considering the role of depression and substance use, only HIV status emerged as a significant predictor of NP impairment. These findings confirm NP impairment in HIV-infected substance abusing patients independent of comorbid depression and severity of substance use. C1 [Applebaum, Allison J.; Safren, Steven A.] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. [Richardson, Mark A.] Boston Univ, Sch Med, Div Psychiat, Boston, MA 02118 USA. [Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA. RP Safren, SA (reprint author), Massachusetts Gen Hosp, Behav Med Serv, 1 Bowdoin Sq,BS07-B, Boston, MA 02114 USA. EM ssafren@partners.org OI Richardson, Mark/0000-0003-4730-3431 FU National Institute of Drug Abuse [DA018603-03]; Clara Mayo Memorial Fellowship Dissertation Award FX This project was funded by Grant DA018603-03 from the National Institute of Drug Abuse to Steven Safren and the Clara Mayo Memorial Fellowship Dissertation Award to Allison Applebaum. NR 123 TC 5 Z9 5 U1 6 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2010 VL 32 IS 6 BP 579 EP 589 AR PII 916563250 DI 10.1080/13803390903313572 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 619TA UT WOS:000279452000003 PM 19890760 ER PT J AU Jones, RN Rudolph, JL Inouye, SK Yang, FM Fong, TG Milberg, WP Tommet, D Metzger, ED Cupples, LA Marcantonio, ER AF Jones, Richard N. Rudolph, James L. Inouye, Sharon K. Yang, Frances M. Fong, Tamara G. Milberg, William P. Tommet, Douglas Metzger, Eran D. Cupples, L. Adrienne Marcantonio, Edward R. TI Development of a unidimensional composite measure of neuropsychological functioning in older cardiac surgery patients with good measurement precision SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Cognition; Cardiac surgery; Aged; Item response theory; Neuropsychology ID BYPASS GRAFT-SURGERY; ITEM RESPONSE THEORY; ALZHEIMERS-DISEASE; OUTCOMES; VARIABLES; MODELS; NUMBER; TESTS AB The objective of this analysis was to develop a measure of neuropsychological performance for cardiac surgery and to assess its psychometric properties. Older patients (n = 210) underwent a neuropsychological battery using nine assessments. The number of factors was identified with variable reduction methods. Factor analysis methods based on item response theory were used to evaluate the measure. Modified parallel analysis supported a single factor, and the battery formed an internally consistent set (coefficient alpha = .82). The developed measure provided a reliable, continuous measure (reliability .90) across a broad range of performance (-1.5 SDs to +1.0 SDs) with minimal ceiling and floor effects. C1 [Rudolph, James L.; Milberg, William P.] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA 02130 USA. [Jones, Richard N.; Inouye, Sharon K.; Yang, Frances M.; Tommet, Douglas; Metzger, Eran D.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA. [Jones, Richard N.; Inouye, Sharon K.; Yang, Frances M.; Fong, Tamara G.; Tommet, Douglas; Marcantonio, Edward R.] Hebrew SeniorLife, Aging Brain Ctr, Boston, MA USA. [Rudolph, James L.; Milberg, William P.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Inouye, Sharon K.; Fong, Tamara G.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Marcantonio, Edward R.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Jones, Richard N.; Yang, Frances M.] Beth Israel Deaconess Med Ctr, Div Gerontol, Boston, MA 02215 USA. [Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Jones, Richard N.; Rudolph, James L.; Inouye, Sharon K.; Yang, Frances M.; Fong, Tamara G.; Milberg, William P.; Metzger, Eran D.; Marcantonio, Edward R.] Harvard Univ, Sch Med, Boston, MA USA. RP Rudolph, JL (reprint author), VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, 150 S Huntington Ave, Boston, MA 02130 USA. EM jrudolph@partners.org RI Jones, Richard/J-3488-2013; OI Jones, Richard/0000-0002-1049-218X; Cupples, L. Adrienne/0000-0003-0273-7965 FU Harvard Older Americans Independence Center [AG08812-14, R03 AG029861, K24 AG00949, R21AG025193, R21 AG027549, R21 AG026566, R01 AG 030618, R03 AG028189]; VA (U.S. Department of Veterans Affairs); Milton and Shirley F. Levy Family Chair FX The first two authors contributed equally to this work and agreed to share first authorship. The authors acknowledge the contributions of David Alsop to this paper. The authors report no financial conflict of interest. This work was funded by the Harvard Older Americans Independence Center AG08812-14 (E.R.M., R.N.J.), R03 AG029861 (J.L.R.), K24 AG00949 (S.K.I.), R21AG025193 (S.K.I.), R21 AG027549 (E.R.M.), R21 AG026566 (E.R.M.), R01 AG 030618 (E.R.M.), and R03 AG028189 (E.R.M.). J. L. Rudolph is supported by a VA (U.S. Department of Veterans Affairs) Rehabilitation Career Development Award. S. K. Inouye is supported by the Milton and Shirley F. Levy Family Chair. NR 46 TC 19 Z9 20 U1 4 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2010 VL 32 IS 10 BP 1041 EP 1049 AR PII 921896933 DI 10.1080/13803391003662728 PG 9 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 692JV UT WOS:000285150000001 PM 20446144 ER PT J AU Wolitzky-Taylor, KB Ruggiero, KJ McCart, MR Smith, DW Hanson, RF Resnick, HS de Arellano, MA Saunders, BE Kilpatrick, DG AF Wolitzky-Taylor, Kate B. Ruggiero, Kenneth J. McCart, Michael R. Smith, Daniel W. Hanson, Rochelle F. Resnick, Heidi S. de Arellano, Michael A. Saunders, Benjamin E. Kilpatrick, Dean G. TI Has Adolescent Suicidality Decreased in the United States? Data From Two National Samples of Adolescents Interviewed in 1995 and 2005 SO JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY LA English DT Article ID DEPRESSION PREVENTION PROGRAM; RISK-FACTORS; YOUNG-ADULTS; CONTROLLED TRIAL; BEHAVIOR; IDEATION; YOUTH; COMORBIDITY; PREVALENCE; ABUSE AB We compared the prevalence and correlates of adolescent suicidal ideation and attempts in two nationally representative probability samples of adolescents interviewed in 1995 (National Survey of Adolescents; N = 4,023) and 2005 (National Survey of Adolescents-Replication; N = 3,614). Participants in both samples completed a telephone survey that assessed major depressive episode (MDE), post-traumatic stress disorder, suicidal ideation and attempts, violence exposure, and substance use. Results demonstrated that the lifetime prevalence of suicidal ideation among adolescents was lower in 2005 than 1995, whereas the prevalence of suicide attempts remained stable. MDE was the strongest predictor of suicidality in both samples. In addition, several demographic, substance use, and violence exposure variables were significantly associated with increased risk of suicidal ideation and attempts in both samples, with female gender, nonexperimental drug use, and direct violence exposure being consistent risk factors in both samples. C1 [Wolitzky-Taylor, Kate B.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Wolitzky-Taylor, KB (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC861, Charleston, SC 29425 USA. EM wolitzky@musc.edu FU NICHD NIH HHS [1R01 HD046830-01, R01 HD046830-01, R01 HD046830] NR 63 TC 22 Z9 22 U1 4 U2 10 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1537-4416 J9 J CLIN CHILD ADOLESC JI J. Clin. Child Adolesc. Psychol. PY 2010 VL 39 IS 1 BP 64 EP 76 DI 10.1080/15374410903401146 PG 13 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA 554BX UT WOS:000274411600006 PM 20390799 ER PT J AU Zinman, B Haffner, SM Herman, WH Holman, RR Lachin, JM Kravitz, BG Paul, G Jones, NP Aftring, RP Viberti, G Kahn, SE AF Zinman, Bernard Haffner, Steven M. Herman, William H. Holman, Rury R. Lachin, John M. Kravitz, Barbara G. Paul, Gitanjali Jones, Nigel P. Aftring, R. Paul Viberti, Giancarlo Kahn, Steven E. CA A Diabet Outcome Progression Trial TI Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PROGRESSION TRIAL ADOPT; OSTEOBLAST DIFFERENTIATION; MINERAL DENSITY; DECREASES; TROGLITAZONE; GAMMA; WOMEN AB Context: An increase in bone fractures has been observed in women taking thiazolidinediones. Objective: The objective of the study was to examine whether changes in circulating bone biomarkers provide insight into the underlying mechanisms responsible for the increase in bone fractures in female participants randomized to rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). Research Design and Methods: Paired stored baseline and 12-month serum samples were available from 1605 participants (689 women, 916 men) in ADOPT, a long-term clinical trial comparing the effects of rosiglitazone, glyburide, and metformin on glycemic control in patients with type 2 diabetes. Results: This subset was well matched to the total ADOPT study population. In women a marker of osteoclast activity, C-terminal telopeptide (for type 1 collagen), increased by 6.1% with rosiglitazone compared with reductions of 1.3% (P = 0.03 vs. rosiglitazone) and 3.3% (P = 0.002 vs. rosiglitazone) with metformin and glyburide, respectively. In men, C-terminal telopeptide was unchanged on rosiglitazone (-1.0%) and fell on metformin (-12.7%; P < 0.001) and glyburide (-4.3%, P = NS). Markers of osteoblast activity, procollagen type 1 N-propeptide (P1NP) and bone alkaline phosphatase, were reduced for women and men in almost all treatment groups, with the greatest changes in the metformin group (P1NP in females, -14.4%; P1NP in males, -19.3%), intermediate for rosiglitazone (P1NP in females, -4.4%; P1NP in males, -14.4%), and smallest for glyburide (P1NP in males, +0.2%; bone alkaline phosphatase in females, -11.6%). Conclusions: Commonly measured bone biomarkers suggest that changes in bone resorption may be partly responsible for the increased risk of fracture in women taking thiazolidinediones. (J Clin Endocrinol Metab 95: 134-142, 2010) C1 [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON MT5 3L9, Canada. [Zinman, Bernard] Univ Toronto, Toronto, ON MT5 3L9, Canada. [Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Holman, Rury R.] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford OX3 7LJ, England. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Kravitz, Barbara G.; Paul, Gitanjali; Aftring, R. Paul] GlaxoSmithKline Inc, King Of Prussia, PA 19406 USA. [Jones, Nigel P.] GlaxoSmithKline Inc, Harlow CM19 5AW, Essex, England. [Viberti, Giancarlo] Kings Coll London, Sch Med, London SE5 9RS, England. RP Kahn, SE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013; OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002; Jones, Nigel/0000-0002-1080-8439 FU GlaxoSmithKline FX This work was supported by funds from GlaxoSmithKline from whom the academic members of the ADOPT Steering Committee (B. Z., S. M. H., W. H. H., R. R. H., J. M. L., G. V., and S. E. K.) received honoraria, consulting fees, and/or grant/research support. NR 17 TC 69 Z9 78 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2010 VL 95 IS 1 BP 134 EP 142 DI 10.1210/jc.2009-0572 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 541CV UT WOS:000273391300020 PM 19875477 ER PT J AU Fazeli, PK Misra, M Goldstein, M Miller, KK Klibanski, A AF Fazeli, Pouneh K. Misra, Madhusmita Goldstein, Mark Miller, Karen K. Klibanski, Anne TI Fibroblast Growth Factor-21 May Mediate Growth Hormone Resistance in Anorexia Nervosa SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INSULIN SENSITIVITY; ADOLESCENT GIRLS; PPAR-ALPHA; FIBROBLAST-GROWTH-FACTOR-21; METABOLISM; INDUCTION; REGULATOR; SECRETION; OBESITY; FGF-21 AB Context: Anorexia nervosa (AN), a state of chronic nutritional deprivation, is characterized by GH resistance with elevated GH levels and decreased levels of IGF-I. Fibroblast growth factor (FGF)-21, a hormone produced in the liver and adipocytes, is induced in the liver by fasting and peroxisome proliferator-activated receptor-alpha agonists. In a transgenic mouse model, FGF-21 reduces IGF-I levels by inhibiting signal transducer and activator of transcription-5, a mediator of the intracellular effects of GH. Objective: The objective of the study was to investigate the relationship between FGF-21, GH, and IGF-I in AN. Design: This was a cross-sectional study. Setting: The study was conducted at a clinical research center. Patients: Patients included 23 girls: 11 with AN (16.5 +/- 0.6 yr) and 12 normal-weight controls (15.7 +/- 0.5 yr). Interventions: There were no interventions. Main Outcome Measures: We measured fasting FGF-21, glucose, insulin, IGF-I, and total area under the curve for GH (GH-AUC) and leptin during 12-h overnight frequent sampling. Results: FGF-21 levels were significantly higher in AN compared with controls, and there was a positive correlation between FGF-21 and GH-AUC (P = 0.03) after controlling for percent body fat and insulin resistance. In subjects with elevated FGF-21 levels, there was a strong inverse association between FGF-21 and IGF-I (R = -0.88, P = 0.004). FGF-21 strongly correlated with total area under the curve for leptin (R = 0.67, P = 0.02). Conclusions: FGF-21 levels are higher in AN independent of the effects of percent body fat and insulin resistance. The positive association between FGF-21 and GH-AUC and the inverse association between elevated FGF-21 levels and IGF-I suggests that above the normal range, FGF-21 may mediate a state of GH resistance in AN. (J Clin Endocrinol Metab 95: 369-374, 2010) C1 [Fazeli, Pouneh K.; Misra, Madhusmita; Miller, Karen K.; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Goldstein, Mark] Massachusetts Gen Hosp, Div Adolescent Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Klibanski, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA. EM aklibanski@partners.org FU National Institutes of Health [R01 DK062249, T32 DK007028]; National Center for Research Resources [ULI RR025758] FX This work was supported in part by National Institutes of Health Grants R01 DK062249 and T32 DK007028 and National Center for Research Resources Grant ULI RR025758 to the Harvard Clinical and Translational Science Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 21 TC 37 Z9 38 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2010 VL 95 IS 1 BP 369 EP 374 DI 10.1210/jc.2009-1730 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 541CV UT WOS:000273391300053 PM 19926712 ER PT J AU Wide, L Eriksson, K Sluss, PM Hall, JE AF Wide, Leif Eriksson, Karin Sluss, Patrick M. Hall, Janet E. TI The Common Genetic Variant of Luteinizing Hormone Has a Longer Serum Half-Life than the Wild Type in Heterozygous Women SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BETA-SUBUNIT VARIANT; INCREASED PREVALENCE; MOLECULAR-BASIS; LH; RECOGNITION; LUTROPIN; GONADOTROPINS; STIMULATION; SIALYLATION; SULFONATION AB Context: The common genetic variant of human LH has two mutations and an extra N-linked oligosaccharide chain, a modification expected to affect the half-life in the circulation. Objectives: Our objectives were to determine the half-lives of variant and wild-type forms of LH during GnRH receptor blockade in heterozygous women and to determine the time-related changes in isoform composition. Design and Participants: Serum samples were obtained from three healthy women heterozygous for variant LH before and up to 20 h after administration of the NAL-GLU GnRH antagonist. Main Outcome Measures: The half-lives were estimated by monoexponential decay. The number of sialic acid and sulfonated N-acetylgalactosamine residues per wild-type and variant LH molecule and the distribution of molecules with zero, one, two, or three sulfonated residues were measured. Results: The variant LH had a half-life that was approximately 40% longer than the corresponding forms of wild-type LH(148 vs. 108 min; P < 0.001). Variant LH had more sialic acid residues per molecule than wild type(3.6 vs. 2.4; P < 0.05), where as the number of sulfonated residues was similar (1.0 vs. 0.98). The decline in the variant LH during GnRH receptor blockade was associated with a decrease in sulfonated and an increase in sialic acid residues similar to that for in wild-type LH. Isoforms of either variant or wild-type LH with two to three sulfonate groups per molecule had the shortest half-life. Conclusion: Variant LH remains longer in circulation than wild type during GnRH receptor blockade in heterozygous women, in accord with its higher content of sialic acid. (J Clin Endocrinol Metab 95: 383-389, 2010) C1 [Wide, Leif; Eriksson, Karin] Univ Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden. [Sluss, Patrick M.; Hall, Janet E.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Wide, L (reprint author), Univ Hosp, Dept Clin Chem, SE-75185 Uppsala, Sweden. EM leif.wide@medsci.uu.se FU Uppsala University; National Institutes of Health (NIH) [R01 AG13241] FX This work was supported by grants from Uppsala University to L. W. and from the National Institutes of Health to J. E. H. (NIH R01 AG13241). NR 26 TC 14 Z9 14 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2010 VL 95 IS 1 BP 383 EP 389 DI 10.1210/jc.2009-1679 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 541CV UT WOS:000273391300055 PM 19890021 ER PT J AU Fazeli, PK Bredella, MA Misra, M Meenaghan, E Rosen, CJ Clemmons, DR Breggia, A Miller, KK Klibanski, A AF Fazeli, Pouneh K. Bredella, Miriam A. Misra, Madhusmita Meenaghan, Erinne Rosen, Clifford J. Clemmons, David R. Breggia, Anne Miller, Karen K. Klibanski, Anne TI Preadipocyte Factor-1 Is Associated with Marrow Adiposity and Bone Mineral Density in Women with Anorexia Nervosa SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GROWTH-FACTOR-I; IGF-BINDING PROTEINS; INHIBITS ADIPOGENESIS; STEM-CELLS; LEPTIN; FAT; DIFFERENTIATION; OSTEOPOROSIS; ADULTS; YOUNG AB Context: Despite having low visceral and sc fat depots, women with anorexia nervosa (AN) have elevated marrow fat mass, which is inversely associated with bone mineral density (BMD). Adipocytes and osteoblasts differentiate from a common progenitor cell, the human mesenchymal stem cell. Therefore, understanding factors that regulate this differentiation process may provide insight into bone loss in AN. Objective: The objective of the study was to investigate the relationship between preadipocyte factor-1 (Pref-1), a member of the epidermal growth factor-like family of proteins and regulator of adipocyte and osteoblast differentiation, and fat depots and BMD in AN. Design: This was a cross-sectional study. Setting: The study was conducted at a clinical research center. Patients: Patients included 20 women with AN (26.8 +/- 1.5 yr) and 10 normal-weight controls (29.2 +/- 1.7 yr). Interventions: There were no interventions. Main Outcomes Measure: Pref-1, leptin, IGF-I, IGF binding protein (IGF-BP)-2 and estradiol levels were measured. BMD of the spine and hip was measured by dual-energy x-ray absorptiometry. Marrow fat content of the L4 vertebra and femur was measured by H-1-magnetic resonance spectroscopy. Results: Pref-1 levels were significantly higher in AN compared with controls (P = 0.01). There was a positive correlation between Pref-1 and marrow fat of the proximal femoral metaphysis (R = 0.50, P = 0.01) and an inverse association between leptin and L4 marrow fat (R = -0.45, P = 0.05). There was an inverse association between Pref-1 and BMD of both the anteroposterior spine and lateral spine (R = -0.54, P = 0.003; R = -0.44, P = 0.02, respectively). Conclusions: Pref-1 is elevated in AN. Pref-1, IGF-I, IGF-BP2 and leptin are associated with marrow adiposity and BMD. (J Clin Endocrinol Metab 95: 407-413, 2010) C1 [Fazeli, Pouneh K.; Misra, Madhusmita; Meenaghan, Erinne; Miller, Karen K.; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. [Rosen, Clifford J.; Breggia, Anne] Maine Med Ctr Res Inst, Scarborough, ME 04074 USA. [Clemmons, David R.] Univ N Carolina, Dept Med, Div Endocrinol, Chapel Hill, NC 27599 USA. RP Klibanski, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA. EM aklibanski@partners.org FU National Center for Research Resources [UL1 RR025758]; National Institutes of Health [R01 DK052625, R01 HL077674, M01 RR01066, ULI RR0257801, T32 DK007028] FX This work was supported by Grant UL1 RR025758 from the National Center for Research Resources (to Harvard Clinical and Translational Science Center), and Grants R01 DK052625, R01 HL077674, M01 RR01066, ULI RR0257801, and T32 DK007028 from the National Institutes of Health. NR 40 TC 45 Z9 45 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2010 VL 95 IS 1 BP 407 EP 413 DI 10.1210/jc.2009-1152 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 541CV UT WOS:000273391300058 PM 19850693 ER PT J AU Daley, GQ AF Daley, George Q. TI Stem cells: roadmap to the clinic SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID HUMAN SOMATIC-CELLS; DEFINED FACTORS; FIBROBLASTS; LINES; EMBRYOS AB Over the last decade, a remarkable number of papers have been published in which the biology of stem cells is introduced with words and phrases such as "promise," "rapid progress," and "future therapies." To separate myth and hype from reality, the articles in this Stem Cells Review series comprise a rich resource on the state of this fast-paced field and provide a balanced perspective on some of the major advances. They recount what the field has achieved over the past decade and where the field is headed. They also highlight the challenges to be faced in translating what is indeed highly promising science into proven therapies that will regenerate and repair diseased tissues. C1 [Daley, George Q.] Childrens Hosp Boston, Boston, MA 02115 USA. [Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Daley, George Q.] Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA. [Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Daley, George Q.] Harvard Stem Cell Inst, Boston, MA USA. RP Daley, GQ (reprint author), Childrens Hosp Boston, Karp Family Res Bldg 7214,300 Longwood Ave, Boston, MA 02115 USA. EM george.daley@childrens.harvard.edu FU Howard Hughes Medical Institute NR 22 TC 42 Z9 43 U1 0 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 8 EP 10 DI 10.1172/JCI41801 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700003 PM 20051631 ER PT J AU Yi, BA Wernet, O Chien, KR AF Yi, B. Alexander Wernet, Oliver Chien, Kenneth R. TI Pregenerative medicine: developmental paradigms in the biology of cardiovascular regeneration SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID BONE-MARROW-CELLS; DUCHENNE MUSCULAR-DYSTROPHY; HEMATOPOIETIC STEM-CELLS; INFILTRATION FOLLOWING ALLOMYOBLAST; ADULT MAMMALIAN CARDIOMYOCYTES; ACUTE MYOCARDIAL-INFARCTION; PROGENITOR CELLS; SKELETAL-MUSCLE; MYOBLAST TRANSPLANTATION; LIMB REGENERATION AB The ability to create new functional cardiomyocytes is the holy grail of cardiac regenerative medicine. From studies using model organisms, new insights into the fundamental pathways that drive heart muscle regeneration have begun to arise as well as a growing knowledge of the distinct families of multipotent cardiovascular progenitors that generate diverse lineages during heart development. In this Review, we highlight this intersection of the "pregenerative" biology of heart progenitor cells and heart regeneration and discuss the longer term challenges and opportunities in moving toward a therapeutic goal of regenerative cardiovascular medicine. C1 [Yi, B. Alexander; Wernet, Oliver; Chien, Kenneth R.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Chien, Kenneth R.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. RP Chien, KR (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charles River Plaza CPZN 3200,185 Cambridge St, Boston, MA 02114 USA. EM krchien@partners.org NR 108 TC 53 Z9 54 U1 0 U2 6 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 20 EP 28 DI 10.1172/JCI40820 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700005 PM 20051633 ER PT J AU Frank, NY Schatton, T Frank, MH AF Frank, Natasha Y. Schatton, Tobias Frank, Markus H. TI The therapeutic promise of the cancer stem cell concept SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN-MELANOMA CELLS; ACUTE MYELOBLASTIC-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; HUMAN-MALIGNANT MELANOMA; BREAST-CANCER; VASCULOGENIC MIMICRY; PROGENITOR CELLS AB Cancer stem cells (CSCs) are a subpopulation of tumor cells that selectively possess tumor initiation and self-renewal capacity and the ability to give rise to bulk populations of nontamorigenic cancer cell progeny through differentiation. As we discuss here, they have been prospectively identified in several human malignancies, and their relative abundance in clinical cancer specimens has been correlated with malignant disease progression in human patients. Furthermore, recent findings suggest that clinical cancer progression driven by CSCs may contribute to the failure of existing therapies to consistently eradicate malignant tumors. Therefore, CSC-directed therapeutic approaches might represent translationally relevant strategies to improve clinical cancer therapy, in particular for those malignancies that are currently refractory to conventional anticancer agents directed predominantly at tumor bulk populations. C1 [Schatton, Tobias; Frank, Markus H.] Childrens Hosp Boston, Transplantat Res Ctr, Boston, MA 02115 USA. [Frank, Markus H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Frank, Natasha Y.] VA Boston Healthcare Syst, Dept Med, W Roxbury, MA USA. [Frank, Natasha Y.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. RP Frank, MH (reprint author), Childrens Hosp Boston, Transplantat Res Ctr, 300 Longwood Ave, Boston, MA 02115 USA. EM markus.frank@childrens.harvard.edu RI Frank, Markus/O-1625-2014 OI Frank, Markus/0000-0002-1312-0488 FU National Cancer Institute, NIH [1RO1CA113796, 1RO1CA138231, 2P50CA093683-06A20006]; National institute of Neurological Disorders and Stroke, NIH [1KO8NS051349]; American Heart Association FX This work was supported by National Cancer Institute, NIH, grants 1RO1CA113796, 1RO1CA138231, and 2P50CA093683-06A20006 (to M.H. Frank) and by National institute of Neurological Disorders and Stroke, NIH, grant 1KO8NS051349 (to N.Y. Frank). T. Schatton is the recipient of a Postdoctoral Fellowship Award From the American Heart Association Founders Affiliate. NR 125 TC 282 Z9 302 U1 6 U2 66 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 41 EP 50 DI 10.1172/JCI41004 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700007 PM 20051635 ER PT J AU Ma, JH Meng, Y Kwiatkowski, DJ Chen, XX Feng, HY Sun, Q Zha, XJ Wang, F Wang, Y Jing, YL Zhang, S Chen, RR Wang, LM Wu, E Cai, GF Malinowska-Kolodziej, I Liao, Q Liu, YQ Zhao, Y Sun, Q Xu, KF Dai, JW Han, JH Wu, LZ Zhao, RC Shen, HX Zhang, HB AF Ma, Jianhui Meng, Yan Kwiatkowski, David J. Chen, Xinxin Feng, Haiyong Sun, Qian Zha, Xiaojun Wang, Fang Wang, Ying Jing, Yanling Zhang, Shu Chen, Rongrong Wang, Lianmei Wu, Erxi Cai, Guifang Malinowska-Kolodziej, Izabela Liao, Qi Liu, Yuqin Zhao, Yi Sun, Qiang Xu, Kaifeng Dai, Jianwu Han, Jiahuai Wu, Lizi Zhao, Robert Chunhua Shen, Huangxuan Zhang, Hongbing TI Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID TUBEROUS SCLEROSIS COMPLEX; NOTCH SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MTOR PATHWAY; RAG GTPASES; CANCER; ACTIVATION; GENES; P53; TRANSCRIPTION AB The receptor tyrosine kinase/PI3K/AKT/mammalian target of rapamycin (RTK/PI3K/AKT/mTOR) pathway is frequently altered in cancer, but the underlying mechanism leading to tumorigenesis by activated mTOR remains less clear. Here we show that mTOR is a positive regulator of Notch signaling in mouse and human cells, acting through induction of the STAT3/p63/jagged signaling cascade. Furthermore, in response to differential cues from mTOR, we found that Notch served as a molecular switch to shift the balance between cell proliferation and differentiation. We determined that hyperactive mTOR signaling impaired cell differentiation of murine embryonic fibroblasts via potentiation of Notch signaling. Elevated mTOR signaling strongly correlated with enhanced Notch signaling in poorly differentiated but not in well-differentiated human breast cancers. Both human lung lymphangioleiomyomatosis (LAM) and mouse kidney tumors with hyperactive mTOR due to tumor suppressor TSC1 or TSC2 deficiency exhibited enhanced STAT3/p63/Notch signaling. Furthermore, tumorigenic potential of cells with uncontrolled mTOR signaling was suppressed by Notch inhibition. Our data therefore suggest that perturbation of cell differentiation by augmented Notch signaling might be responsible for the underdifferentiated phenotype displayed by certain tumors with an aberrantly activated RTK/PI3K/AKT/mTOR pathway. Additionally, the STAT3/p63/Notch axis may be a useful target for the treatment of cancers exhibiting hyperactive mTOR signaling. C1 [Zhang, Hongbing] Peking Union Med Coll, Inst Basic Med Sci, Dept Physiol, Beijing 100005, Peoples R China. [Ma, Jianhui; Meng, Yan; Chen, Xinxin; Feng, Haiyong; Sun, Qian; Zha, Xiaojun; Wang, Fang; Wang, Ying; Jing, Yanling; Zhang, Shu; Chen, Rongrong; Wang, Lianmei; Zhang, Hongbing] Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Dept Physiol & Pathophysiol, Beijing 100730, Peoples R China. [Ma, Jianhui; Meng, Yan; Chen, Xinxin; Feng, Haiyong; Sun, Qian; Zha, Xiaojun; Wang, Fang; Wang, Ying; Jing, Yanling; Zhang, Shu; Chen, Rongrong; Wang, Lianmei; Liu, Yuqin; Zhao, Robert Chunhua; Zhang, Hongbing] Chinese Acad Med Sci, Sch Basic Med, Beijing 100037, Peoples R China. [Ma, Jianhui; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Lab Ocular Genet, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China. [Meng, Yan; Zhao, Robert Chunhua] Chinese Acad Med Sci, Inst Basic Med Sci, Ctr Excellence Tissue Engn, Beijing 100730, Peoples R China. [Kwiatkowski, David J.; Malinowska-Kolodziej, Izabela] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Translat Med,Dept Med, Boston, MA 02115 USA. [Zhang, Shu; Sun, Qiang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Surg, Div Breast Surg, Beijing 100037, Peoples R China. [Wang, Lianmei; Xu, Kaifeng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Med, Div Resp Med, Beijing 100037, Peoples R China. [Wu, Erxi] N Dakota State Univ, Dept Pharmaceut Sci, Fargo, ND 58105 USA. [Cai, Guifang] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Liao, Qi; Zhao, Yi] Chinese Acad Sci, Inst Comp Technol, Ctr Adv Comp Res, Beijing, Peoples R China. [Liu, Yuqin] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, Beijing 100730, Peoples R China. [Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol Dev Biol, Beijing, Peoples R China. [Han, Jiahuai] Xiamen Univ, Sch Life Sci, Key Lab, Minist Educ Cell Biol & Tumor Cell Engn, Xiamen, Fujian, Peoples R China. [Wu, Lizi] Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, Gainesville, FL USA. RP Zhang, HB (reprint author), Peking Union Med Coll, Inst Basic Med Sci, Dept Physiol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China. EM hbzhang2006@gmail.com RI Zhang, HB/G-4124-2010; Han, J/G-4671-2010; Malinowska, Izabela/A-4816-2013; Zhao, Yi/A-2962-2011; Peng, Haiyong/S-8045-2016 OI Zhao, Yi/0000-0001-6046-8420; FU National Natural Science Foundation of China [30772466, 30788004, 30872840, 30971503]; National Basic Research Program of China (973 Program) [2009CB522203, 2009CBS22106]; Innovation Project of Key Laboratory of Ophthalmology; NIH National Cancer Institute [1P01CA120964] FX We thank Jihua Chen for instruction on Notch reporter assay and June Goto for help with reagents. This Study was Supported by grants from the National Natural Science Foundation of China (grants 30772466, 30788004, 30872840, and 30971503), the National Basic Research Program of China (973 Program) (grants 2009CB522203 and 2009CBS22106), the Innovation Project of Key Laboratory of Ophthalmology, and the NIH National Cancer Institute (grant 1P01CA120964, to DJ. Kwiatkowski). NR 66 TC 119 Z9 126 U1 0 U2 27 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 103 EP 114 DI 10.1172/JCI37964 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700017 PM 20038814 ER PT J AU Smyth, JW Hong, TT Gao, DC Vogan, JM Jensen, BC Fong, TS Simpson, PC Stainier, DYR Chi, NC Shaw, RM AF Smyth, James W. Hong, Ting-Ting Gao, Danchen Vogan, Jacob M. Jensen, Brian C. Fong, Tina S. Simpson, Paul C. Stainier, Didier Y. R. Chi, Neil C. Shaw, Robin M. TI Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GAP-JUNCTION PROTEIN; RIGHT-VENTRICULAR CARDIOMYOPATHY; EPICARDIAL BORDER ZONE; MICROTUBULE PLUS-END; HEART-FAILURE; OXIDATIVE STRESS; PLASMA-MEMBRANE; FLUORESCENT PROTEIN; ZONULA OCCLUDENS-1; CARDIAC MYOCYTES AB Gap junctions form electrical conduits between adjacent myocardial cells, permitting rapid spatial passage of the excitation current essential to each heartbeat. Arrhythmogenic decreases in gap junction coupling are a characteristic of stressed, failing, and aging myocardium, but the mechanisms of decreased coupling are poorly understood. We previously found that microtubules bearing gap junction hemichannels (connexons) can deliver their cargo directly to adherens junctions. The specificity of this delivery requires the microtubule plus-end tracking protein EB1. We performed this study to investigate the hypothesis that the oxidative stress that accompanies acute and chronic ischemic disease perturbs connexon forward trafficking. We found that EB1 was displaced in ischemic human hearts, stressed mouse hearts, and isolated cells subjected to oxidative stress. As a result, we observed limited microtubule interaction with adherens junctions at intercalated discs and reduced connexon delivery and gap junction coupling. A point mutation within the tubulin-binding domain of EB1 reproduced EB1 displacement and diminished connexon delivery, confirming that EB1 displacement can limit gap junction coupling. In zebrafish hearts, oxidative stress also reduced the membrane localization of connexin and slowed the spatial spread of excitation. We anticipate that protecting the microtubule-based forward delivery apparatus of connexons could improve cell-cell coupling and reduce ischemia-related cardiac arrhythmias. C1 [Smyth, James W.; Hong, Ting-Ting; Gao, Danchen; Vogan, Jacob M.; Fong, Tina S.; Simpson, Paul C.; Stainier, Didier Y. R.; Shaw, Robin M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Smyth, James W.; Hong, Ting-Ting; Jensen, Brian C.; Simpson, Paul C.; Chi, Neil C.; Shaw, Robin M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Jensen, Brian C.; Simpson, Paul C.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA. [Stainier, Didier Y. R.; Chi, Neil C.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. RP Shaw, RM (reprint author), 505 Parnassus Ave, San Francisco, CA 94143 USA. EM shawrm@medicine.ucsf.edu OI Shaw, Robin/0000-0001-7429-6092; Smyth, James/0000-0003-4246-7904 FU American Federation for Aging Research [A112457]; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease; UCSF Foundation for Cardiac Research; Department of Veterans Affairs Research Service; NIH [HL31113, HL54737, HL094414, HL07S449] FX The authors are grateful to Kevin Chu, Jose Sanchez, Lily Jan, and Samy Lamouille (UCSF) for critical review of this manuscript, Farah Sheikh for technical advice on tissue Fractionation, Ivy Hsieh and Margaret Mayes for tissue cryosectioning, and Sean Van Slyck (California Transplant Donor Network) for human tissue. This work was supported in part by the American Federation for Aging Research grant A112457 (to J.W. Smyth), the Young Investigators Award from the GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease (to B.C. Jensen and R.M. Shaw), the UCSF Foundation for Cardiac Research (to B.C. Jensen), the Department of Veterans Affairs Research Service (to P.C. Simpson), and NIH grants HL31113 (to P.C. Simpson), HL54737 (to D.Y.R. Stainier), and HL094414 and HL07S449 (to R.M. Shaw). NR 66 TC 105 Z9 109 U1 0 U2 9 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 266 EP 279 DI 10.1172/JCI39740 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700030 PM 20038810 ER PT J AU Rached, MT Kode, A Silva, BC Jung, DY Gray, S Ong, H Paik, JH DePinho, RA Kim, JK Karsenty, G Kousteni, S AF Rached, Marie-Therese Kode, Aruna Silva, Barbara C. Jung, Dae Young Gray, Susan Ong, Helena Paik, Ji-Hye DePinho, Ronald A. Kim, Jason K. Karsenty, Gerard Kousteni, Stavroula TI FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID TRANSCRIPTION FACTOR FOXO1; BETA-CELL; CAENORHABDITIS-ELEGANS; TRANSGENIC MICE; INSULIN ACTION; DIABETES-MELLITUS; SIGNALING PATHWAY; OXIDATIVE STRESS; GLYCEMIC CONTROL; GENE-EXPRESSION AB Osteoblasts have recently been found to play a role in regulating glucose metabolism through secretion of osteocalcin. it is unknown, however, how this osteoblast function is regulated transcriptionally. As FoxO1 is a forkhead family transcription factor known to regulate several key aspects of glucose homeostasis, we investigated whether its expression in osteoblasts may contribute to its metabolic functions. Here we show that mice lacking Foxo1 only in osteoblasts had increased pancreatic beta cell proliferation, insulin secretion, and insulin sensitivity. The ability of osteoblast-specific FoxO1 deficiency to affect metabolic homeostasis was due to increased osteocalcin expression and decreased expression of Esp, a gene that encodes a protein responsible for decreasing the bioactivity of osteocalcin. These results indicate that FoxO1 expression in osteoblasts contributes to FoxO1 control of glucose homeostasis and identify FoxO1 as a key modulator of the ability of the skeleton to function as an endocrine organ regulating glucose metabolism. C1 [Rached, Marie-Therese; Kode, Aruna; Silva, Barbara C.; Kousteni, Stavroula] Columbia Univ, Coll Phys & Surg, Dept Med, Div Endocrinol, New York, NY USA. [Jung, Dae Young; Gray, Susan; Ong, Helena; Kim, Jason K.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA. [Paik, Ji-Hye; DePinho, Ronald A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Paik, Ji-Hye; DePinho, Ronald A.] Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA. [Kim, Jason K.] Univ Massachusetts, Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Worcester, MA USA. [Karsenty, Gerard] Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY USA. RP Kousteni, S (reprint author), Russ Berrie Med Sci Pavil,1150 St Nicholas Ave,Ro, New York, NY 10032 USA. EM sk2836@columbia.edu FU NIH [AR055931, AR054447, AR045548, DK078042]; Brazilian National Council of Technological and Scientific Development FX The anchors are grateful to John P. Bilezikian, Domenico Accili, and Anthony Ferrante for helpful discussions; Eiichi Hinoi for helpful suggestions on osteocalcin carboxylation assays; Luis Garcia for help in the HPLC measurements; Chiyuan A. Zhang for help with the statistical analysis; and Charles Duncan for technical assistance. We are grateful to the histology facility of the Diabetes and Endocrinology Research Center (DERC) of Columbia University Medical Center (supported by NIDDK DK063608-07) for help with histological analysis. This work was supported by NIH grants AR055931 and AR054447 (to S. Kousteni) and AR045548 and DK078042 (to G. Karsenty) and grants from the Brazilian National Council of Technological and Scientific Development (to B,C. Silva). NR 53 TC 108 Z9 116 U1 0 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 357 EP 368 DI 10.1172/JCI39901 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700037 PM 20038793 ER PT J AU Hall, NDP Fabinyi, G Gul, SM Cher, L Leibsch, NJ AF Hall, Nick D. P. Fabinyi, Gavin Gul, Shahid M. Cher, Lawrence Leibsch, Norbert J. TI Spinal drop metastasis from grade I skull base chondrosarcoma SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Chondrosarcoma; Metastasis; Spinal ID MAFFUCCIS-SYNDROME; CHONDROMA; CHORDOMA; EMPHASIS; TUMORS; FALX AB Chondrosarcoma of the skull base is a rare turnout with a good prognosis following surgical resection. We describe a patient with low-grade chondrosarcoma of the skull base with intradural extramedullary spinal metastases. A 31-year-old female with grade I chondrosarcoma involving the cavernous sinus, sphenoid wing and clivus presented at age 19. The turnout was subtotally excised at initial surgery and over the following 4 years, 3 subsequent resections were undertaken for tumour progression followed by proton beam radiotherapy to the residual turnout. The patient re-presented with cervical radiculopathy 7 years later. MRI showed multiple, intradural extramedullary spinal drop metastases. Following surgical excision of the symptomatic lesion, histological diagnosis was confirmed as a mixed hyaline/myxoid grade I chondrosarcoma. Patients with skull base chondrosarcoma with intradural extension should have whole spine imaging as part of long-term monitoring to exclude drop metastases, particularly after intradural Surgery. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Hall, Nick D. P.; Fabinyi, Gavin; Gul, Shahid M.] Austin Hosp, Dept Neurosurg, Heidelberg, Vic 3084, Australia. [Cher, Lawrence] Austin Hosp, Dept Neurooncol, Heidelberg, Vic 3084, Australia. [Leibsch, Norbert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Hall, NDP (reprint author), Austin Hosp, Dept Neurosurg, POB 5555, Heidelberg, Vic 3084, Australia. EM drndphall@mac.com NR 20 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD JAN PY 2010 VL 17 IS 1 BP 135 EP 137 DI 10.1016/j.jocn.2009.02.033 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 547BQ UT WOS:000273860500032 PM 19864142 ER PT J AU Yao, JC Lombard-Bohas, C Baudin, E Kvols, LK Rougier, P Ruszniewski, P Hoosen, S St Peter, J Haas, T Lebwohl, D Van Cutsem, E Kulke, MH Hobday, TJ O'Dorisio, TM Shah, MH Cadiot, G Luppi, G Posey, JA Wiedenmann, B AF Yao, James C. Lombard-Bohas, Catherine Baudin, Eric Kvols, Larry K. Rougier, Philippe Ruszniewski, Philippe Hoosen, Sakina St Peter, Jessica Haas, Tomas Lebwohl, David Van Cutsem, Eric Kulke, Matthew H. Hobday, Timothy J. O'Dorisio, Thomas M. Shah, Manisha H. Cadiot, Guillaume Luppi, Gabriele Posey, James A. Wiedenmann, Bertram TI Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ISLET-CELL-CARCINOMA; ADVANCED SOLID TUMORS; INTERFERON-ALPHA; MAMMALIAN TARGET; SOMATOSTATIN ANALOGS; ENDOCRINE CARCINOMA; RAD001 EVEROLIMUS; RAPAMYCIN; OCTREOTIDE; STREPTOZOTOCIN AB Purpose No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. Patients and Methods This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months. Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline. Trough concentrations of everolimus and octreotide were assessed. Results By central radiology review, in stratum 1, there were 11 partial responses (9.6%), 78 patients (67.8%) with stable disease (SD), and 16 patients (13.9%) with progressive disease; median progression-free survival (PFS) was 9.7 months. In stratum 2, there were two partial responses (4.4%), 36 patients (80%) with SD, and no patients with progressive disease; median PFS was 16.7 months. Patients with an early CgA or NSE response had a longer PFS compared with patients without an early response. Coadministration of octreotide LAR and everolimus did not impact exposure to either drug. Most adverse events were mild to moderate and were consistent with those previously seen with everolimus. Conclusion Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy. C1 [Yao, James C.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Novartis Oncol, Florham Pk, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Univ Iowa, Iowa City, IA USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. Univ Alabama, Birmingham, AL USA. Hosp Civils Lyon, Lyon, France. Inst Gustave Roussy, Villejuif, France. Hop Ambroise Pare, Boulogne Billancourt, France. Hop Beaujon, Clichy, France. Hop Robert Debre, Reims, France. Novartis Pharma AG, Basel, Switzerland. Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium. Azienda Osped Univ Modena, Modena, Italy. Charite, Campus Virchow Klinikum, Berlin, Germany. RP Yao, JC (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Unit 426, Houston, TX 77030 USA. EM jyao@mdanderson.org FU Novartis Pharma AG, Basel, Switzerland FX Supported by Novartis Pharma AG, Basel, Switzerland. NR 36 TC 308 Z9 312 U1 0 U2 9 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2010 VL 28 IS 1 BP 69 EP 76 DI 10.1200/JCO.2009.24.2669 PG 8 WC Oncology SC Oncology GA 537HM UT WOS:000273103900013 PM 19933912 ER PT J AU Chen, RC Chin, MS Ng, AK Feng, Y Neuberg, D Silver, B Pinkus, GS Stevenson, MA Mauch, PM AF Chen, Ronald C. Chin, Michael S. Ng, Andrea K. Feng, Yang Neuberg, Donna Silver, Barbara Pinkus, Geraldine S. Stevenson, Mary Ann Mauch, Peter M. TI Early-Stage, Lymphocyte-Predominant Hodgkin's Lymphoma: Patient Outcomes From a Large, Single-Institution Series With Long Follow-Up SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 44th Annual Meeting of the American-Society-of-Clinical-Oncology CY MAY 30-JUN 03, 2008 CL Chicago, IL SP Amer Soc Clin Oncol ID STUDY-GROUP GHSG; CLINICAL PRESENTATION; PHASE-2 TRIAL; DISEASE; RADIOTHERAPY; RITUXIMAB; CHEMOTHERAPY AB Purpose The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined. Treatment has become less aggressive over time in an attempt to reduce iatrogenic complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear. We present the long-term outcome of patients treated at a single institution. Patients and Methods The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005. Pathologic diagnosis for all patients was confirmed using standard criteria. Ninety-three patients received radiation therapy (RT) alone, 13 received RT with chemotherapy, and seven received chemotherapy alone. Among patients treated with RT, 25 received limited-field, 35 received regional-field, and 46 received extended-field RT. Results Median follow-up was 136 months. Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively. PFS and OS did not differ among patients who received limited-field, regional-field, or extended-field RT. In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment. Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99). The addition of chemotherapy to RT did not improve PFS or OS compared with RT alone. Conclusion RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease. C1 [Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Harvard Radiat Oncol Program, Boston, MA 02215 USA. Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. Univ Massachusetts, Sch Med, Worcester, MA USA. RP Ng, AK (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM ang@lroc.harvard.edu NR 23 TC 45 Z9 47 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2010 VL 28 IS 1 BP 136 EP 141 DI 10.1200/JCO.2009.24.0945 PG 6 WC Oncology SC Oncology GA 537HM UT WOS:000273103900023 PM 19933914 ER PT J AU Penson, RT Dizon, DS Cannistra, SA Roche, MR Krasner, CN Berlin, ST Horowitz, NS DiSilvestro, PA Matulonis, UA Lee, H King, MA Campos, SM AF Penson, Richard T. Dizon, Don S. Cannistra, Stephen A. Roche, Maria R. Krasner, Carolyn N. Berlin, Suzanne T. Horowitz, Neil S. DiSilvestro, Paul A. Matulonis, Ursula A. Lee, Hang King, Modjulie A. Campos, Susana M. TI Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ENDOTHELIAL GROWTH-FACTOR; GYNECOLOGIC-ONCOLOGY-GROUP; METRONOMIC ORAL CYCLOPHOSPHAMIDE; RECURRENT OVARIAN-CANCER; EPITHELIAL OVARIAN; CLINICAL-TRIAL; SOLID TUMORS; PERITONEAL; PLATINUM; CALIFORNIA AB Purpose New strategies are needed to improve outcomes for patients with advanced ovarian cancer. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor but is associated with GI perforations (GIPs) in patients with recurrent disease. Patients and Methods An open-label, phase II clinical trial was conducted in newly diagnosed patients with stage >= IC epithelial mullerian tumors. Patients received intravenous (IV) carboplatin (area under the curve = 5), paclitaxel (175 mg/m(2) IV), and bevacizumab (15 mg/kg IV) for six to eight cycles on day 1 every 21 days. Bevacizumab was omitted in the first cycle and continued as a single agent for 1 year. Results Sixty-two women participated in this study. Fifty-one patients (82%) were optimally surgically cytoreduced before treatment. The median age was 58 years (range, 18 to 77 years). Forty-five women (73%) had ovarian cancer, 10 (16%) had peritoneal cancer, four (6%) had fallopian tube cancers, and three (5%) had uterine papillary serous tumors. The majority of patients (90%) had stage III or IV disease. A median of 17 maintenance cycles (range, 0 to 25+ cycles) of bevacizumab (556 cycles) were administered with mild toxicity. Treatment was associated with two pulmonary embolisms and two GIPs, all occurring during the chemotherapy phase of treatment (364 total cycles). No grade 4 toxicities were seen during maintenance bevacizumab treatment. Radiographic responses were documented in 21 (75%) of 28 women with measurable disease (11 complete responses and 10 partial responses), with CA-125 responses in 76% of patients (11 complete responses, 21%; and 35 partial responses, 55%). The progression-free survival rate at 36 months was 58%. Conclusion The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer. C1 [Penson, Richard T.] Massachusetts Gen Hosp, Div Hematol Oncol, Dana Farber Harvard Canc Ctr, Dana Farber Canc Inst,Beth Israel Deaconess Med C, Boston, MA 02114 USA. Brown Univ, Women & Infants Hosp, Providence, RI USA. RP Penson, RT (reprint author), Massachusetts Gen Hosp, Div Hematol Oncol, Dana Farber Harvard Canc Ctr, Dana Farber Canc Inst,Beth Israel Deaconess Med C, Yawkey 9-064,32 Fruit St, Boston, MA 02114 USA. EM rpenson@partners.org FU Dana-Farber/Harvard Cancer Center FX Supported by an investigator-initiated grant from Genentech and the clinical trials program at the Dana-Farber/Harvard Cancer Center. NR 22 TC 62 Z9 68 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2010 VL 28 IS 1 BP 154 EP 159 DI 10.1200/JCO.2009.22.7900 PG 6 WC Oncology SC Oncology GA 537HM UT WOS:000273103900026 PM 19917843 ER PT J AU Mauch, P AF Mauch, Peter TI What Is the Appropriate Systemic Chemotherapy for Lymphocyte-Predominant Hodgkin's Lymphoma? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Letter ID CLINICAL PRESENTATION; DISEASE; TRIAL; ABVD C1 Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. RP Mauch, P (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2010 VL 28 IS 1 BP E8 EP E8 DI 10.1200/JCO.2009.26.3293 PG 1 WC Oncology SC Oncology GA 537HM UT WOS:000273103900036 ER PT J AU Goff, DC Hill, M Freudenreich, O AF Goff, Donald C. Hill, Michele Freudenreich, Oliver TI Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ANTIPSYCHOTIC MEDICATION ADHERENCE; RANDOMIZED CONTROLLED-TRIAL; SERIOUS MENTAL-ILLNESS; FINANCIAL INCENTIVES; RISK-FACTORS; 1ST-EPISODE SCHIZOPHRENIA; COMPLIANCE THERAPY; CLINICAL-TRIALS; PHARMACY DATA; 1ST EPISODE AB Nonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse. (J Clin Psychiatry 2010;71[suppl 2]:20-26) C1 Harvard Univ, Sch Med, Schizophrenia Program, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Goff, DC (reprint author), Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA. EM goff@psych.mgh.harvard.edu FU Janssen, Division of Ortho-McNeill-Janssen Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis; Pfizer; Otsuka (Data Safety Monitoring Board); Lippincott Williams Wilkins FX This article was supported by an educational grant from Janssen, Division of Ortho-McNeill-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeill Janssen Scientific Affairs, LLC.; Dr Goff is a consultant for Schering-Plough, Eli Lilly, E Hoffman-La Roche, Takeda, Biovail, Solvay, and Dainippon Sumitomo; has received grant/research support from GlaxoSmithKline, Novartis, and Pfizer; and has received other financial support from Otsuka (Data Safety Monitoring Board). Dr Freudenreich is a consultant for Beacon Health Strategies, has received grant/research support from Pfizer, has received honoraria from Reed Medical Education, and has received other financial support from Lippincott Williams & Wilkins. Dr Hill has no personal affiliations or financial relationships with any commercial interest to disclose relative to this article. NR 65 TC 53 Z9 53 U1 3 U2 24 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2010 VL 71 SU 2 BP 20 EP 26 DI 10.4088/JCP.9096su1cc.04 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 705VX UT WOS:000286169900004 PM 21190649 ER PT J AU Garanger, E Blois, J Hilderbrand, SA Shao, FW Josephson, L AF Garanger, Elisabeth Blois, Joseph Hilderbrand, Scott A. Shao, Fangwei Josephson, Lee TI Divergent Oriented Synthesis For the Design of Reagents for Protein Conjugation SO JOURNAL OF COMBINATORIAL CHEMISTRY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; ANNEXIN-V; IMAGING AGENTS; APOPTOSIS AB Instead of using diversity oriented syntheses (DOS) to obtain compounds with biological activities, we employed the DOS method to efficiently obtain multifunctional single attachment point (MSAP) reagents for the conjugation to proteins. Acid insensitive functional groups (chelators, fluorochromes) were attached to Lys-Cys-NH(2) or Lys-Lys-beta Ala-Cys-NH(2), peptide scaffolds. After cleavage from solid Supports, the modified peptide intermediates were split and further modified by two solution phase, chemoselective reactions employing the single amine and single thiol presented oil the intermediates. MSAP-based fluorochrome-chelates were obtained, some possessing a third functional group like a polyethylene glycol (PEG) polymer or "click chemistry" reactive alkynes and azides. The DOS of MSAP reagents permitted the efficient generation of panels of MSAP reagents that can be used to obtain multifunctional proteins with a single modified amino acid (a single attachment point). C1 [Garanger, Elisabeth; Blois, Joseph; Josephson, Lee] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Nucl Med & Mol Imaging,Ctr Translat Nucl Med, Charlestown, MA 02129 USA. [Garanger, Elisabeth; Blois, Joseph; Josephson, Lee] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. [Garanger, Elisabeth] Univ Bordeaux 1, IPB ENSCBP, CNRS, LCPO,UMR 5629, F-33607 Pessac, France. [Hilderbrand, Scott A.; Shao, Fangwei] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Hilderbrand, Scott A.; Shao, Fangwei] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. RP Josephson, L (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Nucl Med & Mol Imaging,Ctr Translat Nucl Med, 149 13th St, Charlestown, MA 02129 USA. EM ljosephson@mgh.harvard.edu RI Shao, Fangwei/B-7026-2011 FU [R01 EB004472]; [R01 E13009691]; [P50 CA86355] FX This work was supported by R01 EB004472, ROI E13009691, and P50 CA86355. All authors declare no conflict of interest. NR 16 TC 12 Z9 12 U1 0 U2 6 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1520-4766 J9 J COMB CHEM JI J. Comb. Chem. PD JAN-FEB PY 2010 VL 12 IS 1 BP 57 EP 64 DI 10.1021/cc900141b PG 8 WC Chemistry, Applied; Chemistry, Medicinal; Chemistry, Multidisciplinary SC Chemistry; Pharmacology & Pharmacy GA 541HQ UT WOS:000273406300013 PM 19928910 ER PT J AU Prakash, P Kalra, MK Digumarthy, SR Hsieh, J Pien, H Singh, S Gilman, MD Shepard, JAO AF Prakash, Priyanka Kalra, Mannudeep K. Digumarthy, Subba R. Hsieh, Jiang Pien, Homer Singh, Sarabjeet Gilman, Matthew D. Shepard, Jo-Anne O. TI Radiation Dose Reduction With Chest Computed Tomography Using Adaptive Statistical Iterative Reconstruction Technique: Initial Experience SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE chest CT; ASIR; radiation dose ID CONE-BEAM CT; HELICAL CT; OPTIMIZATION; MODULATION; ALGORITHMS; MULTISLICE; RESOLUTION AB Purpose: To assess radiation dose reduction and image quality for weight-based chest computed tomographic (CT) examination results reconstructed using adaptive statistical iterative reconstruction (ASIR) technique. Materials and Methods: With local ethical committee approval, weight-adjusted chest CT examinations were performed using ASIR in 98 patients and filtered backprojection (FBP) in 54 weight-matched patients oil a 64-slice multidetector CT Patients were categorized into 3 groups: 60 kg or less (n = 32), 61 to 90 kg (n = 77), and 91 kg or more (n = 43) for weight-based adjustment of noise indices for automatic exposure control (Auto mA; GE Healthcare, Waukesha, Wis). Remaining scan parameters were held constant at 0.984:1 pitch, 120 kilovolts (peak), 40-mm table feed per rotation, and 2.5-mm section thickness. Patients' weight, scanning parameters, and CT dose index volume were recorded. Effective doses (EDs) were estimated. linage noise was measured in the descending thoracic aorta at the level of the carina. Data were analyzed using analysis of variance. Results: Compared with FBP, ASIR was associated with all overall mean (SD) decrease of 27.6% in ED (ASIR. 8.8 [2.3] mSv: FBP, 12.2 [2.1] mSv; P < 0.0001). With the use of ASIR, the ED values were 6.5 (1.8) mSv (28.8% decrease), 7.3 (1.6) mSv (27.3% decrease), and 12.8 (2.3) mSv (26.8% decrease) for the weight groups of 60 kg or less, 61 to 90 kg, and 91 kg or more, respectively, compared with 9.2 (2.3) mSv, 10.0 (2.0) mSv, and 17.4 (2.1) mSv with FBP (P < 0.0001). Despite dose reduction, there was less noise with ASIR (12.6 [2.9] mSv) than with FBP (16.6 [6.2] mSv; P < 0.0001). Conclusions: Adaptive statistical iterative reconstruction helps reduce chest CT radiation dose and improve image quality compared with the conventionally used FBP image reconstruction. C1 [Prakash, Priyanka; Kalra, Mannudeep K.; Digumarthy, Subba R.; Pien, Homer; Singh, Sarabjeet; Gilman, Matthew D.; Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging, Boston, MA 02114 USA. [Prakash, Priyanka; Kalra, Mannudeep K.; Digumarthy, Subba R.; Pien, Homer; Singh, Sarabjeet; Gilman, Matthew D.; Shepard, Jo-Anne O.] Harvard Univ, Sch Med, Boston, MA USA. [Hsieh, Jiang] GE Healthcare, Waukesha, WI USA. RP Kalra, MK (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging, 25 New Chardon St, Boston, MA 02114 USA. EM mkalra@partners.org NR 15 TC 137 Z9 158 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD JAN-FEB PY 2010 VL 34 IS 1 BP 40 EP 45 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 552EZ UT WOS:000274272300008 PM 20118720 ER PT J AU Sangwaiya, MJ Kalra, MK Sharma, A Halpern, EF Shepard, JAO Digumarthy, SR AF Sangwaiya, Minal J. Kalra, Mannudeep K. Sharma, Amita Halpern, Elkan F. Shepard, Jo-Anne O. Digumarthy, Subba R. TI Dual-Energy Computed Tomographic Pulmonary Angiography: A Pilot Study to Assess the Effect on Image Quality and Diagnostic Confidence SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE dual energy; thoracic CT; pulmonary embolism ID CT ANGIOGRAPHY; INITIAL-EXPERIENCE; EMBOLISM; DIFFERENTIATION; EXPOSURE AB Purpose: The aim of this study was to assess if dual-energy computed tomographic pulmonary angiography (DE-CTPA) protocol performed on a dual-source CT scanner can improve image quality and diagnostic confidence compared with 80- and 140-kilovolt (peak) (kVp) image data sets. Materials and Methods: In an international review board-approved study, 22 patients (women-men, 12: 10; mean [SD] age, 58.5 [16.5] years; age range, 18-85 years) underwent DE-CTPA on a dual-source CT for assessing pulmonary embolism. Scan parameters comprised reference milliampere-second of 140 at 140 kVp and 400 at 80 kVp with a pitch of 1.1- and 1.25-mm reconstructed slice thicknesses, respectively. Two radiologists analyzed the 140-kV, 80-kV, and dual-kilovolt images for vessel contrast, subjective image noise, presence of motion, artifacts, and diagnostic confidence at the level of main, lobar, and segmental or sub-segmental pulmonary arteries on a 5-point scale (1, uninterpretable: 5, excellent). Computed tomographic numbers and objective noise were measured in these arteries. Data were analyzed using Student t tests Friedman X 2 analysis of variance, and Wilcoxon rank sum test (with Bonferroni correction). Results: At 80 kVp, regardless of motion artifacts, there was a 104% increase in intravascular CT numbers, (mean [SD], 257 [104] Hounsfield units [HU] at 140 kVp and 525 [214] HU at 80 kVp) and 75% increase in objective noise (20 HU at 140 kVp and 35 HU at 80 kVp). Improvement in subjective contrast opacification and CT numbers with 80kVp compared with 140 kVp was most marked in interlobar,. segmental, and subsegmental arteries. Effective radiation dose decrease approximately 28% from a CTDI vol of 26.7 mGy to 20.1 mGy between dual-energy (case) and single-energy (control) groups. In conclusion, DE-CTPA has potential advantages for evaluations of pulmonary embolism and regarding improved image noise, vessel contrast, and diagnostic confidence compared with single higher-kilovolt (peak) protocols. C1 [Sangwaiya, Minal J.; Kalra, Mannudeep K.; Sharma, Amita; Halpern, Elkan F.; Shepard, Jo-Anne O.; Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Digumarthy, SR (reprint author), Massachusetts Gen Hosp, Dept Radiol, Founders 202,55 Fruit St, Boston, MA 02114 USA. EM sdigumarthy@partners.org NR 16 TC 12 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD JAN-FEB PY 2010 VL 34 IS 1 BP 46 EP 51 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 552EZ UT WOS:000274272300009 PM 20118721 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI To Do It Right, Dental Residency Education Is Expensive: Get Over It SO JOURNAL OF DENTAL EDUCATION LA English DT Letter C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Hosp Dent Serv, Med Ctr, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL EDUCATION ASSOC PI WASHINGTON PA 1400 K STREET, NW, STE 1100, WASHINGTON, DC 20005 USA SN 0022-0337 J9 J DENT EDUC JI J. Dent. Educ. PD JAN PY 2010 VL 74 IS 1 BP 3 EP 4 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 566SY UT WOS:000275394600001 PM 20061522 ER PT J AU Pomarico, L de Souza, IPR Castro, GFBD Teles, RP Luiz, RR Maia, LC AF Pomarico, Luciana Ribeiro de Souza, Ivete Pomarico Barbosa de Araujo Castro, Gloria Fernanda Teles, Ricardo Palmier Luiz, Ronir Raggio Maia, Lucianne Cople TI Levels of salivary IgA antibodies to Candida spp. in HIV-infected adult patients: A systematic review SO JOURNAL OF DENTISTRY LA English DT Review DE HIV; Antibodies; Immunoglobulin A secretory; Mouth mucosa; Oral candidiasis ID HUMAN-IMMUNODEFICIENCY-VIRUS; EPITHELIAL-CELLS; IMMUNOGLOBULIN-A; ORAL CANDIDIASIS; SECRETORY IMMUNOGLOBULIN; ANTIRETROVIRAL THERAPY; PAROTID-SALIVA; ALBICANS; CHILDREN; ADHERENCE AB Objective: To perform a systematic review of published data with the aim of evaluating the levels of IgA antibodies to Candida albicans in HIV-infected adult patients. Methods: The search strategy was based on PubMed, Web of Science, Google Scholar, Cochrane and EMBASE databases. Also, the reference lists of included studies were searched. All abstracts found by electronic searches were independently scrutinized by two reviewers. To be eligible for review, the controlled studies had to present the following characteristics: samples of both HIV-infected adults and noninfected adults; appropriate HIV-diagnostic tests for both patient groups (case and control); IgA-diagnostic test applied to a similar population sample. Results: Of 144 studies found, only six met the initial eligibility criteria, but three were excluded after a thorough analysis. To assess the methodological quality of the three remaining studies, they were categorized according the risk of bias. The three selected studies revealed that the levels of C. albicans-specific IgA antibody were higher in HIV-infected individuals compared with the control group. Conclusion: Adequate IgA antibody responses to C. albicans appear to be maintained, since the levels of these antibodies were higher in all studies selected. Although the findings of this systematic review are encouraging, the scientific evidence should be interpreted carefully because there are only a few reports in the literature, mostly because of the lack of important methodological details or the varying methodologies employed. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Pomarico, Luciana; Ribeiro de Souza, Ivete Pomarico; Barbosa de Araujo Castro, Gloria Fernanda; Maia, Lucianne Cople] Univ Fed Rio de Janeiro, Sch Dent, Dept Paediat Dent & Orthodont, BR-21941 Rio De Janeiro, Brazil. [Teles, Ricardo Palmier] Forsyth Inst, Dept Periodontol, Boston, MA USA. [Luiz, Ronir Raggio] Univ Fed Rio de Janeiro, Inst Publ Hlth Studies, BR-21941 Rio De Janeiro, Brazil. RP Pomarico, L (reprint author), Praia Flamengo,370-202 Flamengo, BR-22210030 Rio De Janeiro, Brazil. EM lupomarico@superig.com.br RI Maia, Lucianne/E-9938-2011; Luiz, Ronir/C-3372-2013; OI Luiz, Ronir/0000-0002-7784-9905; Maia, Lucianne/0000-0003-1026-9401 NR 32 TC 3 Z9 4 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0300-5712 J9 J DENT JI J. Dent. PD JAN PY 2010 VL 38 IS 1 BP 10 EP 15 DI 10.1016/j.jdent.2009.09.005 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 544MC UT WOS:000273660000003 PM 19761812 ER PT J AU Bonn-Miller, MO Babson, KA Vujanovic, AA Feldner, MT AF Bonn-Miller, Marcel O. Babson, Kimberly A. Vujanovic, Anka A. Feldner, Matthew T. TI Sleep Problems and PTSD Symptoms Interact to Predict Marijuana Use Coping Motives: A Preliminary Investigation SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE Marijuana; post-traumatic stress; PTSD; sleep; motives; coping ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-USE; CANNABIS WITHDRAWAL; SUBSTANCE USE; INDIVIDUALS; VETERANS; QUALITY; SCALE AB The present study empirically tested the theory-based hypothesis that greater sleep problems and post-traumatic stress disorder (PTSD) symptom severity would both individually and multiplicatively predict higher levels of coping-motivated marijuana use. Twenty (15 women) adults (M(age) = 34.00 years, SD = 11.96) who had PTSD and were currently using marijuana participated. Results indicated a positive independent relation with sleep problems and a significant interaction between sleep problems and PTSD symptom severity in relation to coping-motivated marijuana use. Results also indicated nonsignificant omnibus regression models for all other marijuana use motives. The results suggest that there may be segments of the PTSD population that are more likely to use marijuana to cope by virtue of individual differences in sleep problems. C1 [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Natl Ctr PTSD Disseminat & Training Div, Menlo Pk, CA USA. [Babson, Kimberly A.; Feldner, Matthew T.] Univ Arkansas, Dept Psychol, Fayetteville, AR 72701 USA. [Vujanovic, Anka A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Vujanovic, Anka A.] VA Boston Healthcare Syst, Natl Ctr PTSD Behav Sci Div, Boston, MA USA. RP Bonn-Miller, MO (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk Div 152,795 Willow Rd, Menlo Pk, CA 94025 USA. EM mbonnmil@gmail.com NR 32 TC 23 Z9 24 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2010 VL 6 IS 2 BP 111 EP 122 DI 10.1080/15504261003751887 PG 12 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 668XR UT WOS:000283309300004 ER PT J AU Prisciandaro, JJ Myrick, DH AF Prisciandaro, James J. Myrick, D. Hugh TI Co-morbid Bipolar and Alcohol Use Disorders: A Treatment-Focused Review SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE Bipolar disorders; alcohol use disorders; alcohol dependence; treatment; pharmacological; psychosocial; therapy ID SUBSTANCE USE DISORDERS; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; I-DISORDER; KINDLING HYPOTHESIS; RELAPSE PREVENTION; CLINICAL-TRIAL; GROUP-THERAPY; SUICIDE RISK; ACUTE MANIA AB Co-morbid bipolar and alcohol use disorders are common, difficult to properly diagnose, and associated with poor outcome. The present article concisely reviews the diagnosis, epidemiology, consequences, and neurobiological similarities among individuals with dual diagnoses and reviews the pharmacological and psychosocial treatment of bipolar and alcohol use disorders both alone and in combination. Evidence for the efficacy of treatments for individuals with dual diagnoses (i.e., divalproex, atypical antipsychotics, naltrexone, cognitive-behavioral therapy, and integrated group therapy) is discussed, and areas for future treatment development and evaluation are identified. C1 [Prisciandaro, James J.; Myrick, D. Hugh] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Myrick, D. Hugh] Ralph H Johnson Vet Affairs Ctr, Mental Hlth Serv Line, Charleston, SC USA. RP Prisciandaro, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM priscian@musc.edu NR 79 TC 0 Z9 0 U1 5 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 EI 1550-4271 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2010 VL 6 IS 2 BP 171 EP 188 DI 10.1080/15504261003701858 PG 18 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 668XR UT WOS:000283309300008 ER PT J AU Chagin, AS Karimian, E Sundstrom, K Eriksson, E Savendahl, L AF Chagin, Andrei S. Karimian, Elham Sundstrom, Katja Eriksson, Emma Savendahl, Lars TI Catch-up growth after dexamethasone withdrawal occurs in cultured postnatal rat metatarsal bones SO JOURNAL OF ENDOCRINOLOGY LA English DT Article ID ESTROGEN-RECEPTOR-ALPHA; FACTOR-I; CHONDROCYTE HYPERTROPHY; PLATE CHONDROGENESIS; LONGITUDINAL GROWTH; CUSHINGS SYNDROME; PRETERM INFANTS; FOLLOW-UP; RETARDATION; APOPTOSIS AB Children exposed to systemic glucocorticoids often exhibit growth retardation and after the cessation of therapy catch-up growth occurs in many, but not all patients. The developmental regulation and underlying cellular mechanisms of catch-up growth are not fully understood. To clarify this issue, we established an in vitro model of catch-up growth. Here we present a protocol for the long-term culture (up to 160 days) of fetal (E20) as well as postnatal (P8) rat metatarsal bones which allowed us to characterize ex vivo the phenomenon of catch-up growth without any influence by systemic factors. The relevance of the model was confirmed by the demonstration that the growth of fetal and postnatal bones were stimulated by IGF1 (100 ng/ml) and inhibited by dexamethasone (Dexa; 1 mu M). We found that the capacity to undergo catch-up growth was restricted to postnatal bones. Catch-up growth occurred after postnatal bones had been exposed to Dexa for 7 or 12 days but not after a more prolonged exposure (19 days). Incomplete catch-up growth resulted in compromised bone length when assessed at the end of the 4-month period of culture. While exposure to Dexa was associated with decreased chondrocyte proliferation and differentiation, catch-up growth was only associated with increased cell proliferation. We conclude that the phenomenon of catch-up growth after Dexa treatment is intrinsic to the growth plate and primarily mediated by an upregulation of chondrocyte proliferation. Journal of Endocrinology (2010) 204, 21-29 C1 [Chagin, Andrei S.; Karimian, Elham; Sundstrom, Katja; Eriksson, Emma; Savendahl, Lars] Karolinska Inst, Dept Womens & Childrens Hlth, Pediat Endocrinol Lab, SE-17176 Stockholm, Sweden. RP Chagin, AS (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 1101,50 Blossom St, Boston, MA 02114 USA. EM achagin@partners.org RI Chagin, Andrei/F-4080-2014; OI Chagin, Andrei/0000-0002-2696-5850; Savendahl, Lars/0000-0003-1067-4976 FU Swedish Research Council, Sallskapet Barnavard; Stiftelsen Frimurare Barnhuset i Stockholm; HKH Kronprinsessan Lovisas forening for Barnasjukvard FX This study was funded by the Swedish Research Council, Sallskapet Barnavard, Stiftelsen Frimurare Barnhuset i Stockholm and HKH Kronprinsessan Lovisas forening for Barnasjukvard. NR 39 TC 21 Z9 21 U1 0 U2 1 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 J9 J ENDOCRINOL JI J. Endocrinol. PD JAN PY 2010 VL 204 IS 1 BP 21 EP 29 DI 10.1677/JOE-09-0307 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 568MW UT WOS:000275527500003 PM 19815587 ER PT J AU Chi, T Eisner, BH Berger, AD Stoller, ML AF Chi, Thomas Eisner, Brian H. Berger, Aaron D. Stoller, Marshall L. TI An Ex-Vivo Evaluation of the Application and Strength of a Novel Laparoscopic Knot Substitute Device SO JOURNAL OF ENDOUROLOGY LA English DT Article ID RADICAL PROSTATECTOMY; LAPRA-TY AB Background and Purpose: Intracorporeal suturing can be challenging, especially in the case of laparoscopic partial nephrectomy. During these procedures, suturing must reapproximate renal tissue to achieve hemostasis but not tear through tissue. We present a new device, the ANPA Suturelock (R), which can be adjusted to increase or decrease suture tension, optimizing tissue apposition. Materials and Methods: Two participants ( one experienced laparoscopist, one junior resident) completed the protocol. A laparoscopic trainer was used to secure 2-0 polyglactin suture ends in rubber foam using five of each of the following: Traditional laparoscopic suture knots ( one surgeon's knot and two square knots), square-to-slip knots, Weston extracorporeal knots, ANPA Suturelock, Lapra-Ty devices, Hem-O-Lock clips, and titanium clips. Tensile strength of each knot and knot substitute was measured using an Instron machine ( Instron, Norwood, MA). Time to secure the two suture ends was measured for ANPA Suturelock and laparoscopic surgeon's knot. Statistical analysis was performed using the Student t test. Results: Mean tensile strength of the three knot-tying methods was 53.0 newtons (N) while that of the four knot substitute devices was 8.3N (P < 0.001). Each of the three individual knot-tying methods had significantly greater tensile strength than any of the knot substitutes (P < 0.001 for all). Of the knot-tying methods, the surgeon's knot was the strongest ( mean tensile strength 63.2 N) and was significantly stronger than square-to-slip and Weston extracorporeal knots (39.1N and 48.4 N, respectively, P < 0.05 for both). Of the knot substitutes, ANPA Suturelock ( mean tensile strength 14.7 N) was significantly stronger than Lapra-Ty (6.1 N), Hem-O-Lock (5.4 N), and titanium clip (3.0 N) (P < 0.01 for all). When compared with a laparoscopic surgeon's knot, the time to securing the ANPA Suturelock was significantly quicker for a third year resident ( 106 sec vs 38 sec, P < 0.001) and an experienced laparoscopist ( 75 sec vs 23 sec, P = 0.02). Conclusions: The tensile strengths of traditional knot-tying techniques were greater than that of any knot substitute device. The ANPA Suturelock provided the greatest tensile strength of any knot substitute. The time to secure a knot using the ANPA device was also significantly quicker than tying a standard surgeon's knot. C1 [Chi, Thomas; Eisner, Brian H.; Berger, Aaron D.; Stoller, Marshall L.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA. RP Eisner, BH (reprint author), Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA. EM beisner@partners.org NR 7 TC 5 Z9 5 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0892-7790 J9 J ENDOUROL JI J. Endourol. PD JAN PY 2010 VL 24 IS 1 BP 95 EP 98 DI 10.1089/end.2009.0007 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 541RC UT WOS:000273435600017 PM 19929424 ER PT J AU Mattson, RE O'Farrell, TJ Monson, CM Panuzio, J Taft, CT AF Mattson, Richard E. O'Farrell, Timothy J. Monson, Candice M. Panuzio, Jillian Taft, Casey T. TI Female Perpetrated Dyadic Psychological Aggression Predicts Relapse in a Treatment Sample of Men with Substance Use Disorders SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE Psychological aggression; Relationship satisfaction; Alcohol use; Relapse ID MALE ALCOHOLIC PATIENTS; DRUG-ABUSING PATIENTS; VERBAL AGGRESSION; COUPLES; ADJUSTMENT; PARTNER; MARRIAGE; VIOLENCE; QUALITY; SCALES AB This study examined whether female-to-male (FTM) psychological aggression predicted men's relapse of substance use disorder (SUD) 6 months following substance use treatment. Men diagnosed with either a substance abuse or dependence disorder who had recently begun an SUD treatment program participated in the study with their female relationship partners (N = 173). Logistic regression was used to examine the relationship between baseline FTM psychological aggression and SUD relapse when controlling for baseline demographic, dyadic, substance abuse- and treatment-related variables, as well as frequencies of other male- and female-perpetrated aggressive dyadic behaviors. Higher frequencies of severe, but not minor, forms of FTM psychological aggression uniquely predicted an increased risk of relapse at 6 months follow-up. These data add to the developing research program highlighting the negative sequelae of female-perpetrated psychological aggression and also provide an empirical basis for targeting specific dyadic behaviors in the context of SUD treatment and relapse prevention. C1 [O'Farrell, Timothy J.] Harvard Univ, Sch Med, Dept Psychiat, VAMC, Brockton, MA 02301 USA. [Monson, Candice M.; Panuzio, Jillian; Taft, Casey T.] VA Boston Healthcare Syst, VA Natl Ctr PTSD, Boston, MA USA. [Monson, Candice M.; Taft, Casey T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [O'Farrell, Timothy J.] Harvard Univ, Sch Med, Dept Psychiat, Families & Addict Program, Brockton, MA 02301 USA. [O'Farrell, Timothy J.] VA Boston Healthcare Syst, Brockton, MA USA. [Mattson, Richard E.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. RP O'Farrell, TJ (reprint author), Harvard Univ, Sch Med, Dept Psychiat, VAMC, 116B1-940 Belmont St, Brockton, MA 02301 USA. EM timothy_ofarrell@hms.harvard.edu NR 42 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD JAN PY 2010 VL 25 IS 1 BP 33 EP 42 DI 10.1007/s10896-009-9267-y PG 10 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 536GQ UT WOS:000273033300004 ER PT J AU Graham, DY Asaka, M AF Graham, David Y. Asaka, Masahiro TI Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod SO JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Gastric cancer; Surveillance; Pepsinogen; Helicobacter pylori; Natural history ID HELICOBACTER-PYLORI INFECTION; ATROPHIC GASTRITIS; ENDOSCOPIC RESECTION; IRON-DEFICIENCY; EPIDEMIOLOGY; POPULATION; ANTIBODIES; CARCINOMA; ANEMIA; ULCER AB We provide a historical review and update on current thinking regarding the possibility of elimination of gastric cancer from Japan. Because Helicobacter pylori infection is the cause gastric cancer, its elimination forms the cornerstone of eradication of gastric cancer. However, simply eradicating H. pylori from the entire population will not immediately solve the problem because many patients with H. pylori infections have already developed the precursor lesion, atrophic gastritis. Cure of H. pylori in these high risk patients will only reduce the risk of subsequent cancer. In contrast, treatment of low risk patients will prevent cancer. Thus, to eliminate gastric cancer it is necessary to identify and treat all infected individuals. In addition, those at increased risk for gastric cancer (i.e., atrophic gastritis irrespective of age) should be considered for endoscopic surveillance to identify those cancers that develop at an early stage. We propose that severity and extent of atrophy be used to separate those expected to benefit from endoscopy and annual surveillance from those with little or no potential benefit. We suggest an algorithm for eradicating gastric cancer that incorporates H. pylori and atrophic gastritis testing, H. pylori therapy, and surveillance to institute a program of surveillance restricted to those who could benefit most (i.e., those with moderate or severe atrophy). This will also allow a much closer matching of surveillance capacity and surveillance need making surveillance more clinically- and cost-effective. C1 [Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Asaka, Masahiro] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan. RP Graham, DY (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu RI Asaka, Masahiro/A-5948-2012 FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Public Health Service [DK56338] FX This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338 which funds the Texas Gulf Coast Digestive Diseases Center. NR 41 TC 44 Z9 50 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PD JAN PY 2010 VL 45 IS 1 BP 1 EP 8 DI 10.1007/s00535-009-0117-8 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 546LA UT WOS:000273811100001 PM 19714291 ER PT J AU Shokrzadeh, L Baghaei, K Yamaoka, Y Dabiri, H Jafari, F Sahebekhtiari, N Tahami, A Sugimoto, M Zojaji, H Zali, MR AF Shokrzadeh, Leila Baghaei, Kaveh Yamaoka, Yoshio Dabiri, Hossein Jafari, Fereshteh Sahebekhtiari, Navid Tahami, Ali Sugimoto, Mitsushige Zojaji, Homayon Zali, Mohammad Reza TI Analysis of 3'-end variable region of the cagA gene in Helicobacter pylori isolated from Iranian population SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE cagA; Helicobacter pylori; pathogenesis; repeat region; virulence factors ID GASTRIC EPITHELIAL-CELLS; VIRULENCE FACTOR CAGA; TYROSINE PHOSPHORYLATION; PATHOGENICITY ISLAND; CYTOTOXIN PRODUCTION; BIOLOGICAL-ACTIVITY; ULCER-DISEASE; IV SECRETION; PROTEIN; TRANSLOCATION AB Background and Aims: The 3' region of the cagA gene, the most well-known virulence factor of Helicobacter pylori, contains Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs. Four segments flanking the EPIYA motifs, EPIYA-A, -B, -C, or -D, were reported to play important roles in H. pylori-related gastroduodenal pathogenesis. The aim was to determine the roles of EPIYA segments in gastroduodenal pathogenesis in an Iranian population. Methods: A total of 92 cagA-positive Iranian strains isolated from dyspepsia patients with non-ulcer dyspepsia (n = 77), peptic ulcer (n = 11) and gastric cancer (n = 4) were studied. The EPIYA motif genotyping was determined by polymerase chain reaction and sequencing. Results: A total of 86 (93.5%) strains had three copies of EPIYA (ABC type), three (3.3%) had four copies (ABCC type) and three (3.3%) had two copies (AB type). The alignment of the deduced protein sequences confirmed that there were no East Asian type EPIYA-D sequences (EPIYATIDFDEANQAG) in Iranian strains. When the prevalence of strains with multiple EPIYA-C segments in Iran was compared with previously published data, it was much lower than that in Colombia and Italy, but was higher than that of Iraq, and the patterns were parallel to the incidence of gastric cancer in these countries. Conclusion: The structure of the 3' region of the cagA gene in Iranian strains was Western type. Although we could not find differences between EPIYA types and clinical outcomes, low prevalence of strains with multiple EPIYA-C segments might be reasons for low incidence of gastric cancer in Iran. C1 [Yamaoka, Yoshio] Oita Univ, Dept Environm & Prevent Med, Fac Med, Oita 8795593, Japan. [Shokrzadeh, Leila; Baghaei, Kaveh; Dabiri, Hossein; Jafari, Fereshteh; Sahebekhtiari, Navid; Tahami, Ali; Zojaji, Homayon; Zali, Mohammad Reza] Shaheed Beheshti Univ, Res Ctr Gastroenterol & Liver Dis, MC, Tehran, Iran. [Yamaoka, Yoshio; Sugimoto, Mitsushige] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. [Yamaoka, Yoshio; Sugimoto, Mitsushige] Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Oita Univ, Dept Environm & Prevent Med, Fac Med, Oita 8795593, Japan. EM yyamaoka@med.oita-u.ac.jp OI Dabiri, Hossein/0000-0002-2782-8970 FU RCGLD; Taleghani Hospital; Shahid Beheshti University, M.C., Tehran, Iran; National Institutes of Health (NIH) [R01 DK62813] FX This study was supported by a grant from RCGLD, Taleghani Hospital, Shahid Beheshti University, M.C., Tehran, Iran. The project described was also supported by grant number R01 DK62813 from the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 40 TC 22 Z9 25 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD JAN PY 2010 VL 25 IS 1 BP 172 EP 177 DI 10.1111/j.1440-1746.2009.05979.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 536CU UT WOS:000273020600030 PM 19793167 ER PT J AU Thayer, S Wong, J Sarr, M AF Thayer, Sarah Wong, Joyce Sarr, Michael TI Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Cancer-Specific Newcastle Disease Virus Discussant SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Editorial Material C1 [Thayer, Sarah] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sarr, Michael] Mayo Clin, Rochester, MN USA. RP Thayer, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN PY 2010 VL 14 IS 1 BP 12 EP 14 PG 3 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 533CM UT WOS:000272800000004 ER PT J AU Hauer, KE Papadakis, MA AF Hauer, Karen E. Papadakis, Maxine A. TI Assessment of the Contributions of Clinician Educators SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID PROMOTION; COMPONENTS; MEDICINE; EMPATHY C1 [Hauer, Karen E.; Papadakis, Maxine A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Papadakis, Maxine A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, 533 Parnassus Ave,U113A,Box 0131, San Francisco, CA 94143 USA. EM Karen.hauer@ucsf.edu NR 16 TC 6 Z9 6 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 5 EP 6 DI 10.1007/s11606-009-1186-3 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000003 PM 20016952 ER PT J AU Henderson, M Keenan, C Kohlwes, J Dhaliwal, G AF Henderson, Mark Keenan, Craig Kohlwes, Jeff Dhaliwal, Gupreet TI Introducing Exercises in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Henderson, Mark; Keenan, Craig] Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA. [Kohlwes, Jeff; Dhaliwal, Gupreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kohlwes, Jeff; Dhaliwal, Gupreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Henderson, M (reprint author), Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA. EM mark.henderson@ucdmc.ucdavis.edu NR 0 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 9 EP 9 DI 10.1007/s11606-009-1185-4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000005 PM 20016953 ER PT J AU Williams, EC Lapham, G Achtmeyer, CE Volpp, B Kivlahan, DR Bradley, KA AF Williams, Emily C. Lapham, Gwen Achtmeyer, Carol E. Volpp, Bryan Kivlahan, Daniel R. Bradley, Katharine A. TI Use of an Electronic Clinical Reminder for Brief Alcohol Counseling is Associated with Resolution of Unhealthy Alcohol Use at Follow-Up Screening SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE alcohol drinking; brief alcohol counseling; brief intervention; clinical reminder; implementation ID HEALTH-CARE-SYSTEM; DECISION-SUPPORT-SYSTEMS; AT-RISK DRINKING; PROBLEM DRINKERS; BRIEF PHYSICIAN; PATIENT; INTERVENTIONS; PERFORMANCE; ADVICE; IMPACT AB Brief alcohol counseling is a foremost US prevention priority, but no health-care system has implemented it into routine care. This study evaluated the effectiveness of an electronic clinical reminder for brief alcohol counseling ("reminder"). The specific aims were to (1) determine the prevalence of use of the reminder and (2) evaluate whether use of the reminder was associated with resolution of unhealthy alcohol use at follow-up screening. The reminder was implemented in February 2004 in eight VA clinics where providers routinely used clinical reminders. Patients eligible for this retrospective cohort study screened positive on the AUDIT-C alcohol screening questionnaire (February 2004-April 2006) and had a repeat AUDIT-C during the 1-36 months of follow-up (mean 14.5). Use of the alcohol counseling clinical reminder was measured from secondary electronic data. Resolution of unhealthy alcohol use was defined as screening negative at follow-up with a a parts per thousand yen2-point reduction in AUDIT-C scores. Logistic regression was used to identify adjusted proportions of patients who resolved unhealthy alcohol use among those with and without reminder use. Among 4,198 participants who screened positive for unhealthy alcohol use, 71% had use of the alcohol counseling clinical reminder documented in their medical records. Adjusted proportions of patients who resolved unhealthy alcohol use were 31% (95% CI 30-33%) and 28% (95% CI 25-30%), respectively, for patients with and without reminder use (p-value = 0.031). The brief alcohol counseling clinical reminder was used for a majority of patients with unhealthy alcohol use and associated with a moderate decrease in drinking at follow-up. C1 [Williams, Emily C.; Lapham, Gwen; Achtmeyer, Carol E.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. [Achtmeyer, Carol E.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Emily C.; Lapham, Gwen] Univ Washington, Hlth Serv, Seattle, WA 98195 USA. [Volpp, Bryan] VA No Calif Healthcare Syst, Martinez, CA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res Dev, Seattle, WA USA. EM emily.williams3@va.gov FU Robert Wood Johnson Foundation; Veteran's Affairs (VA); VA's Northwest Center of Excellence for Health Services Research and Development FX The clinical reminder evaluated in this study was developed with funding from The Robert Wood Johnson Foundation's Generalist Physicians Faculty Scholars Program. This study was supported by the Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QuERI) and the VA's Northwest Center of Excellence for Health Services Research and Development. Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the University of Washington. Preliminary versions of this work were presented at the 2008 Addiction Health Services Research annual meeting and included in the dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy from the University of Washington ( completed by ECW June 2009). NR 50 TC 19 Z9 19 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 11 EP 17 DI 10.1007/s11606-009-1100-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000003 PM 20077146 ER PT J AU Cohen, BE Gima, K Bertenthal, D Kim, S Marmar, CR Seal, KH AF Cohen, Beth E. Gima, Kris Bertenthal, Daniel Kim, Sue Marmar, Charles R. Seal, Karen H. TI Mental Health Diagnoses and Utilization of VA Non-Mental Health Medical Services Among Returning Iraq and Afghanistan Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE veterans; post-traumatic stress disorder; psychiatry; health services research; utilization ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; MILITARY SERVICE; 1ST ONSET; CARE; WAR; SYMPTOMS; SOLDIERS; RISK; PTSD AB Over 35% of returned Iraq and Afghanistan veterans in VA care have received mental health diagnoses; the most prevalent is post-traumatic stress disorder (PTSD). Little is known about these patients' use of non-mental health medical services and the impact of mental disorders on utilization. To compare utilization across three groups of Iraq and Afghanistan veterans: those without mental disorders, those with mental disorders other than PTSD, and those with PTSD. National, descriptive study of 249,440 veterans newly utilizing VA healthcare between October 7, 2001 and March 31, 2007, followed until March 31, 2008. We used ICD9-CM diagnostic codes to classify mental health status. We compared utilization of outpatient non-mental health services, primary care, medical subspecialty, ancillary services, laboratory tests/diagnostic procedures, emergency services, and hospitalizations during veterans' first year in VA care. Results were adjusted for demographics and military service and VA facility characteristics. Veterans with mental disorders had 42-146% greater utilization than those without mental disorders, depending on the service category (all P < 0.001). Those with PTSD had the highest utilization in all categories: 71-170% greater utilization than those without mental disorders (all P < 0.001). In adjusted analyses, compared with veterans without mental disorders, those with mental disorders other than PTSD had 55% higher utilization of all non-mental health outpatient services; those with PTSD had 91% higher utilization. Female sex and lower rank were also independently associated with greater utilization. Veterans with mental health diagnoses, particularly PTSD, utilize significantly more VA non-mental health medical services. As more veterans return home, we must ensure resources are allocated to meet their outpatient, inpatient, and emergency needs. C1 [Cohen, Beth E.; Gima, Kris; Bertenthal, Daniel; Kim, Sue; Marmar, Charles R.; Seal, Karen H.] San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Cohen, Beth E.; Bertenthal, Daniel; Kim, Sue; Marmar, Charles R.; Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bertenthal, Daniel; Marmar, Charles R.; Seal, Karen H.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA. RP Cohen, BE (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, Box 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Beth.Cohen@ucsf.edu FU VA Health Services Research and Development (HSRD); VA Seattle Epidemiological Research and Information Center; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]; San Francisco VA Medical Center HSR&D Research Enhancement [REA 01-097] FX We acknowledge and thank veterans of the wars in Iraq and Afghanistan for their service. This study was funded by a VA Health Services Research and Development (HSR&D) Career Development Transition Award and a grant from the VA Seattle Epidemiological Research and Information Center. Dr. Cohen was supported by NIH/NCRR/OD UCSF-CTSI grant no. KL2 RR024130. We are grateful for the support of the San Francisco VA Medical Center HSR&D Research Enhancement Award Program (REA 01-097). The manuscript contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or other funding agencies. Preliminary data for this paper were presented as an abstract at the Society of General Internal Medicine 2008 National Meeting. The authors have no conflicts of interest. NR 38 TC 91 Z9 91 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 18 EP 24 DI 10.1007/s11606-009-1117-3 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000007 PM 19787409 ER PT J AU Hynes, DM Weddle, T Smith, N Whittier, E Atkins, D Francis, J AF Hynes, Denise M. Weddle, Timothy Smith, Nina Whittier, Erika Atkins, David Francis, Joseph TI Use of Health Information Technology to Advance Evidence-Based Care: Lessons from the VA QUERI Program SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE data; health information technology; quality enhancement research initiative; implementation research; veterans health administration ID QUALITY IMPROVEMENT; DECISION-SUPPORT; IMPLEMENTATION; SCHIZOPHRENIA; PHYSICIANS; RECORDS; COSTS AB As the Department of Veterans Affairs (VA) Health Services Research and Development Service's Quality Enhancement Research Initiative (QUERI) has progressed, health information technology (HIT) has occupied a crucial role in implementation research projects. We evaluated the role of HIT in VA QUERI implementation research, including HIT use and development, the contributions implementation research has made to HIT development, and HIT-related barriers and facilitators to implementation research. Key informants from nine disease-specific QUERI Centers. Documentation analysis of 86 implementation project abstracts followed up by semi-structured interviews with key informants from each of the nine QUERI centers. We used qualitative and descriptive analyses. We found: (1) HIT provided data and information to facilitate implementation research, (2) implementation research helped to further HIT development in a variety of uses including the development of clinical decision support systems (23 of 86 implementation research projects), and (3) common HIT barriers to implementation research existed but could be overcome by collaborations with clinical and administrative leadership. Our review of the implementation research progress in the VA revealed interdependency on an HIT infrastructure and research-based development. Collaboration with multiple stakeholders is a key factor in successful use and development of HIT in implementation research efforts and in advancing evidence-based practice. C1 [Hynes, Denise M.; Weddle, Timothy; Whittier, Erika] Edward Hines Jr VA Hosp, VA Informat Resource Ctr, Hines, IL USA. [Hynes, Denise M.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Hynes, Denise M.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Hynes, Denise M.] Univ Illinois, Coll Med, Chicago, IL USA. [Smith, Nina] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Atkins, David] Dept Vet Affairs, Hlth Serv Res & Dev, Washington, DC USA. [Francis, Joseph] Dept Vet Affairs, Off Qual & Performance, Washington, DC USA. RP Hynes, DM (reprint author), Hines VA Hosp 578, VA Informat Resource Ctr 151V, 5000 S 5th Ave,Bldg 1,C302B, Hines, IL 60141 USA. EM Denise.Hynes@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service [TRA 01-001]; VA Information Resource Center [SDR-98-004]; VA Research Career Scientist Award FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service, Translation Data Initiative for QUERI Groups, Project Number TRA 01-001, and the VA Information Resource Center, project no. SDR-98-004. Dr. Hynes also received support for a VA Research Career Scientist Award. NR 32 TC 8 Z9 9 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 44 EP 49 DI 10.1007/s11606-009-1144-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000008 PM 20077151 ER PT J AU Huang, AJ Luft, J Grady, D Kuppermann, M AF Huang, Alison J. Luft, Janis Grady, Deborah Kuppermann, Miriam TI The Day-to-Day Impact of Urogenital Aging: Perspectives from Racially/Ethnically Diverse Women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med DE urogenital atrophy; vaginal dryness; dyspareunia; menopause; quality of life ID QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; SYMPTOMS; HEALTH; ATROPHY AB Urogenital symptoms affect up to half of women after menopause, but their impact on women's day-to-day functioning and wellbeing is poorly understood. Postmenopausal women aged 45 to 80 years reporting urogenital dryness, soreness, itching, or pain during sex were recruited to participate in in-depth focus groups to discuss the impact of their symptoms. Focus groups were homogenous with respect to race/ethnicity and stratified by age (for White or Black women) or language (for Latina women). Transcripts of sessions were analyzed according to grounded theory. Six focus groups were conducted, involving 44 women (16 White, 14 Black, 14 Latina). Five domains of functioning and wellbeing affected by symptoms were identified: sexual functioning, everyday activities, emotional wellbeing, body image, and interpersonal relations. For some participants, symptoms primarily affected their ability to have and enjoy sex, as well as be responsive to their partners. For others, symptoms interfered with everyday activities, such as exercising, toileting, or sleeping. Participants regarded their symptoms as a sign that they were getting old or their body was deteriorating; women also associated symptoms with a loss of womanhood or sexuality. Additionally, participants reported feeling depressed, embarrassed, and frustrated about their symptoms, and expressed reluctance to discuss them with friends, family, or health care providers. Urogenital symptoms can have a marked impact on sexual functioning, everyday activities, emotional wellbeing, body image, and interpersonal relations after menopause. Clinicians may need to question women actively about these symptoms, as many are reluctant to seek help for this problem. C1 [Huang, Alison J.; Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Huang, Alison J.; Luft, Janis; Grady, Deborah] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94143 USA. [Huang, Alison J.; Kuppermann, Miriam] Univ Calif San Francisco, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94143 USA. [Luft, Janis; Kuppermann, Miriam] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Huang, AJ (reprint author), 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM ahuang@ucsfmed.org FU NCRR NIH HHS [KL2 RR024130, KL2RR024130]; NIA NIH HHS [P30 AG015272, R03 AG035207, P30AG15272] NR 19 TC 6 Z9 7 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 45 EP 51 DI 10.1007/s11606-009-1135-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000011 PM 19908103 ER PT J AU Holt, DT Helfrich, CD Hall, CG Weiner, BJ AF Holt, Daniel T. Helfrich, Christian D. Hall, Carmen G. Weiner, Bryan J. TI Are You Ready? How Health Professionals Can Comprehensively Conceptualize Readiness for Change SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE organizational change; change readiness; measuring readiness for change; implementation ID ORGANIZATIONAL-CHANGE; PRACTICE GUIDELINES; MODEL; CARE; QUALITY; IMPLEMENTATION; MANAGEMENT; FRAMEWORK; OUTCOMES; SMOKING AB One important factor influencing the successful implementation of system-wide change is initial readiness. Readiness is defined as the degree to which those involved are individually and collectively primed, motivated, and technically capable of executing the change. We present a conceptual framework that highlights three broad areas to be considered if health-care professionals are to comprehensively evaluate readiness that includes psychological factors (i.e., characteristics of those being asked to change), structural factors (i.e., circumstances under which the change is occurring) as well as the level of analysis (i.e., individual and organizational levels). We also describe more specific dimensions within each of these broad categories that have both empirical and theoretical support, presenting several valid and reliable survey instruments that measure key dimensions of readiness quantitatively. C1 [Holt, Daniel T.] USAF, Inst Technol, Dept Syst & Engn Management, AFTT ENV, Wright Patterson AFB, OH 45433 USA. [Helfrich, Christian D.] VA Puget Sound Hlth Care Syst, Ischem Heart Dis QUERI, Seattle, WA USA. [Hall, Carmen G.] VA Minneapolis Hlth Care Syst, Polytrauma & Blast Related Injuries QUERI, Minneapolis, MN USA. [Weiner, Bryan J.] Univ N Carolina, Chapel Hill, NC USA. RP Holt, DT (reprint author), USAF, Inst Technol, Dept Syst & Engn Management, AFTT ENV, 2950 Hobson Way, Wright Patterson AFB, OH 45433 USA. EM daniel.holt@afit.edu RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 NR 40 TC 33 Z9 35 U1 1 U2 21 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 50 EP 55 DI 10.1007/s11606-009-1112-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000009 PM 20077152 ER PT J AU Yano, EM Hayes, P Wright, S Schnurr, P Lipson, L Bean-Mayberry, B Washington, DL AF Yano, Elizabeth M. Hayes, Patricia Wright, Steven Schnurr, Paula P. Lipson, Linda Bean-Mayberry, Bevanne Washington, Donna L. TI Integration of Women Veterans into VA Quality Improvement Research Efforts: What Researchers Need to Know SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE quality improvement; disparities; implementation research; women's health; veterans ID AFFAIRS HEALTH-CARE; CARDIOVASCULAR-DISEASE; OF-CARE; GENDER; MILITARY; TRANSFORMATION; RECRUITMENT; PERFORMANCE; DISPARITIES; SYSTEM AB The Department of Veterans Affairs (VA) and other federal agencies require funded researchers to include women in their studies. Historically, many researchers have indicated they will include women in proportion to their VA representation or pointed to their numerical minority as justification for exclusion. However, women's participation in the military-currently 14% of active military-is rapidly changing veteran demographics, with women among the fastest growing segments of new VA users. These changes will require researchers to meet the challenge of finding ways to adequately represent women veterans for meaningful analysis. We describe women veterans' health and health-care use, note how VA care is organized to meet their needs, report gender differences in quality, highlight national plans for women veterans' quality improvement, and discuss VA women's health research. We then discuss challenges and potential solutions for increasing representation of women veterans in VA research, including steps for implementation research. C1 [Yano, Elizabeth M.; Bean-Mayberry, Bevanne; Washington, Donna L.] VA Greater Angeles HSR&D Ctr Excellence, Sepulveda, CA 91343 USA. [Bean-Mayberry, Bevanne; Washington, Donna L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Hayes, Patricia] US Dept Vet Affairs, Women Vet Hlth Strateg Hlth Care Grp, Off Publ Hlth & Environm Hazards, Washington, DC USA. [Wright, Steven] Vet Hlth Adm, Off Qual & Performance, Providence, RI USA. [Schnurr, Paula P.] Natl Ctr PTSD, White River Junct VA Med Ctr, White River Jct, VT USA. [Schnurr, Paula P.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Lipson, Linda] Vet Hlth Adm, Off Res & Dev, VA HSR&D Serv, Washington, DC USA. RP Yano, EM (reprint author), VA Greater Angeles HSR&D Ctr Excellence, Mailcode 152,16111 Plummer St, Sepulveda, CA 91343 USA. EM Elizabeth.yano@va.gov FU VA Health Services Research and Development (HSRD) Service [IIR-04-036, IAE-07-170, 05-195, RCD 02-039]; Women Veterans Ambulatory Care [IAE-06-083] FX Several VA Health Services Research and Development (HSR&D) Service funded studies provided source information for this paper, including Impact of Practice Structure on the Quality of Care for Women Veterans (phase 1 project no. IIR-04-036 and phase 2 project no. IAE-07-170), and the Women Veterans Ambulatory Care Use project phase II (project no. IAE-06-083). Dr. Yano's effort was funded by a VA HSR&D Research Career Scientist Award (project no. 05-195), while Dr. Bean-Mayberry's effort was funded by a VA HSR&D Career Development Transition Award (project no. RCD 02-039). We acknowledge the VA Office of Quality and Performance for direct contribution of results from internal reports on gender disparities in VA quality of care. The issues summarized in this paper were presented at the National VA Quality Enhancement Research Initiative (QUERI) Meeting, Phoenix, AZ, December 12, 2008, and the VA HSR&D Meeting, Baltimore, MD, February 12, 2009. NR 39 TC 49 Z9 49 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 56 EP 61 DI 10.1007/s11606-009-1116-4 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000010 PM 20077153 ER PT J AU Egede, LE Ellis, C AF Egede, Leonard E. Ellis, Charles TI Development and Psychometric Properties of the 12-Item Diabetes Fatalism Scale SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Diabetese Fatalism Scale; type 2 diabetes; DFS ID AFRICAN-AMERICANS; CANCER; EXPECTANCIES; RELIABILITY; VALIDATION; VALIDITY; LOCUS; WOMEN AB This study describes the development and validation of the Diabetes Fatalism Scale (DFS) in adults with type 2 diabetes. Thirty-five items were derived from focus groups, literature review, and expert opinion. The items were pilot tested on 20 adults with diabetes and then administered to 216 primary care patients with type 2 diabetes to assess the validity and reliability of the scale. Exploratory factor analysis (Principal Component Analysis with Varimax rotation) yielded a 12-item scale with three subscales. Pearson's correlation was used to test the DFS's association with diabetes self-care, HbA1c and quality of life. Multiple linear regression was used to assess association between the DFS and HbA1c controlling for demographics, comorbidity and insulin use. Cronbach's alpha for the 12-item DFS scale was 0.804 indicating internal consistency. The DFS is scored in such a way that higher scores represent greater diabetes fatalism. The DFS scores were not significantly correlated with age, years of education, or diabetes duration. Whites, men, those with government or no insurance, and those with 3+ comorbid conditions had significantly higher DFS scores. DFS was significantly correlated with self management understanding (r = -0.35, p < 0.001), control problems (r = 0.22, p = 0.002), self-care ability (r = -0.30, p < 0.001), and self-care adherence (r = -0.23, p < 0.001). The DFS was significantly correlated with HbA1c (r = 0.20, p = 0.004) and mental health component of SF-12 (r = -0.24, p = 0.001). In multivariate models, adjusting for demographics, comorbidity and insulin use, the DFS was independently associated with increased HbA1c (beta 0.21, p = 0.005). The DFS is a valid and reliable measure of diabetes fatalism. Diabetes fatalism is associated with self-care problems, poor glycemic control, and decreased quality of life. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [R01 DK081121, R01 DK081121-01A1, R01 DK081121-02, R01 DK081121-03] NR 24 TC 16 Z9 16 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 61 EP 66 DI 10.1007/s11606-009-1168-5 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000014 PM 19908102 ER PT J AU Nazi, KM Hogan, TP Wagner, TH McInnes, DK Smith, BM Haggstrom, D Chumbler, NR Gifford, AL Charters, KG Saleem, JJ Weingardt, KR Fischetti, LF Weaver, FM AF Nazi, Kim M. Hogan, Timothy P. Wagner, Todd H. McInnes, D. Keith Smith, Bridget M. Haggstrom, David Chumbler, Neale R. Gifford, Allen L. Charters, Kathleen G. Saleem, Jason J. Weingardt, Kenneth R. Fischetti, Linda F. Weaver, Frances M. TI Embracing a Health Services Research Perspective on Personal Health Records: Lessons Learned from the VA My HealtheVet System SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE personal health records; health information; health services research; PHR ID INFORMATION; CARE AB Personal health records (PHRs) are designed to help people manage information about their health. Over the past decade, there has been a proliferation of PHRs, but research regarding their effects on clinical, behavioral, and financial outcomes remains limited. The potential for PHRs to facilitate patient-centered care and health system transformation underscores the importance of embracing a broader perspective on PHR research. Drawing from the experiences of VA staff to evaluate the My HealtheVet (MHV) PHR, this article advocates for a health services research perspective on the study of PHR systems. We describe an organizing framework and research agenda, and offer insights that have emerged from our ongoing efforts regarding the design of PHR-related studies, the need to address PHR data ownership and consent, and the promotion of effective PHR research collaborations. These lessons are applicable to other PHR systems and the conduct of PHR research across different organizational contexts. C1 [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Hlth Informat, Vet Hlth Adm, Washington, DC USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Management Complex Chron, Hines, IL USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Edward J Hines Jr Vet Affairs Hosp, Vet Hlth Adm, Hines, IL 60141 USA. [Wagner, Todd H.; Weingardt, Kenneth R.] US Dept Vet Affairs, Vet Hlth Adm, Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA. [Wagner, Todd H.; Weingardt, Kenneth R.] Stanford Univ, Stanford, CA 94305 USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, HIV Hepatitis Qual Enhancement Res Initiat QUERI, Bedford, MA USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Hlth Qual Outcomes & Econ, Bedford, MA USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, Vet Hlth Adm, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Smith, Bridget M.; Weaver, Frances M.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Haggstrom, David; Saleem, Jason J.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Implementing Evidence Bas, Indianapolis, IN USA. [Haggstrom, David; Chumbler, Neale R.; Saleem, Jason J.] Vet Hlth Adm, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA. [Haggstrom, David; Saleem, Jason J.] Regenstrief Inst Hlth Care, Univ Ctr Hlth Serv & Outcomes Res, Indianapolis, IN USA. [Haggstrom, David] Indiana Univ, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. [Chumbler, Neale R.] US Dept Vet Affairs, Stroke Qual Enhancement Res Initiat QUERI, Indianapolis, IN USA. [Chumbler, Neale R.] Indiana Univ Purdue Univ, Dept Sociol, Indiana Univ Sch Liberal Arts, Indianapolis, IN 46202 USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Charters, Kathleen G.] Creat Comp Solut Inc, Rockville, MD USA. [Saleem, Jason J.] Indiana Univ Purdue Univ, Dept Elect & Comp Engn, Indianapolis, IN 46202 USA. [Weingardt, Kenneth R.] US Dept Vet Affairs, Subst Use Disorders Qual Enhancement Res Initiat, Houston, TX USA. [Weingardt, Kenneth R.] Vet Hlth Adm, Michael E DeBakey VA Med Ctr, Houston, TX USA. [Fischetti, Linda F.] US Dept Vet Affairs, Vet Hlth Adm, Off Hlth Informat, Washington, DC USA. [Weaver, Frances M.] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA. RP Nazi, KM (reprint author), US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Hlth Informat, Vet Hlth Adm, Washington, DC USA. EM kim.nazi@va.gov NR 46 TC 30 Z9 30 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 62 EP 67 DI 10.1007/s11606-009-1114-6 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000011 PM 20077154 ER PT J AU Damush, TM Jackson, GL Powers, BJ Bosworth, HB Cheng, E Anderson, J Gulhan, M LaVela, S Rajan, S Plue, L AF Damush, T. M. Jackson, G. L. Powers, B. J. Bosworth, H. B. Cheng, E. Anderson, J. Gulhan, M. LaVela, S. Rajan, S. Plue, L. TI Implementing Evidence-Based Patient Self-Management Programs in the Veterans Health Administration: Perspectives on Delivery System Design Considerations SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE self-management; implementation; veterans health administration ID PRIMARY-CARE PATIENTS; LOW-BACK-PAIN; CHRONIC DISEASE; RANDOMIZED-TRIAL; CHRONIC ILLNESS; HYPERTENSION; INTERVENTION; METHODOLOGY; EDUCATION; IMPROVE AB While many patient self-management (PSM) programs have been developed and evaluated for effectiveness, less effort has been devoted to translating and systematically delivering PSM in primary and specialty care. Therefore, the purpose of this paper is to review delivery system design considerations for implementing self-management programs in practice. As lessons are learned about implementing PSM programs in Veterans Health Administration (VHA), resource allocation by healthcare organization for formatting PSM programs, providing patient access, facilitating PSM, and incorporating support tools to foster PSM among its consumers can be refined and tailored. Redesigning the system to deliver and support PSM will be important as implementation researchers translate evidence based PSM practices into routine care and evaluate its impact on the health-related quality of life of veterans living with chronic disease. C1 [Damush, T. M.; Plue, L.] Indiana Univ, Dept Gen Internal Med & Geriatr, Ctr Aging Res, Regenstrief Inc,HSRD COE, Indianapolis, IN 46204 USA. [Damush, T. M.; Plue, L.] VA Stroke QUERI Ctr, Richard L Roudebush VAMC, Indianapolis, IN USA. [Jackson, G. L.; Powers, B. J.; Bosworth, H. B.] Durham VAMC, HSRD COE, Durham, NC USA. [Cheng, E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Anderson, J.] Michael E DeBakey VAMC, Houston, TX USA. [Gulhan, M.; LaVela, S.] Spinal Cord Injury QUERI Ctr, Edward Hines Jr VAMC, Chicago, IL USA. [Rajan, S.] Spinal Cord Injury QUERI Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Damush, T. M.] Roudebush VAMC, Indianapolis, IN USA. RP Damush, TM (reprint author), Roudebush VAMC, 1481 W 10th St,HSRD 11H, Indianapolis, IN 46202 USA. EM Teresa.Damush@va.gov FU VA HSRD [STR-03-168]; HSRD [IMV 04-096]; NINDS/NIH [5K23NS058571-03]; NCRR/NIH [KL2 RR024127]; National HSRD VA QUERI Program FX The project was supported in part by the following funding: VA HSRD STR-03-168 (Stroke QUERI Center); HSRD IMV#04-096 (Dr. Damush/Ms. Plue); NINDS/NIH Career Development Award (5K23NS058571-03) to Dr. Eric Cheng; VA senior career award to Dr. Bosworth; and a NCRR/NIH career development award KL2 RR024127 to Dr. Ben Powers and the National HSRD VA QUERI Program (Workshop sponsor). NR 46 TC 7 Z9 7 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 68 EP 71 DI 10.1007/s11606-009-1123-5 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000012 PM 20077155 ER PT J AU Box, TL McDonell, M Helfrich, CD Jesse, RL Fihn, SD Rumsfeld, JS AF Box, Tamara L. McDonell, Mary Helfrich, Christian D. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. TI Strategies from a Nationwide Health Information Technology Implementation: The VA CART STORY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health information technology; implementation; barriers; facilitators; EMR; organizational culture ID RECORDS; SYSTEM; PHYSICIANS; BARRIERS; ADOPTION; LESSONS AB The VA Cardiovascular Assessment, Reporting, and Tracking (CART) system is a customized electronic medical record system which provides standardized report generation for cardiac catheterization procedures, serves as a national data repository, and is the centerpiece of a national quality improvement program. Like many health information technology projects, CART implementation did not proceed without some barriers and resistance. We describe the nationwide implementation of CART at the 77 VA hospitals which perform cardiac catheterizations in three phases: (1) strategic collaborations; (2) installation; and (3) adoption. Throughout implementation, success required a careful balance of technical, clinical, and organizational factors. We offer strategies developed through CART implementation which are broadly applicable to technology projects aimed at improving the quality, reliability, and efficiency of health care. C1 [Box, Tamara L.; Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [McDonell, Mary; Helfrich, Christian D.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.] VA Cent Off, Washington, DC USA. [Jesse, Robert L.] Richmond VA Med Ctr, Richmond, VA USA. RP Box, TL (reprint author), VA Eastern Colorado Hlth Care Syst, 1055 Clermont St 111B, Denver, CO 80220 USA. EM tamara.box@va.gov RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 FU Veterans Health Administration Office of Patient Care Services, Washington, DC FX This material is based upon a workshop led during the 2008 National Meeting of the Quality Enhancement Research Initiative (QUERI) of the Health Services R&D Service, Department of Veterans Affairs. The views expressed here are those of the authors, who are responsible for its contents, and do not necessarily represent the views of the U.S. Department of Veterans Affairs. Funding for this work was provided by the Veterans Health Administration Office of Patient Care Services, Washington, DC. NR 28 TC 30 Z9 30 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 72 EP 76 DI 10.1007/s11606-009-1130-6 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000013 PM 20077156 ER PT J AU Henderson, MC Dhaliwal, G Jones, SR Culbertson, C Bowen, JL AF Henderson, Mark C. Dhaliwal, Gurpreet Jones, Stephen R. Culbertson, Charles Bowen, Judith L. TI Doing What Comes Naturally SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE diagnostic reasoning; secondary hypertension; problem representation; illness scripts; clinical problem solving C1 [Henderson, Mark C.; Bowen, Judith L.] UC Davis Med Ctr, Dept Internal Med, Sacramento, CA 95718 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. [Jones, Stephen R.; Culbertson, Charles] Legacy Hlth Syst, Dept Internal Med, Portland, OR USA. [Jones, Stephen R.; Culbertson, Charles] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Henderson, MC (reprint author), UC Davis Med Ctr, Dept Internal Med, 4150 V St,Suite 3100, Sacramento, CA 95718 USA. EM MCHenderson@ucdavis.edu NR 6 TC 9 Z9 9 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 84 EP 87 DI 10.1007/s11606-009-1187-2 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000018 PM 20087787 ER PT J AU Yeung, HH Walton, DS AF Yeung, Helen H. Walton, David S. TI Goniotomy for Juvenile Open-Angle Glaucoma SO JOURNAL OF GLAUCOMA LA English DT Article DE goniotomy; juvenile open-angle glaucoma; JOAG ID YAG LASER TRABECULOPUNCTURE; CHRONIC CHILDHOOD UVEITIS; SURGICAL TECHNIQUE; MITOMYCIN-C; TRABECULECTOMY; TRABECULOTOMY; GONIOSURGERY; SECONDARY; NEODYMIUM AB Purpose: To report the surgical results of goniotomy Surgery for patients with acquired juvenile open-angle glaucoma (JOAG). Patients and Methods: The medical records of 10 patients with bilateral acquired JOAG were reviewed to learn the results of goniotomy for their glaucoma. Twenty goniotomy procedures Were performed for 17 eyes. Sex, ethnicity, family history, refraction, preoperative gonioscopic findings, surgical outcome, age at initial goniotomy. duration of postoperative observation, preoperative and postoperative intraocular pressures (IOP), and glaucoma medication used were reviewed. Complete success was defined as in IOP <= 21 mm Hg qualified success as IOP <= 21 mm Hg with use of glaucoma medications, and failure as IOP > 21 mm Hg despite medical therapy. The surgical technique used to perform the goniotomy procedures was reviewed and the absence of significant complications noted. Results: Overall surgical success was achieved in 77% (13 out of 17) of the eyes. Average IOP for complete success (9 eyes) was 14.7 +/- 2.1 mm Hg (range: 12 to 18 mm Hg), qualified success (4 eyes) 16.5 +/- 2.4 mm Hg (range: 14 to 19 mm Hg), and Failure (4 eyes) 33.5 +/- 5.7 mm Hg (range: 30 to 42 mm Hg). The mean age at surgery was 16.3 +/- 8.1 years (range: 7.3 to 32 y). Mean follow-up interval was 7.8 +/- 6.2 years (range: 0.1 to 16.3 v). Gonioscopy demonstrated normal appearing filtration angles in all eyes. No significant surgical complications occurred. Mean refractive error was -3.3 +/- 2.8 (range: 0.0 to -7.8). Sixty percent of patients possessed a family history of JOAG. Conclusions: Goniotomy is a potentially effective initial surgical treatment of JOAG. Goniotomy for JOAG call be successfully performed using a standard goniotomy technique. C1 [Walton, David S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Yeung, Helen H.] Tufts Univ, Sch Med, Medford, MA 02155 USA. RP Walton, DS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 2 Longfellow Pl,Suite 201, Boston, MA 02114 USA. EM blacki@att.net NR 26 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1057-0829 J9 J GLAUCOMA JI J. Glaucoma PD JAN PY 2010 VL 19 IS 1 BP 1 EP 4 DI 10.1097/IJG.0b013e3181a2fa31 PG 4 WC Ophthalmology SC Ophthalmology GA 546EH UT WOS:000273792200001 PM 19373104 ER PT J AU O'Neil-Pirozzi, TM Strangman, GE Goldstein, R Katz, DI Savage, CR Kelkar, K Supelana, C Burke, D Rauch, SL Glenn, MB AF O'Neil-Pirozzi, Therese M. Strangman, Gary E. Goldstein, Richard Katz, Douglas I. Savage, Cary R. Kelkar, Kalika Supelana, Christina Burke, David Rauch, Scott L. Glenn, Mel B. TI A Controlled Treatment Study of Internal Memory Strategies (I-MEMS) Following Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE group; memory deficit; rehabilitation; traumatic brain injury ID CLOSED-HEAD-INJURY; COGNITIVE REHABILITATION; FREE-RECALL; PEOPLE; TRIAL; ERRORLESS; THERAPY; DEVICES AB Objective: To evaluate the effects of participation in a memory group intervention focusing on internal strategy use on persons with traumatic brain injury-related memory impairment. Participants: Ninety-four adults with traumatic brain injury (54 in the experimental group and 40 controls) and resulting memory impairment, with severities ranging from mild to severe. All participants were at least 18 years of age at the time of injury and at least 1 year post injury at the time of study. Design: Non randomized pre/posttest group comparison design. Main Outcome Measures: Hopkins Verbal Learning Test-Revised and Rivermead Behavioral Memory Test II. Results: Participation in the memory group intervention was associated with improved memory performance immediately postintervention, and improvements were maintained I month postintervention. Severe injury was associated with less improvement in memory outcomes than mild and moderate injuries. Age and preinjury education were not related to outcome. Conclusions: Individuals with traumatic brain injury may benefit from memory group intervention focusing on internal strategy use. Study hypotheses should be retested using a randomized, controlled design, and further research is needed to better delineate influences on intervention candidacy and outcomes. C1 [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA. [O'Neil-Pirozzi, Therese M.; Strangman, Gary E.; Goldstein, Richard; Kelkar, Kalika; Glenn, Mel B.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Strangman, Gary E.; Supelana, Christina] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Katz, Douglas I.] Boston Univ, Sch Med, Braintree Rehabil Hosp, Dept Neurol, Braintree, MA USA. [Savage, Cary R.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66103 USA. [Burke, David] Emory Univ, Dept Rehabil Med, Atlanta, GA 30322 USA. [Rauch, Scott L.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA. RP O'Neil-Pirozzi, TM (reprint author), Northeastern Univ, Dept Speech Language Pathol & Audiol, 250 Huntington Ave,Forsyth Bldg,Room 103, Boston, MA 02115 USA. EM t.oneil-pirozzi@neu.edu FU National Institute on Disability and Rehabilitation Research, US Department of Education [H133A020513] FX This project was supported by grant NIDRR: H133A020513 from the National Institute on Disability and Rehabilitation Research, US Department of Education. NR 57 TC 13 Z9 14 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2010 VL 25 IS 1 BP 43 EP 51 PG 9 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 550XC UT WOS:000274165800006 PM 20051897 ER PT J AU Wallington, SF Blake, K Taylor-Clark, K Viswanath, K AF Wallington, Sherrie Flynt Blake, Kelly Taylor-Clark, Kalahn Viswanath, K. TI Antecedents to Agenda Setting and Framing in Health News: An Examination of Priority, Angle, Source, and Resource Usage from a National Survey of US Health Reporters and Editors SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID TELEVISION-NEWS; WEB SITES; MEDIA; JOURNALISTS; PERCEPTIONS; TELEPHONE; EVOLUTION; COVERAGE C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wallington, SF (reprint author), Georgetown Univ, Med Ctr, Lombard Comprehens Canc Ctr, Res Bldg,W326A,3970 Reservoir Rd NW, Washington, DC 20057 USA. EM sfw49@georgetown.edu FU NCI NIH HHS [R25 CA057711, U01 CA114644, R25 CA057711-18, 5R25CA057711-14, 5 U01 CA114644, U01 CA114644-05, R25 CA057711-14]; PHS HHS [OMB#0925-0541] NR 54 TC 20 Z9 21 U1 1 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PD JAN-FEB PY 2010 VL 15 IS 1 BP 76 EP 94 DI 10.1080/10810730903460559 PG 19 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 563HE UT WOS:000275118000006 PM 20390978 ER PT J AU Kontos, EZ Emmons, KM Puleo, E Viswanath, K AF Kontos, Emily Z. Emmons, Karen M. Puleo, Elaine Viswanath, K. TI Communication Inequalities and Public Health Implications of Adult Social Networking Site Use in the United States SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID INTERNET PARADOX; SELF-ESTEEM; FACEBOOK; ADOLESCENTS; INFORMATION; INVOLVEMENT; TWITTER; CONTEXT; MEDIA; LIFE AB Social media, and specifically social networking sites (SNSs), are emerging as an important platform for communication and health information exchange. Yet, despite the increase in popularity and use, only a limited number of empirical studies document which segments of the adult population are and are not using social networking sites and with what, if any, affect on health. The purpose of this study is to identify potential communication inequalities in social networking site use among a representative sample of U.S. adults and to examine the association between SNS use and psychological well-being. We analyzed data from the National Cancer Institute's 2007 Health Information National Trends Survey (HINTS). Thirty-five percent of online adults reported SNS use within the past 12 months, and there were no significant differences in SNS use by race/ethnicity or socioeconomic position. Younger age (p=.00) was the most significant predictor of SNS use, while being married (p=.02) and having a history of cancer (p=.02) were associated with a decreased odds of SNS use. SNS use was significantly associated with a 0.80 (p=.00) increment in psychological distress score after controlling for other factors. The absence of inequalities in adult SNS use across race/ethnicity and class offers some support for the continued use of social media to promote public health efforts; however, issues such as the persisting digital divide and potential deleterious effects of SNS use on psychological well-being need to be addressed. C1 [Kontos, Emily Z.; Emmons, Karen M.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Emmons, Karen M.; Viswanath, K.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Puleo, Elaine] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA. RP Kontos, EZ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave, Boston, MA 02115 USA. EM ekontos@hsph.harvard.edu FU NCI NIH HHS [5R01CA122894-04, 5R25CA057711-14, R01 CA122894, R01 CA122894-05, R25 CA057711, R25 CA057711-18] NR 59 TC 48 Z9 48 U1 7 U2 51 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PY 2010 VL 15 SU 3 BP 216 EP 235 AR PII 930958416 DI 10.1080/10810730.2010.522689 PG 20 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 693BI UT WOS:000285199200018 PM 21154095 ER PT J AU Clayman, ML Manganello, JA Viswanath, K Hesse, BW Arora, NK AF Clayman, Marla L. Manganello, Jennifer A. Viswanath, K. Hesse, Bradford W. Arora, Neeraj K. TI Providing Health Messages to Hispanics/Latinos: Understanding the Importance of Language, Trust in Health Information Sources, and Media Use SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID NATIONAL TRENDS SURVEY; CANCER KNOWLEDGE; CERVICAL-CANCER; CARE; DISPARITIES; BREAST; WOMEN; ACCULTURATION; ETHNICITY; SEEKING AB Health communication is critical to promoting healthy lifestyles and preventing unhealthy behaviors. However, populations may differ in terms of their trust in and use of health information sources, including mass media, the Internet, and interpersonal channels. We used the 2005 Health Information National Trends Survey (HINTS) to test the hypothesis that Hispanics who are less comfortable speaking English would differ from Hispanics who are comfortable speaking English with respect to trust in health information sources and media use. Hispanics/Latinos comprised 9% of the 2005 HINTS sample (n=496). Respondents not born in the United States regardless of race/ethnicity and all Hispanics were asked, oHow comfortable do you feel speaking English?o Responses of ocompletely,o overy,o or onative speakero were combined into ocomfortable speaking Englisho: all other responses were categorized as oless comfortable speaking English.o Those comfortable speaking English reported higher trust for health information from newspapers (p.05), magazines (p.05), and the Internet (p.01) compared with those less comfortable speaking English. They also reported more media exposure: daily hours listening to the radio and watching television (both p.05) and days per week reading newspapers (p.05). Hispanics comfortable speaking English reported much higher levels of Internet use (54% versus 14%, p.0001). Hispanics who are not comfortable speaking English may be difficult to reach, not only because of language barriers and lower trust in media, but also because they report relatively little use of various media channels. These findings have important implications for health communications toward non-native speakers of English in general and Hispanics in particular. C1 [Clayman, Marla L.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Gen Internal Med, Chicago, IL 60611 USA. [Manganello, Jennifer A.] SUNY Albany, Sch Publ Hlth, Dept Hlth Policy Management & Behav, Albany, NY USA. [Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Viswanath, K.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hesse, Bradford W.] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA. [Arora, Neeraj K.] NCI, Outcomes Res Branch, Bethesda, MD 20892 USA. RP Clayman, ML (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Gen Internal Med, 750 N Lake Shore Dr, Chicago, IL 60611 USA. EM m-clayman@northwestern.edu OI Clayman, Marla/0000-0001-8491-3672; Hesse, Bradford/0000-0003-1142-1161 FU NICHD NIH HHS [K12 HD055884, K12 HD055884-02, K12HD055884] NR 36 TC 37 Z9 37 U1 3 U2 17 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2010 VL 15 SU 3 BP 252 EP 263 AR PII 930958227 DI 10.1080/10810730.2010.522697 PG 12 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 693BI UT WOS:000285199200020 PM 21154097 ER PT J AU Miller, MJ Allison, JJ Schmitt, MR Ray, MN Funkhouser, EM Cobaugh, DJ Saag, KG LaCivita, C AF Miller, Michael J. Allison, Jeroan J. Schmitt, Michael R. Ray, Midge N. Funkhouser, Ellen M. Cobaugh, Daniel J. Saag, Kenneth G. LaCivita, Cynthia TI Using Single-Item Health Literacy Screening Questions to Identify Patients Who Read Written Nonsteroidal Anti-Inflammatory Medicine Information Provided at Pharmacies SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID CHRONIC DISEASE; MEDICATION; KNOWLEDGE; CARE; EDUCATION; ABILITY; SKILLS; SHAME; RISK AB Our goal was to assess the relationships between single-item health literacy screening questions and reading prescription nonsteroidal anti-inflammatory drug (NSAID) written medicine information (WMI) provided at pharmacies. The health literacy of 382 patients from primary care physician practices in Alabama was estimated using validated health literacy screening questions related to understanding written medical information (SQ1); confidence in completing medical forms alone (SQ2); and need for assistance in reading hospital materials (SQ3). Reading WMI was measured by a oYeso response to the question, oOften the drug store gives you written information such as pamphlets or handouts along with your prescription. Have you read about the risks of NSAIDs in this written material provided by the drug store?o Relationships were assessed using generalized linear latent and mixed models. Two-thirds (67.6%) of patients read WMI. Higher estimated health literacy was associated with increased odds of reading WMI. Adjusted odds ratios (95% CI) were 2.08 (1.08-4.03); 2.09 (1.12-3.91); and 1.98 (1.04-3.77) using SQ1-SQ3. Current WMI may be unable to meet the needs of those with inadequate health literacy. Health literacy screening questions can be used to triage patients at risk for not reading WMI so they can be assisted with supplemental educational strategies. C1 [Miller, Michael J.; Schmitt, Michael R.] Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, Tulsa, OK 74135 USA. [Allison, Jeroan J.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Ray, Midge N.] Univ Alabama Birmingham, Deep S Musculoskeletal Ctr Educ & Res Therapeut, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. [Ray, Midge N.] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL USA. [Funkhouser, Ellen M.] Univ Alabama Birmingham, VA Res Enhancement Award Program REAP, Birmingham VA Med Ctr, Dept Med,Sch Med, Birmingham, AL USA. [Cobaugh, Daniel J.; LaCivita, Cynthia] Amer Soc Hlth Syst Pharmacists Res & Educ Fdn, Bethesda, MD USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Ctr Educ & Res Therapeut CERTs, Birmingham, AL USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Sch Med, COERE, Birmingham, AL USA. RP Miller, MJ (reprint author), Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, 4502 E 41st St, Tulsa, OK 74135 USA. EM michael-miller@ouhsc.edu OI Allison, Jeroan/0000-0003-4472-2112 FU AHRQ HHS [U18 HS016956] NR 39 TC 5 Z9 5 U1 4 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PY 2010 VL 15 IS 4 BP 413 EP 427 AR PII 923240176 DI 10.1080/10810731003753091 PG 15 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 615FW UT WOS:000279120500006 PM 20574879 ER PT J AU Kelly, B Hornik, R Romantan, A Schwartz, JS Armstrong, K DeMichele, A Fishbein, M Gray, S Hull, S Kim, A Nagler, R Niederdeppe, J Ramirez, AS Smith-McLallen, A Wong, N AF Kelly, Bridget Hornik, Robert Romantan, Anca Schwartz, J. Sanford Armstrong, Katrina DeMichele, Angela Fishbein, Martin Gray, Stacy Hull, Shawnika Kim, Annice Nagler, Rebekah Niederdeppe, Jeff Ramirez, A. Susana Smith-McLallen, Aaron Wong, Norman TI Cancer Information Scanning and Seeking in the General Population SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID HEALTH; BEHAVIOR; EXPOSURE; MESSAGE; MEDIA; WEB; COMMUNICATION; ENVIRONMENT; TELEVISION; DISTRUST AB The amount of cancer-related information available in the media and other sources continues to increase each year. We wondered how people make use of such content in making specific health decisions. We studied both the information they actively seek (oseekingo) and that which they encounter in a less purposive way (oscanningo) through a nationally representative survey of adults aged 40-70 years (n=2,489) focused on information use around three prevention behaviors (dieting, fruit and vegetable consumption, and exercising) and three screening test behaviors (prostate-specific antigen, colonoscopy, mammogram). Overall, respondents reported a great deal of scanning and somewhat less seeking (on average 62% versus 28% for each behavior), and they used a range of sources including mass media, interpersonal conversations, and the Internet, alongside physicians. Seeking was predicted by female gender, age of 55-64 vs. 40-44, higher education, Black race and Hispanic ethnicity, and being married. Scanning was predicted by older age, female gender, and education. Respondents were fairly consistent in their place on a typology of scanning and seeking across behaviors. Seeking was associated with all six behaviors, and scanning was associated with three of six behaviors. C1 [Hornik, Robert; Fishbein, Martin; Hull, Shawnika; Nagler, Rebekah; Ramirez, A. Susana] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Kelly, Bridget] RTI Int, Washington, DC USA. [Romantan, Anca] Univ Massachusetts, Dept Commun, Amherst, MA 01003 USA. [Schwartz, J. Sanford; Armstrong, Katrina; DeMichele, Angela] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Schwartz, J. Sanford] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Gray, Stacy] Harvard Univ, Dept Med, Boston, MA USA. [Gray, Stacy] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kim, Annice] RTI Int, Res Triangle Pk, NC USA. [Niederdeppe, Jeff] Cornell Univ, Dept Commun, Ithaca, NY USA. [Smith-McLallen, Aaron] Independence Blue Cross, Dept Informat, Philadelphia, PA USA. [Wong, Norman] Univ Oklahoma, Dept Commun, Norman, OK 73019 USA. RP Hornik, R (reprint author), Univ Penn, Annenberg Sch Commun, 3620 Walnut St, Philadelphia, PA 19104 USA. EM rhornik@asc.upenn.edu OI Hornik, Robert/0000-0002-2148-8805 FU NCI NIH HHS [P50 CA095856, P50-CA095856-05] NR 58 TC 58 Z9 58 U1 4 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2010 VL 15 IS 7 BP 734 EP 753 AR PII 929760220 DI 10.1080/10810730.2010.514029 PG 20 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 682NX UT WOS:000284411400004 PM 21104503 ER PT J AU Brau, N Kikuchi, L Nunez, M Barreiro, P Nelson, M Bini, EJ Kristen, M Fox, R Sherman, M Puoti, M AF Braeu, N. Kikuchi, L. Nunez, M. Barreiro, P. Nelson, M. Bini, E. J. Kristen, M. Fox, R. Sherman, M. Puoti, M. CA Liver Canc HIV Study Grp TI IMPROVED SURVIVAL OF HEPATOCELLULAR CARCINOMA (HCC) IN HIV-INFECTED PATIENTS WITH UNDETECTABLE HIV RNA SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Braeu, N.] Mt Sinai Sch Med, Div Infect Dis, New York, NY USA. [Braeu, N.] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA. [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Kikuchi, L.] Univ Sao Paulo, Sao Paulo, Brazil. [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Barreiro, P.] Hosp Carlos III, Madrid, Spain. [Nelson, M.] Chelsea & Westminster Hosp, London, England. [Bini, E. J.] NYU, New York, NY USA. [Bini, E. J.] Vet Affairs New York Harbor Hlth Care Ctr, New York, NY USA. [Kristen, M.] Cornell Univ, New York, NY 10021 USA. [Fox, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sherman, M.] Univ Toronto, Toronto, ON, Canada. [Puoti, M.] Univ Brescia, Brescia, Italy. EM norbert.brau@va.gov NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S219 EP S219 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018001174 ER PT J AU Chung, RT Di Bisceglie, A Poordad, FF Hassanein, T Zhou, X Lentz, E Prabhakar, A Hamzeh, FM AF Chung, R. T. Di Bisceglie, A. Poordad, F. F. Hassanein, T. Zhou, X. Lentz, E. Prabhakar, A. Hamzeh, F. M. TI ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Chung, R. T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Di Bisceglie, A.] St Louis Univ, Sch Med, St Louis, MO USA. [Poordad, F. F.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Hassanein, T.] Univ Calif San Diego, San Diego, CA 92103 USA. [Lentz, E.; Prabhakar, A.; Hamzeh, F. M.] Genentech Inc, San Francisco, CA 94080 USA. [Zhou, X.] RTI Hlth Solut, Res Triangle Pk, NC USA. EM dibiscam@slu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S106 EP S107 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018000254 ER PT J AU Hillebrand, DJ Frederick, RT Williams, WW Brown, RS Napotilano, LM Te, HS Millis, JM Ashley, RA Pockros, PJ AF Hillebrand, D. J. Frederick, R. T. Williams, W. W. Brown, R. S., Jr. Napotilano, L. M. Te, H. S. Millis, J. M. Ashley, R. A. Pockros, P. J. TI SAFETY AND EFFICACY OF THE EXTRACORPOREAL LIVER ASSIST DEVICE (ELAD (R)) IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Hillebrand, D. J.; Pockros, P. J.] Scripps Clin, La Jolla, CA USA. [Frederick, R. T.] Calif Pacific Med Ctr, San Francisco, CA USA. [Williams, W. W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. [Brown, R. S., Jr.] Columbia Univ, Med Ctr, New York, NY USA. [Napotilano, L. M.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Te, H. S.; Millis, J. M.] Univ Chicago, Chicago, IL 60637 USA. [Ashley, R. A.] Vital Therapies, San Diego, CA USA. EM hillebrand.donald@scrippshealth.org NR 0 TC 3 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S323 EP S324 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002029 ER PT J AU Kikuchi, L Nunez, M Barreiro, P Nelson, M Vispo, ME Page, E Puoti, M Fox, R Sherman, M Carrilho, F Brau, N AF Kikuchi, L. Nunez, M. Barreiro, P. Nelson, M. Vispo, M. E. Page, E. Puoti, M. Fox, R. Sherman, M. Carrilho, F. Braeu, N. TI IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Kikuchi, L.; Carrilho, F.] Univ Sao Paulo, Liver Canc HIV Study Grp, Sao Paulo, Brazil. [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Barreiro, P.; Vispo, M. E.] Hosp Carlos III, Madrid, Spain. [Nelson, M.; Page, E.] Chelsea & Westminster Hosp, London, England. [Puoti, M.] Univ Brescia, Brescia, Italy. [Fox, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sherman, M.] Univ Toronto, Toronto, ON, Canada. [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, N.] Mt Sinai Sch Med, Div Infect Dis & Liver Dis, New York, NY USA. EM lu1912@gmail.com RI Carrilho, Flair/I-3046-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S412 EP S412 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002265 ER PT J AU Lau, D Zhang, Y Chen, J Holder, S Bhasin, M Libermann, T Gale, M AF Lau, D. Zhang, Y. Chen, J. Holder, S. Bhasin, M. Libermann, T. Gale, M., Jr. TI DIFFERENTIAL HEPATIC MICRORNA EXPRESSION PROFILES ASSOCIATED WITH INTERFERON ALPHA TREATMENT RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Bhasin, M.; Libermann, T.] Harvard Univ, Sch Med, BIDMC Genom & Prote Ctr, Boston, MA USA. [Gale, M., Jr.] Univ Washington, Sch Med, Seattle, WA USA. EM dlau@bidmc.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S51 EP S51 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018000115 ER PT J AU Nahmias, Y AF Nahmias, Y. TI OXYGEN-MEDIATED ENHANCEMENT OF PRIMARY HEPATOCYTE METABOLISM, FUNCTIONAL POLARIZATION, AND GENE EXPRESSION: ACHIEVING IN VIVO LEVELS OF DRUG CLEARANCE AND HCV INFECTION IN VITRO SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Nahmias, Y.] Hebrew Univ Jerusalem, Selim & Rachel Benin Sch Engn, Jerusalem, Israel. [Nahmias, Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. EM ynahmias@gmail.com RI Nahmias, Yaakov/H-4725-2013 NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S374 EP S374 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002167 ER PT J AU Nahmias, Y Polyak, SJ Chung, RT AF Nahmias, Y. Polyak, S. J. Chung, R. T. TI NARINGENIN INHIBITS THE ASSEMBLY AND LONG-TERM PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS (HCV) PARTICLES THROUGH A PPAR-MEDIATED MECHANISM SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Nahmias, Y.] Hebrew Univ Jerusalem, Selim & Rachel Benin Sch Engn, Jerusalem, Israel. [Nahmias, Y.; Chung, R. T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Polyak, S. J.] Univ Washington, Seattle, WA 98195 USA. EM ynahmias@gmail.com RI Polyak, Stephen/B-5743-2011; Nahmias, Yaakov/H-4725-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S297 EP S297 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018001389 ER PT J AU Nevzorova, YA Bangen, JM Gassler, N Haas, U Weiskirchen, R Tacke, F Sicinski, P Trautwein, C Liedtke, C AF Nevzorova, Y. A. Bangen, J. M. Gassler, N. Haas, U. Weiskirchen, R. Tacke, F. Sicinski, P. Trautwein, C. Liedtke, C. TI CYCLIN E1 CONTROLS THE CELL CYCLE ACTIVITY OF HEPATIC STELLATE CELLS AND TRIGGERS FIBROGENESIS IN MICE SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Nevzorova, Y. A.; Bangen, J. M.; Haas, U.; Tacke, F.; Trautwein, C.; Liedtke, C.] Univ Hosp Aachen, Dept Med 3, Aachen, Germany. [Gassler, N.] Univ Hosp Aachen, Inst Pathol, Aachen, Germany. [Weiskirchen, R.] Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, Aachen, Germany. [Sicinski, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S374 EP S375 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002169 ER PT J AU O'Brien, T Bonkovsky, H Pfeiffer, R Chung, R Everhart, J Shiffman, M Sninsky, J Morgan, T AF O'Brien, T. Bonkovsky, H. Pfeiffer, R. Chung, R. Everhart, J. Shiffman, M. Sninsky, J. Morgan, T. CA HALT-C Trial Grp TI ASSOCIATION OF IL28B GENOTYPE WITH VIROLOGICAL RESPONSE TO PEGYLATED-INTERFERON PLUS RIBAVIRIN IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C ENROLLED IN THE HALT-C TRIAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [O'Brien, T.; Pfeiffer, R.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Bonkovsky, H.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Chung, R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA. [Everhart, J.] NIDDKD, Div Digest Dis & Nutr, Bethesda, MD 20892 USA. [Shiffman, M.] Virginia Commonwealth Univ, Med Ctr, Hepatol Sect, Richmond, VA USA. [Sninsky, J.] Celera, Alameda, CA USA. [Morgan, T.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA. [Morgan, T.] VA Long Beach Healthcare Syst, Serv Gastroenterol, Long Beach, CA USA. EM obrient@mail.nih.gov RI Pfeiffer, Ruth /F-4748-2011 NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S454 EP S454 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002374 ER PT J AU Shafaroodi, H Ebrahimi, F Moezi, L Hashemi, M Doostar, Y Ghasemi, M Dehpour, AR AF Shafaroodi, H. Ebrahimi, F. Moezi, L. Hashemi, M. Doostar, Y. Ghasemi, M. Dehpour, A. R. TI CHOLESTASIS INDUCES APOPTOSIS IN MICE CARDIAC CELLS: THE POSSIBLE ROLE OF NO AND OXIDATIVE STRESS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Shafaroodi, H.; Hashemi, M.] Islamic Azad Univ, Tehran Med Branch, Tehran, Iran. [Ebrahimi, F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Moezi, L.] Shiraz Univ Med Sci, Sch Med, Shiraz, Iran. [Doostar, Y.] Islamic Azad Univ, Tabriz Branch, Tabriz, Iran. [Ghasemi, M.; Dehpour, A. R.] Univ Tehran Med Sci, Sch Med, Tehran, Iran. EM dehpour@yahoo.com RI moezi, leila/D-5127-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S423 EP S423 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002294 ER PT J AU Sulkowski, M Chung, RT Slim, J Bhatti, L Sterling, R Hassanein, T Serrao, R Sola, R Bertasso, A Stancic, S Rodriguez-Torres, M AF Sulkowski, M. Chung, R. T. Slim, J. Bhatti, L. Sterling, R. Hassanein, T. Serrao, R. Sola, R. Bertasso, A. Stancic, S. Rodriguez-Torres, M. CA PARADIGM Study Investigators TI SHIFTS IN CHILD-PUGH SCORE IN PATIENTS COINFECTED WITH HIV-HCV UNDERGOING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN ARE NOT PREDICTIVE OF HEPATIC DECOMPENSATION SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Sulkowski, M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Chung, R. T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA. [Slim, J.] St Michaels Hosp, Newark, NJ USA. [Bhatti, L.] Aids Healthcare Fdn, Los Angeles, CA USA. [Sterling, R.] Virginia Commonwealth Univ, Richmond, VA USA. [Hassanein, T.] Univ Calif San Diego, San Diego, CA 92103 USA. [Serrao, R.] Hosp Sao Joao, Oporto, Portugal. [Sola, R.] Hosp Mar, Barcelona, Spain. [Bertasso, A.; Stancic, S.] Roche, Nutley, NJ USA. [Rodriguez-Torres, M.] Fdn Invest Diego, Santurce, PR USA. [Rodriguez-Torres, M.] Ponce Sch Med, Santurce, PR USA. EM msulkows@jhmi.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S127 EP S127 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018000304 ER PT J AU Walker, LJ Smith, M Khan, Y Oo, Y Barnes, E Lauer, G Adams, D Klenerman, P AF Walker, L. J. Smith, M. Khan, Y. Oo, Y. Barnes, E. Lauer, G. Adams, D. Klenerman, P. TI CD8AA T CELLS: A NOVEL LINEAGE ENRICHED IN THE LIVER IN CHRONIC HCV SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Walker, L. J.; Smith, M.; Khan, Y.; Barnes, E.; Klenerman, P.] Univ Oxford, Nuffield Dept Med, Oxford, England. [Oo, Y.; Adams, D.] Univ Birmingham, Liver Res Grp, Birmingham, W Midlands, England. [Lauer, G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. EM lucyjanewalker@doctors.net.uk NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S275 EP S275 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018001333 ER PT J AU Paige, NM Vazirani, SS Graber, CJ AF Paige, Neil M. Vazirani, Sondra S. Graber, Christophe J. TI The Top 10 Infectious Disease Pitfalls That Hospitalists Can Avoid SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review DE antimicrobials bacteremia; candida; clostridium difficile infection; penicillin allergy ID CLOSTRIDIUM-DIFFICILE INFECTION; ASYMPTOMATIC BACTERIURIA; BODY-TEMPERATURE; OCCAMS RAZOR; LEUKOCYTOSIS; MANAGEMENT; ALLERGY; GUIDELINES; CANDIDEMIA; DIAGNOSIS AB Infectious diseases are commonly encountered by hospitalists in their day-to-day care of patients. Challenges involved in caring for patients with infectious diseases include choosing the correct antibiotic, treating patients with a penicillin allergy, interpreting blood cultures, and caring for patients with human immunodeficiency virus (HIV). The evidence-based pearls in this article will help hospitalists avoid common pitfalls in the recognition and treatment of such disorders and guide their decision about when to consult an infectious diseases specialist. Journal of Hospital Medicine 2010;5:42-45. (c) 2010 Society of Hospital Medicine. C1 [Paige, Neil M.] Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. [Vazirani, Sondra S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hosp Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Graber, Christophe J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Paige, NM (reprint author), Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med,David Geffen Sch Med, 11301 Wilshire Blvd 111A, Los Angeles, CA 90073 USA. EM neil.paige@va.gov NR 26 TC 3 Z9 3 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2010 VL 5 IS 1 BP 42 EP 45 DI 10.1002/jhm.515 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 545QI UT WOS:000273751000007 PM 20063396 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Spironolactone for all hypertensive patients? SO JOURNAL OF HYPERTENSION LA English DT Editorial Material ID SELECTIVE ALDOSTERONE BLOCKER; RESISTANT HYPERTENSION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; EPLERENONE; AMLODIPINE C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111,134 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD JAN PY 2010 VL 28 IS 1 BP 13 EP 14 DI 10.1097/HJH.0b013e328334262f PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 541HM UT WOS:000273405900003 PM 20016304 ER PT J AU Wang, JH Li, J Wu, Q Yang, PA Pawar, RD Xie, ST Timares, L Raman, C Chaplin, DD Lu, L Mountz, JD Hsu, HC AF Wang, John H. Li, Jun Wu, Qi Yang, PingAr Pawar, Rahul D. Xie, Shutao Timares, Laura Raman, Chander Chaplin, David D. Lu, Lu Mountz, John D. Hsu, Hui-Chen TI Marginal Zone Precursor B Cells as Cellular Agents for Type I IFN-Promoted Antigen Transport in Autoimmunity SO JOURNAL OF IMMUNOLOGY LA English DT Article ID PLASMACYTOID DENDRITIC CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; T-CELLS; PATHOGENIC AUTOANTIBODIES; FOLLICULAR EXCLUSION; RHEUMATOID-ARTHRITIS; THERAPEUTIC TARGET; BXD2 MICE; NZB MICE; INTERFERON AB The pathogenic connection of type I IFN and its role in regulating the migration response of Ag delivery by B cells into lymphoid follicles in an autoimmune condition has not been well-identified. Here, we show that there was a significantly larger population of marginal zone precursor (MZ-P) B cells, defined as being IgM(hi)CD1d(hi)CD21(hi)CD23(hi) in the spleens of autoimmune BXD2 mice compared with B6 mice. MZ-P B cells were highly proliferative compared with marginal zone (MZ) and follicular (FO) B cells. The intrafollicular accumulation of MZ-P B cells in proximity to germinal centers (GCs) in BXD2 mice facilitated rapid Ag delivery to the GC area, whereas Ag-carrying MZ B cells, residing predominantly in the periphery, had a lower ability to carry Ag into the GCs. IFN-alpha, generated by plasmacytoid dendritic cells, induced the expression of CD69 and suppressed the sphingosine-1-phosphate-induced chemotactic response, promoting FO-oriented Ag transport by MZ-P B cells. Knockout of type I IFN receptor in BXD2 (MID2-Ifn alpha r(-/-)) mice substantially diffused the intrafollicular MZ-P B cell conglomeration and shifted their location to the FO-MZ border near the marginal sinus, making Ag delivery to the FO interior less efficient. The development of spontaneous GCs was decreased in BXD2-Ifn alpha r(-/-) mice. Together, our results suggest that the MZ-P B cells are major Ag-delivery B cells and that the FO entry of these B cells is highly regulated by type I IFN-producing plasmacytoid dendritic cells in the marginal sinus in the spleens of autoimmune BXD2 mice. The Journal of Immunology, 2010, 184: 442-451. C1 [Wang, John H.; Li, Jun; Wu, Qi; Yang, PingAr; Pawar, Rahul D.; Xie, Shutao; Raman, Chander; Mountz, John D.; Hsu, Hui-Chen] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Timares, Laura] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Chaplin, David D.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Lu, Lu] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Hsu, HC (reprint author), Univ Alabama, Dept Med, 1825 Univ Blvd,SHELB 311, Birmingham, AL 35294 USA. EM rheu078@uab.edu OI Chaplin, David/0000-0002-1354-3069 FU American College of Rheumatology Research and Education Foundation; Department of Veterans Affairs Merit Review [1101BX000600-01]; Daiichi-Sankyo; National Institutes of Health [IA1 071110-01A1, ARRA 3RO1A171110-02S1]; The University of Alabama at Birmingham Skin Diseases Research Center; Arthritis Foundation FX This work was supported by a grant from the American College of Rheumatology Research and Education Foundation Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign, the Alliance for lupus Research - Target Identification in Lupus program, a Department of Veterans Affairs Merit Review Grant (1101BX000600-01). Daiichi-Sankyo, and National Institutes of Health Grants (IA1 071110-01A1 and ARRA 3RO1A171110-02S1) (all to J.D.M.), The University of Alabama at Birmingham Skin Diseases Research Center (to L.T.), and the Arthritis Investigator Award supported by the Arthritis Foundation (to H.-C.H). NR 55 TC 18 Z9 19 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2010 VL 184 IS 1 BP 442 EP 451 DI 10.4049/jimmunol.0900870 PG 10 WC Immunology SC Immunology GA 535QL UT WOS:000272985300050 PM 19949066 ER PT J AU Salisch, NC Kaufmann, DE Awad, AS Reeves, RK Tighe, DP Li, Y Piatak, M Lifson, JD Evans, DT Pereyra, F Freeman, GJ Johnson, RP AF Salisch, Nadine C. Kaufmann, Daniel E. Awad, Amany S. Reeves, R. Keith Tighe, Daniel P. Li, Yuan Piatak, Michael, Jr. Lifson, Jeffrey D. Evans, David T. Pereyra, Florencia Freeman, Gordon J. Johnson, R. Paul TI Inhibitory TCR Coreceptor PD-1 Is a Sensitive Indicator of Low-Level Replication of SIV and HIV-1 SO JOURNAL OF IMMUNOLOGY LA English DT Article ID SIMIAN-IMMUNODEFICIENCY-VIRUS; T-CELL EXHAUSTION; MAJOR HISTOCOMPATIBILITY COMPLEX; CHRONIC VIRAL-INFECTION; CLASS-I MOLECULE; TYPE-1 ELITE CONTROLLERS; PROGRAMMED DEATH-1; RHESUS MACAQUES; NEF GENE; VACCINE PROTECTION AB Ongoing antigenic stimulation appears to be an important prerequisite for the persistent expression of programmed death 1 (PD-1), an inhibitory TCR coreceptor of the CD28 family. Although recent publications have emphasized the utility of PD-1 as a marker for dysfunctional T cells in chronic viral infections, its dependence on antigenic stimulation potentially renders it a sensitive indicator of low-level viral replication. To explore the antigenic threshold for the maintenance of PD-1 expression on virus-specific T cells, we compared PD-1 expression on virus-specific and memory T cell populations in controlled and uncontrolled SIV and HIV-1 infection. In both controlled live attenuated SIV infection in rhesus macaques and HIV-1 infection in elite controllers, elevated levels of PD-1 expression were observed on SIV- and HIV-1-specific CD8(+) T cells. However, in contrast to chronic wild-type SIV infection and uncontrolled HIV-1 infection, controlled SIV/HIV-1 infection did not result in increased expression of PD-1 on total memory T cells. PD-1 expression on SIV-specific CD8(+) T cells rapidly decreased after the emergence of CTL escape in cognate epitopes, but was maintained in the setting of low or undetectable levels of plasma viremia in live attenuated SIV-infected macaques. After inoculation of naive macaques with a single-cycle SIV, PD-1 expression on SIV-specific CD8(+) T cells initially increased, but was rapidly downregulated. These results demonstrate that PD-I can serve as a sensitive indicator of persistent, low-level virus replication and that generalized PD-1 expression on T lymphocytes is a distinguishing characteristic of uncontrolled lentiviral infections. The Journal of Immunology, 2010, 184: 476-487. C1 [Salisch, Nadine C.; Awad, Amany S.; Reeves, R. Keith; Johnson, R. Paul] Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Div Immunol, Southborough, MA 01772 USA. [Evans, David T.] Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA. [Kaufmann, Daniel E.; Tighe, Daniel P.; Pereyra, Florencia; Johnson, R. Paul] Massachusetts Gen Hosp, MIT, Ragon Inst, Charlestown, MA 02129 USA. [Kaufmann, Daniel E.; Tighe, Daniel P.; Pereyra, Florencia; Johnson, R. Paul] Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA. [Li, Yuan; Piatak, Michael, Jr.; Lifson, Jeffrey D.] NCI, Sci Applicat Int Corp Frederick, AIDS & Canc Virus Program, Frederick, MD 21702 USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Johnson, RP (reprint author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Div Immunol, Southborough Campus,Pine Hill Dr, Southborough, MA 01772 USA. EM paul_johnson@hms.harvard.edu FU National Institutes of Health [AI062412, AI071306, RR00168, AI063993, HL092565, AI080192, HHSN266200400088C]; International AIDS Vaccine Initiative; Center for HIV/AIDS Vaccine Immunology; HIV Vaccine Trials Network Early Career Investigator award [U19 Al 067854]; International HIV Controllers Study; National Cancer Institute; Elizabeth Glaser Pediatric AIDS Foundation FX This work was funded through National Institutes of Health Grants AI062412, AI071306, RR00168. AI063993, HL092565, HL092565, and AI080192, the International AIDS Vaccine Initiative, a Center for HIV/AIDS Vaccine Immunology and HIV Vaccine Trials Network Early Career Investigator award (U19 Al 067854) to R. K.R., and the International HIV Controllers Study. It was also supported in part with federal funds front the National Cancer Institute, National Institutes of Health, under Contract HHSN266200400088C. D.T.E. is air Elizabeth Glaser Scientist supported by the Elizabeth Glaser Pediatric AIDS Foundation. NR 76 TC 32 Z9 34 U1 0 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2010 VL 184 IS 1 BP 476 EP 487 DI 10.4049/jimmunol.0902781 PG 12 WC Immunology SC Immunology GA 535QL UT WOS:000272985300053 PM 19949078 ER PT J AU Kamei, A Koh, AY Gadjeva, M Priebe, GP Lory, S Pier, GB AF Kamei, Akinobu Koh, Andrew Y. Gadjeva, Mihaela Priebe, Gregory P. Lory, Stephen Pier, Gerald B. TI Analysis of Acquisition of Pseudomonas aeruginosa Gastrointestinal Mucosal Colonization and Horizontal Transmission in a Murine Model SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID INTENSIVE-CARE-UNIT; CYSTIC-FIBROSIS PATIENTS; OROPHARYNGEAL COLONIZATION; VIRULENCE FACTORS; EPIDEMIC STRAIN; LUNG INFECTION; TAP WATER; LIPOPOLYSACCHARIDE; IDENTIFICATION; OUTBREAK AB Background. Laboratory systems to study bacterial transmission and mucosal colonization leading to infection have not been utilized. Methods. We determined whether transmission of various strains of Pseudomonas aeruginosa among individual mice could occur and investigated the properties of such strains in establishing gastrointestinal (GI) mucosal colonization as well as in disseminating systemically after induction of neutropenia. Results. P. aeruginosa isolates associated with epidemic spread among patients with cystic fibrosis (CF) readily established GI colonization at higher levels than did strains associated with acute infections in patients without CF, and they outcompeted these strains. Colonization was associated with resistance to bile salts. However, epidemic CF isolates did not disseminate after induction of neutropenia and did not induce as much mucosal pathology as did strains that were capable of disseminating. Conclusion. Murine models can be used to study P. aeruginosa transmission and early colonization, and the properties of these strains associated with their known clinical behaviors are mimicked in this setting. C1 [Kamei, Akinobu; Koh, Andrew Y.; Gadjeva, Mihaela; Priebe, Gregory P.; Pier, Gerald B.] Harvard Univ, Sch Med, Channing Lab, Dept Med,Brigham & Womens Hosp, Boston, MA 02115 USA. [Lory, Stephen] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA. [Koh, Andrew Y.; Priebe, Gregory P.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Koh, Andrew Y.] Childrens Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA. [Priebe, Gregory P.] Childrens Hosp, Dept Anesthesia, Div Crit Care Med, Boston, MA 02115 USA. [Koh, Andrew Y.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Kamei, A (reprint author), Harvard Univ, Sch Med, Channing Lab, Dept Med,Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA. EM akamei@rics.bwh.harvard.edu OI Pier, Gerald/0000-0002-9112-2331 FU National Institutes of Health [R01 AI22535, AI48917, AI62983, AI50036] FX National Institutes of Health (grants R01 AI22535 [to G. B. P.], AI48917 [to G. B. P.], AI62983 [to A.Y.K.], and AI50036 [to G. P. P.]). NR 50 TC 3 Z9 3 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 1 PY 2010 VL 201 IS 1 BP 71 EP 80 DI 10.1086/648616 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536XU UT WOS:000273078000010 PM 19938976 ER PT J AU Skovbjerg, S Martner, A Hynsjo, L Hessle, C Olsen, I Dewhirst, FE Tham, W Wold, AE AF Skovbjerg, Susann Martner, Anna Hynsjo, Lars Hessle, Christina Olsen, Ingar Dewhirst, Floyd E. Tham, Wilhelm Wold, Agnes E. TI Gram-Positive and Gram-Negative Bacteria Induce Different Patterns of Cytokine Production in Human Mononuclear Cells Irrespective of Taxonomic Relatedness SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH LA English DT Article ID LISTERIA-MONOCYTOGENES; GROWTH-FACTOR; B-CELLS; PEPTIDOGLYCAN; INTERLEUKIN-12; RESISTANCE; INFECTION; IL-10; ALPHA; NOD1 AB Upon bacterial stimulation, tissue macrophages produce a variety of cytokines that orchestrate the immune response that clears the infection. We have shown that Gram-positives induce higher levels of interleukin-12 (IL-12), interferon-gamma (IFN-gamma), and tumor necrosis factor (TNF) from human peripheral blood mononuclear cells (PBMCs) than do Gram-negatives, which instead induce more of IL-6, IL-8, and IL-10. Here, we study whether these patterns follows or crosses taxonomic borders. PBMCs from blood donors were incubated with UV-inactivated bacteria representing 37 species from five phyla. IL-12, TNF, IL-1 beta, IL-6, IL-8, and IL-10 were measured in the supernatants after 24 h and IFN-gamma after 5 days. Irrespective of phylogenetic position, Gram-positive bacteria induced much more IL-12 (nine times more on average) and IFN-gamma (seven times), more TNF (three times), and slightly more IL-1 beta (1.5 times) than did Gram-negatives, which instead induced more IL-6 (1.5 times), IL-8 (1.9 times), and IL-10 (3.3 times) than did Gram-positives. A notable exception was the Gram-positive Listeria monocytogenes, which induced very little IL-12, IFN-gamma, and TNF. The results confirm the fundamental difference in innate immune responses to Gram-positive and Gram-negative bacteria, which crosses taxonomic borders and probably reflects differences in cell wall structure. C1 [Skovbjerg, Susann; Martner, Anna; Hessle, Christina; Wold, Agnes E.] Univ Gothenburg, Inst Biomed, Dept Infect Med Clin Bacteriol, SE-41346 Gothenburg, Sweden. [Hynsjo, Lars] Univ Gothenburg, Inst Biomed, Dept Clin Chem & Transfus Med, SE-41346 Gothenburg, Sweden. [Olsen, Ingar] Univ Oslo, Inst Oral Biol, Fac Dent, N-0316 Oslo, Norway. [Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Mol Genet, Forsyth Inst, Boston, MA 02115 USA. [Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Tham, Wilhelm] Univ Orebro, Dept Restaurant & Culinary Arts, Orebro, Sweden. RP Skovbjerg, S (reprint author), Univ Gothenburg, Inst Biomed, Dept Infect Med Clin Bacteriol, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden. EM susann.skovbjerg@vgregion.se RI Wold, Agnes/M-6310-2013; OI Wold, Agnes/0000-0001-9196-5040 FU Swedish Research Council [14017]; Medical Faculty at the University of Gothenburg FX This work was supported by a grant from the Swedish Research Council No. 14017 and the Medical Faculty at the University of Gothenburg. NR 29 TC 23 Z9 23 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1079-9907 J9 J INTERF CYTOK RES JI J. Interferon Cytokine Res. PD JAN PY 2010 VL 30 IS 1 BP 23 EP 32 DI 10.1089/jir.2009.0033 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 543FO UT WOS:000273557300004 PM 20028205 ER PT J AU Paola, R Wojcik, J Succurro, E Marucci, A Chandalia, M Padovano, L Powers, C Merla, G Abate, N Sesti, G Doria, A Trischitta, V AF Di Paola, R. Wojcik, J. Succurro, E. Marucci, A. Chandalia, M. Padovano, L. Powers, C. Merla, G. Abate, N. Sesti, G. Doria, A. Trischitta, V. TI GRB10 gene and type 2 diabetes in Whites SO JOURNAL OF INTERNAL MEDICINE LA English DT Letter ID ASSOCIATION C1 [Di Paola, R.; Marucci, A.; Padovano, L.; Trischitta, V.] IRCCS Casa Sollievo Sofferenza, Res Unit Diabet & Endocrine Dis, I-71013 San Giovanni Rotondo, Italy. [Wojcik, J.; Powers, C.; Doria, A.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA. [Wojcik, J.; Doria, A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Succurro, E.; Sesti, G.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy. [Chandalia, M.; Abate, N.] Univ Texas Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX USA. [Merla, G.] IRCCS Casa Sollievo Sofferenza, Med Genet Unit, I-71013 San Giovanni Rotondo, Italy. [Trischitta, V.] Univ Roma La Sapienza, Dept Med Pathophysiol, Rome, Italy. [Trischitta, V.] IRCCS Casa Sollievo Sofferenza, Mendel Inst, Rome, Italy. RP Paola, R (reprint author), IRCCS Casa Sollievo Sofferenza, Res Unit Diabet & Endocrine Dis, Viale Padre Pio, I-71013 San Giovanni Rotondo, Italy. EM r.dipaola@operapadrepio.it; vincenzo.trischitta@uniroma1.it RI Sesti, Giorgio/B-1509-2012; Trischitta, Vincenzo/K-1487-2016; marucci, antonella/B-8722-2017; OI Trischitta, Vincenzo/0000-0003-1174-127X; marucci, antonella/0000-0001-8131-8317; Sesti, Giorgio/0000-0002-1618-7688; Succurro, Elena/0000-0003-2578-692X NR 5 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0954-6820 EI 1365-2796 J9 J INTERN MED JI J. Intern. Med. PD JAN PY 2010 VL 267 IS 1 BP 132 EP 133 DI 10.1111/j.1365-2796.2009.02089.x PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 531IS UT WOS:000272658900012 ER PT J AU Kaysen, D Rosen, G Bowman, M Resick, PA AF Kaysen, Debra Rosen, Gerald Bowman, Marilyn Resick, Patricia A. TI Duration of Exposure and the Dose-Response Model of PTSD SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE sexual assault; victimization; posttraumatic stress disorder; crime victims; rape; injuries ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; MISSING DATA; VICTIMS; TRAUMA; METAANALYSIS; ADULTS; CRIME AB A dose-response model underlies posttraumatic stress disorder (PTSD) and posits a relationship between event magnitude and clinical outcome. The present study examines whether one index of event magnitude-duration of exposure-contributes to risk of PTSD among female victims of sexual assault. Findings support a small but significant contribution of event duration to clinical status in the immediate aftermath of trauma but not at 3-month follow-up. The opposite pattern is obtained for subjective appraisals of threat. These findings add to a growing literature that suggests that a simple application of the dose-response model to objective event characteristics may be insufficient to explain the risk of PTSD. C1 [Kaysen, Debra; Rosen, Gerald] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rosen, Gerald] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Bowman, Marilyn] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. [Resick, Patricia A.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA. [Resick, Patricia A.] Boston Univ, Boston, MA 02215 USA. RP Kaysen, D (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. EM dkaysen@u.washington.edu FU NIAAA NIH HHS [F32-AA-014728, F32 AA014728]; NIMH NIH HHS [R01-MH-46992, R01 MH046992, R01 MH046992-05] NR 26 TC 26 Z9 27 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD JAN PY 2010 VL 25 IS 1 BP 63 EP 74 DI 10.1177/0886260508329131 PG 12 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA 524LW UT WOS:000272145800004 PM 19252066 ER PT J AU Aqel, R Hage, FG AlJaroudi, W Lawson, D Sweeney, A Hansalia, S Pothineni, K Heo, J Pajaro, O McGiffin, D Dell'Italia, L Iskandrian, AE AF Aqel, Raed Hage, Fadi G. AlJaroudi, Wael Lawson, David Sweeney, Aaron Hansalia, Sachin Pothineni, Koteswara Heo, Jaekyeong Pajaro, Octavio McGiffin, David Dell'Italia, Louis Iskandrian, Ami E. TI How Much Alcohol Should We Infuse in the Coronary Artery of Hypertrophic Cardiomyopathy Patients? SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article DE alcohol septal ablation; left ventricular outflow gradient; infarct mass ID OUTFLOW TRACT OBSTRUCTION; PERCUTANEOUS SEPTAL ABLATION; INFARCT SIZE; SUDDEN-DEATH; FOLLOW-UP; EXPERIENCE; THERAPY AB Background. Although alcohol septal ablation (ASA) is increasingly used in hypertrophic cardiomyopathy (HC) patients who are refractory to medical therapy, the amount of alcohol that is required has not been well studied. This study sought to determine the amount of alcohol that is necessary to achieve clinical benefits of ASA. Methods. Myocardial perfusion imaging was used to determine the size of the myocardial infarction produced by ASA in 54 HC patients. Left ventricular outflow gradients (LVOTg) were determined invasively before and after ASA and by Doppler echocardiography before and at a median of 3 months after ASA. Results. LVOTg decreased at rest and after provocation in response to ASA and this was maintained on follow-up at 3 months. There was no relationship between the amount of alcohol infused and the infarct mass as determined by myocardial perfusion imaging. While the infarct mass was not correlated with the drop in the LVOTg at rest or with provocation, the quantity of alcohol infused was correlated with the drop in LVOTg at rest (r = 0.27, p = 0.05) and with provocation (r = 0.34, p = 0.02). Furthermore, infusing more than 2ml of absolute alcohol was associated with a drop in the LVOTg by more than 60 mmHg at rest (p = 0.02) and by more than 130 mmHg with provocation (p = 0.05). Conclusions. Although lower amounts of alcohol infusion are desirable to avoid side-effects, it might be prudent to infuse around 2ml of absolute alcohol in order to achieve the desirable degree of LVOTg reduction in ASA. C1 [AlJaroudi, Wael; Lawson, David; Sweeney, Aaron; Hansalia, Sachin; Pothineni, Koteswara; Heo, Jaekyeong; Pajaro, Octavio; McGiffin, David; Dell'Italia, Louis; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Aqel, Raed; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Aqel, R (reprint author), BDB 383,1530 3rd Ave S, Birmingham, AL 35294 USA. EM raed.aqel@yahoo.com OI Hage, Fadi/0000-0002-1397-4942 NR 25 TC 2 Z9 4 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JAN PY 2010 VL 22 IS 1 BP 22 EP 26 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 687VX UT WOS:000284807400008 PM 20048395 ER PT J AU Purschke, M Laubach, HJ Anderson, RR Manstein, D AF Purschke, Martin Laubach, Hans-Joachim Anderson, R. Rox Manstein, Dieter TI Thermal Injury Causes DNA Damage and Lethality in Unheated Surrounding Cells: Active Thermal Bystander Effect SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID DOUBLE-STRAND BREAKS; PRIMARY HUMAN FIBROBLASTS; ALPHA-PARTICLES; CHO CELLS; MAMMALIAN-CELLS; LOW FLUENCES; TUMOR-CELLS; IN-VITRO; X-RAYS; RADIATION AB Direct heat exposure to cells causes protein degradation and DNA damage, which can lead to genetic alteration and cell death, but little is known about heat-induced effects on the surrounding tissue. After burns or laser surgery, loss of viability in the surrounding tissue has been explained by a temperature gradient due to heat diffusion. This study shows that, in the absence of any direct heating, heat diffusion, or cell-to-cell contact, "bystander'' cells that share the medium with heat-exposed cells exhibit DNA damage, apoptosis, and loss of viability. We coin this phenomenon "active thermal bystander effect'' (ATBE). Significant ATBE was induced by fibroblasts exposed for 10 minutes to a temperature range of 44-50 degrees C (all P<0.011). The ATBE was not induced by cells heated to lethality above 54 degrees C and immediate medium exchange did not suppress the effect. Therefore, the thermal bystander effect appears to be an active process in which viable, heat-injured cells induce a signal cascade and/or mediator that damages or kills surrounding bystander cells. The ATBE may have clinical relevance for acute burn trauma, hyperthermic treatments, and distant tissue damage after localized heat stress. C1 [Purschke, Martin; Laubach, Hans-Joachim; Anderson, R. Rox; Manstein, Dieter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02115 USA. RP Purschke, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, 55 Fruit St,BHX 631, Boston, MA 02115 USA. EM mpurschke@partners.org FU Wellman Center for Photomedicine FX We thank Prof Franz Hillenkamp for critical and productive scientific discussions and Dr David Zurakowski for statistical analysis. This study was supported by discretionary funds of the investigators, at the Wellman Center for Photomedicine. NR 43 TC 21 Z9 21 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2010 VL 130 IS 1 BP 86 EP 92 DI 10.1038/jid.2009.205 PG 7 WC Dermatology SC Dermatology GA 539HX UT WOS:000273245700013 PM 19587691 ER PT J AU Page, ST Lin, DW Mostaghel, E Marck, B Wright, J Amory, JK Matsumoto, AM AF Page, S. T. Lin, D. W. Mostaghel, E. Marck, B. Wright, J. Amory, J. K. Matsumoto, A. M. TI EXOGENOUS DIHYDROTESTOSTERONE DOES NOT INCREASE INTRAPROSTATIC DIHYDROTESTOSTERONE CONCENTRATIONS IN HEALTHY MEN: IMPLICATIONS FOR MALE HORMONAL THERAPIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Page, S. T.; Lin, D. W.; Mostaghel, E.; Wright, J.; Amory, J. K.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Marck, B.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 4 BP 103 EP 103 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400018 ER PT J AU Richter, LL Kogai, T Brent, G AF Richter, L. L. Kogai, T. Brent, G. TI THE REGULATION OF THE SODIUM IODIDE SYMPORTER IN BREAST CANCER BY RETINOIC ACID SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Richter, L. L.; Kogai, T.; Brent, G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kogai, T.; Brent, G.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 63 BP 119 EP 120 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400077 ER PT J AU Hirano, LA Page, ST Matsumoto, AM AF Hirano, L. A. Page, S. T. Matsumoto, A. M. TI DUTASTERIDE REDUCES PROSTATE SPECIFIC ANTIGEN (PSA) IN HYPOGONADAL MEN WITH BENIGN PROSTATIC HYPERPLASIA UNDERGOING TESTOSTERONE (T) REPLACEMENT THERAPY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Hirano, L. A.; Page, S. T.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Hirano, L. A.; Page, S. T.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 67 BP 121 EP 121 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400081 ER PT J AU Page, ST Lin, DW Mostaghel, E Marck, B Wright, J Amory, JK Matsumoto, AM AF Page, S. T. Lin, D. W. Mostaghel, E. Marck, B. Wright, J. Amory, J. K. Matsumoto, A. M. TI EXOGENOUS DIHYDROTESTOSTERONE DOES NOT INCREASE INTRAPROSTATIC DIHYDROTESTOSTERONE CONCENTRATIONS IN HEALTHY MEN: IMPLICATIONS FOR MALE HORMONAL THERAPIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Page, S. T.; Lin, D. W.; Mostaghel, E.; Wright, J.; Amory, J. K.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Marck, B.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 68 BP 121 EP 121 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400082 ER PT J AU Sand, JP Janeway, K Perry, J Orkin, S AF Sand, J. P. Janeway, K. Perry, J. Orkin, S. TI PROTEASE-ACTIVATED RECEPTOR 1 IS UPREGULATED AND PROMOTES INVASION IN A MURINE MODEL OF METASTATIC OSTEOSARCOMA SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Janeway, K.; Perry, J.; Orkin, S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sand, J. P.] Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 106 BP 132 EP 132 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400120 ER PT J AU Toukatly, MN Jurgens, C Kahn, SE Hull, RL AF Toukatly, M. N. Jurgens, C. Kahn, S. E. Hull, R. L. TI HUMAN TYPE 2 DIABETES IS ASSOCIATED WITH ISLET AMYLOID DEPOSITION, DECREASED beta-CELL AREA, AND INCREASED beta-CELL APOPTOSIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 109 BP 133 EP 133 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400123 ER PT J AU Bartholomew, E Hull, RL AF Bartholomew, E. Hull, R. L. TI ALTERED EXPRESSION OF ENZYMES INVOLVED IN NITRIC OXIDE PRODUCTION IN ISLETS FROM DIABETIC MICE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Bartholomew, E.; Hull, R. L.] Univ Washington, Sch Med, Seattle, WA USA. [Bartholomew, E.; Hull, R. L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 493 BP 244 EP 244 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400505 ER PT J AU Warren, HS Lin, T AF Warren, H. Shaw Lin, Tian TI Hemopexin: anti-inflammatory, pro-inflammatory, or both? Response to letter by Bakker et al. SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Letter DE inflammation; cytokines; innate immunity; macrophage ID PLASMA HEMOPEXIN C1 [Warren, H. Shaw; Lin, Tian] Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA. RP Warren, HS (reprint author), Massachusetts Gen Hosp, Infect Dis Unit, 149 13th St,5th Fl, Charlestown, MA 02129 USA. EM swarren1@partners.org NR 6 TC 1 Z9 1 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JAN PY 2010 VL 87 IS 1 BP 3 EP 3 DI 10.1189/jlb.0909612 PG 1 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 539DO UT WOS:000273233900002 ER PT J AU Hamilton, AM Rogers, KA Belisle, AJL Ronald, JA Rutt, BK Weissleder, R Boughner, DR AF Hamilton, Amanda M. Rogers, Kem A. Belisle, Andre J. L. Ronald, John A. Rutt, Brian K. Weissleder, Ralph Boughner, Derek R. TI Early Identification of Aortic Valve Sclerosis Using Iron Oxide Enhanced MRI SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE aortic valve sclerosis; macrophage infiltration; iron oxide; contrast-enhanced MRI ID ULTRASMALL SUPERPARAMAGNETIC PARTICLES; ATHEROSCLEROTIC PLAQUE; HYPERLIPIDEMIC RABBITS; POSITIVE CONTRAST; IMAGING PROBES; STENOSIS; PROGRESSION; NANOPARTICLES; ASSOCIATION; STATINS AB Purpose: To test the ability of MION-47 enhanced MRI to identify tissue macrophage infiltration in a rabbit model of aortic valve sclerosis (AVS). Materials and Methods: The aortic valves of control and cholesterol-fed New Zealand White rabbits were imaged in vivo pre- and 48 h post-intravenous administration of MION-47 using a 1.5 Tesla (T) MR clinical scanner and a CINE fSPGR sequence. MION-47 aortic valve cusps were imaged ex vivo on a 3.0T whole-body MR system with a custom gradient insert coil and a three-dimensional (3D) FIESTA sequence and compared with aortic valve cusps from control and cholesterol-fed contrast-free rabbits. Histopathological analysis was performed to determine the site of iron oxide uptake. Results: MION-47 enhanced the visibility of both control and cholesterol-fed rabbit valves in in vivo images. Ex vivo image analysis confirmed the presence of significant signal voids in contrast-administered aortic valves. Signal voids were not observed in contrast-free valve cusps. In MION-47 administered rabbits, histopathological analysis revealed iron staining not only in fibrosal macrophages of cholesterol-fed valves but also in myoflbroblasts from control and cholesterol-fed valves. Conclusion: Although iron oxide labeling of macrophage infiltration in AVS has the potential to detect the disease process early, a macrophage-specific iron compound rather than passive targeting may be required. C1 [Hamilton, Amanda M.; Rogers, Kem A.; Belisle, Andre J. L.; Boughner, Derek R.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada. [Hamilton, Amanda M.; Belisle, Andre J. L.; Ronald, John A.; Rutt, Brian K.; Boughner, Derek R.] Univ Western Ontario, Imaging Res Labs, Robarts Res Inst, London, ON N6A 5C1, Canada. [Rutt, Brian K.] Univ Western Ontario, Dept Radiol, London, ON N6A 5C1, Canada. [Weissleder, Ralph] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boughner, Derek R.] Univ Western Ontario, Dept Med, London, ON N6A 5C1, Canada. RP Rogers, KA (reprint author), Univ Western Ontario, Dept Anat & Cell Biol, Med Sci Bldg M426, London, ON N6A 5C1, Canada. EM kem.rogers@schulich.uwo.ca RI Ronald, John/B-7123-2008 OI Ronald, John/0000-0003-3665-173X FU Heart and Stroke Foundation of Ontario [T6332] FX Contract grant sponsor: Heart and Stroke Foundation of Ontario; Contract grant number: T6332. NR 27 TC 6 Z9 7 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JAN PY 2010 VL 31 IS 1 BP 110 EP 116 DI 10.1002/jmri.22008 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 540MO UT WOS:000273336100014 PM 20027578 ER PT J AU Ayaz, M Boikov, AS Haacke, EM Kido, DK Kirsch, WM AF Ayaz, Muhammad Boikov, Alexander S. Haacke, E. Mark Kido, Daniel K. Kirsch, Wolff M. TI Imaging Cerebral Microbleeds Using Susceptibility Weighted Imaging: One Step Toward Detecting Vascular Dementia SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE imaging; cerebral microbleeds; susceptibility weighted imaging; vascular dementia ID AMYLOID ANGIOPATHY; INTRACEREBRAL HEMORRHAGE; STROKE RECURRENCE; HEMOSIDERIN SPOTS; PHASE-BEHAVIOR; RISK-FACTORS; MR-IMAGES; BRAIN; PREVALENCE; ASSOCIATIONS AB Purpose: To monitor changes in the number of cerebral microbleeds (CMBs) in a longitudinal study of healthy controls (HQ and mild-cognitively impaired (MCI) patients using susceptibility weighted imaging (SWI). Materials and Methods: SWI was used to image 28 HC and 75 MCI patients annually at 1.5 Tesla over a 4-year period. Magnitude and phase data were used to visualize CMBs for the first and last scans of 103 subjects. Results: Preliminary analysis revealed that none of the 28 HC had more than three CMBs. In the 75 MCI patients, five subjects had more than three CMBs in both first and last scans, while one subject had more than three bleeds only in the last scan. In five of these six MCI patients, the number of CMBs increased over time and six went on to develop progressive cognitive impairment (PCI). Of the 130 total CMBs seen in the last scans of the six MCI cases. most were less than 4 mm in diameter. Conclusion: SWI can reveal small CMBs on the order of 1 mm in diameter and this technique can be used to follow their development longitudinally. Monitoring CMBs may be a means by which to evaluate patients for the presence of microvascular disease that leads to PCI. C1 [Ayaz, Muhammad; Boikov, Alexander S.; Haacke, E. Mark] MRI Inst Biomed Res, Detroit, MI USA. [Ayaz, Muhammad] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Boikov, Alexander S.] Wayne State Univ, Sch Med, Detroit, MI 48201 USA. [Haacke, E. Mark; Kido, Daniel K.] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92350 USA. [Kirsch, Wolff M.] Loma Linda Univ, Neurosurg Ctr Res Training & Educ, Loma Linda, CA 92350 USA. RP Haacke, EM (reprint author), Wayne State Univ, MR Res Facil, Dept Radiol, HUH MR Res Radiol G030, 3990 John R Rd, Detroit, MI 48201 USA. EM nmrimaging@aol.com FU National Institutes of Health [AG20948]; State of Michigan [085P5200251]; Siemens Medical Solutions FX Contract grant sponsor: National Institutes of Health; Contract grant number: AG20948: Contract grant sponsor: State of Michigan; Contract grant number: 085P5200251: Contract grant sponsor: Siemens Medical Solutions. NR 32 TC 61 Z9 72 U1 0 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JAN PY 2010 VL 31 IS 1 BP 142 EP 148 DI 10.1002/jmri.22001 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 540MO UT WOS:000273336100018 PM 20027582 ER PT J AU Chiang, LY Padmawar, PA Rogers-Haley, JE So, G Canteenwala, T Thota, S Tan, LS Pritzker, K Huang, YY Sharma, SK Kurup, DB Hamblin, MR Wilson, B Urbas, A AF Chiang, Long Y. Padmawar, Prashant A. Rogers-Haley, Joy E. So, Grace Canteenwala, Taizoon Thota, Sammaiah Tan, Loon-Seng Pritzker, Kenneth Huang, Ying-Ying Sharma, Sulbha K. Kurup, Divya Balachandran Hamblin, Michael R. Wilson, Brian Urbas, Augustine TI Synthesis and characterization of highly photoresponsive fullerenyl dyads with a close chromophore antenna-C-60 contact and effective photodynamic potential SO JOURNAL OF MATERIALS CHEMISTRY LA English DT Article ID ELECTRON-TRANSFER PROCESSES; C-60-DIPHENYLAMINOFLUORENE DYAD; 2-PHOTON EXCITATION; ENERGY-TRANSFER; CROSS-SECTIONS; TRIPLET C-60; THERAPY; PHOTOSENSITIZERS; ABSORPTION; DESIGN AB We report the synthesis of a new class of photoresponsive C-60-DCE-diphenylaminofluorene nanostructures and their intramolecular photoinduced energy and electron transfer phenomena. Structural modification was made by chemical conversion of the keto group in C-60(>DPAF-C-n) to a stronger electron-withdrawing 1,1-dicyanoethylenyl (DCE) unit leading to C-60(>CPAF-C-n) with an increased electronic polarization of the molecule. The modification also led to a large bathochromic shift of the major band in visible spectrum giving measureable absorption up to 600 nm and extended the photoresponsive capability of C-60-DCE-DPAF nanostructures to longer red wavelengths than C-60(>DPAF-C-n). Accordingly, C-60(>CPAF-C-n) may allow 2 gamma-PDT using a light wavelength of 1000-1200 nm for enhanced tissue penetration depth. Production efficiency of singlet oxygen by closely related C-60(>DPAF-C-2M) was found to be comparable with that of tetraphenylporphyrin photosensitizer. Remarkably, the O-1(2) quantum yield of C-60(>CPAF-C-2M) was found to be nearly 6-fold higher than that of C-60(>DPAF-C-2M), demonstrating the large light-harvesting enhancement of the CPAF-C-2M moiety and leading to more efficient triplet state generation of the C-60> cage moiety. This led to highly effective killing of HeLa cells by C-60(>CPAF-C-2M) via photodynamic therapy (200 J cm(-2) white light). We interpret the phenomena in terms of the contributions by the extended p-conjugation and stronger electron-withdrawing capability associated with the 1,1-dicyanoethylenyl group compared to that of the keto group. C1 [Chiang, Long Y.; Padmawar, Prashant A.; Canteenwala, Taizoon; Thota, Sammaiah] Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. [Rogers-Haley, Joy E.; Tan, Loon-Seng; Urbas, Augustine] USAF, Res Lab, AFRL RX, Wright Patterson AFB, OH 45433 USA. [So, Grace; Pritzker, Kenneth] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada. [So, Grace; Pritzker, Kenneth] Univ Toronto, Toronto, ON, Canada. [Huang, Ying-Ying; Sharma, Sulbha K.; Kurup, Divya Balachandran; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Ying-Ying; Sharma, Sulbha K.; Kurup, Divya Balachandran; Hamblin, Michael R.; Wilson, Brian] Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02114 USA. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China. [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Chiang, LY (reprint author), Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. EM Long_Chiang@uml.edu; Loon-Seng.Tan@wpafb.af.mil; kpritzker@yorkmp.com; hamblin@helix.mgh.harvard.edu; wilson@uhnres.utoronto.ca RI Huang, Ying-ying/G-3153-2011; Tan, Loon-Seng/F-6985-2012; OI Huang, Ying-ying/0000-0003-3066-6981; Tan, Loon-Seng/0000-0002-2134-9290; Hamblin, Michael/0000-0001-6431-4605 FU National Institute of Health [1R01CA137108]; Air Force Office of Scientific Research [FA9550-09-1-0183] FX We thank financial support of National Institute of Health under the contract number 1R01CA137108 and Air Force Office of Scientific Research under the contract number FA9550-09-1-0183. We thank Yi-Hung Liu of National Taiwan University Instrumentation Center for X-ray single-crystal structural analysis. NR 40 TC 26 Z9 26 U1 0 U2 5 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0959-9428 EI 1364-5501 J9 J MATER CHEM JI J. Mater. Chem. PY 2010 VL 20 IS 25 BP 5280 EP 5293 DI 10.1039/c0jm00037j PG 14 WC Chemistry, Physical; Materials Science, Multidisciplinary SC Chemistry; Materials Science GA 611YO UT WOS:000278861400018 PM 20890406 ER PT J AU Ganguly, K Carmena, JM AF Ganguly, Karunesh Carmena, Jose M. TI Neural Correlates of Skill Acquisition with a Cortical Brain-Machine Interface SO JOURNAL OF MOTOR BEHAVIOR LA English DT Article DE brain-machine interface; learning; electrophysiology; motor control; skill acquisition ID PRIMARY MOTOR CORTEX; COMPUTER INTERFACES; NEURONAL-ACTIVITY; MOVEMENT SIGNAL; CONSOLIDATION; MONKEYS; MEMORY; REPRESENTATIONS; PROSTHETICS; TETRAPLEGIA AB Research into the development of brain-machine interfaces (BMIs) has led to demonstrations of rodents, nonhuman primates, and humans controlling prosthetic devices in real time through modulation of neural signals. In particular, cortical BMI studies have shown that improvements in performance require learning and are associated with changes in neuronal tuning properties. These studies have further shown evidence of long-term improvements in performance with practice. The authors conducted experiments to understand long-term skill acquisition with BMIs and to characterize the neural correlates of improvements in task performance. They specifically assessed long-term acquisition of neuroprosthetic skill (i.e., accurate task performance readily recalled across days). In 2 monkeys performing a center-out task using a brain-controlled (BC) computer cursor, they closely monitored daily performance trends and the neural correlates under different conditions. Importantly, they assessed BC performance using a continuous-control multistep task. The authors first conducted experiments that mimicked experimental conditions commonly used. Specifically, a large set of neurons was incorporated with daily recalibration of the transform of neural activity to BC. Under such conditions, they found evidence of variable daily performance. In contrast, when a fixed transform was applied to stable recordings from an ensemble of neurons across days, there was consistent evidence of long-term skill acquisition. Such skill acquisition was associated with the crystallization of a cortical map for prosthetic control. Taken together, the results suggest that the primate motor cortex can achieve skilled control of a neuroprosthetic device through consolidation of a cortical representation. C1 [Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Helen Wills Neurosci Inst, Program Congat Sci, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. RP Carmena, JM (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Helen Wills Neurosci Inst, Program Congat Sci, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu NR 35 TC 22 Z9 22 U1 1 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-2895 J9 J MOTOR BEHAV JI J. Mot. Behav. PY 2010 VL 42 IS 6 SI SI BP 355 EP 360 AR PII 929867255 DI 10.1080/00222895.2010.526457 PG 6 WC Neurosciences; Psychology; Psychology, Experimental; Sport Sciences SC Neurosciences & Neurology; Psychology; Sport Sciences GA 683KW UT WOS:000284475700005 PM 21184353 ER PT J AU Perron, BE Fries, LE Kilbourne, AM Vaughn, MG Bauer, MS AF Perron, Brian E. Fries, Lauren E. Kilbourne, Amy M. Vaughn, Michael G. Bauer, Mark S. TI Racial/Ethnic Group Differences in Bipolar Symptomatology in a Community Sample of Persons With Bipolar I Disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Bipolar disorder; ethnic differences; ethnic disparities ID NATIONAL EPIDEMIOLOGIC SURVEY; ETHNIC-DIFFERENCES; GENERAL-POPULATION; ANXIETY DISORDERS; DIAGNOSIS; MOOD; PREVALENCE; DEPRESSION; ALCOHOL; RACE AB To better understand the problems associated with diagnosis of bipolar disorder, especially problems related to race and ethnicity, this study compared whites, African Americans, and Latinos with bipolar I disorder in the presentation of manic symptoms, depressive episodes, functional impairments (Short Form-12), and self-reports of schizophrenia diagnosis. Data for this study were derived from the 2001 National Epidemiologic Survey on Alcohol and Related Conditions, which are nationally representative of United States households. African Americans and Latinos expressed similar rates in presentation of 14 out of 16 manic symptoms compared with whites, with the exception of grandiosity/self-esteem, in which they were more likely to exhibit this symptom compared with whites. Higher rates of depressive episodes were observed among whites, and these episodes occurred significantly earlier compared with African Americans and Latinos. Latinos had slightly higher vitality scores on the SF-12 measures after adjusting for sociodemographic and clinical factors, but no other differences across the groups were observed. Overall, these data show that the expression and functional impairments of bipolar I disorder is very similar across racial ethnic groups using this community-based sample. This is the first community-based study making Such comparisons, with results suggesting that provider biases are more likely to explain problems in misdiagnosis than fundamental differences in the presentation of bipolar disorder across racial/ethnic groups. C1 [Perron, Brian E.; Fries, Lauren E.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48103 USA. [Perron, Brian E.; Kilbourne, Amy M.] VA Ann Arbor Healthcare Syst, Serious Mental Illness Treatment Res & Educ Ctr, Ann Arbor, MI USA. [Kilbourne, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48103 USA. [Vaughn, Michael G.] St Louis Univ, Sch Publ Hlth, Sch Social Work, Dept Policy Studies,Div Epidemiol, St Louis, MO 63103 USA. [Bauer, Mark S.] Harvard Univ, Sch Med, Harvard S Shore Psychiat Residency Training Progr, Boston, MA USA. [Bauer, Mark S.] VA Boston Healthcare Syst, Boston, MA USA. RP Perron, BE (reprint author), Univ Michigan, Sch Social Work, 1080 S Univ Ave, Ann Arbor, MI 48103 USA. EM beperron@umich.edu FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service and Office of Mental Health Services; Curtis Center of the University of Michigan School of Social Work FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service and Office of Mental Health Services, and by the Curtis Center of the University of Michigan School of Social Work. NR 32 TC 6 Z9 7 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2010 VL 198 IS 1 BP 16 EP 21 DI 10.1097/NMD.0b013e3181c818c5 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 544EZ UT WOS:000273637200003 PM 20061864 ER PT J AU Gaspar, LE Mehta, MP Patchell, RA Burri, SH Robinson, PD Morris, RE Ammirati, M Andrews, DW Asher, AL Cobbs, CS Kondziolka, D Linskey, ME Loeffler, JS McDermott, M Mikkelsen, T Olson, JJ Paleologos, NA Ryken, TC Kalkanis, SN AF Gaspar, Laurie E. Mehta, Minesh P. Patchell, Roy A. Burri, Stuart H. Robinson, Paula D. Morris, Rachel E. Ammirati, Mario Andrews, David W. Asher, Anthony L. Cobbs, Charles S. Kondziolka, Douglas Linskey, Mark E. Loeffler, Jay S. McDermott, Michael Mikkelsen, Tom Olson, Jeffrey J. Paleologos, Nina A. Ryken, Timothy C. Kalkanis, Steven N. TI The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Whole brain radiation therapy; Radiotherapy; Surgical resection; Fractionation; Histopathology; Systematic review; Practice guideline ID RANDOMIZED PHASE-III; CELL LUNG-CANCER; ONCOLOGY GROUP; ACCELERATED-FRACTIONATION; PROGNOSTIC-FACTORS; RADIOTHERAPY; IRRADIATION; TRIAL; SCHEDULES; SURGERY AB Target population This recommendation applies to adults with newly diagnosed single brain metastases amenable to surgical resection; however, the recommendation does not apply to relatively radiosensitive tumors histologies (i.e., small cell lung cancer, leukemia, lymphoma, germ cell tumors and multiple myeloma). Recommendation Surgical resection plus WBRT versus WBRT alone Level 1 Class I evidence supports the use of surgical resection plus post-operative WBRT, as compared to WBRT alone, in patients with good performance status (functionally independent and spending less than 50% of time in bed) and limited extra-cranial disease. There is insufficient evidence to make a recommendation for patients with poor performance scores, advanced systemic disease, or multiple brain metastases. If WBRT is used, is there an optimal dosing/fractionation schedule? Target population This recommendation applies to adults with newly diagnosed brain metastases. Recommendation Level 1 Class I evidence suggests that altered dose/fractionation schedules of WBRT do not result in significant differences in median survival, local control or neurocognitive outcomes when compared with "standard" WBRT dose/fractionation. (i.e., 30 Gy in 10 fractions or a biologically effective dose (BED) of 39 Gy10). If WBRT is used, what impact does tumor histopathology have on treatment outcomes? Target population This recommendation applies to adults with newly diagnosed brain metastases. Recommendation Given the extremely limited data available, there is insufficient evidence to support the choice of any particular dose/fractionation regimen based on histopathology. The following question is fully addressed in the surgery guideline paper within this series by Kalkanis et al. Given that the recommendation resulting from the systematic review of the literature on this topic is also highly relevant to the discussion of the role of WBRT in the management of brain metastases, this recommendation has been included below. Does the addition of WBRT after surgical resection improve outcomes when compared with surgical resection alone? Target population This recommendation applies to adults with newly diagnosed single brain metastases amenable to surgical resection. Recommendation Surgical resection plus WBRT versus surgical resection alone Level 1 Surgical resection followed by WBRT represents a superior treatment modality, in terms of improving tumor control at the original site of the metastasis and in the brain overall, when compared to surgical resection alone. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Robinson, Paula D.; Morris, Rachel E.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 38 TC 141 Z9 149 U1 0 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 17 EP 32 DI 10.1007/s11060-009-0060-9 PG 16 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400004 PM 19960231 ER PT J AU Kalkanis, SN Kondziolka, D Gaspar, LE Burri, SH Asher, AL Cobbs, CS Ammirati, M Robinson, PD Andrews, DW Loeffler, JS McDermott, M Mehta, MP Mikkelsen, T Olson, JJ Paleologos, NA Patchell, RA Ryken, TC Linskey, ME AF Kalkanis, Steven N. Kondziolka, Douglas Gaspar, Laurie E. Burri, Stuart H. Asher, Anthony L. Cobbs, Charles S. Ammirati, Mario Robinson, Paula D. Andrews, David W. Loeffler, Jay S. McDermott, Michael Mehta, Minesh P. Mikkelsen, Tom Olson, Jeffrey J. Paleologos, Nina A. Patchell, Roy A. Ryken, Timothy C. Linskey, Mark E. TI The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Surgical resection; Stereotactic radiosurgery; Radiotherapy; Systematic review; Practice guideline ID STEREOTACTIC RADIOSURGERY; RANDOMIZED-TRIAL; SINGLE METASTASES; RADIOTHERAPY; SURGERY; RADIATION; MICROSURGERY; NEUROSURGERY; IRRADIATION; MELANOMA AB Should patients with newly-diagnosed metastatic brain tumors undergo open surgical resection versus whole brain radiation therapy (WBRT) and/or other treatment modalities such as radiosurgery, and in what clinical settings? Target population These recommendations apply to adults with a newly diagnosed single brain metastasis amenable to surgical resection. Recommendations Surgical resection plus WBRT versus surgical resection alone Level 1 Surgical resection followed by WBRT represents a superior treatment modality, in terms of improving tumor control at the original site of the metastasis and in the brain overall, when compared to surgical resection alone. Surgical resection plus WBRT versus SRS +/- A WBRT Level 2 Surgical resection plus WBRT, versus stereotactic radiosurgery (SRS) plus WBRT, both represent effective treatment strategies, resulting in relatively equal survival rates. SRS has not been assessed from an evidence-based standpoint for larger lesions (> 3 cm) or for those causing significant mass effect (> 1 cm midline shift). Level 3 Underpowered class I evidence along with the preponderance of conflicting class II evidence suggests that SRS alone may provide equivalent functional and survival outcomes compared with resection + WBRT for patients with single brain metastases, so long as ready detection of distant site failure and salvage SRS are possible. Note The following question is fully addressed in the WBRT guideline paper within this series by Gaspar et al. Given that the recommendation resulting from the systematic review of the literature on this topic is also highly relevant to the discussion of the role of surgical resection in the management of brain metastases, this recommendation has been included below. Question Does surgical resection in addition to WBRT improve outcomes when compared with WBRT alone? Target population This recommendation applies to adults with a newly diagnosed single brain metastasis amenable to surgical resection; however, the recommendation does not apply to relatively radiosensitive tumors histologies (i.e., small cell lung cancer, leukemia, lymphoma, germ cell tumors and multiple myeloma). Recommendation Surgical resection plus WBRT versus WBRT alone Level 1 Class I evidence supports the use of surgical resection plus post-operative WBRT, as compared to WBRT alone, in patients with good performance status (functionally independent and spending less than 50% of time in bed) and limited extra-cranial disease. There is insufficient evidence to make a recommendation for patients with poor performance scores, advanced systemic disease, or multiple brain metastases. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 27 TC 132 Z9 139 U1 0 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 33 EP 43 DI 10.1007/s11060-009-0061-8 PG 11 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400005 PM 19960230 ER PT J AU Linskey, ME Andrews, DW Asher, AL Burri, SH Kondziolka, D Robinson, PD Ammirati, M Cobbs, CS Gaspar, LE Loeffler, JS McDermott, M Mehta, MP Mikkelsen, T Olson, JJ Paleologos, NA Patchell, RA Ryken, TC Kalkanis, SN AF Linskey, Mark E. Andrews, David W. Asher, Anthony L. Burri, Stuart H. Kondziolka, Douglas Robinson, Paula D. Ammirati, Mario Cobbs, Charles S. Gaspar, Laurie E. Loeffler, Jay S. McDermott, Michael Mehta, Minesh P. Mikkelsen, Tom Olson, Jeffrey J. Paleologos, Nina A. Patchell, Roy A. Ryken, Timothy C. Kalkanis, Steven N. TI The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Stereotactic radiosurgery; Surgical resection; Radiotherapy; Systematic review; Practice guideline ID RECURSIVE PARTITIONING ANALYSIS; GAMMA-KNIFE RADIOSURGERY; RADIATION-THERAPY; CEREBRAL METASTASES; RANDOMIZED-TRIAL; SINGLE METASTASES; TREATMENT OPTIONS; ANALYSIS CLASS-1; LUNG-CANCER; RADIOTHERAPY AB Should patients with newly-diagnosed metastatic brain tumors undergo stereotactic radiosurgery (SRS) compared with other treatment modalities? Target population These recommendations apply to adults with newly diagnosed solid brain metastases amenable to SRS; lesions amenable to SRS are typically defined as measuring less than 3 cm in maximum diameter and producing minimal (less than 1 cm of midline shift) mass effect. Recommendations SRS plus WBRT vs. WBRT alone Level 1 Single-dose SRS along with WBRT leads to significantly longer patient survival compared with WBRT alone for patients with single metastatic brain tumors who have a KPS a parts per thousand yen 70. Level 2 Single-dose SRS along with WBRT is superior in terms of local tumor control and maintaining functional status when compared to WBRT alone for patients with 1-4 metastatic brain tumors who have a KPS a parts per thousand yen 70. Level 3 Single-dose SRS along with WBRT may lead to significantly longer patient survival than WBRT alone for patients with 2-3 metastatic brain tumors. Level 4 There is class III evidence demonstrating that single-dose SRS along with WBRT is superior to WBRT alone for improving patient survival for patients with single or multiple brain metastases and a KPS < 70. SRS plus WBRT vs. SRS alone Level 2 Single-dose SRS alone may provide an equivalent survival advantage for patients with brain metastases compared with WBRT + single-dose SRS. There is conflicting class I and II evidence regarding the risk of both local and distant recurrence when SRS is used in isolation, and class I evidence demonstrates a lower risk of distant recurrence with WBRT; thus, regular careful surveillance is warranted for patients treated with SRS alone in order to provide early identification of local and distant recurrences so that salvage therapy can be initiated at the soonest possible time. Surgical Resection plus WBRT vs. SRS +/- WBRT Level 2 Surgical resection plus WBRT, vs. SRS plus WBRT, both represent effective treatment strategies, resulting in relatively equal survival rates. SRS has not been assessed from an evidence-based standpoint for larger lesions (> 3 cm) or for those causing significant mass effect (> 1 cm midline shift). Level 3: Underpowered class I evidence along with the preponderance of conflicting class II evidence suggests that SRS alone may provide equivalent functional and survival outcomes compared with resection + WBRT for patients with single brain metastases, so long as ready detection of distant site failure and salvage SRS are possible. SRS alone vs. WBRT alone Level 3 While both single-dose SRS and WBRT are effective for treating patients with brain metastases, single-dose SRS alone appears to be superior to WBRT alone for patients with up to three metastatic brain tumors in terms of patient survival advantage. C1 [Mikkelsen, Tom; Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 64 TC 202 Z9 212 U1 1 U2 27 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 45 EP 68 DI 10.1007/s11060-009-0073-4 PG 24 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400006 PM 19960227 ER PT J AU Mehta, MP Paleologos, NA Mikkelsen, T Robinson, PD Ammirati, M Andrews, DW Asher, AL Burri, SH Cobbs, CS Gaspar, LE Kondziolka, D Linskey, ME Loeffler, JS McDermott, M Olson, JJ Patchell, RA Ryken, TC Kalkanis, SN AF Mehta, Minesh P. Paleologos, Nina A. Mikkelsen, Tom Robinson, Paula D. Ammirati, Mario Andrews, David W. Asher, Anthony L. Burri, Stuart H. Cobbs, Charles S. Gaspar, Laurie E. Kondziolka, Douglas Linskey, Mark E. Loeffler, Jay S. McDermott, Michael Olson, Jeffrey J. Patchell, Roy A. Ryken, Timothy C. Kalkanis, Steven N. TI The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Brain metastases; Chemotherapy; Whole brain radiation therapy; Targeted agents; Systematic review; Practice guideline ID CELL LUNG-CANCER; II RANDOMIZED-TRIAL; PHASE-III; RADIOTHERAPY; RADIATION; TEMOZOLOMIDE; CARCINOMA AB This recommendation applies to adults with newly diagnosed brain metastases; however, the recommendation below does not apply to the exquisitely chemosensitive tumors, such as germinomas metastatic to the brain. Should patients with brain metastases receive chemotherapy in addition to whole brain radiotherapy (WBRT)? Level 1 Routine use of chemotherapy following WBRT for brain metastases has not been shown to increase survival and is not recommended. Four class I studies examined the role of carboplatin, chloroethylnitrosoureas, tegafur and temozolomide, and all resulted in no survival benefit. Two caveats are provided in order to allow the treating physician to individualize decision-making: First, the majority of the data are limited to non small cell lung (NSCLC) and breast cancer; therefore, in other tumor histologies, the possibility of clinical benefit cannot be absolutely ruled out. Second, the addition of chemotherapy to WBRT improved response rates in some, but not all trials; response rate was not the primary endpoint in most of these trials and end-point assessment was non-centralized, non-blinded, and post-hoc. Enrollment in chemotherapy-related clinical trials is encouraged. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM skalkan1@hfhs.org OI mehta, minesh/0000-0002-4812-5713 NR 17 TC 75 Z9 79 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 71 EP 83 DI 10.1007/s11060-009-0062-7 PG 13 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400008 PM 19960229 ER PT J AU Ammirati, M Cobbs, CS Linskey, ME Paleologos, NA Ryken, TC Burri, SH Asher, AL Loeffler, JS Robinson, PD Andrews, DW Gaspar, LE Kondziolka, D McDermott, M Mehta, MP Mikkelsen, T Olson, JJ Patchell, RA Kalkanis, SN AF Ammirati, Mario Cobbs, Charles S. Linskey, Mark E. Paleologos, Nina A. Ryken, Timothy C. Burri, Stuart H. Asher, Anthony L. Loeffler, Jay S. Robinson, Paula D. Andrews, David W. Gaspar, Laurie E. Kondziolka, Douglas McDermott, Michael Mehta, Minesh P. Mikkelsen, Tom Olson, Jeffrey J. Patchell, Roy A. Kalkanis, Steven N. TI The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Recurrent/progressive brain metastases; Surgical resection; Whole brain radiotherapy; Stereotactic radiosurgery; Chemotherapy; Histopathology; Retreatment; Systematic review; Practice guideline ID CELL LUNG-CANCER; GAMMA-KNIFE RADIOSURGERY; PHASE-II TRIAL; STEREOTACTIC RADIOSURGERY; CEREBRAL METASTASES; MALIGNANT-MELANOMA; BREAST-CANCER; RECURRENT; TEMOZOLOMIDE; TUMORS AB What evidence is available regarding the use of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), surgical resection or chemotherapy for the treatment of recurrent/progressive brain metastases? Target population This recommendation applies to adults with recurrent/progressive brain metastases who have previously been treated with WBRT, surgical resection and/or radiosurgery. Recurrent/progressive brain metastases are defined as metastases that recur/progress anywhere in the brain (original and/or non-original sites) after initial therapy. Recommendation Level 3 Since there is insufficient evidence to make definitive treatment recommendations in patients with recurrent/progressive brain metastases, treatment should be individualized based on a patient's functional status, extent of disease, volume/number of metastases, recurrence or progression at original versus non-original site, previous treatment and type of primary cancer, and enrollment in clinical trials is encouraged. In this context, the following can be recommended depending on a patient's specific condition: no further treatment (supportive care), re-irradiation (either WBRT and/or SRS), surgical excision or, to a lesser extent, chemotherapy. Question If WBRT is used in the setting of recurrent/progressive brain metastases, what impact does tumor histopathology have on treatment outcomes? No studies were identified that met the eligibility criteria for this question. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 34 TC 62 Z9 64 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 85 EP 96 DI 10.1007/s11060-009-0055-6 PG 12 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400009 PM 19957016 ER PT J AU Mikkelsen, T Paleologos, NA Robinson, PD Ammirati, M Andrews, DW Asher, AL Burri, SH Cobbs, CS Gaspar, LE Kondziolka, D Linskey, ME Loeffler, JS McDermott, M Mehta, MP Olson, JJ Patchell, RA Ryken, TC Kalkanis, SN AF Mikkelsen, Tom Paleologos, Nina A. Robinson, Paula D. Ammirati, Mario Andrews, David W. Asher, Anthony L. Burri, Stuart H. Cobbs, Charles S. Gaspar, Laurie E. Kondziolka, Douglas Linskey, Mark E. Loeffler, Jay S. McDermott, Michael Mehta, Minesh P. Olson, Jeffrey J. Patchell, Roy A. Ryken, Timothy C. Kalkanis, Steven N. TI The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Anticonvulsant; Prophylaxis; Seizures; Systematic review; Practice guideline ID QUALITY AB Do prophylactic anticonvulsants decrease the risk of seizure in patients with metastatic brain tumors compared with no treatment? Target population These recommendations apply to adults with solid brain metastases who have not experienced a seizure due to their metastatic brain disease. Recommendation Level 3 For adults with brain metastases who have not experienced a seizure due to their metastatic brain disease, routine prophylactic use of anticonvulsants is not recommended. Only a single underpowered randomized controlled trial (RCT), which did not detect a difference in seizure occurrence, provides evidence for decision-making purposes. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON L8S 4L8, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Hermelin Brain Tumor Ctr, Dept Neurosurg, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 7 TC 33 Z9 36 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 97 EP 102 DI 10.1007/s11060-009-0056-5 PG 6 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400010 PM 19957015 ER PT J AU Ryken, TC McDermott, M Robinson, PD Ammirati, M Andrews, DW Asher, AL Burri, SH Cobbs, CS Gaspar, LE Kondziolka, D Linskey, ME Loeffler, JS Mehta, MP Mikkelsen, T Olson, JJ Paleologos, NA Patchell, RA Kalkanis, SN AF Ryken, Timothy C. McDermott, Michael Robinson, Paula D. Ammirati, Mario Andrews, David W. Asher, Anthony L. Burri, Stuart H. Cobbs, Charles S. Gaspar, Laurie E. Kondziolka, Douglas Linskey, Mark E. Loeffler, Jay S. Mehta, Minesh P. Mikkelsen, Tom Olson, Jeffrey J. Paleologos, Nina A. Patchell, Roy A. Kalkanis, Steven N. TI The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Steroids; Neurologic symptoms; Steroid dosage; Systematic review; Practice guideline ID DEXAMETHASONE TREATMENT; CEREBRAL METASTASES; RADIATION-THERAPY; TUMORS; TRIAL; EDEMA AB Do steroids improve neurologic symptoms in patients with metastatic brain tumors compared to no treatment? If steroids are given, what dose should be used? Comparisons include: (1) steroid therapy versus none. (2) comparison of different doses of steroid therapy. Target population These recommendations apply to adults diagnosed with brain metastases. Recommendations Steroid therapy versus no steroid therapy Asymptomatic brain metastases patients without mass effect Insufficient evidence exists to make a treatment recommendation for this clinical scenario. Brain metastases patients with mild symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. It is recommended for patients who are symptomatic from metastatic disease to the brain that a starting dose of 4-8 mg/day of dexamethasone be considered. Brain metastases patients with moderate to severe symptoms related to mass effect Level 3 Corticosteroids are recommended to provide temporary symptomatic relief of symptoms related to increased intracranial pressure and edema secondary to brain metastases. If patients exhibit severe symptoms consistent with increased intracranial pressure, it is recommended that higher doses such as 16 mg/day or more be considered. Choice of Steroid Level 3 If corticosteroids are given, dexamethasone is the best drug choice given the available evidence. Duration of Corticosteroid Administration Level 3 Corticosteroids, if given, should be tapered slowly over a 2 week time period, or longer in symptomatic patients, based upon an individualized treatment regimen and a full understanding of the long-term sequelae of corticosteroid therapy. Given the very limited number of studies (two) which met the eligibility criteria for the systematic review, these are the only recommendations that can be offered based on this methodology. Please see "Discussion" and "Summary" section for additional details. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Robinson, Paula D.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 17 TC 76 Z9 81 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 103 EP 114 DI 10.1007/s11060-009-0057-4 PG 12 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400011 PM 19957014 ER PT J AU Olson, JJ Paleologos, NA Gaspar, LE Robinson, PD Morris, RE Ammirati, M Andrews, DW Asher, AL Burri, SH Cobbs, CS Kondziolka, D Linskey, ME Loeffler, JS McDermott, M Mehta, MP Mikkelsen, T Patchell, RA Ryken, TC Kalkanis, SN AF Olson, Jeffrey J. Paleologos, Nina A. Gaspar, Laurie E. Robinson, Paula D. Morris, Rachel E. Ammirati, Mario Andrews, David W. Asher, Anthony L. Burri, Stuart H. Cobbs, Charles S. Kondziolka, Douglas Linskey, Mark E. Loeffler, Jay S. McDermott, Michael Mehta, Minesh P. Mikkelsen, Tom Patchell, Roy A. Ryken, Timothy C. Kalkanis, Steven N. TI The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics SO JOURNAL OF NEURO-ONCOLOGY LA English DT Review DE Brain metastases; Radiation sensitizers; Interstitial modalities; New chemotherapeutic agents; Molecular targeted agents; Anti-angiogenesis agents; Systematic review; Practice guideline ID CELL LUNG-CANCER; PHASE-II TRIAL; COOPERATIVE ONCOLOGY GROUP; ENDOTHELIAL GROWTH-FACTOR; QUALITY-OF-LIFE; CEREBRAL METASTASES; MALIGNANT-MELANOMA; RADIATION-THERAPY; MOTEXAFIN GADOLINIUM; RANDOMIZED-TRIAL AB What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors? Target population These recommendations apply to adults with brain metastases. Recommendations New radiation sensitizers Level 2 A subgroup analysis of a large prospective randomized controlled trial (RCT) suggested a prolongation of time to neurological progression with the early use of motexafin-gadolinium (MGd). Nonetheless this was not borne out in the overall study population and therefore an unequivocal recommendation to use the currently available radiation sensitizers, motexafin-gadolinium and efaproxiral (RSR 13) cannot be provided. Interstitial modalities There is no evidence to support the routine use of new or existing interstitial radiation, interstitial chemotherapy and or other interstitial modalities outside of approved clinical trials. New chemotherapeutic agents Level 2 Treatment of melanoma brain metastases with whole brain radiation therapy and temozolomide is reasonable based on one class II study. Level 3 Depending on individual circumstances there may be patients who benefit from the use of temozolomide or fotemustine in the therapy of their brain metastases. Molecular targeted agents Level 3 The use of epidermal growth factor receptor inhibitors may be of use in the management of brain metastases from non-small cell lung carcinoma. C1 [Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, Detroit, MI 48202 USA. [Olson, Jeffrey J.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA. [Paleologos, Nina A.] Northshore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Gaspar, Laurie E.] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA. [Robinson, Paula D.; Morris, Rachel E.] McMaster Univ, Evidence Based Practice Ctr, Hamilton, ON, Canada. [Ammirati, Mario] Ohio State Univ, Med Ctr, Dept Neurosurg, Columbus, OH 43210 USA. [Andrews, David W.] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA. [Asher, Anthony L.] Carolina Neurosurg & Spine Associates, Dept Neurosurg, Charlotte, NC USA. [Burri, Stuart H.] Carolinas Med Ctr, Dept Radiat Oncol, Charlotte, NC 28203 USA. [Cobbs, Charles S.] Calif Pacific Med Ctr, Dept Neurosci, San Francisco, CA USA. [Kondziolka, Douglas] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA. [Linskey, Mark E.] Univ Calif Irvine, Med Ctr, Dept Neurosurg, Orange, CA USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [McDermott, Michael] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA. [Mehta, Minesh P.] Univ Wisconsin, Dept Human Oncol, Sch Publ Hlth & Med, Madison, WI USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA. [Patchell, Roy A.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ryken, Timothy C.] Iowa Spine & Brain Inst, Dept Neurosurg, Iowa City, IA USA. RP Kalkanis, SN (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, Hermelin Brain Tumor Ctr, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA. EM kalkanis@neuro.hfh.edu OI mehta, minesh/0000-0002-4812-5713 NR 78 TC 26 Z9 28 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 1 SI SI BP 115 EP 142 DI 10.1007/s11060-009-0058-3 PG 28 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DJ UT WOS:000273788400012 PM 19957013 ER PT J AU Norden, AD Raizer, JJ Abrey, LE Lamborn, KR Lassman, AB Chang, SM Yung, WKA Gilbert, MR Fine, HA Mehta, M DeAngelis, LM Cloughesy, TF Robins, HI Aldape, K Dancey, J Prados, MD Lieberman, F Wen, PY AF Norden, Andrew D. Raizer, Jeffrey J. Abrey, Lauren E. Lamborn, Kathleen R. Lassman, Andrew B. Chang, Susan M. Yung, W. K. Alfred Gilbert, Mark R. Fine, Howard A. Mehta, Minesh DeAngelis, Lisa M. Cloughesy, Timothy F. Robins, H. Ian Aldape, Kenneth Dancey, Janet Prados, Michael D. Lieberman, Frank Wen, Patrick Y. TI Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Meningioma; Erlotinib; Gefitinib; Epidermal growth factor receptor inhibitor ID EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; CHEMOTHERAPY; EXPRESSION; GLIOMAS; MULTICENTER AB There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted. The epidermal growth factor receptor (EGFR) is often over-expressed in meningiomas and may promote tumor growth. In open label, single arm phase II studies of the EGFR inhibitors gefitinib (NABTC 00-01) and erlotinib (NABTC 01-03) for recurrent malignant gliomas, we included exploratory subsets of recurrent meningioma patients. We have pooled the data and report the results here. Patients with recurrent histologically confirmed meningiomas with no more than 2 previous chemotherapy regimens were treated with gefitinib 500 mg/day or erlotinib 150 mg/day until tumor progression or unacceptable toxicity. Twenty-five eligible patients were enrolled with median age 57 years (range 29-81) and median Karnofsky performance status (KPS) score 90 (range 60-100). Sixteen patients (64%) received gefitinib and 9 (36%) erlotinib. Eight patients (32%) had benign tumors, 9 (36%) atypical, and 8 (32%) malignant. For benign tumors, the 6-month progression-free survival (PFS6) was 25%, 12-month PFS (PFS12) 13%, 6-month overall survival (OS6) 63%, and 12-month OS (OS12) 50%. For atypical and malignant tumors, PFS6 was 29%, PFS12 18%, OS6 71%, and OS12 65%. The PFS and OS were not significantly different by histology. There were no objective imaging responses, but 8 patients (32%) maintained stable disease. Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted. C1 [Norden, Andrew D.; Wen, Patrick Y.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [Raizer, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Abrey, Lauren E.; Lassman, Andrew B.; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Lamborn, Kathleen R.; Chang, Susan M.; Prados, Michael D.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Yung, W. K. Alfred; Gilbert, Mark R.; Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. [Fine, Howard A.] Natl Canc Inst, Neurooncol Branch, NIH, Bethesda, MD 20892 USA. [Mehta, Minesh; Robins, H. Ian] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Cloughesy, Timothy F.] Univ Calif Los Angeles, Neurooncol Program, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Dancey, Janet] Natl Canc Inst, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA. [Lieberman, Frank] Univ Pittsburgh, Neurooncol Program, Inst Canc, Pittsburgh, PA 15232 USA. RP Wen, PY (reprint author), Dana Farber Canc Inst, Ctr Neurooncol, 44 Binney St,SW430B, Boston, MA 02115 USA. EM pwen@partners.org RI Gilbert, Mark/J-7494-2016; OI Gilbert, Mark/0000-0003-2556-9722; mehta, minesh/0000-0002-4812-5713 FU NABTC [CA62399, CA62422]; GCRC [M01-RR00079, CA62412, CA16672, U01CA62407-08, U01CA62421-08, M01 RR03186, U01CA62405, M01-RR00056, U01 CA62399, M01-RR0865]; [5-U01CA62399-09] FX Grant Support: 5-U01CA62399-09 (J. J. Raizer, L. E. Abrey, A. B. Lassman and L. M. DeAngelis), NABTC # CA62399 and Member # CA62422, GCRC Grant # M01-RR00079 (S. M. Chang, K. R. Lamborn and M. D. Prados); CA62412, GCRC Grant # CA16672 (W. K. A. Yung and M. R. Gilbert); U01CA62407-08 (P. Y. Wen), U01CA62421-08, GCRC Grant # M01 RR03186 (M. Mehta and I. H. Robins); U01CA62405, GCRC Grant # M01-RR00056 (F. Lieberman); U01 CA62399, GCRC Grant # M01-RR0865 (T. F. Cloughesy). NR 28 TC 63 Z9 64 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2010 VL 96 IS 2 BP 211 EP 217 DI 10.1007/s11060-009-9948-7 PG 7 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 546DK UT WOS:000273788600008 PM 19562255 ER PT J AU Van Dijk, KRA Hedden, T Venkataraman, A Evans, KC Lazar, SW Buckner, RL AF Van Dijk, Koene R. A. Hedden, Trey Venkataraman, Archana Evans, Karleyton C. Lazar, Sara W. Buckner, Randy L. TI Intrinsic Functional Connectivity As a Tool For Human Connectomics: Theory, Properties, and Optimization SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Review ID DEFAULT-MODE NETWORK; RESTING-STATE FMRI; INDEPENDENT COMPONENT ANALYSIS; TRANSCRANIAL MAGNETIC STIMULATION; LOW-FREQUENCY FLUCTUATIONS; ANTERIOR CINGULATE CORTEX; BOLD SIGNAL FLUCTUATIONS; HUMAN CEREBRAL-CORTEX; HUMAN BRAIN NETWORKS; EVENT-RELATED FMRI AB Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization. J Neurophysiol 103: 297-321, 2010. First published November 4, 2009; doi: 10.1152/jn.00783.2009. Resting state functional connectivity MRI (fcMRI) is widely used to investigate brain networks that exhibit correlated fluctuations. While fcMRI does not provide direct measurement of anatomic connectivity, accumulating evidence suggests it is sufficiently constrained by anatomy to allow the architecture of distinct brain systems to be characterized. fcMRI is particularly useful for characterizing large-scale systems that span distributed areas (e. g., polysynaptic cortical pathways, cerebro-cerebellar circuits, cortical-thalamic circuits) and has complementary strengths when contrasted with the other major tool available for human connectomics-high angular resolution diffusion imaging (HARDI). We review what is known about fcMRI and then explore fcMRI data reliability, effects of preprocessing, analysis procedures, and effects of different acquisition parameters across six studies (n = 98) to provide recommendations for optimization. Run length (2-12 min), run structure (1 12-min run or 2 6-min runs), temporal resolution (2.5 or 5.0 s), spatial resolution (2 or 3 mm), and the task (fixation, eyes closed rest, eyes open rest, continuous word-classification) were varied. Results revealed moderate to high test-retest reliability. Run structure, temporal resolution, and spatial resolution minimally influenced fcMRI results while fixation and eyes open rest yielded stronger correlations as contrasted to other task conditions. Commonly used preprocessing steps involving regression of nuisance signals minimized nonspecific (noise) correlations including those associated with respiration. The most surprising finding was that estimates of correlation strengths stabilized with acquisition times as brief as 5 min. The brevity and robustness of fcMRI positions it as a powerful tool for large-scale explorations of genetic influences on brain architecture. We conclude by discussing the strengths and limitations of fcMRI and how it can be combined with HARDI techniques to support the emerging field of human connectomics. C1 [Van Dijk, Koene R. A.; Hedden, Trey; Buckner, Randy L.] Harvard Univ, Ctr Brain Sci, Dept Psychol, Cambridge, MA 02138 USA. [Van Dijk, Koene R. A.; Hedden, Trey; Buckner, Randy L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. [Evans, Karleyton C.; Lazar, Sara W.; Buckner, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Van Dijk, Koene R. A.] Maastricht Univ, Fac Psychol, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands. [Venkataraman, Archana] MIT, CSAIL, Cambridge, MA 02139 USA. [Buckner, Randy L.] Howard Hughes Med Inst, Cambridge, MA USA. RP Buckner, RL (reprint author), Harvard Univ, Ctr Brain Sci, Dept Psychol, NW Bldg,Rm 280-05,52 Oxford St, Cambridge, MA 02138 USA. EM randy_buckner@harvard.edu RI Van Dijk, Koene/G-3317-2012; Lazar, Sara/G-3809-2012 OI Van Dijk, Koene/0000-0001-6137-4282; Lazar, Sara/0000-0003-1126-8363 FU Howard Hughes Medical Institute; Netherlands Organization for Scientific Research FX Support for scanning was supplied by the Athinoula A. Martinos Center for Biomedical Imaging. This research was supported by the Howard Hughes Medical Institute. The Netherlands Organization for Scientific Research supported K. R. A. Van Dijk. NR 185 TC 641 Z9 644 U1 14 U2 125 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2010 VL 103 IS 1 BP 297 EP 321 DI 10.1152/jn.00783.2009 PG 25 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 542VD UT WOS:000273526000029 PM 19889849 ER PT J AU Valencia, A Reeves, PB Sapp, E Li, XY Alexander, J Kegel, KB Chase, K Aronin, N DiFiglia, M AF Valencia, Antonio Reeves, Patrick B. Sapp, Ellen Li, Xueyi Alexander, Jonathan Kegel, Kimberly B. Chase, Kathryn Aronin, Neil DiFiglia, Marian TI Mutant Huntingtin and Glycogen Synthase Kinase 3-beta Accumulate in Neuronal Lipid Rafts of a Presymptomatic Knock-In Mouse Model of Huntington's Disease SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE Huntington; lipid rafts; GSK3-beta; detergent-resistant membranes; neurodegeneration ID GPI-ANCHORED PROTEINS; ETHYL-EICOSAPENTAENOIC ACID; GROWTH-FACTOR RECEPTORS; PLASMA-MEMBRANE; STRIATAL CELLS; CANNABINOID RECEPTORS; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; CONTROLLED-TRIAL; NADPH OXIDASE AB Patients with Huntington's disease have an expanded polyglutamine tract in huntingtin and suffer severe brain atrophy and neurodegeneration. Because membrane dysfunction can occur in Huntington's disease, we addressed whether mutant huntingtin in brain and primary neurons is present in lipid rafts, which are cholesterol-enriched membrane domains that mediate growth and survival signals. Biochemical analysis of detergent-resistant membranes from brains and primary neurons of wild-type and presymptomatic Huntington's disease knock-in mice showed that wild-type and mutant huntingtin were recovered in lipid raft-enriched detergent-resistant membranes. The association with lipid rafts was stronger for mutant huntingtin than wild-type huntingtin. Lipid rafts extracted from Huntington's disease mice had normal levels of lipid raft markers (G(alpha q), Ras, and flotillin) but significantly more glycogen synthase kinase 3-beta. Increases in glycogen synthase kinase 3-beta have been associated with apoptotic cell death. Treating Huntington's disease primary neurons with inhibitors of glycogen synthase kinase 3-beta reduced neuronal death. We speculate that accumulation of mutant huntingtin and glycogen synthase kinase 3-beta in lipid rafts of presymptomatic Huntington's disease mouse neurons contributes to neurodegeneration in Huntington's disease. (C) 2009 Wiley-Liss, Inc. C1 [Valencia, Antonio; Reeves, Patrick B.; Sapp, Ellen; Li, Xueyi; Alexander, Jonathan; Kegel, Kimberly B.; DiFiglia, Marian] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Valencia, Antonio; Reeves, Patrick B.; Sapp, Ellen; Li, Xueyi; Alexander, Jonathan; Kegel, Kimberly B.; DiFiglia, Marian] Harvard Univ, Sch Med, Charlestown, MA USA. [Chase, Kathryn; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med & Cell Biol, Worcester, MA USA. RP DiFiglia, M (reprint author), Massachusetts Gen Hosp East, Dept Neurol, 114 16th St,Room 2125-H, Charlestown, MA 02129 USA. EM difiglia@helix.mgh.harvard.edu FU Hereditary Disease Foundation [2008A051302]; NIH [NS35711, NS038194]; HighQ Foundation/CHDI; Huntington's Disease Society of America; Fundacion Mexico en Harvard FX Contract grant sponsor: Hereditary Disease Foundation; Contract grant number 2008A051302 (to A.V.); Contract grant sponsor NIH; Contract grant number: NS35711 (to M.D.); Contract grant number: NS038194 (to N.A.); Contract grant sponsor: HighQ Foundation/CHDI (to M.D.); Contract grant sponsor: Huntington's Disease Society of America (to M.D.); Contract grant sponsor Fundacion Mexico en Harvard A.C. (to A.V.). NR 71 TC 39 Z9 39 U1 0 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JAN PY 2010 VL 88 IS 1 BP 179 EP 190 DI 10.1002/jnr.22184 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 526UQ UT WOS:000272320500018 PM 19642201 ER PT J AU Bethune, W Nozari, A AF Bethune, Walter Nozari, Ala TI Cerebral Aneurysm Surgery in a Patient With Brugada Syndrome: Anesthetic Implications and Perioperative Management SO JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY LA English DT Letter ID ST SEGMENT ELEVATION C1 [Bethune, Walter; Nozari, Ala] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. RP Bethune, W (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. NR 5 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0898-4921 J9 J NEUROSURG ANESTH JI J. Neurosurg. Anesthesiol. PD JAN PY 2010 VL 22 IS 1 BP 82 EP 83 PG 2 WC Anesthesiology; Clinical Neurology; Surgery SC Anesthesiology; Neurosciences & Neurology; Surgery GA 540FH UT WOS:000273316200016 PM 20027013 ER PT J AU Seo, Y Aparici, CM Cooperberg, MR Konety, BR Hawkins, RA AF Seo, Youngho Aparici, Carina Mari Cooperberg, Matthew R. Konety, Badrinath R. Hawkins, Randall A. TI In Vivo Tumor Grading of Prostate Cancer Using Quantitative In-111-Capromab Pendetide SPECT/CT SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE prostate cancer; capromab pendetide; SPECT; SPECT/CT; quantification; tracer quantification; quantitative SPECT; prostate-specific membrane antigen (PSMA) ID MEMBRANE ANTIGEN; ATTENUATION CORRECTION; RADICAL PROSTATECTOMY; FOLLOW-UP; PET; VALIDATION; SIMULATION AB We have developed an in vivo method to quantify antibody uptake using In-111-capromab pendetide SPECT combined with CT (SPECT/CT). Our goal was to evaluate this method for potential grading of prostate tumors. Methods: Our phantom experiments focused on the robustness of an advanced iterative reconstruction algorithm that involves corrections for photon attenuation, scatter, and geometric blurring caused by radionuclide collimators. The conversion factors between image values and tracer concentrations (in Bq/mL) were calculated from a uniform phantom filled with an aqueous solution of (InCl3)-In-111 using the same acquisition protocol and reconstruction parameters as for patient studies. In addition, the spatial resolution of the reconstructed images was measured from a point source phantom. The measured spatial resolution was modeled into a point-spread function, and the point-spread function was implemented in a deconvolution-based partial-volume-error correction algorithm. The recovery capability to correctly estimate true tracer concentrations was tested using prostatelike and bladderlike lesion phantoms fitted in the modified National Electrical Manufacturers Association/International Electrotechnical Commission body phantom. Patients with biopsy-proven prostate cancer (n = 10) who underwent prostatectomy were prospectively enrolled in the preoperative SPECT/CT studies at the San Francisco Veterans Affairs Medical Center. The CT portion of SPECT/CT was used to generate CT-based attenuation maps and as an anatomic localization tool for clinical interpretation. Pathologic Gleason grades were compared with in vivo antibody uptake value (AUV) normalized by injected dose, effective half-life, and injection-scan time difference. AUVs were calculated in each lobe of the prostate gland with cylindric volumes of interest having dimensions of 1.5 cm in both diameter and height. Results: Reconstructed SPECT images further corrected by the deconvolution-based partial-volume-error correction could recover tracer concentrations up to 90% of true values in measurements of phantom volumes as small as 7.77 mL. From patient studies, there was a statistically significant correlation (rho = 0.71, P = 0.033) between higher AUVs (from either left or right lobe) and higher components of pathologic Gleason scores. Conclusion: Our results strongly indicate potential for noninvasive prostate tumor grading using quantitative In-111-capromab pendetide SPECT/CT. C1 [Seo, Youngho; Aparici, Carina Mari; Hawkins, Randall A.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Seo, Youngho; Hawkins, Randall A.] Univ Calif San Francisco, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA. [Seo, Youngho; Hawkins, Randall A.] Univ Calif Berkeley, Joint Grad Grp Bioengn, Berkeley, CA 94720 USA. [Seo, Youngho] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Radiat Oncol, San Francisco, CA 94143 USA. [Aparici, Carina Mari; Cooperberg, Matthew R.; Konety, Badrinath R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cooperberg, Matthew R.; Konety, Badrinath R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Seo, Y (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. EM youngho.seo@radiology.ucsf.edu FU National Cancer Institute [5 K25 CA114254]; University of California Industry-University Cooperative Research Program [0610210] FX We thank Marilyn Morrissey and Charisa Thomas at the San Francisco Veterans Affairs Medical Center for technical assistance with the imaging studies. This work was funded in part by National Cancer Institute grant 5 K25 CA114254 and by the University of California Industry-University Cooperative Research Program grant dig 0610210 with Philips Healthcare. NR 25 TC 13 Z9 13 U1 0 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 2010 VL 51 IS 1 BP 31 EP 36 DI 10.2967/jnumed.109.067108 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 539OG UT WOS:000273263800010 PM 20008977 ER PT J AU Melo, MFV Winkler, T Harris, RS Musch, G Greene, RE Venegas, JG AF Melo, Marcos F. Vidal Winkler, Tilo Harris, R. Scott Musch, Guido Greene, Reginald E. Venegas, Jose G. TI Spatial Heterogeneity of Lung Perfusion Assessed with N-13 PET as a Vascular Biomarker in Chronic Obstructive Pulmonary Disease SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE positron-emission tomography; pulmonary circulation; chronic obstructive pulmonary disease; pulmonary gas exchange; length scale analysis ID REGIONAL VENTILATION; COMPUTED-TOMOGRAPHY; EMPHYSEMA; HYPERTENSION; IMPAIRMENT; ANESTHESIA; MECHANICS; PRESSURE; GRAVITY; ASTHMA AB Although it is known that structural and functional changes in the pulmonary vasculature and parenchyma occur in the progress of chronic obstructive pulmonary disease (COPD), information is limited on early regional perfusion (Q(r))alterations. Methods: We studied 6 patients with mild or moderate COPD and 9 healthy subjects (6 young and 3 age-matched). The PET (NN)-N-13-labeled saline injection method was used to compute images of Q(r) and regional ventilation (V-r). Transmission scans were used to assess regional density. We used the squared coefficient of variation to quantify Q(r) heterogeneity and length-scale analysis to quantify the contribution to total perfusion heterogeneity of regions ranging from less than 12 to more than 108 mm. Results: Perfusion distribution in COPD subjects showed larger Q(r) heterogeneity, higher contribution from large length scales and lower contribution from small length scales, and larger heterogeneity of Q(r) normalized by tissue density than did healthy subjects. Dorsoventral gradients of V-r were present in healthy subjects, with larger ventilation in dependent regions, whereas no gradient was present in COPD. Heterogeneity of ventilation-perfusion ratios was larger in COPD. Conclusion: Q(r) is significantly redistributed in COPD. Q(r) heterogeneity in COPD patients is greater than in healthy subjects, mainly because of the contribution of large lung regions and not because of changes in tissue density or V-r. The assessment of spatial heterogeneity of lung perfusion with (NN)-N-13-saline PET may serve as a vascular biomarker in COPD. C1 [Melo, Marcos F. Vidal] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Greene, Reginald E.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Melo, MFV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA. EM mvidalmelo@partners.org RI Winkler, Tilo/B-5337-2009 OI Winkler, Tilo/0000-0002-7276-5550 FU NIH [R01-HL-086827, HL-068011] FX We thank Steven B. Weise, PET Imaging Laboratory, Massachusetts General Hospital, for his expert support in the acquisition of images. This study was funded by NIH grants R01-HL-086827 and HL-068011. NR 40 TC 30 Z9 30 U1 0 U2 3 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 2010 VL 51 IS 1 BP 57 EP 65 DI 10.2967/jnumed.109.065185 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 539OG UT WOS:000273263800014 ER PT J AU Fang, YHD Asthana, P Salinas, C Huang, HM Muzic, RF AF Fang, Yu-Hua Dean Asthana, Pravesh Salinas, Cristian Huang, Hsuan-Ming Muzic, Raymond F., Jr. TI Integrated Software Environment Based on COMKAT for Analyzing Tracer Pharmacokinetics with Molecular Imaging SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE kinetic modeling; imaging software; pharmacokinetics; COMKAT ID KINETIC-PARAMETERS; METABOLIC-RATE; PET; QUANTIFICATION; REGISTRATION; VALIDATION; MICROPET; GLUCOSE; HUMANS; MODEL AB An integrated software package, Compartment Model Kinetic Analysis Tool (COMKAT), is presented in this report. Methods: COMKAT is an open-source software package with many functions for incorporating pharmacokinetic analysis in molecular imaging research and has both command-line and graphical user interfaces. Results: With COMKAT, users may load and display images, draw regions of interest, load input functions, select kinetic models from a predefined list, or create a novel model and perform parameter estimation, all without having to write any computer code. For image analysis, COMKAT image tool supports multiple image file formats, including the Digital Imaging and Communications in Medicine (DICOM) standard. Image contrast, zoom, reslicing, display color table, and frame summation can be adjusted in COMKAT image tool. It also displays and automatically registers images from 2 modalities. Parametric imaging capability is provided and can be combined with the distributed computing support to enhance computation speeds. For users without MATLAB licenses, a compiled, executable version of COMKAT is available, although it currently has only a subset of the full COMKAT capability. Both the compiled and the noncompiled versions of COMKAT are free for academic research use. Extensive documentation, examples, and COMKAT itself are available on its wiki-based Web site, http://comkat.case.edu. Users are encouraged to contribute, sharing their experience, examples, and extensions of COMKAT. Conclusion: With integrated functionality specifically designed for imaging and kinetic modeling analysis, COMKAT can be used as a software environment for molecular imaging and pharmacokinetic analysis. C1 [Muzic, Raymond F., Jr.] Case Western Reserve Univ, Univ Hosp Cleveland, Case Med Ctr, Dept Radiol, Cleveland, OH 44106 USA. [Muzic, Raymond F., Jr.] Case Western Reserve Univ, Univ Hosp Cleveland, Case Med Ctr, Case Ctr Imaging Res, Cleveland, OH 44106 USA. [Salinas, Cristian; Huang, Hsuan-Ming] Univ London Imperial Coll Sci Technol & Med, GSK Clin Imaging Ctr, London, England. [Asthana, Pravesh] Crossrate Technol, Windham, ME USA. [Fang, Yu-Hua Dean; Asthana, Pravesh; Salinas, Cristian; Muzic, Raymond F., Jr.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. [Fang, Yu-Hua Dean] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Nucl Med & Mol Imaging, Boston, MA USA. RP Muzic, RF (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Case Med Ctr, Dept Radiol, BSH 5056,11100 Euclid Ave, Cleveland, OH 44106 USA. EM raymond.muzic@case.edu FU NIH [R33-CA-101073, R24-CA-110943] FX The work was supported by NIH grants R33-CA-101073 and R24-CA-110943. NR 22 TC 13 Z9 13 U1 0 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 2010 VL 51 IS 1 BP 77 EP 84 DI 10.2967/jnumed.109.064824 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 539OG UT WOS:000273263800016 PM 20008992 ER PT J AU Kirschling, JM Erickson, JI AF Kirschling, Jane Marie Erickson, Jeanette Ives TI The STTI Practice-Academe Innovative Collaboration Award: Honoring Innovation, Partnership, and Excellence SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Article DE Nursing education; nursing practice; collaboration; innovation; partnership ID FACULTY PRACTICE AB Purpose: To describe the benefits and barriers associated with practice-academe partnerships and introduce Sigma Theta Tau International's (STTI's) Practice-Academe Innovative Collaboration Award and the 2009 award recipients. Design and Methods: In 2008, STTI created the CNO-Dean Advisory Council and charged it with reviewing the state of practice-academe collaborations and developing strategies for optimizing how chief nursing officers (CNOs) and deans work together to advance the profession and discipline of nursing. The Council, in turn, developed the Practice-Academe Innovative Collaboration Award to encourage collaboration across sectors, recognize innovative collaborative efforts, and spotlight best practices. A call for award submissions resulted in 24 applications from around the globe. Findings: An award winner and seven initiatives receiving honorable mentions were selected. The winning initiatives reflect innovative academe-service partnerships that advance evidence-based practice, nursing education, nursing research, and patient care. The proposals were distinguished by their collaborators' shared vision and unity of purpose, ability to leverage strengths and resources, and willingness to recognize opportunities and take risks. Conclusions: By partnering with one another, nurses in academe and in service settings can directly impact nursing education and practice, often effecting changes and achieving outcomes that are more extensive and powerful than could be achieved by working alone. Clinical Relevance: The award-winning initiatives represent best practices for bridging the practice-academe divide and can serve as guides for nurse leaders in both settings. C1 [Kirschling, Jane Marie] Univ Kentucky, Coll Nursing, Lexington, KY 40536 USA. [Erickson, Jeanette Ives] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Kirschling, JM (reprint author), Univ Kentucky, Coll Nursing, 315 CON Bldg, Lexington, KY 40536 USA. EM janek@email.uky.edu NR 26 TC 4 Z9 5 U1 2 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1527-6546 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PY 2010 VL 42 IS 3 BP 286 EP 294 DI 10.1111/j.1547-5069.2010.01352.x PG 9 WC Nursing SC Nursing GA 643HA UT WOS:000281285000008 PM 20738739 ER PT J AU Wan, JB Kang, JX AF Wan, Jlan-Bo Kang, Jing X. TI Effect of Tissue n-6/n-3 Fatty Acid Ratio on the Expression of Inflammatory Factors and Atherosclerotic Plaque Formation SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RI Wan, Jian-Bo/D-8368-2014 OI Wan, Jian-Bo/0000-0002-6750-2617 NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2010 VL 3 IS 2-3 BP 60 EP 60 PG 1 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 678ZP UT WOS:000284126800015 ER PT J AU Cheng, C Wang, XW Weakley, SM Kougias, P Lin, PH Yao, QZ Chen, CY AF Cheng, Charlie Wang, Xinwen Weakley, Sarah M. Kougias, Panagiotis Lin, Peter H. Yao, Qizhi Chen, Changyi TI The Soybean Isoflavonoid Equol Blocks Ritonavir-Induced Endothelial Dysfunction in Porcine Pulmonary Arteries and Human Pulmonary Artery Endothelial Cells SO JOURNAL OF NUTRITION LA English DT Article ID PROTEASE INHIBITOR RITONAVIR; INDUCED VASCULAR DYSFUNCTION; CORONARY-ARTERIES; MEDROXYPROGESTERONE ACETATE; ANTIOXIDANT ACTIVITY; METABOLITE EQUOL; SOY ISOFLAVONES; HIV-INFECTION; RECEPTOR-BETA; JAPANESE MEN AB HIV protease inhibitor (PI) ritonavir(RTV) may cause vascular injury through oxidative stress. Our purpose in this study was to determine whether equol, a soy isoflavone, could prevent RTV-induced endothelial dysfunction in porcine pulmonary arteries and in human pulmonary artery endothelial cells (HPAEC). Fresh porcine pulmonary artery rings were treated with 15 mu mol/L of RTV and/or equol in concentrations of 0.1, 1, and 10 mu mol/L for 24 In. A control was set with no amount of equol or RTV administered. Based on myograph tension analysis, RTV significantly reduced endothelium-dependent relaxation in response to bradykinin in the artery rings compared with untreated vessels, whereas the antioxidant equol effectively reversed the RTV effect in a concentration-dependent manner. RTV also reduced the contraction of artery rings in response to thromboxane A(2) analogue U46619 and this reduction was blocked by equol. In addition, RTV treatment significantly reduced endothelial nitric oxide synthase (eNOS) expression in both porcine pulmonary arteries and HPAEC, whereas equol effectively blocked RTV-induced eNOS downregulation. Furthermore, RTV significantly increased superoxide anion production, whereas equol reversed this effect of RTV in porcine pulmonary arteries. Thus, the antioxidant equol effectively protects vascular function from the detrimental effects of HIV PI RTV in both porcine pulmonary arteries and HPAEC via a reduction in the vasomotor dysfunction, eNOS downregulation, and oxidative stress induced by RTV. These novel data suggest that equol may have a clinical application in preventing HIV-associated cardiovascular complications. J. Nutr. 140: 12-17, 2010. C1 [Cheng, Charlie; Wang, Xinwen; Weakley, Sarah M.; Kougias, Panagiotis; Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Baylor Coll Med, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Kougias, Panagiotis; Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Chen, CY (reprint author), Baylor Coll Med, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. EM jchen@bcm.tmc.edu FU NIH [HL076345, HL65916, HL72716]; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX FX Supported by research grants from the NIH (no. HL076345 to P. H. Lin and nos. HL65916 and HL72716 to C. Chen) and by the Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX. NR 36 TC 13 Z9 15 U1 0 U2 0 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JAN PY 2010 VL 140 IS 1 BP 12 EP 17 DI 10.3945/jn.109.110981 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 535EH UT WOS:000272949100003 PM 19923382 ER PT J AU Resnick, CM Margolis, J Susarla, SM Schwab, JH Hornicek, FJ Dodson, TB Kaban, LB AF Resnick, Cory M. Margolis, Jeffrey Susarla, Srinivas M. Schwab, Joseph H. Hornicek, Francis J. Dodson, Thomas B. Kaban, Leonard B. TI Maxillofacial and Axial/Appendicular Giant Cell Lesions: Unique Tumors or Variants of the Same Disease?-A Comparison of Phenotypic, Clinical, and Radiographic Characteristics SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID TERM-FOLLOW-UP; ANTIANGIOGENIC THERAPY; BONE; JAWS; GRANULOMA; CURETTAGE; SKELETON AB Purpose: The relationship between giant cell lesions (GCLs) of the maxillofacial (MF) skeleton and those of the axial/appendicular (AA) skeleton has been long debated. The present study compared the clinical and radiographic characteristics of subjects with MF and AA GCLs. Materials and Methods: This was a retrospective cohort study of patients treated for GCLs at Massachusetts General Hospital from 1993 to 2008. The predictor variables included tumor location (MF or AA) and clinical behavior (aggressive or nonaggressive). The outcome variables included demographic, clinical, and radiographic parameters, treatments, and outcomes. Descriptive and bivariate statistics were computed, and P <= .05 was considered significant. Results: The sample included 93 subjects: 45 with MF (38 with aggressive and 7 with nonaggressive) and 48 with AA (30 with aggressive and 18 with nonaggressive). Comparing the patients with MF and AA GCLs, those with MF lesions presented younger (P < .001), and the lesions were more commonly asymptomatic (P < .001), smaller (P <.001), and managed differently (P < .001) than AA lesions. When stratified by clinical behavior, aggressive tumors were diagnosed earlier than nonaggressive tumors (P <.001). Controlling for location and clinical behavior, patients with MF aggressive lesions were younger (P <.001) than those with AA aggressive lesions. MF nonaggressive lesions were more commonly asymptomatic (P = .04), smaller (P = .05), and less commonly locally destructive (P = .05) than AA nonaggressive lesions. Conclusions: These results suggest that MF and AA GCLs represent a similar, if not the same, disease. Comparing the aggressive and nonaggressive subgroups, more similarities were found than when evaluating without stratification by clinical behavior. The remaining differences could be explained by C1 [Dodson, Thomas B.; Kaban, Leonard B.] Harvard Univ, Massachusetts Gen Hosp, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Margolis, Jeffrey] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Hornicek, Francis J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped Surg,Div Orthoped Oncol, Boston, MA 02114 USA. [Dodson, Thomas B.] Harvard Univ, Massachusetts Gen Hosp, Sch Dent Med, Ctr Appl Clin Invest, Boston, MA 02114 USA. RP Kaban, LB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. EM lkaban@partners.org OI Susarla, Srinivas/0000-0003-0155-8260; Resnick, Cory/0000-0002-6391-9618 FU Massachusetts General Physicians Organization FX Supported by Massachusetts General Hospital Department of Oral and Maxillofacial Surgery's Center for Applied Clinical Investigation and Education and Research Fund, Massachusetts General Physicians Organization. NR 31 TC 9 Z9 9 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JAN PY 2010 VL 68 IS 1 BP 130 EP 137 DI 10.1016/j.joms.2009.04.106 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 617KV UT WOS:000279280500022 PM 20006167 ER PT J AU Yamano, S Nissenbaum, M Dodson, TB Gallucci, GO Sukotjo, C AF Yamano, Seiichi Nissenbaum, Mark Dodson, Thomas B. Gallucci, German O. Sukotjo, Cortino TI Multidisciplinary Treatment for a Young Patient With Severe Maxillofacial Trauma From a Snowmobile Accident: A Case Report SO JOURNAL OF ORAL IMPLANTOLOGY LA English DT Article DE multidisciplinary treatment; maxillofacial trauma; implant; snowmobile accident ID IMPLANTS AB This clinical report describes the oral rehabilitation of a 15-year-old male patient who was involved in a snowmobile accident and suffered multiple mid-face and mandibular fractures. Consequences of the accident included avulsion of teeth numbers 5 to 10 and 21 to 26, and a significant amount of maxillary and mandibular anterior alveolar bone loss. The patient underwent open reduction and rigid fixation of the fractured left zygoma, comminuted Le Fort I maxillary fracture, and left body of the mandible; closed reduction of the bilateral condylar fractures; autologous corticocancellous bone grafting to the maxilla and mandible; implant placement; and prosthesis fabrication. This multidisciplinary approach successfully restored function and esthetics. C1 [Sukotjo, Cortino] Univ Illinois, Coll Dent, Dept Restorat Dent, Comprehens Dent Implant Ctr, Chicago, IL 60607 USA. [Yamano, Seiichi] NYU, Coll Dent, Dept Prosthodont, New York, NY USA. [Dodson, Thomas B.] Harvard Univ, Sch Dent Med, Ctr Appl Clin Invest, Boston, MA 02115 USA. [Dodson, Thomas B.] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA. [Dodson, Thomas B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gallucci, German O.] Harvard Univ, Sch Dent Med, Dept Restorat Dent & Biomat Sci, Boston, MA 02115 USA. RP Sukotjo, C (reprint author), Univ Illinois, Coll Dent, Dept Restorat Dent, Comprehens Dent Implant Ctr, Chicago, IL 60607 USA. EM csukotjo@uic.edu RI Gallucci, German/H-4505-2011; Sukotjo, Cortino/D-1766-2013; OI Yamano, Seiichi/0000-0003-2056-4359 NR 7 TC 3 Z9 3 U1 0 U2 3 PU ALLEN PRESS INC PI LAWRENCE PA 810 E 10TH ST, LAWRENCE, KS 66044 USA SN 0160-6972 J9 J ORAL IMPLANTOL JI J. Oral Implant. PY 2010 VL 36 IS 2 BP 141 EP 144 DI 10.1563/AAID-JOI-D-09-00058R1 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 592RS UT WOS:000277397900009 PM 20426591 ER PT J AU Birdi, H Schulte, J Kovacs, A Weed, M Chuang, SK AF Birdi, Hardeep Schulte, John Kovacs, Alejandro Weed, Meghan Chuang, Sung-Kiang TI Crown-to-Implant Ratios of Short-Length Implants SO JOURNAL OF ORAL IMPLANTOLOGY LA English DT Article DE crown-implant ratios; proximal bone-to-implant contact ID SHORT DENTAL IMPLANTS; 3-YEAR PROSPECTIVE MULTICENTER; PARTIALLY EDENTULOUS PATIENTS; CLINICAL-EVALUATION; FOLLOW-UP; SURVIVAL; RATES; PARAMETERS; PROSTHESES; OUTCOMES AB Excessive crown-implant ratios have been cited in the literature as being detrimental to long-term implant survival. However, unfavorable crown-implant ratios have not yet been established. The primary aim of this study was to determine the crown-implant ratios of single-tooth implant-supported restorations on short-length implants in a clinical practice, and to evaluate the health of these implants via mesial and distal first bone-to-implant contact levels. Additionally, the relationship between crown-implant ratios and proximal first bone-to-implant contact levels will be evaluated. In this retrospective cohort study, the cohort was composed of 194 patients who possessed at least 1 single 5.7 mm or 6 mm length plateau design implant-supported restoration that had been surgically placed between February 1997 and December 2005. A chart review was performed to acquire the most recent radiographs in which both the entire crown and the implant were visible. The length of the crown and implant was measured directly from the radiographs using consistent magnification to calculate the crown-implant ratio. Mesial and distal first bone-to-implant contact levels were measured using 3 times magnification and were mathematically corrected for distortion. The last available radiograph was used to measure bone levels. Follow-up time was calculated from the day of implant placement to the date of the last available radiograph. Statistical analyses with analysis of variance mixed models were used. Data from 309 single implant-supported fixed restorations were tabulated and included in the study. The mean (SD) follow-up time was 20.9 (23.2) months, with a range of 15.6 to 122.8 months. The mean crown length (SD) was 13.4 (2.6) mm, with a range of 6.2 to 21.7 mm. The mean (SD) crown-implant ratio was 2.0 (0.4) and ranged from 0.9 to 3.2. The average mesial and distal first bone-to-implant contact levels (SD) measured from the radiographs were -0.2 (0.7) mm and -0.2 (0.9) mm, respectively. No statistically significant relationship was observed between increasing crown-implant ratios and decreasing mesial and distal first bone-to-implant contact levels around the implant with P values of .94 and .57, respectively. In this investigation, mesial and distal first bone-to-implant contact levels on short-length implants fall within the established guidelines for success. Also, there are no associations between crown-implant ratios and first bone-to-implant contact levels. C1 [Birdi, Hardeep; Schulte, John; Kovacs, Alejandro] Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA. [Weed, Meghan] Implant Dent Ctr, Boston, MA USA. [Chuang, Sung-Kiang] Massachusetts Gen Hosp, Dept OMFS, Boston, MA 02114 USA. [Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Birdi, H (reprint author), Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA. EM bobbirdi@gmail.com NR 41 TC 28 Z9 34 U1 1 U2 3 PU ALLEN PRESS INC PI LAWRENCE PA 810 E 10TH ST, LAWRENCE, KS 66044 USA SN 0160-6972 J9 J ORAL IMPLANTOL JI J. Oral Implant. PY 2010 VL 36 IS 6 BP 425 EP 433 DI 10.1563/AAID-JOI-D-09-00071 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 696GV UT WOS:000285430800003 PM 20545533 ER PT J AU Kumar, NL Rosenberg, AE Raskin, KA AF Kumar, Navin L. Rosenberg, Andrew E. Raskin, Kevin A. TI Osteoblastoma-like Osteosarcoma of the Cuboid: A Case Report SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH LA English DT Article AB Osteosarcoma most commonly arises in the long bones of the skeleton, and rarely develops in the bones of the foot. We describe a patient who presented with left foot pain, whose radiographic evaluation revealed a lytic destructive mass in the cuboid bone. A biopsy showed an osteoblastoma-like variant of osteosarcoma and the patient was treated with preoperative chemotherapy and amputation. Osteosarcoma of the foot is uncommon and the literature reveals that it is often associated with a delay in diagnosis. C1 [Kumar, Navin L.; Rosenberg, Andrew E.; Raskin, Kevin A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rosenberg, Andrew E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol WRN 2, Boston, MA 02114 USA. [Raskin, Kevin A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Yawkey Outpatient Ctr,Orthopaed Oncol Serv, Boston, MA 02114 USA. RP Kumar, NL (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM navin_kumar@hms.harvard.edu NR 10 TC 3 Z9 3 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-799X J9 J ORTHOP SURG RES JI J. Orthop. Surg. Res. PY 2010 VL 5 AR 52 DI 10.1186/1749-799X-5-52 PG 5 WC Orthopedics SC Orthopedics GA V24BR UT WOS:000208386400052 PM 20691084 ER PT J AU Kwon, JY Johnson, CE Appleton, P Rodriguez, EK AF Kwon, John Y. Johnson, Catherine E. Appleton, Paul Rodriguez, Edward K. TI Lateral femoral traction pin entry: risk to the femoral artery and other medial neurovascular structures SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH LA English DT Article AB Background: Femoral skeletal traction assists in the reduction and transient stabilization of pelvic, acetabular, hip, and femoral fractures when splinting is ineffective. Traditional teaching has recommended a medial entry site for insertion of the traction pin in order to minimize injury to the femoral artery as it passes through Hunter's canal. The present anatomical study evaluates the risk to the femoral artery and other medial neurovascular structures using a lateral entry approach. Methods: Six embalmed cadavers (twelve femurs) were obtained for dissection. Steinman pins were drilled from lateral to medial at the level of the superior pole of the patella, at 2 cm, and at 4 cm proximal to this point. Medial superficial dissection was then performed to identify the saphenous nerve, the superior medial geniculate artery, the adductor hiatus, the tendinous insertion of the adductor magnus and the femoral artery. Measurements localizing these anatomic structures relative to the pins were obtained. Results: The femoral artery was relatively safe and was no closer than 29.6 mm (mean) from any of the three Steinman pins. The superior medial geniculate artery was the medial structure at most risk. Conclusions: Lateral femoral traction pin entry is a safe procedure with minimal risk to the saphenous nerve and femoral artery. Of the structures examined, only the superior medial geniculate artery is at a risk of iatrogenic injury due to its position. The incidence of such injury in clinical practice and its clinical significance is not known. Lateral insertion facilitates traction pin placement since it minimizes the need to move the contralateral extremity out of the way of the drilling equipment or the need to elevate or externally rotate the injured extremity relative to the contralateral extremity. C1 [Kwon, John Y.; Johnson, Catherine E.] Massachusetts Gen Hosp, Harvard Combined Orthopaed Residency Program, Dept Orthopaed Surg, Boston, MA 02114 USA. [Appleton, Paul; Rodriguez, Edward K.] Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Boston, MA 02215 USA. RP Kwon, JY (reprint author), Massachusetts Gen Hosp, Harvard Combined Orthopaed Residency Program, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA. EM johnkwonmd@gmail.com NR 5 TC 8 Z9 8 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-799X J9 J ORTHOP SURG RES JI J. Orthop. Surg. Res. PY 2010 VL 5 AR 4 DI 10.1186/1749-799X-5-4 PG 6 WC Orthopedics SC Orthopedics GA V24BR UT WOS:000208386400004 PM 20205875 ER PT J AU Liu, F Yue, B Gadikota, HR Kozanek, M Liu, WJ Gill, TJ Rubash, HE Li, GA AF Liu, Fang Yue, Bing Gadikota, Hemanth R. Kozanek, Michal Liu, Wanjun Gill, Thomas J. Rubash, Harry E. Li, Guoan TI Morphology of the medial collateral ligament of the knee SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH LA English DT Article AB Background: Quantitative knowledge on the anatomy of the medial collateral ligament (MCL) is important for treatment of MCL injury and for MCL release during total knee arthroplasty (TKA). The objective of this study was to quantitatively determine the morphology of the MCL of human knees. Methods: 10 cadaveric human knees were dissected to investigate the MCL anatomy. The specimens were fixed in full extension and this position was maintained during the dissection and morphometric measurements. The outlines of the insertion sites of the superficial MCL (sMCL) and deep MCL (dMCL) were digitized using a 3D digitizing system. Results: The insertion areas of the superficial MCL (sMCL) were 348.6 +/- 42.8 mm(2) and 79.7 +/- 17.6 mm(2) on the tibia and femur, respectively. The insertion areas of the deep MCL (dMCL) were 63.6 +/- 13.4 mm(2) and 71.9 +/- 14.8 mm(2) on the tibia and femur, respectively. The distances from the centroids of the tibial and femoral insertions of the sMCL to the tibial and femoral joint line were 62.4 +/- 5.5 mm and 31.1 +/- 4.6 mm, respectively. The distances from the centroids of dMCL in the tibial insertion and the femoral insertion to the tibial and femoral joint line were 6.5 +/- 1.3 mm and 20.5 +/- 4.2 mm, respectively. The distal portion of the dMCL (meniscotibial ligament - MTL) was approximately 1.7 times wider than the proximal portion of the dMCL (meniscofemoral ligament - MFL), whereas the MFL was approximately 3 times longer than the MTL. Conclusions: The morphologic data on the MCL may provide useful information for improving treatments of MCL-related pathology and performing MCL release during TKA. C1 [Liu, Fang; Gadikota, Hemanth R.; Kozanek, Michal; Gill, Thomas J.; Rubash, Harry E.; Li, Guoan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed,Bioengn Lab, Boston, MA 02114 USA. [Yue, Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthopaed Surg, Shanghai, Peoples R China. [Liu, Wanjun] Yantaishan Hosp, Dept Orthopaed Surg, Yantai, Peoples R China. RP Li, GA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Orthopaed,Bioengn Lab, Boston, MA 02114 USA. EM GLI1@PARTNERS.ORG FU National Institutes of Health [R01AR055612] FX The authors gratefully acknowledge the support of the National Institutes of Health (R01AR055612). NR 21 TC 26 Z9 30 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-799X J9 J ORTHOP SURG RES JI J. Orthop. Surg. Res. PY 2010 VL 5 AR 69 DI 10.1186/1749-799X-5-69 PG 8 WC Orthopedics SC Orthopedics GA V24BR UT WOS:000208386400069 PM 20846377 ER PT J AU Zukotynski, K Curtis, C Grant, FD Micheli, L Treves, ST AF Zukotynski, Katherine Curtis, Christine Grant, Frederick D. Micheli, Lyle Treves, S. Ted TI The value of SPECT in the detection of stress injury to the pars interarticularis in patients with low back pain SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH LA English DT Review AB The medical cost associated with back pain in the United States is considerable and growing. Although the differential diagnosis of back pain is broad, epidemiological studies suggest a correlation between adult and adolescent complaints. Injury of the pars interarticularis is one of the most common identifiable causes of ongoing low back pain in adolescent athletes. It constitutes a spectrum of disease ranging from bone stress to spondylolysis and spondylolisthesis. Bone stress may be the earliest sign of disease. Repetitive bone stress causes bone remodeling and may result in spondylolysis, a non-displaced fracture of the pars interarticularis. A fracture of the pars interarticularis may ultimately become unstable leading to spondylolisthesis. Results in the literature support the use of bone scintigraphy to diagnose bone stress in patients with suspected spondylolysis. Single photon emission computed tomography (SPECT) provides more contrast than planar bone scintigraphy, increases the sensitivity and improves anatomic localization of skeletal lesions without exposing the patient to additional radiation. It also provides an opportunity for better correlation with other imaging modalities, when necessary. As such, the addition of SPECT to standard planar bone scintigraphy can result in a more accurate diagnosis and a better chance for efficient patient care. It is our expectation that by improving our ability to correctly diagnose bone stress in patients with suspected injury of the posterior elements, the long-term cost of managing this condition will be lowered. C1 [Grant, Frederick D.; Treves, S. Ted] Childrens Hosp, Dept Radiol, Div Nucl Med, Boston, MA 02115 USA. [Zukotynski, Katherine] Dana Farber Canc Inst, Div Nucl Med, Dept Imaging, Boston, MA 02115 USA. [Curtis, Christine; Micheli, Lyle] Childrens Hosp, Dept Orthoped Surg, Div Sports Med, Boston, MA 02115 USA. [Zukotynski, Katherine; Grant, Frederick D.; Micheli, Lyle; Treves, S. Ted] Harvard Univ, Sch Med, Boston, MA USA. RP Treves, ST (reprint author), Childrens Hosp, Dept Radiol, Div Nucl Med, 300 Longwood Ave, Boston, MA 02115 USA. EM Ted.Treves@childrens.harvard.edu NR 36 TC 8 Z9 11 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-799X J9 J ORTHOP SURG RES JI J. Orthop. Surg. Res. PY 2010 VL 5 AR 13 DI 10.1186/1749-799X-5-13 PG 6 WC Orthopedics SC Orthopedics GA V24BR UT WOS:000208386400013 PM 20199678 ER PT J AU Xian, W Miron, A Roh, M Semmel, DR Yassin, Y Garber, J Oliva, E Goodman, A Mehra, K Berkowitz, RS Crum, CP Quade, BJ AF Xian, Wa Miron, Alexander Roh, Michael Semmel, Dana R. Yassin, Yosuf Garber, Judy Oliva, Esther Goodman, Annekathryn Mehra, Karishma Berkowitz, Ross S. Crum, Christopher P. Quade, Bradley J. TI The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube SO JOURNAL OF PATHOLOGY LA English DT Article DE p53; BRCA; Li-Fraumeni syndrome; p53 signature; serous cancer; Fallopian tube; ovarian cancer ID OVARIAN-CANCER; SEROUS CARCINOMA; INTRAEPITHELIAL CARCINOMA; PATHOLOGICAL FINDINGS; CANDIDATE PRECURSOR; WOMEN; MUTATIONS; OOPHORECTOMY; PREVENTION; CARRIERS AB A candidate early precursor to pelvic serous cancer, the 'p53 signature', is commonly found in the benign mucosa of the distal Fallopian tube and harbours p53 mutations and evidence of DNA damage. We examined tubes from women with pre-existing (germ-line) mutations in p53 [Li-Fraumeni syndrome (LFS)] for evidence of this precursor. Fallopian tubes from two cases of LFS were immunostained for p53, Ki-67 (proliferation) and H2AX (DNA damage response) and analysed for p53 mutations by laser capture microdissection (LCM) and p53 genomic sequencing (exons 2-11). A common single nucleotide repeat (snp) in exon 3 (rs1042522) and deletion sequencing chromatograms in exon 4 were examined in combination to estimate LOH in both LFS tubes and advanced serous carcinomas from the general population. LFS tubal epithelium contained abundant (10-20 per section) p53 signatures with evidence of DNA damage and low proliferative activity. Six of 11 LFS microdissected p53 signatures (55%) and 15 of 21 serous carcinomas (71%) revealed LOH at the p53 locus, relative to background epithelium. The LFS model confirms prior observations that the distal Fallopian tube is particularly prone to focal epithelial p53 gene inactivation - p53 mutation and LOH - in the absence of malignancy or increased epithelial proliferation. The fact that the LFS is not associated with ovarian cancers is consistent with the concept that loss of p53 function must be accompanied by at least one more genotoxic event (including BRCA1/2 functional inactivation) to produce the malignant phenotype. This is in keeping with a general model of carcinogenesis, in which different and often independent risk factors operate at multiple points in the serous carcinogenic spectrum. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. C1 [Xian, Wa; Roh, Michael; Semmel, Dana R.; Mehra, Karishma; Crum, Christopher P.; Quade, Bradley J.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA. [Miron, Alexander; Yassin, Yosuf] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Garber, Judy] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Goodman, Annekathryn] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Berkowitz, Ross S.] Brigham & Womens Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Boston, MA 02115 USA. RP Crum, CP (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA. EM ccrum@partners.org FU NCI [P50CA10500, 1R21CA124688-01A1]; Columbia Hospital For Women Research Foundation; Division of Women's and Perinatal Pathology, Brigham and Women's Hospital FX This work was supported by grants from the NCI (P50CA10500 [SPORE] to DC), NCI 1R21CA124688-01A1 (to CPC), the Columbia Hospital For Women Research Foundation (to CPC), the Francis Ward Paine and TSA Pemberton Funds from the Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, and a gift in memory of Elizabeth Ford 15 Smith. NR 30 TC 18 Z9 18 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0022-3417 J9 J PATHOL JI J. Pathol. PD JAN PY 2010 VL 220 IS 1 BP 17 EP 23 DI 10.1002/path.2624 PG 7 WC Oncology; Pathology SC Oncology; Pathology GA 538LN UT WOS:000273186100004 PM 19834951 ER PT J AU Fishman, DS Sailhamer, EA Cohen, DT Mino-Kenudson, M Doody, DP Winter, HS AF Fishman, Douglas S. Sailhamer, Elizabeth A. Cohen, Daniel T. Mino-Kenudson, Mari Doody, Daniel P. Winter, Harland S. TI Intussusception of the Appendix Causing Small Bowel Obstruction in a Patient With Cystic Fibrosis SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Editorial Material ID PANCREATIC-ENZYME SUPPLEMENTS; COLONOPATHY C1 [Fishman, Douglas S.] Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Gastroenterol Nutr & Hepatol, Clin Care Ctr 1010 20, Houston, TX 77019 USA. [Sailhamer, Elizabeth A.; Doody, Daniel P.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. [Cohen, Daniel T.] Radiol Imaging Consultants, St Charles, MO USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Winter, Harland S.] MassGen Hosp Children, Dept Pediat Gastroenterol & Nutr, Boston, MA USA. RP Fishman, DS (reprint author), Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Gastroenterol Nutr & Hepatol, Clin Care Ctr 1010 20, 6621 Fannin St, Houston, TX 77019 USA. EM dougfishman@gmail.com NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD JAN PY 2010 VL 50 IS 1 BP 1 EP 1 DI 10.1097/MPG.0b013e3181c15ef8 PG 1 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 538GX UT WOS:000273173700001 PM 19934768 ER PT J AU Loprinzi, CL Schapira, L Moynihan, T Kalemkerian, GP von Gunten, C Steensma, D AF Loprinzi, Charles L. Schapira, Lidia Moynihan, Timothy Kalemkerian, Gregory P. von Gunten, Charles Steensma, David TI Workshop on Psycho-Oncology: Alleviation of Fear, Frustration and Sense of Loss Through Non-Pharmacological Treatment Modalities Abstracts SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Meeting Abstract ID BAD-NEWS; DISCUSSING PROGNOSIS; ADVANCED CANCER; HOSPICE CARE; COMMUNICATION; TELL; WANT; INFORMATION; EXPERIENCE; COLLUSION C1 [Loprinzi, Charles L.; Moynihan, Timothy; Steensma, David] Mayo Clin, Rochester, MN USA. [Schapira, Lidia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kalemkerian, Gregory P.] Univ Michigan, Ann Arbor, MI 48109 USA. [von Gunten, Charles] San Diego Hosp, Ctr Palliat Studies, San Diego, CA USA. NR 38 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1077-4114 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD JAN PY 2010 VL 32 IS 1 BP 22 EP 25 PG 4 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 541YR UT WOS:000273458300008 ER PT J AU Barron, AM Coakley, AB AF Barron, Anne-Marie Coakley, Amanda Bulette TI Therapeutic Touch Practice and Research on an Inpatient Oncology and Bone Marrow Transplant Unit: Creating a Caring and Healing Environment SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY LA English DT Meeting Abstract C1 [Barron, Anne-Marie] Simmons Coll, Fac Nurse Scientist, Boston, MA 02115 USA. [Coakley, Amanda Bulette] Northeastern Univ, Massachusetts Gen Hosp, Sch Profess Studies, Boston, MA 02115 USA. NR 15 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1077-4114 J9 J PEDIAT HEMATOL ONC JI J. Pediatr. Hematol. Oncol. PD JAN PY 2010 VL 32 IS 1 BP 33 EP 36 PG 4 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 541YR UT WOS:000273458300011 ER PT J AU Conley, SB Curry, JO Hines, M Baker, K Schmidt, K Zwier, K Siever, B Mirisola, T Burke, S Thom, B Kline, NE AF Conley, Susanne B. Curry, Joan O'Hanlon Hines, Melissa Baker, Kelley Schmidt, Kaye Zwier, Kathy Siever, Beth Mirisola, Therese Burke, Susie Thom, Bridgette Kline, Nancy E. TI Consensus Statements: Ambulatory Pediatric Oncology Nursing Practice SO JOURNAL OF PEDIATRIC ONCOLOGY NURSING LA English DT Article DE ambulatory nursing; pediatric-oncology; staffing; concensus statements ID INTENSITY; WORKLOAD; SYSTEM; CARE AB The pre-conference workshop at the 32nd Annual Conference of the Association of Pediatric Hematology/Oncology Nursing, held in September 2008, focused on issues faced by pediatric oncology nurses in the ambulatory setting. The workshop was developed after several years of intense discussions at several forums. Therefore the need for an extended discussion period with ambulatory pediatric oncology nurses across the country to address these concerns was evident. There has been a major shift over the past ten years from inpatient to outpatient treatment in oncology (Chabot & Fox, 2005). This shift has resulted in numerous unique challenges for the pediatric oncology nurse. Challenges include lack of staffing resources for fluctuating patient volume and acuity, telephone triage volume and management, home care patient issues, scheduling systems, patient flow and wait time, and multi-institutional communication. This article reports the results of the APHON workshop which utilized the evidence from adult ambulatory oncology literature and standards and the recommendations of the expert pediatric oncology nurse participants to develop global statements about pediatric oncology ambulatory practice standards. The energy and productivity of the group was evidence of a common theme and demand for attention to the ambulatory nursing staff and practice. The ability to identify common threads and reach consensus with powerful statements of practice supports the continued use of such forums to move practice forward. C1 [Conley, Susanne B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Curry, Joan O'Hanlon] Childrens Hosp Montefiore, Pediat Ambulatory Hematol Oncol Program, Bronx, NY USA. [Hines, Melissa] Seattle Childrens Hosp, Seattle, WA USA. [Schmidt, Kaye] Childrens Med Ctr, Dallas, TX USA. [Zwier, Kathy] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Siever, Beth] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Mirisola, Therese] Childrens Hosp & Reg Med Ctr, Seattle, WA USA. [Burke, Susie] Childrens Hosp Wisconsin, MACC Fund Ctr Canc & Blood Disorders, Milwaukee, WI USA. [Thom, Bridgette; Kline, Nancy E.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. RP Conley, SB (reprint author), 6 Whiting Lane, Plymouth, MA 02360 USA. EM susanne_conley@dfci.harvard.edu NR 9 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1043-4542 J9 J PEDIATR ONCOL NURS JI J. Pediatr. Oncol. Nurs. PD JAN-FEB PY 2010 VL 27 IS 1 BP 6 EP 9 DI 10.1177/1043454209344577 PG 4 WC Oncology; Nursing SC Oncology; Nursing GA 536ZB UT WOS:000273081400002 PM 19897837 ER PT J AU Tabaddor, RR Banffy, MB Andersen, JS McFeely, E Ogunwole, O Micheli, LJ Kocher, MS AF Tabaddor, Ramin R. Banffy, Michael B. Andersen, Jason S. McFeely, Eric Ogunwole, Olabode Micheli, Lyle J. Kocher, Mininder S. TI Fixation of Juvenile Osteochondritis Dissecans Lesions of the Knee Using Poly 96L/4D-lactide Copolymer Bioabsorbable Implants SO JOURNAL OF PEDIATRIC ORTHOPAEDICS LA English DT Article DE osteochondritis dissecans; knee; bioabsorbable; implants; SmartNail ID INTERNAL-FIXATION; FEMORAL CONDYLES; BIODEGRADABLE PINS; FRACTURE FIXATION; ARTHROSCOPIC USE; HERBERT SCREW; IN-VITRO; FRAGMENTS; DEGRADATION; BIOFIX(R) AB Background: The fixation of juvenile osteochondritis dissecans (OCD) lesions has been described using metal implants, staples, bone pegs, and bioabsorbable implants. Bioabsorbable fixation has potential benefits including not requiring a second surgery for implant removal, no interference on postoperative magnetic resonance imaging (MRI) scans, and a potentially lower incidence of prominent hardware. The possible complications of bioabsorbable fixation include synovitis, loss of fixation owing to noncompressive properties, and sterile abscess formation. The results of bioabsorbable fixation of juvenile OCD lesions of the knee have not been well studied. The purpose of this study was to evaluate the efficacy and safety of a bioabsorbable copolymer fixation in the management of unstable OCD lesions of the knee in adolescents. Methods: This is a retrospective case series of patients with unstable OCD lesions of the knee that were treated with poly 96L/4D-lactide copolymer bioabsorable implants. Information was gathered through 3 standardized and validated knee-function questionnaires, participants' medical records, plain films, MRIs, and pain level and satisfaction scale questionnaires. Results: Twenty-four knees in 24 patients were evaluated. The mean age at the time of surgery was 14.4 years. The mean follow-up was 39.6 months. The mean International Knee Documentation Committee score at follow-up was 84.9, the mean Lysholm score was 88.0, and the mean Tegner score was 7.9. Plain films at an average of 19.2 months postoperatively revealed interval healing in 9 patients, no significant change in 1 patient, complete healing in 13 patients, and loose bodies with no interval healing in 1 patient. MRIs were obtained postoperatively in 17 knees, with a mean follow-up of 22.4 months. Interval healing was present in 16 of 17 MRIs, consistent with the plain film findings. Twenty-two of 24 patients had good-to-excellent outcomes. Conclusion: Poly 96L/4D-lactide copolymer bioabsorable implants seem to be safe and effective for the management of unstable juvenile OCD lesions of the knee. They offer stability for the healing OCD lesions, with minimal reaction from degradation products. C1 [Tabaddor, Ramin R.; Banffy, Michael B.; Andersen, Jason S.; McFeely, Eric; Ogunwole, Olabode; Micheli, Lyle J.; Kocher, Mininder S.] Harvard Univ, Childrens Hosp, Sch Med, Div Sports Med,Dept Orthopaed Surg, Boston, MA 02115 USA. RP Banffy, MB (reprint author), Massachusetts Gen Hosp, Harvard Combinded Orthopaed Residency Program, Dept Orthopaed Surg, 55 Fruit St,WHT 535, Boston, MA 02114 USA. EM mbanffy@partners.org NR 45 TC 23 Z9 23 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-6798 J9 J PEDIATR ORTHOPED JI J. Pediatr. Orthop. PD JAN-FEB PY 2010 VL 30 IS 1 BP 14 EP 20 DI 10.1097/BPO.0b013e3181c6318c PG 7 WC Orthopedics; Pediatrics SC Orthopedics; Pediatrics GA 538QF UT WOS:000273198300003 PM 20032736 ER PT J AU Christison-Lagay, ER Rodriguez, L Kurtz, M Pierre, KS Doody, DP Goldstein, AM AF Christison-Lagay, Emily R. Rodriguez, Leonel Kurtz, Michael Pierre, Kristin St. Doody, Daniel P. Goldstein, Allan M. TI Antegrade colonic enemas and intestinal diversion are highly effective in the management of children with intractable constipation SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 40th Annual Meeting of the American-Pediatric-Surgical-Association CY MAY 28-JUN 01, 2009 CL Fajardo, PR SP Amer Pediat Surg Assoc DE Constipation; Colonic dysmotility; Ileostomy; Colostomy; Antegrade colonic enemas; Colectomy ID SLOW-TRANSIT CONSTIPATION; IDIOPATHIC MEGARECTUM; CONTINENCE ENEMA; DEFECATION DISORDERS; COLECTOMY; MEGACOLON; EXPERIENCE; CECOSTOMY; MANOMETRY; RESECTION AB Purpose: Intractable constipation in children is an uncommon but debilitating condition. When medical therapy fails, surgery is warranted; but the optimal surgical approach has not been clearly defined. We reviewed our experience with operative management of intractable constipation to identify predictors of success and to compare outcomes after 3 surgical approaches: antegrade continence enema (ACE), enteral diversion, and primary resection. Methods: A retrospective review of pediatric patients undergoing ACE, diversion, or resection for intractable, idiopathic constipation from 1994 to 2007 was performed. Satisfactory outcome was defined as minimal fecal soiling and passage of stool at least every other day (ACE, resection) or functional enterostomy without abdominal distension (diversion). Results: Forty-four patients (range = 1-26 years, mean = 9 years) were included. Sixteen patients underwent ACE, 19 underwent primary diversion (5 ileostomy, 14 colostomy), and 9 had primary colonic resections. Satisfactory outcomes were achieved in 63%, 95%, and 22%, respectively. Of the 19 patients diverted, 14 had intestinal continuity reestablished at a mean of 27 months postdiversion, with all of these having a satisfactory outcome at an average follow-up of 56 months. Five patients underwent closure of the enterostomy without resection, whereas the remainder underwent resection of dysmotile colon based on preoperative colonic manometry studies. Of those undergoing ACE procedures, age younger than 12 years was a predictor of success, whereas preoperative colonic manometry was not predictive of outcome. Second manometry 1 year post-ACE showed improvement in all patients tested. On retrospective review, patient noncompliance contributed to ACE failure. Conclusions: Antegrade continence enema and enteral diversion are very effective initial procedures in the management of intractable constipation. Greater than 90% of diverted patients have an excellent outcome after the eventual restoration of intestinal continuity. Colon resection should not be offered as initial therapy, as it is associated with nearly 80% failure rate and the frequent need for additional surgery. (C) 2010 Elsevier Inc. All rights reserved. C1 [Pierre, Kristin St.; Doody, Daniel P.; Goldstein, Allan M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. [Christison-Lagay, Emily R.; Kurtz, Michael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Rodriguez, Leonel] Childrens Hosp, Dept Pediat Gastroenterol, Boston, MA 02115 USA. RP Goldstein, AM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA. EM agoldstein@partners.org FU NIDDK NIH HHS [R01DK080914] NR 26 TC 13 Z9 16 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2010 VL 45 IS 1 BP 213 EP 219 DI 10.1016/j.jpedsurg.2009.10.034 PG 7 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 553VB UT WOS:000274393800034 PM 20105606 ER PT J AU Dello Russo, NM AF Dello Russo, Nicholas M. TI Re: Influence of Recombinant Human Platelet-Derived Growth Factor on Lateral Ridge Augmentation Using Biphasic Calcium Phosphate and Guided Bone Regeneration: A Histomorphometric Study in Dogs. Schwarz F, Sager M, Ferrari D, Mihatovic I, Becker J. (J Periodontol 2009;80:1315-1323.) SO JOURNAL OF PERIODONTOLOGY LA English DT Letter C1 [Dello Russo, Nicholas M.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Div Dent, Boston, MA 02114 USA. RP Dello Russo, NM (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Div Dent, Boston, MA 02114 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD JAN PY 2010 VL 81 IS 1 BP 1 EP 1 DI 10.1902/jop.2009.090497 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 665FI UT WOS:000283020200001 PM 20059409 ER PT J AU Teles, R Sakellari, D Teles, F Konstantinidis, A Kent, R Socransky, S Haffajee, A AF Teles, Ricardo Sakellari, Dimitra Teles, Flavia Konstantinidis, Antonis Kent, Ralph Socransky, Sigmund Haffajee, Anne TI Relationships Among Gingival Crevicular Fluid Biomarkers, Clinical Parameters of Periodontal Disease, and the Subgingival Microbiota SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Cytokines; gingival crevicular fluid; matrix metalloproteinases; microbiology; periodontal diseases ID UNTREATED ADULT PERIODONTITIS; GRANULOCYTE ELASTASE; INTERLEUKIN-1-BETA; PERIODONTOPATHOGENS; PATHOGENS; SMOKING; TISSUE; PLAQUE; ALPHA; RISK AB Background: The objectives of this study were to measure levels of gingival crevicular fluid (GCF) biomarkers and subgingival bacterial species in periodontally healthy subjects and subjects with periodontitis to explore the relationships among these biomarkers, the subgingival microbiota, and the clinical parameters of periodontal disease. Methods: Clinical periodontal parameters were measured at six sites per tooth in 20 subjects with periodontitis and 20 periodontally healthy subjects. GCF and subgingival plaque samples were obtained from the mesio-buccal aspect of every tooth. GCF levels of interleukin (IL)-1 beta and IL-8 and matrix metalloproteinase 8 were measured using checkerboard immunoblotting, and the levels of 40 bacterial taxa were quantified using checkerboard DNA-DNA hybridization. A subset of "clinically healthy" sites from each group was analyzed separately. The significance of the differences between groups was determined using the unpaired t test or the Mann-Whitney test. Correlations among immunologic, microbiologic, and clinical data were determined using the Spearman rank correlation coefficient. Results: There were positive correlations among mean clinical parameters, mean levels of the three biomarkers, and the proportions of orange and red complex species (P < 0.05). Clinically healthy sites from subjects with periodontitis had higher levels of IL-1 beta and IL-8 and higher proportions of orange and red complex species (P < 0.05) than clinically healthy sites from periodontally healthy subjects. Red complex species were positively associated with the expression of all biomarkers (P < 0.05), whereas purple and yellow complex species had negative correlations with IL-1 beta and IL-8 (P < 0.05). Conclusions: Clinically healthy sites from subjects with periodontitis have higher levels of GCF biomarkers and periodontal pathogens than clinically healthy sites from periodontally healthy subjects. Different microbial complexes demonstrated distinct associations with specific GCF biomarkers. J Periodontol 2010;81:89-98. C1 [Teles, Ricardo; Teles, Flavia; Kent, Ralph; Socransky, Sigmund; Haffajee, Anne] Forsyth Inst, Dept Periodontol, Boston, MA 02115 USA. [Sakellari, Dimitra; Konstantinidis, Antonis] Aristotle Univ Thessaloniki, Dept Periodontol, GR-54006 Thessaloniki, Greece. RP Teles, R (reprint author), Forsyth Inst, Dept Periodontol, 140 Fenway, Boston, MA 02115 USA. EM rteles@forsyth.org RI SAKELLARI, DIMITRA/F-3299-2011 FU National Institute of Dental and Craniofacial Research, Bethesda, Maryland [DE-016700, T32 DE-07327, DE-14242] FX This work was supported, in part, by research grants DE-016700, T32 DE-07327, and DE-14242 from the National Institute of Dental and Craniofacial Research, Bethesda, Maryland. The authors have no conflicts of interest related to this study. NR 29 TC 57 Z9 61 U1 0 U2 5 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD JAN PY 2010 VL 81 IS 1 BP 89 EP 98 DI 10.1902/jop.2009.090397 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 665FI UT WOS:000283020200013 PM 20059421 ER PT J AU Osman, A Gutierrez, PM Smith, K Fang, QJ Lozano, G Devine, A AF Osman, Augustine Gutierrez, Peter M. Smith, Kimberly Fang, Qijuan Lozano, Gregorio Devine, Aimee TI The Anxiety Sensitivity Index-3: Analyses of Dimensions, Reliability Estimates, and Correlates in Nonclinical Samples SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID NEGATIVE AFFECT; PSYCHOMETRIC PROPERTIES; CONSTRUCT-VALIDITY; VALIDATION; BIFACTOR; PANAS; DISORDERS; MODELS; SCALES; ISSUES AB We investigated the factor structure, reliability estimates, and correlates of the Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) in 2 studies. We established a bifactor model in Study 1 as an alternative representation of the structure of the ASI-3. Analyses of gender differences on the total ASI-3 and subscale scores were not statistically significant (Study 1, N = 462). In Study 2 (N = 293), results of a series of confirmatory factor analyses provided stronger support for the fit of the bifactor model compared with 2 alternative models. Estimates of scale reliability were adequate (all values epsilon .80) and not opo (as in italic p for significance). in the 2 studies. In addition, using simultaneous regression analyses, we found anxiety-specific correlates for the total ASI-3 and subscale scores to include responses on self-report measures of interpersonal sensitivity, obsessive-compulsive anxiety, paranoid ideation, and phobic anxiety. C1 [Osman, Augustine; Smith, Kimberly; Lozano, Gregorio; Devine, Aimee] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA. [Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA. [Fang, Qijuan] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. RP Osman, A (reprint author), Univ Texas San Antonio, Dept Psychol, 1 UTSA Circle, San Antonio, TX 78249 USA. EM augustine.osman@utsa.edu NR 48 TC 31 Z9 33 U1 6 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2010 VL 92 IS 1 BP 45 EP 52 AR PII 917722372 DI 10.1080/00223890903379332 PG 8 WC Psychology, Clinical; Psychology, Social SC Psychology GA 531PM UT WOS:000272680300005 PM 20013455 ER PT J AU Smith, SR Chang, J Kochinski, S Patz, S Nowinski, LA AF Smith, Steven R. Chang, Jenss Kochinski, Sivan Patz, Sarah Nowinski, Lisa A. TI Initial Validity of the Logical Rorschach in the Assessment of Trauma SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID COMPREHENSIVE SYSTEM; INTERRATER RELIABILITY; POSTTRAUMATIC-STRESS; FORENSIC SETTINGS; INKBLOT METHOD; SEXUAL-ABUSE; DATA SETS; VETERANS; SAMPLE; METAANALYSIS AB Wagner's (2001) Logical Rorschach (LR) was designed to be a simple but reliable and valid system for assessing psychological distress and cognitive slippage using the Rorschach Inkblot Method (Exner, 2003). In this investigation, we administered the Rorschach to 50 adults with and without trauma histories. Scoring of the test followed both the Comprehensive System (CS; Exner, 2003) and the LR guidelines. Results indicate that the Perceptual Thinking Index (Exner, 2000, 2003), the CS-derived Trauma Content Index (Armstrong Loewenstein, 1990) and Aggressive Past (Gacono Meloy, 1994), and the LR Perceptual Accuracy Score (Wagner, 2001) scores were able to differentiate the 2 groups. Despite largely equivocal findings, it appears that some aspects of the LR may have some validity in the assessment of trauma-related phenomena. C1 [Smith, Steven R.; Chang, Jenss; Patz, Sarah] Univ Calif Santa Barbara, Dept Counseling Clin & Sch Psychol, Santa Barbara, CA 93106 USA. [Nowinski, Lisa A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Nowinski, Lisa A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Smith, SR (reprint author), Univ Calif Santa Barbara, Dept Counseling Clin & Sch Psychol, Santa Barbara, CA 93106 USA. EM ssmith@education.ucsb.edu NR 64 TC 4 Z9 4 U1 2 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0022-3891 EI 1532-7752 J9 J PERS ASSESS JI J. Pers. Assess. PY 2010 VL 92 IS 3 BP 222 EP 231 AR PII 921412763 DI 10.1080/00223891003670174 PG 10 WC Psychology, Clinical; Psychology, Social SC Psychology GA 594PO UT WOS:000277549800004 PM 20408022 ER PT J AU Breshears, RE Brenner, LA Harwood, JEF Gutierrez, PM AF Breshears, Ryan E. Brenner, Lisa A. Harwood, Jeri E. F. Gutierrez, Peter M. TI Predicting Suicidal Behavior in Veterans With Traumatic Brain Injury: The Utility of the Personality Assessment Inventory SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID PSYCHIATRIC-PATIENTS; MMPI-2 PROFILES; HEAD-INJURY; POPULATION; IRAQ; TBI; AFGHANISTAN; DEPRESSION; RISK AB In this study, we investigated the Personality Assessment Inventory's (PAI; Morey, 1991, 2007) Suicide Potential Index (SPI) and Suicide Ideation scale (SUI) as predictors of suicidal behavior (SB) in military Veterans with traumatic brain injury (TBI; N = 154). We analyzed electronic medical records were searched for SB in the 2 years post-PAI administration and data via logistic regressions. We obtained statistical support for the SPI and SUI as predictors of SB. Analyses we performed using receiver operating characteristics suggested an optimal SPI cutoff of epsilon 15 for this sample. Findings suggest that SPI and SUI scores may assist in assessing suicide risk in those with TBI, particularly when population-based cutoffs are considered. C1 [Breshears, Ryan E.; Brenner, Lisa A.; Harwood, Jeri E. F.; Gutierrez, Peter M.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. [Brenner, Lisa A.; Gutierrez, Peter M.] Univ Colorado, Denver Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Phys Med & Rehabil, Boulder, CO 80309 USA. [Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Neurol, Boulder, CO 80309 USA. [Harwood, Jeri E. F.] Univ Colorado, Denver Sch Med, Dept Pediat, Boulder, CO 80309 USA. RP Breshears, RE (reprint author), WellStar Hlth Syst, 2000 S Pk Pl, Atlanta, GA 30339 USA. EM ryan.breshears@wellstar.org NR 43 TC 5 Z9 5 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2010 VL 92 IS 4 BP 349 EP 355 AR PII 923051207 DI 10.1080/00223891.2010.482011 PG 7 WC Psychology, Clinical; Psychology, Social SC Psychology GA 611EL UT WOS:000278794000007 PM 20552509 ER PT J AU Kiziltepe, T Anderson, KC Kutok, JL Jia, L Boucher, KM Saavedra, JE Keefer, LK Shami, PJ AF Kiziltepe, Tanyel Anderson, Kenneth C. Kutok, Jeffery L. Jia, Lee Boucher, Kenneth M. Saavedra, Joseph E. Keefer, Larry K. Shami, Paul J. TI JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo SO JOURNAL OF PHARMACY AND PHARMACOLOGY LA English DT Article DE angiogenesis; HUVEC; JS-K; myeloma; nitric oxide ID BONE-MARROW ANGIOGENESIS; NITRIC-OXIDE MODULATION; LEUKEMIA-CELLS; S-GLUTATHIONYLATION; PROGNOSTIC VALUE; GENE-EXPRESSION; DIFFERENTIATION; RESISTANCE; APOPTOSIS; GROWTH AB Objectives Glutathione S-transferases (GSTs) play an important role in multidrug resistance and are upregulated in multiple cancers. We have designed a prodrug class that releases nitric oxide on metabolism by GST. O(2-)(2,4-Dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K, a member of this class) has potent antineoplastic activity. Methods We studied the effect of JS-K on angiogenesis in human umbilical vein endothelial cells (HUVECs), OPM1 multiple myeloma cells, chick aortic rings and in mice. Key findings JS-K inhibited the proliferation of HUVECs with a 50% inhibitory concentration (IC50) of 0.432, 0.466 and 0.505 mu M at 24, 48 and 72 h, respectively. In the cord formation assay, JS-K led to a decrease in the number of cord junctions and cord length with an IC50 of 0.637 and 0.696 mu M, respectively. JS-K inhibited cell migration at 5 h using VEGF as a chemoattractant. Migration inhibition occurred with an IC50 of 0.493 mu M. In the chick aortic ring assay using VEGF or FGF-2 for vessel growth stimulation, 0.5 mu M JS-K completely inhibited vessel growth. JS-K inhibited tumour angiogenesis in vivo in NIH III mice implanted subcutaneously with OPM1 multiple myeloma cells. Conclusions JS-K is a potent inhibitor of angiogenesis in vitro and tumour vessel growth in vivo. As such, it establishes a new class of antineoplastic agent that targets the malignant cells directly as well as their microenvironment. C1 [Kiziltepe, Tanyel; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Kutok, Jeffery L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Kutok, Jeffery L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Jia, Lee] NCI, Dev Therapeut Branch, Rockville, MD USA. [Boucher, Kenneth M.; Shami, Paul J.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA. [Saavedra, Joseph E.] SAIC Frederick, Frederick, MD USA. [Keefer, Larry K.] NCI, Comparat Carcinogenesis Lab, Frederick, MD 21701 USA. [Shami, Paul J.] Univ Utah, Dept Internal Med, Div Med Oncol, Salt Lake City, UT 84112 USA. RP Shami, PJ (reprint author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Suite 2100,2000 Circle Hope, Salt Lake City, UT 84112 USA. EM paul.shami@utah.edu RI Keefer, Larry/N-3247-2014; OI Keefer, Larry/0000-0001-7489-9555; Boucher, Kenneth/0000-0003-2833-0127 FU Leukemia and Lymphoma Society; NCI RAID; NIH [R01 CA84496, R01 CA129611]; National Cancer Institute [N01-CO-12400]; Center for Cancer Research FX We acknowledge Jagadambal Thillainathan (SAIC-Frederick, Frederick, USA) for technical assistance. This work was funded by the Translational Research Award from the Leukemia and Lymphoma Society, NCI RAID Grant, NIH Grants R01 CA84496 and R01 CA129611 (P.J.S) and the National Cancer Institute contract No. N01-CO-12400. It was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The following contributions were made by the authors: Tanyel Kiziltepe performed research, reviewed and edited the manuscript; Kenneth C. Anderson oversaw research, reviewed and edited the manuscript; Jeffery Kutok performed research, reviewed and edited the manuscript; Lee Jia oversaw research, reviewed and edited the manuscript; Kenneth M. Boucher performed statistical analysis, reviewed and edited the manuscript; Joseph E. Saavedra designed, synthesized and provided JS-K and reviewed and edited the manuscript; Larry K. Keefer designed J-S-K and reviewed and edited the manuscript; Paul J. Shami analysed and interpreted data and wrote the manuscript. NR 25 TC 12 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3573 J9 J PHARM PHARMACOL JI J. Pharm. Pharmacol. PD JAN PY 2010 VL 62 IS 1 BP 145 EP 151 DI 10.1211/jpp/62.01.0017 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 554XV UT WOS:000274470700017 PM 20723011 ER PT J AU Saydam, O Senol, O Schaaij-Visser, TBM Pham, TV Piersma, SR Stemmer-Rachamimov, AO Wurdinger, T Peerdeman, SM Jimenez, CR AF Saydam, Okay Senol, Ozlem Schaaij-Visser, Tieneke B. M. Pham, Thang V. Piersma, Sander R. Stemmer-Rachamimov, Anat O. Wurdinger, Thomas Peerdeman, Saskia M. Jimenez, Connie R. TI Comparative Protein Profiling Reveals Minichromosome Maintenance (MCM) Proteins As Novel Potential Tumor Markers for Meningiomas SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE meningiomas; proteomics; tumor markers; MCMs ID PROGESTERONE-RECEPTOR EXPRESSION; DNA-REPLICATION; STATISTICAL-MODEL; GENETIC MODEL; CANCER; NF2; PROGRESSION; RECURRENCE; BENIGN; MIB-1 AB Meningiomas are among the most frequent tumors of the brain and spinal cord accounting for 15-20% of all central nervous system tumors and frequently associated with neurofibromatosis type 2. In this study, we aimed to unravel molecular meningioma tumorigenesis and discover novel protein biomarkers for diagnostic and/or prognostic purposes and performed in-depth proteomic profiling of meningioma cells compared to human primary arachnoidal cells. We isolated proteins from meningioma cell line SF4433 and human primary arachnoidal cells and analyzed the protein profiles by Gel-nanoLC-MS/MS in conjunction with protein identification and quantification by shotgun nanoLC tandem mass spectrometry and spectral counting. Differential analysis of meningiomas revealed changes in the expression levels of 281 proteins (P < 0.01) associated with various biological functions such as DNA replication, recombination, cell cycle, and apoptosis. Among several interesting proteins, we focused on a subset of the highly significantly up-regulated proteins, the minichromosome maintenance (MCM) family. We performed subsequent validation studies by qRT-PCR in human meningioma tissue samples (WHO grade I, 14 samples; WHO grade II, 7 samples; and WHO grade III, 7 samples) compared to arachnoidal tissue controls (from fresh autopsies; 3 samples) and found that MCMs are highly and significantly up-regulated in human meningioma tumor samples compared to arachnoidal tissue controls. We found a significant increase in MCM2 (8 fold), MCM3 (5 fold), MCM4 (4 fold), MCM5 (4 fold), MCM6 (3 fold), and MCM7 (5 fold) expressions in meningiomas. This study suggests that MCM family proteins are up-regulated in meningiomas and can be used as diagnostic markers. C1 [Schaaij-Visser, Tieneke B. M.; Pham, Thang V.; Piersma, Sander R.; Jimenez, Connie R.] Vrije Univ Amsterdam Med Ctr, OncoProte Lab, Dept Med Oncol, VUmc Canc Ctr Amsterdam, Amsterdam, Netherlands. [Saydam, Okay; Senol, Ozlem] Harvard Univ, Dept Neurol, Sch Med, Boston, MA 02129 USA. [Saydam, Okay; Senol, Ozlem] Harvard Univ, Dept Radiol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02129 USA. [Saydam, Okay; Senol, Ozlem] Harvard Univ, Neurosci Program, Sch Med, Boston, MA 02129 USA. [Stemmer-Rachamimov, Anat O.] Harvard Univ, Mol Neurooncol Lab, Sch Med, Boston, MA 02129 USA. [Stemmer-Rachamimov, Anat O.] Harvard Univ, Dept Pathol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02129 USA. Vrije Univ Amsterdam Med Ctr, Neurooncol Res Grp, Amsterdam, Netherlands. [Peerdeman, Saskia M.] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands. RP Jimenez, CR (reprint author), Vrije Univ Amsterdam Med Ctr, OncoProte Lab, Dept Med Oncol, VUmc Canc Ctr Amsterdam, Amsterdam, Netherlands. EM osaydam@partners.org; c.jimenez@vumc.nl FU Children's Tumor Foundation [2007-01-043]; NINDS [NS24279]; VUmc-Cancer Center Amsterdam FX This study was supported by the Children's Tumor Foundation 2007-01-043 (O.S.) and NINDS NS24279 (O.S.). We thank Ms. Silvina A. Fratantoni for assistance with the SDS-PAGE and in-gel digestion of the samples, Marianne F. James for human primary arachnoidal cells (Massachusetts General Hospital), and Dr. Xandra O. Breakefield for providing laboratory facilities for this work. The VUmc-Cancer Center Amsterdam is acknowledged for financial support for the proteornics infrastructure (T.V.P. and C.R.J.). NR 58 TC 25 Z9 28 U1 1 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD JAN PY 2010 VL 9 IS 1 BP 485 EP 494 DI 10.1021/pr900834h PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 539PI UT WOS:000273267900046 PM 19877719 ER PT J AU Inslicht, SS McCaslin, SE Metzler, TJ Henn-Haase, C Hart, SL Maguen, S Neylan, TC Marmar, CR AF Inslicht, Sabra S. McCaslin, Shannon E. Metzler, Thomas J. Henn-Haase, Clare Hart, Stacey L. Maguen, Shira Neylan, Thomas C. Marmar, Charles R. TI Family psychiatric history, peritraumatic reactivity, and posttraumatic stress symptoms: A prospective study of police SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Family history; Police stress; Peritraumatic distress; Posttraumatic stress disorder; Substance use ID DISORDER SYMPTOMS; CHILDHOOD TRAUMA; ENVIRONMENTAL-INFLUENCES; ANXIETY DISORDERS; MENTAL-DISORDERS; SUBSTANCE-ABUSE; ALCOHOL-ABUSE; RISK-FACTORS; PTSD; TWIN AB Background: Family history of psychiatric and substance use disorders has been associated with posttraumatic stress disorder (PTSD) in cross-sectional studies. Method: Using a prospective design, we examined the relationships of family history of psychiatric and substance use disorders to posttraumatic stress symptoms in 278 healthy police recruits. During academy training, recruits were interviewed on family and personal psychopathology, prior cumulative civilian trauma exposure, and completed self-report questionnaires on nonspecific symptoms of distress and alcohol use. Twelve months after commencement of active duty, participants completed questionnaires on critical incident exposure over the previous year, peritraumatic distress to the worst critical incident during this time, and posttraumatic stress symptoms. Results: A path model indicated: (1) family loading for mood and anxiety disorders had an indirect effect on posttraumatic stress symptoms at 12 months that was mediated through peritraumatic distress to the officer's self-identified worst critical incident, (2) family loading for substance use disorders also predicted posttraumatic stress symptoms at 12 months and this relationship was mediated through peritraumatic distress. Conclusion: These findings support a model in which family histories of psychopathology and substance abuse are pre-existing vulnerability factors for experiencing greater peritraumatic distress to critical incident exposure which, in turn, increases the risk for development of symptoms of posttraumatic stress disorder. Replication in other first responders, military and civilians will be important to determine generalizability of these findings. Published by Elsevier Ltd. C1 [Inslicht, Sabra S.; McCaslin, Shannon E.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Inslicht, Sabra S.; McCaslin, Shannon E.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hart, Stacey L.] Ryerson Univ, Toronto, ON, Canada. RP Inslicht, SS (reprint author), Vet Affairs Med Ctr, PTSD Res Program, 4150 Clement St 116P, San Francisco, CA 94121 USA. EM Sabra.Inslicht@ucsf.edu RI Hart, Stacey/E-4819-2011 FU National Institute of Mental Health [R01 - MH056350-06] FX Funding for this study was provided by National Institute of Mental Health Grant (R01 - MH056350-06) to Dr. Marmar; the NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 59 TC 15 Z9 15 U1 4 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2010 VL 44 IS 1 BP 22 EP 31 DI 10.1016/j.jpsychires.2009.05.011 PG 10 WC Psychiatry SC Psychiatry GA 555HG UT WOS:000274499100004 PM 19683259 ER PT J AU Manoach, DS Tahkkar, KN Stroynowski, E Ely, A McKinley, SK Wamsley, E Djonlagic, I Vangel, MG Goff, DC Stickgold, R AF Manoach, Dara S. Tahkkar, Katharine N. Stroynowski, Eva Ely, Alice McKinley, Sophia K. Wamsley, Erin Djonlagic, Ina Vangel, Mark G. Goff, Donald C. Stickgold, Robert TI Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Sleep; Schizophrenia; Procedural learning; Motor skill; Memory; Consolidation ID PRIMARY MOTOR CORTEX; SLOW-WAVE SLEEP; NON-REM SLEEP; MEMORY CONSOLIDATION; ANTIPSYCHOTIC-DRUGS; DEPENDENT CHANGES; DELTA SLEEP; SPINDLES; PERFORMANCE; DISCRIMINATION AB We previously reported that patients with schizophrenia failed to demonstrate normal sleep-dependent improvement in motor procedural learning. Here, we tested whether this failure was associated with the duration of Stage 2 sleep in the last quartile of the night (S2q4) and with spindle activity during this epoch. Fourteen patients with schizophrenia and 15 demographically matched controls performed a motor sequence task (MST) before and after a night of polysomnographically monitored sleep. Patients showed no significant overnight task improvement and significantly less than controls, who did show significant improvement. While there were no group differences in overall sleep architecture, patients showed significant reductions in fast sigma frequency power (45%) and in spindle density (43%) during S2q4 sleep at the electrode proximal to the motor cortex controlling the hand that performed the MST. Although spindle activity did not correlate with ovemight improvement in either group, S2q4 sleep duration in patients significantly correlated with the plateau level of overnight improvement seen at the end of the morning testing session, and slow wave sleep (SWS) duration correlated with the delay in reaching this plateau. SWS and S2q4 sleep each predicted the initial level of overnight improvement in schizophrenia, and their product explained 77% of the variance, suggesting that both sleep stages are necessary for consolidation. These findings replicate our prior observation of reduced sleep-dependent consolidation of motor procedural learning in schizophrenia and link this deficit to specific sleep stages. They provide further evidence that sleep is an important contributor to cognitive deficits in schizophrenia. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Manoach, Dara S.; Tahkkar, Katharine N.; Goff, Donald C.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Vangel, Mark G.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. [Manoach, Dara S.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Stroynowski, Eva; Ely, Alice; McKinley, Sophia K.; Wamsley, Erin; Djonlagic, Ina; Stickgold, Robert] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Manoach, Dara S.; Tahkkar, Katharine N.; Stroynowski, Eva; Ely, Alice; McKinley, Sophia K.; Wamsley, Erin; Djonlagic, Ina; Vangel, Mark G.; Goff, Donald C.; Stickgold, Robert] Harvard Univ, Sch Med, Boston, MA 02215 USA. RP Manoach, DS (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 149 13th St,Room 2608, Charlestown, MA 02129 USA. EM dara@nmr.mgh.harvard.edu OI Thakkar, Katharine/0000-0002-0026-2030 FU Mallinckrodt General Clinical Research Centers Program at Massachusetts General Hospital [M01-RR-01066]; NIMH [MH48832]; NIH T32 [HL07901-10] FX Support from: Mallinckrodt General Clinical Research Centers Program at Massachusetts General Hospital (M01-RR-01066); NIMH (MH48832) and NIH T32 training grant HL07901-10 to the Harvard Division of Sleep Medicine. We are grateful to the staff of the Mallinckrodt GCRC program, particularly Mary Sullivan, RN, for their support. NR 54 TC 50 Z9 51 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2010 VL 44 IS 2 BP 112 EP 120 DI 10.1016/j.jpsychires.2009.06.011 PG 9 WC Psychiatry SC Psychiatry GA 562RN UT WOS:000275071600008 PM 19665729 ER PT J AU Davidson, JR Zhang, W Connor, KM Ji, J Jobson, K Lecrubier, Y McFarlane, AC Newport, DJ Nutt, DJ Osser, DN Stein, DJ Stowe, ZN Tajima, O Versiani, M AF Davidson, J. R. Zhang, W. Connor, K. M. Ji, J. Jobson, K. Lecrubier, Y. McFarlane, A. C. Newport, D. J. Nutt, D. J. Osser, D. N. Stein, D. J. Stowe, Z. N. Tajima, O. Versiani, M. TI A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) SO JOURNAL OF PSYCHOPHARMACOLOGY LA English DT Review DE algorithm; generalised anxiety disorder; international psychopharmacology algorithm project; pharmacotherapy ID PLACEBO-CONTROLLED TRIAL; OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN-REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; VENLAFAXINE EXTENDED-RELEASE; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR-THERAPY; ADD-ON TREATMENT; ASSOCIATION-FOR-PSYCHOPHARMACOLOGY AB Generalised anxiety disorder (GAD) is defined as excessive and uncontrollable worry and anxiety about everyday life situations. It is a chronic disorder, and is associated with substantial somatisation, high rates of comorbid depression and other anxiety disorders, and significant disability. The evidence base for pharmacotherapy and psychotherapy has continued to grow, and a wide range of drug choices for GAD now exists. Current guidelines for GAD generally restrict themselves to presentation of the evidence for various treatments, which, as a result, generally do not offer detailed discussion or recommendation of strategies beyond the first level of treatment, or take into account the individual circumstances of the patient. Thus, there is a lack of algorithm-based treatment guidelines for GAD. Our aim is, therefore, to present an algorithm for the psychopharmacologic management of GAD, intended for all clinicians who treat patients with GAD, where issues of pharmacotherapy are under consideration. We also hope that these GAD algorithms and other guidelines can help to identify high-priority areas that need further study. In this algorithm, we provide a sequenced approach to the pharmacotherapy of GAD, taking into account salient symptomatology and comorbidity, levels of evidence and extent of response. Special issues, including comorbidity, insomnia, suicidality, substance abuse, treatment adherence, pregnancy and lactation, cross-cultural issues, use of medication in the elderly, psychosocial treatment and dosing issues are also addressed. C1 [Davidson, J. R.; Zhang, W.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA. [Connor, K. M.] Merck & Co Inc, Merck Res Labs, Clin Neurosci & Ophthalmol, N Wales, PA USA. [Ji, J.] Fudan Univ, Shanghai Med Sch, Dept Mental Hlth, Shanghai, Peoples R China. [Ji, J.] Zhongshan Hosp, Dept Psychol Med, Shanghai, Peoples R China. [Jobson, K.] Univ Tennessee, Dept Psychiat, Knoxville, TN USA. [Lecrubier, Y.] Hop La Pitie Salpetriere, European Coll Neuropsychopharmacol, Paris, France. [McFarlane, A. C.] Univ Adelaide, Ctr Mil & Vet Hlth, Adelaide, SA, Australia. [Newport, D. J.; Stowe, Z. N.] Emory Univ, Sch Med, Womens Mental Hlth Program, Atlanta, GA USA. [Nutt, D. J.] Univ Bristol, Dept Community Based Med, Psychopharmacol Unit, Bristol, Avon, England. [Osser, D. N.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Brockton, MA 02401 USA. [Stein, D. J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [Tajima, O.] Kyorin Univ, Sch Hlth Sci, Dept Mental Hlth, Tokyo, Japan. [Versiani, M.] Univ Fed Rio de Janeiro, Inst Psychiat, Rio De Janeiro, Brazil. RP Zhang, W (reprint author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Box 3812, Durham, NC 27710 USA. EM wei.zhang@duke.edu RI Newport, Donald/H-9846-2013; Stein, Dan/A-1752-2008 OI Stein, Dan/0000-0001-7218-7810 FU International Psychopharmacology Algorithm Project (IPAP) FX This project is supported by a grant from the International Psychopharmacology Algorithm Project (IPAP). Thanks also to Paul Nordstrom August, Dean Hartley, David Penniman and Oakley Ray as consultants for the project. NR 200 TC 21 Z9 23 U1 4 U2 25 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-8811 J9 J PSYCHOPHARMACOL JI J. Psychopharmacol. PD JAN PY 2010 VL 24 IS 1 BP 3 EP 26 DI 10.1177/0269881108096505 PG 24 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 551DR UT WOS:000274186600001 PM 18832431 ER PT J AU Kornblith, AB Mirabeau-Beale, K Lee, H Goodman, AK Penson, RT Pereira, L Matulonis, UA AF Kornblith, Alice B. Mirabeau-Beale, Kristina Lee, Hang Goodman, Anne Kathryn Penson, Richard T. Pereira, Lauren Matulonis, Ursula A. TI Long-Term Adjustment of Survivors of Ovarian Cancer Treated for Advanced-Stage Disease SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE adjustment; quality of life; ovarian cancer; survivor; psychosocial ID QUALITY-OF-LIFE; BREAST-CANCER; FUNCTIONAL-ASSESSMENT; CLINICAL-TRIALS; PSYCHOLOGIC DISTRESS; LEUKEMIA SURVIVORS; ONCOLOGY-GROUP; SCALE; QUESTIONNAIRE; INSTRUMENT AB This study described the long-term adjustment of 42 ovarian cancer survivors diagnosed with advanced-stage disease with no evidence of recurrence, a mean of 6.1 years postdiagnosis. 64% of survivors' mental health was at or above the norm of medical outpatients (Mental Health Inventory-17). No patients reported post-traumatic stress disorder at a diagnosable level (Post-Traumatic Stress Disorder (PTSD) Checklist-Civilian). The majority of survivors (epsilon 75%) reported a positive impact of cancer on their lives (Impact of Cancer Scale) and excellent social support (Medical Outcomes Study Social Support Survey). However, a subset of survivors reported needing more help than was received regarding emotional problems (28.9%). C1 [Kornblith, Alice B.] Canc & Leukemia Grp B, Chicago, IL USA. [Mirabeau-Beale, Kristina] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA. [Lee, Hang; Goodman, Anne Kathryn; Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pereira, Lauren; Matulonis, Ursula A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kornblith, AB (reprint author), 140 8th Ave,Apt 4-O, Brooklyn, NY 11215 USA. EM akornblith@gmail.com NR 35 TC 14 Z9 14 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 EI 1540-7586 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2010 VL 28 IS 5 BP 451 EP 469 AR PII 926034105 DI 10.1080/07347332.2010.498458 PG 19 WC Psychology, Social SC Psychology GA 641UT UT WOS:000281156200001 PM 20730659 ER PT J AU Lee, BT Matsui, A Hutteman, M Lin, SJ Winer, JH Laurence, RG Frangioni, JV AF Lee, Bernard T. Matsui, Aya Hutteman, Merlijn Lin, Samuel J. Winer, Joshua H. Laurence, Rita G. Frangioni, John V. TI Intraoperative Near-infrared Fluorescence Imaging in Perforator Flap Reconstruction: Current Research and Early Clinical Experience SO JOURNAL OF RECONSTRUCTIVE MICROSURGERY LA English DT Article DE Intraoperative imaging; near-infrared fluorescence angiography; microsurgery; perforator flap; indocyanine green ID INDOCYANINE-GREEN FLUORESCENCE; LASER-INDUCED FLUORESCENCE; BREAST RECONSTRUCTION; ANGIOGRAPHY; PERFUSION; SURGERY; DESIGN; SYSTEM; LIGHT; SKIN AB Despite recent advances in perforator flap reconstruction, there can be significant variability in vessel size and location. Although preoperative evaluation may provide valuable information, real-time intraoperative methods have the potential to provide the greatest benefit. Our laboratory has developed the Fluorescence-Assisted Resection and Exploration (FLARE (TM)) near-infrared (NIR) fluorescence imaging system for intraoperative visualization of details of the underlying vasculature. The FLARE (TM) system uses indocyanine green, a safe and reliable NIR fluorophore already FDA-approved for other indications. The system has been optimized in large-animal models for the identification of perforator size, location, and perfusion and has also been translated to the clinic for use during breast reconstruction after mastectomy. In this article, we review our preclinical and clinical data, as well as literature describing the use of similar NIR fluorescence imaging systems in plastic and reconstructive surgery. C1 [Lee, Bernard T.; Lin, Samuel J.] Beth Israel Deaconess Med Ctr, Div Plast & Reconstruct Surg, Boston, MA USA. [Matsui, Aya; Hutteman, Merlijn; Laurence, Rita G.; Frangioni, John V.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA. [Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA USA. [Winer, Joshua H.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Matsui, Aya] Hokkaido Univ, Grad Sch Med, Div Canc Diagnost & Therapeut, Sapporo, Hokkaido, Japan. RP Frangioni, JV (reprint author), BIDMC, Room SL-B05,330 Brookline Ave, Boston, MA 02215 USA. EM jfrangio@bidmc.harvard.edu RI Lee, Bernard/K-1106-2016 OI Lee, Bernard/0000-0002-5533-3166 FU National Institutes of Health [R01-EB-005805, R01-CA-115296] FX We thank Barbara L. Clough for editing and Lorissa A. Moffitt and Eugenia Trabucchi for administrative assistance. This work was funded by the National Institutes of Health grants R01-EB-005805 and R01-CA-115296 to J. V. F. NR 24 TC 41 Z9 42 U1 2 U2 7 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0743-684X J9 J RECONSTR MICROSURG JI J. Reconstr. Microsurg. PD JAN PY 2010 VL 26 IS 1 BP 59 EP 65 DI 10.1055/s-0029-1244805 PG 7 WC Surgery SC Surgery GA 549VJ UT WOS:000274082100008 PM 20027541 ER PT J AU Tarlov, E Stroupe, KT AF Tarlov, Elizabeth Stroupe, Kevin T. TI Advancing veterans' healthcare using electronic data: Lessons learned from researchers in the field SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTRATIVE DATABASES; QUALITY; REHABILITATION; AMPUTATION; EVALUATE; PROGRAM C1 [Tarlov, Elizabeth; Stroupe, Kevin T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA. RP Tarlov, E (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 31 TC 1 Z9 1 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP VII EP XI DI 10.1682/JRRD.2010.08.0148 PG 5 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300001 PM 21110241 ER PT J AU Chumney, D Nollinger, K Shesko, K Skop, K Spencer, M Newton, RA AF Chumney, Douglas Nollinger, Kristen Shesko, Kristina Skop, Karen Spencer, Madeleine Newton, Roberta A. TI Ability of Functional Independence Measure to accurately predict functional outcome of stroke-specific population: Systematic review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE civilian; CVA; discharge disposition; FM; length of stay; outcomes; predictability; rehabilitation; stroke; veterans ID REHABILITATION PATIENTS; BARTHEL INDEX; RECOVERY; VETERANS; MODEL AB Stroke is a leading cause of functional impairments. The ability to quantify the functional ability of poststroke patients engaged in a rehabilitation program may assist in prediction of their functional outcome. The Functional Independence Measure (FIM) is widely used and accepted as a functional-level assessment tool that evaluates the functional status of patients throughout the rehabilitation process. From February to March 2009, we searched MEDLINE, Ovid, CINAHL, and EBSCO for full-text articles written in English. Article inclusion criteria consisted of civilian and veteran patients posthemorrhagic and ischemic stroke with an average age of 50 years or older who participated in an inpatient rehabilitation program. Articles rated 5 or higher on the PEDro (Physiotherapy Evidence Database) scale were analyzed, including one cluster randomized trial and five cohort studies. Descriptive and psychometric data were outlined for each study. Key findings, clinical usefulness of the FIM, potential biases, and suggestions for further research were summarized. Although limited, evidence exists that FIM scores can be used as an accurate predictor of outcomes in poststroke patients. C1 [Chumney, Douglas] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Murfreesboro, TN 37129 USA. [Shesko, Kristina] Henry M Jackson Fdn Advancement Mil Med Inc, Phys Therapy, Johnstown, PA USA. [Skop, Karen] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA. [Spencer, Madeleine] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Newton, Roberta A.] Temple Univ, Philadelphia, PA 19122 USA. RP Chumney, D (reprint author), Tennessee Valley Healthcare Syst, Dept Vet Affairs, Alvin C York Campus,3400 Lebanon Pike, Murfreesboro, TN 37129 USA. EM douglas.chumney@va.gov NR 26 TC 36 Z9 37 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 1 BP 17 EP 29 DI 10.1682/JRRD.2009.08.0140 PG 13 WC Rehabilitation SC Rehabilitation GA 577HH UT WOS:000276212700004 PM 20437324 ER PT J AU Arredondo, J Foote, N Pruden, JD McFarland, MJ McFarland, LV AF Arredondo, Juan Foote, Ned Pruden, Jonathan D. McFarland, Marc J. McFarland, Lynne V. TI Wounded warriors' perspectives: Helping others to heal SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 [Arredondo, Juan; Pruden, Jonathan D.] Wounded Warrior Project, Universal City, TX USA. [Foote, Ned] New York State Council, Vietnam Vet Amer, Queensbury, NY USA. [Pruden, Jonathan D.] Gainesville VA Med Ctr, Gainesville, FL USA. [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Arredondo, J (reprint author), Wounded Warrior Project, Universal City, TX USA. EM Lynne.McFarland@va.gov NR 2 TC 1 Z9 1 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP XXI EP XXVIII DI 10.1682/JRRD.2009.02.0021 PG 8 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700004 PM 20803397 ER PT J AU Russell, JA Connor, NP Hartig, GK AF Russell, John A. Connor, Nadine P. Hartig, Gregory K. TI Iontophoretic delivery of nitric oxide donor improves local skin flap viability SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE iontophoretic; necrosis; nitric oxide; NO; NO donor; rehabilitation; skin flaps; tissue; vascular supply; wound healing ID ENDOTHELIAL GROWTH-FACTOR; MUSCLE FLAP; MYOCUTANEOUS FLAPS; SURVIVAL; TISSUE; ANGIOGENESIS; REPERFUSION; ISCHEMIA; INJURY; MODEL AB The dimensions of local flaps are often limited by the vascular supply to the distal aspect of the flap. Distal flap necrosis occurs if the vascular supply is inadequate. The purpose of this study was to investigate the use of iontophoretic delivery of nitric oxide (NO) donors to a local skin flap model to improve the survival area of the flap. Thirty-two male Sprague-Dawley rats (300 g) were divided into seven experimental groups to determine the effect of iontophoretic delivery of NO on surface perfusion and flap survival area. A caudally based 3 x 11 cm dorsal skin flap was used to measure the effect of iontophoretic delivery of NO donors to a local skin flap to improve survival area of the flap. Iontophoretic delivery of the NO donors sodium nitroprusside (SNP) and diethylenetriamine NONOate (DETA-NO) resulted in a significant increase in survival area and surface perfusion when compared with sham controls. Iontophoretic delivery of saline was associated with a 13% improvement in flap survival when compared with non-treated controls. Iontophoretic delivery and subcutaneous injection of NO donors (SNP and DETA-NO) increased skin flap viability by demonstrating improved flap survival areas. The results of this study suggest that NO may serve as a postoperative treatment of skin flaps to encourage skin flap survival and prevent distal necrosis. C1 [Connor, Nadine P.] Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. [Connor, Nadine P.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53792 USA. [Hartig, Gregory K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. EM connor@surgery.wisc.edu FU Department of Veterans Affairs, Rehabilitation Research and Development Service FX This material was based on work supported by the Department of Veterans Affairs, Rehabilitation Research and Development Service. NR 27 TC 0 Z9 3 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 1 BP 61 EP 66 DI 10.1682/JRRD.2008.10.0144 PG 6 WC Rehabilitation SC Rehabilitation GA 577HH UT WOS:000276212700007 PM 20437327 ER PT J AU Souza, A Kelleher, A Cooper, R Cooper, RA Iezzoni, LI Collins, DM AF Souza, Ana Kelleher, Annmarie Cooper, Rosemarie Cooper, Rory A. Iezzoni, Lisa I. Collins, Diane M. TI Multiple sclerosis and mobility-related assistive technology: Systematic review of literature SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE assistive technology; cane; level of evidence; mobility; multiple sclerosis; quality of life; rehabilitation; scooter; walker; wheelchair ID QUALITY-OF-LIFE; OLDER-ADULTS; POWER MOBILITY; PEOPLE; INDIVIDUALS; PERFORMANCE; WHEELCHAIR; DISABILITY; DELIVERY; DEVICE AB Multiple sclerosis (MS) causes a wide variety of neurological deficits, with ambulatory impairment the most obvious cause of disability. Within 10 to 15 years of disease onset, 80% of persons with MS experience gait problems due to muscle weakness or spasticity, fatigue, and loss of balance. To facilitate mobility, persons with MS frequently use mobility assistive technology (MAT), such as canes, crutches, walkers, wheelchairs, and scooters. We systematically reviewed the published literature on MAT use among persons with MS. We used electronic reference lists such as Ovid MEDLINE and PubMed to search the literature. We located 50 articles that met the initial criteria of providing good evidence of the types of MAT devices and their benefits for individuals with MS. A limited number of articles with higher levels of evidence was found regarding benefits of MAT use specifically for persons with MS. Evidence-based literature provides the basis for the strongest method of measurable clinical performance; therefore, having a strong research study design is vital to the justification of MAT prescription and reimbursement decisions. However, a paucity of studies with higher levels of evidence-based practice exists. C1 [Souza, Ana; Kelleher, Annmarie; Cooper, Rosemarie; Cooper, Rory A.; Collins, Diane M.] Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Souza, Ana; Kelleher, Annmarie; Cooper, Rosemarie; Cooper, Rory A.; Collins, Diane M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Iezzoni, Lisa I.] Harvard Univ, Sch Med, Boston, MA USA. [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA. RP Cooper, RA (reprint author), VAPHS, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2nd Floor,151R1-HD, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU Massachusetts General Hospital National Multiple Sclerosis Society [HC 0079T]; Human Engineering Research Laboratories, Department of Veterans Affairs Pittsburgh Healthcare System FX This material was based on work supported by the Massachusetts General Hospital National Multiple Sclerosis Society (contract No. HC 0079T) and is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, Department of Veterans Affairs Pittsburgh Healthcare System. NR 53 TC 38 Z9 38 U1 2 U2 17 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 3 BP 213 EP 223 DI 10.1682/JRRD.2009.07.0096 PG 11 WC Rehabilitation SC Rehabilitation GA 609JL UT WOS:000278652400006 PM 20665347 ER PT J AU McFarland, LV Winkler, SLH Heinemann, AW Jones, M Esquenazi, A AF McFarland, Lynne V. Winkler, Sandra L. Hubbard Heinemann, Allen W. Jones, Melissa Esquenazi, Alberto TI Unilateral upper-limb loss: Satisfaction and prosthetic-device use in veterans and servicemembers from Vietnam and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE abandonment; activity measure; limb loss; OIF/OEF; prosthetic device; rehabilitation; satisfaction; upper-limb loss; veterans; Vietnam conflict ID EXTREMITY VASCULAR INJURY; ARMY-MEDICAL-CENTER; TERM-FOLLOW-UP; RISK-FACTORS; COMBAT AMPUTEES; WARTIME REPORT; AMPUTATION; CARE; DEFICIENCY; WAR AB Prosthetic use and satisfaction in wounded servicemembers and veterans with unilateral upper-limb loss has not been thoroughly explored. Through a national survey, we enrolled 47 participants from the Vietnam conflict and 50 from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) with combat-associated major unilateral upper-limb loss. Upper-limb prosthetic devices were used by 70% of the Vietnam group and 76% of the OIF/OEF group. Mechanical/body-powered upper-limb devices were favored by the Vietnam group, while a combination of myoelectric/hybrid and mechanical/body-powered devices were favored by the OIF/OEF group. Upper-limb devices were completely abandoned in 30% of the Vietnam and 22% of the OIF/OEF groups. Abandonment was more frequent for transhumeral and more proximal levels (42% of Vietnam and 40% of OIF/OEF) than more distal limb-loss levels. Upper-limb prostheses were rejected because of dissatisfaction with the device by significantly fewer (23%) members of the Vietnam group than the OIF/OEF group (45%) (p < 0.001). Most common reasons for rejection included pain, poor comfort, and lack of functionality. A significant paradigm shift has been noted in the OIF/OEF group, who use a greater number and diversity of upper-limb prostheses than the Vietnam group. C1 [McFarland, Lynne V.] Univ Washington, Seattle, WA 98195 USA. [Winkler, Sandra L. Hubbard] N Florida S Georgia Vet Hlth Syst, Rehabil Outcomes Res Ctr, Res Enhancement Award Program, Gainesville, FL USA. [Winkler, Sandra L. Hubbard] Univ Florida, Gainesville, FL USA. [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Heinemann, Allen W.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA. [Jones, Melissa] USA, Manhattan, KS USA. [Esquenazi, Alberto] MossRehab & Albert Einstein Med Ctr, Dept Phys Med & Rehabil, Elkins Pk, PA USA. [McFarland, Lynne V.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov RI Heinemann, Allen /K-6283-2012 OI Heinemann, Allen /0000-0003-2782-7326 FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by VA Health Services Research and Development Service (grant IIR 05-244) and a Career Scientist Award to Dr. Reiber (grant RCS 98-353). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or DOD. NR 57 TC 50 Z9 50 U1 2 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 299 EP 316 DI 10.1682/JRRD.2009.03.0027 PG 18 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700007 PM 20803400 ER PT J AU Gailey, R McFarland, LV Cooper, RA Czerniecki, J Gambel, JM Hubbard, S Maynard, C Smith, DG Raya, M Reiber, GE AF Gailey, Robert McFarland, Lynne V. Cooper, Rory A. Czerniecki, Joseph Gambel, Jeffrey M. Hubbard, Sharon Maynard, Charles Smith, Douglas G. Raya, Michele Reiber, Gayle E. TI Unilateral lower-limb loss: Prosthetic device use and functional outcomes in servicemembers from Vietnam war and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE abandonment; amputation; limb loss; lower-limb loss; OIF/OEF; prostheses; prosthetic device; rehabilitation; satisfaction; Vietnam ID PERIPHERAL ARTERIAL-DISEASE; TRAUMA-RELATED AMPUTATIONS; ARMY-MEDICAL-CENTER; LONG-TERM; VASCULAR INJURY; CARE; REHABILITATION; SATISFACTION; AMPUTEES; POPULATION AB Rehabilitation goals following major combat-associated limb loss in World War 11 and the Vietnam war focused on treatment of the injury and a return to civilian life. The goal for Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) servicemembers is to restore function to the greatest possible degree and, if they desire, return them to Active Duty, by providing them with extensive rehabilitation services and a variety of prosthetic devices. Our study determines the usefulness of these diverse types of prosthetic devices for restoring functional capability and documents prosthesis use and satisfaction. We compare servicemembers and veterans with major combat-associated unilateral lower-limb loss: 178 from the Vietnam war and 172 from OIF/OEF conflicts. Of survey participants with unilateral lower-limb loss, 84% of the Vietnam group and 94% of the OIF/OEF group currently use at least one prosthetic device. Reasons for rejection varied by type of device, but common reasons were pain, prosthesis too heavy, and poor fit. Abandonment is infrequent (11% Vietnam group, 4% OIF/OEF group). Future efforts should aim to improve prosthetic-device design, decrease pain, and improve quality of life for these veterans and servicemembers. C1 [McFarland, Lynne V.; Reiber, Gayle E.] Hlth Serv Res & Dev Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Gailey, Robert] Dept Vet Affairs VA Miami Healthcare Syst, Miami, FL USA. [Gailey, Robert] Univ Miami, Miller Sch Med, Dept Phys Sci, Coral Gables, FL 33124 USA. [Cooper, Rory A.] VA Rehabil Res & Dev Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Gambel, Jeffrey M.] Rehabil Care Serv, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Czerniecki, Joseph] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Gambel, Jeffrey M.] USA, Med Corps, Washington, DC USA. [Gambel, Jeffrey M.] Walter Reed Army Med Ctr, Armed Forces Amputee Patient Care Program, Washington, DC 20307 USA. [Hubbard, Sharon] Prosthet Res Study, Seattle, WA USA. [Smith, Douglas G.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Raya, Michele] Univ Miami, Miller Sch Med, Dept Phys Therapy, Coral Gables, FL 33124 USA. RP McFarland, LV (reprint author), Hlth Serv Res & Dev Serv, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported in part by VA Health Services Research and Development Service (IIR 05-244) and a Career Scientist Award (RCS 98-353) to Dr. Reiber. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or DOD. NR 34 TC 19 Z9 19 U1 3 U2 11 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 317 EP 331 DI 10.1682/JRRD.2009.04.0039 PG 15 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700008 PM 20803401 ER PT J AU Laferrier, JZ McFarland, LV Boninger, ML Cooper, RA Reiber, GE AF Laferrier, Justin Z. McFarland, Lynne V. Boninger, Michael L. Cooper, Rory A. Reiber, Gayle E. TI Wheeled mobility: Factors influencing mobility and assistive technology in veterans and servicemembers with major traumatic limb loss from Vietnam war and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE combat operations; mobility; mobility assistive technology; OIF/OEF; prosthetic device; rehabilitation; traumatic amputation; Vietnam; wheelchair; wounded servicemember ID RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY AMPUTATIONS; OPERATION ENDURING FREEDOM; SKILLS TRAINING-PROGRAM; WHEELCHAIR USERS; ELDERLY VETERANS; PROSTHETIC USE; IRAQI-FREEDOM; PEOPLE; AMPUTEES AB Returning wounded veterans and servicemembers to their highest level of function following traumatic injury is a priority of the Departments of Defense and Veterans Affairs. We surveyed 245 veterans from the Vietnam war and 226 servicemembers and veterans from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) conflicts with at least one major traumatic lower-limb loss to determine their use of mobility assistive technology (AT) and patterns of limb abandonment. Prosthetic device use without wheelchair use is found in 50.5% of Vietnam and 42.8% of OIF/OEF groups. Prostheses and supplementary wheelchairs are used by Vietnam (32%) and OIF/OIEF (53%) groups (p < 0.01). Exclusive wheelchair use is more frequent in the Vietnam group (18%) than in the OIF/OFF group (4.0%, p < 0.01). In Vietnam participants, multivariate analysis found that multiple-limb loss (adjusted odds ratio [AOR] = 14.5; 95% confidence interval [CI] 5.5-38.5), bilateral lower-limb loss (AOR = 12.7; 95% Cl 6.2-26.1), and number of comorbidities (AOR = 1.3; 95% Cl 1.2-1.5) are associated with increased likelihood of wheelchair use. In OIF/OEF participants, bilateral lower-limb loss (AOR = 29.8; 95% CI 11.0-80.7), multiple-limb loss (AOR = 16.3; 95% Cl 3.1-85.3), cumulative trauma disorder (AOR = 2.4; 95% Cl 1.2-4.9), and number of combat injuries (AOR = 1.4; 95% Cl 1.2-1.7) are associated with wheelchair use. Combined use of different types of mobility ATs promotes improved rehabilitation and ability to function. C1 [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Laferrier, Justin Z.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [McFarland, Lynne V.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA USA. [McFarland, Lynne V.; Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [McFarland, Lynne V.; Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Laferrier, Justin Z.; Boninger, Michael L.; Cooper, Rory A.] Dept Vet Affairs Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7108 Highland Dr,Bldg 4, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU VA, Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by the VA, Health Services Research and Development Service, grant IIR 05-244, and a Career Scientist Award to Dr. Reiber, grant RCS 98-353. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the DOD. NR 40 TC 10 Z9 10 U1 6 U2 13 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 349 EP 360 DI 10.1682/JRRD.2009.03.0022 PG 12 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700010 PM 20803403 ER PT J AU Berke, GM Fergason, J Milani, JR Hattingh, J McDowell, M Nguyen, V Reiber, GE AF Berke, Gary M. Fergason, John Milani, John R. Hattingh, John McDowell, Martin Nguyen, Viet Reiber, Gayle E. TI Comparison of satisfaction with current prosthetic care in veterans and servicemembers from Vietnam and OIF/OEF conflicts with major traumatic limb loss SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputation site; OIF/OEF; prosthesis; prosthetic care; prosthetic device; rehabilitation; satisfaction; traumatic limb loss; veteran; Vietnam; wounded servicemember ID AMPUTEES; AMPUTATIONS; PAIN; DEVICES AB Prosthetic care is a vital aspect of healthcare and rehabilitation for veterans and servicemembers with major traumatic limb loss. Our survey queried 581 veterans and servicemembers with limb loss from the Vietnam and Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) conflicts. Among survey participants, 78.2% from the Vietnam conflict and 90.5% from the OIF/OEF conflict currently use prosthetic devices. In Vietnam respondents, 78% received prosthetic care From private sources, 16% from Department of Veterans Affairs (VA) prosthetic laboratories, 0.9% from Department of Defense (DOD), and 5% from multiple sources. In OIF/OEF respondents, 42% received prosthetic care from private sources, 9% percent from VA, 39% from DOD, and 10% from multiple sources. Participants identified their satisfaction with current prosthetic devices and prosthetic services. Reports of pain, sweating, skin irritation, and problems with socket fit continue to be significant issues for participants from both conflicts regardless of level of amputation or site of service. In those with upper-limb loss who used myoelectric prostheses, minimal effect on prosthesis use and satisfaction was noted. Among lower-limb loss participants from both conflicts, notable differences existed in prosthesis satisfaction by source of care. C1 [Fergason, John] Brooke Army Med Ctr, Prosthet Orthot Clin, Ft Sam Houston, TX 78234 USA. [Milani, John R.] Prosthet & Clin Logist Off, Dept Vet Affairs Cent Off, Washington, DC USA. [Hattingh, John] NW Prosthet & Orthot Clin, Seattle, WA USA. [McDowell, Martin] VA Puget Sound Hlth Care Syst, Prosthet Orthot Lab, Seattle, WA USA. [Nguyen, Viet; Reiber, Gayle E.] Univ Washington, Sch Med, Seattle, WA USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. RP Berke, GM (reprint author), 801 Brewster Ave,Suite 270, Redwood City, CA 94063 USA. EM gmberke@gmail.com FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by the VA Health Services Research and Development Service (grant IIR 05-244) and a Career Scientist Award to Dr. Reiber (grant RCS 98-353). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of VA or DOD. NR 22 TC 18 Z9 18 U1 4 U2 14 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 361 EP 371 DI 10.1682/JRRD.2009.12.0193 PG 11 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700011 PM 20803404 ER PT J AU Liu, HY Pearlman, J Cooper, R Hong, EK Wang, HW Salatin, B Cooper, RA AF Liu, Hsin-yi Pearlman, Jonathan Cooper, Rosemarie Hong, Eun-kyoung Wang, Hongwu Salatin, Benjamin Cooper, Rory A. TI Evaluation of aluminum ultralight rigid wheelchairs versus other ultralight wheelchairs using ANSI/RESNA standards SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE aluminum wheelchair; ANSI/RESNA; durability; fatigue life; fatigue mode; manual wheelchair; titanium wheelchair; ultralight wheelchair; wheelchair; wheelchair standards ID MANUAL WHEELCHAIRS; MAINTENANCE; ACCIDENTS; LIFE AB Previous studies found that select titanium ultralight rigid wheelchairs (TURWs) had fewer equivalent cycles and less value than select aluminum ultralight folding wheelchairs (AUFWs). The causes of premature failure of TURWs were not clear because the TURWs had different frame material and design than the AUFWs. We tested 12 aluminum ultralight rigid wheelchairs (AURWs) with similar frame designs and dimensions as the TURWs using the American National Standards Institute/Rehabilitation Engineering and Assistive Technology Society of North America and International Organization for Standardization wheelchair standards and hypothesized that the AURWs would be more durable than the TURWs. Across wheelchair models, no significant differences were found in the test results between the AURWs and TURWs, except in their overall length. Tire pressure, tube-wall thickness, and tube manufacturing were proposed to be the factors affecting wheelchair durability through comparison of the failure modes, frames, and components. The frame material did not directly affect the performance of AURWs and TURWs, but proper wheelchair manufacture and design based on mechanical properties are important. C1 [Liu, Hsin-yi; Pearlman, Jonathan; Cooper, Rosemarie; Hong, Eun-kyoung; Wang, Hongwu; Salatin, Benjamin; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs VA Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Liu, Hsin-yi; Pearlman, Jonathan; Cooper, Rosemarie; Hong, Eun-kyoung; Wang, Hongwu; Salatin, Benjamin; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rosemarie] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R 1H, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013; OI Wang, Hongwu/0000-0002-6567-9144; Pearlman, Jon/0000-0003-0830-9136 FU VA Rehabilitation Research and Development Service [B3142C] FX This material was based on work supported by VA Rehabilitation Research and Development Service (grant B3142C). NR 25 TC 11 Z9 12 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 5 BP 441 EP 455 DI 10.1682/JRRD.2009.08.0137 PG 15 WC Rehabilitation SC Rehabilitation GA 636OS UT WOS:000280748000007 PM 20803388 ER PT J AU Harada, ND Dhanani, S Elrod, M Hahn, T Kleinman, L Fang, MK AF Harada, Nancy D. Dhanani, Shawkat Elrod, Michelle Hahn, Theodore Kleinman, Leonard Fang, Meika TI Feasibility study of home telerehabilitation for physically inactive veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE deconditioning; exercise; exercise adherence; exercise monitoring; Health Buddy; older adults; physical activity; telephone; telerehabilitation; text messaging ID OLDER PERSONS; FRAILTY; COORDINATION; ASSOCIATION; TECHNOLOGY; OUTCOMES; ADULTS; CARE AB The aim of this study was to develop a system for and determine the feasibility of monitoring home exercise for physically inactive older adults using a Health Buddy (HB) text messaging device (Robert Bosch Healthcare; Palo Alto, California). Questions and messages related to exercise adherence are displayed on the HB screen and participants choose a response by pressing the corresponding button on the device. Responses are transmitted through a landline connection and high-risk responses are highlighted by the system for follow-up. We developed the questions and messages based on input from patient and clinician focus groups. We evaluated feasibility by administering the intervention to inpatient and outpatient adults aged 60 or older. We gave participants a choice of exercise monitoring by HB (n = 20) or telephone (n = 18). The results showed that home exercise monitoring by HB and telephone is safe, as evidenced by low adverse event rates. We saw a decline in exercise adherence rates to both the HB and telephone after 8 weeks, although adherence was better for HB than telephone. Taken together, the results demonstrate the feasibility of using text messaging to monitor home exercise adherence in physically inactive older adults. C1 [Harada, Nancy D.] VA Greater Los Angeles Healthcare Syst, ACOS Educ, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90073 USA. [Harada, Nancy D.; Dhanani, Shawkat; Hahn, Theodore; Kleinman, Leonard; Fang, Meika] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kleinman, Leonard] VA Greater Los Angeles Healthcare Syst, Ambulatory Care Home Telehlth Sect, Los Angeles, CA 90073 USA. [Fang, Meika] VA Greater Los Angeles Healthcare Syst, Rheumatol Sect, Los Angeles, CA 90073 USA. RP Harada, ND (reprint author), VA Greater Los Angeles Healthcare Syst, ACOS Educ, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Nancy.Harada@va.gov FU VA Rehabilitation Research and Development Service [E4204-R] FX This material was based on work supported by the VA Rehabilitation Research and Development Service (grant E4204-R). NR 28 TC 10 Z9 10 U1 1 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 5 BP 465 EP 475 DI 10.1682/JRRD.2009.09.0149 PG 11 WC Rehabilitation SC Rehabilitation GA 636OS UT WOS:000280748000009 PM 20803390 ER PT J AU Moy, ML Janney, AW Nguyen, HQ Matthess, KR Cohen, M Garshick, E Richardson, CR AF Moy, Marilyn L. Janney, Adrienne W. Nguyen, Huong Q. Matthess, Kirby R. Cohen, Miriam Garshick, Eric Richardson, Caroline R. TI Use of pedometer and Internet-mediated walking program in patients with chronic obstructive pulmonary disease SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accuracy; ambulation; COPD; exercise capacity; HRQL; Internet; intervention; pedometer; physical activity; pulmonary rehabilitation; walking ID DYSPNEA SELF-MANAGEMENT; PHYSICAL-ACTIVITY; DAILY-LIFE; TRIAL; COPD; ACCELEROMETER; EMPHYSEMA; MORTALITY; ACCURACY AB We evaluated an Internet-mediated, pedometer-based program to promote walking in chronic obstructive pulmonary disease (COPD). First, we assessed the accuracy of the Omron HJ-720ITC pedometer (OMRON Healthcare, Inc; Bannockburn, Illinois) in 51 persons with COPD. The Bland-Altman plot showed a median difference of 3 steps (5th and 95th quintiles, -8.0 and 145.0, respectively). We calculated percent difference = ([manual - Omron step counts]/manual step counts) x 100. Variability in percent difference occurred at the lowest usual walking speeds. At speeds <= 0.94 m/s, the mean +/- standard deviation percent difference was 14 +/- 26%. Nevertheless, the Omron captured >80% of the manual step counts in 20 of the 23 persons with walking speed <= 0.94 m/s. Second, we examined step counts in 24 persons with COPD who used the Omron and an Internet-mediated, 16-week walking program. At baseline, participants with COPD walked an average of 3429 +/- 1502 steps per day. Sixteen participants completed the program with an average increase in daily step count of 988 +/- 1048 steps (p = 0.002). The Omron is accurate in persons with COPD with usual walking speeds > 0.94 m/s. Accuracy is more variable at lower speeds, but the Omron captures more than 80% of manual step counts in most persons. In this preliminary study, an Internet-mediated walking program using the Omron significantly increased step counts in COPD. C1 [Moy, Marilyn L.] Dept Vet Affairs VA, Vet Hlth Adm, Rehabil Res & Dev Serv, Washington, DC USA. [Moy, Marilyn L.; Matthess, Kirby R.; Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. [Moy, Marilyn L.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Moy, Marilyn L.; Matthess, Kirby R.; Garshick, Eric] Harvard Univ, Sch Med, Boston, MA USA. [Janney, Adrienne W.; Richardson, Caroline R.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI 48109 USA. [Nguyen, Huong Q.] Univ Washington, Seattle, WA 98195 USA. [Cohen, Miriam] New York Harbor, VA, Brooklyn, NY USA. [Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Richardson, Caroline R.] Ann Arbor VA Med Ctr, Ann Arbor, MI USA. RP Moy, ML (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, 1400 VFW Pkwy,Mail Code 111PI, W Roxbury, MA 02132 USA. EM marilyn.moy@va.gov FU VA, Veterans Health Administration FX This material was based on work supported in part by the VA, Veterans Health Administration, Rehabilitation Research and Development Service, through a VA Career Development Award to Dr. Moy. Awarded to Dr. Richardson was the Robert Wood Johnson Foundation (grant 57408); the National Heart, Blood, and Lung Institute (grant 1 K23 HL075098); the Center for Health Communications Research University of Michigan; and the Michigan Diabetes Research and Training Center (grant 5 P60 DK020572). The National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, grant RO1 HD42 141 was awarded to Dr. Garshick. NR 30 TC 26 Z9 26 U1 2 U2 7 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 5 BP 485 EP 496 DI 10.1682/JRRD.2009.07.0091 PG 12 WC Rehabilitation SC Rehabilitation GA 636OS UT WOS:000280748000011 PM 20803392 ER PT J AU Lewis, MS Lilly, DJ Hutter, MM Bourdette, DN McMillan, GP Fitzpatrick, MA Fausti, SA AF Lewis, M. Samantha Lilly, David J. Hutter, Michele M. Bourdette, Dennis N. McMillan, Garnett P. Fitzpatrick, Mary A. Fausti, Stephen A. TI Audiometric hearing status of individuals with and without multiple sclerosis SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE audiometric hearing status; auditory function; hearing; hearing loss multiple sclerosis; pure tone thresholds; relapsing-remitting multiple sclerosis; secondary progressive multiple sclerosis; speech reception threshold word recognition ID IMPAIRMENT; PREVALENCE; NOISE; EPIDEMIOLOGY; DEAFNESS; LESION; ADULTS; HEALTH AB The purpose of the present investigation was to determine whether differences exist in audiometric hearing status between individuals with and without multiple sclerosis (MS) and between individuals with relapsing-remitting MS (RRMS) and individuals with secondary progressive MS (SPMS) Forty-seven subjects with MS (26 with RRMS and 21 with SPMS) and forty-nine control subjects without MS completed both a comprehensive case-history questionnaire and a conventional hearing evaluation Statistical analyses, accounting for the potential confounding factors of age sex, noise exposure, and use of ototoxic medications, revealed significant differences in hearing thresholds between subjects with and without MS at select audiometric test frequencies < 0 05) At these audiometric test frequencies, the subjects with MS had poorer hearing thresholds Additional analyses revealed significant differences in hearing sensitivity at select audiometric frequencies between the subjects with RRMS and the subjects with SPMS, such that those with SPMS had poorer hearing thresholds These findings have significant clinical implications for practitioners working with patients with MS C1 [Lewis, M. Samantha; Lilly, David J.; Hutter, Michele M.; Bourdette, Dennis N.; McMillan, Garnett P.; Fausti, Stephen A.] Portland Dept Vet Affairs Med Ctr VAMC, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Lewis, M. Samantha; Bourdette, Dennis N.; Fausti, Stephen A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Lilly, David J.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Carver Coll Med, Iowa City, IA 52242 USA. [Bourdette, Dennis N.; Fitzpatrick, Mary A.] Neurol Serv Portland VAMC, Portland, OR USA. [Fausti, Stephen A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Lewis, MS (reprint author), Portland VA Med Ctr, NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. FU Department of Veterans Affairs (VA); Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development (RRD) [B2568R, C3758V]; RR&D National Center for Rehabilitative Auditory Research [C2659C] FX This material was based on work supported by the Department of Veterans Affairs (VA) Veterans Health Administration Office of Research and Development Rehabilitation Research and Development (RR&D) Service Merit Review grant (grant B2568R) RR&D Research Career Development Award (grant C3758V), and RR&D National Center for Rehabilitative Auditory Research (grant C2659C) NR 38 TC 3 Z9 5 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 7 BP 669 EP 678 DI 10.1682/JRRD.2010.01.0010 PG 10 WC Rehabilitation SC Rehabilitation GA 679BF UT WOS:000284133700009 PM 21110263 ER PT J AU Smith, BM Evans, CT Ullrich, P Burns, S Guihan, M Miskevics, S LaVela, SL Rajan, S Weaver, FM AF Smith, Bridget M. Evans, Charlesnika T. Ullrich, Philip Burns, Stephen Guihan, Marylou Miskevics, Scott LaVela, Sherri L. Rajan, Suparna Weaver, Frances M. TI Using VA data for research in persons with spinal cord injuries and disorders: Lessons from SCI QUERI SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE data quality; paraplegia; pressure ulcers; rehabilitation; respiratory; spinal cord injuries and disorders; spinal cord injury; tetraplegia; VA; veterans ID PRESSURE ULCERS; RISK-FACTORS; VETERANS; PREVALENCE; INFECTION; ILLNESS; OBESITY; VISITS; TRENDS; RATES AB The Department of Veterans Affairs (VA) provides integrated services to more than 25,000 veterans with spinal cord injuries and disorders (SCUD) VA data offer great potential for providing insights into healthcare utilization and morbidity, and these capabilities are central to efforts to improve healthcare for veterans with SCI/D The objective of this article is to introduce researchers to the use of VA data to examine questions related to SCI/D using examples from Spinal Cord Injury (SCI) Quality Enhancement Research Initiative studies Sources of VA data available to investigators interested in SCI/D-related research include national-level VA administrative and clinical databases and primary data (medical record review, patient surveys) Methods used to identify veterans with SCUD include the Allocation Resource Center cohort, the Spinal Cord Dysfunction (SCD) Registry, and the VA inpatient SCI flag, only 33% of veterans were included in all three groups (n = 12,306) While neurological level of SCI was unknown for approximately a third of veterans (from SCD Registry data alone), the percent decreased to 13% when augmented with diagnostic codes Primary data can be used to augment other missing SCI data and to provide more detailed information about complications commonly associated with SCI/D C1 [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; Miskevics, Scott; LaVela, Sherri L.; Weaver, Frances M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat S, Hines, IL USA. [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; LaVela, Sherri L.; Weaver, Frances M.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Ullrich, Philip; Burns, Stephen; Rajan, Suparna] VA Puget Sound Healthcare Syst, SCI QUERI, Seattle, WA USA. [Ullrich, Philip; Burns, Stephen] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; Miskevics, Scott; LaVela, Sherri L.; Weaver, Frances M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. RP Smith, BM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, SCI QUERI, 5000 S 5th Ave,151-H, Hines, IL 60141 USA. FU SCI QUERI center from the VA HSRD Service [SCI 98-000]; HSR&D Service study, "Characterizing Variability in Respiratory Care in SCI/D" [SCS 03-216] FX This material was based on work supported by the SCI QUERI center from the VA HSR&D Service (grant SCI 98-000) and by the HSR&D Service study, "Characterizing Variability in Respiratory Care in SCI/D" (grant SCS 03-216) NR 35 TC 22 Z9 22 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 679 EP 688 DI 10.1682/JRRD.2009.08.0117 PG 10 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300003 PM 21110243 ER PT J AU Carlson, KF Nugent, SM Grill, J Sayer, NA AF Carlson, Kathleen F. Nugent, Sean M. Grill, Joseph Sayer, Nina A. TI Accuracy of external cause-of-injury coding in VA polytrauma patient discharge records SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE administrative data; causes of injury; E-codes; hospital discharge records; ICD codes; injury surveillance; medical records; missing data; rehabilitation; veterans ID BLAST; VETERANS; CODES; CARE; WAR AB Valid and efficient methods of identifying the etiology of treated injuries are critical for characterizing patient populations and developing prevention and rehabilitation strategies We examined the accuracy of external cause-of-injury codes (E-codes) in Veterans Health Administration (VHA) administrative data for a population of injured patients Chart notes and E-codes were extracted for 566 patients treated at any one of four VHA Polytrauma Rehabilitation Center sites between 2001 and 2006 Two expert coders, blinded to VHA E-codes, used chart notes to assign "gold standard" E-codes to injured patients The accuracy of VHA E-coding was examined based on these gold standard E-codes Only 382 of 517 (74%) injured patients were assigned E-codes in VHA records Sensitivity of VHA E-codes varied significantly by site (range 59%-91%, p < 0 001) Sensitivity was highest for combat-related injuries (81%) and lowest for fall-related injuries (60%) Overall specificity of E-codes was high (92%) E-coding accuracy was markedly higher when we restricted analyses to records that had been assigned VHA E-codes E-codes may not be valid for ascertaining source-of-injury data for all injuries among VHA rehabilitation inpatients at this time Enhanced training and policies may ensure more widespread, standardized use and accuracy of E-codes for injured veterans treated in the VHA C1 [Carlson, Kathleen F.; Nugent, Sean M.; Grill, Joseph; Sayer, Nina A.] Dept Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Carlson, Kathleen F.; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. RP Carlson, KF (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RI Sayer, Nina/E-3249-2016 FU VA Health Services Research and Development (HSRD) Service [RRP 06-150, TPP 67-005, CDA 08-025]; VA HSR&D Service Center for Chronic Disease Outcomes Research [LIP 67-032]; HSR&D Service Polytrauma and Blast-Related Injuries Quality Enhancement Research Initiative FX This material was based on work supported by research and training grants from VA Health Services Research and Development (HSR&D) Service (grants RRP 06-150, TPP 67-005, and CDA 08-025), a locally-initiated project grant from the VA HSR&D Service Center for Chronic Disease Outcomes Research (LIP 67-032), and support from the HSR&D Service Polytrauma and Blast-Related Injuries Quality Enhancement Research Initiative NR 35 TC 9 Z9 9 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 689 EP 697 DI 10.1682/JRRD.2009.08.0118 PG 9 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300004 PM 21110244 ER PT J AU Noel, PH Copeland, LA Perrin, RA Lancaster, AE Pugh, MJ Wang, CP Bollinger, MJ Hazuda, HP AF Noel, Polly Hitchcock Copeland, Laurel A. Perrin, Ruth A. Lancaster, A. Elizabeth Pugh, Mary Jo Wang, Chen-Pin Bollinger, Mary J. Hazuda, Helen P. TI VHA Corporate Data Warehouse height and weight data: Opportunities and challenges for health services research SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE anthropometric measurements; body mass index; data error; electronic medical record; height; obesity; rehabilitation; secondary data; veterans; Veterans Health Administration; weight ID PRIMARY-CARE; OBESITY; MANAGEMENT; OVERWEIGHT; VETERANS; ADULTS; RISK AB Within the Veterans Health Administration (VHA), anthropometric measurements entered into the electronic medical record are stored in local information systems, the national Corporate Data Warehouse (CDW), and in some regional data warehouses This article describes efforts to examine the quality of weight and height data within the CDW and to compare CDW data with data from warehouses maintained by several of VHA's regional groupings of healthcare facilities (Veterans Integrated Service Networks [VISNs]) We found significantly fewer recorded heights than weights in both the CDW and VISN data sources In spite of occasional anomalies, the concordance in the number and value of records in the CDW and the VISN warehouses was generally 97% to 99% or greater Implausible variation in same-day and same-year heights and weights was noted, suggesting measurement or data-entry errors Our work suggests that the CDW, over time and through validation, has become a generally reliable source of anthropometric data Researchers should assess the reliability of data contained within any source and apply strategies to minimize the impact of data errors appropriate to their study population C1 [Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Bollinger, Mary J.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Perrin, Ruth A.] Ctr Management Complex Chron Care, Hines, IL USA. [Perrin, Ruth A.] VA Informat Resource Ctr, Hines, IL USA. [Lancaster, A. Elizabeth] Vet Hlth Adm Support Serv Ctr, Washington, DC USA. RP Noel, PH (reprint author), S Texas Vet Hlth Care Syst, Dept Vet Affairs, 7400 Merton Minter Blvd,11C6, San Antonio, TX 78229 USA. OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 FU HSRD [IIR 05-121]; VA; VHA FX This material was based on work supported by the VA, VHA, and HSR&D, grant IIR 05-121 Dr Noel is a Research Psychologist at the South Texas Veterans Health Care System The views expressed in this article are those of the authors and do not necessarily represent the views of the VA NR 23 TC 19 Z9 19 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 739 EP 750 DI 10.1682/JRRD.2009.08.0110 PG 12 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300009 PM 21141302 ER PT J AU Fischer, MJ Stroupe, KT Hynes, DM Blemur, P Sohn, MW Browning, MM Huo, ZP O'Hare, AM Kaufman, JS AF Fischer, Michael J. Stroupe, Kevin T. Hynes, Denise M. Blemur, Pierre Sohn, Min-Woong Browning, Margaret M. Huo, Zhiping O'Hare, Ann M. Kaufman, James S. TI Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accuracy; elderly; end-stage renal disease; erythropoiesis; Medicare; predialysis; sensitivity; specificity; stimulating agent; validity; veteran ID CHRONIC KIDNEY-DISEASE; ANEMIA MANAGEMENT; UNITED-STATES; MORTALITY; DIALYSIS; CARE; INITIATION; VETERANS; BENEFIT; IMPACT AB Data from Medicare's End-Stage Renal Disease Medical Evidence Report (Form 2728) suggest that underuse of erythropoiesis-stimulating agents (ESAs) may be contributing to anemia in predialysis patients However, the data quality of Form 2728 is not known ESA prescription records were confirmed in Department of Veterans Affairs (VA) data sets and/or ESA claims in Medicare files and compared with data collected on Form 2728 among 8,033 veterans who initiated dialysis in 2000 and 2001 and were eligible for both VA and Medicare coverage in the 12 months preceding dialysis initiation Among the cohort, predialysis ESA use was found in 4% (n = 323) more veterans by VA/Medicare data sets (n = 2,810) than by Form 2728 (n = 2,487) With the use of VA/Medicare data sets (gold standard), the accuracy of Form 2728 for predialysis ESA use was sensitivity 57 0%, specificity 83 1%, positive predictive value 64 5%, negative predictive value 78 2%, and kappa coefficient 0 41 Sensitivity for reported predialysis ESA use on Form 2728 was lowest among veterans who were female and nonwhite, of low socioeconomic status, and with anemia or other comorbid illnesses The poor sensitivity and specificity of predialysis ESA use data on Form 2728 raise concerns about the validity of previous reports and study findings Investigators should recognize these shortcomings and the introduction of possible bias in future research and reports C1 [Fischer, Michael J.; Stroupe, Kevin T.; Hynes, Denise M.; Sohn, Min-Woong; Browning, Margaret M.; Huo, Zhiping] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Fischer, Michael J.; Blemur, Pierre] Jesse Brown Dept Vet Affairs Med Ctr, Chicago, IL USA. [Fischer, Michael J.; Blemur, Pierre] Univ Illinois, Med Ctr, Chicago, IL USA. [Stroupe, Kevin T.; Sohn, Min-Woong] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Stroupe, Kevin T.; Hynes, Denise M.; Browning, Margaret M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Med Nephrol, Seattle, WA USA. [Kaufman, James S.] VA Boston Healthcare Syst, Med Nephrol, Boston, MA USA. [Kaufman, James S.] Boston Univ, Boston, MA 02215 USA. RP Fischer, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave,151H, Hines, IL 60141 USA. RI Sohn, Min-Woong/C-3560-2015 OI Sohn, Min-Woong/0000-0002-9474-2907 FU VA, Veterans Health Administration, Health Services Research and Development Service (HSRD) [IIR 02-244, IIR 20-016]; VA HSRD; National Kidney Foundation of Illinois; National Institutes of Health [K23AG28980] FX This material was based on work supported by the VA, Veterans Health Administration, Health Services Research and Development Service (HSR&D) grants IIR 02-244 and IIR 20-016 (awarded to K Stroupe, D Hynes, and M Browning), VA HSR&D Research Career Scientist Award to D M Hynes, VA HSR&D Career Development Award to M Fischer, the National Kidney Foundation of Illinois (awarded to M Fischer), and National Institutes of Health grant K23AG28980 (awarded to A O'Hare) NR 34 TC 10 Z9 10 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 751 EP 762 DI 10.1682/JRRD.2009.08.0108 PG 12 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300010 PM 21110249 ER PT J AU Washington, DL Sun, S Canning, M AF Washington, Donna L. Sun, Su Canning, Mark TI Creating a sampling frame for population-based veteran research: Representativeness and overlap of VA and Department of Defense databases SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE administrative databases; ambulatory care/utilization; hospital; VA nonuser; veteran indicator; veteran population; veteran sampling frame; veterans/utilization; women veterans; women's health services ID HEALTH-CARE; REGISTRY; LESSONS AB Most veteran research is conducted in Department of Veterans Affairs (VA) healthcare settings, although most veterans obtain healthcare outside the VA Our objective was to determine the adequacy and relative contributions of Veterans Health Administration (VHA), Veterans Benefits Administration (VBA), and Department of Defense (DOD) administrative databases for representing the U S veteran population, using as an example the creation of a sampling frame for the National Survey of Women Veterans In 2008, we merged the VHA, VBA, and DOD databases We identified the number of unique records both overall and from each database The combined databases yielded 925,946 unique records, representing 51% of the 1,802,000 U S women veteran population The DOD database included 30% of the population (with 8% overlap with other databases) The VHA enrollment database contributed an additional 20% unique women veterans (with 6% overlap with VBA databases) VBA databases contributed an additional 2% unique women veterans (beyond 10% overlap with other databases) Use of VBA and DOD databases substantially expands access to the population of veterans beyond those in VHA databases, regardless of VA use Adoption of these additional databases would enhance the value and generalizability of a wide range of studies of both male and female veterans C1 [Washington, Donna L.; Sun, Su; Canning, Mark] Dept Vet Affairs VA Greater Los Angeles Healthcar, Los Angeles, CA USA. [Washington, Donna L.; Sun, Su; Canning, Mark] VA Sepulveda Ambulatoly Care Ctr & Nursing Home, VA Greater Los Angeles Hlth Serv Res & Dev Ctr Ex, Sepulveda, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. FU VA, Office of Public Health and Environmental Hazards, Women Veterans Health Strategic Healthcare Group (NSWV); VA Health Services Research and Development Service (HSRD) [SDR-08-270] FX This material was based on work supported in part by the VA, Office of Public Health and Environmental Hazards, Women Veterans Health Strategic Healthcare Group (NSWV), with supplemental funding from the VA Health Services Research and Development Service (HSR&D) (SDR-08-270) NR 22 TC 19 Z9 19 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 763 EP 771 DI 10.1682/JRRD.2009.08.0127 PG 9 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300011 PM 21110250 ER PT J AU Stroupe, KT Tarlov, E Zhang, QY Haywood, T Owens, A Hynes, DM AF Stroupe, Kevin T. Tarlov, Elizabeth Zhang, Qiuying Haywood, Thomas Owens, Arika Hynes, Denise M. TI Use of Medicare and DOD data for improving VA race data quality SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE African American; data quality; ethnicity; health science; Hispanic; Medicare; minority; race; validity; veterans ID OF-VETERANS-AFFAIRS; ADMINISTRATIVE DATA; RACIAL DISPARITIES; ETHNIC DISPARITIES; AFRICAN-AMERICAN; CARE; SURVIVAL; RACE/ETHNICITY; MORTALITY; ACCURACY AB We evaluated the improvement in Department of Veterans Affairs (VA) race data completeness that could be achieved by linking VA data with data from Medicare and the Department of Defense (DOD) and examined agreement in values across the data sources After linking VA with Medicare and DOD records for a 10% sample of VA patients, we calculated the percentage for which race could be identified in those sources To evaluate race agreement, we calculated sensitivities, specificities, positive predictive values (PPVs), negative predictive values, and kappa statistics Adding Medicare (and DOD) data improved race data completeness from 48% to 76% Among older patients (65 years), adding Medicare data improved data completeness to nearly 100% Among younger patients (<65 years), combining Medicare and DOD data improved completeness to 75%, 18 percentage points beyond that achieved with Medicare data alone PPVs for white and African-American categories were 98 6 and 94 7, respectively, in Medicare and 97 0 and 96 5, respectively, in DOD data using VA self-reported race as the gold standard PPVs for the non African-American minority groups were lower, ranging from 30 5 to 48 2 Kappa statistics reflected these patterns Supplementing VA with Medicare and DOD data improves VA race data completeness substantially More study is needed to understand poor rates of agreement between VA and external sources in identifying non African-American minority individuals C1 [Stroupe, Kevin T.; Tarlov, Elizabeth; Zhang, Qiuying; Hynes, Denise M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Stroupe, Kevin T.; Tarlov, Elizabeth; Haywood, Thomas; Owens, Arika; Hynes, Denise M.] VA Inormat Resource Ctr, Hines, IL USA. [Stroupe, Kevin T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Hynes, Denise M.] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA. RP Stroupe, KT (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, 151H,5000 S 5th Ave,Bldg 1B260, Hines, IL 60141 USA. FU VA Information Resource Center, VA Health Services Research & Development Service [SD4 98-004]; VA/CMS [SDR 02-237]; VA; VA Health Services Research and Development Service [IIR 03-196] FX This material was based on work supported by the VA Information Resource Center, VA Health Services Research & Development Service (grant SD4 98-004) and the VA/CMS Data for Research Project (SDR 02-237) Dr Hynes was also supported by a VA Research Career Scientist Award and the VA Health Services Research and Development Service (grant IIR 03-196) NR 57 TC 26 Z9 26 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 781 EP 795 DI 10.1682/JRRD.2009.08.0122 PG 15 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300013 PM 21110252 ER PT J AU Manaster, I Gazit, R Goldman-Wohl, D Stern-Ginossar, N Mizrahi, S Yagel, S Mandelboim, O AF Manaster, Irit Gazit, Roi Goldman-Wohl, Debra Stern-Ginossar, Noam Mizrahi, Saar Yagel, Simcha Mandelboim, Ofer TI Notch activation enhances IFN gamma secretion by human peripheral blood and decidual NK cells SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE Peripheral blood NK cells; Decidual NK cells; Cytokine secretion; Notch receptor ID NATURAL-KILLER-CELLS; ENDOTHELIAL-CELLS; LINE; ANGIOGENESIS; PREGNANCY; MOUSE; LYSIS AB NK cells specialize in killing tumor cells and vitally infected cells and also possess non-cytotoxic functions, which include secretion of a variety of cytokines and growth factors. Their activity is mediated by a vast repertoire of inhibitory and activating NK receptors. Recently, it was demonstrated that ligation of the Notch receptor plays a significant role not only in T cell development but also in human T cell and mouse NK cell activation. However, the involvement of Notch triggering in human NK cell activity has not yet been determined. Here we show that Notch1 and Notch2, but not Notch3 and Notch4, are expressed in human peripheral blood NK cells and in decidual NK cells. We demonstrate that in peripheral blood NK cells only the Notch ligand Delta4 could interact with Notch, whereas in decidual NK cells both Delta1 and Delta4 can interact with Notch. Finally, we show that Notch activation in these cells leads to increased secretion of IFN gamma. We therefore present here a new function of the Notch receptors as enhancers of peripheral blood NK cell and decidual NK cell functions. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Manaster, Irit; Stern-Ginossar, Noam; Mizrahi, Saar; Mandelboim, Ofer] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Biomed Res Inst, IL-91120 Jerusalem, Israel. [Gazit, Roi] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Immune Dis Inst, Boston, MA USA. [Gazit, Roi] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Goldman-Wohl, Debra; Yagel, Simcha] Hadassah Univ Hosp Mt Scopus, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel. RP Mandelboim, O (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Biomed Res Inst, IL-91120 Jerusalem, Israel. EM oferm@ekmd.huji.ac.il OI Gazit, Roi/0000-0002-0548-2147 FU Israeli Cancer Research Foundation; Israeli Science Foundation; ISF (Morasha); Rosenkratz foundation; European Consortium [MRTN-CT-2005, LSCH-CT-2005-518178]; Association for International Cancer Research AICR FX This study was supported by grants from the Israeli Cancer Research Foundation, The Israeli Science Foundation, The ISF (Morasha), The Rosenkratz foundation, The European Consortium (MRTN-CT-2005 and LSCH-CT-2005-518178) and by the Association for International Cancer Research AICR (all to O.M). O.M. is a Crown professor of Molecular Immunology. We thank Dr. Tom Kadesch for providing us with the Delta4 and Jagged1-Fc plasmids. We thank Dr. Spyros Artavanis-Tsakonas for providing us with the cDNA of Delta1. NR 30 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-0378 J9 J REPROD IMMUNOL JI J. Reprod. Immunol. PD JAN PY 2010 VL 84 IS 1 BP 1 EP 7 DI 10.1016/j.jri.2009.10.009 PG 7 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 554OZ UT WOS:000274445600001 PM 20004979 ER PT J AU Wierman, ME Nappi, RE Avis, N Davis, SR Labrie, F Rosner, W Shifren, JL AF Wierman, Margaret E. Nappi, Rossella E. Avis, Nancy Davis, Susan R. Labrie, Ferdinand Rosner, Willam Shifren, Jan L. TI Endocrine Aspects of Women's Sexual Function SO JOURNAL OF SEXUAL MEDICINE LA English DT Review DE Testosterone; Estrogen; Hypoactive Sexual Desire Disorder (HSDD); Menopause; Polycystic Ovarian Syndrome (PCOS); Premature Ovarian Failure (POF); Diabetes; Metabolic Syndrome ID TANDEM MASS-SPECTROMETRY; POLYCYSTIC-OVARY-SYNDROME; QUALITY-OF-LIFE; HEALTH-RELATED QUALITY; POSTMENOPAUSAL HORMONE-THERAPY; SURGICALLY MENOPAUSAL WOMEN; ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA; ANDROGEN INSENSITIVITY SYNDROME; CONGENITAL ADRENAL-HYPERPLASIA; PLACEBO-CONTROLLED TRIAL AB Introduction. Endocrine changes during aging as well as endocrine disorders may either directly or indirectly modulate female sexual function by altering sex hormones, or by impacting on vascular, neurogenic, or psychologic factors. Aim. To review information on the impact of the hormonal changes associated with aging or those caused by endocrine disorders on female sexual function and current information on the risks and benefits of hormonal treatments. Methods. Committee members outlined topics and reviewed the published literature on endocrine aspects of female sexual function over a 2-year period. Presentation of the recommendations were presented at the International Consultation on Sexual Medicine Paris, France 2009 and revised accordingly. Main Outcome Measures. Quality of data published in the literature and recommendations were based on the GRADES system. Results. Recommendations and guidelines concerning the role of sex hormones and endocrine disorders in female sexual function were derived. Conclusions. Hormones are only one component of the many factors that contribute to normal sexual function in women. Further research is needed as to the impact of hormones and endocrine disorders on female sexual dysfunction and the benefits and risks of hormonal therapies. Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, and Shifren JL. Endocrine aspects of women's sexual function. J Sex Med 2010;7:561-585. C1 [Wierman, Margaret E.] Univ Colorado Denver, Aurora, CO USA. [Wierman, Margaret E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Nappi, Rossella E.] Univ Pavia, Res Ctr Reprod Med, I-27100 Pavia, Italy. [Nappi, Rossella E.] IRCCS S Maugeri Fdn, Gynecol Endocrinol Unit, Pavia, Italy. [Avis, Nancy] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Davis, Susan R.] Monash Univ, Womens Hlth Program, Prahran, Vic, Australia. [Labrie, Ferdinand] Univ Laval, Mol Endocrinol Oncol & Genom Res Ctr, Quebec City, PQ, Canada. [Labrie, Ferdinand] Laval Univ Hosp Res Ctr, Quebec City, PQ, Canada. [Rosner, Willam] Columbia Univ, New York, NY USA. [Shifren, Jan L.] Massachusetts Gen Hosp, Menopause Program, Boston, MA 02114 USA. [Shifren, Jan L.] Harvard Univ, Sch Med, Boston, MA USA. RP Wierman, ME (reprint author), UCDHSC VAMC, 111H Endocrinol,VAMC 1055 Clermont St, Denver, CO 80220 USA. EM Margaret.wierman@ucdenver.edu RI Davis, Susan/A-3111-2009; OI Davis, Susan R/0000-0002-2955-0415 FU Procter & Gamble Pharmaceuticals FX Dr. Wierman has nothing to declare; Dr. Nappi is a consultant to or researcher for Bayer- Schering Pharma, Boehringer- Ingelhein, Merck- Theramex, Novo Nordisk, Procter & Gamble Pharmaceuticals, Schering- Plough/Organon; Dr. Avis has no conflict of interest; Dr. Davis is a consultant to or researcher for Acrux Australia, Astra Zeneca, BayerSchering Pharma, Novarits, Procter & Gamble Pharmaceuticals and Schering- Plough/Organon; Dr. Rosner has nothing to declare; Dr. Shifren serves on a scientific advisory board for New England Research Institutes, receives research support from Procter & Gamble Pharmaceuticals, and serves as a research study consultant for Boehringer Ingelheim and Eli Lilly & Co. NR 185 TC 36 Z9 41 U1 5 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD JAN PY 2010 VL 7 IS 1 BP 561 EP 585 DI 10.1111/j.1743-6109.2009.01629.x PN 2 PG 25 WC Urology & Nephrology SC Urology & Nephrology GA 540EM UT WOS:000273313800015 PM 20092453 ER PT J AU Rineer, CA Guitton, TG Ring, D AF Rineer, Craig A. Guitton, Thierry G. Ring, David TI Radial head fractures: Loss of cortical contact is associated with concomitant fracture or dislocation SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Radial head fracture; dislocation; instability; displacement ID INTERNAL-FIXATION; ELBOW AB Hypothesis: Among radial head fractures displaced greater than 2 mm (Broberg and Morrey modified Mason type 2), separation (complete loss of cortical contact) of at least I radial head fracture fragment is associated with a complex injury pattern, meaning that there are other concomitant elbow fractures or ligament injuries. Materials and methods: We identified 291 consecutive skeletally mature patients with 296 radial head fractures treated during a 6-year period. Of these, 121 consecutive fractures of part of the radial head displaced greater than 2 mm (type 2) were classified according to whether there was complete lack of cortical contact between a fracture fragment and the rest of the proximal radius. Predictors of isolated vs complex injury pattern were sought in bivariate and multivariable analyses. Results: Of 121 fractures, 30 (25%) were classified as having cortical contact, and 91 (75%) were classified as not having cortical contact. Ten (33%) with cortical contact were part of a complex elbow injury, and 83 of 91 fractures (91%) without cortical contact were part of a complex elbow injury (P<.01). Among the Mason type 2 fractures, loss of cortical contact was a significant predictor of a complex elbow injury in both bivariate and multivariable analyses, with an odds ratio of 21 (95% confidence interval, 7-59). Conclusions: Among Mason type 2 fractures, complete loss of cortical contact of at least one fracture fragment is strongly predictive of a complex injury pattern. C1 [Ring, David] Harvard Univ, Yawkey Ctr, Massachusetts Gen Hosp, Sch Med,Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Harvard Univ, Yawkey Ctr, Massachusetts Gen Hosp, Sch Med,Orthopaed Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org OI Guitton, Thierry/0000-0002-2599-1985 FU Wright Medical; Acumed; Tornier FX Dr Ring is a consultant for Wright Medical, Acumed, and Tornier. Research support was received from all three companies. NR 16 TC 15 Z9 17 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD JAN PY 2010 VL 19 IS 1 BP 21 EP 25 DI 10.1016/j.jse.2009.05.015 PG 5 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 592HA UT WOS:000277367800005 PM 19733485 ER PT J AU Chang, BH Sommers, E Herz, L AF Chang, Bei-Hung Sommers, Elizabeth Herz, Lawrence TI Acupuncture and relaxation response for substance use disorder recovery SO JOURNAL OF SUBSTANCE USE LA English DT Article DE Substance use disorder; acupuncture; relaxation response; randomized control trial; recovery ID QUALITY-OF-LIFE; NITRIC-OXIDE; VETERANS-HEALTH; CLINICAL-TRIALS; MISSING DATA; DRUG-USE; ALCOHOL; SPIRITUALITY; MEDITATION; BRAIN AB Methods: We conducted a controlled trial at a US Veterans Administration homeless residential rehabilitation programme. Study participants were randomly assigned to acupuncture, relaxation response or usual care groups. Results: Both acupuncture and the relaxation response interventions were well received by the veterans with high intervention attendance rates (75% and 80%, respectively). The acupuncture group had significantly greater reductions in craving and anxiety levels and greater improvements in the spirituality dimension of quality of life, while the relaxation response group had significantly greater reductions in anxiety level and greater improvements in mental health and spirituality dimensions of quality of life than usual care. The two intervention groups had no significant difference in any outcome measures. Conclusions: This trial provided promising pilot data for larger studies to validate the effects of acupuncture and the relaxation response for relapse prevention. C1 [Chang, Bei-Hung; Sommers, Elizabeth] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Chang, Bei-Hung] VA Boston Hlth Care Syst, Boston, MA USA. [Sommers, Elizabeth] Pathways Wellness AIDS Care Project, Boston, MA USA. [Herz, Lawrence] Boston Univ, Sch Med, Boston, MA 02215 USA. [Herz, Lawrence] Bedford VA Med Ctr, Bedford, MA USA. RP Chang, BH (reprint author), 150 S Huntington Ave,152H, Boston, MA 02130 USA. EM bhchang@bu.edu NR 53 TC 12 Z9 12 U1 0 U2 5 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1465-9891 J9 J SUBST USE JI J. Subst. Use PY 2010 VL 15 IS 6 BP 390 EP 401 DI 10.3109/14659890903580466 PG 12 WC Substance Abuse SC Substance Abuse GA 688IB UT WOS:000284841900003 ER PT J AU Stahl, JE Dixon, RF AF Stahl, James E. Dixon, Ronald F. TI Acceptability and willingness to pay for primary care videoconferencing: a randomized controlled trial SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID JOINT TELECONSULTATIONS; INTERFACE AB We examined videoconferencing in comparison with face-to-face office visits in primary care. Four physicians took part in the study and 175 patients were recruited from a general medical practice. Patients were interviewed and examined in both face-to-face and virtual settings, the order being randomized. Patients and clinicians were surveyed by questionnaire after each visit. Physicians were very satisfied with videoconferencing but preferred face-to-face overall (P < 0.0001). For videoconferencing, the physical examination and the ability to order appropriate laboratory tests were the least satisfying elements of the encounter. Patients were also very satisfied with videoconferencing but overall preferred face-to-face (P < 0.0001). This difference was significant for gastrointestinal, musculoskeletal and respiratory complaints. However, in terms of willingness to pay (WTP) for videoconferencing access, patients with musculoskeletal and respiratory complaints were the most willing. Age and gender did not significantly predict WTR The technical quality of the videoconference had a significant effect on satisfaction with the clinical encounter but did not correlate with the patients' WTP for videoconferencing. Travel costs up to $40 and travel times up to 4 hours did not influence the WTP of patients. For non-rural, relatively mobile patients, videoconferencing appears suitable for short visits for relatively simple complaints. C1 [Stahl, James E.; Dixon, Ronald F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Stahl, JE (reprint author), Massachusetts Gen Hosp, Dept Med, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM James@mgh-ita.org FU Massachusetts General Physicians Organization FX The study was supported by the Massachusetts General Physicians Organization. NR 10 TC 9 Z9 9 U1 0 U2 2 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2010 VL 16 IS 3 BP 147 EP 151 DI 10.1258/jtt.2009.090502 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 596DV UT WOS:000277665600008 PM 20386035 ER PT J AU Sun, BC Knapp, H Shamouelian, A Golden, J Goetz, MB Asch, SM AF Sun, Benjamin C. Knapp, Herschel Shamouelian, Albert Golden, Joya Goetz, Matthew Bidwell Asch, Steven M. TI Effect of an education kiosk on patient knowledge about rapid HIV screening SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID EMERGENCY-DEPARTMENT; PROGRAM; ADULTS; HEALTH AB Patient education is an important part of routine HIV screening. In a pilot study, we assessed the effect of a computer kiosk education module on patient knowledge about routine HIV screening. A systematic sample of walk-in clinic patients completed a questionnaire before and after using the education module. The primary outcome was a composite nine-point knowledge score. Secondary outcomes included willingness to undergo HIV screening and patient satisfaction. Of 185 patients who were eligible to participate, 100 completed the study. The median duration of kiosk interaction was 3.9 min. The median knowledge score increased from 7 to 8 (P<0.0001) after viewing the module. There was no significant change in the proportion of patients who were interested in HIV screening. The majority of patients expressed excellent (38%) or very good (39%) satisfaction with the kiosk module. The results suggest that a computer kiosk can deliver brief and targeted education to improve knowledge about HIV screening. C1 [Sun, Benjamin C.; Knapp, Herschel; Shamouelian, Albert; Golden, Joya; Goetz, Matthew Bidwell; Asch, Steven M.] VA Greater Los Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Sun, Benjamin C.; Goetz, Matthew Bidwell; Asch, Steven M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Off 3214A,Mail Stop 111,Bldg 500,Wing 3E, Los Angeles, CA 90073 USA. EM bsun@mednet.ucla.edu OI Goetz, Matthew/0000-0003-4542-992X FU VA [RRP 08-255] FX The study was supported by VA grant RRP 08-255. We thank Dr Ralph Gonzales for his donation of a computer kiosk. The authors have no competing financial interests. NR 13 TC 5 Z9 5 U1 1 U2 5 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2010 VL 16 IS 3 BP 158 EP 161 DI 10.1258/jtt.2009.090815 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 596DV UT WOS:000277665600010 PM 20386037 ER PT J AU Faraone, SV Spencer, TJ Kollins, SH Glatt, SJ AF Faraone, Stephen V. Spencer, Thomas J. Kollins, Scott H. Glatt, Stephen J. TI Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE attention-deficit/hyperactivity disorder; growth; lisdexamfetamine dimesylate; amphetamine; stimulants ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; STIMULANT MEDICATION; EXTENDED-RELEASE; FOLLOW-UP; CHILDREN; METHYLPHENIDATE; EFFICACY; WEIGHT AB Objective: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD). Method: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control. Results: At study entry, children were taller and heavier than average. Growth delays were largest for weight and BMI, and there was a 13 percentile point decrease in height. Children continued to grow in terms of height while treated with LDX; we found no increase in raw weight or BMI during the study period. LDX treatment was significantly associated with diminished gains in height, weight, and BMI compared to levels that would be expected based on age-appropriate standards from the Centers for Disease Control. Growth delays were greatest for the heaviest and tallest children, for those who had not previously received stimulant therapy, and for those with a greater cumulative exposure to LDX. More work is needed to determine effects on ultimate adult height. Conclusions: Consistent with prior studies of stimulants, treatment with LDX leads to statistically significant reductions in expected height, weight, and BMI. Growth of patients with ADHD treated with LDX should be closely monitored and corrective action taken should growth delays be observed. J. Am. Acad. Child Adolesc. Psychiatry, 2010;49(1):24-32. Clinical trial registry information-Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD, URL: http://www.clinicaltrials.gov, unique identifier: NCT00556296; NRP104, Adderall XR or Placebo in Children Aged 6-12 Years with ADHD; URL: http://www.clinicaltrials.gov, unique identifier: NCT00557011. C1 [Faraone, Stephen V.; Glatt, Stephen J.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Spencer, Thomas J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Spencer, Thomas J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kollins, Scott H.] Duke Univ, Med Sch Ctr, Durham, NC 27706 USA. RP Faraone, SV (reprint author), SUNY Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA. EM faraones@upstate.edu RI Kollins, Scott/G-2965-2012; OI Faraone, Stephen/0000-0002-9217-3982 FU Shire Development, Inc FX This work was supported by Shire Development, Inc. NR 16 TC 14 Z9 14 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 2010 VL 49 IS 1 BP 24 EP 32 DI 10.1016/j.jaac.2009.10.003 PG 9 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 548IW UT WOS:000273955800005 PM 20215923 ER PT J AU Mendez, MF AF Mendez, Mario F. TI The Unique Predisposition to Criminal Violations in Frontotemporal Dementia SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID ACQUIRED SOCIOPATHY; MORAL JUDGMENT; LOBAR DEGENERATION; PREFRONTAL CORTEX; FRONTAL DAMAGE; BEHAVIOR; EMPATHY; DISEASE; BRAIN; DISTURBANCES AB Brain disorders can lead to criminal violations. Patients with frontotemporal dementia (FTD) are particularly prone to sociopathic behavior while retaining knowledge of their acts and of moral and conventional rules. This report describes four FTD patients who committed criminal violations in the presence of clear consciousness and sufficiently intact cognition. They understood the nature of their acts and the potential consequences, but did not feel sufficiently concerned to be deterred. FTD involves a unique pathologic combination affecting the ventromedial prefrontal cortex, with altered moral feelings, right anterior temporal loss of emotional empathy, and orbitofrontal changes with disinhibited, compulsive behavior. These case histories and the literature indicate that those with right temporal FTD retain the capacity to tell right from wrong but have the slow and insidious loss of the capacity for moral rationality. Patients with early FTD present a challenge to the criminal justice system to consider alterations in moral cognition before ascribing criminal responsibility. C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Los Angeles, CA 90073 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU NIA NIH HHS [R01 AG034499, R01 AG034499-03] NR 42 TC 18 Z9 19 U1 2 U2 11 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2010 VL 38 IS 3 BP 318 EP 323 PG 6 WC Law; Psychiatry SC Government & Law; Psychiatry GA 663ZL UT WOS:000282928600004 PM 20852216 ER PT J AU Soulier, MF Maislen, A Beck, JC AF Soulier, Matthew F. Maislen, Andrea Beck, James C. TI Status of the Psychiatric Duty to Protect, Circa 2006 SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID TARASOFF DUTY; CRITIQUE; WARN AB States have responded to the Tarasoff duty to protect by passing statutes in all but 13 states. Such statutes either mandate or permit warning a potential victim. In this study, we analyzed 70 Tarasoff-related cases from a Westlaw-based search between 1985 and 2006. We determined the extent to which clinicians are being held liable for breach of the Tarasoff duty in statutory and nonstatutory states, whether there is language in the statutes that permits warning compared with statutes that mandate warning, and whether recent Tarasoff decisions better reflect the inherent ambiguities in clinical mental health practice. We found 70 appellate cases, and only 6 were plaintiff verdicts. Statutes that mandate warning a victim appear to be the most protective of clinicians. Seven of the 17 remanded cases came from the jurisdictions with permission-to-warn statutes, suggesting that permission rather than a strict mandate to warn may increase the liability for clinicians. Notwithstanding the language of statutes, the protections from Tarasoff are not extended to poor clinical judgment, particularly in the controlled inpatient setting. C1 [Soulier, Matthew F.] Univ Calif Davis, Med Ctr, Div Psychiat & Law, Sacramento, CA USA. [Maislen, Andrea] Harvard Univ, Fac Arts & Sci Comm Use Human Subjects, Cambridge, MA 02138 USA. [Beck, James C.] Harvard Univ, Sch Med, Boston, MA USA. [Beck, James C.] Massachusetts Gen Hosp, Law & Psychiat Serv, Boston, MA 02114 USA. RP Beck, JC (reprint author), WAC 812,Fruit St, Boston, MA 02114 USA. EM jamesbeck56@gmail.com NR 14 TC 13 Z9 13 U1 1 U2 5 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2010 VL 38 IS 4 BP 457 EP 473 PG 17 WC Law; Psychiatry SC Government & Law; Psychiatry GA 712WL UT WOS:000286696900003 PM 21156904 ER PT J AU Thrall, JH AF Thrall, James H. TI US Preventive Services Task Force Recommendations for Screening Mammography: Evidence-Based Medicine or the Death of Science? SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Thrall, JH (reprint author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St,Room 216, Boston, MA 02114 USA. EM jthrall@partners.org NR 0 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JAN PY 2010 VL 7 IS 1 BP 2 EP 4 DI 10.1016/j.jacr.2009.11.019 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V23RF UT WOS:000208359200001 PM 20129260 ER PT J AU Miller, JC Hirsch, JA Colon, RA Buonanno, FS Thrall, JH Uppot, RN AF Miller, Janet C. Hirsch, Joshua A. Colon, Rivka A. Buonanno, Ferdinando S. Thrall, James H. Uppot, Raul N. TI Cerebral Aneurysms SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Miller, Janet C.; Hirsch, Joshua A.; Colon, Rivka A.; Thrall, James H.; Uppot, Raul N.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Buonanno, Ferdinando S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM jahirsch@partners.org FU NCI NIH HHS [R25 CA089017] NR 10 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JAN PY 2010 VL 7 IS 1 BP 73 EP 76 DI 10.1016/j.jacr.2009.06.015 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA V23RF UT WOS:000208359200019 PM 20129278 ER PT J AU Shiloach, M Frencher, SK Steeger, JE Rowell, KS Bartzokis, K Tomeh, MG Richards, KE Ko, CY Hall, BL AF Shiloach, Mira Frencher, Stanley K., Jr. Steeger, Janet E. Rowell, Katherine S. Bartzokis, Kristine Tomeh, Majed G. Richards, Karen E. Ko, Clifford Y. Hall, Bruce L. TI Toward Robust Information: Data Quality and Inter-Rater Reliability in the American College of Surgeons National Surgical Quality Improvement Program SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID RISK ADJUSTMENT; CARE; VALIDITY; OUTCOMES; REGISTRY; AUDIT AB BACKGROUND: Data used for evaluating quality of medical care need to be of high reliability to ensure valid quality assessment and benchmarking. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has continually emphasized the collection of highly reliable clinical data through its program infrastructure. STUDY DESIGN: We provide a detailed description of the various mechanisms used in ACS NSQIP to assure collection of high quality data, including training of data collectors (surgical clinical reviewers) and ongoing audits of data reliability. For the 2005 through 2008 calendar years, inter-rater reliability was calculated overall and for individual variables using percentages of agreement between the data collector and the auditor. Variables with > 5% disagreement are flagged for educational efforts to improve accurate collection. Cohen's kappa was estimated for selected variables from the 2007 audit year. RESULTS: Inter-rater reliability audits show that overall disagreement rates on variables have fallen from 3.15% in 2005 (the first year of public enrollment in ACS NSQIP) to 1.56% in 2008. In addition, disagreement levels for individual variables have continually improved, with 26 individual variables demonstrating > 5% disagreement in 2005, to only 2 such variables in 2008. Estimated kappa values suggest substantial or almost perfect agreement for most variables. CONCLUSIONS: The ACS NSQIP has implemented training and audit procedures for its hospital participants that are highly effective in collecting robust data. Audit results show that data have been reliable since the program's inception and that reliability has improved every year. (J Am Coll Surg 2010;210:6-16. (C) 2010 by the American College of Surgeons) C1 [Shiloach, Mira; Richards, Karen E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Frencher, Stanley K., Jr.] UCLA RAND, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Steeger, Janet E.; Rowell, Katherine S.; Bartzokis, Kristine; Tomeh, Majed G.] QCMetrix Inc, Waltham, MA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, Ctr Hlth Policy, John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. RP Shiloach, M (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL 60611 USA. NR 21 TC 385 Z9 385 U1 4 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JAN PY 2010 VL 210 IS 1 BP 6 EP 16 DI 10.1016/j.jamcollsurg.2009.09.031 PG 11 WC Surgery SC Surgery GA 617KO UT WOS:000279279800002 PM 20123325 ER PT J AU Buracchio, T Arvanitakis, Z Leurgans, S Bennett, DA AF Buracchio, Teresa Arvanitakis, Zoe Leurgans, Sue Bennett, David A. TI PARKINSONIAN SIGNS AND INCIDENT FALLS IN OLDER PERSONS WITHOUT PARKINSON'S DISEASE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID COMMUNITY POPULATION; ALZHEIMERS-DISEASE; PEOPLE; PREVALENCE C1 [Buracchio, Teresa] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. [Buracchio, Teresa] Portland VA Med Ctr, Portland, OR USA. [Arvanitakis, Zoe; Leurgans, Sue; Bennett, David A.] Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Arvanitakis, Zoe; Leurgans, Sue; Bennett, David A.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. RP Buracchio, T (reprint author), Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. FU NIA NIH HHS [K23 AG23675, K23 AG023675, R01 AG017917, R01 AG17917] NR 10 TC 4 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2010 VL 58 IS 1 BP 205 EP 206 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 540DR UT WOS:000273311500049 PM 20122072 ER PT J AU Hysong, SJ Sawhney, MK Wilson, L Sittig, DF Espadas, D Davis, T Singh, H AF Hysong, Sylvia J. Sawhney, Mona K. Wilson, Lindsay Sittig, Dean F. Espadas, Donna Davis, Traber Singh, Hardeep TI Provider management strategies of abnormal test result alerts: a cognitive task analysis SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID DECISION-MAKING; FOLLOW-UP; WORKLOAD; SYSTEMS; DESIGN; STYLE AB Objective Electronic medical records (EMRs) facilitate abnormal test result communication through "alert" notifications. The aim was to evaluate how primary care providers (PCPs) manage alerts related to critical diagnostic test results on their EMR screens, and compare alert-management strategies of providers with high versus low rates of timely follow-up of results. Design 28 PCPs from a large, tertiary care Veterans Affairs Medical Center (VAMC) were purposively sampled according to their rates of timely follow-up of alerts, determined in a previous study. Using techniques from cognitive task analysis, participants were interviewed about how and when they manage alerts, focusing on four alert-management features to filter, sort and reduce unnecessary alerts on their EMIR screens. Results Provider knowledge of alert-management features ranged between 4% and 75%. Almost half (46%) of providers did not use any of these features, and none used more than two. Providers with higher versus lower rates of timely follow-up used the four features similarly, except one (customizing alert notifications). Providers with low rates of timely follow-up tended to manually scan the alert list and process alerts heuristically using their clinical judgment. Additionally, 46% of providers used at least one workaround strategy to manage alerts. Conclusion Considerable heterogeneity exists in provider use of alert-management strategies; specific strategies may be associated with lower rates of timely follow-up. Standardization of alert-management strategies including improving provider knowledge of appropriate tools in the EMR to manage alerts could reduce the lack of timely follow-up of abnormal diagnostic test results. C1 [Hysong, Sylvia J.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev,Ctr Excellence 152, Houston, TX 77030 USA. [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsay; Espadas, Donna; Davis, Traber; Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsay; Espadas, Donna; Davis, Traber; Singh, Hardeep] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Sch Hlth Informat Sci, Houston, TX USA. [Sittig, Dean F.] Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA. RP Hysong, SJ (reprint author), Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev,Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hysong@bcm.edu RI Hysong, Sylvia/B-8420-2008; OI Hysong, Sylvia/0000-0002-9063-5207; Davis Giardina, Traber/0000-0002-9184-6524 FU VA Career Development Award [CD2-07-0818]; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence [HFP90-020]; VA Career Development Award FX The research reported here was supported in part by a VA Career Development Award (CD2-07-0818) to SJH, the VA National Center of Patient Safety, and the Houston VA HSR&D Center of Excellence (HFP90-020). Other funders: VA Career Development Award; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence. NR 31 TC 17 Z9 17 U1 5 U2 6 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN PY 2010 VL 17 IS 1 BP 71 EP 77 DI 10.1197/jamia.M3200 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 538GY UT WOS:000273173800013 PM 20064805 ER PT J AU Gradman, AH Basile, JN Carter, BL Bakris, GL AF Gradman, Alan H. Basile, Jan N. Carter, Barry L. Bakris, George L. CA Hypertension Writing Grp TI Combination therapy in hypertension SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Hypertension; combination therapy; drug therapy; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; beta blockers diuretic; calcium channel blocker ID BLOOD-PRESSURE CONTROL; LOW-DOSE HYDROCHLOROTHIAZIDE; FELODIPINE EXTENDED-RELEASE; CONVERTING-ENZYME-INHIBITOR; HIGH CARDIOVASCULAR RISK; CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE TREATMENT; SYSTEMIC HYPERTENSION AB The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed. J Am Soc Hypertens 2010;4(1):42-50. (C) 2010 American Society of Hypertension. All rights reserved. C1 [Gradman, Alan H.] Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA. [Gradman, Alan H.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Carter, Barry L.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA. [Bakris, George L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. RP Gradman, AH (reprint author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA. EM gradmanmd@aol.com NR 65 TC 88 Z9 103 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD JAN-FEB PY 2010 VL 4 IS 1 BP 42 EP 50 DI 10.1016/j.jash.2010.02.005 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 583HM UT WOS:000276664500007 PM 20374950 ER PT J AU Subramanya, AR Ellison, DH AF Subramanya, Arohan R. Ellison, David H. TI Sorting out Lysosomal Trafficking of the Thiazide-Sensitive Na-Cl Co-transporter SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID PROVOKES ACUTE TRAFFICKING; WNK KINASES; BLOOD-PRESSURE; TRANSPORT; TUBULE; POTASSIUM; PATHWAY; SALT; NCC C1 [Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. [Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Res Serv, Pittsburgh, PA USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3181 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [DK051496, R01 DK051496, DK084566] NR 17 TC 6 Z9 7 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2010 VL 21 IS 1 BP 7 EP 9 DI 10.1681/ASN.2009111138 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 546BK UT WOS:000273781900005 PM 19959708 ER PT J AU Bondi, CD Manickam, N Lee, DY Block, K Gorin, Y Abboud, HE Barnes, JL AF Bondi, Corry D. Manickam, Nagaraj Lee, Duck Yoon Block, Karen Gorin, Yves Abboud, Hanna E. Barnes, Jeffrey L. TI NAD(P)H Oxidase Mediates TGF-beta 1-Induced Activation of Kidney Myofibroblasts SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SMOOTH MUSCLE ACTIN; GROWTH-FACTOR-BETA; UNILATERAL URETERAL OBSTRUCTION; ANGIOTENSIN-II; MESANGIAL CELLS; TGF-BETA; RENAL FIBROSIS; PROLIFERATIVE GLOMERULONEPHRITIS; DIABETIC-NEPHROPATHY; CARDIAC FIBROBLASTS AB TGF-beta 1 expression closely associates with activation and conversion of fibroblasts to a myofibroblast phenotype and synthesis of an alternatively spliced cellular fibronectin variant, Fn-ED-A. Reactive oxygen species (ROS), such as superoxide, which is a product of NAD(P)H oxidase, also promote the transition of fibroblasts to myofibroblasts, but whether these two pathways are interrelated is unknown. Here, we examined a role for NAD(P)H oxidase-derived ROS in TGF-beta 1-induced activation of rat kidney fibroblasts and expression of alpha-smooth muscle actin (alpha-SMA) and Fn-ED-A. In vitro, TGF-beta 1 stimulated formation of abundant stress fibers and increased expression of both alpha-SMA and Fn-ED-A. In addition, TGF-beta 1 increased both the activity of NADPH oxidase and expression of Nox2 and Nox4, homologs of the NAD(P)H oxidase family, indicating that this growth factor induces production of ROS. Small interfering RNA targeted against Nox4 markedly inhibited TGF-beta 1-induced stimulation of NADPH oxidase activity and reduced alpha-SMA and Fn-ED-A expression. Inhibition of TGF-beta 1 receptor 1 blocked Smad3 phosphorylation; reduced TGF-beta 1-enhanced NADPH oxidase activity; and decreased expression of Nox4, alpha-SMA, and Fn-ED-A. Diphenyleneiodonium, an inhibitor of flavin-containing enzymes such as the Nox oxidases, had no effect on TGF-beta 1-induced Smad3 but reduced both alpha-SIMA and Fn-ED-A protein expression. The Smad3 inhibitor SIS3 reduced NADPH oxidase activity, Nox4 expression, and blocked alpha-SIMA and Fn-ED-A, indicating that stimulation of myofibroblast activation by ROS is downstream of Smad3. In addition, TGF-beta 1 stimulated phosphorylation of extracellular signal-regulated kinase (ERK1/2), and this was inhibited by blocking TGF-beta 1 receptor 1, Smad3, or the Nox oxidases; ERK1/2 activation increased alpha-SMA and Fn-ED-A. Taken together, these results suggest that TGF-beta 1-induced conversion of fibroblasts to a myofibroblast phenotype involves a signaling cascade through Smad3, NAD(P)H oxidase, and ERK1/2. C1 [Bondi, Corry D.; Manickam, Nagaraj; Lee, Duck Yoon; Block, Karen; Gorin, Yves; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Abboud, Hanna E.; Barnes, Jeffrey L.] S Texas Vet Hlth Care Syst, Med Res Serv, Audie Murphy Mem Vet Adm Hosp, San Antonio, TX USA. RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Department of Veterans Affairs [0555006Y]; American Heart Association, Texas Affiliate; George O'Brien Kidney Center, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [P50DK061597] FX This work was supported by grants from the Merit Review Program, Department of Veterans Affairs; grant 0555006Y from the American Heart Association, Texas Affiliate; and the George O'Brien Kidney Center (P50DK061597), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NR 69 TC 130 Z9 137 U1 0 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2010 VL 21 IS 1 BP 93 EP 102 DI 10.1681/ASN.2009020146 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 546BK UT WOS:000273781900017 PM 19926889 ER PT J AU Herlitz, LC Markowitz, GS Farris, AB Schwimmer, JA Stokes, MB Kunis, C Colvin, RB D'Agati, VD AF Herlitz, Leal C. Markowitz, Glen S. Farris, Alton B. Schwimmer, Joshua A. Stokes, Michael B. Kunis, Cheryl Colvin, Robert B. D'Agati, Vivette D. TI Development of Focal Segmental Glomerulosclerosis after Anabolic Steroid Abuse SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ANDROGENIC STEROIDS; TESTOSTERONE; PROTEINURIA; OBESITY; WEIGHT; RATS; HYPERTENSION; PODOCYTE; INJURY; MASS AB Anabolic steroid abuse adversely affects the endocrine system, blood lipids, and the liver, but renal injury has not been described. We identified an association of focal segmental glomerulosclerosis (FSGS) and proteinuria in a cohort of 10 bodybuilders (six white and four Hispanic; mean body mass index 34.7) after long-term abuse of anabolic steroids. The clinical presentation included proteinuria (mean 10.1 g/d; range 1.3 to 26.3 g/d) and renal insufficiency (mean serum creatinine 3.0 mg/dl; range 1.3 to 7.8 mg/dl); three (30%) patients presented with nephrotic syndrome. Renal biopsy revealed FSGS in nine patients, four of whom also had glomerulomegaly, and glomerulomegaly alone in one patient. Three biopsies revealed collapsing lesions of FSGS, four had perihilar lesions, and seven showed >= 40% tubular atrophy and interstitial fibrosis. Among eight patients with mean follow-up of 2.2 yr, one progressed to ESRD, the other seven received renin-angiotensin system blockade, and one also received corticosteroids. All seven patients discontinued anabolic steroids, leading to weight loss, stabilization or improvement in serum creatinine, and a reduction in proteinuria. One patient resumed anabolic steroid abuse and suffered relapse of proteinuria and renal insufficiency. We hypothesize that secondary FSGS results from a combination of postadaptive glomerular changes driven by increased lean body mass and potential direct nephrotoxic effects of anabolic steroids. Because of the expected rise in serum creatinine as a result of increased muscle mass in bodybuilders, this complication is likely underrecognized. C1 [Herlitz, Leal C.; Markowitz, Glen S.; Stokes, Michael B.; D'Agati, Vivette D.] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA. [Schwimmer, Joshua A.; Kunis, Cheryl] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Schwimmer, Joshua A.] Lenox Hill Hosp, Dept Med, New York, NY 10021 USA. [Farris, Alton B.; Colvin, Robert B.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP D'Agati, VD (reprint author), Columbia Univ, Coll Phys & Surg, Dept Pathol, VC14-224,630 W 168th St, New York, NY 10032 USA. EM vdd1@columbia.edu OI Herlitz, Leal/0000-0003-2665-8559; Stokes, Michael/0000-0003-0958-7672 NR 38 TC 37 Z9 39 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2010 VL 21 IS 1 BP 163 EP 172 DI 10.1681/ASN.2009040450 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 546BK UT WOS:000273781900024 PM 19917783 ER PT J AU Policastro, SA Carnahan, JC Zangari, G Bart-Smith, H Seker, E Begley, MR Reed, ML Reynolds, PF Kelly, RG AF Policastro, S. A. Carnahan, J. C. Zangari, G. Bart-Smith, H. Seker, E. Begley, M. R. Reed, M. L. Reynolds, P. F. Kelly, R. G. TI Surface Diffusion and Dissolution Kinetics in the Electrolyte-Metal Interface SO JOURNAL OF THE ELECTROCHEMICAL SOCIETY LA English DT Article ID NANOPOROUS METALS; CORROSION; EVOLUTION AB Modeling of dealloying has often used a local bond-breaking approach to define the energy barrier to simulate dissolution and surface diffusion. The energy barriers are tacitly assumed to be independent of the local solution chemistry at the metal/solution interface. In this work, an interaction energy parameter is added to the local bond-breaking model that accounts for the species-specific physics of the actual atom-water molecule, atom-ion interactions and allows complex atomistic behavior to be abstracted in the modeling of the diffusion and dissolution processes. Variations in the interactions of the electrolyte components with the metal atoms led to the prediction of different surface morphologies on a binary alloy sample surface that mirror the behaviors experimentally observed in dealloying experiments in Au-Cu alloys including the formation of Au-enriched surface islands at applied potentials below the critical potential and three-dimensional porosity at applied potentials above the critical potential. (C) 2010 The Electrochemical Society. [DOI: 10.1149/1.3478572] All rights reserved. C1 [Policastro, S. A.] USN Acad, Dept Mech Engn, Annapolis, MD 21402 USA. [Carnahan, J. C.; Reynolds, P. F.] Univ Virginia, Dept Comp Sci, Charlottesville, VA 22904 USA. [Zangari, G.; Kelly, R. G.] Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA. [Bart-Smith, H.; Begley, M. R.] Univ Virginia, Dept Mech & Aerosp Engn, Charlottesville, VA 22904 USA. [Reed, M. L.] Univ Virginia, Dept Elect & Comp Engn, Charlottesville, VA 22904 USA. [Seker, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Children,Ctr Engn Med,Dept Surg, Boston, MA 02114 USA. RP Policastro, SA (reprint author), USN Acad, Dept Mech Engn, Rickover Hall,MS 11-C, Annapolis, MD 21402 USA. EM sap8b@virginia.edu RI Seker, Erkin/A-5762-2010; OI Seker, Erkin/0000-0003-2401-3562 FU National Science Foundation, NIRT [0507023] FX Research supported by the National Science Foundation, NIRT grant award no. 0507023. NR 23 TC 16 Z9 16 U1 0 U2 27 PU ELECTROCHEMICAL SOC INC PI PENNINGTON PA 65 SOUTH MAIN STREET, PENNINGTON, NJ 08534 USA SN 0013-4651 J9 J ELECTROCHEM SOC JI J. Electrochem. Soc. PY 2010 VL 157 IS 10 BP C328 EP C337 DI 10.1149/1.3478572 PG 10 WC Electrochemistry; Materials Science, Coatings & Films SC Electrochemistry; Materials Science GA 643OQ UT WOS:000281306900045 ER PT J AU Grover, S Syngal, S AF Grover, Shilpa Syngal, Sapna TI Risk Assessment, Genetic Testing, and Management of Lynch Syndrome SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article DE Lynch syndrome; hereditary nonpolyposis colorectal cancer; HNPCC; mismatch repair genes; familial colorectal cancer ID NONPOLYPOSIS COLORECTAL-CANCER; DNA-MISMATCH-REPAIR; REVISED BETHESDA GUIDELINES; GENOME-WIDE ASSOCIATION; MICROSATELLITE-INSTABILITY; COLON-CANCER; ENDOMETRIAL CANCER; MUTATION CARRIERS; CLINICAL-CRITERIA; HMSH2 GENE AB Of the estimated 150,000 colorectal cancer (CRC) cases diagnosed annually, approximately 30% have a familial basis and 3% to 5% are from high-penetrance inherited cancer syndromes. Lynch syndrome, or hereditary nonpolyposis colorectal cancer, caused by inherited germline mutations in mismatch repair (MMR) genes, is the most commonly inherited CRC syndrome. It is characterized by young-onset CRC and an increased risk for extracolonic tumors, including gynecologic, urinary tract, and other gastrointestinal cancers. Commercial testing is available for mutations in the MMR genes, but testing all patients with CRC would be economically prohibitive. Therefore, a comprehensive evaluation of a multigenerational family cancer history is essential for the identification of at-risk individuals. The presence of tumors diagnosed at a young age, multiple first- and second-degree relatives with cancer, or 2 or more primary cancers may be indicative of an inherited cancer syndrome and these individuals should undergo genetic evaluation. Genetic test results, when conclusive, can guide management for patients and their families. However, indeterminate test results may provide false reassurance to patients who should be managed as being at higher-than-average risk. Online risk assessment tools and commercial genetic testing offer the potential to identify a greater number of at-risk individuals at an earlier age. However, for these measures to improve outcomes, patients must receive screening recommendations and counseling appropriate for their cancer risk. (JNCCN 2010;8:98-105) C1 [Grover, Shilpa; Syngal, Sapna] Dana Farber Canc Inst, Boston, MA 02114 USA. [Grover, Shilpa; Syngal, Sapna] Brigham & Womens Hosp, Div Gastroenterol, Dept Med, Boston, MA 02115 USA. [Grover, Shilpa; Syngal, Sapna] Harvard Univ, Sch Med, Boston, MA USA. [Grover, Shilpa] Massachusetts Gen Hosp, Program Canc Outcomes Res Training, Boston, MA 02114 USA. RP Syngal, S (reprint author), Dana Farber Canc Inst, 44 Binney St,Smith 209, Boston, MA 02114 USA. EM ssyngal@partners.org FU National Cancer Institute [R25 CA 092203]; National Cancer Institute FX Dr. Grover has disclosed that she receives research funding from the National Cancer Institute Grant Number R25 CA 092203. Dr. Syngal has disclosed that she receives research support funding from the National Cancer Institute, is a consultant for Interquest Inc., and is an advisor for Archimedes, Inc. NR 57 TC 14 Z9 14 U1 0 U2 1 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PINE DR, SUDBURY, MA 01776 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JAN PY 2010 VL 8 IS 1 BP 98 EP 105 PG 8 WC Oncology SC Oncology GA 543LB UT WOS:000273577800006 PM 20064292 ER PT J AU Gilbert, GE Pope, C AF Gilbert, Gregory E. Pope, Charlene TI A Brief Introduction to Evaluating the Literature SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Editorial Material DE evidence-based measures; quantitative research; decision making C1 [Gilbert, Gregory E.] Ralph H Johnson VAMC, Res Serv 151, Charleston VA REAP, Charleston, SC 29401 USA. [Gilbert, Gregory E.] Natl Med Assoc, Washington, DC USA. [Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. RP Gilbert, GE (reprint author), Ralph H Johnson VAMC, Res Serv 151, Charleston VA REAP, 109 Bee St, Charleston, SC 29401 USA. EM gregory.e.gilbert@gmail.com RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496 NR 2 TC 0 Z9 0 U1 0 U2 2 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD JAN PY 2010 VL 102 IS 1 BP 65 EP 67 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 547HX UT WOS:000273878800011 PM 20158140 ER PT J AU Chu, SG Becker, RC Berger, PB Bhatt, DL Eikelboom, JW Konkle, B Mohler, ER Reilly, MP Berger, JS AF Chu, S. G. Becker, R. C. Berger, P. B. Bhatt, D. L. Eikelboom, J. W. Konkle, B. Mohler, E. R. Reilly, M. P. Berger, J. S. TI Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Article DE mean platelet volume; meta-analysis; mortality; myocardial infarction; platelets ID ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; UNSTABLE ANGINA; SUBSEQUENT RESTENOSIS; SIZE; ACTIVATION; HETEROGENEITY; INDEXES; ANGIOPLASTY; THERAPY AB Aim: To determine whether an association exists between mean platelet volume (MPV) and acute myocardial infarction (AMI) and other cardiovascular events. Platelet activity is a major culprit in atherothrombotic events. MPV, which is widely available in clinical practice, is a potentially useful biomarker of platelet activity in the setting of cardiovascular disease. Methods and Results: We performed a systematic review and meta-analysis investigating the association between MPV and AMI, all-cause mortality following myocardial infarction, and restenosis following coronary angioplasty. Results were pooled using random-effects modeling. Pooled results from 16 cross-sectional studies involving 2809 patients investigating the association of MPV and AMI indicated that MPV was significantly higher in those with AMI than those without AMI [mean difference 0.92 fL, 95% confidence interval (CI) 0.67-1.16, P < 0.001). In subgroup analyses, significant differences in MPV existed between subjects with AMI, subjects with stable coronary disease (P < 0.001), and stable controls (P < 0.001), but not vs. those with unstable angina (P = 0.24). Pooled results from three cohort studies involving 3184 patients evaluating the risk of death following AMI demonstrated that an elevated MPV increased the odds of death as compared with a normal MPV (11.5% vs. 7.1%, odds ratio 1.65, 95% CI 1.12-2.52, P = 0.012). Pooled results from five cohort studies involving 430 patients who underwent coronary angioplasty revealed that MPV was significantly higher in patients who developed restenosis than in those who did not develop restenosis (mean difference 0.98 fL, 95% CI 0.74-1.21, P < 0.001). Conclusions: Elevated MPV is associated with AMI, mortality following myocardial infarction, and restenosis following coronary angioplasty. These data suggest that MPV is a potentially useful prognostic biomarker in patients with cardiovascular disease. Whether the relationship is causal, and whether MPV should influence practice or guide therapy, remains unknown. C1 [Berger, J. S.] NYU, Sch Med, Dept Med Cardiol & Hematol, New York, NY 10016 USA. [Chu, S. G.; Konkle, B.; Mohler, E. R.; Reilly, M. P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Becker, R. C.] Duke Clin Res Inst, Durham, NC USA. [Berger, P. B.] Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA. [Bhatt, D. L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, D. L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Eikelboom, J. W.] McMaster Univ, Hamilton, ON, Canada. RP Berger, JS (reprint author), NYU, Sch Med, Dept Med Cardiol & Hematol, 530 1st Ave,SKR 9R, New York, NY 10016 USA. EM jeffrey.berger@nyumc.org OI Eikelboom, John/0000-0003-4126-1285 FU NHLBI NIH HHS [K12 HL083772] NR 65 TC 351 Z9 367 U1 1 U2 17 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1538-7933 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JAN PY 2010 VL 8 IS 1 BP 148 EP 156 DI 10.1111/j.1538-7836.2009.03584.x PG 9 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 533ZD UT WOS:000272864200025 PM 19691485 ER PT J AU Hursting, MJ Jang, IK AF Hursting, Marcie J. Jang, Ik-Kyung TI Impact of renal function on argatroban therapy during percutaneous coronary intervention SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Argatroban; Percutaneous coronary intervention; Creatinine clearance; Heparin-induced thrombocytopenia; Direct thrombin inhibitor; Renal impairment ID HEPARIN-INDUCED THROMBOCYTOPENIA; ANTICOAGULATION; PHARMACODYNAMICS; DYSFUNCTION; PHARMACOKINETICS AB Argatroban, a hepatically metabolized direct thrombin inhibitor, is approved for anticoagulation in patients with or at risk of heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI). We investigated the effect of renal function on argatroban therapy during PCI. From previous argatroban studies in PCI, we evaluated relationships between estimated creatinine clearance (CrCl) and activated clotting times (ACTs), dosage, and outcomes in 219 patients with or at risk of HIT (HIT group, n = 67) or administered glycoprotein IIb/IIIa inhibition (non-HIT group, n = 152). Patients received an argatroban bolus (350 mcg/kg, HIT group; 250 or 300 mcg/kg, non-HIT group) then 25-30 mcg/kg/min (adjusted to achieve ACTs 300-450 s, HIT group) or 15 mcg/kg/min (target ACTs 275-325 s, non-HIT group), with additional 150-mcg/kg boluses if needed. Of 219 patients, 55 (25%) had CrCl a parts per thousand currency sign 60 ml/min (8 with CrCl a parts per thousand currency sign 30 ml/min). Regression analyses detected no association between CrCl (range 7-231 ml/min) and initial ACT (by bolus) or mean infusion dose. Multi-bolus usage was similar in patients with, versus without, CrCl a parts per thousand currency sign 60 ml/min. In the non-HIT group, CrCl was associated (P = 0.01) with the time to ACT a parts per thousand currency sign 160 s after argatroban cessation (similar to 17 min slower per 30-ml/min CrCl decrease). Eight patients (none with CrCl a parts per thousand currency sign 60 ml/min) had ischemic complications. Three patients (1 with CrCl 40 ml/min) experienced major bleeding. Argatroban dose adjustment for renal function appears unnecessary during PCI. Renal dysfunction may be associated with slower (by minutes) ACT effect decay after argatroban cessation. Argatroban is well tolerated in PCI patients with renal impairment. C1 [Hursting, Marcie J.] Clin Sci Consulting, Austin, TX USA. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, Bigelow 800,55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org NR 31 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD JAN PY 2010 VL 29 IS 1 BP 1 EP 7 DI 10.1007/s11239-009-0357-8 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 537BU UT WOS:000273088700001 PM 19504050 ER PT J AU Burch, JB Svendsen, E Siegel, PD Wagner, SE von Essen, S Keefe, T Mehaffy, J Martinez, AS Bradford, M Baker, L Cranmer, B Saito, R Tessari, J Linda, P Andersen, C Christensen, O Koehncke, N Reynolds, SJ AF Burch, James B. Svendsen, Erik Siegel, Paul D. Wagner, Sara E. von Essen, Susanna Keefe, Thomas Mehaffy, John Martinez, Angelica Serrano Bradford, Mary Baker, Laura Cranmer, Brian Saito, Rena Tessari, John Linda, Prinz Andersen, Colene Christensen, Opal Koehncke, Niels Reynolds, Stephen J. TI Endotoxin Exposure and Inflammation Markers Among Agricultural Workers in Colorado and Nebraska SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID DOSE-RESPONSE RELATIONSHIPS; CHROMATOGRAPHY MASS-SPECTROMETRY; UPPER AIRWAY INFLAMMATION; AMEBOCYTE LYSATE ASSAY; 3-HYDROXY FATTY-ACIDS; SETTLED HOUSE-DUST; GAS-CHROMATOGRAPHY; ORGANIC DUST; BACTERIAL-ENDOTOXIN; ENVIRONMENTAL EXPOSURES AB The adverse respiratory effects of agricultural dust inhalation are mediated in part by endotoxin, a constituent of gram-negative bacterial cell walls. This study quantified personal work-shift exposures to inhalable dust, endotoxin, and its reactive 3-hydroxy fatty acid (3-OHFA) constituents among workers in grain elevators, cattle feedlots, dairies, and on corn farms. Exposures were compared with post-work-shift nasal lavage fluid inflammation markers and respiratory symptoms. Breathing-zone personal air monitoring was performed over one work shift to quantify inhalable dust (Institute of Medicine samplers), endotoxin (recombinant factor C [rFC] assay), and 3-OHFA (gas chromatography/mass spectrometry). Post-shift nasal lavage fluids were assayed for polymorphonuclear neutrophils (PMN), myeloperoxidase (MPO), interleukin 8 (IL-8), albumin, and eosinophilic cation protein (ECP) concentrations. The geometric mean (GSD) of endotoxin exposure (rFC assay) among the 125 male participants was 888 +/- (6.5) EU/m3, and 93% exceeded the proposed exposure limit (50 EU/m3). Mean PMN, MPO, albumin, and ECP levels were two- to threefold higher among workers in the upper quartile of 3-OHFA exposure compared to the lowest exposure quartile. Even numbered 3-OHFA were most strongly associated with nasal inflammation. Symptom prevalence was not elevated among exposed workers, possibly due to endotoxin tolerance or a healthy worker effect in this population. This is the first study to evaluate the relationship between endotoxin's 3-OHFA constituents in agricultural dust and nasal airway inflammation. More research is needed to characterize the extent to which these agents contribute to respiratory disease among agricultural workers. C1 [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] Univ S Carolina, Dept Epidemiol & Biostat, Canc Prevent & Control Program, Columbia, SC 29208 USA. [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA. [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] US Dept Vet Affairs, Med Ctr, Columbia, SC USA. [Svendsen, Erik] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Siegel, Paul D.] NIOSH, Morgantown, WV USA. [von Essen, Susanna; Linda, Prinz; Andersen, Colene; Christensen, Opal] Univ Nebraska, Med Ctr, Omaha, NE USA. [Keefe, Thomas; Mehaffy, John; Martinez, Angelica Serrano; Bradford, Mary; Baker, Laura; Cranmer, Brian; Saito, Rena; Tessari, John; Reynolds, Stephen J.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Koehncke, Niels] Univ Saskatchewan, Saskatoon, SK, Canada. RP Burch, JB (reprint author), Univ S Carolina, Dept Epidemiol & Biostat, Canc Prevent & Control Program, 915 Greene St,Room 228, Columbia, SC 29208 USA. EM burch@mailbox.sc.edu RI Svendsen, Erik/J-2671-2015 OI Svendsen, Erik/0000-0003-3941-0907 FU NIOSH CDC HHS [CDC NIOSH 5U50 OH008085, CDC NIOSH R01 OH007841] NR 53 TC 28 Z9 28 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PY 2010 VL 73 IS 1 BP 5 EP 22 AR PII 917265269 DI 10.1080/15287390903248604 PG 18 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 525QQ UT WOS:000272231800002 PM 19953416 ER PT J AU Simon, JB Schoenfeld, AJ Katz, JN Kamuth, A Wood, K Bono, CM Harris, MB AF Simon, Josef B. Schoenfeld, Andrew J. Katz, Jeffrey N. Kamuth, Atul Wood, Kirkham Bono, Christopher M. Harris, Mitchel B. TI Are "Normal" Multidetector Computed Tomographic Scans Sufficient to Allow Collar Removal in the Trauma Patient? SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Article DE Cervical spine; Trauma; Clearance; Multidetector computed tomographic scan; Cervical collar ID CERVICAL-SPINE INJURY; MULTIPLE IMAGING TECHNIQUES; BLUNT TRAUMA; EASTERN ASSOCIATION; PRACTICE GUIDELINES; UNRELIABLE PATIENT; OBTUNDED PATIENTS; CLEARANCE; SURGERY; VICTIMS AB Background: Controversy continues as to the most safe and reliable method for clearing the cervical spine (C-spine) in a trauma patient who is rendered unable to participate in a clinical examination. Although magnetic resonance imaging (MRI) is the most sensitive test to detect soft-tissue injuries, it is impractical for routine use in every patient largely because of its cost and time of acquiescence. Recent studies have advocated the sole use of multidetector computed tomographic (MDCT) scans of the C-spine to decide if cervical collar immobilization can be discontinued. The current investigation retrospectively reviewed a series of MDCT scans obtained after an acute traumatic event that were used to direct treatment in the emergency department (ED) or intensive care unit. Methods: Seven-hundred and eight trauma patients consecutively admitted to the ED between June 2001 and July 2006 underwent a computed tomographic scan of their C-spine as part of an institutional protocol. We identified 91 patients with MDCT scans that were officially recorded as adequate and negative by an attending ED radiologist who had also undergone an MRI during the same trauma admission period. Retrospectively, two fellowship-trained spine surgeons independently reviewed these MDCT studies to address the following questions: (1) Is the study adequate? (2) Is it suggestive of an acute injury? (3) Is there sufficient information to safely recommend collar removal? Institutional Review Board approval was obtained before the images were reviewed. Neither clinical examination findings nor MRI readings were made available to the surgeon evaluators. Results: Both spine surgeons agreed that 76 of the 91 studies (84%) were adequate to evaluate for possible C-spine injuries. Seven of 91 MDCT scans (8%) were deemed inadequate by both Surgeons (95% confidence interval, 2.3-13.1). Reasons for inadequacy included motion artifact, insufficient visualization of the cervical-thoracic or occipital-cervical junctions, incomplete reconstructive views, or poor quality. Three of the adequate MDCT scans had fractures that were identified by both of the spine surgeons; 4 additional fractures and 15 findings suspicious for instability were identified by at least one of the surgeons. Ultimately, 22 of 91 MDCT scans read as adequate and normal by attending radiologists were deemed suspicious for abnormality by the spine surgeons. Of these 22 cases, the official MRI reading was positive for a trauma-related abnormality in 17 cases. Conclusions: C-spine clearance of patients without the ability participate in a clinical examination remains difficult. A multidisciplinary, algorithmic approach generally yields the most consistent results. However, our data highlight that reliance on a single imaging modality may lead to missed diagnosis of C-spine injuries. These data suggest that early involvement of the spine service for radiographic clearance may help identify occult injuries or suspicious findings necessitating further evaluation. C1 [Schoenfeld, Andrew J.; Harris, Mitchel B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Katz, Jeffrey N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Simon, Josef B.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Harvard Combined Orthopaed Residency Program, Dept Orthopaed Surg, Boston, MA 02115 USA. RP Harris, MB (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg,Massachusetts Gen Hosp, 75 Francis St, Boston, MA 02115 USA. EM mbharris@partners.org OI Schoenfeld, Andrew/0000-0002-3691-1215 FU NIAMS NIH HHS [K24 AR002123-10, K24 AR002123] NR 23 TC 10 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2010 VL 68 IS 1 BP 103 EP 108 DI 10.1097/TA.0b013e3181b021da PG 6 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 543NR UT WOS:000273585800020 PM 20065764 ER PT J AU Davidovitch, RI Jordan, CJ Egol, KA Vrahas, MS AF Davidovitch, Roy I. Jordan, Charles J. Egol, Kenneth A. Vrahas, Mark S. TI Challenges in the Treatment of Femoral Neck Fractures in the Nonelderly Adult SO JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE LA English DT Review DE Femoral neck fractures; Young; Hip fracture; Avascular necrosis ID TERM-FOLLOW-UP; CANNULATED SCREW FIXATION; AVASCULAR NECROSIS; INTERNAL-FIXATION; YOUNG-ADULTS; INTRACAPSULAR FRACTURES; PAUWELS CLASSIFICATION; JOINT PRESSURE; HIP-JOINT; HEAD AB Femoral neck fractures in young patients are a relatively rare event and are often the consequence of a high-energy injury. Concomitant injuries are present more than 50% of the time. Previous reports have found the rate of nonunion and avascular necrosis in this population to be as high as 35% and 45%, respectively. The salvage options. which tend to yield more acceptable results in elderly patients with femoral neck fractures, yield disproportionately poor results in young, active patients who are often productive members of the labor force. Many reports exist in the literature evaluating the various treatment options of these injuries. This review will address the epidemiology and diagnosis of the injury. In addition, the various treatment options in the acute presentation, as well as options available for treating the sequelae of femoral neck fractures in the voting, will be discussed. Although longer life expectancy and the sustained activity level of many people previously considered elderly has blurred the definition of "young," this review will use the available literature dealing with skeletally mature patients Lip to the age of 60 years. C1 [Davidovitch, Roy I.; Jordan, Charles J.; Egol, Kenneth A.] NYU, Dept Orthopaed Surg, Orthopaed Trauma Serv, Hosp Joint Dis, New York, NY 10003 USA. [Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Orthopaed Trauma Serv, Boston, MA 02114 USA. RP Davidovitch, RI (reprint author), NYU, Dept Orthopaed Surg, Orthopaed Trauma Serv, Hosp Joint Dis, 301 E l7th St,Suite 1402, New York, NY 10003 USA. EM roy.davidovitch@nyumc.org NR 47 TC 30 Z9 42 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5282 J9 J TRAUMA JI J. Trauma-Injury Infect. Crit. Care PD JAN PY 2010 VL 68 IS 1 BP 236 EP 242 DI 10.1097/TA.0b013e3181c428ce PG 7 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA 543NR UT WOS:000273585800046 PM 20065780 ER PT J AU McDougal, WS AF McDougal, W. Scott TI Multidetector Computerized Tomography Urography is More Accurate Than Excretory Urography for Diagnosing Transitional Cell Carcinoma of the Upper Urinary Tract in Adults With Hematuria EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2010 VL 183 IS 1 BP 55 EP 55 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 531FO UT WOS:000272649300013 PM 19913251 ER PT J AU Garzotto, M AF Garzotto, Mark TI Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Portland VA Med Ctr, Dept Urol & Radiat Med, Portland, OR USA. RP Garzotto, M (reprint author), Portland VA Med Ctr, Dept Urol & Radiat Med, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2010 VL 183 IS 1 BP 123 EP 124 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 531FO UT WOS:000272649300042 PM 19913241 ER PT J AU Kundu, S Grassi, CJ Khilnani, NM Fanelli, F Kalva, SP Khan, AA McGraw, JK Maynar, M Millward, SF Owens, CA Stokes, LS Wallace, MJ Zuckerman, DA Cardella, JF Min, RJ AF Kundu, Sanjoy Grassi, Clement J. Khilnani, Neil M. Fanelli, Fabrizia Kalva, Sanjeeva P. Khan, Arshad Ahmed McGraw, J. Kevin Maynar, Manuel Millward, Steven F. Owens, Charles A. Stokes, Leann S. Wallace, Michael J. Zuckerman, Darryl A. Cardella, John F. Min, Robert J. CA Cardiovasc Interventional Radiolog Amer Coll Phlebology Soc Interventional Radiology Stand TI Multi-disciplinary Quality Improvement Guidelines for the Treatment of Lower Extremity Superficial Venous Insufficiency with Ambulatory Phlebectomy from the Society of Interventional Radiology, Cardiovascular Interventional Radiological Society of Europe, American College of Phlebology and Canadian Interventional Radiology Association SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID UIP CONSENSUS DOCUMENT; VARICOSE-VEINS; LOWER-LIMBS; MINISURGICAL PHLEBECTOMY; CEAP CLASSIFICATION; MULLERS PHLEBECTOMY; TRANS-ILLUMINATION; LOCAL-ANESTHESIA; SAPHENOUS-VEIN; DISEASE C1 [Kundu, Sanjoy] Vein Inst Toronto, Toronto, ON, Canada. [Millward, Steven F.] Peterborough Reg Hlth Ctr, Dept Radiol, Peterborough, ON, Canada. [Grassi, Clement J.] Boston Healthcare Syst VAMC, Dept Radiol, Boston, MA USA. [Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Cardella, John F.] Geisinger Hlth Syst, Danville, PA USA. [Khan, Arshad Ahmed] Washington Hosp Ctr, Dept Intervent Radiol, Bethesda, MD USA. [Min, Robert J.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, New York, NY USA. [Zuckerman, Darryl A.] Univ Cincinnati Hosp, Dept Radiol, Cincinnati, OH USA. [Owens, Charles A.] Univ Illinois, Med Ctr, Dept Radiol, Cincinnati, OH USA. [Owens, Charles A.] Univ Illinois, Med Ctr, Dept Surg, Cincinnati, OH USA. [Stokes, Leann S.] Vanderbilt Univ, Med Ctr, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA. [Wallace, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX 77030 USA. [Fanelli, Fabrizia] Univ Roma La Sapienza, Dept Radiol Sci, Intervent Radiol Unit, Rome, Italy. [Maynar, Manuel] Las Palmas Gran Canaria Univ, Hospiten Rambla Hosp, Santa Cruz de Tenerife, Spain. RP Kundu, S (reprint author), Care Of Katsarelis D, 3975 Fair Ridge Dr,Suite 400 N, Fairfax, VA 22033 USA. EM sanjoy_kundu40@hotmail.com NR 76 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2010 VL 21 IS 1 BP 1 EP 13 DI 10.1016/j.jvir.2009.01.035 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 592GX UT WOS:000277367500001 PM 19959374 ER PT J AU Slovut, DP Romero, JM Hannon, KM Dick, J Jaff, MR AF Slovut, David P. Romero, Javier M. Hannon, Kathleen M. Dick, James Jaff, Michael R. TI Detection of common carotid artery stenosis using duplex ultrasonography: A validation study with computed tomographic angiography SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID CONSECUTIVE SURGICAL RECONSTRUCTIONS; DIGITAL-SUBTRACTION-ANGIOGRAPHY; CT ANGIOGRAPHY; CERVICAL RECONSTRUCTION; TRANSTHORACIC REPAIR; 16-YEAR EXPERIENCE; SUPRAAORTIC TRUNKS; AORTIC-ARCH; DISEASE; VELOCITY AB Background: Severe stenosis of the common carotid artery (CCA), while uncommon, is associated with increased risk of transient ischemic attack and stroke. To date, no validated duplex ultrasound criteria have been established for grading the severity of CCA stenosis. The goal of this study was to use receiver-operating curve (ROC) analysis with computed tomographic angiography as the reference standard to establish duplex ultrasound criteria for diagnosing >= 50% CCA stenosis. Methods: The study cohort included 64 patients (42 men, 22 women) with a mean age of 65 +/- 12 years (range, 16-89 years) who had CCA peak systolic velocity (PSV) >= 150 cm/sec and underwent computed tomographic angiography (CTA) of the cervical and intracerebral vessels within 1 month of the duplex examination. One study was excluded because the CTA was technically inadequate, whereas another was excluded because the patient underwent bilateral CCA stenting. The CCA ipsilateral to any of the following was excluded from the analysis: innominate artery occlusion (n = 1), previous stenting of the ICA or CCA (n = 7), carotid endarterectomy (it = 1), or carotid-to-carotid bypass (n = 1). Thus, the data set included 62 patients and 115 vessels. Bland-Altman analysis was used to examine the agreement between two measures of luminal reduction measured by CTA: percent diameter stenosis and percent area stenosis. Receiver operating characteristic (ROC) analysis was used to determine optimal PSV and EDV thresholds for diagnosing >= 50% CCA stenosis. Results: Severity of CCA stenosis was <50% in 76 vessels, 50%-59% in eight, 60%-69% in eight, 70%-79% in nine, 80%-89% in three, 90%-99% in five, and occluded in six. Duplex ultrasonography identified six of six (100%) patients with 100% CCA occlusion by CTA. Bland-Altman analysis showed poor agreement between percent stenosis determined by vessel diameter compared with percent stenosis determined by reduction in lumen area. Therefore, subsequent analysis was performed using percent stenosis by at-ea. ROC analysis of different PSV thresholds for detecting stenosis >= 50% showed that >182 cm/sec was the most accurate with a sensitivity of 64% and specificity of 88% (P < .0001). Sensitivity, specificity, and accuracy of carotid duplex were higher when the stenosis was located in the mid or distal aspects of the CCA (sensitivity 76%, specificity 89%, area under curve 0.84, P < .001) than in the intrathoracic and proximal segment of the artery (P = NS). ROC analysis of different EDV thresholds for detecting CCA stenosis >= 50% showed that >30 cm/sec was the most accurate with a sensitivity of 54% and a specificity of 74% (P < .0239). Conclusions: Duplex ultrasonography is highly sensitive, specific, and accurate for detecting CCA lesions in the mid and distal CCA. Use of peak systolic velocity may lead to improved detection of CCA disease and initiation of appropriate therapy to reduce the risk of stroke. (J Vase Surg 2010;51:65-70.) C1 [Slovut, David P.; Hannon, Kathleen M.; Dick, James; Jaff, Michael R.] Massachusetts Gen Hosp, Vasc Ctr, Boston, MA 02114 USA. [Slovut, David P.] N Shore Med Ctr, Dept Cardiol, Salem, MA USA. [Slovut, David P.] N Shore Med Ctr, Dept Vasc Med, Salem, MA USA. [Romero, Javier M.] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. RP Jaff, MR (reprint author), Massachusetts Gen Hosp, Vasc Ctr, Boston, MA 02114 USA. EM mjaff@partners.org NR 33 TC 8 Z9 8 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2010 VL 51 IS 1 BP 65 EP 70 DI 10.1016/j.jvs.2009.08.002 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 545BX UT WOS:000273708500012 PM 19879097 ER PT J AU Peck, MA Conrad, MF Kwolek, CJ LaMuraglia, GM Paruchuri, V Cambria, RP AF Peck, Michael A. Conrad, Mark F. Kwolek, Christopher J. LaMuraglia, Glenn M. Paruchuri, Vikram Cambria, Richard P. TI Intermediate-term outcomes of endovascular treatment for symptomatic chronic mesenteric ischemia SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 35th Annual Meeting of the New-England-Society-for-Vascular-Surgery CY OCT 03-05, 2008 CL Newport, RI SP New England Soc Vasc Surg ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; CHRONIC INTESTINAL ISCHEMIA; SURGICAL REVASCULARIZATION; OCCLUSIVE DISEASE; FOLLOW-UP; THERAPY; ARTERY; EXPERIENCE; CATHETER; STENOSES AB Objective: Endovascular therapy for chronic mesenteric ischemia (CMI) has been increasingly utilized. Early outcomes compare favorably with open mesenteric bypass-the current gold standard. The goal of this study is documentation of intermediate-term anatomic and functional outcomes of endovascular mesenteric revascularization for symptomatic CMI. Methods: This is a retrospective review of all patients undergoing endovascular treatment of symptomatic CMI from July 2002 to March 2008. Study endpoints included periprocedural mortality, major morbidity, patency, symptomatic recurrence, and survival. Endpoints were analyzed using actuarial methods. Results: Sixty-six mesenteric arteries (78.8% stenotic/21.2% occluded) were treated in 49 patients. One or more vessels were treated in each case; however, four mesenteric artery total occlusions (3 SMAs/I IMA,) could not be crossed. Initial symptom relief was noted in 89.8% (n = 44) with no change in 5 patients. Single-vessel treatments were performed in 32 patients (65.3%) and two-vessel interventions in 17 (34.7%). The 30-day mortality rate was 2.0% (it = 1). Major complications occurred in 8 patients (16.3%). The mean follow-up duration was 37.4 +/- 2.98 months (range, 0-66). Restenosis on follow-up imaging occurred in 64.9% (n = 24) of the 37 patients who had radiographic surveillance at a mean follow-up interval of 8.5 +/- 1.9 months and was diagnosed most often by Duplex scan or computed tomographic angiography (CTA). Fourteen patients (28.6%) developed recurrent symptoms with 13 requiring a reintervention. Actuarial 36-month freedom from symptomatic recurrence was 60.9% +/- 9.4%. Two-vessel treatment was protective against symptom recurrence (P = .0014) and reintervention (P = .0060) by univariate analysis. A total of 19 reinterventions were required in 14 patients (28.6%) at a mean of 17 months from the original treatment. Primary patency at 36 months,vas 63.9 +/- 8.5%. Actuarial survival at 48 months was 81.1% +/- 6.1% with no CMI-related deaths in the study cohort. Conclusion: Intermediate (3-year) follow-up indicates that significant restenosis and symptom recurrence are common following the endovascular treatment of symptomatic CMI. Thirty percent of the cohort required a reintervention, one-third of which were conversions to surgical reconstruction. Similar to the surgical paradigm of two-vessel revascularization, endovascular treatment of multiple mesenteric arteries produced better outcomes. A first-line endovascular approach to patients with CMI is a reasonable clinical strategy, but close follow-up is mandatory. (J Vase Surg 2010;51:140-7.) C1 [Peck, Michael A.] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Peck, MA (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,WAC 440, Boston, MA 02114 USA. EM peckmic@gmail.com NR 36 TC 20 Z9 22 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JAN PY 2010 VL 51 IS 1 BP 140 EP 147 DI 10.1016/jvs.2009.06.064 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 545BX UT WOS:000273708500025 PM 19837530 ER PT J AU Karmali, F Shelhamer, M AF Karmali, Faisal Shelhamer, Mark TI Neurovestibular considerations for sub-orbital space flight: A framework for future investigation SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article ID VERTICAL VESTIBULOOCULAR REFLEX; CONTEXT-SPECIFIC ADAPTATION; SACCADIC EYE-MOVEMENTS; MOTION SICKNESS; PARABOLIC FLIGHT; GRAVITOINERTIAL FORCE; SPATIAL ORIENTATION; ORTHOSTATIC INTOLERANCE; VESTIBULAR EXPERIMENTS; ROTATIONAL KINEMATICS AB Commercial sub-orbital operators will soon offer the excitement of traveling to space to thousands of people. Based on previous experience in space flight and parabolic flight, sensorimotor disruptions in eye movements, postural stability, and motor coordination are likely in these travelers. Here we propose a framework for developing strategies to overcome these sensorimotor disruptions. We delineate how approaches should differ from those applied to orbital flight and between sub-orbital passengers and pilots based on differing frequency of flights and mission objectives. Sensorimotor adaptation is one strategy for overcoming disruptions; an important question is whether it occurs quickly enough to be of use during periods of reduced and enhanced gravity lasting less than five minutes. Data are presented showing that sensorimotor adaptation of the pitch vestibulo-ocular reflex during parabolic flight takes a few consecutive days of flying to overcome an initial disruption. We conclude with recommendations for operators and researchers to improve safety and comfort during sub-orbital operations. We recommend using parabolic flight as a tool for pre-adapting sub-orbital passengers, along with further research into the required quantity and timing of these pre-adaptation flights and the tasks conducted during these flights. Likewise, for sub-orbital pilots, we recommend emphasizing recency of experience. C1 [Karmali, Faisal] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Shelhamer, Mark] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA. [Shelhamer, Mark] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA. RP Shelhamer, M (reprint author), Johns Hopkins Univ Hosp, 2-210 Pathol Bldg,600 N Wolfe St, Baltimore, MD 21287 USA. EM mjs@dizzy.med.jhu.edu OI Karmali, Faisal/0000-0002-1140-4954 FU NIDCD NIH HHS [R21 DC006090] NR 73 TC 9 Z9 9 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2010 VL 20 IS 1-2 BP 31 EP 43 DI 10.3233/VES-2010-0349 PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 636OT UT WOS:000280748200004 PM 20555165 ER PT J AU Wall, C Kentala, E AF Wall, C., III Kentala, E. TI Effect of displacement, velocity, and combined vibrotactile tilt feedback on postural control of vestibulopathic subjects SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE Vestibular; postural control; balance prosthesis; vibrotactile feedback; balance rehabilitation ID BILATERAL VESTIBULAR LOSS; BALANCE PROSTHESIS; AUDIO-BIOFEEDBACK; STIMULATION; IMPROVEMENT; DEFICITS; SYSTEM; SWAY AB Vibrotactile tilt feedback was used to help vestibulopathic subjects control their anterioposterior (AP) sway during sensory organization tests 5 and 6 of Equitest computerized dynamic posturography. We used four kinds of signals to activate the feedback. The first signal was proportional (P) to the measured tilt of the subject, while the second used the first derivative (D) of the tilt. The third signal was the sum of the proportional and one half of the first derivative signals (PD). The final signal used a prediction of the subject's sway projected 100 msec in advance. The signals were used to activate vibrators mounted on the front of the torso to signal forward motion, and on the back of the torso for backward motion. Subject responses varied significantly with the kind of feedback signal. Proportional and derivative feedback resulted in similar root mean squared tilt, but the PD signal significantly reduced the tilt compared to either P or D feedback. The predicted motion signal also reduced the response compared to the PD signal. These preliminary results are somewhat consistent with an inverted pendulum model of postural control, but need to be confirmed with a larger study that also considers mediolateral tilt and feedback. The improvement by using a predictor is consistent with compensating for a neural processing delay. C1 [Wall, C., III; Kentala, E.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Wall, C., III; Kentala, E.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Kentala, E.] Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland. RP Wall, C (reprint author), Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. EM cwall@mit.edu FU Leiras Research Foundation; National Institutes of Health [NIH NIDCD R01 DC6201] FX We gratefully acknowledge the help of David Balk-will for programming assistance, Joseph B. Nadol, Jr., M. D., the Massachusetts Eye and Ear Infirmary for facilities support, and the Leiras Research Foundation for support of Dr. Kentala. We thank Drs. Steven Rauch and Richard Lewis for providing well-selected subjects for this study. Finally, we acknowledge NeuroCom International for the generous donation of Balance Master software, and the National Institutes of Health for support in developing and validating the motion sensor arrays (NIH NIDCD R01 DC6201). NR 27 TC 17 Z9 17 U1 4 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2010 VL 20 IS 1-2 BP 61 EP 69 DI 10.3233/VES-2010-0369 PG 9 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 636OT UT WOS:000280748200007 PM 20555168 ER PT J AU Merfeld, DM Priesol, A Lee, D Lewis, RF AF Merfeld, Daniel M. Priesol, Adrian Lee, Daniel Lewis, Richard F. TI Potential solutions to several vestibular challenges facing clinicians SO JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION LA English DT Article DE Perception; prosthesis; psychophysics; threshold; clinical; spatial disorientation; imbalance ID QUALITATIVELY DIFFERENT MECHANISMS; SEMICIRCULAR CANAL PROSTHESIS; CONTEXT-SPECIFIC ADAPTATION; ELECTRICAL-STIMULATION; MIGRAINOUS VERTIGO; PERCEPTUAL RESPONSES; NERVE STIMULATION; POSTURAL CONTROL; AUDITORY-NERVE; TILT AB Among other problems, patients with vestibular problems suffer imbalance, spatial disorientation, and blurred vision. These problems lead to varying degrees of disability and can be debilitating. Unfortunately, a large number of patients with vestibular complaints cannot be diagnosed with the clinical tests available today. Nor do we have treatments for all patients that we can diagnose. These clinical problems provide challenges to and opportunities for the field of vestibular research. In this paper, we discuss some new diagnostic and treatment options that could become available for tomorrow's patients. As a new diagnostic, we have begun measuring patient's perceptual direction-detection thresholds. Preliminary results appear encouraging; patients diagnosed with bilateral loss have yaw rotation thresholds almost ten times greater than normals, while patients diagnosed with migraine associated vertigo have roll tilt thresholds well below normal at 0.1 Hz. As a new treatment, we have performed animal studies looking at responses evoked by electrical stimulation provided by a vestibular prosthesis. Results measuring the VOR demonstrate promise and preliminary studies of balance and perception are also encouraging. While electrical stimulation is a standard means of stimulation, optical stimulation is also being investigated as a way to improve prosthetic stimulation specificity. C1 [Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA. [Merfeld, Daniel M.; Priesol, Adrian; Lee, Daniel; Lewis, Richard F.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Merfeld, DM (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Room 421,243 Charles St, Boston, MA 02114 USA. EM dan_merfeld@meei.harvard.edu FU NIDCD NIH HHS [R01 DC008362, R01 DC004158, R01 DC004158-05, R01 DC008362-02] NR 57 TC 14 Z9 14 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0957-4271 J9 J VESTIBUL RES-EQUIL JI J. Vestib. Res.-Equilib. Orientat. PY 2010 VL 20 IS 1-2 BP 71 EP 77 DI 10.3233/VES-2010-0347 PG 7 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 636OT UT WOS:000280748200008 PM 20555169 ER PT J AU Sroczynski, G Esteban, E Conrads-Frank, A Schwarzer, R Muhlberger, N Wright, D Zeuzem, S Siebert, U AF Sroczynski, G. Esteban, E. Conrads-Frank, A. Schwarzer, R. Muehlberger, N. Wright, D. Zeuzem, S. Siebert, U. TI Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE antiviral treatment; chronic hepatitis C; cost-effectiveness; effectiveness ID ALPHA-2B PLUS RIBAVIRIN; VIRUS-INFECTED PATIENTS; COMBINATION THERAPY; INITIAL TREATMENT; ECONOMIC-EVALUATION; INTERFERON-ALPHA; NAIVE PATIENTS; FOLLOW-UP; PEGINTERFERON; HEALTH AB We systematically reviewed the evidence for long-term effectiveness and cost-effectiveness of antiviral treatment in patients with chronic hepatitis C. We performed a systematic literature search on the long-term effectiveness and cost-effectiveness of AVT in hepatitis C (1990-March 2007), and included health technology assessment (HTA) reports, systematic reviews, long-term clinical trials, economic studies conducted alongside clinical trials and decision-analytic modelling studies. All costs were converted to 2005(sic). Antiviral therapy with peginterferon plus ribavirin in treatment-naive patients with chronic hepatitis C was the most effective (3.6-4.7 life years gained [LYG]) treatment and was reasonably cost-effective (cost-saving to 84 700(sic)/quality adjusted life years [QALY]) when compared to interferon plus ribavirin. Some results also suggest cost-effectiveness (below 8400(sic)/(QALY) of re-treatment in nonresponders/relapsers. Results for patients with persistently normal alanine aminotransferase (ALT) levels or with special co-morbidities (e. g. HIV) or risk profiles were rare. We conclude that antiviral therapy may prolong life, improve long-term health-related quality-of-life and be reasonably cost-effective in treatment-naive patients with chronic hepatitis C as well as in former relapsers/nonresponders. Further research is needed in patients with specific co-morbidities or risk profiles. C1 [Sroczynski, G.; Esteban, E.; Schwarzer, R.; Muehlberger, N.; Siebert, U.] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Informat Syst & Hlth Technol Asses, Inst Publ Hlth Med Decis Making & Hlth Technol As, A-6060 Hall In Tirol, Austria. [Conrads-Frank, A.; Wright, D.; Siebert, U.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA. [Conrads-Frank, A.; Wright, D.; Siebert, U.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Zeuzem, S.] Goethe Univ Frankfurt, Dept Internal Med Gastroenterol Hepatol Pneumol &, Frankfurt, Germany. [Siebert, U.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Dept Hlth Policy & Management, Boston, MA 02115 USA. RP Siebert, U (reprint author), UMIT, A-6060 Hall In Tirol, Austria. EM public-health@umit.at FU Hoffmann La-Roche Ltd, Basel, Switzerland FX This project was supported in part by an unrestricted educational grant from Hoffmann La-Roche Ltd, Basel, Switzerland. The authors had complete and independent control over study design, analysis and interpretation of data, report writing, and publication, regardless of results. NR 69 TC 24 Z9 25 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2010 VL 17 IS 1 BP 34 EP 50 DI 10.1111/j.1365-2893.2009.01147.x PG 17 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 545KT UT WOS:000273731700005 PM 19656290 ER PT J AU Henderson, WA Shankar, R Gill, JM Kim, KH Ghany, MG Skanderson, M Butt, AA AF Henderson, Wendy A. Shankar, Ravi Gill, Jessica M. Kim, Kevin H. Ghany, Marc G. Skanderson, Melissa Butt, Adeel A. TI Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE co-morbidity; dialysis; end stage renal disease; hepatitis C; hepatocellular carcinoma ID CHRONIC-HEMODIALYSIS PATIENTS; HIV-INFECTED VETERANS; VIRUS-INFECTION; UNITED-STATES; RISK; COINFECTION; CIRRHOSIS; IMPACT; COMORBIDITIES; SURVIVAL AB Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection; the primary cause for adult liver transplantation and a significant burden on healthcare resources. The role of HCV and other risk factors in development of HCC in patients with chronic kidney disease is not well defined. We studied predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic HCV by analyzing factors associated with its development. Data were extracted from the United States Renal Database System (USRDS) using ICD-9 codes. Variables included were gender, race, duration on dialysis and co-morbidities (alcohol abuse, drug abuse, HIV, hepatitis B, diabetes and/or presence of cirrhosis). Among the 32 806 HCV infected subjects, 262 cases had HCC. HCC was 12 times more likely in subjects with cirrhosis (P < 0.001), three times more likely in subjects with alcohol abuse (P < 0.001), and 1.3 times more likely in subjects with diabetes (P = 0.04). Asians were three times more likely (P < 0.001) to have HCC. Females were less likely to have HCC compared to males (P = 0.002). The likelihood of having HCC increased with age (P = 0.001). This population-based study demonstrates that among subjects with HCV on dialysis, those with cirrhosis, Asian race and history of alcohol abuse are at highest risk for development of HCC. Furthermore, these findings indicate links between HCV and HCC which are valuable in case management for identifying; monitoring, and managing dialysis patients with HCC. C1 [Henderson, Wendy A.] NINR, Symptoms Management Branch, Biobehav Unit, NIH, Bethesda, MD 20892 USA. [Kim, Kevin H.] Univ Pittsburgh, Sch Educ, Pittsburgh, PA 15260 USA. [Ghany, Marc G.] NIDDK, NIH, Bethesda, MD USA. [Skanderson, Melissa] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Henderson, WA (reprint author), NINR, Symptoms Management Branch, Biobehav Unit, NIH, 10 Ctr Dr,2-1339, Bethesda, MD 20892 USA. EM hendersw@mail.nih.gov OI Henderson, Wendy/0000-0003-3924-7118 FU National Institutes of Health [NIH, 1TL1 RR024155-01, NIH/NIDA, DA016175-01A1]; University of Pittsburgh School of Nursing; Educational Innovation Fund; Duquesne University School of Nursing FX Support was provided by the Symptoms Management Branch, Intramural Research Program, National Institute of Nursing Research, National Institutes of Health. Additional support was provided by the following: Clinical & Translational Science Institute Fellowship (Henderson): NIH, 1TL1 RR024155-01(Reis), NIH/NIDA, DA016175-01A1, (Butt); University of Pittsburgh School of Nursing, Educational Innovation Fund; Duquesne University School of Nursing, Dean's Fund (Henderson). Special thanks to Drs. Thelma Patrick and Mary Ann Thurkettle for their assistance with the pilot phase of this study. NR 28 TC 13 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2010 VL 17 IS 1 BP 59 EP 64 DI 10.1111/j.1365-2893.2009.01151.x PG 6 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 545KT UT WOS:000273731700007 PM 19566787 ER PT J AU Krishnan, L Matreyek, KA Oztop, I Lee, K Tipper, CH Li, X Dar, MJ KewalRamani, VN Engelman, A AF Krishnan, Lavanya Matreyek, Kenneth A. Oztop, Ilker Lee, Kyeongeun Tipper, Christopher H. Li, Xiang Dar, Mohd J. KewalRamani, Vineet N. Engelman, Alan TI The Requirement for Cellular Transportin 3 (TNPO3 or TRN-SR2) during Infection Maps to Human Immunodeficiency Virus Type 1 Capsid and Not Integrase SO JOURNAL OF VIROLOGY LA English DT Article ID MURINE LEUKEMIA-VIRUS; REVERSE TRANSCRIPTION COMPLEXES; NUCLEAR IMPORT RECEPTOR; NONDIVIDING CELLS; GENE-TRANSFER; HIV-1 INFECTION; ANEMIA-VIRUS; PREINTEGRATION COMPLEXES; RETROVIRAL VECTORS; LENTIVIRAL VECTOR AB Recent genome-wide screens have highlighted an important role for transportin 3 in human immunodeficiency virus type 1 (HIV-1) infection and preintegration complex (PIC) nuclear import. Moreover, HIV-1 integrase interacted with recombinant transportin 3 protein under conditions whereby Moloney murine leukemia virus (MLV) integrase failed to do so, suggesting that integrase-transportin 3 interactions might underscore active retroviral PIC nuclear import. Here we correlate infectivity defects in transportin 3 knockdown cells with in vitro protein binding affinities for an expanded set of retroviruses that include simian immunodeficiency virus (SIV), bovine immunodeficiency virus (BIV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), and Rous sarcoma virus (RSV) to critically address the role of integrase-transportin 3 interactions in viral infection. Lentiviruses, with the exception of FIV, display a requirement for transportin 3 in comparison to MLV and RSV, yielding an infection-based dependency ranking of SIV > HIV-1 > BIV and EIAV > MLV, RSV, and FIV. In vitro pulldown and surface plasmon resonance assays, in contrast, define a notably different integrase-transportin 3 binding hierarchy: FIV, HIV-1, and BIV > SIV and MLV > EIAV. Our results therefore fail to support a critical role for integrase binding in dictating transportin 3 dependency during retrovirus infection. In addition to integrase, capsid has been highlighted as a retroviral nuclear import determinant. Accordingly, MLV/HIV-1 chimera viruses pinpoint the genetic determinant of sensitization to transportin 3 knockdown to the HIV-1 capsid protein. We therefore conclude that capsid, not integrase, is the dominant viral factor that dictates transportin 3 dependency during HIV-1 infection. C1 [Krishnan, Lavanya; Matreyek, Kenneth A.; Oztop, Ilker; Tipper, Christopher H.; Li, Xiang; Dar, Mohd J.; Engelman, Alan] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Krishnan, Lavanya; Matreyek, Kenneth A.; Oztop, Ilker; Tipper, Christopher H.; Li, Xiang; Dar, Mohd J.; Engelman, Alan] Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA. [Lee, Kyeongeun; KewalRamani, Vineet N.] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA. RP Engelman, A (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,CLSB-1010, Boston, MA 02115 USA. EM alan_engelman@dfci.harvard.edu RI Li, Xiang/C-4588-2011; OI Matreyek, Kenneth/0000-0001-9149-551X FU HIV Drug Resistance Program; NIH [AI052014]; Harvard University Center for AIDS Research [P30AI060354]; NIH FX This work was supported by the HIV Drug Resistance Program (V.N.K.), NIH grant AI052014 (A. E.), and the Harvard University Center for AIDS Research, an NIH-funded program (grant P30AI060354), which is supported by the following NIH institutes and centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, and NCCAM. NR 55 TC 100 Z9 101 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2010 VL 84 IS 1 BP 397 EP 406 DI 10.1128/JVI.01899-09 PG 10 WC Virology SC Virology GA 530BQ UT WOS:000272564300038 PM 19846519 ER PT J AU Prado, JG Prendergast, A Thobakgale, C Molina, C Tudor-Williams, G Ndung'u, T Walker, BD Goulder, P AF Prado, Julia G. Prendergast, Andrew Thobakgale, Christina Molina, Claudia Tudor-Williams, Gareth Ndung'u, Thumbi Walker, Bruce D. Goulder, Philip TI Replicative Capacity of Human Immunodeficiency Virus Type 1 Transmitted from Mother to Child Is Associated with Pediatric Disease Progression Rate SO JOURNAL OF VIROLOGY LA English DT Article ID C-INFECTED CHILDREN; LONG-TERM SURVIVOR; HIV-1-INFECTED CHILDREN; ESCAPE MUTATIONS; VIRAL LOAD; AFRICAN INFANTS; HIGH-FREQUENCY; HIV-INFECTION; GAG; FITNESS AB Human immunodeficiency virus (HIV)-infected infants in the developing world typically progress to AIDS or death within the first 2 years of life. However, a minority progress relatively slowly. This study addresses the potential contribution of viral factors to HIV disease progression in eight infants selected from a well-characterized cohort of C clade HIV-infected infants, monitored prospectively from birth in Durban, South Africa. Three infants were defined as "progressors," and five were defined as "slow progressors." We observed that slow-progressor infants carry HIV isolates with significantly lower replicative capacity compared to virus from progressors. Furthermore, our data suggest a link between the attenuated viral phenotype and HLA-B* 57/5801 epitope-specific Gag mutational patterns of the transmitted virus and not to coreceptor usage or to the presence of Nef deletions or insertions. These data underline the importance of virus-host interactions and highlight the contribution of viral attenuation through Gag-specific CD8(+) T-cell escape mutations, among other factors, in the control of pediatric HIV infection. C1 [Prado, Julia G.; Prendergast, Andrew; Molina, Claudia; Walker, Bruce D.; Goulder, Philip] Univ Oxford, Dept Pediat, Oxford OX1 3SY, England. [Thobakgale, Christina; Ndung'u, Thumbi; Goulder, Philip] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa. [Tudor-Williams, Gareth] Univ London Imperial Coll Sci Technol & Med, Dept Pediat, London, England. [Walker, Bruce D.] Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA 02129 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20185 USA. [Prado, Julia G.] Hosp Badalona Germans Trias & Pujol, Fdn IrsiCaixa, Barcelona 08916, Spain. RP Prado, JG (reprint author), Hosp Badalona Germans Trias & Pujol, Fdn IrsiCaixa, Crta Canyet SN, Barcelona 08916, Spain. EM jgarciaprado@irsicaixa.es; philip.goulder@paediatrics.ox.ac.uk OI Ndung'u, Thumbi/0000-0003-2962-3992 FU Doris Duke Charitable foundation [2001 1031]; Wellcome Trust; Bristol Myers Squibb Secure the Future [RES 16/01]; Marie Curie [41811 (IEF-FP6)] FX This project was funded by the Doris Duke Charitable foundation (2001 1031 to P. G.), the Wellcome Trust (P. G.), and Bristol Myers Squibb Secure the Future (RES 16/01 to P. G.). J. G. P. holds Marie Curie contract 41811 (IEF-FP6). T. N. holds the South African Department of Science and Technology/National Research Foundation Chair in Systems Biology of HIV/AIDS. NR 44 TC 20 Z9 20 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2010 VL 84 IS 1 BP 492 EP 502 DI 10.1128/JVI.01743-09 PG 11 WC Virology SC Virology GA 530BQ UT WOS:000272564300047 PM 19828603 ER PT J AU Ghorashi, S Enns, JT Klein, RM Di Lollo, V AF Ghorashi, Shahab Enns, James T. Klein, Raymond M. Di Lollo, Vincent TI Spatial selection and target identification are separable processes in visual search SO JOURNAL OF VISION LA English DT Article DE attention; visual search; spatial selection; identification; attentional blink ID ATTENTIONAL BLINK; OPTIC ATAXIA; OBJECTS; VISION; MODEL; TASK; INTERFERENCE; PERCEPTION; DISPLAYS AB Visual search involves deciding both where to look (spatial selection) and whether any given object is a target or a nontarget (identification). The aim of the present study was to determine whether these two functions are separable in performance. Spatial selection was manipulated by an exogenous cue and identification was manipulated by whether a second target appeared after a short or long delay following a first target (the attentional blink, AB). Experiment 1 indicated an additive relation between non-informative spatial cueing and the AB, pointing to independent spatial and identification processes. Experiment 2 tested an informative spatial cue with similar results. Experiment 3 also showed an additive relationship, using a response measure that avoided possible floor effects. We interpret the separability of spatial selection and identification as reflecting the independent operation of dorsal and ventral visual pathways, respectively, at least at the early stages of processing. C1 [Ghorashi, Shahab] Harvard Univ, Cambridge, MA 02138 USA. [Enns, James T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Klein, Raymond M.] Dalhousie Univ, Halifax, NS B3H 3J5, Canada. [Di Lollo, Vincent] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. RP Ghorashi, S (reprint author), VA Boston Healthcare Syst, Res 151C,150 S Huntington Ave, Boston, MA 02130 USA. EM shahab.ghorashi@gmail.com FU Natural Sciences and Engineering Research Council (Canada) FX This research was supported by individual Discovery Research Grants from the Natural Sciences and Engineering Research Council (Canada) to V. Di Lollo, J. T. Enns, and R. M. Klein. NR 52 TC 12 Z9 13 U1 2 U2 6 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 1534-7362 J9 J VISION JI J. Vision PY 2010 VL 10 IS 3 AR 7 DI 10.1167/10.3.7 PG 12 WC Ophthalmology SC Ophthalmology GA 589UQ UT WOS:000277180100007 ER PT J AU Nasr, S AF Nasr, Shahin TI Differential impact of attention on the early and late categorization related human brain potentials SO JOURNAL OF VISION LA English DT Article DE event-related potential (ERP); object-selective attention; visual backward masking; N170; P400 ID EVENT-RELATED POTENTIALS; HUMAN FACE PERCEPTION; CORTICAL RESPONSES; BACKWARD-MASKING; REACTION-TIME; VISUAL-ATTENTION; DECISION-MAKING; RECOGNITION; CORTEX; MODULATION AB Previous human studies have shown that object-selective attention enhances neural activities evoked in response to target stimuli. However, it is not clear whether the magnitude of activity enhancement is constant or varies according to the level of stimulus visibility. To examine the effect of attentional modulation on different event-related potentials (ERPs) and the relationship between attentional modulation and level of stimulus visibility, subjects were instructed to perform face detection and leaf detection tasks in separate blocks while the level of stimulus visibility varied randomly from trial to trial. As a result of object-selective attention, N170 and P400 ERP components were both modulated in response to the task target category compared to when the same category was used as distracter. We found that the magnitude of modulation of the N170 component was independent of the stimulus visibility level, while the P400 ERP component showed increased enhancement as the level of stimulus visibility increased. These findings demonstrate that attention impacts the neural populations, indexed by early (N170) and late (P400) evoked potentials, differentially and that attentional modulation becomes increasingly dependent on the level of stimulus visibility through the course of brain activities. C1 [Nasr, Shahin] Inst Res Fundamental Sci IPM, Sch Cognit Sci, Tehran, Iran. [Nasr, Shahin] Shahid Beheshti Univ, Sch Med, Res Ctr Brain & Cognit Sci, Tehran, Iran. RP Nasr, S (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM shahin@nmr.mgh.harvard.edu NR 55 TC 2 Z9 2 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 1534-7362 J9 J VISION JI J. Vision PY 2010 VL 10 IS 11 AR 18 DI 10.1167/10.11.18 PG 18 WC Ophthalmology SC Ophthalmology GA 674XF UT WOS:000283783500018 PM 20884513 ER PT J AU Herring, SJ Platek, DN Elliott, P Riley, LE Stuebe, AM Oken, E AF Herring, Sharon J. Platek, Deborah N. Elliott, Patricia Riley, Laura E. Stuebe, Alison M. Oken, Emily TI Addressing Obesity in Pregnancy: What Do Obstetric Providers Recommend? SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GESTATIONAL WEIGHT-GAIN; BODY-MASS INDEX; PRIMARY-CARE; LOSE WEIGHT; PHYSICIANS; WOMEN; PREVENTION; EXERCISE; MOTHERS; ADVICE AB Objective: Maternal obesity is associated with adverse pregnancy outcomes. To improve outcomes, obstetric providers must effectively evaluate and manage their obese pregnant patients. We sought to determine the knowledge, attitudes, and practice patterns of obstetric providers regarding obesity in pregnancy. Methods: In 2007-2008, we surveyed 58 practicing obstetricians, nurse practitioners, and certified nurse-midwives at a multispecialty practice in Massachusetts. We administered a 26-item questionnaire that included provider self-reported weight, sociodemographic characteristics, knowledge, attitudes, and management practices. We created an 8-point score for adherence to 8 practices recommended by the American College of Obstetricians and Gynecologists (ACOG) for the management of obese pregnant women. Results: Among the respondents, 37% did not correctly report the minimum body mass index (BMI) for diagnosing obesity, and most reported advising gestational weight gains that were discordant with 1990 Institute of Medicine (IOM) guidelines, especially for obese women (71%). The majority of respondents almost always recommended a range of weight gain (74%), advised regular physical activity (74%), or discussed diet (64%) with obese mothers, but few routinely ordered glucose tolerance testing during the first trimester (26%), planned anesthesia referrals (3%), or referred patients to a nutritionist (14%). Mean guideline adherence score was 3.4 (SD 1.9, range 0-8). Provider confidence (beta = 1.0, p = 0.05) and body satisfaction (beta = 1.5, p = 0.02) were independent predictors of higher guideline adherence scores. Conclusions: Few obstetric providers were fully compliant with clinical practice recommendations, defined obesity correctly, or recommended weight gains concordant with IOM guidelines. Provider personal factors were the strongest correlates of self-reported management practices. Our findings suggest a need for more education around BMI definitions and weight gain guidelines, along with strategies to address provider personal factors, such as confidence and body satisfaction, that may be important predictors of adherence to recommendations for managing obese pregnant women. C1 [Herring, Sharon J.] Temple Univ, Sch Med, Ctr Obes Res & Educ, Philadelphia, PA 19140 USA. [Platek, Deborah N.] Harvard Vanguard Med Associates, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA USA. [Elliott, Patricia; Oken, Emily] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Obes Prevent Program, Boston, MA USA. [Elliott, Patricia; Oken, Emily] Harvard Pilgrim Hlth Care, Boston, MA USA. [Riley, Laura E.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02114 USA. [Stuebe, Alison M.] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chapel Hill, NC USA. RP Herring, SJ (reprint author), Temple Univ, Sch Med, Ctr Obes Res & Educ, 3223 N Broad St,Suite 175, Philadelphia, PA 19140 USA. EM Sharon_Herring@post.harvard.edu FU Harvard Pilgrim Health Care Foundation; Health Resources and Services Administration [5 T32 HP11001-19]; Department of Ambulatory Care and Prevention at Harvard Medical School and Harvard Pilgrim Health Care in Boston, Massachusetts FX This study was supported by a grant from the Harvard Pilgrim Health Care Foundation. S.J.H. was supported by an institutional Ruth L. Kirschstein National Research Service Award (5 T32 HP11001-19) from the Health Resources and Services Administration and the Department of Ambulatory Care and Prevention at Harvard Medical School and Harvard Pilgrim Health Care in Boston, Massachusetts. NR 24 TC 41 Z9 43 U1 1 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JAN PY 2010 VL 19 IS 1 BP 65 EP 70 DI 10.1089/jwh.2008.1343 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 545ZN UT WOS:000273776500010 PM 20088660 ER PT J AU O'Donnell, EH Moreau, M Cardemil, EV Pollastri, A AF O'Donnell, Ellen H. Moreau, Melissa Cardemil, Esteban V. Pollastri, Alisha TI Interparental Conflict, Parenting, and Childhood Depression in a Diverse Urban Population: The Role of General Cognitive Style SO JOURNAL OF YOUTH AND ADOLESCENCE LA English DT Article DE Interparental conflict; Child depression; Parenting; Cognitive style ID YOUTH PROBLEM BEHAVIORS; MARITAL CONFLICT; CHILDRENS DEPRESSION; ATTRIBUTIONAL STYLE; LOW-INCOME; ADOLESCENT ADJUSTMENT; CONTEXTUAL FRAMEWORK; LEARNED HELPLESSNESS; MEDIATIONAL MODEL; MEXICAN-AMERICAN AB Research on the mechanisms by which interparental conflict (IPC) affects child depression suggests that both parenting and children's conflict appraisals play important roles, but few studies have explored the role of general cognitive style or included both parenting and cognitions in the same design. Moreover, the effects of IPC on minority children are not well understood. In this longitudinal study, parenting was examined as a mediator of the relation between increasing IPC and change in depression. General cognitive style was included as a moderator. The combined influence of parenting and cognitions was also explored. A racially and ethnically diverse sample of 88 fifth and sixth graders from two urban schools reported their cognitive style, depressive symptoms, and perceptions of conflict and parenting at two time points separated by one year. Parental warmth/rejection mediated the relation between IPC and depression, and general cognitive style acted as a moderator. Parenting, cognitive style, and IPC did not significantly interact to predict change in depression over time. Findings indicate that both parenting and children's general cognitive style play a role in understanding the impact of increasing IPC on children's well-being. C1 [O'Donnell, Ellen H.] Massachusetts Gen Hosp, LEAP Program, Boston, MA 02114 USA. [Cardemil, Esteban V.] Clark Univ, Dept Psychol, Worcester, MA 01610 USA. RP O'Donnell, EH (reprint author), Massachusetts Gen Hosp, LEAP Program, 151 Merrimac St, Boston, MA 02114 USA. EM ehodonnell@partners.org FU NIMH NIH HHS [K01 MH67571] NR 66 TC 9 Z9 11 U1 0 U2 16 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0047-2891 J9 J YOUTH ADOLESCENCE JI J. Youth Adolesc. PD JAN PY 2010 VL 39 IS 1 BP 12 EP 22 DI 10.1007/s10964-008-9357-9 PG 11 WC Psychology, Developmental SC Psychology GA 534RZ UT WOS:000272916300002 PM 20091213 ER PT J AU Ludman, EJ Russo, JE Katon, WJ Simon, GE Williams, LH Lin, EHB Heckbert, SR Ciechanowski, P Young, BA AF Ludman, Evette J. Russo, Joan E. Katon, Wayne J. Simon, Gregory E. Williams, Lisa H. Lin, Elizabeth H. B. Heckbert, Susan R. Ciechanowski, Paul Young, Bessie A. TI How Does Change in Depressive Symptomatology Influence Weight Change in Patients With Diabetes? Observational Results From the Pathways Longitudinal Cohort SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Depression; Obesity; Diabetes ID RANDOMIZED-TRIAL; SELF-REPORT; HEALTH; RISK; CARE; INDIVIDUALS; OBESITY; ADJUDICATION; PREVENTION; MORTALITY AB Little is known about how change in depressive symptoms over time is associated with change in weight. Longitudinal associations between change in depression (Patient Health Questionnaire-9 [PHQ-9]) and weight (self-reported and chart abstracted) were examined in 2,600 patients with type 2 diabetes (mean age 62, SD = 11.6) who were surveyed by telephone in 2001-2002 and 5 years later as part of the Pathways study. Mixed effects regression analyses compared a) patients with persistently low depression symptoms with those whose depression worsened (increased at least 5 points on PHQ-9) over 5 years and b) patients with persistently high depression symptoms with those who improved (decreased at least 5 points on PHQ-9) over 5 years. Those who worsened in comparison to those with persistently low depression symptoms did not differ in their pattern of weight change (z = 1.54, p = .12). Both groups weighed approximately 92 kg at baseline and lost approximately 2 kg. A significantly different pattern of change over time was observed for those with persistently high depression symptoms in comparison to those whose depression improved (z = 1.98, p = .04). Although the groups had almost identical weight at baseline (approximately 100 kg), at the 5-year assessment, those with persistently high depression symptoms had about half the weight loss (M = -1.71, SD = 9.08) in comparison to those whose depression improved (M = -3.62, SD = 19.93). In persons with diabetes who have clinically significant levels of depressive symptoms, improvement in depression is accompanied by significantly greater, clinically significant weight loss. C1 [Ludman, Evette J.; Simon, Gregory E.; Lin, Elizabeth H. B.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA. [Russo, Joan E.; Katon, Wayne J.; Ciechanowski, Paul] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Lisa H.] Univ Washington, Sch Med, VA Hlth Serv Res & Dev, Ctr Excellence, Seattle, WA USA. [Williams, Lisa H.] Univ Washington, Div Dermatol, Sch Med, Seattle, WA 98195 USA. [Heckbert, Susan R.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Sch Med, Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Young, Bessie A.] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. RP Ludman, EJ (reprint author), Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM ludman.e@ghc.org FU National Institute of Mental Health [K24 MH067587, MH 073686] FX This research was supported by grants from the National Institute of Mental Health (K24 MH067587 to W. J. K. and MH 073686 to Michael Von Korff). NR 27 TC 7 Z9 7 U1 0 U2 1 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2010 VL 65 IS 1 BP 93 EP 98 DI 10.1093/gerona/glp151 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 537LV UT WOS:000273115300013 PM 19822623 ER PT J AU Alley, DE Chang, VW AF Alley, Dawn E. Chang, Virginia W. TI Metabolic Syndrome and Weight Gain in Adulthood SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Metabolic syndrome; Weight history; Body mass index; Lipids ID CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; US ADULTS; CARDIOMETABOLIC RISK; SUBSEQUENT RISK; OBESITY; WOMEN AB The influence of long-term adult weight history on metabolic risk independent of attained body mass index (BMI) is unknown. Using nationally representative data on adults aged 50-64 years from the 1999-2006 National Health and Nutrition Examination Surveys, we examined weight change for two periods of adulthood: prime age (age 25-10 years ago) and midlife (the last 10 years). Weight changes in each period were categorized as stable (gain < 10 kg) or gain (gain >= 10 kg) to create weight history comparison groups: stable-stable, gain-stable (prime age gain), stable-gain (midlife gain), and gain-gain (continuous gain). Persons who lost weight were excluded. Logistic regression predicted odds of metabolic syndrome and its subcomponents based on weight history, adjusting for current BMI and covariates. Participants in the gain-stable group had 89% elevated odds of metabolic syndrome (odds ratio = 1.89, 95% CI: 1.19-3.01) relative to the stable-stable group, even after adjustment for current BMI. All weight gain groups had increased odds of low HDL and high triglycerides relative to participants with continuously stable weights. No significant associations were found between weight history and hypertension or high glucose. Weight history confers information about metabolic risk factors above and beyond attained weight status. In particular, adult weight gain is related to risk of low HDL and high triglycerides. Weight history may contribute to our understanding of why some obese older persons are metabolically healthy but others are not. C1 [Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Chang, Virginia W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chang, Virginia W.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. RP Alley, DE (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St 221B, Baltimore, MD 21201 USA. EM dalley@epi.umaryland.edu FU Robert Wood Johnson Foundation Health; National Institute of Child Health and Human Development [K12-HD043459] FX Robert Wood Johnson Foundation Health and Society Scholars program and National Institute of Child Health and Human Development (K12-HD043459). NR 35 TC 15 Z9 17 U1 0 U2 0 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2010 VL 65 IS 1 BP 111 EP 117 DI 10.1093/gerona/glp177 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 537LV UT WOS:000273115300016 PM 19906821 ER PT S AU Pitteloud, N Durrani, S Raivio, T Sykiotis, GP AF Pitteloud, Nelly Durrani, Sadia Raivio, Taneli Sykiotis, Gerasimos P. BE Quinton, R TI Complex Genetics in Idiopathic Hypogonadotropic Hypogonadism SO KALLMANN SYNDROME AND HYPOGONADOTROPIC HYPOGONADISM SE Frontiers of Hormone Research LA English DT Review; Book Chapter ID GONADOTROPIN-RELEASING-HORMONE; REVERSIBLE KALLMANN-SYNDROME; GROWTH-FACTOR RECEPTOR-1; FIBROBLAST-GROWTH-FACTOR-RECEPTOR-1 GENE; REPRODUCTIVE PHENOTYPES; DIGENIC MUTATIONS; CHARGE SYNDROME; NEUROKININ B; KAL1; DEFICIENCY AB Idiopathic hypogonadotropic hypogonadism (IHH) is an important human disease model. Investigations of the genetics of IHH have facilitated insights into critical pathways regulating sexual maturation and fertility. IHH has been traditionally considered a monogenic disorder. This model holds that a single gene defect is responsible for the disease in each patient. In the case of IHH, 30% of cases are explained by mutations in one of eleven genes. In recent years, several lines of evidence have challenged the monogenic paradigm in IHH. First, disease-associated mutations display striking incomplete penetrance and variable expressivity within and across IHH families. Second, each locus is responsible for only a small percentage of cases. Third, more than one disease-associated mutation seems to be segregating in some families with IHH, and their combined or separate presence in individuals accounts for the variability in disease severity. Finally, IHH is not strictly a congenital and life-long disorder; occasionally it manifests itself during adulthood (adult-onset IHH); in other cases, the disease is not permanent, as evidenced by normal activity of the hypothalamic-pituitary-gonadal axis after discontinuation of treatment in adulthood (IHH reversal). Together, these observations suggest that IHH is not strictly a monogenic mendelian disease, as previously thought. Rather, it is emerging as a digenic, and potentially oligogenic disease, in which hormonal and/or environmental factors may critically influence genetic predisposition and clinical course. Future investigations of IHH should characterize the extent of the involvement of multiple genes in disease pathogenesis, and elucidate the contributions of epigenetic factors. Copyright (C) 2010 S. Karger AG, Basel C1 [Pitteloud, Nelly; Durrani, Sadia; Sykiotis, Gerasimos P.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Raivio, Taneli] Univ Helsinki, Inst Biomed & Physiol, Biomedicum Helsinki, Helsinki, Finland. RP Pitteloud, N (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, 55 Fruit St, Boston, MA 02114 USA. EM npitteloud@partners.org RI PITTELOUD, Nelly/K-2709-2014; OI Sykiotis, Gerasimos/0000-0002-9565-4941 FU NICHD NIH HHS [R01 HD056264] NR 61 TC 28 Z9 31 U1 0 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0301-3073 BN 978-3-8055-8617-7 J9 FRONT HORM RES JI Front.Horm.Res. PY 2010 VL 39 BP 142 EP 153 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BOR20 UT WOS:000277370800013 PM 20389092 ER PT S AU Ravikumar, B Crowley, WF AF Ravikumar, Balasubramanian Crowley, William F., Jr. BE Quinton, R TI Kallmann Syndrome and Hypogonadotropic Hypogonadism Concluding Remarks SO KALLMANN SYNDROME AND HYPOGONADOTROPIC HYPOGONADISM SE Frontiers of Hormone Research LA German DT Editorial Material; Book Chapter C1 [Ravikumar, Balasubramanian; Crowley, William F., Jr.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, 55 Fruit St, Boston, MA 02114 USA. EM wcrowley@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0301-3073 BN 978-3-8055-8617-7 J9 FRONT HORM RES JI Front.Horm.Res. PY 2010 VL 39 BP 168 EP 169 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BOR20 UT WOS:000277370800015 PM 20389094 ER PT J AU Perkins, BA Ficociello, LH Roshan, B Warram, JH Krolewski, AS AF Perkins, Bruce A. Ficociello, Linda H. Roshan, Bijan Warram, James H. Krolewski, Andrzej S. TI In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria SO KIDNEY INTERNATIONAL LA English DT Article DE angiotensin; chronic kidney disease; glomerular filtration rate; microalbuminuria; renal function decline ID GLOMERULAR-FILTRATION-RATE; URINARY ALBUMIN EXCRETION; CONVERTING ENZYME-INHIBITORS; CREATININE-BASED METHODS; RENAL-FUNCTION DECLINE; CYSTATIN-C; SERUM CREATININE; NEPHROPATHY; MELLITUS; RISK AB We sought to study new-onset microalbuminuria, its progression, and the decline of renal function in patients with type 1 diabetes. Using a cohort of 109 patients who developed new-onset microalbuminuria in the first 4 years following enrollment in the 1st Joslin Kidney Study, we simultaneously tracked the change in their renal function and urinary albumin excretion. Of these, 79 patients were followed for an average of 12 years after microalbuminuria onset, wherein their glomerular filtration rate was estimated by the Modification of Diet in Renal Disease Study formula and compared with their microalbuminuria and proteinuria. The concordance between these outcomes was weak. Only 12 of the 23 patients who progressed to advanced (stage 3-5) chronic kidney disease developed proteinuria, which, in general, did not precede but accompanied the progression to advanced chronic kidney disease. The remaining 11 patients who developed advanced disease had persistent microalbuminuria or returned to normal albuminuria. Thus, we found that one-third of patients with type 1 diabetes developed advanced chronic kidney disease relatively soon after the onset of microalbuminuria and this was not conditional on the presence of proteinuria. Contrary to the existing concept of early nephropathy in type 1 diabetes, less emphasis should be placed on the mechanisms of progression to proteinuria and more placed on mechanisms initiating and promoting the early decline of renal function that eventually progresses to advanced chronic kidney disease. Kidney International (2010) 77, 57-64; doi:10.1038/ki.2009.399; published online 21 October 2009 C1 [Perkins, Bruce A.] Univ Toronto, Div Endocrinol, Toronto, ON M5G 2C4, Canada. [Ficociello, Linda H.; Warram, James H.; Krolewski, Andrzej S.] Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. [Roshan, Bijan] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA. RP Perkins, BA (reprint author), Univ Toronto, Div Endocrinol & Metab, 200 Elizabeth St,Room EN 12-217, Toronto, ON M5G 2C4, Canada. EM bruce.perkins@uhn.on.ca FU NIH [DK041526, DK067638]; Banting and Best Diabetes Center FX This research was supported by NIH grants DK041526 and DK067638 (to ASK) and the Joslin Diabetes Center. BAP is a Canadian Diabetes Association Scholar and was supported by the Banting and Best Diabetes Center. NR 44 TC 112 Z9 117 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2010 VL 77 IS 1 BP 57 EP 64 DI 10.1038/ki.2009.399 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 531WG UT WOS:000272701900010 PM 19847154 ER PT B AU Hanto, RL Roth, AE Unver, MU Delmonico, FL AF Hanto, Ruthanne L. Roth, Alvin E. Uenver, M. Utku Delmonico, Francis L. BE McKay, DB Steinberg, SM TI New Sources in Living Kidney Donation SO KIDNEY TRANSPLANTATION: A GUIDE TO THE CARE OF KIDNEY TRANSPLANT RECIPIENTS LA English DT Article; Book Chapter ID PAIRED DONATION; LIVE DONOR; EXCHANGE; TRANSPLANTATION; GUIDELINES; OUTCOMES; PROGRAM C1 [Hanto, Ruthanne L.] Organ Procurement Org, New England Program Kidney Exchange, New England Organ Bank, Newton, MA USA. [Delmonico, Francis L.] Massachusetts Gen Hosp, Transplant Ctr, WHO, Transplantat Soc, Newton, MA USA. [Roth, Alvin E.] Harvard Univ, Sch Med, Dept Econ, Boston, MA USA. [Uenver, M. Utku] Boston Coll, Dept Econ, Chestnut Hill, MA 02167 USA. RP Hanto, RL (reprint author), Organ Procurement Org, New England Program Kidney Exchange, New England Organ Bank, Newton, MA USA. EM rhanto@neob.org OI Unver, Utku/0000-0001-7693-1635 NR 27 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-1689-1 PY 2010 BP 103 EP 117 DI 10.1007/978-1-4419-1690-7_8 D2 10.1007/978-1-4419-1690-7 PG 15 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA BOY71 UT WOS:000278069900008 ER PT J AU Prakash, P Kalra, MK Gilman, MD Shepard, JAO Digumarthy, SR AF Prakash, Priyanka Kalra, Mannudeep K. Gilman, Matthew D. Shepard, Jo-Anne O. Digumarthy, Subba R. TI Is Weight-Based Adjustment of Automatic Exposure Control Necessary for the Reduction of Chest CT Radiation Dose? SO KOREAN JOURNAL OF RADIOLOGY LA English DT Article DE Automatic exposure control (AEC); Chest CT; Weight based; Radiation dose ID Z-AXIS MODULATION; ROW CT; OPTIMIZATION AB Objective: To assess the effects of radiation dose reduction in the chest CT using a weight-based adjustment of the automatic exposure control (AEC) technique. Materials and Methods: With Institutional Review Board Approval, 60 patients (mean age, 59.1 years; M:F = 35:25) and 57 weight-matched patients (mean age, 52.3 years, M:F = 25:32) were scanned using a weight-adjusted AEC and non-weight-adjusted AEC, respectively on a 64-slice multidetector CT with a 0.984:1 pitch, 0.5 second rotation time, 40 mm table feed/rotation, and 2.5 mm section thickness. Patients were categorized into 3 weight categories; < 60 kg (n = 17), 60-90 kg (n = 52), and > 90 kg (n = 48). Patient weights, scanning parameters, CT dose index volumes (CTDIvol) and dose length product (DLP) were recorded, while effective dose (ED) was estimated. Image noise was measured in the descending thoracic aorta. Data were analyzed using a standard statistical package (SAS/STAT) (Version 9.1, SAS institute Inc, Cary, NC). Results: Compared to the non-weight-adjusted AEC, the weight-adjusted AEC technique resulted in an average decrease of 29% in CTDIvol and a 27% effective dose reduction (p < 0.0001). With weight-adjusted AEC, the CTDIvol decreased to 15.8, 15.9, and 27.3 mGy for the < 60, 60-90 and > 91 kg weight groups, respectively, compared to 20.3, 27.9 and 32.8 mGy, with non-weight-adjusted AEC. No significant difference was observed for objective image noise between the chest CT acquired with the non-weight-adjusted (15.0 +/- 3.1) and weight-adjusted (16.1 +/- 5.6) AEC techniques (p > 0.05). Conclusion: The results of this study suggest that AEC should be tailored according to patient weight. Without weight-based adjustment of AEC, patients are exposed to a 17 - 43% higher radiation-dose from a chest CT. C1 [Prakash, Priyanka; Kalra, Mannudeep K.; Gilman, Matthew D.; Shepard, Jo-Anne O.; Digumarthy, Subba R.] Massachusetts Gen Hosp, Div Thorac Imaging, Dept Radiol, Boston, MA 02114 USA. [Prakash, Priyanka; Kalra, Mannudeep K.; Gilman, Matthew D.; Shepard, Jo-Anne O.; Digumarthy, Subba R.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Kalra, MK (reprint author), Massachusetts Gen Hosp, Div Thorac Imaging, Dept Radiol, 25 New Chardon St, Boston, MA 02114 USA. EM mkalra@partners.org FU GE Healthcare (Waukesha, WI). FX M.K.K. received research funding from GE Healthcare (Waukesha, WI). The remaining authors (P.P., S.D., J.S., and M.G.) have no financial disclosures and had complete and unrestricted access to the study data and manuscript at all stages of the study. NR 13 TC 8 Z9 8 U1 0 U2 1 PU KOREAN RADIOLOGICAL SOC PI SEOUL PA 121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA SN 1229-6929 EI 2005-8330 J9 KOREAN J RADIOL JI Korean J. Radiol. PD JAN-FEB PY 2010 VL 11 IS 1 BP 46 EP 53 DI 10.3348/kjr.2010.11.1.46 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 546SZ UT WOS:000273833300006 PM 20046494 ER PT J AU Boudreau, E Chen, G Li, X Buck, K Hitzemann, R Hickman, D AF Boudreau, Eilis Chen, Gang Li, Xin Buck, Kari Hitzemann, Robert Hickman, Debra TI Intraperitoneal catheter placement for pharmacological imaging studies in conscious mice SO LAB ANIMAL LA English DT Article ID IN-VIVO; INJECTION; RATS; MRI; RECEPTORS; STRESS AB Imaging studies that use rodents sometimes involve intraperitoneal administration of pharmacological compounds. To facilitate such studies, the authors developed a simple and easily mastered technique for placing an intraperitoneal catheter in a conscious mouse. This technique eliminates the need to remove the animal from the scanner to administer a drug through the intraperitoneal route. C1 [Boudreau, Eilis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Boudreau, Eilis; Chen, Gang; Buck, Kari; Hitzemann, Robert; Hickman, Debra] Portland VA Med Ctr, Portland, OR USA. [Chen, Gang; Buck, Kari; Hitzemann, Robert] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Chen, Gang; Buck, Kari; Hitzemann, Robert] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA. [Li, Xin] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA. RP Boudreau, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM boudreau@ohsu.edu RI Hickman, Debra/D-3289-2009 FU NIAAA NIH HHS [P60 AA010760] NR 14 TC 1 Z9 1 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0093-7355 J9 LAB ANIMAL JI Lab Anim. PD JAN PY 2010 VL 39 IS 1 BP 23 EP 25 DI 10.1038/laban0110-23 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA 537ZF UT WOS:000273152500011 PM 20023678 ER PT J AU Chen, C Skog, J Hsu, CH Lessard, RT Balaj, L Wurdinger, T Carter, BS Breakefield, XO Toner, M Irimia, D AF Chen, Chihchen Skog, Johan Hsu, Chia-Hsien Lessard, Ryan T. Balaj, Leonora Wurdinger, Thomas Carter, Bob S. Breakefield, Xandra O. Toner, Mehmet Irimia, Daniel TI Microfluidic isolation and transcriptome analysis of serum microvesicles SO LAB ON A CHIP LA English DT Article ID TUMOR-DERIVED EXOSOMES; POLYMERASE CHAIN-REACTION; DENDRITIC CELLS; DIAGNOSTIC BIOMARKERS; MAJOR INHIBITOR; PLASMA-MEMBRANE; CANCER; BLOOD; IDENTIFICATION; AMPLIFICATION AB Microvesicles (exosomes) shed from both normal and cancerous cells may serve as means of intercellular communication. These microvesicles carry proteins, lipids and nucleic acids derived from the host cell. Their isolation and analysis from blood samples have the potential to provide information about state and progression of malignancy and should prove of great clinical importance as biomarkers for a variety of disease states. However, current protocols for isolation of microvesicles from blood require high-speed centrifugation and filtration, which are cumbersome and time consuming. In order to take full advantage of the potential of microvesicles as biomarkers for clinical applications, faster and simpler methods of isolation will be needed. In this paper, we present an easy and rapid microfluidic immunoaffinity method to isolate microvesicles from small volumes of both serum from blood samples and conditioned medium from cells in culture. RNA of high quality can be extracted from these microvesicles providing a source of information about the genetic status of tumors to serve as biomarkers for diagnosis and prognosis of cancer. C1 [Chen, Chihchen; Hsu, Chia-Hsien; Toner, Mehmet; Irimia, Daniel] Harvard Univ, Sch Med, Shriners Hosp Children,Massachusets Gen Hosp, BioMEMS Resource Ctr,Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. [Skog, Johan; Lessard, Ryan T.; Balaj, Leonora; Wurdinger, Thomas; Breakefield, Xandra O.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Program,Dept Neurol, Boston, MA 02114 USA. [Skog, Johan; Lessard, Ryan T.; Balaj, Leonora; Wurdinger, Thomas; Breakefield, Xandra O.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Program,Dept Radiol, Boston, MA 02114 USA. [Wurdinger, Thomas] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, Neurooncol Res Grp, NL-1007 MB Amsterdam, Netherlands. [Carter, Bob S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. RP Irimia, D (reprint author), Harvard Univ, Sch Med, Shriners Hosp Children,Massachusets Gen Hosp, BioMEMS Resource Ctr,Ctr Engn Med & Surg Serv, Boston, MA 02114 USA. EM dirimia@hms.harvard.edu RI Hsu, Chia-Hsien/E-4957-2010; Hsu, Chia-Hsien /E-3946-2010; OI Chen, Chihchen/0000-0002-2195-4802; Irimia, Daniel/0000-0001-7347-2082 FU NIBIB [P41 EB002503]; NCI [CA86355, CA69246]; Wenner-Gren Foundation; Stiftelsen Olle Engkvist Byggm_astare FX We thank Octavio Hurtado for valuable assistance with microfabrication. This work was supported in part by the NIBIB P41 EB002503 (MT), NCI CA86355 (XOB), NCI CA69246 (XOB), Wenner-Gren Foundation (JS) and Stiftelsen Olle Engkvist Byggm_astare (JS). NR 47 TC 122 Z9 124 U1 6 U2 67 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2010 VL 10 IS 4 BP 505 EP 511 DI 10.1039/b916199f PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 551KR UT WOS:000274207700014 PM 20126692 ER PT J AU Berdichevsky, Y Staley, KJ Yarmush, ML AF Berdichevsky, Yevgeny Staley, Kevin J. Yarmush, Martin L. TI Building and manipulating neural pathways with microfluidics SO LAB ON A CHIP LA English DT Article ID ORGANOTYPIC SLICE CULTURES; TEMPORAL-LOBE EPILEPSY; SYNAPTIC ACTIVITY; STRIATE CORTEX; NERVOUS-TISSUE; VISUAL-CORTEX; AXON GUIDANCE; IN-VITRO; ACTIVATION; CIRCUITS AB Communication between different brain regions, and between local circuits in the same brain region, is an important area of study for basic and translational neuroscience research. Selective and chronic manipulation of one of the components in a given neural pathway is frequently required for development and plasticity studies. We designed an in vitro platform that captures some of the complexity of mammalian brain pathways but permits easy experimental manipulation of their constituent parts. Organotypic cultures of brain slices were carried out in compartments interconnected by microchannels. We show that co-cultures from cortex and hippocampus formed functional connections by extending axons through the microchannels. We report synchronization of neural activity in co-cultures, and demonstrate selective pharmacological manipulation of activity in the constituent slices. Our platform enables chronic, spatially-restricted experimental manipulation of pre- and post-synaptic neurons in organotypic cultures, and will be useful to investigators seeking to understand development, plasticity, and pathologies of neural pathways. C1 [Berdichevsky, Yevgeny; Yarmush, Martin L.] Ctr Engn Med, Dept Surg, Boston, MA USA. [Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Berdichevsky, Yevgeny; Staley, Kevin J.; Yarmush, Martin L.] Harvard Univ, Sch Med, Boston, MA USA. RP Berdichevsky, Y (reprint author), Ctr Engn Med, Dept Surg, Boston, MA USA. EM yberdichevsky@partners.org FU NIH [P41EB002503, F32MH079662] FX We thank Helen Sabolek for helpful discussion and for proofreading the manuscript. This work was supported in part by NIH Grant P41EB002503. Y.B. was supported by NIH F32MH079662. NR 47 TC 32 Z9 34 U1 2 U2 25 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2010 VL 10 IS 8 BP 999 EP 1004 DI 10.1039/b922365g PG 6 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 577JL UT WOS:000276218900005 PM 20358106 ER EF